Clustering O 0 4.881800487055443e-05
of O 0 1.9559547581593506e-07
missense O 0 0.00014268196537159383
mutations O 0 2.3207916456158273e-05
in O 0 1.1397185062378412e-07
the O 0 6.175084763526684e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.692073783488013e-05
in O 0 4.3750318923230225e-08
a O 0 2.1854883414107462e-07
sporadic B-Disease 0 0.015418331138789654
T I-Disease 1 0.9981778860092163
- I-Disease 0 0.21334798634052277
cell I-Disease 0 0.003381188726052642
leukaemia I-Disease 0 0.027902279049158096
. O 0 1.3678255754712154e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.34562283754348755
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.036316087445812e-08
is O 0 1.102669067165607e-09
a O 0 5.871187980233117e-09
recessive B-Disease 0 3.501690662233159e-05
multi I-Disease 0 0.0001196820885525085
- I-Disease 1 0.9999829530715942
system I-Disease 0 0.01194004062563181
disorder I-Disease 0 0.1498727798461914
caused O 0 7.201246887689194e-08
by O 0 7.65505880906403e-10
mutations O 0 1.1337473893036076e-07
in O 0 7.582039440734434e-10
the O 0 1.1476862793458054e-09
ATM O 0 2.7507385880198854e-07
gene O 0 1.3764525874648825e-07
at O 0 4.789130159110755e-08
11q22 O 0 1.6081331750683603e-06
- O 0 1.6095376849989407e-05
q23 O 0 4.632709988072747e-06
( O 0 2.565686685329638e-08
ref O 0 1.358873396384297e-05
. O 0 1.0642952297246211e-08
3 O 0 4.974353373654594e-08
) O 0 3.705301310219511e-08
. O 0 1.3938736742602487e-07

The O 0 7.029051403151243e-07
risk O 0 8.987325941234303e-07
of O 0 1.971439544945497e-08
cancer B-Disease 0 5.603228146355832e-06
, O 0 7.055766193531099e-09
especially O 0 5.49606360422672e-09
lymphoid B-Disease 0 1.1620704754022881e-06
neoplasias I-Disease 0 5.178602077648975e-05
, O 0 4.3175663932970565e-08
is O 0 6.778245964511598e-09
substantially O 0 3.258315643961396e-07
elevated O 0 5.0969701987924054e-06
in O 0 2.3144968963606516e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.7935426512849517e-05
and O 0 4.7546350856464414e-07
has O 0 3.6102846934227273e-07
long O 0 7.904739618425083e-08
been O 0 1.74422840615307e-08
associated O 0 1.5307971779066065e-08
with O 0 7.98004435864641e-08
chromosomal O 1 1.0
instability O 1 1.0
. O 0 3.0554640488844598e-06

By O 0 7.560182098131918e-07
analysing O 0 1.993401747313328e-05
tumour B-Disease 1 0.9999997615814209
DNA O 0 1.3267285794427153e-06
from O 0 8.306528798129875e-09
patients O 0 1.7937258789402222e-08
with O 0 2.6928388408009596e-09
sporadic B-Disease 0 9.710391896078363e-05
T I-Disease 1 0.8740580677986145
- I-Disease 0 0.005793279968202114
cell I-Disease 0 0.0005332400323823094
prolymphocytic I-Disease 0 0.0007243602885864675
leukaemia I-Disease 0 0.08409705013036728
( O 0 4.021284780719725e-07
T B-Disease 0 0.0004397373122628778
- I-Disease 0 3.848486812785268e-05
PLL I-Disease 0 5.318051262293011e-05
) O 0 1.9899813352708406e-08
, O 0 1.6009137349115576e-09
a O 0 3.5677585330518014e-09
rare O 0 1.8016773850604295e-08
clonal B-Disease 0 1.0351650416851044e-06
malignancy I-Disease 0 1.6562036762479693e-05
with O 0 2.7667481639070957e-09
similarities O 0 7.173883886935073e-08
to O 0 7.036816462857587e-09
a O 0 8.376648708008361e-08
mature B-Disease 0 8.497984822497529e-07
T I-Disease 0 0.00013793529069516808
- I-Disease 0 3.353846841491759e-05
cell I-Disease 0 2.7493391826283187e-05
leukaemia I-Disease 0 9.030586807057261e-05
seen O 0 6.488249937319779e-07
in O 0 2.8100034299427534e-08
A B-Disease 1 0.9999983310699463
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
, O 0 8.474856372231443e-08
we O 0 5.270070158047702e-09
demonstrate O 0 1.0612984935320924e-09
a O 0 8.978102705725632e-10
high O 0 3.264755354948079e-09
frequency O 0 6.2882650198048395e-09
of O 0 4.718780921564303e-10
ATM O 0 1.7823305142883328e-06
mutations O 0 5.575428190240928e-07
in O 0 5.0182375588292416e-08
T B-Disease 0 0.027768492698669434
- I-Disease 0 0.0004842400667257607
PLL I-Disease 0 0.000367627915693447
. O 0 1.2110108400520403e-06

In O 0 1.0950645901175449e-06
marked O 0 1.234330738952849e-06
contrast O 0 9.867166994581567e-08
to O 0 9.079741958295529e-10
the O 0 1.5484982185398621e-09
ATM O 0 8.530976174370153e-07
mutation O 0 2.6210685177829873e-07
pattern O 0 5.486207101057516e-06
in O 0 1.2499441481850226e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 1.3915965269006847e-08
the O 0 3.2146718620396086e-10
most O 0 2.520324504651228e-10
frequent O 0 3.3126148490936203e-09
nucleotide O 0 2.730799764094627e-08
changes O 0 3.781840618444221e-09
in O 0 1.4736639686319108e-09
this O 0 1.0910314429679602e-08
leukaemia B-Disease 0 0.0001237740507349372
were O 0 1.9192246725197037e-07
missense O 0 5.093075742479414e-05
mutations O 0 1.5449842976522632e-05
. O 0 2.7343028818904713e-07

These O 0 1.152979365315332e-07
clustered O 0 6.262867486839241e-07
in O 0 5.820143922363741e-09
the O 0 3.185443020470302e-09
region O 0 2.70640310162662e-08
corresponding O 0 4.626437455357291e-09
to O 0 8.594034928144367e-10
the O 0 7.883126373897653e-10
kinase O 0 3.208571399682114e-07
domain O 0 7.288329584298481e-08
, O 0 1.698521501225514e-08
which O 0 1.734190391289303e-08
is O 0 1.0565259778161362e-09
highly O 0 8.588397770736833e-10
conserved O 0 5.54822099374519e-09
in O 0 1.1150117495972722e-09
ATM O 0 1.860681919652052e-07
- O 0 3.632806624409568e-07
related O 0 5.0721227218275544e-09
proteins O 0 6.787897799398479e-09
in O 0 3.210574028855717e-09
mouse O 0 1.1147187251481228e-05
, O 0 1.077979305819099e-08
yeast O 0 8.136487963383843e-07
and O 0 3.500502288034113e-08
Drosophila O 0 1.0168095059270854e-06
. O 0 4.1198003941644856e-07

The O 0 1.0045649787571165e-06
resulting O 0 3.9238071281033626e-07
amino O 0 2.2785684450354893e-07
- O 0 4.7313895379375026e-07
acid O 0 1.0842710196357075e-07
substitutions O 0 4.644104478757072e-08
are O 0 1.9252743843622966e-09
predicted O 0 7.739453167232568e-08
to O 0 1.2405684257643657e-09
interfere O 0 1.1486635642654619e-08
with O 0 2.150647882004364e-09
ATP O 0 1.317042688242509e-07
binding O 0 1.6747122799642966e-07
or O 0 1.082908980265529e-07
substrate O 0 1.1895532452399493e-06
recognition O 0 2.9877810447942466e-07
. O 0 3.9062888390617445e-07

Two O 0 5.23583764788782e-07
of O 0 1.500478852278775e-08
seventeen O 0 3.182035754889512e-07
mutated O 0 5.82904021939612e-06
T B-Disease 0 0.001000736141577363
- I-Disease 0 1.1057318261009641e-05
PLL I-Disease 0 1.5579216778860427e-05
samples O 0 2.466112789534236e-07
had O 0 1.0678866146918153e-07
a O 0 1.0175837950043842e-08
previously O 0 3.097850651556655e-07
reported O 0 1.0484671292942949e-05
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
allele O 0 2.472102096362505e-05
. O 0 4.1404911144127254e-07

In O 0 3.9026656395435566e-07
contrast O 0 1.8692189485136623e-07
, O 0 6.682584707817796e-09
no O 0 8.599385203922338e-09
mutations O 0 2.2680708866573696e-07
were O 0 1.693578433048515e-08
detected O 0 3.08173184748739e-08
in O 0 1.0820058182758885e-09
the O 0 1.003583882663861e-09
p53 O 0 4.44594583370872e-08
gene O 0 4.4737110016512815e-08
, O 0 4.806872233587001e-09
suggesting O 0 3.1654881382792155e-08
that O 0 2.4899178274750966e-09
this O 0 6.659325979541109e-09
tumour B-Disease 1 1.0
suppressor O 0 0.0008953430224210024
is O 0 1.934430429173517e-07
not O 0 7.636585586112687e-09
frequently O 0 7.889887854162225e-08
altered O 0 1.229530198543216e-06
in O 0 3.521570235420768e-08
this O 0 1.1461909821264271e-07
leukaemia B-Disease 0 0.001032172585837543
. O 0 6.675325607830018e-07

Occasional O 0 5.152400626684539e-05
missense O 0 0.00028308742912486196
mutations O 0 5.293604317557765e-06
in O 0 1.4529000225138589e-08
ATM O 0 3.953932719014119e-06
were O 0 7.044096719255322e-07
also O 0 1.2440527541457413e-07
found O 0 2.3764050283148208e-08
in O 0 7.13466619117753e-08
tumour B-Disease 1 1.0
DNA O 0 1.7210088572028326e-06
from O 0 4.573715184363891e-09
patients O 0 4.536971243140897e-09
with O 0 1.6173891115300876e-09
B B-Disease 0 6.537117656080227e-07
- I-Disease 0 1.6996196791296825e-05
cell I-Disease 0 9.417947148904204e-05
non I-Disease 0 3.621575388024212e-06
- I-Disease 1 0.9792948365211487
Hodgkins I-Disease 1 0.999963641166687
lymphomas I-Disease 0 0.41429248452186584
( O 0 8.700357057023211e-08
B B-Disease 0 2.405083137091424e-07
- I-Disease 0 2.063707597699249e-06
NHL I-Disease 0 3.874824415106559e-06
) O 0 7.849432215323304e-09
and O 0 7.994025885693645e-09
a O 0 3.318396579743421e-08
B B-Disease 0 8.281234613605193e-07
- I-Disease 0 1.0498359188204631e-05
NHL I-Disease 0 5.233699084783439e-06
cell O 0 1.6856667571119033e-05
line O 0 4.438350515556522e-05
. O 0 2.1687331752673344e-07

The O 0 2.4852653268681024e-07
evidence O 0 1.1027641910743569e-08
of O 0 7.809600188757315e-10
a O 0 2.4375148566235794e-09
significant O 0 1.250334058511271e-09
proportion O 0 1.1872957728087385e-08
of O 0 1.3026884015943097e-09
loss O 0 3.862314201796835e-08
- O 0 7.353011710620194e-07
of O 0 1.6046708406491916e-09
- O 0 1.8888713384512812e-06
function O 0 3.1540913880689914e-08
mutations O 0 9.338037187944792e-08
and O 0 6.1333138567931655e-09
a O 0 7.084003161850205e-09
complete O 0 5.929508262170202e-08
absence O 0 1.8615795127630008e-08
of O 0 3.039065110677086e-10
the O 0 1.753701517337447e-09
normal O 0 6.6498571094086856e-09
copy O 0 8.519555194652639e-08
of O 0 5.423509419344441e-10
ATM O 0 8.392720474148518e-08
in O 0 1.5486872895209558e-09
the O 0 4.251794472054371e-09
majority O 0 2.2176106284632624e-08
of O 0 1.6378697509367157e-08
mutated O 0 0.022226978093385696
tumours B-Disease 1 1.0
establishes O 0 4.073744094057474e-06
somatic O 0 1.1741930165953818e-06
inactivation O 0 4.323848315834766e-06
of O 0 1.199411014951579e-09
this O 0 7.203768692676249e-10
gene O 0 2.5176266404969283e-08
in O 0 3.063714615336721e-09
the O 0 3.5451088731264235e-09
pathogenesis O 0 1.7328932244708994e-07
of O 0 3.595713504722653e-09
sporadic B-Disease 0 0.00023010201402939856
T I-Disease 1 0.8842927813529968
- I-Disease 0 0.0020800726488232613
PLL I-Disease 0 4.4477648771135136e-05
and O 0 5.3999908544710706e-08
suggests O 0 8.630341774562567e-09
that O 0 3.919894131509949e-10
ATM O 0 9.176271476007969e-08
acts O 0 6.476145841816106e-08
as O 0 1.5804204167579883e-08
a O 0 7.36635513476358e-07
tumour B-Disease 1 1.0
suppressor O 0 0.005972242448478937
. O 0 1.331969428974844e-06

As O 0 2.547143935771601e-07
constitutional O 0 9.83505543672436e-08
DNA O 0 4.489773459681601e-07
was O 0 3.5374824847167474e-07
not O 0 5.559563365231668e-10
available O 0 2.590091474630185e-10
, O 0 7.5269396271338e-10
a O 0 7.0929266904329324e-09
putative O 0 2.2240792532102205e-05
hereditary O 0 0.2903457283973694
predisposition O 0 0.00016771830269135535
to O 0 2.8539884056044684e-07
T B-Disease 0 0.0008854360785335302
- I-Disease 0 1.1677000657073222e-05
PLL I-Disease 0 8.36387880553957e-06
will O 0 1.6700145266668187e-08
require O 0 2.478952376705479e-09
further O 0 3.2568316932213293e-09
investigation O 0 1.4868780873200649e-08
. O 0 6.7584942087250965e-09
. O 0 6.297533872157146e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.00013916112948209047
kinase O 0 5.9157922805752605e-05
is O 0 3.602353260134805e-08
involved O 0 5.070826869513212e-09
in O 0 6.593939283483508e-10
the O 0 8.308932986089701e-10
modulation O 0 3.795080516511007e-08
of O 0 6.528551588225184e-10
the O 0 9.503594355919631e-09
Ca2 O 0 1.1238045772188343e-05
+ O 0 1.1073148016293999e-05
homeostasis O 0 0.0001349073281744495
in O 0 4.5140004090171715e-07
skeletal O 0 0.027630051597952843
muscle O 0 0.00011753223952837288
cells O 0 3.7514359974011313e-06
. O 0 3.636990868471912e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9968144297599792
DM B-Disease 1 1.0
) O 0 1.8478732499715989e-06
, O 0 1.0643318226755127e-08
the O 0 1.661419779530604e-09
most O 0 1.1159122514925457e-08
prevalent O 0 2.6735200663097203e-05
muscular B-Disease 1 0.8313013315200806
disorder I-Disease 0 0.00027478431002236903
in O 0 7.156387926698926e-09
adults O 0 7.153400929382769e-07
, O 0 5.309722883595214e-09
is O 0 8.513054261527486e-09
caused O 0 2.4882528038006058e-08
by O 0 7.526193557261251e-10
( O 0 8.093226533389952e-09
CTG O 0 1.1393440217943862e-06
) O 0 4.929684660481826e-09
n O 0 2.522871795918036e-07
- O 0 1.6172269852177124e-06
repeat O 0 2.2574646152406785e-07
expansion O 0 5.661967783510136e-09
in O 0 4.658142760405326e-10
a O 0 1.145809558344979e-09
gene O 0 2.7576877670298927e-08
encoding O 0 2.446010860523984e-08
a O 0 3.098695344760927e-08
protein O 0 8.367480859305942e-07
kinase O 0 3.901905074599199e-05
( O 0 2.1337443456559413e-07
DM B-Disease 1 0.9999979734420776
protein O 0 1.8678323385756812e-06
kinase O 0 8.522953976353165e-06
; O 0 9.18190892207349e-08
DMPK O 0 6.150329681986477e-06
) O 0 3.347088828320466e-09
and O 0 3.83278020432698e-10
involves O 0 1.4594455644001414e-09
changes O 0 2.4016202360144234e-09
in O 0 2.7858964024574107e-09
cytoarchitecture O 0 1.0767215599116753e-06
and O 0 4.52337332035313e-08
ion O 0 4.218316917103948e-06
homeostasis O 0 0.0001076226108125411
. O 0 7.421680834340805e-07

To O 0 1.2404831295498298e-07
obtain O 0 5.526466395622265e-08
clues O 0 3.753600879008445e-07
to O 0 1.4524235147916897e-08
the O 0 2.60830690379521e-09
normal O 0 1.1212461181742128e-08
biological O 0 7.471759211341578e-09
role O 0 7.134118629181785e-09
of O 0 1.2732692677985824e-09
DMPK O 0 1.119594003284874e-06
in O 0 2.0698089908677275e-09
cellular O 0 5.107462186515477e-08
ion O 0 1.8191279593793297e-07
homeostasis O 0 3.0160103960952256e-06
, O 0 3.141842697118591e-08
we O 0 1.050161735349775e-08
have O 0 2.2299224688993036e-09
compared O 0 2.3626871570314734e-09
the O 0 1.0365357461239455e-09
resting O 0 1.6682882630902895e-07
[ O 0 1.7988137201996324e-08
Ca2 O 0 2.917723520567961e-07
+ O 0 5.351084837457165e-07
] O 0 1.2048294593114406e-06
i O 0 4.434276377196511e-07
, O 0 5.615395926028555e-10
the O 0 3.664770709121967e-10
amplitude O 0 8.637653259313538e-09
and O 0 3.6671010672506554e-09
shape O 0 4.477996284890651e-08
of O 0 1.034724306236967e-09
depolarization O 0 9.431887804112193e-08
- O 0 1.7940376437763916e-06
induced O 0 4.0832037484506145e-06
Ca2 O 0 3.0111707474134164e-06
+ O 0 8.906592938728863e-07
transients O 0 1.1475047358544543e-05
, O 0 1.3986455549286347e-08
and O 0 5.319119367186431e-09
the O 0 7.53512752194041e-10
content O 0 7.330275497707817e-09
of O 0 2.5479424126118033e-10
ATP O 0 5.1766249953288934e-08
- O 0 1.2648629308387171e-06
driven O 0 2.945876076410059e-07
ion O 0 9.720250915279394e-08
pumps O 0 1.873811328323427e-07
in O 0 4.3753045630978704e-09
cultured O 0 1.7992069842875935e-06
skeletal O 0 6.852231308585033e-05
muscle O 0 8.958521675594966e-07
cells O 0 2.0243902554284432e-08
of O 0 4.4048101277560647e-10
wild O 0 3.683443239310691e-08
- O 0 1.3436651897791307e-06
type O 0 6.746596170614794e-08
and O 0 1.844874475409597e-08
DMPK O 0 1.5977838074832107e-06
[ O 0 5.142035419680724e-08
- O 0 1.2319328561716247e-06
/ O 0 4.320786047173897e-06
- O 0 4.2008734453702345e-05
] O 0 3.869168267556233e-06
knockout O 0 5.56900558876805e-05
mice O 0 0.00021467106125783175
. O 0 5.757147505391913e-07

In O 0 1.4623800552726607e-06
vitro O 0 1.612780943105463e-05
- O 0 3.28988280671183e-05
differentiated O 0 6.730479981342796e-06
DMPK O 0 3.203339656465687e-05
[ O 0 6.268526249186834e-07
- O 0 3.050816985705751e-06
/ O 0 2.975788675030344e-06
- O 0 7.313907644856954e-06
] O 0 2.671739878223889e-07
myotubes O 0 2.5322316332676564e-07
exhibit O 0 4.0595850236968545e-08
a O 0 9.193558803133328e-09
higher O 0 9.48819867119255e-09
resting O 0 1.4426338168505026e-07
[ O 0 3.183009056328956e-08
Ca2 O 0 5.390533033278189e-07
+ O 0 1.264657953470305e-06
] O 0 9.942856422640034e-07
i O 0 2.0650392684729013e-07
than O 0 1.068242272417308e-09
do O 0 1.1009437805853395e-09
wild O 0 7.540177371367918e-09
- O 0 8.883196755959943e-07
type O 0 1.207598927521758e-07
myotubes O 0 1.230949806085846e-06
because O 0 1.7260322060508315e-09
of O 0 9.358386288127463e-11
an O 0 1.5064678671183884e-10
altered O 0 2.887123855543905e-07
open O 0 5.655397572468246e-08
probability O 0 3.860795239063464e-09
of O 0 1.1849535797026078e-09
voltage O 0 1.9081865048065083e-06
- O 0 1.7786695707400213e-06
dependent O 0 1.2331982190971758e-07
l O 0 4.6538048081856687e-07
- O 0 3.513975741498143e-07
type O 0 1.6876732900072966e-07
Ca2 O 0 1.5616765267623123e-06
+ O 0 7.700667197241273e-07
and O 0 4.646009088560277e-08
Na O 0 3.6057433590030996e-06
+ O 0 2.5744618596945656e-06
channels O 0 2.9754055503872223e-06
. O 0 6.555346772074699e-07

The O 0 4.039299597025092e-07
mutant O 0 5.004405920772115e-06
myotubes O 0 7.870160516176838e-06
exhibit O 0 3.356546471877664e-07
smaller O 0 5.1232198927664285e-08
and O 0 9.559770752787244e-09
slower O 0 3.469977514214406e-07
Ca2 O 0 2.4813011805235874e-06
+ O 0 6.51895163628069e-07
responses O 0 3.9782801053434014e-08
upon O 0 2.1620407686384624e-09
triggering O 0 5.3091280705075405e-08
by O 0 1.0463563349105698e-09
acetylcholine O 0 1.170695554719714e-06
or O 0 6.002951380423838e-08
high O 0 6.005092956229419e-08
external O 0 4.4324369241621753e-07
K O 0 2.1387345441326033e-06
+ O 0 3.0343940125021618e-06
. O 0 3.518764799537166e-07

In O 0 2.38047263678709e-07
addition O 0 4.5335998066775574e-08
, O 0 1.3495742301472546e-08
we O 0 2.9761109132664387e-09
observed O 0 6.207576230821132e-09
that O 0 3.1580310588807947e-10
these O 0 1.2697405349371138e-09
Ca2 O 0 2.804558107527555e-06
+ O 0 6.659303835476749e-06
transients O 0 0.00022454564168583602
partially O 0 7.631610060343519e-06
result O 0 8.865896461429656e-09
from O 0 2.571931001504879e-10
an O 0 1.480201516912416e-10
influx O 0 1.1624556872646963e-09
of O 0 3.065911136079791e-10
extracellular O 0 3.154380223691078e-08
Ca2 O 0 1.286171936953906e-06
+ O 0 2.6254389240421006e-07
through O 0 3.751165156273828e-09
the O 0 4.078092530335198e-09
l O 0 3.2167147878681135e-07
- O 0 3.8611770492025244e-07
type O 0 1.9570015297176724e-07
Ca2 O 0 3.7395234357973095e-06
+ O 0 4.003944013675209e-06
channel O 0 2.631760435178876e-05
. O 0 8.622231462140917e-07

Neither O 0 1.240023357240716e-05
the O 0 5.0626923098207044e-08
content O 0 2.2163912660744245e-07
nor O 0 1.7322134837627345e-08
the O 0 7.957238756794993e-10
activity O 0 4.121947227986311e-09
of O 0 9.82585901532218e-10
Na O 0 1.3899858686272637e-06
+ O 0 1.5690003465351765e-06
/ O 0 1.7810119743444375e-06
K O 0 1.3425418501356035e-06
+ O 0 1.2179438044768176e-06
ATPase O 0 8.042346962611191e-06
and O 0 4.55815921895919e-07
sarcoplasmic O 0 4.461741627892479e-05
reticulum O 0 6.361318082781509e-05
Ca2 O 0 3.702209869516082e-05
+ O 0 4.251579866831889e-06
- O 0 2.966879492305452e-06
ATPase O 0 1.46488696373126e-06
are O 0 9.481577301073685e-09
affected O 0 1.8808236745826434e-08
by O 0 4.862281688389203e-09
DMPK O 0 3.1369170756079257e-05
absence O 0 1.0528069651627447e-06
. O 0 3.095275360465166e-07

In O 0 5.73820386762236e-07
conclusion O 0 6.972010879735535e-08
, O 0 3.4196074860659564e-09
our O 0 2.1401886929339753e-09
data O 0 5.8556421933531055e-09
suggest O 0 4.761493421767682e-09
that O 0 1.2173790864267175e-09
DMPK O 0 2.1108342025399907e-06
is O 0 1.6708899819306566e-09
involved O 0 3.8999750651136367e-10
in O 0 2.9816207836041997e-10
modulating O 0 3.534355386136667e-08
the O 0 2.010467570201513e-09
initial O 0 4.542894060932667e-09
events O 0 3.679677673673609e-09
of O 0 8.371832671549839e-10
excitation O 0 1.8380576705112617e-07
- O 0 0.0023776281159371138
contraction O 0 3.224748797947541e-05
coupling O 0 1.332754777649825e-06
in O 0 3.293885342259273e-08
skeletal O 0 0.0005449971067719162
muscle O 0 1.5517918654950336e-05
. O 0 3.871459597348803e-08
. O 0 1.2944715876983537e-07

Constitutional O 0 7.630260370206088e-05
RB1 O 0 0.004059617407619953
- O 0 8.200991578632966e-05
gene O 0 1.2244645404280163e-05
mutations O 0 8.887214789865538e-06
in O 0 2.0029132130616745e-08
patients O 0 9.751057916673744e-08
with O 0 1.4935377379288184e-08
isolated O 0 2.446692087687552e-05
unilateral B-Disease 0 0.00012259541836101562
retinoblastoma I-Disease 0 0.002373629715293646
. O 0 3.6208812161930837e-06

In O 0 8.062797292041068e-07
most O 0 3.12035517424647e-08
patients O 0 1.0411017825617819e-07
with O 0 3.780189050672789e-09
isolated O 0 2.176539283027523e-06
unilateral B-Disease 0 2.5652234398876317e-05
retinoblastoma I-Disease 0 0.00032223734888248146
, O 0 1.4040546147953137e-07
tumor B-Disease 0 3.371404545760015e-06
development O 0 3.82253917408093e-09
is O 0 1.806342297960839e-09
initiated O 0 1.076015365697458e-08
by O 0 5.406756153902847e-10
somatic O 0 4.692936173000817e-08
inactivation O 0 1.4562190244760131e-06
of O 0 9.131723710531503e-10
both O 0 1.665064752742751e-09
alleles O 0 5.2933948779809725e-08
of O 0 2.662126297181544e-09
the O 0 7.36708614113013e-08
RB1 O 0 0.0002489836188033223
gene O 0 6.84437600284582e-06
. O 0 9.643592875363538e-07

However O 0 1.976410885617952e-06
, O 0 6.509121242004312e-09
some O 0 2.4916743668335073e-10
of O 0 2.0434164083038553e-10
these O 0 2.108664354238954e-09
patients O 0 1.4254290192639019e-08
can O 0 1.2845297270303035e-08
transmit O 0 5.445683655125322e-06
retinoblastoma B-Disease 0 3.5596793168224394e-05
predisposition O 0 0.0002015755308093503
to O 0 1.8215565944501577e-07
their O 0 3.226789715427003e-07
offspring O 0 1.54451590788085e-05
. O 0 2.265180825133939e-07

To O 0 1.2527868875622516e-07
determine O 0 1.414910943964287e-08
the O 0 2.1251664872323772e-09
frequency O 0 2.0043391657509346e-07
and O 0 1.3220910588529478e-08
nature O 0 5.72104363882886e-09
of O 0 7.703202520303876e-10
constitutional O 0 2.2780078268169746e-07
RB1 O 0 0.0002360174257773906
- O 0 1.1222815373912454e-05
gene O 0 2.100398205584497e-06
mutations O 0 1.6392970110246097e-06
in O 0 8.626523495536276e-09
patients O 0 2.536008203435358e-08
with O 0 2.672871923792286e-09
isolated O 0 1.6764570318628103e-06
unilateral B-Disease 0 5.078750746179139e-06
retinoblastoma I-Disease 0 1.5997529771993868e-05
, O 0 1.329109799996786e-08
we O 0 2.476674421103553e-09
analyzed O 0 1.577435959632112e-08
DNA O 0 7.734259099834162e-08
from O 0 2.0666846012318274e-09
peripheral O 0 4.532326329353964e-06
blood O 0 2.467680133122485e-06
and O 0 7.071518837165058e-08
from O 0 3.628959177603974e-08
tumor B-Disease 0 4.4221691496204585e-05
tissue O 0 1.764881562849041e-05
. O 0 2.8224286552358535e-07

The O 0 2.633325379974849e-07
analysis O 0 1.813560572827555e-07
of O 0 3.1865141636444605e-08
tumors B-Disease 1 1.0
from O 0 1.615765121698587e-08
54 O 0 1.749994140709532e-07
( O 0 5.497908794893647e-09
71 O 0 5.216071841118719e-08
% O 0 1.3951729771477517e-09
) O 0 3.2830374530057327e-10
of O 0 3.3983243996615897e-10
76 O 0 9.184921623273112e-08
informative O 0 1.1446347798482748e-06
patients O 0 6.704200927742932e-07
showed O 0 1.0162754733755719e-05
loss O 0 4.87150231265332e-08
of O 0 2.8262401308154494e-09
constitutional O 0 6.903031248839397e-07
heterozygosity O 0 0.0012835781089961529
( O 0 1.1485909681141493e-06
LOH O 1 0.9999817609786987
) O 0 6.957225195947103e-08
at O 0 6.505933924927376e-08
intragenic O 0 1.0882074093387928e-05
loci O 0 7.703812116233166e-06
. O 0 2.92023742076708e-07

Three O 0 1.0279087518938468e-06
of O 0 2.3186034425748403e-08
13 O 0 2.456878007706109e-07
uninformative O 0 7.196648948593065e-05
patients O 0 2.230652398793609e-06
had O 0 4.501250145949598e-07
constitutional O 0 2.8573435884027276e-07
deletions O 0 7.065678801154718e-05
. O 0 1.1462689144536853e-06

For O 0 7.78211187935085e-07
39 O 0 2.238289880551747e-06
randomly O 0 1.1927384093723958e-06
selected O 0 2.3780567062203772e-06
tumors B-Disease 1 1.0
, O 0 6.51168150511694e-08
SSCP O 0 1.1725945114449132e-05
, O 0 1.4692415284400795e-08
hetero O 0 1.5440433571711765e-06
- O 0 5.086822625344212e-07
duplex O 0 5.25854375155177e-06
analysis O 0 1.9110727222937385e-08
, O 0 6.539643271352702e-10
sequencing O 0 8.616936497674033e-09
, O 0 2.0571317982387427e-09
and O 0 3.424718286737516e-09
Southern O 0 1.5651155038653997e-08
blot O 0 5.736300863645738e-06
analysis O 0 1.4658713354265274e-08
were O 0 5.309287232080351e-09
used O 0 2.552958955348572e-09
to O 0 3.0911848636350214e-09
identify O 0 3.46381142435348e-07
mutations O 0 2.4589692202425795e-06
. O 0 1.5557202459604014e-07

Mutations O 0 0.00024121759633999318
were O 0 2.0397976641106652e-07
detected O 0 7.399730606039157e-08
in O 0 1.772256119636495e-09
21 O 0 4.630182814935324e-08
( O 0 4.295026112544065e-09
91 O 0 2.9119709310521102e-08
% O 0 2.824370071152771e-09
) O 0 2.3222579415005384e-09
of O 0 1.1718372938673838e-08
23 O 0 0.0027308575809001923
tumors B-Disease 1 1.0
with O 0 4.619434548658319e-05
LOH O 1 1.0
. O 0 4.10577285947511e-06

In O 0 5.017510034122097e-07
6 O 0 3.481795260995568e-07
( O 0 1.830349916076557e-08
38 O 0 9.214259932832647e-08
% O 0 2.9472224660764823e-09
) O 0 1.1387180087751858e-09
of O 0 5.2908686321018195e-09
16 O 0 7.38623712095432e-05
tumors B-Disease 1 1.0
without O 0 5.406379273154016e-07
LOH O 1 0.9999268054962158
, O 0 1.2000225702024636e-08
one O 0 5.0500745807369185e-09
mutation O 0 4.3949707873025545e-08
was O 0 1.5061367264479486e-07
detected O 0 9.81069874228524e-08
, O 0 1.3373252505388677e-09
and O 0 1.193989906944637e-09
in O 0 1.4742093101816067e-09
9 O 0 3.803196335638859e-08
( O 0 2.970723000927933e-09
56 O 0 2.1859339227603414e-08
% O 0 8.638538773197979e-10
) O 0 4.679863163659093e-10
of O 0 1.1766161378545803e-09
the O 0 5.338119535736041e-06
tumors B-Disease 1 1.0
without O 0 1.09338975562423e-06
LOH O 1 0.9999682903289795
, O 0 1.7647080241545154e-08
both O 0 3.111521929000105e-09
mutations O 0 2.5508975909360743e-07
were O 0 1.6343870257173876e-08
found O 0 7.497487786167767e-08
. O 0 1.1304555869173782e-07

Thus O 0 2.3627483187738108e-06
, O 0 1.598372989519703e-08
a O 0 3.6203360309627897e-09
total O 0 1.5372773054522781e-09
of O 0 6.116616102502803e-10
45 O 0 3.1634300512450864e-08
mutations O 0 1.3915732210989518e-07
were O 0 2.3190235509673585e-08
identified O 0 1.055523398463265e-06
in O 0 7.353285127464915e-07
tumors B-Disease 1 1.0
of O 0 2.115974062633086e-08
36 O 0 1.6565102214372018e-06
patients O 0 5.637788262902177e-07
. O 0 1.6634712096674775e-07

Thirty O 0 4.5695178414462134e-05
- O 0 4.874209116678685e-05
nine O 0 1.7527818840790133e-07
of O 0 9.473113404823152e-10
the O 0 1.6524411838858555e-09
mutations O 0 6.110861505703724e-08
- O 0 6.73783873139655e-08
including O 0 1.4988477126109956e-09
34 O 0 1.6981974937380073e-08
small O 0 2.5632005407061342e-09
mutations O 0 1.6326602292338066e-07
, O 0 1.0199422417755954e-09
2 O 0 3.754507815756369e-09
large O 0 1.5943317777100674e-09
structural O 0 3.599956528432813e-07
alterations O 0 1.5243165307765594e-06
, O 0 4.454041135915077e-09
and O 0 5.092285704222377e-09
hypermethylation O 0 4.992088634026004e-06
in O 0 2.4211594507050904e-08
3 O 0 2.3015397800918436e-06
tumors O 1 1.0
- O 0 0.006591607816517353
were O 0 2.6542697924014647e-06
not O 0 8.22683965395754e-09
detected O 0 4.3240028446689394e-08
in O 0 6.260485463371879e-10
the O 0 1.5176846446252057e-09
corresponding O 0 1.7342697944400243e-08
peripheral O 0 4.1957732719311025e-06
blood O 0 1.3142588386472198e-06
DNA O 0 2.3419609078700887e-06
. O 0 2.620106158701674e-07

In O 0 5.172668124941993e-07
6 O 0 6.556285256920091e-07
( O 0 3.979539542342536e-08
17 O 0 4.996452673822205e-08
% O 0 2.5448838592012635e-09
) O 0 5.828272864327744e-10
of O 0 1.4548175164552646e-10
the O 0 4.272834530638647e-09
36 O 0 2.04844724294162e-07
patients O 0 4.570898326505812e-09
, O 0 2.247693836610054e-10
a O 0 2.347342986652734e-09
mutation O 0 9.853305726892359e-08
was O 0 1.1697832036361433e-07
detected O 0 1.8765879516990935e-08
in O 0 3.6829758687240144e-10
constitutional O 0 7.069775875834239e-09
DNA O 0 1.8884429664467461e-07
, O 0 2.2694668366796122e-09
and O 0 1.4133754167033885e-09
1 O 0 8.208810298171443e-10
of O 0 7.88425019715433e-11
these O 0 1.4827566952035909e-09
mutations O 0 9.78349135039025e-08
is O 0 2.2389021747670768e-09
known O 0 8.317959654391416e-09
to O 0 4.042499668344135e-09
be O 0 4.540849474210518e-09
associated O 0 3.6006202464022863e-09
with O 0 9.224983443800738e-09
reduced O 0 7.727297770543373e-07
expressivity O 0 0.0002425818529445678
. O 0 9.230827799910912e-07

The O 0 1.7938582175247575e-07
presence O 0 2.5911910839226948e-08
of O 0 6.665319962628757e-10
a O 0 3.5905458606322327e-09
constitutional O 0 4.8926679596661415e-08
mutation O 0 1.7902964373206487e-06
was O 0 7.630656000401359e-06
not O 0 5.569128713744931e-09
associated O 0 2.2144859279649154e-09
with O 0 6.847529765430238e-10
an O 0 1.13973486204344e-09
early O 0 1.1172907221634887e-07
age O 0 3.0399032624472966e-08
at O 0 1.1920132436671338e-08
treatment O 0 1.4021904348737735e-07
. O 0 1.1205452210560907e-07

In O 0 1.2114219316572417e-06
1 O 0 6.44595331777964e-07
patient O 0 8.33915237308247e-07
, O 0 1.6336796804239384e-08
somatic O 0 1.2903342394565698e-06
mosaicism O 0 0.00028606673004105687
was O 0 5.888960913580377e-06
demonstrated O 0 1.681931749430987e-08
by O 0 1.6217654996708575e-10
molecular O 0 6.381640549335543e-09
analysis O 0 3.9462650924804166e-09
of O 0 9.75430514138509e-10
DNA O 0 1.7037527300090005e-07
and O 0 1.5800708297319943e-08
RNA O 0 3.6465138464336633e-07
from O 0 1.436197827331398e-08
peripheral O 0 1.183586755360011e-05
blood O 0 8.076487574726343e-06
. O 0 5.170147687749704e-07

In O 0 5.234479658611235e-07
2 O 0 6.659531095465354e-07
patients O 0 1.6866147234395612e-07
without O 0 5.012093851064492e-09
a O 0 1.1331567684180754e-08
detectable O 0 2.5923534394678427e-06
mutation O 0 3.831783033092506e-07
in O 0 6.988250866868384e-09
peripheral O 0 4.142086618230678e-05
blood O 0 6.0662491705443244e-06
, O 0 4.211199922110609e-08
mosaicism O 0 1.896869252959732e-05
was O 0 2.272241545142606e-06
suggested O 0 5.083553844542621e-08
because O 0 8.276160312625791e-10
1 O 0 6.387981810185295e-10
of O 0 2.2641909180887154e-10
the O 0 1.3970405277063946e-08
patients O 0 3.286280332304159e-07
showed O 0 9.18771984288469e-05
multifocal O 1 0.9999512434005737
tumors B-Disease 1 1.0
and O 0 1.4317690784082515e-06
the O 0 3.743402920974859e-09
other O 0 2.1377570824654413e-09
later O 0 4.211352688798797e-08
developed O 0 1.2425017814621242e-07
bilateral B-Disease 0 6.634174951614114e-07
retinoblastoma I-Disease 0 5.2419909479795024e-05
. O 0 8.865085874276701e-07

In O 0 3.209810870430374e-07
conclusion O 0 1.0963826468923799e-07
, O 0 1.602836441350064e-08
our O 0 8.652295768740714e-09
results O 0 4.747183535158683e-09
emphasize O 0 7.547274094577006e-08
that O 0 4.624620242310584e-09
the O 0 1.2823307971032705e-09
manifestation O 0 7.5666747534342e-08
and O 0 5.850808282303888e-09
transmissibility O 0 2.9667191370208457e-07
of O 0 4.468436176630064e-10
retinoblastoma B-Disease 0 2.6551609266789455e-07
depend O 0 9.06503760944588e-09
on O 0 8.260255413006234e-08
the O 0 4.548954990468701e-09
nature O 0 6.6843179880038406e-09
of O 0 1.3291870382126092e-10
the O 0 7.458200723675645e-10
first O 0 6.429239807204112e-09
mutation O 0 1.0675012873662126e-08
, O 0 4.800776443047994e-10
its O 0 5.26586774185489e-10
time O 0 2.46754594535048e-09
in O 0 2.1494044044612082e-10
development O 0 3.128068637447967e-10
, O 0 1.193065757298939e-09
and O 0 2.839673163279599e-09
the O 0 2.555301248374775e-10
number O 0 1.6117934764636743e-09
and O 0 1.2023612105949155e-09
types O 0 1.2573747598665364e-09
of O 0 2.807910848279249e-10
cells O 0 5.457704954636711e-09
that O 0 1.1188037163378795e-09
are O 0 4.704797662569149e-10
affected O 0 6.476822633771917e-09
. O 0 5.169656258630084e-09
. O 0 6.404897590073233e-08

Hereditary B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999897480010986
of I-Disease 0 4.922405949514541e-08
the I-Disease 0 1.3181076674584347e-08
fifth I-Disease 0 8.612722695033881e-07
component I-Disease 0 5.82504462443012e-08
of I-Disease 0 1.589312903504947e-09
complement I-Disease 0 9.090008035173014e-08
in O 0 3.8302768956555155e-08
man O 0 4.864277070737444e-05
. O 0 2.126729299334329e-07

I O 0 0.002871693577617407
. O 0 5.570805569732329e-06

Clinical O 0 9.606099047232419e-05
, O 0 3.680887346035888e-07
immunochemical O 0 1.7846467017079704e-05
, O 0 3.724659691783927e-08
and O 0 1.766465906882786e-08
family O 0 6.034543531541203e-08
studies O 0 4.6078401538807157e-08
. O 0 1.12687231990094e-07

The O 0 2.525625859561842e-07
first O 0 3.539874171565316e-08
recognized O 0 3.99172570553219e-08
human O 0 4.5826855199493366e-08
kindred O 0 0.00030641217017546296
with O 0 4.135747440159321e-05
hereditary B-Disease 1 1.0
deficiency I-Disease 1 0.984320878982544
of I-Disease 0 3.860699315794136e-09
the I-Disease 0 2.652669728320234e-08
fifth I-Disease 0 1.6578899248997914e-06
component I-Disease 0 8.090528069715219e-08
of I-Disease 0 3.1648283993490622e-09
complement I-Disease 0 7.223408147183363e-07
( O 0 9.392339705982522e-08
C5 O 0 4.615128636942245e-05
) O 0 1.9481074531313425e-08
is O 0 1.851692310594899e-08
described O 0 4.757465035254427e-07
. O 0 3.3902551876963116e-07

The O 0 5.004148988518864e-07
proband O 0 6.02953741690726e-06
, O 0 2.04445154139421e-08
a O 0 8.12901035374125e-09
20 O 0 2.010058430812478e-08
- O 0 9.740422228787793e-07
year O 0 2.9805661938553385e-08
- O 0 3.4990289350389503e-06
old O 0 9.995430445997044e-06
black O 0 2.3544121177110355e-06
female O 0 1.5921345948299859e-06
with O 0 2.539881961638457e-06
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9999784231185913
erythematosus I-Disease 1 1.0
since O 0 3.2321070193574997e-06
age O 0 1.5235390549150907e-07
11 O 0 3.2881164457876366e-08
, O 0 8.916518190460465e-09
lacked O 0 4.2661264387788833e-07
serum O 0 2.2118290416983655e-06
hemolytic O 0 2.5242261472158134e-05
complement O 0 6.236726335373532e-08
activity O 0 7.987902250761181e-08
, O 0 3.2413078887572055e-09
even O 0 1.0286895779643146e-08
during O 0 4.672955000728507e-08
remission O 0 1.6710266663721995e-06
. O 0 1.1176700098758374e-07

C5 O 0 0.1568949818611145
was O 0 3.541510159266181e-05
undetectable O 0 6.435016985051334e-06
in O 0 2.2163968438349002e-08
her O 0 3.359643585554295e-07
serum O 0 6.668084893135529e-07
by O 0 2.0554180579779313e-09
both O 0 6.968564836284941e-09
immunodiffusion O 0 1.9400151359150186e-05
and O 0 3.9114928540584515e-07
hemolytic O 0 0.0011659095762297511
assays O 0 3.3906686439877376e-05
. O 0 9.926749271471635e-07

Other O 0 8.409802632058927e-08
complement O 0 1.0130565186727836e-07
components O 0 1.2423785733517434e-07
were O 0 1.6931521074070588e-08
normal O 0 4.20033856585178e-08
during O 0 2.131146636941139e-08
remission O 0 1.8860437478451786e-07
of O 0 7.990138328750618e-09
lupus O 0 0.0005445998394861817
, O 0 1.582245268139104e-08
but O 0 8.776154025724736e-09
C1 O 0 2.105295607179869e-06
, O 0 4.960300614698099e-09
C4 O 0 1.418157921762031e-06
, O 0 3.88234475678928e-08
C2 O 0 7.559753157693194e-06
, O 0 6.42258379812688e-09
and O 0 1.5008138731786858e-08
C3 O 0 1.7262495020986535e-05
levels O 0 1.7345814740110654e-07
fell O 0 7.81125982030062e-06
during O 0 9.927669708531539e-08
exacerbations O 0 0.00013241797569207847
. O 0 4.0861110051082505e-07

A O 0 1.1226316019019578e-05
younger O 0 8.577168955525849e-06
half O 0 2.4138606136148155e-07
- O 0 9.283371582569089e-06
sister O 0 3.476227357168682e-05
, O 0 4.187459978766128e-08
who O 0 1.4859176644677063e-06
had O 0 3.904124241671525e-06
no O 0 1.21155323995481e-07
underlying O 0 4.220932623866247e-06
disease O 0 1.3958232557342853e-05
, O 0 2.7605823404996954e-08
was O 0 3.680224153868039e-06
also O 0 6.672525643125482e-08
found O 0 1.572563412821637e-08
to O 0 1.4896571087774646e-08
lack O 0 8.424251518590609e-08
immunochemically O 0 2.18019777094014e-05
detectable O 0 2.4059594579739496e-05
C5 O 0 7.8743883932475e-05
. O 0 4.3843124331033323e-07

By O 0 1.3587532521341927e-06
hemolytic O 0 0.0005615534610114992
assay O 0 1.0421192200738005e-05
, O 0 1.2124293391480023e-07
she O 0 2.4264926423711586e-07
exhibited O 0 7.909520149951277e-08
1 O 0 9.060284078543646e-09
- O 0 6.600274673473905e-07
2 O 0 4.136866849080434e-08
% O 0 7.668385926251631e-10
of O 0 1.1885453732318751e-10
the O 0 5.834548844063647e-09
normal O 0 1.2340653654518974e-07
serum O 0 1.1453226989033283e-06
C5 O 0 8.293696737382561e-06
level O 0 1.8719406469358546e-08
and O 0 1.8392029010882993e-09
normal O 0 2.243433216975177e-09
concentrations O 0 9.705852122010583e-09
of O 0 2.8747015878849425e-10
other O 0 4.680041354454545e-10
complement O 0 6.861615986508696e-08
components O 0 3.3282600497841486e-07
. O 0 2.8582539357557835e-07

C5 O 0 0.005131819751113653
levels O 0 6.345521796902176e-07
of O 0 1.7925518847050625e-09
other O 0 8.119414030005601e-10
family O 0 1.1349911233082821e-08
members O 0 1.8593927508803176e-09
were O 0 4.314354207224369e-09
either O 0 9.0726443024991e-10
normal O 0 5.396610713859218e-09
or O 0 3.799025538597789e-09
approximately O 0 2.158262457641058e-09
half O 0 1.1196561011672657e-08
- O 0 8.490791287840693e-07
normal O 0 5.262880975465123e-08
, O 0 2.9695899073090004e-09
consistent O 0 3.0067631939800776e-08
with O 0 1.4067063958123072e-08
autosomal O 0 3.8950383896008134e-05
codominant O 0 7.978391295182519e-06
inheritance O 0 5.045283160143299e-07
of O 0 3.586911212494215e-09
the O 0 2.4067849935249797e-08
gene O 0 3.960488174925558e-05
determining O 0 0.0017075155628845096
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.4661716199479997e-06

Normal O 0 0.00016100142966024578
hemolytic O 0 0.01914578303694725
titers O 0 0.0017843216191977262
were O 0 3.08960625261534e-06
restored O 0 6.025854872859782e-07
to O 0 3.1150271695423726e-08
both O 0 2.846659867827839e-07
homozygous O 1 0.9456945657730103
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 6.991464942984749e-06
C5D B-Disease 1 1.0
) O 0 1.679351981920263e-07
sera O 0 2.854750164260622e-06
by O 0 7.446573357938746e-10
addition O 0 9.365355158053035e-10
of O 0 9.879305151727635e-10
highly O 0 5.73828096150919e-08
purified O 0 6.922624038452341e-07
human O 0 2.441630044813792e-07
C5 O 0 0.00011969805927947164
. O 0 7.467651244041917e-07

In O 0 3.7248625517349865e-07
specific O 0 2.160786891636235e-07
C5 O 0 3.5710898373508826e-05
titrations O 0 1.1810667274403386e-05
, O 0 4.256421703985325e-08
however O 0 8.583587174371132e-09
, O 0 2.1786985548999382e-09
it O 0 1.433570595565925e-08
was O 0 1.7557458704686724e-06
noted O 0 2.1663884908207365e-08
that O 0 9.883659446430215e-10
when O 0 6.567769106347043e-10
limited O 0 3.554227190338821e-10
amounts O 0 2.202555221542113e-10
of O 0 3.296886375014907e-10
C5 O 0 4.840806468564551e-06
were O 0 1.4807027604035738e-08
assayed O 0 8.594764722147374e-08
in O 0 2.1425168306166142e-09
the O 0 8.26764101624633e-10
presence O 0 5.357372323544496e-09
of O 0 8.145877306020566e-10
low O 0 1.1541961697503211e-07
dilutions O 0 2.413500169495819e-06
of O 0 8.33077251627401e-09
either O 0 4.0550972357777937e-07
C5D B-Disease 1 1.0
serum O 0 5.016868271923158e-06
, O 0 3.162903494668967e-09
curving O 0 1.303380656736408e-07
rather O 0 3.780232571415354e-09
than O 0 4.4242520758075443e-10
linear O 0 3.770424861215815e-09
dose O 0 2.6338744518739077e-08
- O 0 1.1294759616475858e-07
response O 0 1.1906634789227155e-08
plots O 0 5.816451675855205e-07
were O 0 3.6327790553514205e-07
consistently O 0 4.682626979501947e-07
obtained O 0 2.4270627729805483e-09
, O 0 8.536235607259357e-10
suggesting O 0 6.2392939703670436e-09
some O 0 6.594342294441446e-10
inhibitory O 0 9.016998347988192e-08
effect O 0 1.9252172478445573e-07
. O 0 1.0004751516135002e-07

Further O 0 1.243188535227091e-06
studies O 0 1.0184734833273978e-07
suggested O 0 1.1566621793690501e-07
that O 0 5.643111311570692e-09
low O 0 1.3403499110609118e-07
dilutions O 0 4.860358239966445e-05
of O 0 1.1321548498699485e-07
C5D B-Disease 1 1.0
serum O 0 2.440187472529942e-06
contain O 0 7.590102768517681e-09
a O 0 3.6219385268765336e-09
factor O 0 1.3351289851470938e-08
( O 0 1.4746818211008872e-09
or O 0 8.519190353162287e-10
factors O 0 1.4839817152889623e-09
) O 0 8.419199226672447e-10
interfering O 0 6.400815877327659e-09
at O 0 3.8689558223836684e-09
some O 0 2.209405020048294e-10
step O 0 3.870446185771925e-09
in O 0 6.762604365384561e-10
the O 0 4.4336139204403935e-09
hemolytic O 0 8.342162800545339e-06
assay O 0 2.889737800160219e-07
of O 0 6.2982641324538235e-09
C5 O 0 2.6510153475101106e-05
, O 0 3.777385515491005e-09
rather O 0 2.454552783248687e-09
than O 0 4.982856904867106e-10
a O 0 5.986917628320043e-09
true O 0 6.697401744304443e-08
C5 O 0 8.584149327361956e-06
inhibitor O 0 9.820150808081962e-07
or O 0 8.665974604582516e-08
inactivator O 0 1.2634917766263243e-05
. O 0 5.21269043929351e-07

Of O 0 1.8546727176271816e-07
clinical O 0 1.1959459698118735e-06
interest O 0 1.401078435492309e-07
are O 0 1.0021631524637087e-08
( O 0 9.050456384329664e-09
a O 0 6.886275105699724e-09
) O 0 3.059942077499045e-09
the O 0 1.2511260916170386e-09
documentation O 0 6.798304497124263e-08
of O 0 4.402773257083936e-08
membranous O 1 0.9986490607261658
glomerulonephritis B-Disease 1 1.0
, O 0 0.00012940050510223955
vasculitis B-Disease 1 1.0
, O 0 8.89245347934775e-06
and O 0 0.0014957428211346269
arthritis B-Disease 1 1.0
in O 0 3.515476620918889e-08
an O 0 8.675331564234057e-09
individual O 0 3.103711421204025e-08
lacking O 0 3.5888638194592204e-07
C5 O 0 0.00010395705612609163
( O 0 1.362137336258229e-08
and O 0 2.5800146463694773e-09
its O 0 8.135924156604801e-10
biologic O 0 3.007600923865539e-07
functions O 0 6.630719528999407e-09
) O 0 3.2957312434689356e-09
, O 0 1.95505989175615e-09
and O 0 7.549890490565758e-09
( O 0 2.0131611933038585e-09
b O 0 7.763386378201176e-09
) O 0 5.062841257341688e-10
a O 0 1.6373036260119989e-09
remarkable O 0 2.6234760142074265e-08
propensity O 0 1.3117195294398698e-06
to O 0 1.2305703478432406e-07
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 3.684130112091566e-09
the O 0 2.99383429158695e-09
proband O 0 3.499759714031825e-06
, O 0 3.797192782428738e-09
even O 0 3.6807303871455588e-09
during O 0 2.827696077289943e-09
periods O 0 4.178760892870059e-09
of O 0 4.016059984568443e-10
low O 0 4.5536534543089147e-08
- O 0 2.8302181931394443e-07
dose O 0 5.345106757204121e-08
or O 0 2.4218786975893636e-09
alternate O 0 4.835390399193784e-08
- O 0 8.375101060664747e-06
day O 0 3.129340484520071e-07
corticosteroid O 0 7.905409802333452e-06
therapy O 0 5.276709543977631e-06
. O 0 2.471777804657904e-07

Other O 0 1.2905640289773146e-07
observations O 0 3.426733314881858e-07
indicate O 0 2.2658937837150006e-07
that O 0 5.6758295841063955e-09
the O 0 3.1275170897515636e-08
C5D B-Disease 1 1.0
state O 0 9.730189987067206e-09
is O 0 2.6637008154750674e-09
compatible O 0 1.7187661072171068e-08
with O 0 2.1648134396201613e-09
normal O 0 1.960613715823456e-08
coagulation O 0 6.520965456502381e-08
function O 0 9.242119958230433e-09
and O 0 1.0685504037155624e-08
the O 0 1.5963126376306036e-09
capacity O 0 3.1896807417552964e-09
to O 0 6.416067122039237e-10
mount O 0 1.7060843049421237e-07
a O 0 4.2287226165171887e-07
neutrophilic O 0 0.00149624515324831
leukocytosis O 0 0.0015762653201818466
during O 0 1.7234413007827243e-06
pyogenic B-Disease 0 0.0029057664796710014
infection I-Disease 0 0.00015385699225589633
. O 0 9.391838062811075e-08
. O 0 2.3289909734103276e-07

Susceptibility O 1 0.7803267240524292
to O 0 0.00043137665488757193
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.00018419862317387015
twins O 0 0.0014050859026610851
: O 0 1.59988591263982e-08
the O 0 6.548517839100043e-10
role O 0 3.992393526885962e-09
of O 0 6.072235492204925e-10
genes O 0 8.536065365660761e-08
, O 0 1.1458276105713594e-08
HLA O 0 1.6440628314740025e-05
, O 0 1.0777942094364334e-08
and O 0 1.3004251897541508e-08
the O 0 1.2093490653342087e-08
environment O 0 3.6954489246454614e-07
. O 0 1.0973430164540332e-07

OBJECTIVE O 0 5.913745553698391e-06
To O 0 3.001960990900443e-08
determine O 0 7.420347447606446e-09
the O 0 1.1632276253337182e-09
relative O 0 1.6104115374560024e-08
effects O 0 3.9276290664247426e-08
of O 0 6.549005227007854e-10
genetic O 0 2.3648574654089316e-07
and O 0 4.5363566236744646e-09
environmental O 0 2.6139543862768733e-09
factors O 0 1.6934743607421865e-09
in O 0 6.59413146308907e-09
susceptibility O 0 0.0002344508102396503
to O 0 0.0003652078448794782
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0014677855651825666
AS B-Disease 1 0.9999939203262329
) O 0 2.755603816240182e-07
. O 0 2.323728551800741e-07

METHODS O 0 1.1567428373382427e-05
Twins O 0 7.651966734556481e-05
with O 0 2.650061219355848e-07
AS B-Disease 1 0.9999957084655762
were O 0 2.0163986391708022e-07
identified O 0 6.552134124149234e-08
from O 0 7.252684008918209e-10
the O 0 2.6502207095546737e-09
Royal O 0 1.7415365505257796e-07
National O 0 1.0660017757402329e-08
Hospital O 0 4.2881447370746173e-07
for O 0 5.1058457017916226e-08
Rheumatic B-Disease 1 0.9127470254898071
Diseases I-Disease 0 2.828485048667062e-05
database O 0 1.033858779919683e-06
. O 0 3.7435304989230644e-07

Clinical O 0 3.4356122341705486e-05
and O 0 1.9333975842528162e-07
radiographic O 0 1.0035117156803608e-05
examinations O 0 1.110343305299466e-06
were O 0 1.7346607705803763e-07
performed O 0 7.751996378146941e-08
to O 0 2.7002966529465766e-09
establish O 0 7.971662085992648e-08
diagnoses O 0 0.001051944913342595
, O 0 4.778354423251585e-08
and O 0 7.748137704766123e-07
disease O 0 1.1702831216098275e-05
severity O 0 2.255685785712558e-06
was O 0 3.3683696187836176e-07
assessed O 0 8.87332252119677e-09
using O 0 3.4846727725579285e-09
a O 0 9.872113793107928e-09
combination O 0 5.43377609574236e-08
of O 0 5.588409290879781e-09
validated O 0 3.4514462754486885e-07
scoring O 0 5.14640191795479e-07
systems O 0 1.2689927189057926e-06
. O 0 2.4360826955671655e-07

HLA O 0 0.00261473236605525
typing O 0 4.468136830837466e-05
for O 0 8.860101985419533e-08
HLA O 0 3.1195246265269816e-05
- O 0 2.9763732527499087e-06
B27 O 0 1.41547445764445e-06
, O 0 8.631082515364596e-09
HLA O 0 2.351514922338538e-06
- O 0 7.456386015292082e-07
B60 O 0 8.435472409473732e-07
, O 0 4.326995650671961e-09
and O 0 7.071597085683834e-09
HLA O 0 4.235196684021503e-05
- O 0 0.0018579007592052221
DR1 O 1 0.7721073627471924
was O 0 2.4454195681755664e-06
performed O 0 9.757434860091507e-09
by O 0 1.2696213524954203e-10
polymerase O 0 5.67249891503252e-08
chain O 0 1.42054958018889e-07
reaction O 0 2.6318696111360396e-09
with O 0 2.2354573747662698e-10
sequence O 0 8.619583269364739e-09
- O 0 2.1627100110777064e-08
specific O 0 1.1941654332048302e-09
primers O 0 9.32699833811057e-07
, O 0 3.880854748672391e-09
and O 0 4.631841132862746e-09
zygosity O 0 8.772573778514925e-07
was O 0 8.597748291094831e-08
assessed O 0 2.341057658838963e-08
using O 0 4.6832521860551424e-08
microsatellite O 0 3.8941914681345224e-05
markers O 0 0.00015420815907418728
. O 0 7.239145816129167e-07

Genetic O 0 2.8925060178153217e-05
and O 0 4.8300343280516245e-08
environmental O 0 1.964360762940487e-08
variance O 0 1.5006449416432588e-08
components O 0 7.970901805265385e-08
were O 0 3.9301021104165557e-08
assessed O 0 1.6129291680044844e-08
with O 0 1.143968697547848e-09
the O 0 2.0053125826535734e-09
program O 0 6.308603417437553e-09
Mx O 0 2.494735440450313e-07
, O 0 2.735233151085481e-10
using O 0 3.8145619996043933e-10
data O 0 7.780775135302065e-09
from O 0 8.908489501635586e-10
this O 0 4.962985578060852e-10
and O 0 7.82524534059803e-09
previous O 0 9.99517268951422e-09
studies O 0 1.5038704725967023e-09
of O 0 1.1769752950030465e-09
twins O 0 7.463809197361115e-06
with O 0 2.1085433843381907e-07
AS B-Disease 1 0.9999992847442627
. O 0 7.299736921595468e-07

RESULTS O 0 5.0345347517577466e-06
Six O 0 1.9213361213132885e-07
of O 0 1.0120730031815128e-08
8 O 0 7.242632591442089e-07
monozygotic O 0 6.7616616433952e-05
( O 0 8.223233862736379e-07
MZ O 1 0.9992449283599854
) O 0 2.902409619309765e-07
twin O 0 8.840772352414206e-05
pairs O 0 1.5675252143410034e-05
were O 0 3.372185801708838e-06
disease O 0 2.2189001356309745e-06
concordant O 0 1.934633019118337e-06
, O 0 6.59830856619692e-09
compared O 0 5.9559153164912004e-09
with O 0 9.670977352271848e-10
4 O 0 1.330238408314699e-08
of O 0 1.202189237048401e-09
15 O 0 3.758012923071874e-08
B27 O 0 9.248715286958031e-07
- O 0 9.918101568473503e-06
positive O 0 2.3473671717511024e-07
dizygotic O 0 2.465549187036231e-06
( O 0 2.981737523555239e-08
DZ O 0 3.764800203498453e-05
) O 0 1.3130965648144866e-08
twin O 0 1.338721631327644e-06
pairs O 0 2.4725417802073935e-07
( O 0 5.745583120386755e-09
27 O 0 7.342228514062299e-08
% O 0 1.4368684020382716e-09
) O 0 7.014086533807529e-10
and O 0 3.1800282407346003e-09
4 O 0 7.973270932382093e-09
of O 0 1.958347706221275e-09
32 O 0 7.006898385952809e-07
DZ O 0 0.017284870147705078
twin O 0 8.66242844494991e-05
pairs O 0 1.5503778740821872e-06
overall O 0 1.9197570964024635e-06
( O 0 9.198154238276857e-09
12 O 0 1.1005516498130419e-08
. O 0 1.60329116649649e-09
5 O 0 2.0581298443289597e-08
% O 0 6.222026449620444e-09
) O 0 1.4460877828526009e-08
. O 0 1.2200160881548072e-07

Nonsignificant O 0 0.00016315419634338468
increases O 0 9.588496823198511e-07
in O 0 4.6377106599493345e-09
similarity O 0 2.4951868127232046e-08
with O 0 1.1039359426590067e-09
regard O 0 2.0697021874127586e-09
to O 0 4.329290703708466e-09
age O 0 2.9929051237331805e-08
at O 0 3.617252630760959e-08
disease O 0 2.2445531158155063e-06
onset O 0 8.353734415322833e-07
and O 0 1.706770191844953e-08
all O 0 2.3337393129096995e-10
of O 0 3.2508098990469136e-10
the O 0 2.1067599220714328e-08
disease O 0 3.305294058009167e-06
severity O 0 3.111690318746696e-07
scores O 0 2.1315172205049748e-07
assessed O 0 1.0307757492000746e-07
were O 0 3.782924551387623e-08
noted O 0 7.452761252579876e-08
in O 0 1.0098847980088976e-07
disease O 0 3.3518132113385946e-05
- O 0 0.0003099129826296121
concordant O 0 0.012885667383670807
MZ O 1 0.9992724061012268
twins O 0 9.663761738920584e-05
compared O 0 4.560281183785264e-07
with O 0 1.0836487263077288e-07
concordant O 0 0.0013064711820334196
DZ O 1 0.9185614585876465
twins O 0 0.0006670315051451325
. O 0 3.6846033708570758e-06

HLA O 0 0.0021136580035090446
- O 0 0.00013165072596166283
B27 O 0 9.391349522047676e-06
and O 0 3.1811946854531925e-08
B60 O 0 6.460150530074316e-07
were O 0 2.0537534339837293e-08
associated O 0 3.3559872658628365e-09
with O 0 1.3927934361390726e-09
the O 0 2.720023850599773e-08
disease O 0 7.635604220013192e-07
in O 0 2.3333799337166283e-09
probands O 0 4.8983260967361275e-06
, O 0 7.433720305982661e-09
and O 0 1.8241488319858945e-09
the O 0 1.4443449769530048e-09
rate O 0 7.311302852031076e-08
of O 0 1.4925516378383463e-09
disease O 0 6.685518769700138e-07
concordance O 0 7.149554903662647e-07
was O 0 3.0788390859015635e-07
significantly O 0 1.0648133752511058e-07
increased O 0 1.4358636946099068e-08
among O 0 3.793110270322586e-09
DZ O 0 0.0009527062065899372
twin O 0 2.9766184525215067e-05
pairs O 0 6.714643632221851e-07
in O 0 2.2828743340141955e-08
which O 0 4.634149775029073e-08
the O 0 1.05300186348245e-08
co O 0 8.0141880971496e-06
- O 0 0.0015093565452843904
twin O 0 0.005719308741390705
was O 0 3.0521700864483137e-06
positive O 0 2.103169638445479e-09
for O 0 3.921666602568763e-10
both O 0 4.396460973055127e-09
B27 O 0 1.6729912886148668e-06
and O 0 3.022942109964788e-07
DR1 O 0 0.00157221220433712
. O 0 6.127820597612299e-07

Additive O 0 1.6843232515384443e-05
genetic O 0 5.260269517748384e-06
effects O 0 1.4303851685326663e-06
were O 0 1.4130581149629506e-08
estimated O 0 4.3427546003727e-09
to O 0 7.494592169088321e-10
contribute O 0 2.1864290378204032e-09
97 O 0 1.7377729477630055e-08
% O 0 1.130086912937145e-09
of O 0 1.6036419414611203e-10
the O 0 2.2747019823299297e-09
population O 0 4.091204264256021e-09
variance O 0 7.331033913260399e-08
. O 0 2.019410345610595e-07

CONCLUSION O 0 6.3337720348499715e-06
Susceptibility O 0 0.00025647939764894545
to O 0 1.3684909845324e-06
AS B-Disease 1 0.9999868869781494
is O 0 2.964656609094618e-08
largely O 0 6.182137468613291e-09
genetically O 0 4.49775292565846e-08
determined O 0 4.804459763363411e-07
, O 0 9.07543551420531e-09
and O 0 7.253987188704514e-09
the O 0 9.93673587856847e-10
environmental O 0 4.730769109784205e-09
trigger O 0 2.3162569107171294e-07
for O 0 2.6559998644870575e-09
the O 0 8.137824636378355e-08
disease O 0 7.753378667985089e-06
is O 0 1.241783476046976e-08
probably O 0 5.847943640446829e-08
ubiquitous O 0 1.2822454209526768e-06
. O 0 2.005824910611409e-07

HLA O 0 0.0029442680533975363
- O 0 5.4844742408022285e-05
B27 O 0 4.710283974418417e-06
accounts O 0 6.170759547785565e-08
for O 0 1.259535031827852e-09
a O 0 7.597141582493805e-09
minority O 0 5.2236380554404604e-08
of O 0 4.861834268510279e-10
the O 0 2.5776980550062945e-09
overall O 0 5.264929541226593e-07
genetic O 0 1.6734842347432277e-06
susceptibility O 0 1.0068851224787068e-05
to O 0 4.482589588405972e-07
AS B-Disease 1 0.9999990463256836
. O 0 9.544485237711342e-07

Cell O 0 0.000262102868873626
cycle O 0 5.19165514560882e-05
- O 0 7.195670605142368e-06
dependent O 0 2.394505145275616e-07
colocalization O 0 1.1202305358892772e-06
of O 0 3.97065935686669e-09
BARD1 O 0 3.526271029841155e-05
and O 0 2.0389141042187475e-08
BRCA1 O 0 3.5712093904294306e-07
proteins O 0 1.6086371346091255e-08
in O 0 2.0071952988587327e-09
discrete O 0 2.9707649673582637e-07
nuclear O 0 6.288267968557193e-07
domains O 0 1.1953620742133353e-06
. O 0 4.4381599195730814e-07

Germ O 0 0.007817457430064678
- O 0 0.22361165285110474
line O 0 0.00022368192730937153
mutations O 0 5.924861739003973e-07
of O 0 1.288464890336627e-09
the O 0 5.989956086693837e-09
BRCA1 O 0 2.5911817829182837e-06
gene O 0 4.7674754455329094e-07
predispose O 0 4.367200290289475e-06
women O 0 1.1153977652611502e-07
to O 0 5.47085798885405e-09
early O 0 2.0675892642429972e-07
- O 0 0.24753956496715546
onset O 0 0.23293334245681763
breast B-Disease 1 0.9999794960021973
and I-Disease 1 0.9990793466567993
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 9.39966593449526e-09
compromising O 0 3.715379364166438e-07
the O 0 5.759110965897207e-09
genes O 0 2.9677408974748687e-07
presumptive O 0 8.093088581517804e-06
function O 0 3.29352722872045e-08
as O 0 1.2408103877703525e-08
a O 0 1.3079640837077022e-07
tumor B-Disease 0 4.6227836719481274e-05
suppressor O 0 0.00043270798050798476
. O 0 1.8643067960510962e-06

Although O 0 4.855269253312144e-07
the O 0 6.988490230952493e-09
biochemical O 0 1.1710110214835368e-07
properties O 0 4.6043787449434603e-08
of O 0 1.842095809223565e-09
BRCA1 O 0 2.037220838246867e-06
polypeptides O 0 1.267277752958762e-06
are O 0 1.6686994896986107e-08
not O 0 4.777795936661278e-09
understood O 0 6.85098111574689e-09
, O 0 8.219354086236308e-10
their O 0 1.9849313304121097e-09
expression O 0 5.5846079760613065e-08
pattern O 0 4.230048034514766e-06
and O 0 1.354143197573876e-08
subcellular O 0 1.1581892067624722e-06
localization O 0 3.7227209759294055e-07
suggest O 0 3.1150509727240205e-08
a O 0 2.837215129503079e-09
role O 0 1.7017187659007504e-08
in O 0 1.207026212313167e-08
cell O 0 3.0507587780448375e-06
- O 0 3.8019661587895826e-05
cycle O 0 8.64027788338717e-06
regulation O 0 4.4569159740603936e-07
. O 0 1.26106854736463e-07

When O 0 2.1570883745880565e-06
resting O 0 3.17303124575119e-06
cells O 0 2.3345080535364104e-07
are O 0 1.9630150838167992e-09
induced O 0 2.003018693130798e-07
to O 0 2.590127223811578e-09
proliferate O 0 2.894454382840195e-07
, O 0 8.043101185073454e-10
the O 0 7.048660544128893e-10
steady O 0 7.600579010613728e-07
- O 0 2.5905839606821246e-07
state O 0 7.004594126946984e-10
levels O 0 6.739619418105747e-10
of O 0 1.0545141843065764e-10
BRCA1 O 0 5.5256762721000996e-08
increase O 0 2.329737736062043e-09
in O 0 8.062284173604439e-10
late O 0 2.9573936188853622e-08
G1 O 0 1.5086510529727093e-06
and O 0 9.914231213770108e-09
reach O 0 9.668640110760407e-09
a O 0 3.496817280179698e-09
maximum O 0 1.2169432572761707e-08
during O 0 2.2506647212594544e-08
S O 0 4.17147157349973e-06
phase O 0 5.372785949475656e-07
. O 0 3.6686705584543233e-07

Moreover O 0 1.1801175787695684e-05
, O 0 5.3632643215451026e-08
in O 0 1.1737744998185917e-08
S O 0 4.435398750501918e-06
phase O 0 1.54202879798504e-07
cells O 0 1.2665742588069406e-07
, O 0 4.195324088129837e-09
BRCA1 O 0 9.389175374963088e-07
polypeptides O 0 5.374866418605961e-07
are O 0 6.950431785668343e-09
hyperphosphorylated O 0 1.5089964335857076e-06
and O 0 1.5247186624378628e-08
accumulate O 0 1.0068786338024438e-07
into O 0 7.844149330082928e-09
discrete O 0 2.6664505980988906e-07
subnuclear O 0 1.6955207684077322e-05
foci O 0 5.107813922222704e-05
termed O 0 5.933246029599104e-06
" O 0 1.8617412251842325e-06
BRCA1 O 0 1.8866385289584287e-05
nuclear O 0 2.567640876804944e-06
dots O 0 0.0004978791112080216
. O 0 6.689856490993407e-07

" O 0 0.00016080412024166435
BRCA1 O 0 0.0002788951387628913
associates O 0 5.550781497731805e-05
in O 0 2.8382125094594812e-08
vivo O 0 1.0851218803509255e-06
with O 0 8.845526089373834e-09
a O 0 7.094742215940641e-08
structurally O 0 2.578413659648504e-05
related O 0 1.9320245314702333e-07
protein O 0 2.998241598106688e-06
termed O 0 1.4346722309710458e-05
BARD1 O 0 0.0005930651095695794
. O 0 1.0064301250167773e-06

Here O 0 1.1865069609484635e-05
we O 0 1.637311299873545e-07
show O 0 1.1037516145506743e-07
that O 0 1.0424161533961751e-09
the O 0 1.5192804792008019e-09
steady O 0 5.651935452988255e-07
- O 0 3.796116345711198e-07
state O 0 1.236469815424357e-09
levels O 0 7.538146218344366e-10
of O 0 8.780363935922963e-11
BARD1 O 0 1.704779606370721e-06
, O 0 1.1804668353931902e-09
unlike O 0 8.155313091506855e-10
those O 0 3.60030255608379e-10
of O 0 3.8395994716999837e-10
BRCA1 O 0 1.1924154250664287e-06
, O 0 1.5706479672417117e-08
remain O 0 1.598482768372378e-08
relatively O 0 2.476362892522843e-09
constant O 0 2.751603567219263e-08
during O 0 1.5600875258314773e-08
cell O 0 2.007129296544008e-06
cycle O 0 8.324664122483227e-06
progression O 0 1.1868261026393156e-05
. O 0 2.5486068011559837e-07

However O 0 3.001983941430808e-06
, O 0 1.1194643434464524e-07
immunostaining O 0 4.238374458509497e-06
revealed O 0 1.0075988257085555e-06
that O 0 1.108690561579806e-08
BARD1 O 0 1.2589080142788589e-05
resides O 0 1.8027297699063638e-07
within O 0 8.280870211763158e-09
BRCA1 O 0 1.149729655480769e-06
nuclear O 0 1.2782562919255724e-07
dots O 0 8.192159293685108e-05
during O 0 8.445616117569443e-08
S O 0 1.3226657529230579e-06
phase O 0 6.7087650990060865e-09
of O 0 1.5137983921942322e-10
the O 0 7.143796110220535e-10
cell O 0 5.644405405291764e-07
cycle O 0 3.0557205263903597e-06
, O 0 3.869590425864544e-09
but O 0 1.1361643847962455e-09
not O 0 2.7755153730879556e-10
during O 0 6.368675031787063e-10
the O 0 4.4484376182651886e-09
G1 O 0 5.320569925970631e-06
phase O 0 4.3931521531703766e-07
. O 0 1.4921516822141712e-07

Nevertheless O 0 3.810877024079673e-05
, O 0 8.385791971932122e-08
BARD1 O 0 3.7934016745566623e-06
polypeptides O 0 1.0358800182075356e-06
are O 0 6.443123812260865e-09
found O 0 4.4754497885435285e-09
exclusively O 0 4.00282473833613e-09
in O 0 1.4847915119631239e-09
the O 0 1.1505792985033736e-09
nuclear O 0 8.7675546822652e-09
fractions O 0 8.124855455093893e-09
of O 0 2.932725173820927e-10
both O 0 1.4283486615696006e-09
G1 O 0 2.237145963590592e-06
- O 0 5.166887603991199e-06
and O 0 1.9939200512908428e-07
S O 0 6.990138444962213e-06
- O 0 1.612731239220011e-06
phase O 0 5.723267122448306e-07
cells O 0 4.3832758933604055e-07
. O 0 9.320029903392424e-08

Therefore O 0 2.512806304366677e-06
, O 0 3.264470294084276e-08
progression O 0 4.843356009587296e-07
to O 0 1.2972887653006637e-08
S O 0 1.4126710993878078e-05
phase O 0 1.3425707834358036e-07
is O 0 5.096891353417732e-09
accompanied O 0 1.5458430979720106e-08
by O 0 3.4778585566996867e-10
the O 0 4.908085049493138e-10
aggregation O 0 2.5085626020882046e-08
of O 0 1.1868672711301542e-09
nuclear O 0 8.40293949977422e-08
BARD1 O 0 2.516979520805762e-06
polypeptides O 0 3.818111338205199e-07
into O 0 2.3275005034406604e-08
BRCA1 O 0 7.256783192133298e-06
nuclear O 0 9.68641529652814e-07
dots O 0 0.0002857747604139149
. O 0 6.418949283215625e-07

This O 0 3.5106529594486346e-07
cell O 0 2.2313120098260697e-06
cycle O 0 1.909580760184326e-06
- O 0 8.276150538222282e-07
dependent O 0 6.235203642290799e-08
colocalization O 0 6.28214763764845e-07
of O 0 3.5208838067291026e-09
BARD1 O 0 3.674325125757605e-05
and O 0 1.9097359427178162e-07
BRCA1 O 0 5.081555627839407e-06
indicates O 0 1.5864976887769444e-07
a O 0 3.986428076530046e-09
role O 0 2.2883149597419106e-08
for O 0 2.993777226123484e-09
BARD1 O 0 2.9915695449744817e-06
in O 0 2.7436795946300663e-08
BRCA1 O 0 6.175486487336457e-05
- O 0 0.0003027761704288423
mediated O 0 0.0006647487753070891
tumor B-Disease 0 0.00029298238223418593
suppression O 0 7.267711680469802e-06
. O 0 4.5682600102736615e-07

Ethnic O 0 1.9407183572184294e-05
differences O 0 3.834060407825746e-06
in O 0 3.2004020766862595e-08
the O 0 5.014602066921725e-08
HFE O 0 0.0008694957941770554
codon O 0 3.0227596653276123e-05
282 O 0 6.91787226969609e-06
( O 0 6.065128559384902e-07
Cys O 0 0.010298172943294048
/ O 0 0.00016588858852628618
Tyr O 0 0.0002654109266586602
) O 0 8.143792342707457e-07
polymorphism O 0 9.233115633833222e-06
. O 0 6.633542284362193e-07

Recent O 0 2.2055814952182118e-06
studies O 0 1.3178002689073764e-07
have O 0 8.994290112696035e-08
shown O 0 2.0818758912355406e-06
that O 0 1.4502951671602204e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 5.798146958113648e-05
HH B-Disease 1 0.6611655354499817
) O 0 6.832401311385183e-08
is O 0 8.065226708708906e-09
likely O 0 4.629078631523953e-08
to O 0 1.3213850458271281e-08
be O 0 4.817237098109217e-08
caused O 0 1.0732279065450712e-08
by O 0 3.203977638754907e-10
homozygosity O 0 3.673340529530833e-07
for O 0 7.84332210290728e-10
a O 0 1.1514361908382398e-08
Cys282Tyr O 0 7.567088232462993e-06
mutation O 0 2.0997401861677645e-07
in O 0 3.0437132814142842e-09
the O 0 1.035690377904075e-08
HFE O 0 1.6015756045817398e-05
gene O 0 4.685610690557951e-07
located O 0 3.3252902653657657e-07
4 O 0 4.2540517597444705e-07
. O 0 4.964420554642857e-07

5 O 0 2.3841992515372112e-05
Mb O 0 0.0001806681975722313
telomeric O 0 0.0003918260335922241
to O 0 1.6561896245548269e-06
HLA O 0 0.00043681569513864815
- O 0 6.411775393644348e-05
A O 0 3.1047115953697357e-06
. O 0 6.5694030126906e-07

Population O 0 4.4378637653608166e-07
studies O 0 2.5708153827963542e-08
of O 0 9.306521664420586e-10
this O 0 7.733440554602566e-10
polymorphism O 0 2.404532608579757e-07
are O 0 5.093351296281412e-10
facilitated O 0 6.598195323448408e-09
by O 0 3.867728637363399e-10
the O 0 1.8639734200576186e-09
fact O 0 7.056883077893872e-09
that O 0 1.4266957615305387e-09
the O 0 2.3349606692590896e-09
Cys282Tyr O 0 1.979338549062959e-06
mutation O 0 9.063277417453719e-08
creates O 0 4.850335599826394e-08
a O 0 7.4455828169561755e-09
Rsal O 0 7.615939239258296e-07
restriction O 0 9.029648140312929e-08
site O 0 8.002890581337851e-07
. O 0 3.344828769513697e-07

We O 0 4.94987762067467e-06
have O 0 1.2174586672131227e-08
studied O 0 4.5030037476578855e-09
the O 0 2.7131361601817616e-09
codon O 0 8.217213007810642e-07
282 O 0 7.236411647681962e-07
( O 0 7.278105584873629e-08
Cys O 0 0.0007350860978476703
/ O 0 2.7257026886218227e-05
Tyr O 0 3.795731390709989e-05
) O 0 2.4262446274292415e-08
polymorphism O 0 2.2570146995803952e-07
in O 0 1.4592257402412656e-09
different O 0 3.398825221267998e-09
ethnic O 0 2.27193297064332e-07
groups O 0 1.390950927770973e-07
. O 0 1.963647520142331e-07

In O 0 2.706796067286632e-07
agreement O 0 2.6750205606163036e-08
with O 0 1.4212963028725767e-09
previous O 0 1.836788321440963e-08
observations O 0 4.724504876207902e-08
the O 0 5.2655892979203145e-09
Tyr O 0 4.8746346692496445e-06
allele O 0 9.670004601503024e-07
appeared O 0 4.434649781615008e-06
to O 0 4.753489601938554e-09
be O 0 4.1484726764906554e-09
rare O 0 6.415213693600208e-09
or O 0 2.863557213572676e-08
absent O 0 6.95203894451879e-08
in O 0 7.301489191036126e-09
Asiatic O 0 5.607630555459764e-07
( O 0 3.724345276623353e-09
Indian O 0 2.2584296655026037e-09
, O 0 2.501714169156344e-09
Chinese O 0 2.2804449439917107e-09
) O 0 3.6486820231829142e-09
populations O 0 6.608512848060855e-08
. O 0 7.433538939949358e-08

The O 0 4.118971617117495e-07
highest O 0 1.2523794623575668e-07
allele O 0 3.8330293250510294e-07
frequency O 0 1.204283250899607e-07
( O 0 7.623138564838428e-09
7 O 0 1.3211533200774284e-08
. O 0 2.2853479109130603e-09
5 O 0 1.712486685789827e-08
% O 0 4.798947905726436e-09
) O 0 3.031054962576718e-09
was O 0 4.5399036707749474e-07
found O 0 2.4137543519486826e-08
in O 0 3.4809346516340156e-08
Swedes O 0 5.344278906704858e-05
. O 0 5.460705665427668e-07

Saamis O 0 0.00023564574075862765
( O 0 9.66471361607546e-07
2 O 0 2.2198138083240337e-07
% O 0 1.646982639158523e-08
) O 0 1.889441270108705e-09
and O 0 5.153117488276848e-09
Mordvinians O 0 2.663314489836921e-06
( O 0 2.8566549126196605e-09
1 O 0 1.705906860216544e-09
. O 0 1.221221013203433e-09
8 O 0 1.615290479151099e-08
% O 0 1.6397506685805752e-09
) O 0 1.0458057753126582e-09
had O 0 1.5833145994292863e-07
significantly O 0 3.3253127185162157e-07
lower O 0 6.949069586426049e-08
frequencies O 0 2.5507800316404428e-08
of O 0 1.8388730538276832e-09
the O 0 4.613925952412501e-08
Tyr O 0 4.5012686314294115e-05
allele O 0 7.392799034278141e-06
. O 0 6.369033371811383e-07

Comparisons O 0 2.3236896140588215e-06
with O 0 7.336279850278515e-08
allele O 0 1.2596625538208173e-06
frequencies O 0 9.421316349289555e-08
based O 0 1.3450923930236058e-08
on O 0 4.709183443196707e-08
prevalence O 0 1.8125869019058882e-06
estimates O 0 1.6088772269995388e-07
of O 0 5.565273575314222e-09
HH B-Disease 1 0.9770092368125916
showed O 0 0.0005135777755640447
some O 0 1.0317799947756612e-09
disagreements O 0 1.9482735069686896e-07
with O 0 1.625910406310993e-09
the O 0 3.1789972876339334e-09
RFLP O 0 1.378170850330207e-06
data O 0 3.533843440095552e-08
, O 0 2.4228812289806e-09
particularly O 0 4.745409398765332e-09
in O 0 1.2601411469859158e-08
Finns O 0 2.1136052964720875e-05
. O 0 5.170537065168901e-07

The O 0 6.453248033722048e-07
newly O 0 7.855769013076497e-07
described O 0 1.0508699688216439e-06
HFE O 0 4.1432718717260286e-05
marker O 0 1.968379137906595e-06
provides O 0 1.8902065690440395e-08
a O 0 3.8581595696030035e-09
new O 0 1.820836148525018e-09
approach O 0 1.2203136279254068e-08
to O 0 3.873472376181297e-10
the O 0 1.8209636576393962e-10
screening O 0 3.4027043405160384e-09
of O 0 1.8246603117333393e-09
HH B-Disease 0 0.0022403746843338013
as O 0 6.143502417899072e-08
well O 0 5.173996342477949e-09
as O 0 1.1295697710522745e-09
studies O 0 2.9038871307562886e-10
of O 0 6.127168911129743e-11
the O 0 9.219244256897241e-10
relationship O 0 3.964183648008657e-08
between O 0 1.6662919932741715e-08
the O 0 2.5926643942852934e-08
HFE O 0 0.0009045553160831332
Tyr O 0 5.731780765927397e-05
allele O 0 3.5588955142884515e-06
and O 0 5.6505562895381445e-08
different O 0 1.3283018063248164e-07
disorders O 0 0.00031127900001592934
including O 0 5.124236395204207e-07
cancer B-Disease 0 0.0007238034158945084

Autosomal B-Disease 1 0.9999943971633911
dominant I-Disease 1 0.9831331372261047
neurohypophyseal I-Disease 1 0.9997466206550598
diabetes I-Disease 1 0.9999977350234985
insipidus I-Disease 1 0.9986444115638733
associated O 0 6.530950486194342e-06
with O 0 3.836521145217375e-08
a O 0 9.962953129161178e-08
missense O 0 1.832764428399969e-05
mutation O 0 6.333351620924077e-07
encoding O 0 6.408807848856668e-07
Gly23 O 0 1.5434517990797758e-05
- O 0 4.6647473936900496e-05
- O 0 0.00012430462811607867
> O 0 1.3021597169426968e-06
Val O 0 2.834841507137753e-05
in O 0 1.037800672065714e-07
neurophysin O 0 2.7163716367795132e-05
II O 0 3.265122359152883e-05
. O 0 6.732006454512884e-07

Autosomal B-Disease 1 0.999995231628418
dominant I-Disease 1 0.9945133924484253
neurohypophyseal I-Disease 1 0.9998762607574463
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.9999771118164062
( O 0 3.6349498259369284e-05
ADNDI B-Disease 0 0.0031803029123693705
) O 0 2.437103034935717e-07
is O 0 2.4412615928781634e-08
an O 0 2.6781813744491956e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 1.278168292628834e-05
by O 0 2.3250599667790084e-08
progressive O 0 4.5960143324919045e-05
degeneration O 0 0.02709757350385189
of O 0 1.6632936139515664e-09
the O 0 7.982628780212053e-09
magnocellular O 0 1.800169047783129e-05
neurons O 0 4.999359930479841e-07
of O 0 7.690606484977991e-10
the O 0 1.2814315830667056e-08
hypothalamus O 0 2.0740799300256185e-06
leading O 0 4.521449454841786e-07
to O 0 3.561491723758081e-08
decreased O 0 1.9143508325214498e-06
ability O 0 2.0125096256151664e-08
to O 0 2.3741795196485782e-09
produce O 0 9.304289783074182e-09
the O 0 1.0835822017440933e-08
hormone O 0 1.9267656625743257e-07
arginine O 0 7.535845156780852e-07
vasopressin O 0 2.035492570939823e-06
( O 0 7.74559651972595e-08
AVP O 0 1.1627838830463588e-05
) O 0 2.8710505262097286e-07
. O 0 2.6126704710804916e-07

Affected O 0 5.952572792011779e-06
individuals O 0 3.985153185226409e-08
are O 0 1.882193512159347e-09
not O 0 1.906139246443672e-09
symptomatic O 0 3.0921216875867685e-07
at O 0 4.788034146940845e-08
birth O 0 1.3109803376210039e-06
, O 0 1.4676113657685619e-08
but O 0 1.6693585180860282e-08
usually O 0 1.9081248581187538e-07
develop O 0 3.898670684066019e-07
diabetes B-Disease 0 3.814498631982133e-05
insipidus I-Disease 0 3.2211068173637614e-05
at O 0 5.02881576380787e-08
1 O 0 7.88891014735782e-08
- O 0 4.9039412260754034e-05
6 O 0 2.762990106930374e-06
yr O 0 0.00019523841910995543
of O 0 2.8846734778653627e-08
age O 0 4.330019862663903e-07
. O 0 1.2353004308351956e-07

The O 0 3.1269448186321824e-07
genetic O 0 8.263027098109887e-07
locus O 0 2.5762697077880148e-06
of O 0 1.6174610095731623e-08
the O 0 1.9071478618570836e-07
disease O 0 2.4999058950925246e-05
is O 0 4.581476975573651e-09
the O 0 4.5103103474275485e-09
AVP O 0 2.3272901671589352e-05
- O 0 0.001794123207218945
neurophysin O 0 0.00012751248141285032
II O 0 1.3818539628118742e-05
( O 0 7.751149944112967e-09
NPII O 0 3.1443312309420435e-07
) O 0 8.391704553467605e-10
gene O 0 1.0470037281606892e-08
, O 0 2.4403570275666198e-09
and O 0 1.38515368064418e-08
mutations O 0 1.61879938787024e-07
that O 0 2.445477820245401e-09
cause O 0 2.312420299688256e-08
ADNDI B-Disease 0 1.5568433809676208e-05
have O 0 1.9847945509354759e-07
been O 0 1.0421884866218534e-07
found O 0 8.466854772848365e-09
in O 0 1.4412462334689735e-09
both O 0 4.035604295182793e-09
the O 0 7.442913840804977e-09
signal O 0 9.404454317518685e-07
peptide O 0 5.525873536527115e-09
of O 0 1.6205595199103584e-10
the O 0 1.4865539910147163e-09
prepro O 0 1.7725260477163829e-06
- O 0 3.1245738227880793e-06
AVP O 0 6.373204087140039e-06
- O 0 1.3665550795849413e-05
NPII O 0 4.087391971552279e-06
precursor O 0 1.0046571929933634e-07
and O 0 1.3660817366201172e-08
within O 0 2.3049254949114584e-08
NPII O 0 1.2118184713472147e-05
itself O 0 1.868133381321968e-06
. O 0 3.1804427180759376e-07

An O 0 2.440391710933909e-07
affected O 0 3.9506656435150944e-07
girl O 0 4.03539597755298e-05
who O 0 2.264465877033217e-07
presented O 0 6.97611834965528e-09
at O 0 9.021984048729337e-09
9 O 0 7.266093859925604e-08
months O 0 8.443776344790876e-09
of O 0 6.655754281048587e-10
age O 0 4.513685780693777e-08
and O 0 3.302207574051863e-08
her O 0 2.0164773673059244e-07
similarly O 0 2.4258335429294675e-07
affected O 0 4.3712198305456695e-08
younger O 0 3.878097345477727e-07
brother O 0 2.0837708234466845e-06
and O 0 1.8721911487773468e-07
father O 0 3.293483814559295e-07
were O 0 1.6937658386950716e-08
all O 0 1.9498935799333594e-10
found O 0 1.6552456072460586e-09
to O 0 1.3078419458523172e-09
have O 0 2.2955530809554148e-09
a O 0 3.774569101722136e-09
novel O 0 8.887874400897999e-07
missense O 0 1.5022584193502553e-05
mutation O 0 2.527141305108671e-07
( O 0 3.6850014151212918e-09
G1758 O 0 1.3961592060240946e-07
- O 0 1.665056743149762e-06
- O 0 1.523680202808464e-05
> O 0 5.455708560475614e-07
T O 0 1.6241931461991044e-06
) O 0 1.4554176752668013e-09
encoding O 0 4.927353636219323e-09
the O 0 2.333339965687742e-09
amino O 0 2.1662190263782577e-08
acid O 0 1.0437954500730484e-08
substitution O 0 2.026739309712866e-08
Gly23 O 0 8.010297847249603e-07
- O 0 2.6037212137453025e-06
- O 0 1.1893029295606539e-05
> O 0 8.088350682555756e-07
Val O 0 2.3562501155538484e-05
within O 0 2.0081790808035294e-07
NPII O 0 3.364905569469556e-05
. O 0 5.313286806085671e-07

The O 0 1.065173478309589e-06
mutation O 0 3.735627615242265e-06
was O 0 4.5433512241288554e-07
confirmed O 0 3.044655727535428e-08
by O 0 9.97400939617421e-10
restriction O 0 1.0146711559855248e-07
endonuclease O 0 1.8013384760706685e-05
analysis O 0 6.23169626123854e-07
. O 0 4.5896223355157417e-07

A O 0 9.211689757648855e-06
T1 O 0 0.00021160957112442702
- O 0 6.148007742012851e-06
weighted O 0 5.091506523058342e-07
magnetic O 0 1.8766333198527718e-07
resonance O 0 1.4943375958864635e-07
imaging O 0 3.5922100778407184e-06
of O 0 2.601426984938371e-08
the O 0 3.3784456832108845e-07
fathers O 0 0.00020924008276779205
pituitary O 0 7.493449811590835e-05
gland O 0 1.580174830451142e-05
demonstrates O 0 2.207024181188899e-07
an O 0 1.1404987176888426e-08
attenuated O 0 0.00019014463759958744
posterior O 0 0.000697257521096617
pituitary O 0 0.0006768302409909666
bright O 0 5.6004853831836954e-05
spot O 0 0.00018525029008742422
. O 0 2.0351394596218597e-06

This O 0 3.2442915198771516e-07
mutation O 0 4.429129603522597e-06
may O 0 5.301266128299176e-07
be O 0 7.609363139593484e-10
valuable O 0 9.643458254160464e-10
for O 0 1.8186485650772966e-10
developing O 0 2.5048749741074516e-09
models O 0 6.38278692122185e-08
of O 0 1.532199256359945e-08
dominantly B-Disease 0 0.0076778908260166645
inherited I-Disease 1 0.9569394588470459
neurodegeneration I-Disease 1 1.0
, O 0 1.32144364783926e-07
as O 0 2.9360796016675295e-09
the O 0 7.039255844887293e-10
early O 0 1.3080073024696048e-08
age O 0 5.762440302703453e-09
of O 0 2.8509380967101094e-10
onset O 0 2.187365168992983e-07
of O 0 4.414745902181494e-09
symptoms O 0 1.229258259627386e-06
suggests O 0 5.890480547776633e-09
that O 0 3.057606945411351e-10
this O 0 3.0818758656181444e-10
mutation O 0 5.222671717319827e-08
may O 0 1.8899072529166006e-08
be O 0 8.895738590197766e-10
particularly O 0 1.346971090221416e-09
deleterious O 0 1.5486297400002513e-07
to O 0 8.47462633402074e-09
the O 0 1.3473674620456677e-08
magnocellular O 0 1.3983747521706391e-05
neuron O 0 4.168663508608006e-06
. O 0 5.035793648744402e-08
. O 0 1.9373474913209066e-07

Frequent O 0 9.36761061893776e-05
inactivation O 0 9.600075281923637e-05
of O 0 2.347053680296085e-07
PTEN O 0 0.0004443564102984965
/ O 0 6.848684279248118e-05
MMAC1 O 0 0.000164976401720196
in O 0 8.413393857154006e-07
primary O 0 0.0015819788677617908
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.944122338201851e-06

Sporadic B-Disease 1 0.9999966621398926
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 2.0175575627945364e-06
the O 0 5.919718937263951e-09
most O 0 2.79114065193653e-09
common O 0 2.490745565353336e-08
male B-Disease 0 3.159774450978148e-06
cancer I-Disease 0 3.845360652121599e-07
in O 0 4.21663948202422e-09
the O 0 4.6120938179683435e-09
Western O 0 4.556607535732837e-08
world O 0 2.291775018647968e-07
, O 0 9.684937296583485e-09
yet O 0 1.4839449669068472e-09
many O 0 4.564342306889735e-11
of O 0 2.5593142188862217e-11
the O 0 1.4758065602915593e-10
major O 0 5.263718905190728e-10
genetic O 0 7.848848682101561e-09
events O 0 1.9071864088004986e-09
involved O 0 1.5619655568954727e-09
in O 0 7.811998825602018e-10
the O 0 3.638070733558152e-09
progression O 0 6.458333814407524e-07
of O 0 5.424854454538774e-10
this O 0 2.643304464200469e-09
often O 0 3.055738773127814e-07
fatal O 0 3.3987601000262657e-06
cancer B-Disease 0 5.017394869355485e-06
remain O 0 1.1445371939089455e-07
to O 0 6.2843081849450755e-09
be O 0 2.9397794421015533e-08
elucidated O 0 1.602877273398917e-05
. O 0 3.5257414765510475e-07

Numerous O 0 2.6347370294388384e-06
cytogenetic O 0 0.00012992077972739935
and O 0 2.767388878055499e-07
allelotype O 0 3.7898760183452396e-06
studies O 0 2.720500980046836e-08
have O 0 3.842548679244828e-08
reported O 0 2.6163758093389333e-07
frequent O 0 4.4248392327972397e-07
loss O 0 2.606324471798871e-07
of O 0 3.748490406962901e-09
heterozygosity O 0 4.49749750259798e-05
on O 0 7.730298420938198e-06
chromosomal O 1 0.9554687738418579
arm O 0 0.007448429241776466
10q O 0 8.756293937040027e-06
in O 0 5.192239314055769e-07
sporadic B-Disease 1 0.9991368651390076
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.063268079335103e-06

Deletion O 0 0.0001296467671636492
mapping O 0 8.144654202624224e-06
studies O 0 2.993739087742142e-07
have O 0 2.020583451667335e-07
unambiguously O 0 1.5947414794936776e-05
identified O 0 2.3717100816611492e-07
a O 0 9.79581127324991e-09
region O 0 4.973328771029628e-08
of O 0 1.8980523819323025e-09
chromosome O 0 8.492819688399322e-06
10q23 O 0 6.565293801941152e-07
to O 0 1.701459240166514e-08
be O 0 4.793303975958452e-09
the O 0 1.9554999841631115e-09
minimal O 0 1.427295899247838e-07
area O 0 1.3283728605983924e-07
of O 0 1.5924149110446706e-08
loss O 0 1.3597048109659227e-06
. O 0 5.147275601302681e-07

A O 0 2.2937699668545974e-06
new O 0 3.244947208713711e-07
tumor B-Disease 0 7.791181815264281e-06
suppressor O 0 1.4812734661973082e-05
gene O 0 1.1219990483368747e-06
, O 0 5.760091781326082e-08
PTEN O 0 6.0117778048152104e-05
/ O 0 2.7022331778425723e-05
MMAC1 O 0 0.0001693033700576052
, O 0 8.15933489661802e-08
was O 0 1.9572851783777878e-07
isolated O 0 3.761125810797239e-07
recently O 0 2.7401895295042777e-06
at O 0 1.5768012673333942e-08
this O 0 3.35876465529239e-10
region O 0 5.8304547856380395e-09
of O 0 8.465219636377697e-10
chromosome O 0 8.183684258256108e-06
10q23 O 0 1.1438075944170123e-06
and O 0 4.6513022766703216e-08
found O 0 4.948148557559762e-09
to O 0 1.7524943718427721e-09
be O 0 1.445943698108465e-09
inactivated O 0 4.46395951314571e-08
by O 0 5.527325264154115e-10
mutation O 0 3.931054237682474e-08
in O 0 1.312991493307436e-08
three O 0 6.697487697238103e-05
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
cell O 0 7.194933277787641e-05
lines O 0 0.00012133333075325936
. O 0 7.23374171229807e-07

We O 0 1.7678903532214463e-05
screened O 0 4.548939614323899e-05
80 O 0 4.536979304248234e-06
prostate B-Disease 1 0.8811646103858948
tumors I-Disease 1 1.0
by O 0 1.1912745456754692e-08
microsatellite O 0 5.551331923925318e-06
analysis O 0 5.2898318614325035e-08
and O 0 1.4435415529590045e-08
found O 0 1.9926591932062365e-08
chromosome O 0 5.498013251781231e-06
10q23 O 0 8.872360126588319e-07
to O 0 1.2643327274020066e-08
be O 0 4.222691529776057e-09
deleted O 0 4.785103442372929e-07
in O 0 1.8074944208024135e-08
23 O 0 3.2443531949866156e-07
cases O 0 3.370486467701994e-08
. O 0 1.2297525131543807e-07

We O 0 2.4976588974823244e-05
then O 0 8.626462033589632e-08
proceeded O 0 3.9377031413323493e-08
with O 0 5.886703902113766e-10
sequence O 0 7.0194969836734344e-09
analysis O 0 1.2493590606510452e-09
of O 0 2.5262539282699947e-10
the O 0 1.5950586407242895e-09
entire O 0 6.792161144630882e-08
PTEN O 0 2.6330659238738008e-05
/ O 0 3.103148628724739e-06
MMAC1 O 0 6.479274361481657e-06
coding O 0 6.854068942629965e-06
region O 0 5.857264113728888e-07
and O 0 2.4791759756226384e-08
tested O 0 1.8167261472967766e-08
for O 0 2.946220489796758e-10
homozygous O 0 7.909792287819073e-08
deletion O 0 3.22332596169872e-08
with O 0 8.988915167762457e-10
new O 0 7.941671320566002e-09
intragenic O 0 2.489364760549506e-06
markers O 0 3.4191148188256193e-06
in O 0 2.5417890014978184e-09
these O 0 5.181667317444294e-10
23 O 0 1.2044895747465034e-08
cases O 0 1.020714845978432e-09
with O 0 2.4162312151077003e-09
10q23 O 0 5.79458765059826e-06
loss O 0 2.6398552677164844e-07
of O 0 2.539992216554765e-08
heterozygosity O 0 0.00014529828331433237
. O 0 1.485108782617317e-06

The O 0 1.4833845796147216e-07
identification O 0 4.998587499471796e-08
of O 0 2.0977930503818243e-09
the O 0 5.099847211198494e-09
second O 0 5.8509563416464516e-08
mutational O 0 2.6619379696057877e-06
event O 0 5.658062462998714e-08
in O 0 4.664857833347469e-09
10 O 0 1.1358876506051274e-08
( O 0 3.23883608821518e-09
43 O 0 1.0569461750264963e-07
% O 0 1.3015666766591494e-08
) O 0 1.561573697017593e-07
tumors B-Disease 1 1.0
establishes O 0 6.113085692049935e-05
PTEN O 0 0.00035353898419998586
/ O 0 2.067344030365348e-05
MMAC1 O 0 1.3763854440185241e-05
as O 0 6.921513140412117e-09
a O 0 7.984227501367513e-09
main O 0 6.465654678322608e-08
inactivation O 0 4.5104201262802235e-07
target O 0 2.4289393607546117e-08
of O 0 8.994471834000706e-10
10q O 0 6.611323897232069e-07
loss O 0 9.420633517720489e-08
in O 0 9.455592930862622e-08
sporadic B-Disease 1 0.9999791383743286
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.2553742812524433e-07
. O 0 2.63909754494307e-07

Risk O 0 9.552133269608021e-05
reversals O 0 1.649495243327692e-05
in O 0 4.9038604288398346e-08
predictive O 0 1.5576218856949708e-06
testing O 0 6.943200219211576e-07
for O 0 5.350058813746728e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 7.155509820222505e-07

The O 0 2.0443195580810425e-07
first O 0 2.0080197060678984e-08
predictive O 0 2.9004061730120156e-07
testing O 0 6.190411028228482e-08
for O 0 6.159635290714505e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 2.7961561954725767e-08
HD B-Disease 0 0.0006275865598581731
) O 0 1.3622977235172584e-07
was O 0 1.6216547464864561e-06
based O 0 4.8511283878838185e-09
on O 0 1.4549687676890244e-08
analysis O 0 1.6137654546000135e-09
of O 0 1.9377217885807596e-10
linked O 0 5.444274719934583e-08
polymorphic O 0 8.04633089046547e-08
DNA O 0 3.936997217124372e-08
markers O 0 5.802710916213982e-07
to O 0 3.3786591302487068e-09
estimate O 0 4.49425385795621e-08
the O 0 6.764010462845249e-10
likelihood O 0 5.088411469955645e-09
of O 0 4.465999237091012e-10
inheriting O 0 5.97040781258329e-08
the O 0 4.009564236184815e-09
mutation O 0 8.49863539542639e-08
for O 0 6.0516001099131245e-09
HD B-Disease 0 8.957183308666572e-05
. O 0 8.400485853599093e-07

Limits O 0 1.5644611721654655e-06
to O 0 1.3903999729336647e-08
accuracy O 0 7.981444838378593e-08
included O 0 1.9986303723129595e-09
recombination O 0 1.5695668764692527e-08
between O 0 2.226683726291867e-09
the O 0 1.649424485883344e-09
DNA O 0 1.4379169499534328e-07
markers O 0 4.863782123720739e-06
and O 0 3.581211771574999e-08
the O 0 6.60352084125293e-09
mutation O 0 3.206212966233579e-07
, O 0 1.0249332049738769e-08
pedigree O 0 1.2297836065044976e-06
structure O 0 2.6330809532737476e-08
, O 0 1.0090137614326977e-09
and O 0 4.352471161261917e-10
whether O 0 4.834868616576671e-10
DNA O 0 9.718319482487914e-09
samples O 0 1.096991031346306e-08
were O 0 3.4744191967917004e-09
available O 0 8.891938296784474e-10
from O 0 1.8144776792183848e-09
family O 0 3.2591323417818785e-08
members O 0 2.1063099708840127e-08
. O 0 9.463982308943741e-08

With O 0 1.0416559348414012e-07
direct O 0 3.9842181109861485e-08
tests O 0 9.977001447225575e-09
for O 0 3.4448158214850366e-10
the O 0 1.8364161302741877e-09
HD B-Disease 0 1.623653224669397e-05
mutation O 0 1.211283944257957e-07
, O 0 3.926556413347271e-09
we O 0 5.2101527536763115e-09
have O 0 1.7254824236090371e-09
assessed O 0 3.0103768366984696e-09
the O 0 8.925429284545316e-10
accuracy O 0 1.3520677839551354e-06
of O 0 1.169298213810066e-09
results O 0 7.288423642393127e-09
obtained O 0 9.23518983508842e-10
by O 0 1.157377804705817e-10
linkage O 0 4.7317282536596394e-08
approaches O 0 4.465884373416884e-08
when O 0 4.247952212210748e-09
requested O 0 2.8553583941715033e-09
to O 0 1.590775511317588e-08
do O 0 4.6640593609481584e-08
so O 0 7.961777903631173e-10
by O 0 7.072224056381415e-11
the O 0 9.57235513077137e-10
test O 0 8.363505443753638e-09
individuals O 0 6.314887723846141e-09
. O 0 2.7625997489622023e-08

For O 0 6.423419307566292e-08
six O 0 2.018606792830724e-08
such O 0 6.079107217615842e-10
individuals O 0 1.8414143543310502e-09
, O 0 2.537066556840273e-09
there O 0 5.28470600613673e-09
was O 0 8.263943840347565e-08
significant O 0 1.9172674559087e-09
disparity O 0 4.8777224037621636e-08
between O 0 4.942469988833409e-09
the O 0 7.4492763069144985e-09
tests O 0 9.087771957183577e-08
. O 0 8.155119246566755e-08

Three O 0 2.3598297502758214e-06
went O 0 3.0878223356012313e-07
from O 0 1.9025214736956286e-09
a O 0 4.3988093167968145e-09
decreased O 0 1.8590360184589372e-07
risk O 0 7.742447571956745e-09
to O 0 2.460936454617979e-10
an O 0 3.2140767824984096e-10
increased O 0 5.822412418865497e-08
risk O 0 3.004596393907377e-08
, O 0 9.066174477823097e-10
while O 0 7.103781451966995e-10
in O 0 1.5908467598801934e-10
another O 0 6.6153460487328175e-09
three O 0 1.1800419308372057e-08
the O 0 3.7536576513730324e-08
risk O 0 1.884673821450633e-07
was O 0 1.196628204525041e-06
decreased O 0 6.550934585902723e-07
. O 0 1.024448863518046e-07

Knowledge O 0 6.331605959530862e-07
of O 0 6.6717213975664436e-09
the O 0 1.0971034081208586e-09
potential O 0 3.446348761926288e-09
reasons O 0 9.517665544578335e-10
for O 0 1.2066084242867703e-10
these O 0 2.2503404695228824e-10
changes O 0 2.256302700232027e-09
in O 0 5.418104631615961e-09
results O 0 5.6489181332608496e-08
and O 0 1.6771648958524565e-08
impact O 0 2.0029731206960832e-09
of O 0 1.3151756073082055e-10
these O 0 8.640846371754662e-10
risk O 0 3.1926814525462532e-09
reversals O 0 8.601931966722987e-08
on O 0 7.213454011889553e-08
both O 0 3.941322823663995e-09
patients O 0 3.822889116378292e-09
and O 0 2.3760684531026754e-09
the O 0 8.282177166307747e-10
counseling O 0 1.1626381635210237e-08
team O 0 2.9269542345389254e-09
can O 0 2.864238402011665e-09
assist O 0 9.595186867272787e-10
in O 0 4.103784811970712e-10
the O 0 3.3846686564587003e-10
development O 0 2.1226417845632284e-10
of O 0 3.365926634635308e-11
strategies O 0 1.7606289759442006e-09
for O 0 9.921390098366345e-11
the O 0 4.2013917345151697e-10
prevention O 0 2.0986746562812186e-08
and O 0 1.2845885244416877e-08
, O 0 5.359066523880074e-10
where O 0 1.935130056196499e-09
necessary O 0 1.19034493373249e-09
, O 0 9.067920858640832e-10
management O 0 1.2251966108323131e-09
of O 0 9.374679504903227e-11
a O 0 6.2148148849416884e-09
risk O 0 1.4131336101286252e-08
reversal O 0 2.3900282641875492e-08
in O 0 4.883358162288687e-10
any O 0 9.30283072797522e-10
predictive O 0 9.206109297110743e-08
testing O 0 2.205373839103686e-08
program O 0 3.218153210582386e-08
. O 0 6.544937924957139e-09
. O 0 4.4849542746305815e-08

A O 0 5.688181772711687e-06
novel O 0 4.665448159357766e-06
common O 0 1.1847167797895963e-06
missense O 0 8.164597966242582e-05
mutation O 0 2.8893268790852744e-06
G301C O 0 2.0432487417565426e-06
in O 0 9.764286268421074e-09
the O 0 8.014881203166624e-09
N O 0 3.6229191664460814e-06
- O 0 8.352639270015061e-06
acetylgalactosamine O 0 2.2304388039628975e-05
- O 0 1.8048876881948672e-05
6 O 0 3.143431399621477e-07
- O 0 3.68074006473762e-06
sulfate O 0 3.0652411169285187e-06
sulfatase O 0 6.838882200099761e-06
gene O 0 4.7428827087969694e-07
in O 0 4.441123380161116e-08
mucopolysaccharidosis B-Disease 0 2.4063678210950457e-05
IVA I-Disease 0 0.002911391668021679
. O 0 2.0413049242051784e-06

Mucopolysaccharidosis B-Disease 0 0.03939085081219673
IVA I-Disease 1 0.9998950958251953
( O 0 0.07895924150943756
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
) O 0 2.1903615561313927e-06
is O 0 3.040929641429102e-08
an O 0 6.358133219919182e-08
autosomal B-Disease 1 0.9999556541442871
recessive I-Disease 1 0.9999899864196777
lysosomal I-Disease 1 0.9999321699142456
storage I-Disease 1 0.9998656511306763
disorder I-Disease 1 0.9999949932098389
caused O 0 7.773196557536721e-07
by O 0 2.8985596145503223e-09
a O 0 9.424997529094981e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 6.998484280984485e-08
N O 0 1.796512515284121e-05
- O 0 3.211445437045768e-05
acetylgalactosamine O 0 2.0812898583244532e-05
- O 0 3.4149223210988566e-05
6 O 0 1.9678047920024255e-06
- O 0 8.585111208958551e-05
sulfate O 0 3.348407335579395e-05
sulfatase O 0 0.00010433125135023147
( O 0 1.7108254724007566e-07
GALNS O 0 8.760604032431729e-06
) O 0 1.2949172401022224e-07
. O 0 1.516130936352056e-07

In O 0 1.996304064277865e-07
previous O 0 7.11878911374697e-08
studies O 0 1.0395476479629906e-08
, O 0 6.051900314218983e-09
we O 0 3.195258502231013e-09
have O 0 1.4140117965411036e-09
found O 0 1.3610044202749805e-09
two O 0 1.4210360665956046e-09
common O 0 7.301809379356428e-09
mutations O 0 6.596297907890403e-08
in O 0 4.145885412754069e-09
Caucasians O 0 1.7757475916369003e-06
and O 0 3.0590044275413675e-07
Japanese O 0 1.2510508895502426e-07
, O 0 7.98124411005574e-09
respectively O 0 6.804492613809998e-08
. O 0 7.160513604276275e-08

To O 0 4.0836721382220276e-07
characterize O 0 1.7257734725717455e-06
the O 0 1.7030370003112694e-08
mutational O 0 2.0615536413970403e-05
spectrum O 0 1.0813192830028129e-06
in O 0 8.698175513188744e-10
various O 0 3.2970559615819184e-10
ethnic O 0 3.322468700162062e-08
groups O 0 7.776561616879007e-09
, O 0 1.3699636980391006e-09
mutations O 0 2.7441297234531703e-08
in O 0 3.749074384273854e-10
the O 0 1.7366786897454745e-09
GALNS O 0 2.5059787276404677e-06
gene O 0 1.3191041148274962e-07
in O 0 4.076484572124173e-08
Colombian O 0 6.142268830444664e-05
MPS B-Disease 1 0.9999833106994629
IVA I-Disease 1 1.0
patients O 0 6.971105904085562e-06
were O 0 1.5236080841418698e-08
investigated O 0 2.785324149101598e-08
, O 0 1.4510410650814265e-09
and O 0 2.1626263002616497e-09
genetic O 0 4.53873916228531e-08
backgrounds O 0 6.881550973503181e-08
were O 0 5.8589715301593515e-09
extensively O 0 7.701633997214685e-09
analyzed O 0 3.14775689957969e-08
to O 0 1.0918053128250449e-09
identify O 0 1.804397697924287e-08
racial O 0 6.636934557491259e-08
origin O 0 4.380540374882003e-09
, O 0 9.945059220584085e-10
based O 0 1.0232821257005753e-09
on O 0 1.2829552531457011e-08
mitochondrial O 0 1.2193019927053683e-07
DNA O 0 5.399686529017345e-07
( O 0 1.006317695839698e-08
mtDNA O 0 1.4374397494520963e-07
) O 0 2.5136490222621433e-08
lineages O 0 9.062946446647402e-07
. O 0 2.803023733122245e-07

Three O 0 2.8679110073426273e-06
novel O 0 7.0538708314416e-06
missense O 0 0.0006058894214220345
mutations O 0 0.00010150168964173645
never O 0 6.104045041865902e-06
identified O 0 2.1237620728697948e-07
previously O 0 5.337669861660288e-08
in O 0 1.8430867942953455e-09
other O 0 9.843341697290953e-10
populations O 0 2.0313912330038875e-08
and O 0 5.113818346558219e-08
found O 0 9.55534051882978e-09
in O 0 2.437347434991466e-09
16 O 0 2.7917916867181702e-08
out O 0 2.8528612361355954e-08
of O 0 3.954228944280658e-09
19 O 0 9.758012993188458e-07
Colombian O 0 1.3309409041539766e-05
MPS B-Disease 1 0.9992627501487732
IVA I-Disease 1 0.9999961853027344
unrelated O 0 6.849520559626399e-07
alleles O 0 2.897522790590301e-07
account O 0 7.369826704461957e-08
for O 0 5.813908465768236e-09
84 O 0 2.2734718641004292e-07
. O 0 1.1025733215319633e-07

2 O 0 8.084911314654164e-06
% O 0 1.026545675131274e-07
of O 0 1.059842102968389e-09
the O 0 2.6018076582090544e-09
alleles O 0 7.60060885340863e-08
in O 0 5.5551141464604825e-09
this O 0 4.3014867223689635e-09
study O 0 2.7167313731979448e-08
. O 0 1.292543458930595e-07

The O 0 1.0135864840776776e-06
G301C O 0 7.501737854909152e-06
and O 0 1.282286632431351e-07
S162F O 0 3.020446001755772e-06
mutations O 0 8.338658972206758e-07
account O 0 6.36589945202104e-08
for O 0 1.3496257444955972e-08
68 O 0 1.6425050262114382e-06
. O 0 2.8032482646267454e-07

4 O 0 3.0269569833762944e-05
% O 0 4.2037848402287636e-07
and O 0 7.274385893651925e-08
10 O 0 1.4901891631780018e-07
. O 0 1.6691220139364304e-07

5 O 0 4.827506472793175e-06
% O 0 8.749265845153786e-08
of O 0 2.9325926131917868e-09
mutations O 0 6.586240033357171e-07
, O 0 1.3546340937864443e-08
respectively O 0 7.980364102877502e-08
, O 0 3.5218172822482074e-09
whereas O 0 5.0562913855856095e-09
the O 0 4.0794381206410435e-09
remaining O 0 4.0109893006956554e-07
F69V O 0 6.877304258523509e-05
is O 0 1.4463278574794458e-08
limited O 0 1.198617427533577e-09
to O 0 1.4525446401236763e-09
a O 0 1.2105445534871251e-08
single O 0 3.835841653199168e-07
allele O 0 3.5811890484183095e-06
. O 0 6.207673663993774e-07

The O 0 9.292745062339236e-07
skewed O 0 4.9579612095840275e-06
prevalence O 0 3.8610810406680685e-06
of O 0 5.382116974317341e-09
G301C O 0 4.1484315715933917e-07
in O 0 3.105770307598732e-09
only O 0 4.192364677635396e-09
Colombian O 0 2.7218047193855455e-07
patients O 0 3.245033397547559e-08
and O 0 3.720397767636996e-09
haplotype O 0 3.56200871465262e-07
analysis O 0 5.342382536355217e-09
by O 0 4.721625868064905e-10
restriction O 0 1.5567731992405243e-08
fragment O 0 1.0167959771933965e-06
length O 0 1.3014024489166331e-06
polymorphisms O 0 4.871376859227894e-06
in O 0 1.7628937198921335e-09
the O 0 2.6613140580167283e-09
GALNS O 0 1.6957042134890798e-06
gene O 0 9.698472780428347e-08
suggest O 0 1.975497276873739e-08
that O 0 1.5646042239580993e-09
G301C O 0 1.6671955904712377e-07
originated O 0 1.270504323969135e-08
from O 0 3.714057117409908e-10
a O 0 2.87918067165549e-09
common O 0 1.841053354212363e-08
ancestor O 0 4.0518270338907314e-07
. O 0 3.1449519610760035e-07

Investigation O 0 1.8742757674772292e-06
of O 0 1.1759885509832202e-08
the O 0 1.7573746902144194e-09
genetic O 0 1.1770885777195872e-07
background O 0 1.5829748178930458e-07
by O 0 5.732914698519664e-10
means O 0 1.169347174645452e-09
of O 0 1.9446419474711263e-10
mtDNA O 0 5.995650553813903e-08
lineages O 0 9.93490587575252e-08
indicate O 0 4.743511539118117e-08
that O 0 3.285651084539154e-09
all O 0 1.5554961763086794e-09
our O 0 1.9219109859136552e-08
patients O 0 4.0722705207940635e-09
are O 0 6.132491736643431e-10
probably O 0 1.636767343882184e-08
of O 0 5.14980336152604e-10
native O 0 4.656575214312397e-08
American O 0 7.969106263772119e-07
descent O 0 5.420757588581182e-05

Low O 0 3.0156539651216008e-05
frequency O 0 3.0968160444899695e-06
of O 0 5.939310554481381e-08
BRCA1 O 0 5.254408097243868e-05
germline O 0 2.8127384211984463e-05
mutations O 0 2.202294353992329e-06
in O 0 2.1427794649753196e-08
45 O 0 4.6366250217033667e-07
German O 0 0.015744904056191444
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0673780934666866e-06
. O 0 2.6308802603125514e-07

In O 0 2.2206904759514146e-07
this O 0 2.9697202474920914e-09
study O 0 3.379200474995514e-09
we O 0 2.4848509916353123e-09
investigated O 0 4.373579898242497e-08
45 O 0 2.1588446941223083e-07
German O 0 0.0024182931520044804
breast B-Disease 1 0.9999953508377075
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.1174867609042849e-07
for O 0 2.964315903852821e-09
germline O 0 1.7992103948927252e-06
mutations O 0 2.847031908004283e-07
in O 0 1.6501482402730971e-09
the O 0 1.560358242613802e-08
BRCA1 O 0 1.4406075024453457e-05
gene O 0 5.419840817921795e-06
. O 0 8.419639243584243e-07

We O 0 1.5877676560194232e-06
identified O 0 3.070930176818365e-07
four O 0 1.9973356302216416e-08
germline O 0 5.1853794502676465e-06
mutations O 0 1.6663036603858927e-06
in O 0 1.1924884191216734e-08
three O 0 8.80072946074506e-07
breast B-Disease 1 0.9412125945091248
cancer I-Disease 0 0.0015173966530710459
families O 0 6.312614431180918e-08
and O 0 8.677516483146519e-09
in O 0 1.1108177488949877e-08
one O 0 5.966168100712821e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 4.439633016772859e-07
. O 0 1.5316666823750325e-09
among O 0 4.1281689178163106e-10
these O 0 2.2964934121016967e-10
were O 0 4.1197547595572814e-09
one O 0 8.006737495236393e-09
frameshift O 0 1.4142805412120651e-05
mutation O 0 1.226274264354288e-07
, O 0 2.9545672575181925e-09
one O 0 2.3676596683230855e-08
nonsense O 0 9.114970453083515e-06
mutation O 0 2.006596133696803e-07
, O 0 1.970423602060123e-09
one O 0 2.4338446813487735e-09
novel O 0 7.589280670572407e-08
splice O 0 7.3831390182022e-05
site O 0 5.180708285479341e-06
mutation O 0 3.520322024996858e-07
, O 0 4.58959359406208e-09
and O 0 5.8019118398533465e-09
one O 0 3.866943387720312e-08
missense O 0 2.2673606508760713e-05
mutation O 0 3.814504452748224e-06
. O 0 3.711161582486966e-07

The O 0 9.630524573367438e-07
missense O 0 0.00015032697410788387
mutation O 0 2.7542939278646372e-05
was O 0 2.9034663384663872e-06
also O 0 3.863161524009229e-08
found O 0 6.879422365102528e-09
in O 0 8.948974894451567e-09
2 O 0 4.633009496046725e-07
. O 0 3.6530298075376777e-07

8 O 0 3.059662049054168e-05
% O 0 2.2107042241259478e-07
of O 0 8.136452067653011e-10
the O 0 2.048369251994586e-09
general O 0 3.6272620462796112e-09
population O 0 1.697643026155049e-09
, O 0 1.5775344364143962e-09
suggesting O 0 3.954207983269953e-08
that O 0 4.430444011660484e-09
it O 0 1.1116126685806194e-08
is O 0 1.201683108575935e-08
not O 0 1.9829643704838418e-08
disease O 0 4.0014265323407017e-07
associated O 0 6.260240326128041e-08
. O 0 1.402582512355366e-07

The O 0 6.060635655558144e-07
average O 0 4.5431306716636755e-07
age O 0 1.8575432747525156e-08
of O 0 3.153837191405273e-09
disease O 0 1.9613994481915142e-06
onset O 0 1.698831511021126e-06
in O 0 6.583273481908236e-09
those O 0 1.3235367468666936e-08
families O 0 5.574275263597883e-08
harbouring O 0 9.039346878125798e-06
causative O 0 5.652519121213118e-06
mutations O 0 9.869698260445148e-06
was O 0 6.64316473830695e-07
between O 0 4.9318977346501924e-08
32 O 0 1.4644567727373214e-06
. O 0 1.955065158654179e-07

3 O 0 1.9174614863004535e-05
and O 0 4.5164159701016615e-07
37 O 0 4.754861492983764e-06
. O 0 4.607462358308112e-07

4 O 0 2.785234755720012e-05
years O 0 1.7568618204677477e-07
, O 0 4.871332226485947e-09
whereas O 0 6.9311303363406296e-09
the O 0 1.809493999083145e-09
family O 0 6.606887126281435e-08
harbouring O 0 1.1334851706124027e-06
the O 0 4.536737208127306e-09
missense O 0 2.2128376713226316e-06
mutation O 0 2.0175392023702443e-07
had O 0 1.8320899641821597e-07
an O 0 1.342569722062592e-09
average O 0 8.057695310981217e-08
age O 0 7.861028272770909e-09
of O 0 4.672745523848221e-10
onset O 0 3.60512359520726e-07
of O 0 5.206735043117305e-09
51 O 0 1.5748137229820713e-06
. O 0 1.900857995451588e-07

2 O 0 4.49158251285553e-05
years O 0 2.424002559564542e-06
. O 0 9.737635764395236e-07

These O 0 3.9115263916755794e-07
findings O 0 3.49939170973812e-07
show O 0 1.4016733302923967e-06
that O 0 1.0218236923265067e-08
BRCA1 O 0 4.82927907796693e-06
is O 0 2.3863522713440943e-08
implicated O 0 5.7599930158858115e-08
in O 0 1.1210509187620232e-09
a O 0 3.0791336147473203e-09
small O 0 3.094618339360977e-09
fraction O 0 3.4487310784925285e-08
of O 0 1.4496771427729982e-07
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.401670258223021e-07
suggesting O 0 4.426501476473277e-08
the O 0 1.0427064767171146e-09
involvement O 0 5.861967355969e-09
of O 0 5.685513171371781e-10
another O 0 1.3539315446564615e-08
susceptibility O 0 4.116755007999018e-06
gene O 0 3.979550911026308e-06
( O 0 3.740678948815912e-07
s O 0 0.00012695789337158203
) O 0 2.634038764881552e-06

Paternal O 0 0.010838797315955162
transmission O 0 0.09629295021295547
of O 0 1.4780421224713791e-05
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 9.8917014838662e-05

We O 0 4.775311481353128e-06
report O 0 3.017385807879691e-08
a O 0 5.730020902205979e-09
rare O 0 2.314454405905053e-08
case O 0 9.086610219810609e-08
of O 0 2.2065863447551237e-07
paternally O 1 0.9999645948410034
transmitted O 1 0.9999998807907104
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.008507123216986656
DM B-Disease 1 1.0
) O 0 4.964608706359286e-06
. O 0 2.369190042372793e-06

The O 0 5.114929990668315e-07
proband O 0 1.2635953680728562e-05
is O 0 4.2655567966676244e-08
a O 0 1.6096469934723245e-08
23 O 0 1.7419451125988417e-07
year O 0 2.2220350004431566e-08
old O 0 5.192214666749351e-05
, O 0 1.049124330165796e-05
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.028229983523488045
who O 0 0.00022949202684685588
suffers O 1 0.9545367956161499
severe O 0 0.0010747683700174093
muscular B-Disease 1 0.9886423945426941
weakness I-Disease 0 0.008999119512736797
. O 0 6.650454906775849e-07

He O 0 1.0093192940985318e-05
presented O 0 3.0918150173420145e-07
with O 0 1.7495436566150602e-07
respiratory O 0 0.04010938107967377
and O 0 4.1856392840600165e-07
feeding O 0 1.1423410796851385e-05
difficulties O 0 5.432267471405794e-07
at O 0 4.5536534543089147e-08
birth O 0 2.44617285716231e-06
. O 0 3.13639162641266e-07

His O 0 1.543481084809173e-05
two O 0 4.113147952011786e-06
sibs O 1 0.5116760730743408
suffer O 0 8.476584480376914e-05
from O 0 1.305898820191942e-07
childhood O 0 8.73557582963258e-05
onset O 1 0.81971675157547
DM B-Disease 1 1.0
. O 0 8.872767466527876e-06

Their O 0 2.5164852104353486e-06
late O 0 2.854434114851756e-06
father O 0 1.1092563454440096e-06
had O 0 9.130965850090433e-08
the O 0 5.19307541413383e-10
adult O 0 1.2566562013205385e-08
type O 0 2.4480506510826672e-08
of O 0 1.3103845120099322e-08
DM B-Disease 1 1.0
, O 0 2.435619883556228e-08
with O 0 2.5003734638318065e-09
onset O 0 3.4819646543837734e-07
around O 0 2.8422158848684376e-08
30 O 0 3.4102686896630985e-08
years O 0 1.5999743752104223e-08
. O 0 3.983435448162709e-08

Only O 0 3.7071470160299214e-07
six O 0 2.5234870193457937e-08
other O 0 6.078434422462919e-10
cases O 0 1.3376364460526702e-09
of O 0 9.701406344930774e-10
paternal O 0 7.860134792281315e-05
transmission O 0 0.0464896559715271
of O 0 1.783439188329794e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.00016668267198838294
been O 0 1.780899879122444e-06
reported O 0 8.16320948615612e-07
recently O 0 1.6689754147591884e-06
. O 0 3.805308210758085e-07

We O 0 1.307310981246701e-06
review O 0 1.3459701797557955e-08
the O 0 7.321148132177768e-10
sex O 0 1.2741979915631418e-08
related O 0 6.000087093838147e-09
effects O 0 1.4625918254296266e-07
on O 0 6.839454727014527e-07
transmission O 0 0.00022083889052737504
of O 0 1.2574685115396278e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 1.0264168849971611e-05

Decreased O 0 0.0001824335486162454
fertility O 0 7.188853032857878e-06
of O 0 2.037965352030824e-08
males O 0 6.745258218643357e-08
with O 0 7.211608199497732e-09
adult O 0 4.231887942296453e-06
onset O 0 0.047016993165016174
DM B-Disease 1 1.0
and O 0 6.8947811087127775e-06
contraction O 0 2.8967597245355137e-06
of O 0 2.324264114506036e-10
the O 0 9.337032258471822e-10
repeat O 0 9.992850635853756e-08
upon O 0 2.2193316073781943e-09
male O 0 1.1329314020258607e-07
transmission O 0 4.611911208485253e-07
contribute O 0 3.5260381281432274e-09
to O 0 2.124465270370024e-09
the O 0 1.5235608330499417e-09
almost O 0 1.2608287747184477e-08
absent O 0 4.1323954036442956e-08
occurrence O 0 2.665186293882016e-08
of O 0 1.6726182661130906e-09
paternal O 0 1.8799230019794777e-05
transmission O 0 0.0003741662367247045
of O 0 2.426289938739501e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 1.639930451347027e-05

Also O 0 1.3178295375837479e-05
the O 0 1.756789025364469e-08
fathers O 0 1.0272410122524889e-07
of O 0 1.2224211642930527e-09
the O 0 1.3557326816737714e-08
reported O 0 2.3043862711347174e-06
congenitally O 0 7.858725439291447e-05
affected O 0 1.6082083220680943e-07
children O 0 3.498403771118319e-07
showed O 0 2.2328745217237156e-06
, O 0 1.7799325346956607e-09
on O 0 1.1625765239386965e-07
average O 0 1.5480831905279047e-07
, O 0 2.3786532743486077e-09
shorter O 0 3.6423708138499933e-07
CTG O 0 2.793304702208843e-06
repeat O 0 1.5707879583715112e-06
lengths O 0 6.430237408494577e-05
and O 0 1.0612101419837927e-08
hence O 0 9.427209235468581e-09
less O 0 4.854479040972137e-09
severe O 0 4.196018608126906e-07
clinical O 0 5.278614594317332e-07
symptoms O 0 3.5048899462708505e-06
than O 0 1.7640138239016778e-09
the O 0 4.1052121702023214e-09
mothers O 0 2.1553393025897094e-07
of O 0 1.6683009418372308e-09
children O 0 4.1361144553775375e-07
with O 0 8.576391337555833e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 7.241200364660472e-06

We O 0 3.0512328521581367e-06
conclude O 0 3.466207374458463e-07
that O 0 5.379879652878117e-09
paternal O 0 4.950689344696002e-06
transmission O 0 0.0002514343068469316
of O 0 1.2992396705158171e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 1.919903525049449e-06
rare O 0 3.8902463472823e-08
and O 0 1.773088698087122e-08
preferentially O 0 1.279431955936161e-07
occurs O 0 4.4736490067975865e-09
with O 0 8.260578887586689e-10
onset O 0 5.685561745849554e-07
of O 0 1.060184295909039e-08
DM B-Disease 1 1.0
past O 0 1.1980568160652183e-05
30 O 0 1.0706337860710846e-07
years O 0 2.2432919966064446e-09
in O 0 8.921565708419621e-10
the O 0 7.433521798105858e-09
father O 0 6.877915552649938e-07
. O 0 1.4334393227954934e-08
. O 0 8.283495844807476e-08

The O 0 1.913190089908312e-06
RB1 O 0 0.000335686287144199
gene O 0 3.933506377507001e-06
mutation O 0 1.3499405895345262e-06
in O 0 7.170925631072578e-09
a O 0 3.978363594114853e-08
child O 0 7.763974281260744e-06
with O 0 1.3714384294871707e-06
ectopic B-Disease 1 0.999998927116394
intracranial I-Disease 1 0.9999730587005615
retinoblastoma I-Disease 1 0.9240738153457642
. O 0 1.4095813639869448e-05

The O 0 3.880408712575445e-06
RB1 O 0 0.0003736061044037342
gene O 0 7.635657311766408e-06
mutation O 0 4.040743078803644e-06
was O 0 1.3975447643588268e-07
investigated O 0 1.8478960583934168e-08
in O 0 1.9000807593982927e-09
a O 0 3.083290067706912e-08
child O 0 4.92477693114779e-06
with O 0 3.067306693083083e-07
ectopic B-Disease 1 0.999994158744812
intracranial I-Disease 0 0.3643491566181183
retinoblastoma I-Disease 0 1.185380642709788e-05
using O 0 3.014963922964853e-08
DNA O 0 1.4090352351558977e-07
obtained O 0 4.590828162065463e-09
from O 0 5.95100690947703e-10
both O 0 1.544710581669051e-09
the O 0 1.1304432945280496e-08
pineal B-Disease 0 9.02628235053271e-05
and I-Disease 0 2.4209613911807537e-05
retinal I-Disease 1 0.9991883635520935
tumours I-Disease 1 1.0
of O 0 4.807470332934827e-08
the O 0 2.1777736947115045e-07
patient O 0 1.1434736734372564e-05
. O 0 3.0253619343056926e-07

A O 0 6.224584467418026e-06
nonsense O 0 4.318886203691363e-05
mutation O 0 3.0542169042746536e-06
in O 0 2.1796390470285587e-08
exon O 0 2.6750033157441067e-06
17 O 0 5.358392058951722e-07
( O 0 1.666972160307978e-08
codon O 0 4.2955082335538464e-07
556 O 0 1.0280662365858007e-07
) O 0 4.413078791287717e-09
of O 0 3.9442538124490056e-10
the O 0 6.561036158814204e-09
RB1 O 0 1.3506757568393368e-05
gene O 0 3.0337639600475086e-07
was O 0 1.6275857888103928e-06
found O 0 6.1456324473851964e-09
to O 0 2.0668855515992846e-09
be O 0 1.9255499417170086e-09
present O 0 1.3881231719636844e-09
homozygously O 0 8.441547834081575e-07
in O 0 5.7005768994145e-09
both O 0 4.8556274556688095e-09
the O 0 1.4637087986102415e-08
retinal B-Disease 0 9.310952009400353e-05
and I-Disease 0 2.8014546842314303e-06
the I-Disease 0 1.2021940847262158e-06
pineal I-Disease 1 0.7758429646492004
tumours I-Disease 1 1.0
. O 0 5.998950200591935e-06

The O 0 2.0657206789564952e-07
same O 0 3.5536068310193514e-08
mutation O 0 2.519556119295885e-07
was O 0 5.7218322524477117e-08
present O 0 2.7295747884181765e-09
heterozygously O 0 2.840119464053714e-07
in O 0 9.896770070128014e-10
the O 0 9.727031402562147e-10
DNA O 0 4.229698546964755e-08
from O 0 8.700232756453374e-10
the O 0 2.4740434700909475e-10
constitutional O 0 5.053967466750464e-09
cells O 0 4.814947107689704e-09
of O 0 2.221685335701551e-10
the O 0 3.1631626207229147e-09
patient O 0 1.3269672649585118e-07
, O 0 6.177304445742493e-09
proving O 0 6.337575086945435e-08
it O 0 8.453832300858721e-09
to O 0 1.4772717493727328e-09
be O 0 1.8519492606117183e-09
of O 0 1.3577736712733213e-09
germline O 0 1.0707843784985016e-06
origin O 0 1.1721931514330208e-07
. O 0 2.505655913864757e-07

The O 0 3.251235511925188e-07
initial O 0 2.3333795695634763e-07
mutation O 0 4.836875291402976e-07
was O 0 1.7971733257127198e-07
shown O 0 1.6470925956468818e-08
to O 0 3.4386600233915487e-09
have O 0 3.912965951258229e-08
occurred O 0 6.518826722867743e-08
in O 0 1.7850595446233797e-09
the O 0 1.970195384615181e-08
paternally O 0 1.624192009330727e-05
derived O 0 8.711197665434156e-07
RB1 O 0 0.00019873619021382183
allele O 0 1.2312232684053015e-05
. O 0 7.57965267439431e-07

The O 0 4.191231539607543e-07
mutation O 0 1.4229672160581686e-06
is O 0 9.040501680601665e-09
in O 0 9.303575687624743e-10
an O 0 5.633354338563379e-10
area O 0 4.373921669298397e-08
of O 0 3.8470546193103416e-10
the O 0 1.421849415983445e-09
gene O 0 5.198819152951728e-08
that O 0 5.4668101157062665e-09
encodes O 0 2.122125586367929e-08
the O 0 1.329314436304685e-09
protein O 0 1.936397531210332e-08
- O 0 4.378905487101292e-07
binding O 0 5.252541868117078e-08
region O 0 1.9990704913652735e-07
known O 0 4.391702645989426e-08
as O 0 5.59404034206068e-09
the O 0 4.41760139580083e-09
pocket O 1 0.9311023354530334
region O 0 4.831812475458719e-06
and O 0 4.771086992150231e-07
has O 0 2.8650032390942215e-07
been O 0 1.7150197706428116e-08
detected O 0 6.888902781554407e-09
in O 0 8.926787087304433e-11
other O 0 1.79934719901631e-10
cases O 0 1.0538592221109866e-09
of O 0 1.6773303856965072e-09
retinoblastoma B-Disease 0 2.5785113848542096e-06
. O 0 4.993718150103632e-08
. O 0 1.7932543983079086e-07

Low O 0 3.115731669822708e-05
levels O 0 2.5215103960363194e-07
of O 0 2.2955266576474287e-09
beta O 0 2.1935186111932126e-08
hexosaminidase O 0 2.8752234015883005e-07
A O 0 1.2007849825579342e-08
in O 0 3.981109220063672e-09
healthy O 0 7.960236558801626e-08
individuals O 0 1.8464787476801803e-09
with O 0 1.0607850597921242e-08
apparent O 0 0.0002859709784388542
deficiency O 0 0.0030649725813418627
of O 0 1.0974027242482975e-09
this O 0 3.918274149583567e-09
enzyme O 0 4.664433106427168e-07
. O 0 1.374372260443124e-07

Appreciable O 0 0.00014130931231193244
beta O 0 7.283698778337566e-06
hexosaminidase O 0 1.9886718291672878e-05
A O 0 7.698625381635793e-07
( O 0 8.290592745652248e-08
hex O 0 8.510583938914351e-06
A O 0 5.123503044046629e-08
) O 0 6.467564261924963e-09
activity O 0 1.675176442006432e-08
has O 0 9.899907560395604e-09
been O 0 7.708144345031087e-09
detected O 0 3.5213282956192415e-08
in O 0 3.7929077656428944e-09
cultured O 0 2.1284477043082006e-05
skin O 0 0.13975122570991516
fibroblasts O 0 4.507441190071404e-06
and O 0 3.8995517570583615e-07
melanoma B-Disease 0 0.001185030210763216
tissue O 0 2.543925347708864e-06
from O 0 3.474015075610737e-09
healthy O 0 4.5493301570331823e-08
individuals O 0 1.6164793947837097e-09
previously O 0 5.851503104281619e-08
reported O 0 1.9854828678944614e-06
as O 0 4.4111246211286925e-07
having O 0 2.651293652888853e-05
deficiency B-Disease 0 5.779741331934929e-05
of I-Disease 0 6.655995199444931e-10
hex I-Disease 0 3.6738279050041456e-06
A I-Disease 0 2.201037041515974e-08
activity O 0 2.3739859855709255e-08
indistinguishable O 0 2.226829387552698e-08
from O 0 4.1049591503750094e-10
that O 0 3.0043526000334e-10
of O 0 5.133945490953806e-10
patients O 0 4.4499842033474124e-08
with O 0 4.994984010409098e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.04687875881791115
( O 0 1.4251494917516538e-07
TSD B-Disease 0 2.5641082174843177e-05
) O 0 1.6433308758223575e-07
. O 0 2.3527638859377475e-07

Identification O 0 9.62807553150924e-06
and O 0 3.9785385297363973e-07
quantitation O 0 1.775144482962787e-05
of O 0 2.5138072956565338e-08
hex O 0 6.558705354109406e-05
A O 0 1.409607648383826e-07
, O 0 7.674301194526834e-09
amounting O 0 9.834451475398964e-09
to O 0 4.653340823779217e-09
3 O 0 1.6041077799400227e-07
. O 0 2.0451854254588397e-07

5 O 0 2.138209129043389e-05
% O 0 4.0652807342667074e-07
- O 0 8.35910213936586e-06
6 O 0 1.2553263104564394e-06
. O 0 3.6799994518332824e-07

9 O 0 1.4385906069946941e-05
% O 0 1.0756669865941149e-07
of O 0 2.774198870625355e-09
total O 0 7.286241388015924e-09
beta O 0 2.671548138266644e-08
hexosaminidase O 0 1.1229260508116568e-06
activity O 0 1.4932605552075984e-07
, O 0 3.6878842202270334e-09
has O 0 1.7446009081822922e-08
been O 0 5.605329533864278e-09
obtained O 0 2.573262047889102e-09
by O 0 1.9411854346174096e-09
cellulose O 0 6.066931746318005e-06
acetate O 0 3.0444255116890417e-06
gel O 0 3.335744986543432e-05
electrophoresis O 0 7.293102953553898e-06
, O 0 2.7133705060577995e-08
DEAE O 0 2.1659730009560008e-06
- O 0 8.51768447773793e-07
cellulose O 0 1.671713789619389e-06
ion O 0 1.8298477755251952e-07
- O 0 6.36654363006528e-07
exchange O 0 2.94023916325159e-08
chromatography O 0 3.264402437253011e-07
, O 0 1.0017522811267554e-08
radial O 0 6.227715516615717e-07
immunodiffusion O 0 2.639961167005822e-06
, O 0 1.0223909718831692e-08
and O 0 3.6792442870137165e-08
radioimmunoassay O 0 1.649794285185635e-05
. O 0 2.1082598777866224e-07

Previous O 0 3.435355893088854e-06
family O 0 1.9232170700433926e-07
studies O 0 9.858622362912683e-09
suggested O 0 1.2132720605961822e-08
that O 0 6.495685656027206e-10
these O 0 5.600016006468422e-10
individuals O 0 7.173028282458915e-10
may O 0 1.4852058249914535e-08
be O 0 4.980548196087398e-10
compound O 0 2.0869309835802596e-08
heterozygotes O 0 1.195971748302327e-07
for O 0 5.056356444654853e-10
the O 0 1.5556562704688304e-09
common O 0 1.8076185881454876e-08
mutant O 0 2.0034651697642403e-06
TSD B-Disease 0 7.423333045153413e-06
gene O 0 3.987343291100842e-07
and O 0 3.20115276508659e-08
a O 0 1.7482252090417205e-08
rare O 0 4.0769354114900125e-08
( O 0 1.643113911597993e-08
allelic O 0 9.223013535120117e-07
) O 0 3.1925981858194064e-08
mutant O 0 3.098966772085987e-06
gene O 0 9.425371899851598e-06
. O 0 1.0681977755666594e-06

Thus O 0 2.644965888976003e-06
, O 0 1.3568217660520077e-08
the O 0 2.177784397261462e-09
postulated O 0 1.5337934655690333e-07
rate O 0 3.795724978772341e-08
mutant O 0 1.0919521287178213e-07
gene O 0 9.593109240313424e-08
appears O 0 5.73523891489458e-07
to O 0 1.5488113014328064e-09
code O 0 5.623051801961765e-09
for O 0 4.518953544696558e-10
the O 0 3.0583549026630408e-09
expression O 0 1.1608079830693896e-08
of O 0 5.562130200864601e-10
low O 0 4.5290533989827964e-08
amounts O 0 1.4109944324047774e-09
of O 0 1.2501337742776286e-09
hex O 0 2.2776395780965686e-05
A O 0 5.496526682691183e-07
. O 0 3.288525078914972e-07

Heterozygotes O 0 0.00011067047307733446
for O 0 2.297240442317161e-08
the O 0 3.212227595028594e-09
rare O 0 8.313787880354084e-09
mutant O 0 4.215128228679532e-06
may O 0 4.2311108927606256e-07
be O 0 2.6448980783300158e-09
indistinguishable O 0 2.6289759702535775e-08
from O 0 1.2544978389428252e-09
heterozygotes O 0 1.643468863221642e-07
for O 0 8.082963187661107e-10
the O 0 7.470220886318657e-09
common O 0 1.1110852682350014e-07
TSD B-Disease 0 3.9088208723114803e-05
mutant O 0 1.862577846623026e-05
. O 0 1.0905363296842552e-06

However O 0 5.97586563344521e-07
, O 0 4.8443604683257036e-09
direct O 0 4.657674246288934e-09
visualization O 0 8.171169270099199e-07
and O 0 1.4251074276216968e-07
quantitation O 0 2.9950157113489695e-05
of O 0 7.92674992311504e-09
hex O 0 0.00010570398444542661
A O 0 7.442036320526313e-08
by O 0 3.1102032060914553e-10
the O 0 3.826206296242418e-10
methods O 0 3.1052330484726554e-08
described O 0 8.656952559249476e-07
may O 0 3.897472922176348e-08
prevent O 0 6.7495409261653094e-09
false O 0 1.4217552468664962e-08
- O 0 1.2756954674841836e-06
positive O 0 7.424993953009107e-08
prenatal O 0 1.7288454046138213e-06
diagnosis O 0 5.515363682206953e-06
of O 0 5.480100373489449e-09
TSD B-Disease 0 1.4248671504901722e-05
in O 0 4.7804235236981185e-08
fetuses O 0 6.781068805139512e-06
having O 0 1.7820939390844615e-08
the O 0 2.7095523602582716e-09
incomplete O 0 1.1379785291865119e-07
hex B-Disease 0 0.018064899370074272
A I-Disease 0 5.499198323377641e-06
deficiency I-Disease 0 6.661868246737868e-05
of O 0 3.8030545379541536e-10
the O 0 3.0717015597758746e-09
type O 0 3.0774771175856586e-07
described O 0 3.889390143285709e-07
in O 0 8.970096665450455e-09
the O 0 9.689520297229137e-09
four O 0 4.223032590289222e-07
healthy O 0 2.314016910531791e-06
individuals O 0 1.9860802069615602e-07

The O 0 3.0201292702258797e-06
tumor B-Disease 0 4.823180643143132e-05
suppressor O 0 2.8827495043515228e-05
gene O 0 4.402120339364046e-06
Smad4 O 0 2.597909769974649e-05
/ O 0 9.547722584102303e-06
Dpc4 O 0 1.8072438251692802e-05
is O 0 2.243361585385628e-08
required O 0 8.857677369356054e-10
for O 0 6.567819066383151e-10
gastrulation O 0 1.2734517440549098e-06
and O 0 7.599963396387466e-07
later O 0 5.594575895884191e-07
for O 0 7.553563996509638e-09
anterior O 0 8.846489549796388e-07
development O 0 9.356428964935048e-10
of O 0 4.5962317285486165e-10
the O 0 1.3045067248640407e-08
mouse O 0 0.00028436662978492677
embryo O 0 1.1016218195436522e-05
. O 0 8.142387173393217e-07

Mutations O 0 0.00012502764002420008
in O 0 1.0448535192608688e-07
the O 0 4.0265955902896167e-08
SMAD4 O 0 0.0002801981754601002
/ O 0 8.405853441217914e-05
DPC4 O 0 9.423714800504968e-05
tumor B-Disease 0 6.1772520894010086e-06
suppressor O 0 5.572537702391855e-06
gene O 0 2.85091459772957e-07
, O 0 5.150159854139247e-09
a O 0 6.975811928100484e-09
key O 0 2.757693948751694e-07
signal O 0 1.2555860848806333e-06
transducer O 0 3.555126397714048e-07
in O 0 4.8243236072664786e-09
most O 0 3.3028988433159157e-09
TGFbeta O 0 2.7933474484598264e-06
- O 0 2.3621669242857024e-06
related O 0 2.5170553641373772e-08
pathways O 0 1.5126288133160415e-07
, O 0 1.954828743322423e-09
are O 0 8.549887187125904e-11
involved O 0 2.4405838461305507e-10
in O 0 6.98956670319717e-10
50 O 0 2.1382721371310254e-08
% O 0 3.830728179110565e-09
of O 0 2.0969300962292436e-08
pancreatic B-Disease 0 0.3193270266056061
cancers I-Disease 1 0.6440450549125671
. O 0 1.718424073260394e-06

Homozygous O 0 0.0013705308083444834
Smad4 O 0 0.0005214533302932978
mutant O 0 0.00030444690492004156
mice O 0 0.006089383736252785
die O 0 0.0004861086781602353
before O 0 8.339011259295148e-08
day O 0 1.0201746647453547e-07
7 O 0 3.635260554801789e-07
. O 0 1.8215096986295976e-07

5 O 0 1.0401711733720731e-05
of O 0 1.9074771273608349e-07
embryogenesis O 0 4.085871478309855e-05
. O 0 2.316810196134611e-06

Mutant O 0 2.2747806724510156e-05
embryos O 0 3.662402832560474e-06
have O 0 8.345343616156242e-08
reduced O 0 1.337933142053771e-08
size O 0 1.9805906248393512e-08
, O 0 9.629310682157666e-09
fail O 0 4.857538371538794e-08
to O 0 3.484227351080449e-09
gastrulate O 0 7.7639006121899e-06
or O 0 5.0927248196330765e-08
express O 0 8.69131344671814e-09
a O 0 3.4469207488285747e-09
mesodermal O 0 6.424265279747488e-07
marker O 0 2.982893056469038e-05
, O 0 4.603088044063952e-08
and O 0 5.9264326779384646e-08
show O 0 4.798767804459203e-06
abnormal O 0 3.404427843634039e-06
visceral O 0 5.67529195905081e-06
endoderm O 0 2.1625015506288037e-05
development O 0 1.4729458541751228e-07
. O 0 2.0886159290967043e-07

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 5.6365522027590487e-08
the O 0 2.8762183745811853e-08
Smad4 O 0 0.00013763744209427387
- O 0 0.0017397196497768164
deficient O 0 1.119312128139427e-05
embryos O 0 1.2317114794768713e-07
results O 0 1.9808512163876912e-08
from O 0 1.6365574451171483e-09
reduced O 0 1.0436342456898728e-08
cell O 0 5.684586312781903e-08
proliferation O 0 2.6785892615066587e-08
rather O 0 5.2187361099242935e-09
than O 0 1.9894035307999047e-09
increased O 0 2.3798071069336402e-08
apoptosis O 0 1.2163814062660094e-06
. O 0 2.058982460084735e-07

Aggregation O 0 1.838934258557856e-05
of O 0 1.7397668727880955e-07
mutant O 0 9.235308425559197e-06
Smad4 O 0 3.055970955756493e-05
ES O 0 1.943511279023369e-06
cells O 0 1.8184600492077152e-07
with O 0 3.6326068819647617e-09
wild O 0 2.9733982387369906e-07
- O 0 1.638906542211771e-05
type O 0 1.3709296808883664e-06
tetraploid O 0 1.6868758393684402e-05
morulae O 0 2.2107193217379972e-05
rescues O 0 1.8370483303442597e-05
the O 0 1.3208891402882728e-07
gastrulation B-Disease 0 7.130006270017475e-05
defect I-Disease 0 5.2162347856210545e-05
. O 0 8.731208822609915e-07

These O 0 4.2043663484037097e-07
results O 0 7.232755905306476e-08
indicate O 0 3.8298388460589194e-08
that O 0 2.834759316172608e-09
Smad4 O 0 1.016767964756582e-05
is O 0 2.4323794534097942e-08
initially O 0 2.3420938077833853e-08
required O 0 2.3024933348825272e-10
for O 0 2.960030137666436e-11
the O 0 2.2128000820575977e-10
differentiation O 0 2.5219124566433493e-09
of O 0 2.769730000906634e-10
the O 0 1.522323267444392e-09
visceral O 0 1.5436810940627765e-07
endoderm O 0 2.0074203348485753e-06
and O 0 2.168649793077293e-08
that O 0 1.0968105312869625e-09
the O 0 2.5770734435326403e-09
gastrulation B-Disease 0 9.262149660571595e-07
defect I-Disease 0 4.574668537316029e-07
in O 0 2.3167718854466557e-09
the O 0 1.3839574819485279e-08
epiblast O 0 3.733840640052222e-05
is O 0 1.529273774281137e-08
secondary O 0 4.420154908757468e-09
and O 0 1.4274342596820588e-08
non O 0 3.7275306397077657e-08
- O 0 2.376737757003866e-05
cell O 0 2.6416952096042223e-05
autonomous O 0 4.247110155120026e-06
. O 0 1.1652932698780205e-06

Rescued O 0 0.00012959969171788543
embryos O 0 2.0683255570475012e-05
show O 0 0.00013640004908666015
severe O 0 7.30553874745965e-05
anterior O 0 0.0001711599325062707
truncations O 0 0.00017249159282073379
, O 0 3.211678460957046e-07
indicating O 0 7.928149443614529e-07
a O 0 4.837659517420434e-08
second O 0 2.4572457846261386e-07
important O 0 3.2416789252920353e-09
role O 0 2.2467188998120946e-08
for O 0 8.504549953158858e-09
Smad4 O 0 1.1201728739251848e-05
in O 0 8.559950259723337e-08
anterior O 0 2.119579767168034e-05
patterning O 0 0.0002953431976493448
during O 0 3.761983293770754e-07
embryogenesis O 0 1.2977069673070218e-05
. O 0 1.1749793884519022e-06

Prevalence O 0 0.0005255911382846534
of O 0 3.3200936400135106e-07
p16 O 0 2.0725374270114116e-05
and O 0 1.8675279989111004e-07
CDK4 O 0 3.661188020487316e-05
germline O 0 8.476927177980542e-06
mutations O 0 1.8384482700639637e-06
in O 0 2.5508141376917592e-08
48 O 0 2.714069751164061e-06
melanoma B-Disease 0 0.24658796191215515
- O 1 0.591159462928772
prone O 0 0.0013884414220228791
families O 0 7.227363596484793e-08
in O 0 1.896504464582449e-08
France O 0 4.109768724447349e-06
. O 0 4.840363772018463e-07

The O 0 2.1943069441476837e-06
French O 0 3.989228207501583e-05
Familial B-Disease 0 0.004166667349636555
Melanoma I-Disease 1 0.9735376834869385
Study O 0 5.517113663700002e-07
Group O 0 1.5060404621181078e-06
. O 0 5.310556048243598e-07

Germline O 0 0.0012285291450098157
mutations O 0 3.4021344617940485e-05
in O 0 2.652831732063987e-08
the O 0 5.925514301452495e-09
p16 O 0 5.87468491630716e-07
and O 0 1.2066280419276154e-08
CDK4 O 0 3.3284741220995784e-06
genes O 0 2.1371798197833414e-07
have O 0 1.0133734207329326e-07
been O 0 8.916232019373638e-08
reported O 0 3.038720564063624e-08
in O 0 1.5791201679604683e-10
a O 0 1.1212561989992764e-09
subset O 0 1.0503740988099253e-08
of O 0 9.905329001469454e-09
melanoma B-Disease 0 0.0022256900556385517
pedigrees O 0 2.1866653696633875e-05
, O 0 1.771118363080859e-08
but O 0 2.0135990652647706e-09
their O 0 4.0837120351966405e-09
prevalence O 0 5.090718332212418e-06
is O 0 6.370733984795152e-08
not O 0 2.9475597518313634e-09
well O 0 3.290925754129148e-09
known O 0 1.3125962539106695e-07
. O 0 1.2281434180749784e-07

We O 0 1.9069638028668123e-06
searched O 0 2.1007095085678884e-07
for O 0 2.0516732757158707e-09
such O 0 3.12923376100116e-09
germline O 0 1.4856075267744018e-06
mutations O 0 3.448961933827377e-07
in O 0 6.959372633730254e-09
48 O 0 1.7373628224959248e-07
French O 0 1.0453002687427215e-05
melanoma B-Disease 0 0.36895477771759033
- O 0 0.23207330703735352
prone O 0 0.00046136282617226243
families O 0 2.5358680488807295e-08
selected O 0 4.4043333424781395e-09
according O 0 7.284695069387226e-10
to O 0 5.63048607737926e-10
two O 0 1.6997651064443176e-09
major O 0 3.24933635553748e-09
criteria O 0 5.44683720349326e-09
families O 0 1.067899990658816e-09
with O 0 4.369006267879172e-10
at O 0 9.40138722427264e-09
least O 0 1.6381751510863296e-09
three O 0 1.3378840257871616e-09
affected O 0 2.6992668100689343e-09
members O 0 3.6738409536773986e-10
( O 0 6.111590122870325e-10
n O 0 7.153183645414174e-08
= O 0 3.019810321802652e-07
20 O 0 1.39811469068718e-08
) O 0 5.88636639431428e-10
or O 0 1.5079434367848421e-09
families O 0 8.309138932460769e-10
with O 0 1.84190510066351e-10
two O 0 9.740699802307518e-09
affected O 0 1.1305446356857374e-08
members O 0 1.1298455504515914e-09
, O 0 7.079177244406765e-10
one O 0 6.616655001678851e-10
of O 0 1.3534783016577734e-10
them O 0 1.2283882799835055e-09
affected O 0 1.4923466906680005e-09
before O 0 4.454829005684502e-10
the O 0 2.411487676212687e-10
age O 0 9.551455182332802e-10
of O 0 8.602574208538272e-11
50 O 0 2.0784607368540264e-09
( O 0 9.27267929107245e-10
n O 0 1.6803676317067584e-07
= O 0 1.7209727047884371e-06
28 O 0 8.62382705690834e-07
) O 0 3.3768421392466053e-09
, O 0 1.6296548555061463e-09
and O 0 4.909557649313001e-09
one O 0 1.4388347180371852e-09
additional O 0 3.2604738908759145e-09
minor O 0 3.1913923947968215e-08
criterion O 0 1.2754351246258011e-06
. O 0 4.7632036626055196e-07

Sixteen O 0 2.412204230495263e-05
different O 0 1.1289498615951743e-06
p16 O 0 3.6663233913714066e-05
germline O 0 2.3046935893944465e-05
mutations O 0 5.97043572270195e-06
were O 0 2.682705257939233e-08
found O 0 4.187417967926876e-09
in O 0 1.8586197025882711e-09
21 O 0 1.280137524872771e-07
families O 0 6.390788342969245e-09
, O 0 1.1143823641646122e-09
while O 0 1.285305972764661e-09
one O 0 4.156773147911963e-09
germline O 0 3.2982958941829565e-07
mutation O 0 4.8704336563787365e-08
, O 0 4.030127787046922e-09
Arg24His O 0 1.010481810226338e-06
, O 0 6.021411369516727e-09
was O 0 6.954253706226154e-08
detected O 0 2.7090576892874196e-08
in O 0 8.158736464203287e-10
the O 0 1.0792671645276641e-08
CDK4 O 0 1.9969025743193924e-05
gene O 0 3.1164111078396672e-06
. O 0 7.844359402042755e-07

The O 0 1.703018455145866e-07
frequency O 0 4.403811146858061e-07
of O 0 7.899325638049959e-09
p16 O 0 8.562021776015172e-07
gene O 0 2.2599827786962123e-07
mutation O 0 1.312461108682328e-07
in O 0 2.374745511346532e-09
our O 0 4.4247014940879126e-09
sample O 0 7.083868158730411e-09
( O 0 3.274265303332413e-09
44 O 0 2.3496960821489665e-08
% O 0 1.624273826550393e-09
) O 0 1.0540642803036349e-09
is O 0 1.4832006733911385e-09
among O 0 9.828483582552394e-10
the O 0 1.5902772432241363e-09
highest O 0 4.5509619184258554e-08
rates O 0 6.515794126471519e-08
yet O 0 7.268114110559054e-09
reported O 0 2.56350016769602e-08
and O 0 1.0369113345731762e-09
the O 0 1.3582166502601467e-09
CDK4 O 0 1.0432855560793541e-05
mutation O 0 1.4064011111258878e-07
is O 0 1.5531244068611727e-09
the O 0 5.251404311401586e-10
second O 0 2.5009329718272966e-08
mutation O 0 9.078953411290058e-08
detected O 0 2.6882780446157994e-08
in O 0 4.128066499742289e-10
this O 0 6.667202345767009e-10
gene O 0 1.2112863601032586e-07
worldwide O 0 1.2410782801453024e-07
. O 0 1.679134129517479e-07

In O 0 4.119121115309099e-07
summary O 0 1.981412196983001e-06
, O 0 3.3420633371861186e-08
our O 0 1.9617022672946405e-08
results O 0 1.0958576268649267e-08
show O 0 1.473281656672043e-07
frequent O 0 1.6782914613600042e-08
involvement O 0 1.1918858788817488e-08
of O 0 3.943305959541732e-10
the O 0 1.3096542739177153e-09
p16 O 0 2.3301240048567706e-07
gene O 0 1.592318312759744e-07
in O 0 3.077896337799757e-08
familial B-Disease 0 0.00032260562875308096
melanoma I-Disease 1 0.9951451420783997
and O 0 1.0498291658223025e-06
confirm O 0 2.921047723702941e-07
the O 0 2.0444816950515587e-09
role O 0 2.1271912231668466e-08
of O 0 9.897468400410503e-10
the O 0 4.4869712390038785e-09
CDK4 O 0 3.243163746446953e-06
gene O 0 8.565797315895907e-08
as O 0 1.875528887751443e-08
a O 0 9.114209120753003e-08
melanoma B-Disease 0 0.00048065377632156014
- O 0 6.680479600618128e-06
predisposing O 0 9.556340046401601e-06
gene O 0 2.4385774395341286e-06
. O 0 9.529681221920328e-08
. O 0 3.377923576408648e-07

Progression O 0 0.00019952318689320236
of O 0 1.8252256950290757e-07
somatic O 0 1.972381869563833e-05
CTG O 0 0.00013373614638112485
repeat O 0 1.2746806532959454e-05
length O 0 1.8876215790442075e-06
heterogeneity O 0 2.47852472057275e-06
in O 0 2.750480732061078e-08
the O 0 5.4177561992219125e-08
blood O 0 5.797981884825276e-06
cells O 0 1.8933745877802721e-06
of O 0 4.07937079671683e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.00010088413546327502
. O 0 8.491876428706746e-07

The O 0 2.498049411769898e-07
genetic O 0 1.140233166552207e-06
basis O 0 3.4446884455974214e-07
of O 0 1.8411889186609187e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.09416832029819489
DM B-Disease 1 1.0
) O 0 2.144432755812886e-06
is O 0 5.71876368482549e-09
the O 0 6.804278251948404e-10
expansion O 0 6.0755169783988094e-09
of O 0 5.854790541270916e-10
an O 0 3.5018898891792105e-09
unstable O 0 1.3702481737709604e-05
CTG O 0 2.1210642444202676e-05
repeat O 0 8.178848815987294e-07
in O 0 3.4699554340988925e-09
the O 0 9.715020787837148e-09
34 O 0 7.057465012394459e-08
UTR O 0 1.1772787047448219e-06
of O 0 4.959751720434724e-09
the O 0 6.64946639972186e-08
DM B-Disease 1 0.9999998807907104
protein O 0 1.0690609997254796e-06
kinase O 0 1.1289542953818454e-06
gene O 0 3.0417217544709274e-07
on O 0 2.5827247895904293e-07
chromosome O 0 0.0001132320030592382
19 O 0 3.160597316309577e-06
. O 0 6.807055683566432e-07

One O 0 1.9511849131959025e-06
of O 0 5.900060440211519e-09
the O 0 2.3359940648504107e-09
principal O 0 7.962389858562346e-09
features O 0 2.081068117831819e-08
of O 0 1.7939850716075512e-09
the O 0 2.0871088679541572e-07
DM B-Disease 1 1.0
mutation O 0 2.9794573492836207e-06
is O 0 2.7249398293349714e-09
an O 0 2.745409455329195e-10
extraordinarily O 0 5.6732673670012446e-08
high O 0 2.65587960512903e-08
level O 0 3.2737283994777044e-09
of O 0 4.1483597112979e-10
somatic O 0 2.345648510981846e-07
mosaicism O 0 1.2248032362549566e-05
, O 0 1.9035386600307902e-08
due O 0 4.247944218604971e-09
to O 0 1.485485512375817e-09
an O 0 1.4009087223598726e-09
extremely O 0 2.8670603668956574e-08
high O 0 1.232373669779463e-08
degree O 0 1.0403186090357508e-09
of O 0 3.292229822093873e-10
somatic O 0 3.157164485401154e-07
instability O 0 6.982948889344698e-06
both O 0 9.641845544194894e-09
within O 0 3.333848974662601e-09
and O 0 4.415874332863723e-09
between O 0 5.419396487127415e-09
different O 0 2.8065164414670107e-08
tissues O 0 2.3458928808395285e-06
. O 0 2.3468859922104457e-07

This O 0 6.648635348938114e-07
instability O 0 2.56183943747601e-06
appears O 0 5.18534136517701e-07
to O 0 2.8749003178063504e-09
be O 0 9.081820295797627e-10
biased O 0 2.3087491030082674e-08
towards O 0 1.7883924341433044e-09
further O 0 8.798474726567918e-10
expansion O 0 2.2184725168017394e-09
and O 0 4.018460675325741e-09
continuous O 0 2.324519066121411e-08
throughout O 0 9.76015268605579e-09
the O 0 7.537847679373044e-09
life O 0 1.1565514768108187e-08
of O 0 1.0707486286509749e-10
an O 0 1.7682304231936286e-10
individual O 0 4.181701096506174e-10
, O 0 6.476633673813126e-10
features O 0 2.034020383234747e-07
that O 0 1.0123476101853157e-07
could O 0 4.043219234972639e-07
be O 0 2.2041111158443982e-09
associated O 0 2.6285733589759275e-09
with O 0 1.6513825862318754e-09
the O 0 1.8472125162816155e-08
progressive O 0 5.776451530437043e-07
nature O 0 2.194640025265926e-08
of O 0 2.0575909864817277e-09
the O 0 1.6436695204902207e-07
disease O 0 1.9368651919648983e-05
. O 0 1.8011505176218634e-07

Although O 0 8.987471460386587e-07
increasing O 0 1.5086482108017663e-07
measured O 0 1.7828647003170772e-07
allele O 0 2.6593880875225295e-07
size O 0 4.877164272443224e-08
between O 0 2.1795543148073193e-07
patients O 0 2.920201040979009e-07
clearly O 0 1.160188531912354e-07
correlates O 0 4.040304446562004e-08
with O 0 7.337168095311597e-10
an O 0 1.439543040326896e-09
increased O 0 9.377804843779813e-08
severity O 0 3.0377525490621338e-06
of O 0 9.759520303020963e-09
symptoms O 0 9.630426575313322e-06
and O 0 2.2301183122408474e-09
an O 0 6.148737075051258e-10
earlier O 0 3.412246485368087e-08
age O 0 5.716113804510314e-09
of O 0 2.652388864099464e-10
onset O 0 1.4026186079263425e-07
, O 0 4.3155040652109733e-10
this O 0 5.460385615885244e-11
correlation O 0 2.0419419044515053e-08
is O 0 8.197721612646092e-09
not O 0 4.656748320286397e-10
precise O 0 5.036437400463001e-08
and O 0 5.804582059454333e-08
measured O 0 2.1174865594275616e-07
allele O 0 6.427071497228098e-08
length O 0 8.635332164885767e-07
cannot O 0 9.174066661898905e-08
be O 0 1.217207334924808e-09
used O 0 1.272698613163925e-09
as O 0 1.3575458535086682e-09
an O 0 3.6711234052688724e-10
accurate O 0 2.629864468417509e-07
predictor O 0 1.5028009556772304e-06
of O 0 1.663020832154416e-09
age O 0 2.0864256100594503e-08
of O 0 5.706157324425476e-09
onset O 0 1.3256333659228403e-05
. O 0 2.9070665163999365e-07

In O 0 3.623150064413494e-07
order O 0 2.4131098896873482e-08
to O 0 2.280366784290777e-09
further O 0 1.7923467154901118e-09
characterize O 0 1.5263182717717427e-07
the O 0 9.173362514047767e-09
dynamics O 0 1.2691500614891993e-06
of O 0 1.353782153046268e-07
DM B-Disease 1 1.0
CTG O 0 0.0002531290811020881
repeat O 0 1.8362195532972692e-06
somatic O 0 8.832714684103848e-07
instability O 0 1.976765361177968e-06
, O 0 5.794248192358964e-09
we O 0 2.344108240848186e-09
have O 0 6.760631499069802e-10
studied O 0 2.635913709525539e-09
repeat O 0 1.684700094983782e-07
length O 0 1.4055162012027722e-07
changes O 0 2.3540909221964057e-09
over O 0 2.3182571418089992e-09
time O 0 6.551682307787132e-09
in O 0 9.58913570769937e-09
111 O 0 1.597417394805234e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 5.65057746371167e-07
with O 0 3.664625713994951e-09
varying O 0 6.816794240194213e-08
clinical O 0 6.712876370329468e-07
severity O 0 7.54139091441175e-06
and O 0 4.939363051903456e-08
CTG O 0 2.786445520541747e-06
repeat O 0 2.3683739414082083e-07
size O 0 2.987583869185073e-08
over O 0 2.077922722776293e-08
time O 0 1.2888515144027224e-08
intervals O 0 5.25400452033864e-08
of O 0 4.190971181206038e-10
1 O 0 1.0477948286791161e-08
- O 0 6.9266393438738305e-06
7 O 0 3.858136778944754e-07
years O 0 7.362969967061872e-08
. O 0 7.899494391949702e-08

We O 0 2.7666710593621247e-06
have O 0 1.0707763564710149e-08
found O 0 1.0677064787856239e-09
a O 0 6.198723201400469e-10
direct O 0 3.274671200870216e-09
progression O 0 2.1302319055394037e-06
of O 0 4.77154593614415e-10
the O 0 7.493449194484469e-10
size O 0 1.506917790550233e-08
heterogeneity O 0 1.5041774759083637e-07
over O 0 1.3272503096573018e-08
time O 0 5.115376122688531e-09
related O 0 5.215558540605514e-10
to O 0 7.330845375186357e-10
initial O 0 3.790904479217261e-09
CTG O 0 6.566960450982151e-07
repeat O 0 9.920742627400614e-08
size O 0 5.130181790491406e-08
and O 0 1.96626483983664e-08
the O 0 1.7315948674934134e-09
time O 0 1.7753560399569324e-08
interval O 0 1.0220794877113804e-07
and O 0 8.778581417345777e-09
always O 0 1.453038578347332e-08
biased O 0 4.631171890423502e-08
towards O 0 3.6066210018503853e-09
further O 0 4.687529919777944e-09
expansion O 0 8.006359308865285e-08
. O 0 8.750851776540003e-08

Attempts O 0 6.664163720415672e-06
to O 0 8.370195558882187e-08
mathematically O 0 1.7780865846361849e-07
model O 0 5.9172723609890454e-08
the O 0 6.3592100474352264e-09
dynamics O 0 1.464494516767445e-06
have O 0 9.770509450390819e-07
proved O 0 1.2192083431727951e-06
only O 0 1.2267920013186995e-08
partially O 0 3.7666464436370006e-07
successful O 0 1.256838277896577e-08
suggesting O 0 1.4607803855426482e-08
that O 0 3.425716099680898e-10
individual O 0 1.3967592360497605e-10
specific O 0 2.1578909492614429e-10
genetic O 0 3.81523541648221e-08
and O 0 3.1512772835640135e-08
/ O 0 2.966489091704716e-06
or O 0 2.8333715818007477e-08
environmental O 0 1.2873012877889778e-08
factors O 0 6.166274602037447e-09
also O 0 1.6962931681518967e-07
play O 0 1.5771052019886156e-08
a O 0 4.467543668340568e-09
role O 0 2.305536739299896e-08
in O 0 1.9304492226979164e-08
somatic O 0 1.3738838333665626e-06
mosaicism O 0 5.393120591179468e-05
. O 0 8.830122766312343e-08
. O 0 3.8366022181435255e-07

Aspartylglucosaminuria B-Disease 1 0.9999918937683105
among O 0 4.390381036500912e-06
Palestinian O 0 5.261784099275246e-05
Arabs O 0 5.1836213970091194e-05
. O 0 1.7930609601535252e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 0.1007695123553276
AGU B-Disease 1 1.0
) O 0 8.555932708986802e-07
is O 0 1.1038542524488548e-08
a O 0 1.0474431100249149e-08
rare O 0 2.384341826200398e-07
disorder B-Disease 0 0.00016567598504479975
of I-Disease 0 2.2276778199881164e-09
glycoprotein I-Disease 0 1.2806939594156574e-05
metabolism I-Disease 0 0.001956186257302761
caused O 0 7.195246212177153e-07
by O 0 1.6004955138981813e-09
the O 0 2.6035272071567306e-07
deficiency B-Disease 0 0.00038949487498030066
of I-Disease 0 6.59541143921416e-10
the I-Disease 0 1.8574581872599083e-08
lysosomal I-Disease 0 6.869805656606331e-05
enzyme I-Disease 0 4.04573256673757e-06
aspartylglucosaminidase I-Disease 0 7.238827674882486e-05
( O 0 9.180963900234929e-08
AGA O 0 4.689643901656382e-06
) O 0 2.3067667598297703e-07
. O 0 2.588346603715763e-07

AGU B-Disease 1 1.0
is O 0 2.5844867195701227e-05
inherited O 0 2.6249503207509406e-05
as O 0 2.4423979283483277e-08
an O 0 2.572866009131758e-08
autosomal O 1 0.7086296081542969
recessive O 1 0.927780270576477
trait O 0 0.0007521724910475314
and O 0 1.266543108613405e-06
occurs O 0 2.3235440238522642e-08
with O 0 8.719885369323777e-10
a O 0 2.018668254777367e-08
high O 0 2.099608025218913e-07
frequency O 0 1.208508365380112e-06
in O 0 3.553335758965659e-08
Finland O 0 0.00024506135378032923
because O 0 1.730446719250267e-08
of O 0 4.1807360351420186e-10
a O 0 3.140452520256076e-08
founder O 0 1.6720214262022637e-06
effect O 0 3.03265863976776e-07
. O 0 1.8163109416491352e-07

While O 0 3.44663453688554e-06
very O 0 8.278788499183065e-08
few O 0 2.8856476319560898e-08
patients O 0 4.20235792830681e-08
with O 0 3.317093089094669e-08
AGU B-Disease 1 1.0
have O 0 2.9618558983202092e-06
been O 0 2.1446240339173528e-07
reported O 0 8.273295293292904e-08
from O 0 8.248298155599798e-10
non O 0 9.917937582315517e-09
- O 0 1.3758780141870375e-06
Finnish O 0 3.7922695810266305e-06
origin O 0 1.544823291510511e-08
, O 0 1.6787907952675596e-08
we O 0 2.824305056492449e-07
diagnosed O 0 7.546491815446643e-06
the O 0 1.7689945508436722e-08
disorder O 0 2.0383604351081885e-05
in O 0 2.6588078405609394e-09
8 O 0 6.417933207103488e-08
patients O 0 8.026094455715338e-09
originating O 0 5.2781179427086045e-09
from O 0 6.051988910016348e-10
3 O 0 3.1323090787793717e-09
unrelated O 0 1.7065163504526026e-08
families O 0 1.1490645768219565e-08
, O 0 4.875317927144351e-10
all O 0 3.7565187072097217e-10
Palestinian O 0 1.270031475542055e-06
Arabs O 0 1.1349302440066822e-06
from O 0 3.533046299963871e-09
the O 0 1.8870283113869846e-09
region O 0 5.520577417428285e-08
of O 0 3.549120997092814e-09
Jerusalem O 0 2.919776670751162e-05
. O 0 9.517381158730132e-07

The O 0 5.014118755752861e-07
clinical O 0 4.673107468988746e-06
diagnosis O 0 0.0007648978498764336
of O 0 6.918347139617254e-07
AGU B-Disease 1 1.0
is O 0 4.930026079819072e-06
often O 0 1.909293558810532e-07
difficult O 0 2.3249095093547112e-08
, O 0 7.486648523347128e-10
in O 0 1.188536213891922e-10
particular O 0 5.674635761288016e-10
early O 0 7.286061087796725e-09
in O 0 1.228528834218423e-09
the O 0 4.783485607617877e-09
course O 0 1.2371833690849598e-07
of O 0 5.314015893986834e-10
the O 0 8.309526577932047e-08
disease O 0 2.686853576960857e-06
, O 0 1.2055001441524382e-09
and O 0 1.861358511767719e-09
most O 0 7.943935093068788e-11
of O 0 6.111586930979129e-11
the O 0 2.099005858013925e-09
patients O 0 9.183621862973723e-09
are O 0 4.9912585176059565e-09
diagnosed O 0 2.1313758225005586e-06
after O 0 9.616573315440746e-09
the O 0 5.001055125575249e-09
age O 0 7.705395432822115e-09
of O 0 4.741444459277488e-10
5 O 0 2.426142842182344e-08
years O 0 4.01350668255418e-08
. O 0 1.4946068915833166e-07

However O 0 1.8180835468228906e-06
, O 0 2.9173079951760883e-08
since O 0 1.4392527170059566e-08
these O 0 3.7868357338766145e-09
patients O 0 1.3597077241911393e-08
excrete O 0 2.0815800638729343e-08
early O 0 2.6917912343549233e-09
large O 0 3.343947896361499e-10
amounts O 0 4.875745363008832e-10
of O 0 2.63813554335357e-10
aspartylglucosamine O 0 7.358891025432968e-07
in O 0 3.1597859884158197e-09
urine O 0 4.407873532841222e-08
, O 0 3.4018457495399446e-10
biochemical O 0 1.0171277153858682e-08
screening O 0 2.5818572169100662e-08
is O 0 1.2522773928935749e-08
easy O 0 3.490108824166782e-08
by O 0 3.887804300717335e-09
urine O 0 3.6289179661253e-07
chromatography O 0 1.2240875548741315e-06
. O 0 5.075154518863201e-08
. O 0 1.933744329107867e-07

Detection O 0 7.216671747301007e-06
of O 0 3.8080450792676857e-08
heterozygous O 0 1.2443841796994093e-06
carriers O 0 1.1772480235094918e-07
of O 0 1.2172636232321565e-08
the O 0 1.2410099770931993e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 7.32988667095924e-07
ATM O 0 1.4998515780462185e-06
) O 0 1.7006286157084105e-08
gene O 0 7.415341940486542e-08
by O 0 8.764377668057932e-09
G2 O 0 6.879699867567979e-06
phase O 0 3.571587399164855e-07
chromosomal O 0 7.400909089483321e-05
radiosensitivity O 0 2.5035538783413358e-05
of O 0 4.026679789603804e-08
peripheral O 0 0.0003646637196652591
blood O 0 8.443718252237886e-05
lymphocytes O 0 5.8555127907311544e-05
. O 0 7.403668291772192e-07

In O 0 0.0009825414745137095
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.02596002072095871
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.7753569636624889e-07
patients O 0 3.68838541930927e-08
, O 0 1.7566876842067813e-09
mutations O 0 2.742486593376725e-08
in O 0 3.524510128194436e-10
a O 0 4.233134731634891e-09
single O 0 2.81036260929568e-08
gene O 0 7.465636997494585e-08
, O 0 2.87958146216738e-09
ATM O 0 1.2671324611801538e-07
, O 0 2.4350939042960817e-09
result O 0 2.1510542236313768e-09
in O 0 2.5268345638096434e-08
an O 0 8.152086957124993e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 2.1235392466678604e-07
embraces O 0 2.1241996250864759e-07
a O 0 1.5440161149626874e-08
variety O 0 7.740645457943174e-09
of O 0 1.123422466164925e-09
clinical O 0 6.294495591419036e-08
features O 0 1.9508164768922143e-05
and O 0 3.629226739576552e-06
manifests O 0 1.0237226888420992e-06
extreme O 0 7.064649594212824e-07
radiosensitivity O 0 7.998611181392334e-06
and O 0 1.0631144853334717e-08
a O 0 1.2107062019595105e-08
strong O 0 4.996881131091868e-08
pre O 0 1.2270515981072094e-06
- O 0 0.0002626654750201851
disposition O 0 7.700976311753038e-06
to O 0 1.1314488546076973e-07
malignancy B-Disease 0 0.00010006476804846898
. O 0 2.75359951729115e-07

Heterozygotes O 0 0.00019006614456884563
for O 0 4.303967315877344e-08
the O 0 5.74453062895941e-09
ATM O 0 3.999381590347184e-07
gene O 0 2.886867775941937e-07
have O 0 5.327519048137219e-08
no O 0 5.122679613833725e-09
clinical O 0 1.7594247836427712e-08
expression O 0 5.547165216057692e-08
of O 0 1.069745447779269e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.6483456874993863e-06
may O 0 2.525368074657308e-07
be O 0 2.3088372103075017e-08
cancer B-Disease 0 7.687136758249835e-07
prone O 0 4.446683874448354e-07
with O 0 1.0753644641425808e-09
a O 0 1.5859434654430515e-08
moderate O 0 6.372659981934703e-07
increase O 0 9.154294211555225e-09
in O 0 1.151971629198556e-09
in O 0 9.853133420278937e-09
vitro O 0 7.071416348480852e-06
radiosensitivity O 0 2.4233107978943735e-05
. O 0 3.712389968768548e-07

We O 0 4.68677026219666e-05
performed O 0 6.227430731087225e-07
a O 0 5.1094893649406004e-08
blind O 0 1.3581080793301226e-06
chromosomal O 0 9.056847375177313e-06
analysis O 0 6.061906532295325e-08
on O 0 1.726437091065236e-07
G2 O 0 3.9990482036955655e-05
- O 0 2.362383747822605e-05
phase O 0 1.6539215152988618e-07
lymphocytes O 0 1.7801210105972132e-07
from O 0 1.4640821888178834e-09
7 O 0 1.8323374817441618e-08
unrelated O 0 2.7134643687531934e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 6.590625503122283e-07
, O 0 1.23784549277417e-09
13 O 0 4.472223924523178e-09
obligate O 0 4.945858478322407e-08
A B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 2.875106110877823e-05
( O 0 1.0103025083196826e-08
parents O 0 2.8779838512349443e-09
of O 0 1.46658019062329e-10
the O 0 4.989583413106402e-09
patients O 0 1.684120931599864e-08
) O 0 1.7080297176619297e-09
, O 0 3.2234963587285392e-09
and O 0 7.259108425472505e-09
14 O 0 1.4775937806632555e-08
normal O 0 4.732862990408648e-09
controls O 0 8.171934950951254e-08
following O 0 4.191069269410264e-09
X O 0 3.445895345066674e-06
- O 0 6.412880111383856e-07
irradiation O 0 5.693918581073376e-08
with O 0 2.960863110246237e-09
1 O 0 1.182833919699533e-08
Gy O 0 3.3795229228417156e-06
in O 0 1.6094680033162945e-09
order O 0 1.2963827789036486e-09
to O 0 4.067083614334166e-10
evaluate O 0 4.467433090127315e-09
this O 0 5.153095172794053e-10
cytogenetic O 0 1.356488468218231e-07
method O 0 1.0112471748868757e-08
as O 0 1.682659234170103e-09
a O 0 1.3201374438054359e-09
tool O 0 2.8333337454000684e-08
for O 0 4.160642108619328e-10
detection O 0 1.4594046859883747e-08
of O 0 6.902169391587165e-10
ATM O 0 1.0463587614140124e-06
carriers O 0 2.5946783921426686e-07
. O 0 1.2510723479408625e-07

Both O 0 1.9928618712583557e-05
A B-Disease 1 0.9999752044677734
- I-Disease 1 0.9999991655349731
T I-Disease 1 1.0
homozygotes O 0 0.00020325482182670385
and O 0 1.55452624994723e-07
heterozygotes O 0 3.649910013336921e-06
showed O 0 4.390542756027571e-07
significantly O 0 5.380211121064349e-08
increased O 0 5.872374586601836e-09
levels O 0 1.874969957071926e-09
of O 0 3.7517355888638804e-10
radiation O 0 1.1023216757166665e-06
- O 0 3.4506996598793194e-05
induced O 0 0.00012888442142866552
chromatid O 0 0.00029919244116172194
damage O 0 2.1740852389484644e-06
relative O 0 2.6923625995323164e-08
to O 0 6.509704775226055e-09
that O 0 1.2062270071666603e-09
of O 0 1.2260990001067285e-09
normal O 0 1.5467846026240295e-07
controls O 0 3.628335252869874e-05
. O 0 8.463175049655547e-07

These O 0 4.496303347423236e-07
results O 0 1.3601673742869025e-07
show O 0 4.840280212192738e-07
that O 0 1.1525518317512251e-09
the O 0 1.5467448433170716e-09
G2 O 0 3.160859478157363e-06
- O 0 4.6833949340907566e-07
phase O 0 7.607716412394439e-08
chromosomal O 0 1.7923514405993046e-06
radiosensitivity O 0 1.1949222198381904e-06
assay O 0 5.691876481250802e-07
can O 0 4.425725208534459e-08
be O 0 6.058560875210617e-10
used O 0 6.056700696532857e-10
for O 0 1.5884515924824427e-10
the O 0 4.85886775258848e-10
detection O 0 1.4563347860985232e-08
of O 0 5.593752128163487e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.00023784696531947702
. O 0 1.009957827591279e-06

In O 0 4.5479683308258245e-07
combination O 0 2.3442194674316852e-07
with O 0 3.099521306282327e-09
molecular O 0 4.326222224904086e-08
genetic O 0 1.6746021458402538e-07
analyses O 0 1.86610193964043e-07
, O 0 3.5363092454332445e-09
this O 0 9.278288137792856e-10
test O 0 1.931664606047434e-08
may O 0 1.3674717536105163e-07
be O 0 4.456970625899004e-10
of O 0 5.1216777346985154e-11
value O 0 5.38734223898274e-10
in O 0 4.931902108928909e-10
studies O 0 4.2633480079601327e-10
of O 0 1.9848203636207984e-10
familial B-Disease 0 4.419904655605933e-07
and I-Disease 0 7.251293254739721e-08
sporadic I-Disease 0 1.4584228665626142e-05
cancers I-Disease 0 8.639560110168532e-05
aimed O 0 6.908708201081026e-07
at O 0 8.117579142208342e-08
determination O 0 4.829085753499385e-08
of O 0 1.0976513448168745e-10
the O 0 4.876005710308107e-10
potential O 0 3.194119191363143e-09
involvement O 0 5.286560966766274e-09
of O 0 5.986731665963418e-10
ATM O 0 2.151719627363491e-06
mutations O 0 1.0881573189180926e-06
in O 0 9.575264137140493e-09
tumor B-Disease 0 1.4572522559319623e-05
risk O 0 1.1092007667912185e-07
or O 0 5.287014825938741e-09
development O 0 4.212065363162765e-09
. O 0 1.3312588365010924e-08
. O 0 9.042074111675902e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 9.191964522869966e-07
identification O 0 1.3554874556120922e-07
and O 0 9.78979741717012e-09
detection O 0 4.5002931159388027e-08
of O 0 1.3943457499721035e-09
founder O 0 6.824443516961765e-07
- O 0 5.331800821295474e-06
effect O 0 1.1961805057580932e-07
mutations O 0 9.290762648106465e-08
in O 0 4.6012399446127006e-10
the O 0 6.509799921339265e-10
ATM O 0 7.874778162886287e-08
gene O 0 4.9517389300035575e-08
in O 0 4.251908158892093e-09
ethnic O 0 2.279148816342058e-07
populations O 0 6.78800972764293e-07
. O 0 2.62611507650945e-07

To O 0 1.122641819506498e-07
facilitate O 0 2.4330104153591492e-08
the O 0 1.2264358417723997e-09
evaluation O 0 3.3591507353492034e-09
of O 0 4.516480245353449e-10
ATM O 0 5.676930641129729e-07
heterozygotes O 0 3.766599832033535e-07
for O 0 7.843157789899635e-10
susceptibility O 0 3.8218126974243205e-07
to O 0 5.680389048023926e-09
other O 0 4.836623546111696e-09
diseases O 0 4.71947004143658e-07
, O 0 1.9840973308760113e-10
such O 0 1.425134038557374e-10
as O 0 4.4226698747706905e-08
breast B-Disease 0 0.00018726348935160786
cancer I-Disease 0 4.485130830289563e-06
, O 0 1.150496586888039e-08
we O 0 1.1051436210607335e-08
have O 0 3.622864452879071e-09
attempted O 0 8.549328356366459e-08
to O 0 1.999698184818044e-09
define O 0 3.7815901521298656e-08
the O 0 2.3757511513622376e-09
most O 0 7.454929451533587e-10
common O 0 2.5084321286783506e-09
mutations O 0 3.5038354440075636e-08
and O 0 3.614526455919531e-09
their O 0 3.147040850137728e-09
frequencies O 0 7.149131988626323e-07
in O 0 4.078400706930552e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 9.149791731033474e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.2580368036196887e-07
homozygotes O 0 1.578152819092793e-06
from O 0 4.301420997165906e-09
10 O 0 7.661475009967944e-09
ethnic O 0 8.985374222447717e-08
populations O 0 5.446548811960383e-07
. O 0 1.6873001129624754e-07

Both O 0 8.287349828606239e-07
genomic O 0 1.2054030776198488e-05
mutations O 0 1.6207510270760395e-05
and O 0 4.126370356516418e-08
their O 0 2.822862166240725e-09
effects O 0 5.213605192011528e-08
on O 0 4.94298220132805e-08
cDNA O 0 1.91882168110169e-06
were O 0 6.901108804413525e-07
characterized O 0 3.32466083818872e-06
. O 0 3.7889694226578285e-07

Protein O 0 5.075001536170021e-05
- O 0 1.465849345549941e-05
truncation O 0 5.166290975466836e-06
testing O 0 1.4133875936295226e-07
of O 0 2.5958444282991877e-09
the O 0 1.7699758325662174e-09
entire O 0 2.3293656781220307e-08
ATM O 0 3.10244502088608e-07
cDNA O 0 7.220157272058714e-07
detected O 0 2.2394975474071543e-07
92 O 0 3.52281332993698e-08
( O 0 5.962485172261722e-09
66 O 0 5.038204875518204e-08
% O 0 3.1074769424321858e-09
) O 0 3.708509277444705e-09
truncating O 0 4.978539891453693e-07
mutations O 0 3.027451498383016e-07
in O 0 4.6857246971399036e-09
140 O 0 6.042847644494032e-08
mutant O 0 3.06194579025032e-06
alleles O 0 4.564367827697424e-06
screened O 0 1.5822573914192617e-05
. O 0 8.091668632914661e-07

The O 0 9.760656212165486e-07
haplotyping O 0 7.82134520704858e-06
of O 0 9.658226218789423e-09
patients O 0 3.064943498998218e-08
with O 0 1.0513857562344242e-09
identical O 0 6.127838219072146e-07
mutations O 0 2.0442350887606153e-06
indicates O 0 1.935513722628457e-07
that O 0 2.0175559001245347e-08
almost O 0 2.5298293238051883e-08
all O 0 2.8887561787094285e-10
of O 0 1.2078080202648778e-10
these O 0 5.852579532117375e-10
represent O 0 1.9215216084944586e-09
common O 0 1.0426671970265033e-08
ancestry O 0 5.22174048001034e-07
and O 0 7.708750615620374e-08
that O 0 5.211156395290573e-09
very O 0 6.132939045500052e-09
few O 0 3.19932773606979e-08
spontaneously O 0 1.3398643261552934e-07
recurring O 0 2.1387263586802874e-06
ATM O 0 2.4112150640576147e-05
mutations O 0 1.3241474334790837e-05
exist O 0 3.5700006151273556e-07
. O 0 4.50261126161422e-07

Assays O 0 3.1541047064820305e-05
requiring O 0 3.158341712605761e-07
minimal O 0 7.397966328426264e-08
amounts O 0 6.6350338556731e-09
of O 0 3.6595182439924656e-10
genomic O 0 7.003892221746355e-08
DNA O 0 5.543494694393303e-07
were O 0 1.5409270304189704e-08
designed O 0 2.6699588318024325e-08
to O 0 6.556116205480578e-10
allow O 0 1.135809002406063e-09
rapid O 0 3.6048670715160824e-09
screening O 0 4.029343969591537e-09
for O 0 5.875621100770445e-10
common O 0 1.0170385422725303e-08
ethnic O 0 4.983879193787288e-07
mutations O 0 1.0277332876285072e-05
. O 0 2.828496690199245e-07

These O 0 2.627718629355513e-07
rapid O 0 3.822906080586108e-07
assays O 0 9.365020900986565e-07
detected O 0 2.6363557026343187e-07
mutations O 0 1.0032611896804156e-07
in O 0 1.9929584649247545e-09
76 O 0 1.1880664629870807e-07
% O 0 3.6455864993456544e-09
of O 0 7.802214985197509e-10
Costa O 0 3.0332486744555354e-07
Rican O 0 1.0083216466227896e-06
patients O 0 9.40323801046361e-08
( O 0 2.1870671940149577e-09
3 O 0 3.80053322146523e-09
) O 0 5.027889771191951e-10
, O 0 2.861976211576689e-10
50 O 0 1.4507366419280743e-09
% O 0 1.99016164659227e-10
of O 0 1.9098064796274627e-10
Norwegian O 0 2.6386162062408403e-05
patients O 0 6.885397851874586e-08
( O 0 1.234400914817968e-09
1 O 0 1.5008558840179376e-09
) O 0 6.62755517133462e-10
, O 0 7.554295522460563e-10
25 O 0 3.974053974786784e-09
% O 0 3.5561525946192774e-10
of O 0 2.902364182322259e-10
Polish O 0 1.0948632734653074e-05
patients O 0 3.974358975256109e-08
( O 0 1.31374233713899e-09
4 O 0 6.8547065801283225e-09
) O 0 2.4700888001660815e-09
, O 0 1.460874421432834e-09
and O 0 9.691848212867171e-09
14 O 0 1.6377823541802172e-08
% O 0 3.607361909185869e-10
of O 0 3.326022512961657e-10
Italian O 0 3.952070073864888e-06
patients O 0 4.2172608516466425e-08
( O 0 1.0274791018005658e-09
1 O 0 5.077097409156295e-09
) O 0 5.223595778147683e-09
, O 0 2.8160327403270458e-09
as O 0 3.7115663875653127e-09
well O 0 1.7706984767329459e-09
as O 0 1.4894148137045704e-09
in O 0 1.558308371230055e-09
patients O 0 3.754064170635729e-09
of O 0 5.666189184516668e-10
Amish O 0 4.295096005080268e-06
/ O 0 2.2334622826747363e-06
Mennonite O 0 3.530539743223926e-06
and O 0 5.011991106584901e-07
Irish O 0 3.830716082120489e-07
English O 0 1.0404784234196995e-07
backgrounds O 0 9.328306305178558e-07
. O 0 2.324278085552578e-07

Additional O 0 1.3347008689379436e-06
mutations O 0 5.9274207160342485e-06
were O 0 4.726289049017396e-08
observed O 0 5.283055770632927e-08
in O 0 4.956555166302223e-09
Japanese O 0 7.794072587330447e-08
, O 0 1.806373273183226e-09
Utah O 0 1.4408237269947222e-08
Mormon O 0 7.483200903379839e-08
, O 0 4.072767456619886e-09
and O 0 1.917560110697991e-09
African O 0 6.413280573269731e-09
American O 0 8.985323063370743e-08
patients O 0 4.677770562011574e-07
. O 0 1.3940159249159478e-07

These O 0 1.5773449035805243e-07
assays O 0 3.562892061381717e-07
should O 0 7.329744367012836e-09
facilitate O 0 4.079196980200095e-09
screening O 0 3.902374956510357e-08
for O 0 3.243838975208746e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 9.356110240332782e-06
in O 0 3.1923039767178807e-09
the O 0 1.973443852776313e-09
populations O 0 1.2515706693250195e-08
studied O 0 1.561975260244708e-08
. O 0 9.701095926573089e-09
. O 0 6.710163091838695e-08

The O 0 1.121579589380417e-05
von B-Disease 1 0.8979794383049011
Hippel I-Disease 1 0.9994747042655945
- I-Disease 1 0.9964459538459778
Lindau I-Disease 1 0.654597818851471
tumor I-Disease 0 0.00016740353021305054
suppressor O 0 3.36376360792201e-05
gene O 0 1.531863972559222e-06
is O 0 1.567140728298e-08
required O 0 1.695859785932896e-09
for O 0 6.351897341438928e-10
cell O 0 6.384552762028761e-07
cycle O 0 1.1525939953571651e-06
exit O 0 1.6334419683516899e-07
upon O 0 2.401832155385364e-08
serum O 0 2.531357949919766e-06
withdrawal O 0 3.85318708140403e-06
. O 0 5.917182193115877e-07

The O 0 5.301786245581752e-07
inactivation O 0 6.397659490176011e-06
of O 0 1.2751801392596462e-08
the O 0 5.5490069428287825e-08
von B-Disease 1 0.9998713731765747
Hippel I-Disease 1 0.9999945163726807
- I-Disease 1 0.9999649524688721
Lindau I-Disease 1 0.999774158000946
( I-Disease 0 1.233182388205023e-06
VHL I-Disease 0 0.00029475640621967614
) I-Disease 0 3.529414982494927e-07
tumor I-Disease 0 2.234737439721357e-05
suppressor O 0 0.00012165064254077151
gene O 0 7.634544090251438e-06
predisposes O 0 5.877095100004226e-05
affected O 0 4.611177075730666e-07
individuals O 0 3.92863119813569e-09
to O 0 2.75744960198665e-09
the O 0 6.143924480284113e-08
human O 0 3.7001027521910146e-05
VHL B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
and O 0 1.1060592441936024e-07
is O 0 6.685746178902718e-09
associated O 0 3.503013701333657e-08
with O 0 2.259831859419137e-07
sporadic B-Disease 1 0.9999239444732666
renal I-Disease 1 0.9999992847442627
cell I-Disease 1 0.9999998807907104
carcinomas I-Disease 1 1.0
( O 0 0.0001391747937304899
RCC B-Disease 1 0.9507958292961121
) O 0 8.546113576812786e-07
and O 0 1.3853169775757124e-06
brain B-Disease 0 0.0003093371051363647
hemangioblastomas I-Disease 0 0.000442018877947703
. O 0 1.136067226070736e-06

VHL O 0 0.018720712512731552
- O 0 0.0011086267186328769
negative O 0 1.2729836271319073e-05
786 O 0 2.3782336938893422e-05
- O 0 0.0001290488289669156
0 O 0 1.0682059610189754e-06
RCC B-Disease 0 2.0882445824099705e-05
cells O 0 1.4250666424686642e-07
are O 0 9.790763755290754e-10
tumorigenic O 0 3.678753728308948e-07
in O 0 1.5458342161878136e-08
nude O 1 0.8028210401535034
mice O 0 0.06023404374718666
which O 0 9.216709599968453e-07
is O 0 9.047971261111343e-09
suppressed O 0 2.0002406841967968e-08
by O 0 1.8613646735055056e-10
the O 0 1.0013715412426905e-09
reintroduction O 0 1.0371412599852192e-06
of O 0 4.5108286883532855e-08
VHL B-Disease 0 0.00018629875557962805
. O 0 1.1127145853606635e-06

Remarkably O 0 0.00018737638310994953
, O 0 5.0135401608031316e-08
this O 0 1.7990632317221866e-09
occurs O 0 3.0465709954796694e-09
without O 0 4.344674620071487e-10
affecting O 0 1.4695321626234659e-09
the O 0 7.797931189656993e-10
growth O 0 6.949904474140567e-08
rate O 0 6.363932669728456e-08
and O 0 1.7469843349715575e-09
cell O 0 1.2506177426985232e-07
cycle O 0 1.67624946811884e-07
profile O 0 4.457034563642992e-08
of O 0 5.477767128780897e-10
these O 0 5.441237460601656e-10
cells O 0 4.567064060267967e-09
in O 0 2.5981130580277068e-09
culture O 0 1.1243668751603764e-07
. O 0 9.979955706285182e-08

The O 0 8.423992312600603e-07
786 O 0 6.959786787774647e-06
- O 0 7.63064144848613e-06
0 O 0 8.447469213024306e-08
cell O 0 1.4541802784151514e-06
line O 0 1.2755891475535464e-05
, O 0 1.0593348420684379e-09
like O 0 1.7532599816405536e-09
many O 0 1.3164160872491948e-09
cancer B-Disease 0 1.3644964269587945e-07
cells O 0 3.1739944006403675e-08
, O 0 2.06962336157801e-09
fails O 0 3.15693213792656e-08
to O 0 1.1296581448050347e-09
exit O 0 4.414048859757713e-08
the O 0 4.992743996012905e-09
cell O 0 6.898371225361188e-07
cycle O 0 8.867445444593614e-07
upon O 0 1.2297368456870572e-08
serum O 0 1.2566989653350902e-06
withdrawal O 0 1.6234528175118612e-06
. O 0 2.886171444060892e-07

Here O 0 6.5244139477727e-06
, O 0 5.9594409407282e-08
it O 0 6.071300351351283e-09
is O 0 1.95612659403821e-09
shown O 0 7.959261694168163e-09
that O 0 4.3017964190816826e-10
reintroduction O 0 9.570100445444041e-08
of O 0 6.060190127499254e-10
the O 0 2.54314702630154e-09
wild O 0 9.24395706647374e-08
- O 0 1.0231682608718984e-05
type O 0 4.398526698423666e-07
VHL B-Disease 0 1.0516065231058747e-05
gene O 0 5.118760668665345e-07
restores O 0 6.216486781340791e-06
the O 0 9.41281630417734e-09
ability O 0 3.862270148147218e-08
of O 0 4.035342726638191e-09
VHL O 0 0.0001525083789601922
- O 0 0.011027867905795574
negative O 0 1.876192618510686e-05
RCC B-Disease 0 0.0010268071200698614
cancer I-Disease 0 3.8863786357978825e-06
cells O 0 7.113780498002598e-08
to O 0 1.932935145276815e-09
exit O 0 5.1230632180931934e-08
the O 0 5.6573474793708556e-09
cell O 0 4.340881218922732e-07
cycle O 0 3.338091971727408e-07
and O 0 5.634495980899601e-09
enter O 0 2.9444256810506886e-08
G0 O 0 7.224025011964841e-06
/ O 0 2.1253861177683575e-06
quiescence O 0 5.53065456188051e-06
in O 0 6.539175245734441e-08
low O 0 2.8555125481943833e-06
serum O 0 1.49794659591862e-05
. O 0 3.035526390249288e-07

Both O 0 2.7099522412754595e-06
VHL O 0 0.0003987962263636291
- O 0 0.0004295125254429877
positive O 0 1.0413226618766203e-06
and O 0 1.4328902864235715e-07
VHL O 0 0.0002860429813154042
- O 0 0.0018577503506094217
negative O 0 7.363394615822472e-06
RCC B-Disease 0 9.754188067745417e-05
cells O 0 3.0579630561078375e-07
exit O 0 2.2636000096554199e-07
the O 0 5.50672440979838e-09
cell O 0 1.081985715245537e-06
cycle O 0 4.472217938200629e-07
by O 0 2.0239838693925094e-09
contact O 0 1.6275689063149912e-07
inhibition O 0 8.057916716097679e-07
. O 0 1.524864785551472e-07

The O 0 1.6980831105684047e-06
cyclin O 0 7.43075943319127e-05
- O 0 6.276336534938309e-06
dependent O 0 8.680894438839459e-07
kinase O 0 6.632266831729794e-06
inhibitor O 0 1.9610308754636208e-06
, O 0 1.8845295102210002e-08
p27 O 0 1.1311624348309124e-06
, O 0 7.620492681326141e-09
accumulates O 0 1.3943230214863434e-07
upon O 0 2.2695014756379805e-09
serum O 0 1.0098712976969182e-07
withdrawal O 0 2.820770816924778e-07
, O 0 3.7450385015347365e-09
only O 0 4.0325554007125675e-10
in O 0 1.6026635574206693e-10
the O 0 1.0119702853472745e-09
presence O 0 1.6345646614013276e-08
of O 0 2.0062385086561108e-09
VHL B-Disease 0 1.289156534767244e-05
, O 0 1.514464109675373e-08
as O 0 2.582121627625611e-09
a O 0 7.077263664001521e-09
result O 0 2.384999753246575e-09
of O 0 1.3670160836642964e-10
the O 0 1.5049924639853884e-09
stabilization O 0 4.559841926266017e-08
of O 0 1.4778184231900582e-09
the O 0 9.655831689769911e-09
protein O 0 6.683529818474199e-07
. O 0 1.43470614943908e-07

We O 0 1.0532588703426882e-06
propose O 0 2.3609996446793957e-07
that O 0 4.111245566207344e-09
the O 0 2.0958814683780247e-09
loss O 0 2.5637886480467387e-08
of O 0 8.429257847275551e-10
wild O 0 3.15072185230747e-07
- O 0 0.00016067798424046487
type O 0 1.739038339110266e-06
VHL B-Disease 0 5.908717412239639e-06
gene O 0 2.6868485747399973e-07
results O 0 2.362143014522644e-08
in O 0 5.517666323839876e-10
a O 0 2.850172986512689e-09
specific O 0 8.877758084224752e-09
cellular O 0 6.120314537838567e-06
defect O 0 7.707052645855583e-06
in O 0 1.376591196589061e-08
serum O 0 8.520983101334423e-07
- O 0 1.072453301276255e-06
dependent O 0 6.220580672788856e-08
growth O 0 3.395250303128705e-08
control O 0 3.1714769477275695e-08
, O 0 4.446842449823407e-09
which O 0 1.6293105531417496e-08
may O 0 4.331200997853557e-08
initiate O 0 2.0693644842140202e-07
tumor B-Disease 0 8.113583135127556e-06
formation O 0 8.003501648090605e-07
. O 0 2.1191208077198098e-07

This O 0 6.823102580710838e-07
is O 0 4.284686383471126e-08
corrected O 0 6.528488825097156e-07
by O 0 4.725932423177426e-10
the O 0 9.068802930833897e-10
reintroduction O 0 1.4469851805642975e-07
of O 0 2.4062789538703555e-09
wild O 0 4.3744728372985264e-07
- O 0 0.0006480911979451776
type O 0 5.7482666306896135e-06
VHL B-Disease 0 0.00020721361215692014
, O 0 1.3892208983179444e-07
implicating O 0 5.050163053965662e-06
VHL B-Disease 0 1.5087982319528237e-05
as O 0 2.0057536076478755e-08
the O 0 2.007517041491269e-09
first O 0 9.332763895031349e-09
tumor B-Disease 0 3.853947987408901e-07
suppressor O 0 1.537261141493218e-06
involved O 0 6.09381878291515e-09
in O 0 1.1675709288283542e-09
the O 0 7.50034090390983e-10
regulation O 0 4.090541239065715e-09
of O 0 3.269196302557731e-10
cell O 0 2.925407898146659e-07
cycle O 0 3.2821583317854675e-07
exit O 0 1.8037495408407267e-07
, O 0 1.926991188838656e-08
which O 0 4.3916358549722645e-08
is O 0 5.348367526636366e-09
consistent O 0 8.373306492615029e-09
with O 0 7.099473786631449e-10
its O 0 5.294088722962442e-09
gatekeeper O 0 2.4549392492190236e-06
function O 0 8.44509795427939e-09
in O 0 2.5274358161908594e-09
the O 0 2.8770411830691955e-08
kidney O 0 1.669895709710545e-06
. O 0 4.84050239890621e-08
. O 0 2.1759571211532602e-07

Piebaldism B-Disease 1 1.0
with O 0 0.08149701356887817
deafness B-Disease 1 1.0
: O 0 2.017362135120493e-07
molecular O 0 1.5425068511376594e-07
evidence O 0 1.0436581376893628e-08
for O 0 1.5779105799751392e-09
an O 0 1.8329981088527347e-08
expanded O 0 0.0014721228508278728
syndrome O 1 0.9999959468841553
. O 0 4.136891504913365e-07

In O 0 2.7502349553287786e-07
a O 0 7.992809969437076e-08
South O 0 1.4447596186073497e-07
African O 0 3.8673711344472395e-08
girl O 0 5.39281381861656e-06
of O 0 3.34633565302056e-09
Xhosa O 0 9.722965478431433e-05
stock O 0 1.4649634749730467e-07
with O 0 7.128977408399351e-09
severe O 0 3.651588031061692e-06
piebaldism B-Disease 0 5.624098048429005e-05
and O 0 1.2475330777306226e-06
profound O 0 3.9617425500182435e-05
congenital O 1 1.0
sensorineural B-Disease 1 0.9999998807907104
deafness I-Disease 1 1.0
we O 0 1.6610883903922513e-05
identified O 0 1.445170170200072e-07
a O 0 8.291396014215024e-09
novel O 0 1.0019015661555386e-07
missense O 0 1.3334820323507302e-06
substitution O 0 3.281462923609979e-08
at O 0 9.150226354392998e-09
a O 0 4.701211420155005e-09
highly O 0 6.9720216266944135e-09
conserved O 0 7.533093793199441e-08
residue O 0 1.8491535058728914e-07
in O 0 1.0323468746520348e-09
the O 0 8.611674151559612e-10
intracellular O 0 3.9567204623836005e-08
kinase O 0 2.884745811115863e-07
domain O 0 2.0013283474895616e-08
of O 0 1.0191624211230987e-09
the O 0 1.2012018935081414e-08
KIT O 0 2.2579031792702153e-05
proto O 0 7.050877320580184e-05
- O 0 1.0385237146692816e-05
oncogene O 0 8.30891167424852e-06
, O 0 7.886909259013919e-08
R796G O 0 5.032931312598521e-06
. O 0 2.924261650605331e-07

Though O 0 8.18338776298333e-06
auditory B-Disease 0 2.9797656679875217e-05
anomalies I-Disease 0 0.00011059935786761343
have O 0 1.3196024895023584e-07
been O 0 1.6431014771001173e-08
observed O 0 2.2577157920977697e-08
in O 0 4.31609903372987e-09
mice O 0 1.894448905659374e-05
with O 0 1.6583653561497158e-08
dominant O 0 6.46750777377747e-06
white O 0 4.8934234655462205e-06
spotting O 0 5.333211083780043e-05
( O 0 2.493769670763868e-07
W O 0 0.10194193571805954
) O 0 8.203805634821038e-09
due O 0 4.031742495413937e-09
to O 0 1.1652667275541262e-08
KIT O 0 0.0005914979847148061
mutations O 0 0.00018326395365875214
, O 0 7.074566383380443e-06
deafness B-Disease 1 1.0
is O 0 6.678573072349536e-07
not O 0 9.995954286523556e-09
typical O 0 6.003798347364864e-08
in O 0 1.0065461353292449e-08
human O 0 1.7655942485816922e-07
piebaldism B-Disease 0 4.48873033747077e-05
. O 0 5.956440531917906e-07

Thus O 0 2.275479118907242e-06
, O 0 1.5484340920579598e-08
the O 0 3.645996837775556e-09
occurrence O 0 1.4026132078015507e-07
of O 0 8.832800801883423e-08
sensorineural B-Disease 1 0.9999936819076538
deafness I-Disease 1 1.0
in O 0 2.5753067802725127e-06
this O 0 4.113788776294314e-08
patient O 0 3.875768186389905e-07
extends O 0 9.526646493895896e-08
considerably O 0 6.489883475069291e-08
the O 0 9.750658058749195e-10
phenotypic O 0 1.1727220794455206e-07
range O 0 6.309388567160568e-08
of O 0 1.9656565264369874e-09
piebaldism B-Disease 0 5.4937891036388464e-06
due O 0 6.5002376814504714e-09
to O 0 2.173974555930158e-09
KIT O 0 2.6194068141194293e-06
gene O 0 3.310867384698213e-07
mutation O 0 1.1669352772969432e-07
in O 0 1.8515289301745952e-09
humans O 0 7.440004168302039e-09
and O 0 8.177965860056702e-09
tightens O 0 0.0024033503141254187
the O 0 5.6559557037871855e-09
clinical O 0 4.501426076330972e-08
similarity O 0 8.917967164734364e-08
between O 0 3.2879661659990234e-08
piebaldism B-Disease 0 1.0433423085487448e-05
and O 0 6.146664510708888e-09
the O 0 3.008343574251171e-10
various O 0 7.847227312396399e-10
forms O 0 7.949357438974403e-08
of O 0 3.813729847479408e-07
Waardenburg B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999974966049194
. O 0 7.863506823468924e-08
. O 0 2.0985569904041768e-07

Cycloheximide O 0 0.0002541460271459073
facilitates O 0 5.312178927852074e-06
the O 0 2.7895666221411375e-08
identification O 0 1.7473317015515022e-08
of O 0 2.0681749646200842e-09
aberrant O 0 8.352476470463444e-07
transcripts O 0 1.2726248996841605e-06
resulting O 0 1.0338177958146844e-07
from O 0 1.7279162545236204e-09
a O 0 3.6197078667754568e-09
novel O 0 1.0835660901875599e-07
splice O 0 0.0001172750853584148
- O 0 4.930937575409189e-05
site O 0 4.7271817038563313e-07
mutation O 0 9.85787380614056e-08
in O 0 2.0667278999297878e-09
COL17A1 O 0 1.7245099570573075e-06
in O 0 3.4717893004909683e-09
a O 0 2.8761855119796564e-08
patient O 0 4.502525143834646e-07
with O 0 1.3546798527386272e-07
generalized O 0 0.00020372375729493797
atrophic B-Disease 1 0.9993896484375
benign I-Disease 1 0.9992510676383972
epidermolysis I-Disease 1 0.998975396156311
bullosa I-Disease 1 0.9779729247093201
. O 0 2.918788231909275e-05

Patients O 0 0.00037962498026899993
with O 0 1.3335887842913507e-06
generalized O 0 0.0002099495177390054
atrophic B-Disease 1 0.9902445077896118
benign I-Disease 1 0.960853099822998
epidermolysis I-Disease 1 0.9920291304588318
bullosa I-Disease 1 0.6740356087684631
often O 0 8.32550649647601e-05
show O 0 9.419693014933728e-06
decreased O 0 2.8120946353737963e-06
expression O 0 9.202983619616134e-08
of O 0 4.632918937375052e-09
type O 0 5.909275841986528e-07
XVII O 0 0.00011785511742345989
collagen O 0 1.7734524590196088e-05
, O 0 2.6938112185348473e-08
a O 0 4.9115552513967486e-08
transmembrane O 0 1.027211169457587e-06
hemidesmosomal O 0 2.617249492686824e-06
protein O 0 1.5764682359531434e-07
encoded O 0 1.516120846645208e-07
by O 0 3.291944494776544e-08
COL17A1 O 0 0.00011256089055677876
. O 0 6.50759034215298e-07

This O 0 1.8530001000272023e-07
report O 0 2.932185871884485e-08
documents O 0 1.5465184688423506e-08
a O 0 1.355600698360604e-08
novel O 0 1.9585867505611532e-07
splice O 0 0.00019788039207924157
- O 0 5.950628110440448e-05
site O 0 1.3595880545835826e-06
mutation O 0 1.9379757532078656e-07
in O 0 3.0925886296273575e-09
COL17A1 O 0 2.825794354066602e-06
in O 0 3.960818784065623e-09
a O 0 2.3840822649390248e-08
patient O 0 3.800368801876175e-07
with O 0 6.462239809934545e-08
generalized O 0 5.8309837186243385e-05
atrophic B-Disease 1 0.9884217381477356
benign I-Disease 1 0.9563120603561401
epidermolysis I-Disease 1 0.9501781463623047
bullosa I-Disease 0 0.22258417308330536
, O 0 2.7442195005278336e-07
and O 0 6.414748732197495e-09
applies O 0 4.441197631877003e-09
a O 0 1.493229206950275e-09
new O 0 2.4903927808850312e-09
methodology O 0 2.90258874713345e-08
to O 0 3.0135995920943515e-09
define O 0 1.3086665262562747e-07
and O 0 6.03113718966597e-08
characterize O 0 3.489703601644578e-07
the O 0 1.1846785774594082e-08
resulting O 0 9.982696980159744e-08
mRNA O 0 5.805030127703503e-07
splice O 0 6.659302016487345e-05
variants O 0 1.33883240778232e-05
. O 0 8.343050126313756e-07

Mutational O 0 0.0006070946110412478
analysis O 0 2.3345712634181837e-06
of O 0 3.945235604874142e-08
COL17A1 O 0 2.9321097827050835e-05
identified O 0 6.143069413155899e-07
a O 0 1.164605052395018e-07
maternally O 0 6.29172654953436e-06
inherited O 0 1.1156036634929478e-05
G O 0 6.0937043599551544e-05
- O 0 8.258637535618618e-06
to O 0 1.2950469852057722e-07
- O 0 8.476043149130419e-05
T O 0 5.594538743025623e-05
transversion O 0 1.3089352250972297e-06
at O 0 1.8952533764604595e-08
the O 0 2.1225294855042875e-09
- O 0 1.0517914006413775e-06
1 O 0 2.0013551704778365e-08
position O 0 4.933619379698939e-08
of O 0 2.879630978114278e-09
exon O 0 2.251494834126788e-06
32 O 0 1.0859646408789558e-06
. O 0 2.697277068364201e-07

This O 0 1.8921295463769638e-07
acceptor O 0 7.028475579318183e-07
splice O 0 3.388477489352226e-05
- O 0 1.647096360102296e-05
site O 0 9.255403483621194e-07
mutation O 0 3.6583011819857347e-07
led O 0 6.879422365102528e-09
to O 0 1.287113970960263e-09
the O 0 1.364755419785979e-09
formation O 0 3.6648704071495786e-09
of O 0 2.2120194564934081e-10
aberrant O 0 1.5234083150517108e-07
transcripts O 0 2.3202539978228742e-07
present O 0 2.40054074396312e-08
at O 0 3.4345912780509025e-08
extremely O 0 8.326232858735239e-08
low O 0 4.748436026602576e-07
levels O 0 1.234758713053452e-07
. O 0 7.166116233747744e-08

Based O 0 2.4702703740331344e-06
on O 0 4.7258160407182004e-07
our O 0 1.9709659682121128e-08
recent O 0 9.262572930879287e-09
finding O 0 1.763510226737708e-08
that O 0 4.459370650522487e-09
cycloheximide O 0 3.352654175614589e-06
stabilized O 0 6.433445832954021e-06
mutant O 0 1.1064913678637822e-06
COL17A1 O 0 2.5905394522851566e-06
transcripts O 0 1.0207021006181094e-07
in O 0 3.932124403860371e-09
keratinocytes O 0 1.0243604720017174e-06
homozygous O 0 2.542302581787226e-07
for O 0 7.645909461118094e-10
a O 0 2.1471816324947213e-08
frameshift O 0 0.00021152723638806492
mutation O 0 5.661743784912687e-07
, O 0 2.136795185236906e-09
the O 0 8.067684298396216e-10
effects O 0 6.212945180550378e-08
of O 0 7.735919127505042e-10
the O 0 3.2355202961298346e-09
splice O 0 0.0001112933678086847
- O 0 1.787392102414742e-05
site O 0 4.54189148513251e-07
mutation O 0 2.8040016530894718e-08
on O 0 2.217795502801323e-09
splicing O 0 3.7794485763242847e-08
of O 0 2.100163154494794e-09
COL17A1 O 0 1.2725581655104179e-06
transcripts O 0 2.26067896846871e-07
were O 0 8.450736999066066e-09
determined O 0 4.817491738862145e-09
using O 0 7.234174148607053e-09
reverse O 0 4.6866031766512606e-07
transcriptase O 0 1.2352975318208337e-06
polymerase O 0 1.063771492226806e-06
chain O 0 1.0258590918965638e-06
reaction O 0 2.9627232223106148e-08
of O 0 7.423968106934353e-10
total O 0 2.2565438406729754e-09
RNA O 0 1.025445826030591e-07
from O 0 3.1196869532124083e-09
keratinocytes O 0 2.7818020953418454e-07
incubated O 0 3.0345361778927327e-07
for O 0 3.6298917205357384e-09
2 O 0 1.1837359892297172e-07
. O 0 1.9878690693531098e-07

5 O 0 9.019713615998626e-06
h O 0 1.132106626755558e-05
in O 0 1.205305366624998e-08
the O 0 3.1589786342323123e-09
presence O 0 2.9502723819518906e-08
or O 0 2.066721016547035e-08
absence O 0 9.583503768340051e-09
of O 0 9.173953818830682e-10
10 O 0 2.317170988419548e-08
microg O 0 2.9044549592072144e-06
cycloheximide O 0 9.612643225409556e-06
per O 0 4.521682228642021e-07
ml O 0 2.024707464443054e-05
. O 0 3.655301838989544e-07

Using O 0 3.3347987482557073e-07
this O 0 1.5988304014058485e-08
approach O 0 3.252084823657242e-08
, O 0 1.8323749184645521e-09
an O 0 1.1713316983019695e-09
abnormally O 0 9.781921335161314e-07
spliced O 0 0.19043059647083282
transcript O 0 0.239650696516037
was O 0 7.381463365163654e-05
identified O 0 1.4422926142287906e-07
that O 0 3.816330307326865e-10
contains O 0 3.393634817605573e-10
an O 0 1.2362146029065713e-10
extra O 0 5.324783280968859e-09
264 O 0 1.4943925208399378e-08
bases O 0 2.286696343389849e-08
upstream O 0 2.3773297996854126e-08
from O 0 6.287554366046777e-10
exon O 0 1.3027094780682091e-07
32 O 0 1.0474914802216517e-07
, O 0 1.2873103694133192e-09
resulting O 0 4.962420252496713e-09
in O 0 9.95678872683925e-10
a O 0 2.9614124485988214e-08
premature O 0 4.5960874217598757e-07
termination O 0 2.007243011803439e-07
codon O 0 8.617020057499758e-07
27 O 0 7.852780186112795e-07
bp O 0 1.0536829222473898e-06
downstream O 0 1.3152603628441284e-07
from O 0 2.774500629243448e-09
the O 0 5.427454929929354e-09
cryptic O 0 2.81324810202932e-06
splice O 0 0.00013001136539969593
site O 0 8.924107532948256e-06
. O 0 6.660166036454029e-07

Three O 0 5.428554459285806e-07
other O 0 6.2878209305949895e-09
splice O 0 5.936438810749678e-06
variants O 0 1.1643555808404926e-06
, O 0 6.244293526691536e-09
including O 0 6.537223540270531e-10
one O 0 7.829261683411914e-09
derived O 0 3.194661202243765e-09
from O 0 4.538664999387265e-10
the O 0 3.130581627264206e-10
skipping O 0 1.921866932264038e-08
of O 0 5.785961709747767e-10
exon O 0 2.4827116362757806e-07
32 O 0 5.676394607689872e-07
, O 0 1.0038466058404083e-08
were O 0 4.958259935960996e-08
also O 0 2.216435603941136e-07
identified O 0 1.989095153476228e-06
. O 0 2.2897432927493355e-07

These O 0 5.110200618219096e-07
results O 0 1.1465571958524379e-07
indicate O 0 4.197311298526074e-08
the O 0 1.3925570696571299e-09
usefulness O 0 3.040784690711007e-08
of O 0 1.5402886743842714e-09
cycloheximide O 0 1.803646341613785e-06
treatment O 0 4.988929447335977e-08
in O 0 1.0724661159144944e-09
evaluating O 0 1.1201175098562999e-08
the O 0 3.3527882692396815e-09
abnormal O 0 3.9172224575168e-08
processing O 0 6.791135209738286e-09
of O 0 3.8582978478807206e-10
mRNA O 0 2.5430026084904966e-08
due O 0 2.8916404826162534e-09
to O 0 1.4164304174002496e-09
splice O 0 1.1916155017388519e-05
- O 0 5.544908162846696e-06
site O 0 9.687303190730745e-07
mutations O 0 3.2332954447156226e-07
, O 0 2.88335733067413e-09
because O 0 2.229684215038219e-09
( O 0 7.064680840329629e-09
i O 0 5.140927328284306e-08
) O 0 1.2937644289223726e-09
aberrant O 0 4.74497738878199e-08
splicing O 0 4.466787686396856e-07
often O 0 1.0349955914534803e-07
generates O 0 3.583801699846845e-08
a O 0 8.729609035640351e-09
premature O 0 2.130435916569695e-07
termination O 0 1.07688848061116e-07
codon O 0 3.9375308347189275e-07
, O 0 5.301566297077898e-09
( O 0 6.109728278858029e-09
ii O 0 3.468386466920492e-07
) O 0 2.9484592545259147e-09
transcripts O 0 9.254841870642849e-08
with O 0 9.86334391939181e-09
premature O 0 1.4233918932404777e-07
termination O 0 6.058439083744815e-08
codons O 0 1.5296785704776994e-07
can O 0 6.834823373935706e-09
occur O 0 4.482754167867142e-09
at O 0 2.138638155457784e-09
low O 0 2.118607653756044e-07
or O 0 3.8641637445380184e-08
undetectable O 0 4.4161970436107367e-07
levels O 0 1.1526182674970187e-08
due O 0 1.8846362248581272e-09
to O 0 3.0814073515017526e-09
nonsense O 0 3.428907007219095e-07
- O 0 6.321578638335268e-08
mediated O 0 1.8222343101115257e-07
mRNA O 0 4.2157004997989134e-08
decay O 0 3.661029879253874e-08
, O 0 4.966698163855199e-10
and O 0 1.9351225066799316e-09
( O 0 8.472585966146085e-10
iii O 0 1.4591201136227028e-07
) O 0 2.9772009302320157e-09
the O 0 1.9552686136847797e-09
levels O 0 2.2118264997317283e-09
of O 0 8.766374431923296e-11
these O 0 1.8385355737837727e-10
transcripts O 0 1.2597038079320555e-08
can O 0 4.971249634166952e-09
be O 0 1.1448439973804625e-09
increased O 0 1.9743400248017906e-09
by O 0 1.2492256118434852e-09
cycloheximide O 0 4.720163815363776e-06
. O 0 1.391122026461744e-07

A O 0 2.7134640276926802e-06
deletion O 0 3.6846340663032606e-05
mutation O 0 6.1864725466875825e-06
in O 0 2.3934543236237005e-08
COL17A1 O 0 1.7967473468161188e-05
in O 0 9.468583250793472e-09
five O 0 2.2485149742124122e-08
Austrian O 0 6.947518613742432e-06
families O 0 6.241986483246365e-08
with O 0 3.367761536310354e-08
generalized O 0 4.917638216284104e-05
atrophic B-Disease 1 0.998094379901886
benign I-Disease 1 0.9938845038414001
epidermolysis I-Disease 1 0.995570957660675
bullosa I-Disease 0 0.18400880694389343
represents O 0 5.3664998631575145e-06
propagation O 0 1.1573258689168142e-06
of O 0 5.752096132738416e-09
an O 0 7.0458954226637616e-09
ancestral O 0 8.273488674603868e-06
allele O 0 0.00011497567902551964
. O 0 1.6439624914710294e-06

Patients O 0 0.0006311285542324185
with O 0 1.9868316485371906e-06
generalized O 0 0.0004765154153574258
atrophic B-Disease 1 0.9995266199111938
benign I-Disease 1 0.9988644123077393
epidermolysis I-Disease 1 0.9990231990814209
bullosa I-Disease 1 0.9053001403808594
, O 0 1.3161402421246748e-06
a O 0 4.2585494242075583e-08
usually O 0 1.4995977792864323e-08
nonlethal O 0 2.230185742746471e-07
form O 0 5.993386764657771e-08
of O 0 9.264891076554704e-08
junctional B-Disease 1 0.9027393460273743
epidermolysis I-Disease 1 0.980647623538971
bullosa I-Disease 0 0.040801797062158585
, O 0 1.5566372724151734e-07
have O 0 1.750978206871423e-08
generalized O 0 5.320512173057068e-07
blistering B-Disease 0 0.0008496187510900199
, O 0 9.89013187790988e-07
nail B-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999719858169556
, O 0 2.747561040905566e-07
patchy B-Disease 0 0.016106992959976196
alopecia I-Disease 1 0.9997695088386536
, O 0 8.116384719869529e-07
and O 0 2.0139473235758487e-06
dental B-Disease 0 0.013127211481332779
abnormalities I-Disease 1 0.9999264478683472
. O 0 3.438233761698939e-06

Skin B-Disease 1 0.9999984502792358
fragility I-Disease 0 0.05530748888850212
in O 0 4.906330275389337e-08
most O 0 2.996902059848594e-09
cases O 0 1.8740977658637803e-09
is O 0 2.3549620031815266e-09
due O 0 1.6069434671805993e-09
to O 0 3.431773532014404e-09
mutations O 0 1.4821175398083142e-07
in O 0 8.668694095881335e-10
the O 0 2.0542616496754817e-09
gene O 0 1.30431814682197e-07
encoding O 0 6.929982987458061e-07
type O 0 1.0530808140174486e-05
XVII O 0 0.0006857056287117302
collagen O 0 0.0002663968480192125
( O 0 2.4373773044317204e-07
COL17A1 O 0 4.189711398794316e-05
) O 0 1.280126440406093e-07
. O 0 2.007798229897162e-07

Recently O 0 4.9334637878928334e-05
, O 0 7.0104540839111e-08
we O 0 1.4678409598900544e-08
reported O 0 3.7832279531357926e-08
five O 0 4.0653636013132655e-09
Austrian O 0 1.7503891740489053e-06
families O 0 1.1924430332044267e-08
with O 0 1.7534748764092e-08
generalized O 0 2.3926155336084776e-05
atrophic B-Disease 1 0.9768234491348267
benign I-Disease 1 0.9153565168380737
epidermolysis I-Disease 1 0.8486729264259338
bullosa I-Disease 0 0.35943615436553955
who O 0 4.036304380861111e-05
share O 0 1.2819161554489256e-07
the O 0 2.940888199631786e-09
same O 0 2.1436910913052998e-08
COL17A1 O 0 5.6669632613193244e-05
mutation O 0 2.1122295947861858e-06
. O 0 2.0834178826589778e-07

Affected O 0 1.2732009054161608e-05
individuals O 0 7.380644007071169e-08
in O 0 2.549183308886427e-09
three O 0 1.504823821107948e-08
families O 0 7.456639750103022e-09
are O 0 3.648492341579157e-10
homozygous O 0 8.8715502499781e-08
for O 0 8.99443686197543e-10
4003delTC O 0 7.970504611876095e-07
, O 0 3.897545397535396e-09
whereas O 0 6.4996799054029e-09
those O 0 3.1177047055130913e-10
in O 0 5.730432794948115e-10
two O 0 1.5046861534528944e-08
others O 0 8.436375509290883e-08
are O 0 2.3388651015920914e-09
compound O 0 5.923019443798694e-07
heterozygotes O 0 1.1938916031795088e-05
. O 0 2.2618995387801988e-07

To O 0 1.901340169752075e-07
determine O 0 3.2001150174210125e-08
if O 0 1.931880877492631e-09
the O 0 4.574942924495673e-10
occurrence O 0 7.025417136929946e-09
of O 0 3.4712444030304823e-10
4003delTC O 0 2.483703838151996e-07
in O 0 7.655774347803401e-10
these O 0 5.377127632044676e-10
unrelated O 0 2.0600619876631754e-08
families O 0 1.6587511808552335e-08
signifies O 0 5.068779174166593e-08
propagation O 0 2.549505495608173e-08
of O 0 2.499299656122389e-10
an O 0 3.841152396155678e-10
ancestral O 0 3.420565519718366e-07
allele O 0 1.0795779417094309e-06
or O 0 2.2130766552663772e-08
a O 0 1.417985373564079e-08
mutational O 0 2.0013467292301357e-05
hot O 0 3.79527555196546e-05
spot O 0 5.537426477530971e-05
, O 0 1.2313586594814296e-08
haplotypes O 0 1.108443143493787e-06
were O 0 1.4863681485621782e-07
determined O 0 4.122327013078575e-08
for O 0 2.9914597465818815e-09
polymorphisms O 0 8.10325873317197e-05
both O 0 2.2423733980758698e-08
within O 0 1.973249119657794e-08
and O 0 8.262982476026082e-08
flanking O 0 0.00021993576956447214
COL17A1 O 0 0.0006267257849685848
. O 0 9.484146517024783e-07

Five O 0 5.40728524356382e-06
intragenic O 0 3.351173654664308e-05
polymorphisms O 0 0.000528613687492907
were O 0 4.642749047434336e-07
chosen O 0 2.3088857048492173e-08
based O 0 1.1624496920603633e-08
on O 0 2.625834554237372e-07
their O 0 2.101607350368795e-07
informativeness O 0 0.00010318669956177473
. O 0 5.96017969201057e-07

One O 0 8.148710435307294e-07
of O 0 2.900799600524806e-09
these O 0 1.4573844353549248e-09
, O 0 1.4539026649273978e-09
not O 0 7.81918363390588e-10
previously O 0 1.947104522059817e-08
reported O 0 3.2001156569094746e-07
, O 0 3.9136880403134455e-09
was O 0 8.36006464055572e-08
2988 O 0 5.239194322825824e-08
A O 0 1.7909739469246233e-08
or O 0 1.641322278089774e-08
C O 0 1.0262441207942175e-07
that O 0 5.795018354071146e-10
introduces O 0 7.808055535463154e-09
a O 0 1.309739205979099e-09
new O 0 1.073819144714605e-09
restriction O 0 3.353338273726081e-09
site O 0 1.9098848724752315e-08
for O 0 2.137887644693137e-09
Eco0109 O 0 2.0690895325969905e-06
I O 0 2.5102769996010466e-06
. O 0 9.87490551551673e-08

All O 0 1.0993310439744164e-07
the O 0 1.3882562654998765e-08
4003delTC O 0 1.2669441957768868e-06
alleles O 0 4.936316031489696e-07
showed O 0 6.173609108373057e-07
the O 0 8.136870621733294e-10
same O 0 2.8611479852003185e-09
haplotype O 0 5.198600661060482e-07
for O 0 1.1946346134550367e-09
these O 0 1.8285135627849058e-09
five O 0 9.974052694872171e-09
polymorphic O 0 3.778645350394072e-06
markers O 0 0.00010129052679985762
. O 0 6.850029876659391e-07

Fourteen O 0 2.5391858798684552e-05
microsatellite O 0 8.050992619246244e-05
polymorphisms O 0 0.0008781038923189044
were O 0 5.191942591409315e-07
selected O 0 1.544941241604647e-08
based O 0 4.829552757712463e-09
on O 0 5.871710300198174e-07
their O 0 8.364003889482774e-08
high O 0 6.043626399332425e-07
heterozygosity O 0 4.083378826180706e-06
and O 0 4.8174022992952814e-08
their O 0 1.4989849361768393e-09
location O 0 8.469734069649348e-08
within O 0 1.7954818076759693e-08
10q23 O 0 6.126587663857208e-07
- O 0 3.427106548770098e-06
q25 O 0 5.69989515497582e-06
near O 0 3.400572722966899e-06
COL17A1 O 0 3.537645534379408e-05
. O 0 3.7503949101846956e-07

Three O 0 2.3214590783027234e-06
families O 0 4.3978468511340907e-07
shared O 0 2.3831235296256637e-07
microsatellite O 0 5.842092650709674e-05
polymorphisms O 0 0.00032614119118079543
covering O 0 1.6527972093172139e-06
at O 0 6.355369208677075e-08
most O 0 2.829244394320085e-09
19 O 0 4.989966484458819e-08
cM O 0 9.437194421479944e-07
, O 0 6.0974816307179935e-09
whereas O 0 6.825652043573882e-09
the O 0 1.762520573933557e-09
others O 0 1.8377731336727265e-08
shared O 0 4.15778789175647e-09
smaller O 0 1.122063242320337e-08
regions O 0 2.135492493948732e-08
consistent O 0 4.661480090817349e-08
with O 0 2.626398432070687e-09
cross O 0 8.017557888706506e-07
- O 0 4.804162017535418e-06
over O 0 5.568101002495496e-08
events O 0 7.510852384484679e-09
during O 0 3.149593030826736e-09
passage O 0 4.217781679471955e-09
of O 0 2.706152524289962e-10
this O 0 4.497679728654447e-10
mutation O 0 1.0357693369655863e-08
through O 0 9.566186731646553e-10
several O 0 7.887235753401e-09
generations O 0 2.4726173819544783e-07
. O 0 9.088482499919337e-08

These O 0 2.3207387300772098e-07
results O 0 7.280757330363485e-08
indicate O 0 4.2101881092548865e-08
that O 0 2.74786815523953e-09
4003delTC O 0 1.6578472923356458e-06
occurs O 0 1.832683516056477e-08
on O 0 5.766871424839337e-09
a O 0 6.415066700071748e-09
single O 0 4.4872820126329316e-08
ancestral O 0 4.243605928877514e-07
allele O 0 2.9229390747786965e-06
. O 0 6.702909871592055e-08
. O 0 1.746123103885111e-07

The O 0 1.2410018825903535e-06
haptoglobin O 0 3.7679466913687065e-05
- O 0 6.280683464865433e-06
gene O 0 1.697869379313488e-06
deletion O 0 3.5663226753968047e-06
responsible O 0 1.9033359421882778e-07
for O 0 1.936489724130297e-08
anhaptoglobinemia B-Disease 0 4.4999000238021836e-05
. O 0 6.210302672116086e-07

We O 0 1.1749250006687362e-05
have O 0 1.1107097463991522e-08
found O 0 1.2957647177458398e-09
an O 0 4.566068634304088e-10
allelic O 0 2.022598124540309e-07
deletion O 0 1.3874378055334091e-06
of O 0 6.199258439920641e-09
the O 0 1.5768975458740897e-08
haptoglobin O 0 1.1471108336991165e-05
( O 0 2.139520383082072e-08
Hp O 0 1.5313614198930736e-07
) O 0 8.165414455696407e-10
gene O 0 9.127758104909844e-09
from O 0 1.186980513878666e-09
an O 0 4.818996313105117e-10
individual O 0 2.4611113147443575e-09
with O 0 1.0989554155571568e-08
anhaptoglobinemia B-Disease 0 0.0001095053376047872
. O 0 5.941156473454612e-07

The O 0 2.3763966794376756e-07
Hp O 0 1.4662817875432665e-06
gene O 0 3.2840119956745184e-07
cluster O 0 1.8215078512184846e-07
consists O 0 9.337375317386432e-09
of O 0 1.138012351020734e-09
coding O 0 5.880817298020702e-06
regions O 0 1.628815766707703e-07
of O 0 1.0671771244474826e-09
the O 0 7.243866395612031e-09
alpha O 0 2.0253404287018384e-08
chain O 0 3.2521022603759775e-06
and O 0 1.0265961414290814e-08
beta O 0 3.6640386280595294e-09
chain O 0 5.811029168967252e-08
of O 0 1.360121321125618e-10
the O 0 6.411589592580924e-10
haptoglobin O 0 3.3712234426275245e-07
gene O 0 1.0771390890340626e-07
( O 0 9.957097368840095e-09
Hp O 0 2.2363771279287903e-07
) O 0 4.108987816664467e-09
and O 0 6.084539094786123e-09
of O 0 3.906235890305254e-10
the O 0 2.9445086369150886e-09
alpha O 0 2.007632993183961e-08
chain O 0 1.3251808468339732e-06
and O 0 5.025840632555401e-09
beta O 0 5.600520935900022e-09
chain O 0 8.081968161377517e-08
of O 0 5.543225323201284e-10
the O 0 3.282713212371391e-09
haptoglobin O 0 1.0619287422741763e-06
- O 0 4.950209131493466e-07
related O 0 3.337445164675046e-08
gene O 0 6.463305908255279e-07
( O 0 2.7312632155940264e-08
Hpr O 0 6.3990751186793204e-06
) O 0 1.2698985862868994e-08
, O 0 2.5667621361691317e-09
in O 0 7.970514803723461e-10
tandem O 0 1.3023174005866167e-06
from O 0 5.228948829483215e-09
the O 0 6.216296810634958e-09
5 O 0 1.647941729743252e-07
side O 0 2.6089310267707333e-06
. O 0 4.165963218838442e-07

Southern O 0 1.9319159036967903e-05
blot O 0 0.00011995996464975178
and O 0 1.866598466904179e-07
PCR O 0 2.569058779045008e-06
analyses O 0 2.0669089906277804e-07
have O 0 2.0064232941763294e-08
indicated O 0 4.147857168845803e-08
that O 0 4.0475817142393566e-10
the O 0 5.076030151762723e-10
individual O 0 1.052376852328507e-09
with O 0 2.947801336361522e-09
anhaptoglobinemia B-Disease 0 1.1392742635507602e-05
was O 0 8.571989269512414e-07
homozygous O 0 4.661916008785738e-08
for O 0 1.0010502149437883e-10
the O 0 3.0646832294145554e-10
gene O 0 1.4897793221280153e-08
deletion O 0 1.940616840556686e-07
and O 0 1.9675479023817388e-08
that O 0 2.895182149575959e-10
the O 0 3.1970673330938837e-10
gene O 0 1.754174050461188e-08
deletion O 0 3.8314615835588484e-07
was O 0 1.3867868347006151e-06
included O 0 4.4469952165115956e-09
at O 0 1.6603213026655794e-08
least O 0 2.1481798562206222e-09
from O 0 4.33987096259969e-10
the O 0 1.2816876449051051e-09
promoter O 0 1.0497560651856475e-06
region O 0 4.168708400698051e-08
of O 0 1.4276376747446307e-09
Hp O 0 1.724335731978499e-07
to O 0 3.1353637464093254e-09
Hpr O 0 7.376829671557061e-07
alpha O 0 2.3899417556094704e-08
but O 0 4.126879726840116e-09
not O 0 7.550593483784951e-10
to O 0 4.658518015787649e-09
Hpr O 0 4.818082288693404e-06
beta O 0 2.363858584431e-07
( O 0 4.2052686666238515e-08
Hpdel O 0 4.922349489788758e-06
) O 0 1.0040116649179254e-07
. O 0 2.3710292396117438e-07

In O 0 2.843271431629546e-07
addition O 0 1.6848213491016395e-08
, O 0 5.478000275616068e-09
we O 0 2.7243056699433055e-09
found O 0 8.406025875373757e-10
seven O 0 2.2434760715839275e-09
individuals O 0 9.252958121930277e-11
with O 0 2.2562629542477453e-10
hypohaptoglobinemia B-Disease 0 3.201660092599923e-07
in O 0 4.242405537979721e-09
three O 0 2.84870687039529e-08
families O 0 2.152951594780461e-08
, O 0 1.7418105846545018e-09
and O 0 3.1251721210878713e-09
the O 0 1.1180421033429866e-09
genotypes O 0 2.752320824583876e-07
of O 0 1.667671112315361e-09
six O 0 3.315347285592907e-08
of O 0 2.4954127653131764e-10
the O 0 4.33152891332611e-09
seven O 0 3.131588144356101e-08
individuals O 0 4.2289766133407625e-10
were O 0 1.4695602512659889e-09
found O 0 1.4221044342122013e-09
to O 0 2.8000133323047294e-09
be O 0 9.33308452744086e-09
Hp2 O 0 3.5055384159932146e-06
/ O 0 2.2110318695922615e-06
Hpdel O 0 2.1804242351208813e-05
. O 0 3.44925467743451e-07

The O 0 4.1469917277936474e-07
phenotypes O 0 1.5248168892867398e-05
and O 0 1.4641143764038134e-07
genotypes O 0 4.767789505422115e-06
in O 0 8.928703110200331e-09
one O 0 5.934449820443888e-09
of O 0 1.8088859576881333e-10
these O 0 8.075689561515276e-10
three O 0 2.5140661108480344e-08
families O 0 8.710818377721807e-08
showed O 0 2.364416104683187e-06
the O 0 7.66406138552611e-09
father O 0 1.9478738977340981e-07
to O 0 4.188560165374611e-09
be O 0 3.765092682073146e-09
hypohaptoglobinemic B-Disease 0 6.084443384679616e-07
( O 0 3.074585475104641e-09
Hp2 O 0 1.2191460996291426e-07
) O 0 9.609564255441683e-10
and O 0 1.6701666716301133e-09
Hp2 O 0 6.182140168675687e-07
/ O 0 3.9377411553687125e-07
Hpdel O 0 1.4742979601578554e-06
, O 0 3.884927934905136e-09
the O 0 1.6962220517058313e-09
mother O 0 1.9519427496561548e-07
to O 0 8.095769610250159e-10
be O 0 1.2217009626169784e-09
Hp2 O 0 9.445624726822643e-08
- O 0 7.569229865111993e-08
1 O 0 4.33481828210347e-09
and O 0 3.6160987537670053e-09
Hp1 O 0 4.492266043598647e-07
/ O 0 3.7158397958592104e-07
Hp2 O 0 1.0011525546360645e-06
, O 0 1.6261771929038105e-09
one O 0 7.408012536735953e-10
of O 0 2.8838934712505093e-11
the O 0 4.759257432596087e-10
two O 0 1.4825934258055895e-08
children O 0 2.5567810979509886e-08
to O 0 3.1946980616481824e-09
be O 0 1.0061142141637447e-08
hypohaptoglobinemic B-Disease 0 1.2582218005263712e-06
( O 0 4.868573988403568e-09
Hp2 O 0 2.9155094694033323e-07
) O 0 1.7282852926570058e-09
and O 0 2.179496583210039e-09
Hp2 O 0 6.05287823418621e-07
/ O 0 4.116662637443369e-07
Hpdel O 0 1.64394998591888e-06
, O 0 2.914214203286747e-09
and O 0 1.0445776466028178e-09
the O 0 2.3055256315185346e-10
other O 0 1.8967956372240025e-10
child O 0 1.5576018697061045e-08
to O 0 6.313691791604015e-10
be O 0 8.453844291267387e-10
Hp1 O 0 1.3938789322764933e-07
and O 0 8.030749398812986e-09
Hp1 O 0 1.7444018567402964e-06
/ O 0 5.716312330150686e-07
Hpdel O 0 2.0168768060102593e-06
, O 0 6.36740260517854e-09
showing O 0 2.0366012876138484e-08
an O 0 3.8393430101812953e-10
anomalous O 0 1.0305792130793634e-07
inheritance O 0 1.248565695277648e-07
of O 0 5.739952513295066e-09
Hp O 0 4.601394266501302e-06
phenotypes O 0 1.3022242910665227e-06
in O 0 7.424339809602998e-09
the O 0 1.8687657643567945e-08
child O 0 1.2243536957612378e-06
with O 0 4.420915900027467e-08
Hp1 O 0 0.00011618138523772359
. O 0 3.6765089816981344e-07

The O 0 4.61017890529547e-07
Hp2 O 0 2.2439011445385404e-05
/ O 0 8.95104221854126e-06
Hpdel O 0 1.5981107935658656e-05
individuals O 0 3.7663010488131476e-08
had O 0 1.196666516989353e-07
an O 0 1.3069043625080212e-09
extremely O 0 4.80913051603693e-08
low O 0 2.1990045695474691e-07
level O 0 2.788862918379209e-09
of O 0 6.348941927747376e-10
Hp O 0 3.4008670013463416e-07
( O 0 2.3680828409311516e-09
mean O 0 8.795609574008267e-09
+ O 0 5.386587176303692e-08
/ O 0 2.534671921239351e-07
- O 0 1.132936176873045e-06
SD O 0 1.1954091860388871e-05
= O 0 2.9870659545849776e-07
0 O 0 1.7262239637716448e-08
. O 0 2.9775415466559707e-09
049 O 0 8.006692269191262e-07
+ O 0 1.1305094460567489e-07
/ O 0 1.5384668472506746e-07
- O 0 2.445418942897959e-07
0 O 0 2.1802792460334786e-08
. O 0 1.935159588128954e-09
043 O 0 5.889618250876083e-07
mg O 0 2.2650577591321053e-07
/ O 0 2.1756396506589226e-07
ml O 0 3.1241310693985724e-07
; O 0 9.336466710863078e-09
n O 0 1.1246199704828541e-07
= O 0 1.4418854732412e-07
6 O 0 1.57301034420243e-08
) O 0 1.1194100091316272e-09
, O 0 9.97823379478291e-10
compared O 0 2.2118518128166897e-09
with O 0 5.581471951288108e-10
the O 0 4.799891151208158e-09
level O 0 7.225734233173853e-09
( O 0 5.346345588463919e-10
1 O 0 9.904209674616027e-10
. O 0 6.097617966105418e-10
64 O 0 8.182552413416033e-09
+ O 0 1.6594855267726416e-08
/ O 0 7.644429445008427e-08
- O 0 1.0627174873434342e-07
1 O 0 7.298342374895128e-09
. O 0 1.396171400713797e-09
07 O 0 4.340761350363209e-08
mg O 0 1.1546023870323552e-07
/ O 0 1.2197136811664677e-07
ml O 0 1.3480118354891601e-07
) O 0 1.0210867706916815e-09
obtained O 0 9.958156521605588e-10
from O 0 9.448968274483605e-10
52 O 0 6.494948223689789e-08
healthy O 0 3.398924164343953e-08
volunteers O 0 3.324110409153036e-08
having O 0 8.521176653175644e-09
phenotype O 0 4.465395022634766e-07
Hp2 O 0 5.815048211843532e-07
, O 0 2.680877742022858e-09
whereas O 0 2.4176880497606135e-09
the O 0 1.7607835189892285e-09
serum O 0 5.493728849614854e-07
Hp O 0 2.1252571968943812e-07
level O 0 2.7277113900936456e-09
of O 0 1.0601407945953767e-10
an O 0 1.338881505663636e-10
individual O 0 5.364650390582426e-10
with O 0 4.531444997013523e-09
Hp1 O 0 2.4753100660745986e-05
/ O 0 5.4322390496963635e-06
Hpdel O 0 2.5336996259284206e-05
was O 0 1.2479996485126321e-06
0 O 0 1.3093469419800385e-07
. O 0 1.4537295101035852e-07

50 O 0 4.353631538833724e-06
mg O 0 6.866774128866382e-06
/ O 0 4.468433871807065e-06
ml O 0 2.834939550666604e-06
, O 0 2.2970169766267645e-08
which O 0 1.2208675848057737e-08
was O 0 1.2552862926895614e-07
approximately O 0 2.387789965752063e-09
half O 0 6.6608754067942755e-09
the O 0 5.646198508735267e-10
level O 0 1.3633790763023512e-09
of O 0 4.813007214998777e-10
Hp O 0 9.825380686834251e-08
in O 0 3.2740716804369185e-09
control O 0 2.000616404984612e-06
sera O 0 7.068915692798328e-07
from O 0 6.269065266906182e-10
the O 0 2.427567258322938e-09
Hp1 O 0 5.525998858502135e-06
phenotype O 0 1.180345634566038e-06
( O 0 1.7370463956112303e-09
1 O 0 9.329627070897573e-10
. O 0 7.726775885785742e-10
26 O 0 9.379715670831956e-09
+ O 0 4.486374649559366e-08
/ O 0 1.0489309687500281e-07
- O 0 1.0994254040497253e-07
0 O 0 9.495368047396369e-09
. O 0 5.744583142508475e-10
33 O 0 1.2885934097539575e-08
mg O 0 6.289791087965568e-08
/ O 0 1.1757366280562564e-07
ml O 0 3.2637240110489074e-07
; O 0 7.36246130728091e-09
n O 0 2.5302546191596775e-07
= O 0 3.453994850133313e-07
9 O 0 7.906881194230664e-08
) O 0 2.9968794112988917e-09
, O 0 1.5592062085900693e-09
showing O 0 4.046643908850456e-08
a O 0 5.3667918997746256e-09
gene O 0 2.404420342827507e-07
- O 0 6.302823749138042e-06
dosage O 0 2.5101621758949477e-06
effect O 0 7.281909120138153e-07
. O 0 1.416453301317233e-07

The O 0 1.5935823682866612e-07
other O 0 6.329720303455133e-09
allele O 0 8.168839826794283e-07
( O 0 1.775457647568146e-08
Hp2 O 0 8.537967914890032e-07
) O 0 1.570006236129018e-09
of O 0 1.4853006324866413e-10
individuals O 0 1.9138905738014245e-10
with O 0 6.355387882628349e-10
Hp2 O 0 4.43681574324728e-06
/ O 0 2.6360867195762694e-06
Hpdel O 0 9.815070370677859e-06
was O 0 2.6402128696645377e-06
found O 0 6.412302244740431e-09
to O 0 5.247642320682644e-09
have O 0 1.9385074878641717e-08
, O 0 5.820474657802777e-10
in O 0 6.857619472278031e-10
all O 0 1.1622385276410796e-09
exons O 0 1.0002993349189637e-06
, O 0 1.493432222332558e-08
no O 0 4.432244349317216e-09
mutation O 0 1.4457017805113992e-08
, O 0 3.1594227234421624e-10
by O 0 4.1453934729318576e-10
DNA O 0 6.876840785707827e-08
sequencing O 0 5.029602334616357e-07
. O 0 2.719137341955502e-07

On O 0 2.3665231765335193e-06
the O 0 8.930320483102605e-09
basis O 0 8.221851643952505e-09
of O 0 4.517367868661637e-10
the O 0 1.9483294977362675e-09
present O 0 1.6846534167669347e-09
study O 0 5.714606565732083e-10
, O 0 4.662542574251916e-10
the O 0 1.55952070701737e-10
mechanism O 0 7.54037809969077e-09
of O 0 1.8446658645032699e-09
anhaptoglobinemia B-Disease 0 8.963769687397871e-06
and O 0 3.3844266056348715e-08
the O 0 1.1222703877322715e-09
mechanism O 0 9.257839828080705e-09
of O 0 3.131053472049672e-10
anomalous O 0 3.9508382343456105e-08
inheritance O 0 5.557988913551526e-08
of O 0 5.376289635705689e-09
Hp O 0 2.9339928460103692e-06
phenotypes O 0 7.144230039557442e-06
were O 0 4.6403584974541445e-07
well O 0 1.1504521069127804e-07
explained O 0 1.9903020529454807e-06
. O 0 1.711710098106778e-07

However O 0 2.8684332846751204e-06
, O 0 1.4643343426712363e-08
the O 0 2.017874312087997e-09
mechanism O 0 3.6166316164099044e-08
of O 0 7.945367919148794e-09
hypohaptoglobinemia B-Disease 0 7.176130748121068e-05
remains O 0 7.032778739812784e-06
unknown O 0 9.606686944607645e-06

ATM O 0 0.00041139841778203845
mutations O 0 0.0003519151941873133
and O 0 4.269471958195936e-07
phenotypes O 0 0.0003615466121118516
in O 0 1.6089788914541714e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.9739396520890296e-05
in O 0 1.3059133330273198e-08
the O 0 2.2091713347549558e-08
British O 0 4.406294920045184e-06
Isles O 0 4.861547040491132e-06
: O 0 3.027057049465043e-09
expression O 0 3.5202392112410053e-09
of O 0 9.799763778239878e-11
mutant O 0 8.793349337565814e-08
ATM O 0 3.667019541353511e-07
and O 0 1.1731388305236123e-08
the O 0 3.0337674594704822e-09
risk O 0 4.0263266498641315e-08
of O 0 5.3288982115873296e-09
leukemia B-Disease 0 0.02722977288067341
, O 0 6.8944123086112086e-06
lymphoma B-Disease 1 1.0
, O 0 2.0843222614530532e-07
and O 0 2.4997129912662786e-06
breast B-Disease 1 0.9200202226638794
cancer I-Disease 0 0.00037320327828638256
. O 0 1.3197651469454286e-06

We O 0 1.121838613471482e-05
report O 0 4.3555814954743255e-08
the O 0 1.271939109592779e-09
spectrum O 0 3.741662979450666e-08
of O 0 6.816150976973745e-10
59 O 0 7.029923665413662e-08
ATM O 0 1.1308701459711301e-06
mutations O 0 1.4333949138745083e-06
observed O 0 8.25620588784659e-07
in O 0 2.1354755972424755e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.009157780557870865
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.6187342778457605e-08
patients O 0 1.7166756904885005e-08
in O 0 1.4034093887005383e-09
the O 0 6.9423231607856906e-09
British O 0 1.693348167464137e-06
Isles O 0 1.6306203178828582e-05
. O 0 3.453523618190957e-07

Of O 0 4.5586071450998134e-07
51 O 0 1.920634076668648e-06
ATM O 0 5.041380973125342e-06
mutations O 0 1.9873621113219997e-06
identified O 0 9.040194726139816e-08
in O 0 2.9147535496321098e-09
families O 0 7.117863187744433e-09
native O 0 3.038805873600836e-09
to O 0 3.542175441850759e-09
the O 0 4.82035034110595e-09
British O 0 9.00438919870794e-07
Isles O 0 1.329103042735369e-06
, O 0 9.793308386463195e-09
11 O 0 6.864885992996506e-09
were O 0 6.9093255561369915e-09
founder O 0 2.8129966267442796e-07
mutations O 0 1.1163597690710958e-07
, O 0 2.0210637607931403e-09
and O 0 2.780921937173275e-09
2 O 0 3.147268889946986e-09
of O 0 1.5340341497083188e-10
these O 0 5.653040813236032e-10
11 O 0 4.997326552569348e-09
conferred O 0 2.9133362389188733e-09
a O 0 1.22253149825724e-08
milder O 0 1.0298173037881497e-05
clinical O 0 4.191483355953096e-07
phenotype O 0 3.1683500765211647e-06
with O 0 6.555544107555988e-09
respect O 0 1.407672645115099e-08
to O 0 2.5109320844762806e-08
both O 0 6.685793323413236e-07
cerebellar B-Disease 1 0.7563104033470154
degeneration I-Disease 1 0.9047302007675171
and O 0 9.16680775731038e-08
cellular O 0 1.8968283939102548e-06
features O 0 3.034103792742826e-05
. O 0 1.884977109511965e-06

We O 0 2.3861713998485357e-05
report O 0 4.598095060259766e-08
, O 0 1.4772464362877713e-09
in O 0 1.5450877244305161e-09
two O 0 3.798970169555105e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 9.1694488446592e-08
, O 0 2.966769052648033e-10
an O 0 1.767023610765861e-10
ATM O 0 1.3329692194474774e-07
mutation O 0 6.20779161408791e-08
( O 0 1.8632482223779334e-09
7271T O 0 4.746326354165831e-08
- O 0 3.338913643347041e-07
- O 0 3.6599519717128715e-06
> O 0 1.3795671804928133e-07
G O 0 3.352149406055105e-06
) O 0 3.2117131176789826e-09
that O 0 3.744417220730156e-09
may O 0 1.6788203538453672e-07
be O 0 5.175474493412935e-10
associated O 0 1.0100728031758877e-09
with O 0 2.1958856954995554e-10
an O 0 5.349548581889962e-10
increased O 0 1.766075108378118e-08
risk O 0 1.435833585361479e-08
of O 0 3.173605378492539e-09
breast B-Disease 0 0.003068083431571722
cancer I-Disease 0 3.583191073630587e-06
in O 0 9.387070676325493e-09
both O 0 3.448322871690834e-08
homozygotes O 0 9.215222235070542e-06
and O 0 1.8205216179012496e-07
heterozygotes O 0 6.232326086319517e-07
( O 0 2.3879902499857053e-09
relative O 0 1.4944296466978813e-08
risk O 0 2.075609373264342e-08
12 O 0 2.0688497581744514e-09
. O 0 4.3563080920350217e-10
7 O 0 1.4278398907663359e-08
; O 0 1.0827847063410445e-08
P O 0 1.4001535419083666e-05
= O 0 3.4383936053927755e-07
. O 0 3.716879470871959e-09
0025 O 0 3.3301586199740996e-07
) O 0 1.4853296370631597e-09
, O 0 1.1321236170758198e-09
although O 0 9.119487387465597e-10
there O 0 7.933203538534883e-10
is O 0 3.793325376033607e-10
a O 0 1.4094584388502085e-09
less O 0 1.3606599402748998e-08
severe O 0 7.572964022983797e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 7.172136247390881e-05
in O 0 3.405327131389413e-09
terms O 0 4.998403912992444e-09
of O 0 5.456348706189829e-10
the O 0 5.474657172044317e-09
degree O 0 2.946408983461879e-08
of O 0 7.418694281113858e-08
cerebellar B-Disease 1 0.6769376397132874
degeneration I-Disease 1 0.9985334873199463
. O 0 1.4989507235441124e-06

This O 0 7.098383321135771e-07
mutation O 0 2.532229700591415e-06
( O 0 6.025744880844286e-08
7271T O 0 7.740072192063963e-07
- O 0 1.916130031531793e-06
- O 0 1.1838757018267643e-05
> O 0 7.519627729379863e-07
G O 0 9.090802450373303e-06
) O 0 4.137898468314916e-09
also O 0 1.1535508548377038e-08
allows O 0 3.8800478385780934e-09
expression O 0 8.681190877268818e-09
of O 0 6.681319941748143e-10
full O 0 1.4066849018945504e-08
- O 0 6.840133437435725e-07
length O 0 4.991689550593037e-08
ATM O 0 3.544725402093718e-08
protein O 0 8.730690836955546e-09
at O 0 1.1630745255786223e-09
a O 0 1.8956176628392996e-09
level O 0 3.913934509824912e-09
comparable O 0 7.870105456220244e-09
with O 0 1.5303409650613276e-09
that O 0 6.00810334816515e-09
in O 0 9.53573309203648e-09
unaffected O 0 2.120622184520471e-06
individuals O 0 1.9010787610795887e-08
. O 0 5.51635679357787e-08

In O 0 4.996718985239568e-07
addition O 0 4.4920771102852086e-08
, O 0 9.392282507292293e-09
we O 0 2.3370012591783507e-09
have O 0 1.2033338769867896e-09
studied O 0 1.2338672306100307e-08
18 O 0 5.222114509706444e-07
A B-Disease 1 0.9999988079071045
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 4.1544058149156626e-07
, O 0 9.472245210417896e-10
in O 0 4.699792777174139e-10
15 O 0 7.461747664194718e-09
families O 0 2.1634805058567963e-09
, O 0 1.4374358370261575e-09
who O 0 2.264750946778804e-07
developed O 0 5.070141014584806e-06
leukemia B-Disease 0 0.063867948949337
, O 0 6.8351137088029645e-06
lymphoma B-Disease 1 1.0
, O 0 5.459644114580442e-08
preleukemic O 0 2.7258744012215175e-05
T O 0 0.0001668443437665701
- O 0 4.125129635212943e-06
cell O 0 3.1501408557232935e-06
proliferation O 0 6.927207323315088e-07
, O 0 4.170625089727764e-08
or O 0 1.075479212886421e-05
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.209513271760443e-07
mostly O 0 1.6287295068195817e-08
in O 0 2.4097616346807627e-08
childhood O 0 1.2561342373373918e-05
. O 0 1.3631167803396238e-06

A O 0 5.046200840297388e-06
wide O 0 8.378939355679904e-07
variety O 0 3.577995855152949e-08
of O 0 2.615750060996902e-09
ATM O 0 2.355862989134039e-06
mutation O 0 1.4638993661719724e-07
types O 0 3.676366544524967e-09
, O 0 4.911643869398574e-10
including O 0 1.6069526820317037e-09
missense O 0 2.2620733943767846e-05
mutations O 0 2.5686351818876574e-06
and O 0 1.2925663206431182e-08
in O 0 2.7981019723455347e-09
- O 0 2.575002690718975e-05
frame O 0 0.015078738331794739
deletions O 0 7.616937182319816e-06
, O 0 7.051329475871171e-08
were O 0 9.225127683976098e-08
seen O 0 2.216372223529106e-07
in O 0 5.086926879727116e-09
these O 0 2.3590409625739994e-08
patients O 0 1.2208401756197418e-07
. O 0 7.446353578188791e-08

We O 0 6.755404683644883e-06
also O 0 7.911195609722199e-08
show O 0 3.020985559487599e-07
that O 0 2.0837480629865013e-09
25 O 0 7.853610206609574e-09
% O 0 4.2372685915559316e-10
of O 0 1.769944746321528e-10
all O 0 2.785892583290206e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.9367930665102904e-07
carried O 0 1.9947925977703562e-08
in O 0 7.27254756416329e-10
- O 0 7.677231224079151e-07
frame O 0 1.5284713299479336e-05
deletions O 0 2.603939492473728e-06
or O 0 3.629049061260048e-08
missense O 0 5.0192707021778915e-06
mutations O 0 2.055929257949174e-07
, O 0 1.3170088353220422e-09
many O 0 1.0337630751422466e-10
of O 0 8.708102017251917e-10
which O 0 1.740385528137267e-06
were O 0 9.719414038045215e-07
also O 0 4.3826403839375416e-07
associated O 0 8.486401803509125e-09
with O 0 2.9831066505892068e-09
expression O 0 2.1274995987141665e-08
of O 0 1.7843752031510007e-09
mutant O 0 1.4355988469105796e-06
ATM O 0 3.8059106373111717e-06
protein O 0 4.017814262624597e-06
. O 0 3.094505132139602e-07

The O 0 1.3049381095697754e-06
DMPK O 0 3.501146420603618e-05
gene O 0 3.11911094286188e-06
of O 0 1.553804480636245e-07
severely O 0 0.030209053307771683
affected O 0 8.365455141756684e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0002617891295813024
is O 0 1.0351141099818051e-07
hypermethylated O 0 1.5732490282971412e-05
proximal O 0 1.982988578674849e-05
to O 0 1.4980217599713797e-07
the O 0 1.5891863824890606e-08
largely O 0 4.676655152024978e-08
expanded O 0 4.1532570094204857e-07
CTG O 0 4.716626790468581e-05
repeat O 0 1.1020872079825494e-05
. O 0 8.427206239502993e-07

Using O 0 8.709096164238872e-07
methylation O 0 7.399358764814679e-06
- O 0 4.549535788100911e-06
sensitive O 0 2.567087165061821e-07
restriction O 0 6.403443819635868e-08
enzymes O 0 6.925503726051829e-08
, O 0 2.305166280081039e-09
we O 0 1.3006947741089903e-09
characterized O 0 4.966008493312302e-09
the O 0 3.197494213846852e-10
methylation O 0 1.844283872287633e-07
pattern O 0 0.00013149592268746346
on O 0 1.2245359357621055e-06
the O 0 2.1573047348510954e-08
5 O 0 9.509871290447336e-08
side O 0 1.0388701099373066e-07
of O 0 2.305288182569143e-10
the O 0 1.5951681087145175e-09
CTG O 0 1.848962710937485e-06
repeat O 0 8.240522930691441e-08
in O 0 6.787764794680129e-10
the O 0 1.2520451342368233e-09
DMPK O 0 6.686188385174319e-07
gene O 0 2.8457037615226e-08
of O 0 4.867308778244706e-10
normal O 0 8.808822116179726e-09
individuals O 0 3.97261917806091e-10
and O 0 9.567299175117228e-10
of O 0 7.753792607978482e-10
patients O 0 2.2883543948637453e-08
affected O 0 3.890187372235232e-08
with O 0 1.772969085322984e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 9.536172740354232e-08
showing O 0 1.1361567686662966e-07
expansions O 0 6.829353083048773e-08
of O 0 1.3641178187029368e-09
the O 0 1.387893444615429e-08
repetitive O 0 1.7413552996004e-05
sequence O 0 2.038375441770768e-06
. O 0 3.6776100387214683e-07

The O 0 1.8090157993810863e-07
gene O 0 5.819780426463694e-07
segment O 0 7.551477665401762e-07
analyzed O 0 1.2732071752452612e-07
corresponds O 0 7.6319288666582e-08
to O 0 3.099639434012147e-09
the O 0 4.226623939729279e-09
genomic O 0 1.1624163107626373e-06
SacI O 0 3.136818122584373e-05
- O 0 6.386297172866762e-06
HindIII O 0 2.3996310574148083e-06
fragment O 0 3.591918300571706e-07
carrying O 0 4.685002963356055e-08
exons O 0 2.2304141111817444e-06
11 O 0 3.4436669693604927e-07
- O 0 8.454974704363849e-06
15 O 0 4.904047727904981e-07
. O 0 2.2588085357710952e-07

There O 0 6.168547770357691e-07
is O 0 2.9616668228982235e-08
constitutive O 0 1.599601233692738e-07
methylation O 0 5.236876745584595e-07
in O 0 1.3330475390205265e-08
intron O 0 1.7412092347512953e-05
12 O 0 2.1940422811894678e-07
at O 0 1.725143472519619e-09
restriction O 0 3.1577376269353863e-09
sites O 0 5.070217135028088e-09
of O 0 1.8297799941890958e-09
SacII O 0 4.766820893564727e-06
and O 0 3.3620558781422005e-08
HhaI O 0 5.850632192050398e-07
, O 0 1.0358953694833417e-09
localized O 0 1.4941303305704423e-08
1 O 0 3.968418482713787e-09
, O 0 5.661802693346374e-10
159 O 0 6.723881451620173e-09
- O 0 2.1594972565708304e-07
1 O 0 1.0555093687969475e-08
, O 0 1.933779580909345e-09
232 O 0 1.3225248451931293e-08
bp O 0 1.4351878974139254e-07
upstream O 0 1.4562959727015823e-08
of O 0 2.803768883730129e-10
the O 0 1.685264150452781e-09
CTG O 0 1.0312393214917392e-06
repeat O 0 7.803264878702976e-08
, O 0 9.30174826052621e-10
whereas O 0 1.575201191705844e-09
most O 0 3.6778935452730366e-10
, O 0 1.132607341247649e-09
if O 0 1.724077658415979e-09
not O 0 1.3598731030128874e-09
all O 0 4.805613684766286e-10
, O 0 3.171800322387952e-10
of O 0 2.0971509251399567e-11
the O 0 6.229488452857979e-11
other O 0 5.706935618521314e-11
sites O 0 1.255404891153944e-09
of O 0 4.3261350057832715e-10
SacII O 0 3.7825284948667104e-07
, O 0 1.5495441596513615e-09
HhaI O 0 2.0906009012833238e-07
, O 0 1.988739617431179e-09
and O 0 1.71209368904357e-09
HpaII O 0 2.395219951267791e-07
in O 0 1.9221080282960656e-09
this O 0 9.996540262235953e-10
region O 0 2.5419161886475194e-08
are O 0 6.478956260380642e-10
unmethylated O 0 3.470116780590615e-07
, O 0 2.0446688786535105e-09
in O 0 6.734993118762134e-10
normal O 0 2.9166237425215513e-08
individuals O 0 1.2582047625997461e-09
and O 0 2.377618990578867e-09
most O 0 5.903006417007362e-10
of O 0 3.682919802461271e-10
the O 0 1.4906945011716743e-08
patients O 0 9.395655098387579e-08
. O 0 7.448654315567182e-08

In O 0 1.3866795711692248e-07
a O 0 2.6195309033028025e-08
number O 0 5.00342078879612e-09
of O 0 2.1188888421619367e-09
young O 0 5.39981499514397e-07
and O 0 1.592833314134623e-07
severely O 0 3.698109503602609e-05
affected O 0 2.4192484460172636e-08
patients O 0 1.4894638411533379e-08
, O 0 1.0274595618753324e-09
however O 0 9.751550678060994e-10
, O 0 2.906219709331026e-10
complete O 0 5.515214951401504e-10
methylation O 0 2.1584860121492966e-08
of O 0 5.134807024020915e-10
these O 0 2.788425323974053e-10
restriction O 0 2.7939315305758328e-09
sites O 0 5.209609099665613e-08
was O 0 1.3951945447843173e-06
found O 0 3.0100208991967747e-09
in O 0 8.726740996500837e-10
the O 0 4.735544401057723e-09
mutated O 0 3.270022261858685e-06
allele O 0 4.77061848869198e-06
. O 0 3.209186161257094e-07

In O 0 1.6290145765651687e-07
most O 0 2.452503089500624e-09
of O 0 2.2481827510745234e-10
these O 0 1.6176111561350126e-09
patients O 0 8.216334279609327e-09
, O 0 6.825127685239352e-10
the O 0 1.8746768581934248e-09
onset O 0 5.157860414328752e-07
of O 0 3.4800233805754033e-09
the O 0 5.645987926072848e-07
disease O 0 0.006033905781805515
was O 0 0.0004972885944880545
congenital O 1 0.9999619722366333
. O 0 1.1439352647357737e-06

Preliminary O 0 5.509928087121807e-06
in O 0 3.076432335546997e-07
vivo O 0 1.7854805264505558e-05
footprinting O 0 8.153564704116434e-05
data O 0 2.485338654878433e-07
gave O 0 2.7555268289347623e-08
evidence O 0 1.2432095353176464e-09
for O 0 3.6570549366565785e-10
protein O 0 1.6465460106473984e-08
- O 0 1.0779837822383342e-07
DNA O 0 1.3756522321273223e-07
contact O 0 2.0534869804578193e-08
in O 0 1.582159958601892e-09
normal O 0 1.2390153791841385e-08
genes O 0 2.2103767705061728e-08
at O 0 4.37794245300438e-09
an O 0 1.3443838264848296e-09
Sp1 O 0 1.4376595345311216e-06
consensus O 0 1.3306901358589585e-08
binding O 0 7.086868425432158e-09
site O 0 5.176901751724472e-08
upstream O 0 3.80983244951949e-08
of O 0 4.5459341846409984e-10
the O 0 2.4681108268254093e-09
CTG O 0 1.9917224562959746e-06
repeat O 0 3.984705188031512e-07
and O 0 7.684159086807085e-09
for O 0 1.8506382537530897e-10
a O 0 8.995603706374311e-10
significant O 0 5.536557878826898e-10
reduction O 0 1.803330262895031e-09
of O 0 9.161813668834284e-11
this O 0 1.0912155901099396e-10
interaction O 0 9.276854284756553e-10
in O 0 9.608940310101843e-10
cells O 0 5.521807011632518e-09
with O 0 7.104865029639029e-10
a O 0 2.3679893601524782e-08
hypermethylated O 0 5.361389867175603e-06
DMPK O 0 5.599691121460637e-06
gene O 0 6.908154546181322e-07
. O 0 5.7583783075187966e-08
. O 0 1.414954624578968e-07

The O 0 2.556323806857108e-06
hemochromatosis B-Disease 1 0.9999969005584717
gene O 0 3.0431167488131905e-06
product O 0 1.2170411878287268e-07
complexes O 0 6.977398925300804e-08
with O 0 3.539352810832952e-09
the O 0 3.5199303471955545e-09
transferrin O 0 6.814577204750094e-07
receptor O 0 1.538854235150211e-07
and O 0 6.605122848668543e-08
lowers O 0 6.0531192502821796e-06
its O 0 2.3477684241157704e-09
affinity O 0 8.950271634944329e-09
for O 0 5.94356563965448e-10
ligand O 0 1.5660941699024988e-07
binding O 0 5.058271881352994e-07
. O 0 4.3722621967390296e-07

We O 0 1.5870131392148323e-05
recently O 0 1.4698772474730504e-06
reported O 0 1.609523252454892e-07
the O 0 1.000716620680464e-09
positional O 0 2.6901972205450875e-07
cloning O 0 5.5795403852698655e-08
of O 0 4.582593193802609e-10
a O 0 6.83285517055765e-09
candidate O 0 2.2551041922724835e-07
gene O 0 6.762352768419078e-06
for O 0 1.648752913752105e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.03163992986083031
HFE O 0 0.3856687843799591
. O 0 4.759244347951608e-06

The O 0 1.7344294178656128e-07
gene O 0 4.293829078960698e-07
product O 0 2.8424605602594966e-07
, O 0 5.424805049614179e-09
a O 0 4.540442688494295e-09
member O 0 4.054824032095894e-09
of O 0 1.8805419721434902e-10
the O 0 1.1426734003450179e-09
major O 0 3.1956668422594703e-09
histocompatibility O 0 4.0560248493193285e-08
complex O 0 5.613643327961881e-09
class O 0 1.8721834749158006e-08
I O 0 1.9048299009227776e-06
- O 0 3.9238557292264886e-07
like O 0 4.226489025427327e-08
family O 0 5.6109591639597056e-08
, O 0 3.6582217255443084e-09
was O 0 9.888135821256583e-08
found O 0 3.2009497274998466e-09
to O 0 1.608826516452666e-09
have O 0 3.7459031432263146e-09
a O 0 3.520272517931744e-09
mutation O 0 2.9020737812857078e-08
, O 0 1.86626425424663e-09
Cys O 0 2.4300945824506925e-06
- O 0 1.4506413208437152e-06
282 O 0 6.928264610905899e-07
- O 0 4.825665200769436e-06
- O 0 1.8370483303442597e-05
> O 0 4.1995855326604214e-07
Tyr O 0 4.033439381601056e-06
( O 0 1.4771935674673387e-08
C282Y O 0 1.1279593081781059e-07
) O 0 1.3315805125202473e-09
, O 0 2.882014349392392e-10
in O 0 6.161322008146897e-10
85 O 0 1.0988694398861298e-08
% O 0 1.437690855254914e-09
of O 0 1.4678710469340217e-09
patient O 0 5.792824708805711e-07
chromosomes O 0 2.460741416143719e-05
. O 0 6.717897349517443e-07

This O 0 2.522905617752258e-07
mutation O 0 8.325611702275637e-07
eliminates O 0 5.864021659363061e-07
the O 0 8.248632887841723e-09
ability O 0 2.041501723226702e-08
of O 0 2.595215820022645e-09
HFE O 0 0.00010257354733766988
to O 0 1.6014153558785438e-08
associate O 0 4.0029487280435205e-08
with O 0 1.0702944308604856e-08
beta2 O 0 6.70031804475002e-05
- O 0 0.0004320461885072291
microglobulin O 0 9.875472460407764e-05
( O 0 3.300475981404816e-08
beta2m O 0 1.1299150628474308e-06
) O 0 6.3723839538454286e-09
and O 0 4.42633929509384e-09
prevents O 0 2.268714993647336e-08
cell O 0 1.7075343521355535e-06
- O 0 6.478443538071588e-05
surface O 0 2.4282146114273928e-05
expression O 0 1.601103008397331e-06
. O 0 2.3317468844652467e-07

A O 0 2.892822749345214e-06
second O 0 4.216283571167878e-07
mutation O 0 3.6850670426247234e-07
that O 0 7.921052258552663e-09
has O 0 1.9167455178603632e-08
no O 0 1.6995836960020938e-09
effect O 0 5.752293752436799e-09
on O 0 1.90501040719937e-07
beta2m O 0 1.2852563486376312e-05
association O 0 5.934528868323241e-09
, O 0 1.6334763541792086e-09
H63D O 0 1.6331177903339267e-06
, O 0 1.4240078449745397e-08
was O 0 3.3950956890294037e-07
found O 0 3.3283975575670866e-09
in O 0 7.669307966473582e-10
eight O 0 1.5430416056005924e-08
out O 0 1.830349916076557e-08
of O 0 1.1198904026343826e-09
nine O 0 7.575484062272153e-08
patients O 0 1.6104760192092726e-08
heterozygous O 0 3.573576279336521e-08
for O 0 6.021695364566426e-10
the O 0 6.937267205131548e-09
C282Y O 0 2.2188473849382717e-06
mutant O 0 1.4931985788280144e-05
. O 0 3.7778994510517805e-07

In O 0 3.1970773761713644e-07
this O 0 1.2312741048958742e-08
report O 0 2.1265257998948073e-08
, O 0 3.064561937549115e-09
we O 0 3.672161685841502e-09
demonstrate O 0 2.726650238926709e-09
in O 0 1.896807377832488e-09
cultured O 0 4.635391519514087e-07
293 O 0 2.3668656012887368e-07
cells O 0 1.1952340628340608e-07
overexpressing O 0 1.9625390450528357e-06
wild O 0 1.382191783250164e-07
- O 0 2.5375043151143473e-06
type O 0 1.1937177646359487e-07
or O 0 1.9783742644108315e-08
mutant O 0 6.583514391422796e-07
HFE O 0 4.647228251997149e-06
proteins O 0 1.3267264620253627e-08
that O 0 1.1690506340755746e-09
both O 0 2.1020417351191867e-10
the O 0 7.183419969969407e-10
wild O 0 5.3911506370241113e-08
- O 0 1.2946315109729767e-05
type O 0 6.980299644965271e-07
and O 0 1.0835495345418167e-07
H63D O 0 1.0912604921031743e-05
HFE O 0 1.7407275663572364e-05
proteins O 0 1.1327120574833316e-07
form O 0 1.1259394305795922e-08
stable O 0 1.3020536471231026e-07
complexes O 0 3.055651021099948e-08
with O 0 2.7818396475254303e-09
the O 0 1.2032702834119391e-08
transferrin O 0 3.1585939268552465e-06
receptor O 0 1.4475443776973407e-06
( O 0 1.009414987152013e-07
TfR O 0 6.733742338838056e-05
) O 0 8.80378721035413e-08
. O 0 2.0667710032284958e-07

The O 0 8.968805786935263e-07
C282Y O 0 1.0191571163886692e-05
mutation O 0 3.0603312097809976e-06
nearly O 0 2.041716555822859e-07
completely O 0 2.160988827881738e-07
prevents O 0 3.077490973169006e-08
the O 0 2.3898765189045434e-09
association O 0 1.9287402786005714e-09
of O 0 2.442945012948172e-10
the O 0 4.834308509060747e-09
mutant O 0 3.600506488510291e-06
HFE O 0 2.646226312208455e-05
protein O 0 2.2489017226234864e-07
with O 0 1.2230958468251174e-08
the O 0 5.874416331153043e-08
TfR O 0 0.0005276825977489352
. O 0 3.833087873772456e-07

Studies O 0 8.54508698466816e-07
on O 0 1.4618638033425668e-07
cell O 0 9.395633355779864e-07
- O 0 8.296887585856894e-07
associated O 0 4.356395422178139e-08
transferrin O 0 2.799243929985096e-07
at O 0 7.879192409632196e-09
37 O 0 2.0319918192512887e-08
degrees O 0 4.953892940307014e-08
C O 0 1.6234730537689757e-07
suggest O 0 1.934496296485122e-08
that O 0 7.713464866831998e-10
the O 0 1.2788281544828806e-09
overexpressed O 0 1.1824255352621549e-06
wild O 0 2.570430979176308e-07
- O 0 4.5036858864477836e-06
type O 0 2.9387345534814813e-07
HFE O 0 9.435661013412755e-06
protein O 0 2.321311995956421e-07
decreases O 0 6.940790342468972e-08
the O 0 1.3889069894190698e-09
affinity O 0 7.530978507475083e-09
of O 0 8.973463638817236e-10
the O 0 5.2795274818606686e-09
TfR O 0 1.3288990885484964e-05
for O 0 1.784736980425805e-08
transferrin O 0 8.924107532948256e-06
. O 0 2.4558050881751115e-07

The O 0 1.1866560498674517e-06
overexpressed O 0 4.676925527746789e-05
H63D O 0 1.4159337297314778e-05
protein O 0 3.743698187008704e-07
does O 0 4.189616831240528e-08
not O 0 2.2582617997812804e-09
have O 0 8.632378700745846e-10
this O 0 1.0348086276756874e-10
effect O 0 6.9209713515760996e-09
, O 0 9.081681517919549e-10
providing O 0 3.1540459133339027e-10
the O 0 2.330599047084547e-10
first O 0 1.7635564120155323e-09
direct O 0 1.1359218010653649e-09
evidence O 0 2.861442860435659e-09
for O 0 1.8348467190065776e-10
a O 0 4.1337493428272865e-09
functional O 0 1.7252199668860158e-08
consequence O 0 1.0388458981935855e-08
of O 0 6.04850391994205e-10
the O 0 8.35236235730008e-09
H63D O 0 7.491320866392925e-05
mutation O 0 2.3366112600342603e-06
. O 0 1.784205068133815e-07

Addition O 0 7.170134495027014e-07
of O 0 1.765186041779998e-08
soluble O 0 2.5309330453637813e-07
wild O 0 2.2949485867229669e-07
- O 0 2.14419615076622e-05
type O 0 2.474995881129871e-06
HFE O 0 0.00043042577453888953
/ O 0 2.1462012227857485e-05
beta2m O 0 1.1281641491223127e-05
heterodimers O 0 6.109351033956045e-06
to O 0 2.3642570567972143e-08
cultured O 0 5.497580559676862e-07
cells O 0 1.1574025648997122e-07
also O 0 2.9586121996771908e-08
decreased O 0 9.360095276633729e-08
the O 0 9.432258307739971e-10
apparent O 0 2.1221660873038672e-08
affinity O 0 9.704816505973213e-09
of O 0 8.626568903657983e-10
the O 0 4.650643425918588e-09
TfR O 0 4.47704951511696e-06
for O 0 2.9748609131630133e-10
its O 0 2.732615245193415e-10
ligand O 0 3.5232416983888015e-09
under O 0 5.5234292695161e-09
steady O 0 6.438580726353393e-07
- O 0 5.825733069286798e-07
state O 0 2.2801969201680095e-09
conditions O 0 4.171834433464028e-08
, O 0 3.0485050594997176e-10
both O 0 1.8315005068103574e-10
in O 0 7.788759082139052e-10
293 O 0 2.412663491213607e-08
cells O 0 2.650651786950675e-08
and O 0 6.184767364914023e-09
in O 0 1.6670675506702537e-08
HeLa O 0 0.00016132353630382568
cells O 0 2.2183778582984814e-06
. O 0 2.2871985549954843e-07

Furthermore O 0 8.016450010472909e-06
, O 0 3.558666961112067e-08
at O 0 4.404073106201167e-09
4 O 0 2.8849266087149772e-08
degrees O 0 1.040179313349654e-06
C O 0 8.957728823588695e-06
, O 0 7.1218013708573835e-09
the O 0 5.547120540683181e-09
added O 0 1.5136748743316275e-07
soluble O 0 2.988033998008177e-08
complex O 0 7.392024770069838e-09
of O 0 3.9863063960865475e-09
HFE O 0 0.00022321961296256632
/ O 0 5.798623078590026e-06
beta2m O 0 2.717079041758552e-06
inhibited O 0 1.2221121892252995e-07
binding O 0 2.0363916775067992e-08
of O 0 1.941918625902872e-09
transferrin O 0 5.145724912836158e-07
to O 0 1.5359562510752767e-08
HeLa O 0 3.432120865909383e-05
cell O 0 5.701150712411618e-06
TfR O 0 1.584242818353232e-05
in O 0 5.055857510427586e-09
a O 0 2.3028340123687485e-08
concentration O 0 1.7301285879511852e-06
- O 0 3.8393877730413806e-06
dependent O 0 2.1115516801728518e-07
manner O 0 8.563516189497022e-07
. O 0 2.362641424724643e-07

Scatchard O 0 0.00017392000881955028
plots O 0 5.468906238093041e-06
of O 0 1.4518529489748744e-08
these O 0 1.6966783533689522e-09
data O 0 1.4352613320056662e-08
indicate O 0 3.260158365492316e-08
that O 0 1.5753334192680768e-09
the O 0 4.696568911555232e-09
added O 0 5.175559181225253e-07
heterodimer O 0 2.546225914556999e-07
substantially O 0 2.7117053491565457e-07
reduced O 0 1.4229190270498293e-08
the O 0 1.2984218145106752e-09
affinity O 0 1.6940921554464694e-08
of O 0 3.9976590926471545e-09
TfR O 0 2.2698875909554772e-05
for O 0 2.6011740317244403e-08
transferrin O 0 1.3268679140310269e-05
. O 0 3.727353430349467e-07

These O 0 3.4733747611426224e-07
results O 0 3.865070397068848e-08
establish O 0 8.834886600084246e-09
a O 0 6.060390411732897e-09
molecular O 0 6.284346909524174e-08
link O 0 4.2344513531134e-06
between O 0 4.492308676162793e-07
HFE O 0 0.01296680886298418
and O 0 1.2233972768171952e-07
a O 0 5.2958561980176455e-09
key O 0 4.71690526637758e-08
protein O 0 2.387932163117057e-08
involved O 0 2.7374267297375354e-09
in O 0 7.819780378781616e-10
iron O 0 6.909788680786733e-06
transport O 0 1.0490406765484295e-08
, O 0 1.1654306408814818e-09
the O 0 1.5772456674056912e-09
TfR O 0 1.4036414540896658e-05
, O 0 9.344002904754234e-09
and O 0 8.774212467699272e-09
raise O 0 4.428171607173681e-09
the O 0 1.7448953393284228e-10
possibility O 0 7.580839289644814e-10
that O 0 1.0831352481588397e-09
alterations O 0 7.749689956426664e-08
in O 0 3.916875157550237e-10
this O 0 3.6034972228371487e-10
regulatory O 0 1.3206014948252687e-08
mechanism O 0 1.96374486449713e-07
may O 0 8.925750307753333e-07
play O 0 6.785593420488567e-09
a O 0 1.3857210934276054e-09
role O 0 7.252438205540557e-09
in O 0 3.1701385960758444e-09
the O 0 1.0549297435602512e-08
pathogenesis O 0 7.571071819256758e-06
of O 0 7.650738552911207e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 6.429428140108939e-06
. O 0 7.990826134118834e-07

Genomic O 0 2.5451541660004295e-05
organization O 0 4.940955022902926e-07
of O 0 1.2130499271734152e-08
the O 0 4.239544537654183e-08
UBE3A O 0 0.00010533892054809257
/ O 0 9.449060598853976e-06
E6 O 0 1.4327129974844866e-05
- O 0 1.2516667993622832e-05
AP O 0 7.826090950402431e-06
gene O 0 5.399588758336904e-07
and O 0 2.363170636954237e-08
related O 0 1.0465110023005764e-07
pseudogenes O 0 1.6287536709569395e-05
. O 0 1.3975621868667076e-06

The O 0 1.5308255569834728e-06
UBE3A O 0 9.498198778601363e-05
gene O 0 2.5342299068142893e-06
encodes O 0 9.656209840613883e-07
the O 0 3.162862682870582e-08
E6 O 0 2.80047470369027e-06
- O 0 4.519804406299954e-06
AP O 0 3.1191373182082316e-06
ubiquitin O 0 4.2638328068278497e-07
- O 0 1.421697533032784e-07
protein O 0 4.6078053372866634e-08
ligase O 0 7.942643520664205e-08
and O 0 2.2646553077265708e-08
has O 0 3.2085676338056146e-08
recently O 0 1.7485861292243499e-07
been O 0 4.25903685652429e-08
shown O 0 7.842398730417699e-09
to O 0 9.782588072937415e-10
be O 0 6.688833043000386e-09
mutated O 0 4.4283649913268164e-05
in O 0 0.0005234724376350641
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.4932271369616501e-05
who O 0 2.852638942840713e-07
lack O 0 2.9263976131232994e-08
15q11 O 0 8.272520517493831e-07
- O 0 2.4070479867077665e-06
q13 O 0 4.2432884583831765e-06
deletions O 0 4.257300588506041e-06
or O 0 2.8112987138229073e-07
chromosome O 0 0.00016585065168328583
15 O 0 6.1631084236069e-07
paternal O 0 3.1474406569032e-05
uniparental B-Disease 0 0.004641994368284941
disomy I-Disease 0 0.0007470605196431279
. O 0 1.8718355931923725e-06

Previous O 0 9.62886588240508e-06
UBE3A O 0 0.00011378563067410141
cDNA O 0 8.995919415610842e-06
analysis O 0 6.577941462637682e-07
has O 0 4.2073622807947686e-07
shown O 0 1.9084136937408402e-08
a O 0 4.654361784872663e-09
coding O 0 7.359820756391855e-06
region O 0 5.346672082851001e-07
of O 0 6.477403502458401e-09
approximately O 0 2.257845110875678e-08
2 O 0 1.8153325243019935e-07
. O 0 3.495835869671282e-07

6 O 0 3.822269354714081e-05
kb O 0 0.00012251688167452812
and O 0 4.3911833813581325e-07
a O 0 7.610429975102306e-08
3 O 0 1.1231724101889995e-06
- O 0 0.0034598803613334894
untranslated O 0 0.017977921292185783
region O 0 7.0082478487165645e-06
( O 0 2.496110163008325e-08
UTR O 0 2.5947601898224093e-06
) O 0 4.434535849640042e-09
of O 0 6.351437153995221e-10
< O 0 1.2473196875362191e-07
50 O 0 3.678528770478806e-08
bp O 0 4.000239641754888e-07
, O 0 2.390022402209979e-09
whereas O 0 2.2478148231641626e-09
Northern O 0 7.473540897251496e-09
analysis O 0 1.4820844995711013e-08
has O 0 3.404536741413722e-08
indicated O 0 1.841337926578035e-08
mRNA O 0 1.3207880122934057e-08
sizes O 0 5.0413966334872384e-08
of O 0 2.3951565175650558e-09
5 O 0 6.523914208855786e-08
- O 0 3.944422587665031e-06
8 O 0 3.9257272987924807e-07
kb O 0 3.091269900323823e-05
. O 0 6.313312610473076e-07

We O 0 3.0815729132882552e-06
have O 0 1.648315084423757e-08
analyzed O 0 2.754497074874962e-08
additional O 0 4.178163148793601e-09
cDNA O 0 2.8275363206375914e-07
clones O 0 3.8396006857510656e-05
and O 0 1.71823515415781e-08
provide O 0 1.1275829159274053e-09
evidence O 0 3.7063224711531007e-10
for O 0 9.931917788197353e-11
an O 0 2.6846630474253175e-10
additional O 0 6.309975653095989e-09
0 O 0 1.0485909029966933e-07
. O 0 1.1816910472361997e-07

5 O 0 1.0543017197051086e-05
kb O 0 4.171213731751777e-05
of O 0 7.999611995046507e-08
5 O 0 7.856187949073501e-07
- O 0 1.974205042643007e-05
UTR O 0 6.246710836421698e-05
and O 0 1.7437270116715808e-07
> O 0 1.667912812308714e-07
2 O 0 4.0177191351631336e-08
kb O 0 5.129945293447236e-06
of O 0 9.8216670352258e-09
3 O 0 8.081288456196489e-07
- O 0 0.00029529110179282725
UTR O 0 0.000409519620006904
. O 0 6.158566634439921e-07

We O 0 1.2814012734452263e-05
have O 0 2.0334768535690273e-08
established O 0 2.8925175588057073e-09
the O 0 5.534436242626839e-10
genomic O 0 4.652757468193158e-08
organization O 0 5.3322128934496504e-09
of O 0 1.130099902546533e-09
UBE3A O 0 1.974478072952479e-05
and O 0 2.039925384167418e-08
the O 0 1.1150222967160062e-09
sequence O 0 3.380575464007052e-08
of O 0 2.340681426460378e-09
intron O 0 0.00021567284420598298
- O 0 0.00014604697935283184
exon O 0 2.1802061382913962e-05
borders O 0 1.8025277313427068e-05
. O 0 1.4962113255023723e-06

We O 0 2.3840244466555305e-05
have O 0 6.634707006014651e-08
also O 0 3.260923264747362e-08
mapped O 0 1.6949444443525863e-06
two O 0 5.738715724845633e-09
highly O 0 5.2608708500656576e-09
homologous O 0 4.379840490287279e-08
processed O 0 8.819686314609498e-08
pseudogenes O 0 3.7891356896579964e-07
, O 0 1.7038592758922277e-08
UBE3AP1 O 0 3.282638772361679e-06
and O 0 2.4553173716412857e-08
UBE3AP2 O 0 1.4154934433463495e-06
, O 0 1.2262065807178146e-09
to O 0 3.8435488125543316e-10
chromosomes O 0 6.019036646875975e-08
2 O 0 4.6815191723226235e-08
and O 0 5.887023846185002e-08
21 O 0 5.31826991334583e-08
, O 0 4.191884617199548e-09
respectively O 0 4.713955092938704e-08
, O 0 6.554919274037729e-09
and O 0 1.8790522915423935e-08
determined O 0 2.9119266997668092e-08
their O 0 6.257695250866391e-09
genomic O 0 4.953137135998986e-07
organization O 0 1.0505507219704668e-07
. O 0 7.716665351154006e-08

These O 0 1.4414331417356152e-07
results O 0 6.607807279124245e-08
will O 0 4.256403229874195e-09
form O 0 4.501713446458666e-10
the O 0 3.67444380477977e-10
basis O 0 3.3621123662896935e-09
for O 0 3.291683592365757e-10
studies O 0 1.2249232739236504e-09
of O 0 7.622175113297658e-10
mutation O 0 1.0372524883450751e-07
and O 0 1.0254298743461732e-08
imprinting O 0 4.5480128392227925e-06
of O 0 1.0104358949547532e-07
UBE3A O 0 0.00046978367026895285
. O 0 1.1376437214494217e-06

Mutation O 0 0.00034985257661901414
spectrum O 0 2.847543692041654e-05
and O 0 3.525969987094868e-07
genotype O 0 0.00020601210417225957
- O 0 0.0024612268898636103
phenotype O 0 0.00028099268092773855
analyses O 0 1.0683587561288732e-06
in O 0 5.139025560652044e-08
Cowden B-Disease 0 0.45848703384399414
disease I-Disease 0 0.00023587299801874906
and O 0 3.5867699921254825e-07
Bannayan B-Disease 0 0.460538387298584
- I-Disease 1 0.9999991655349731
Zonana I-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999994039535522
, O 0 6.5399731852267e-08
two O 0 7.156437504818314e-07
hamartoma B-Disease 1 0.9252204895019531
syndromes I-Disease 1 0.8670770525932312
with O 0 1.2489580285546253e-06
germline O 0 0.0019142584642395377
PTEN O 0 0.00424880301579833
mutation O 0 0.0002548902411945164
. O 0 2.560906295911991e-06

The O 0 2.4473922167089768e-05
tumour B-Disease 1 0.9999992847442627
suppressor O 0 0.0024336064234375954
gene O 0 2.167286947951652e-05
PTEN O 0 0.0005014789057895541
, O 0 7.185975903212238e-08
which O 0 1.4793224423215179e-08
maps O 0 1.3926951396570075e-06
to O 0 8.141954310758592e-08
10q23 O 0 3.0075951144681312e-05
. O 0 6.623282615692005e-07

3 O 0 1.0794381523737684e-05
and O 0 6.965790078083955e-08
encodes O 0 8.322730309373583e-07
a O 0 4.663027652895835e-08
403 O 0 2.2443465752530756e-07
amino O 0 3.1090266361388785e-07
acid O 0 1.2085838818620687e-07
dual O 0 2.2942374755530182e-07
specificity O 0 2.75364391200128e-06
phosphatase O 0 0.001777099329046905
( O 0 7.880532848503208e-08
protein O 0 5.014592261431972e-07
tyrosine O 0 1.6368101114494493e-06
phosphatase O 0 1.994006561290007e-05
; O 0 1.949557137947977e-08
PTPase O 0 9.297814926867431e-07
) O 0 3.8455305606532875e-09
, O 0 4.455740221231963e-09
was O 0 1.38964924190077e-06
shown O 0 9.044247661904592e-08
recently O 0 3.9237809801306867e-07
to O 0 1.6527414103961746e-08
play O 0 3.597896736096118e-08
a O 0 1.1025244717188798e-08
broad O 0 4.133223185931456e-08
role O 0 3.078483246099495e-08
in O 0 3.243690471776972e-08
human O 0 3.1987974580260925e-07
malignancy B-Disease 0 9.463229071116075e-05
. O 0 4.345947672845796e-07

Somatic O 0 0.0006567322416231036
PTEN O 0 0.0009950754465535283
deletions O 0 7.202862616395578e-05
and O 0 3.757454862807208e-07
mutations O 0 2.148949079128215e-06
were O 0 1.449395892194616e-08
observed O 0 3.9378683425184136e-08
in O 0 6.9520500467490365e-09
sporadic B-Disease 0 0.1325531005859375
breast I-Disease 1 0.9930014610290527
, I-Disease 0 4.479843028093455e-06
brain I-Disease 0 0.015069924294948578
, I-Disease 0 5.078500180388801e-07
prostate I-Disease 0 0.4186367392539978
and I-Disease 0 2.623556247272063e-05
kidney I-Disease 0 0.00014408788410946727
cancer I-Disease 0 1.8664912204258144e-05
cell O 0 0.00010987362475134432
lines O 0 0.05786023288965225
and O 0 7.463444973154765e-08
in O 0 3.4742202448256876e-09
several O 0 5.11380804368855e-08
primary O 0 2.5203948098351248e-05
tumours B-Disease 1 1.0
such O 0 2.2551896350364586e-08
as O 0 1.2301740753173362e-05
endometrial B-Disease 1 0.9987179040908813
carcinomas I-Disease 1 1.0
, O 0 0.30436089634895325
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.8700892329216003
thyroid B-Disease 1 0.9999998807907104
tumours I-Disease 1 1.0
. O 0 9.684452379588038e-06

In O 0 6.223999093890598e-07
addition O 0 7.868307960734455e-08
, O 0 1.8411832058973232e-08
PTEN O 0 4.6015269617782906e-05
was O 0 1.3923287269790308e-06
identified O 0 3.8849815808816857e-08
as O 0 1.6432760707729699e-09
the O 0 1.687438411224207e-09
susceptibility O 0 4.2951683099090587e-07
gene O 0 1.9028749420613167e-07
for O 0 1.7549570685559956e-08
two O 0 1.5326326320064254e-05
hamartoma B-Disease 1 0.9999827146530151
syndromes I-Disease 1 0.9999966621398926
Cowden B-Disease 1 0.9996271133422852
disease I-Disease 1 0.5155653357505798
( O 0 1.2693337225755386e-07
CD B-Disease 0 1.5115749192773364e-05
; O 0 5.017204216528626e-07
MIM O 0 0.00022763272863812745
158350 O 0 3.3359228837070987e-06
) O 0 2.362125073318566e-08
and O 0 2.6591134627551583e-08
Bannayan B-Disease 0 6.785619189031422e-05
- I-Disease 0 0.007897702977061272
Zonana I-Disease 0 0.0030184986535459757
( I-Disease 0 1.0527813287808385e-07
BZS I-Disease 0 6.090526312618749e-06
) I-Disease 0 2.6818355536306626e-08
or I-Disease 0 2.945212074223491e-08
Ruvalcaba I-Disease 0 3.0069295462453738e-05
- I-Disease 0 0.00031821304582990706
Riley I-Disease 0 0.0004184319404885173
- I-Disease 1 0.9999932050704956
Smith I-Disease 1 0.9941383600234985
syndrome I-Disease 1 0.9999843835830688
( O 0 1.6983150885607756e-07
MIM O 0 8.837713539833203e-05
153480 O 0 7.752388228254858e-06
) O 0 2.307050550598433e-07
. O 0 2.885043102196505e-07

Constitutive O 0 2.2008660380379297e-05
DNA O 0 4.4227226680959575e-06
from O 0 3.9078795310842906e-08
37 O 0 1.222288261715221e-07
CD B-Disease 0 8.054067279772426e-07
families O 0 1.9853940713687734e-08
and O 0 3.997925990262274e-09
seven O 0 1.2690802186909877e-08
BZS B-Disease 0 8.283634088002145e-06
families O 0 5.6475290222124386e-08
was O 0 1.1188837589770628e-07
screened O 0 7.801060064593912e-07
for O 0 7.259278334004193e-08
germline O 0 7.198131788754836e-05
PTEN O 0 0.0006392376963049173
mutations O 0 5.027549195801839e-05
. O 0 1.2778994005202549e-06

PTEN O 0 0.0035046585835516453
mutations O 0 0.00011712332343449816
were O 0 9.974151993219493e-08
identified O 0 3.3199917481852026e-08
in O 0 9.204485507119387e-10
30 O 0 3.6771239386723664e-09
of O 0 4.720185353690454e-10
37 O 0 8.769916348683182e-08
( O 0 5.3247224407471094e-09
81 O 0 3.153357397422951e-08
% O 0 3.5760840955134654e-09
) O 0 1.3392089659447493e-09
CD B-Disease 0 1.2729828995361459e-06
families O 0 4.488785787515326e-09
, O 0 2.2947202471534922e-10
including O 0 4.979768819524111e-10
missense O 0 2.35636639445147e-06
and O 0 1.3138337351392693e-07
nonsense O 0 4.91012633574428e-06
point O 0 2.0203118822337274e-07
mutations O 0 2.8513196070889535e-07
, O 0 2.883709271372936e-09
deletions O 0 3.0015806373739906e-07
, O 0 4.788104579489527e-09
insertions O 0 2.1412397188669274e-07
, O 0 2.3735680088066147e-09
a O 0 9.223031227634237e-09
deletion O 0 3.75617537429207e-06
/ O 0 3.236965312680695e-06
insertion O 0 1.5308153251680778e-06
and O 0 1.1442512715120756e-07
splice O 0 0.0005877765361219645
site O 0 2.1749439838458784e-05
mutations O 0 4.7085017286008224e-05
. O 0 8.453221198578831e-07

These O 0 2.884803791403101e-07
mutations O 0 1.1968381841143128e-06
were O 0 1.1828113599676726e-08
scattered O 0 1.4874339981929552e-08
over O 0 3.695927830449364e-08
the O 0 1.1447375491968614e-08
entire O 0 1.0375790537864304e-07
length O 0 4.3949626160610933e-07
of O 0 1.4421371874462352e-09
PTEN O 0 1.772103314578999e-05
, O 0 7.336192098250649e-09
with O 0 1.3638784546188276e-09
the O 0 2.5936619518773796e-09
exception O 0 4.6323616054166905e-09
of O 0 7.86861520385429e-10
the O 0 8.44089420581895e-09
first O 0 1.9239085702338343e-07
, O 0 5.193071217490797e-08
fourth O 0 3.002253151862533e-06
and O 0 3.069574745495629e-07
last O 0 2.376741150555972e-07
exons O 0 3.429935532039963e-05
. O 0 5.341005362424767e-07

A O 0 5.157425675861305e-06
hot O 0 8.595585313742049e-06
spot O 0 3.0752462407690473e-06
for O 0 1.8186780081919096e-08
PTEN O 0 2.6785726731759496e-05
mutation O 0 7.586949095639284e-07
in O 0 1.4864357744670542e-08
CD B-Disease 0 4.486394391278736e-05
was O 0 1.6665769635437755e-06
identified O 0 2.1817102791032994e-08
in O 0 1.0482540391265616e-09
exon O 0 1.487067180505619e-07
5 O 0 6.684575737381238e-08
that O 0 1.5912360318282026e-09
contains O 0 1.4969735451231259e-09
the O 0 2.5516302404327007e-09
PTPase O 0 1.192037984765193e-06
core O 0 2.9112308652656793e-07
motif O 0 5.740333222092886e-07
, O 0 1.56466106737696e-09
with O 0 2.5484578336509855e-10
13 O 0 1.5397980668296896e-09
of O 0 1.1768713781279416e-10
30 O 0 5.6786015889542796e-09
( O 0 1.0231259173210105e-09
43 O 0 1.6843651806652815e-08
% O 0 1.6311662021095685e-09
) O 0 1.0461826960295184e-09
CD B-Disease 0 1.5921649492156575e-06
mutations O 0 5.340745588000573e-07
identified O 0 4.3160763851801676e-08
in O 0 1.979690855691274e-09
this O 0 3.93840693391212e-09
exon O 0 4.926853307551937e-06
. O 0 1.0554831533227116e-06

Seven O 0 1.1444470828791964e-06
of O 0 1.0619389811949986e-08
30 O 0 2.3873447219102673e-08
( O 0 3.505137291526239e-09
23 O 0 2.17030518001593e-08
% O 0 2.0216728291444497e-09
) O 0 9.732876726786799e-10
were O 0 4.834419087274e-09
within O 0 3.826206296242418e-10
the O 0 3.3240707963955174e-09
core O 0 7.635713927811594e-07
motif O 0 2.467364993208321e-06
, O 0 7.333786022911681e-09
the O 0 3.026606743006255e-09
majority O 0 6.580838096681418e-09
( O 0 2.780306651573028e-09
five O 0 2.1864789978565113e-09
of O 0 9.689460345185807e-10
seven O 0 8.100256110310511e-08
) O 0 9.607254991550462e-10
of O 0 1.0243966785949965e-10
which O 0 4.6579962997839175e-08
were O 0 2.617897720824658e-08
missense O 0 2.971968342535547e-06
mutations O 0 2.9620093755511334e-07
, O 0 2.016912414859462e-09
possibly O 0 8.783588967276046e-09
pointing O 0 8.820298376122082e-07
to O 0 5.867895946920498e-09
the O 0 1.5147465504128377e-09
functional O 0 7.955315517449435e-09
significance O 0 6.1131557593796515e-09
of O 0 2.2423680690053516e-09
this O 0 9.971009795606278e-09
region O 0 7.96081167209195e-07
. O 0 4.3814034711431304e-07

Germline O 0 0.0108930179849267
PTEN O 0 0.0029828872065991163
mutations O 0 0.0002638189762365073
were O 0 1.3395592759479769e-06
identified O 0 2.0304388215208746e-07
in O 0 3.583539909257638e-09
four O 0 1.204976651791867e-08
of O 0 1.3217500427487039e-09
seven O 0 9.742004181134689e-08
( O 0 1.1684716305637721e-08
57 O 0 1.6260128177236766e-07
% O 0 6.123097584520565e-09
) O 0 8.385293348567302e-09
BZS B-Disease 0 5.086229521111818e-06
families O 0 6.598411772529289e-08
studied O 0 1.8657210887340625e-07
. O 0 2.8377152716529963e-07

Interestingly O 0 0.00014528969768434763
, O 0 2.3539087123936042e-07
none O 0 2.993259329286957e-08
of O 0 4.420928345627573e-10
these O 0 2.976604740467792e-09
mutations O 0 1.0578340834399569e-06
was O 0 2.0434242742339848e-06
observed O 0 1.0198750288736846e-07
in O 0 4.001053710567248e-09
the O 0 2.0165172642805373e-08
PTPase O 0 1.1406222256482579e-05
core O 0 2.8198182917549275e-06
motif O 0 1.2605960364453495e-05
. O 0 4.883093538410321e-07

It O 0 4.803873252967605e-06
is O 0 6.53109779591432e-08
also O 0 2.2256701370793053e-08
worthy O 0 1.5916981510599726e-08
of O 0 2.0940993383788964e-09
note O 0 1.5551920284906373e-07
that O 0 3.5309579704545513e-09
a O 0 8.0551725289979e-09
single O 0 2.1334227540137363e-07
nonsense O 0 2.310226363988477e-06
point O 0 5.896081134437736e-08
mutation O 0 3.33303695754239e-08
, O 0 2.271944188336761e-09
R233X O 0 1.9019405783637922e-07
, O 0 8.583522337346494e-09
was O 0 1.1057744586651097e-07
observed O 0 6.743055891433869e-09
in O 0 3.363977152393005e-10
the O 0 1.2077855382486291e-09
germline O 0 5.967106631032948e-08
DNA O 0 2.6801682651012015e-08
from O 0 1.0242564574269863e-09
two O 0 2.1179475950816595e-09
unrelated O 0 3.896194655794716e-08
CD B-Disease 0 2.630438029882498e-05
families O 0 4.109303475274828e-08
and O 0 1.2990418518654678e-08
one O 0 2.8828253562096506e-08
BZS B-Disease 0 1.7393969756085426e-05
family O 0 7.592392989863583e-07
. O 0 2.55193867815251e-07

Genotype O 0 0.0047072842717170715
- O 0 0.0021684353705495596
phenotype O 0 0.00013399028102867305
studies O 0 1.6194124441426538e-07
were O 0 2.992426288983552e-07
not O 0 1.6308122852137785e-08
performed O 0 2.9429639880618197e-07
on O 0 1.472476753860974e-07
this O 0 1.2732596088582682e-09
small O 0 3.6577685325056564e-09
group O 0 3.527896907939976e-08
of O 0 3.5585769886381513e-09
BZS B-Disease 0 1.4298383575805929e-05
families O 0 1.470695849548065e-07
. O 0 1.7914733518864523e-07

However O 0 3.848758296953747e-06
, O 0 1.0654329685166886e-07
genotype O 0 1.3007376765017398e-05
- O 0 3.4796441468643025e-05
phenotype O 0 9.145934200205375e-06
analysis O 0 4.603228376254265e-08
inthe O 0 2.4217426926043117e-06
group O 0 1.7438998156649177e-07
of O 0 1.2034211405165252e-09
CD B-Disease 0 2.2837708456791006e-05
families O 0 4.671903397479582e-08
revealed O 0 1.9368246739759343e-07
two O 0 1.1520221443461764e-09
possible O 0 4.948280452055087e-09
associations O 0 1.9062627032440105e-09
worthy O 0 3.4614611177374854e-09
of O 0 5.389654278431522e-10
follow O 0 3.4041079288726905e-08
- O 0 3.034712108274107e-06
up O 0 5.266591642794083e-07
in O 0 9.52181089530768e-09
independent O 0 1.1229202101503688e-07
analyses O 0 1.0662049589882372e-06
. O 0 1.595285255007184e-07

The O 0 6.582139917554741e-07
first O 0 3.128454295620031e-07
was O 0 4.25058885866747e-07
an O 0 1.7808561292298464e-09
association O 0 5.6352700283923696e-09
noted O 0 2.6533733432643203e-08
in O 0 1.6452706974590114e-09
the O 0 1.201926114191565e-08
group O 0 5.48378338294242e-08
of O 0 4.5644837909364355e-10
CD B-Disease 0 1.3239150575827807e-05
families O 0 1.390567661019304e-07
with O 0 3.7213365544630506e-07
breast B-Disease 1 0.9810969829559326
disease I-Disease 0 0.0006008832715451717
. O 0 3.759756168619788e-07

A O 0 1.3126756357451086e-06
correlation O 0 2.3439542928826995e-06
was O 0 4.5001169723946077e-07
observed O 0 2.1168782282643406e-08
between O 0 2.1896215951500153e-09
the O 0 1.0162644059619197e-09
presence O 0 5.8287458415406945e-08
/ O 0 4.32075694334344e-06
absence O 0 1.6446502826283904e-08
of O 0 7.094302922894258e-10
a O 0 4.342400572454608e-08
PTEN O 0 0.00017430832667741925
mutation O 0 7.346619668169296e-07
and O 0 3.4700082807148647e-09
the O 0 9.878664553042427e-10
type O 0 4.528215669097335e-08
of O 0 9.640705123103999e-09
breast O 0 9.096341818803921e-05
involvement O 0 2.0727532046294073e-06
( O 0 1.1635070507054479e-07
unaffected O 0 3.7239997254800983e-06
versus O 0 1.8072127204504795e-05
benign O 0 0.011664220131933689
versus O 0 0.00034653194597922266
malignant O 0 0.2742614150047302
) O 0 4.049339281664288e-07
. O 0 4.633106698292977e-07

Specifically O 0 2.9208713385742158e-06
and O 0 3.200945286607748e-08
more O 0 7.193635132018983e-10
directly O 0 2.562232648273266e-09
, O 0 9.662054489822935e-10
an O 0 2.7196176421995233e-09
association O 0 3.4553416128346726e-08
was O 0 5.542043254536111e-06
also O 0 5.652140657730342e-07
observed O 0 2.776047658414882e-08
between O 0 9.583883686659078e-10
the O 0 3.3430294643643776e-10
presence O 0 1.6731255270130418e-09
of O 0 4.3745429501029776e-10
a O 0 4.8725894430390326e-08
PTEN O 0 0.0007131958846002817
mutation O 0 4.261340291122906e-05
and O 0 8.076642188825645e-06
malignant B-Disease 1 0.9998444318771362
breast I-Disease 1 0.9999610185623169
disease I-Disease 0 0.05317545682191849
. O 0 7.770713637000881e-07

Secondly O 0 8.826074190437794e-05
, O 0 9.809127021753739e-08
there O 0 8.957359298733536e-09
appeared O 0 1.7772724731912604e-06
to O 0 5.05714981002825e-09
be O 0 3.082647692664864e-09
an O 0 1.6101896482823008e-09
interdependent O 0 7.415875188598875e-06
association O 0 6.115324691080559e-09
between O 0 6.6467120696245274e-09
mutations O 0 2.0834239933265053e-07
upstream O 0 6.808529917634587e-08
and O 0 1.1930800347670356e-08
within O 0 1.1575703728894382e-09
the O 0 4.614751247800086e-09
PTPase O 0 3.557829813871649e-06
core O 0 8.235900850195321e-07
motif O 0 2.6338102543377317e-06
, O 0 4.311384582678102e-09
the O 0 9.664560263189514e-10
core O 0 9.159694513982686e-08
motif O 0 8.909721316285868e-08
containing O 0 1.7856724987552752e-09
the O 0 9.940546163988984e-10
majority O 0 2.3953117267438984e-09
of O 0 4.84653928101153e-10
missense O 0 4.0295485632668715e-06
mutations O 0 9.501745807938278e-07
, O 0 4.194116165479045e-09
and O 0 5.942899949928915e-09
the O 0 9.355214380946109e-10
involvement O 0 6.4333978144759385e-09
of O 0 5.260657465200325e-10
all O 0 1.2024116147202335e-09
major O 0 1.1586047676814815e-08
organ O 0 1.262806790691684e-06
systems O 0 4.046652293254738e-07
( O 0 1.6178713480030638e-08
central O 0 5.701775762645411e-08
nervous O 0 7.477549957002338e-07
system O 0 1.5760713267809479e-07
, O 0 5.002345204729863e-08
thyroid O 0 3.7564444937743247e-05
, O 0 4.503547046397216e-08
breast O 0 0.0032955424394458532
, O 0 4.857774456468178e-06
skin O 1 0.9999721050262451
and O 0 0.00022898148745298386
gastrointestinal O 1 0.6524004340171814
tract O 0 0.012036575004458427
) O 0 5.122682296132552e-07
. O 0 5.259419140202226e-07

However O 0 7.39717563646991e-07
, O 0 6.001219965412474e-09
these O 0 3.6771921618772296e-10
observations O 0 1.5610787329478626e-08
would O 0 3.496978706607479e-08
need O 0 3.586822394652245e-09
to O 0 1.4615181287425116e-09
be O 0 3.754257349442014e-09
confirmed O 0 7.593534689931403e-09
by O 0 2.6344131737188192e-11
studying O 0 8.814292351555508e-11
a O 0 3.8244843403312245e-10
larger O 0 1.1910944452964145e-09
number O 0 2.236955731760304e-09
of O 0 1.0369292091638727e-09
CD B-Disease 0 2.0700801542261615e-05
families O 0 1.8217319563973433e-07
. O 0 7.234715582171702e-08

Molecular O 0 0.0005480883410200477
defects O 1 0.9944354295730591
leading O 0 8.331186904797505e-07
to O 0 1.5770057260056092e-08
human O 0 8.8237079864939e-08
complement B-Disease 0 4.1957009671023116e-05
component I-Disease 1 0.9945474863052368
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.8896260556289235e-08
an O 0 4.072324699677665e-09
African O 0 2.4996262837362337e-08
- O 0 9.874612260318827e-06
American O 0 3.1355273222288815e-07
family O 0 4.557376769298571e-07
. O 0 2.1358840740504093e-07

Complement B-Disease 0 0.008130118250846863
component I-Disease 1 0.973884642124176
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.852720510622021e-06
C6D B-Disease 0 0.0003363006981089711
) O 0 3.657191598449572e-07
was O 0 1.4190849469741806e-05
diagnosed O 0 3.242681486881338e-05
in O 0 3.245038016075341e-09
a O 0 5.70239606645373e-08
16 O 0 3.025137118584098e-07
- O 0 1.1804822861449793e-05
year O 0 1.4329258135603595e-07
- O 0 4.770991381519707e-06
old O 0 7.889774678915273e-06
African O 0 1.3764573481012121e-08
- O 0 4.279581844457425e-07
American O 0 7.023852788279328e-08
male O 0 7.953541398819652e-07
with O 0 1.1782987030528602e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999998807907104
. O 0 1.4814054338785354e-06

The O 0 8.769052328716498e-07
patients O 0 2.635548980833846e-06
father O 0 1.1417826044635149e-06
and O 0 1.48539754718513e-07
two O 0 3.04144919027749e-07
brothers O 0 0.0012469496577978134
also O 0 1.4352633570524631e-06
had O 0 1.8217752995042247e-06
C6D B-Disease 0 1.2890138350485358e-05
, O 0 2.2097740526305643e-08
but O 0 3.2873059829796603e-09
gave O 0 1.7820665831891347e-08
no O 0 2.20000351269789e-09
history O 0 4.201842873641226e-09
of O 0 8.902803827481875e-09
meningitis B-Disease 1 0.999994158744812
or O 0 2.863453474333255e-08
other O 0 2.6706819866717524e-08
neisserial B-Disease 0 0.0006937049329280853
infection I-Disease 0 0.00014981125423219055
. O 0 2.6375727202321286e-07

By O 0 1.2839447549595207e-07
using O 0 9.621199836828964e-08
exon O 0 2.0527604647213593e-06
- O 0 1.3400832585830358e-06
specific O 0 3.252860025781956e-08
polymerase O 0 6.25544771537534e-07
chain O 0 1.4753105688214418e-06
reaction O 0 2.566856416308383e-08
( O 0 2.341440374920012e-09
PCR O 0 2.0464790395635646e-07
) O 0 2.3121191627950566e-09
/ O 0 7.766099940909044e-08
single O 0 3.2947902184332634e-08
- O 0 2.923421106970636e-06
strand O 0 3.5849411688104738e-06
conformation O 0 1.3802647913507826e-07
polymorphism O 0 4.2439378233893876e-08
as O 0 7.053219119868004e-10
a O 0 9.491362140678916e-10
screening O 0 8.823182184869438e-09
step O 0 2.0176367243607274e-08
and O 0 5.696498273088935e-10
nucleotide O 0 5.597733387929793e-09
sequencing O 0 4.593184055323718e-09
of O 0 6.475867619926134e-10
target O 0 3.3953021727484156e-08
exons O 0 6.229479936337157e-07
, O 0 2.8595183110269318e-08
we O 0 1.1455173698493581e-08
determined O 0 3.6549996362822412e-09
that O 0 5.565536365104151e-10
the O 0 6.963034038243165e-10
proband O 0 3.0187441097950796e-06
was O 0 2.4542785581616045e-07
a O 0 4.616538262780523e-09
compound O 0 9.250711485719876e-08
heterozygote O 0 4.0116168520398787e-07
for O 0 2.0052322025065905e-09
two O 0 9.624521624118643e-08
C6 O 0 0.00023266331118065864
gene O 0 1.1350795830367133e-05
mutations O 0 2.20049678318901e-05
. O 0 4.548427909867314e-07

The O 0 5.928275186306564e-07
first O 0 6.445854694447917e-08
, O 0 2.9344504604011945e-09
1195delC O 0 6.096041715863976e-08
located O 0 7.951325819988142e-09
in O 0 1.2995913234448153e-09
exon O 0 5.580902211477223e-07
7 O 0 1.4380063930730103e-06
, O 0 1.1045345971183451e-08
is O 0 2.076012250995518e-09
a O 0 4.445332990599127e-09
novel O 0 3.431543973420048e-07
mutation O 0 1.8079913388646673e-07
, O 0 7.870585072566882e-09
while O 0 2.9171005611061673e-09
the O 0 1.3194023651408315e-09
second O 0 6.154749598863418e-08
, O 0 3.245198998413912e-09
1936delG O 0 5.517819445799432e-08
in O 0 4.976863365868667e-10
exon O 0 1.3090260608805693e-07
12 O 0 1.0881535672524478e-07
, O 0 4.240973794367164e-09
has O 0 5.253213331002371e-08
been O 0 4.1449389698300365e-08
described O 0 5.6828191929980676e-08
before O 0 3.1472988659686507e-09
to O 0 2.447867242238999e-09
cause O 0 1.5808756970159266e-08
C6D B-Disease 0 1.504590613876644e-06
in O 0 1.0913305814597152e-09
an O 0 8.41008318541725e-10
unrelated O 0 3.9666041118380235e-08
African O 0 3.045741792107037e-08
- O 0 7.742472007521428e-06
American O 0 2.1471636557635065e-07
individual O 0 3.2988648257514797e-08
. O 0 1.5373095152426686e-07

Both O 0 3.238824319851119e-06
mutations O 0 1.0812268556037452e-05
result O 0 2.6660963214908406e-08
in O 0 9.483096086171372e-09
premature O 0 1.1094774663433782e-06
termination O 0 2.208724254160188e-06
codons O 0 1.1591369911911897e-05
and O 0 3.944675768252637e-07
C6 O 0 0.000276503007626161
null O 0 2.909964314312674e-05
alleles O 0 2.495197441021446e-05
. O 0 1.7930474314198364e-06

Allele O 0 4.883751898887567e-05
- O 0 3.904277036781423e-06
specific O 0 6.468726354569299e-08
PCR O 0 2.0290076463425066e-06
indicated O 0 1.547548862390613e-07
that O 0 5.293560589869628e-10
the O 0 5.831364280339812e-10
probands O 0 5.8383420764585026e-06
two O 0 6.824300271546235e-07
brothers O 0 0.0019559459760785103
also O 0 4.111412863494479e-07
inherited O 0 1.5090036242781935e-07
the O 0 1.0676860506819708e-09
1195delC O 0 1.5449198542683007e-07
mutation O 0 1.7975446908735648e-08
from O 0 3.9655181915954074e-10
their O 0 3.2955742579332536e-09
heterozygous O 0 2.568421848536673e-07
mother O 0 6.627914217460784e-07
and O 0 2.1176123077282227e-09
the O 0 8.911531512723059e-10
1936delG O 0 2.0974226799808093e-07
mutation O 0 4.007968357200298e-08
from O 0 8.240655935409791e-10
their O 0 5.358251176090789e-09
homozygous O 0 3.6668204757006606e-06
father O 0 6.961903977753536e-07
. O 0 1.0065134503633999e-08
. O 0 4.875899151102203e-08

PAX6 O 0 0.027865411713719368
mutations O 0 0.0029418026097118855
reviewed O 0 5.1121936849085614e-05
. O 0 5.555059942707885e-06

Mutations O 0 0.000283009692793712
in O 0 7.150701009095428e-08
PAX6 O 0 1.3618456250696909e-05
are O 0 5.6441766815851224e-09
responsible O 0 5.524124269129516e-09
for O 0 1.3090698525175526e-09
human O 0 6.065584301495619e-08
aniridia B-Disease 1 1.0
and O 0 7.87549106462393e-06
have O 0 3.1061250638231286e-07
also O 0 1.665187028265791e-07
been O 0 8.646983573612488e-09
found O 0 4.0328189676586135e-09
in O 0 3.009596127867553e-09
patients O 0 1.7737315616273008e-08
with O 0 5.222363341772507e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 3.9561098219564883e-07
with O 0 1.3773700629826635e-05
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999827146530151
, O 0 3.788759173062317e-08
with O 0 1.0751911361239763e-07
autosomal B-Disease 1 0.9973524808883667
dominant I-Disease 0 0.07568800449371338
keratitis I-Disease 1 0.9867476224899292
, O 0 3.03704069892774e-07
and O 0 1.3835673939865956e-07
with O 0 6.434689225898182e-07
isolated B-Disease 1 0.9723195433616638
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 5.445906936074607e-06

No O 0 1.656197355259792e-06
locus O 0 2.584183221188141e-06
other O 0 1.6097112975899108e-08
than O 0 1.038012076293171e-08
chromosome O 0 3.0799150408711284e-05
11p13 O 0 4.36677191828494e-06
has O 0 1.405277600952104e-07
been O 0 1.858868792226076e-08
implicated O 0 7.986425032413536e-08
in O 0 4.55405313459778e-08
aniridia B-Disease 1 1.0
, O 0 5.799347846391356e-08
and O 0 7.645989796856156e-08
PAX6 O 0 6.321847195067676e-06
is O 0 8.890894775959168e-08
clearly O 0 1.1862640292292781e-07
the O 0 8.356086933503093e-10
major O 0 8.122221117901063e-09
, O 0 1.4460822761463987e-08
if O 0 6.267346641664062e-09
not O 0 1.8968617787606945e-09
only O 0 1.2457517239994331e-09
, O 0 1.091880252879207e-09
gene O 0 7.911994970299929e-08
responsible O 0 3.9028481069181e-07
. O 0 1.3606992865788925e-07

Twenty O 0 2.5005547286127694e-05
- O 0 2.198047332058195e-05
eight O 0 3.464260771579575e-07
percent O 0 3.706580642415247e-08
of O 0 1.0041313336373037e-09
identified O 0 1.3124186182267294e-07
PAX6 O 0 8.289236575365067e-06
mutations O 0 7.097185061866185e-07
are O 0 3.793160896492509e-09
C O 0 3.0225388059079705e-07
- O 0 2.3774811779730953e-05
T O 0 8.171736226358917e-06
changes O 0 8.627544012540511e-09
at O 0 3.010956595161929e-09
CpG O 0 2.532596568016743e-07
dinucleotides O 0 2.1076890277527127e-07
, O 0 1.0452353427226058e-09
20 O 0 1.486406553397046e-09
% O 0 2.4695082090353537e-10
are O 0 8.778522353480867e-11
splicing O 0 1.0250801807387688e-07
errors O 0 4.1792995943978895e-06
, O 0 3.420135508136468e-09
and O 0 3.2468829846976632e-09
more O 0 1.6879622699583763e-10
than O 0 4.712799595019135e-10
30 O 0 2.027983336816419e-09
% O 0 3.1553576418374973e-10
are O 0 1.1753326090158112e-10
deletion O 0 7.970020021730306e-08
or O 0 1.3261445275247752e-08
insertion O 0 3.733080689016788e-07
events O 0 5.13709494498471e-07
. O 0 5.075697231404774e-07

There O 0 6.263489353841578e-07
is O 0 1.7605726654323917e-08
a O 0 2.7519657663788166e-08
noticeably O 0 2.372242852288764e-05
elevated O 0 6.501704774564132e-06
level O 0 9.363788855409894e-09
of O 0 4.458526603468016e-10
mutation O 0 2.98734477155449e-08
in O 0 1.5220620319666978e-09
the O 0 2.720800473809959e-09
paired O 0 1.259090680605368e-07
domain O 0 9.124054400899695e-08
compared O 0 1.2360594325855345e-07
with O 0 1.011370631687214e-08
the O 0 2.6300090993913727e-08
rest O 0 1.8872560403337957e-08
of O 0 3.605394593986233e-10
the O 0 2.1623045576291133e-09
gene O 0 7.242059041345783e-07
. O 0 2.1178158249313128e-07

Increased O 0 6.781728188798297e-06
mutation O 0 2.5416361495445017e-06
in O 0 5.91501292390717e-09
the O 0 4.4415870981140415e-09
homeodomain O 0 1.5502728274441324e-06
is O 0 2.2900003671111335e-08
accounted O 0 2.000648890998491e-08
for O 0 1.8045506755548502e-10
by O 0 5.416510573397204e-10
the O 0 7.61267671123278e-09
hypermutable O 0 8.336899554706179e-06
CpG O 0 6.825342552474467e-06
dinucleotide O 0 2.6467221232451266e-06
in O 0 1.3809198229353115e-08
codon O 0 1.47925959481654e-06
240 O 0 5.396834126258909e-07
. O 0 2.9800921197420394e-07

Very O 0 3.670098465136107e-07
nearly O 0 3.3150815426097324e-08
all O 0 7.954127911879993e-10
mutations O 0 8.420347796800343e-08
appear O 0 1.0205697265064373e-07
to O 0 4.455419500004609e-08
cause O 0 6.360183419928944e-07
loss O 0 1.3226288331225078e-07
of O 0 9.089965447017789e-10
function O 0 2.812430954790557e-09
of O 0 2.55832938167444e-10
the O 0 1.929336468364795e-09
mutant O 0 2.0355237211333588e-06
allele O 0 2.6655530405150785e-07
, O 0 3.0818128049503457e-09
and O 0 1.3765721895708793e-09
more O 0 1.5019320509512823e-10
than O 0 2.922612707401129e-10
80 O 0 9.922966892617069e-10
% O 0 3.908233181526555e-10
of O 0 3.528882464021166e-10
exonic O 0 1.0564236845311825e-06
substitutions O 0 2.4500411655026255e-07
result O 0 2.0415095391967952e-08
in O 0 2.992653946876089e-08
nonsense O 0 1.2737510587612633e-05
codons O 0 1.4469742382061668e-05
. O 0 2.909359864133876e-07

In O 0 1.185708669027008e-07
a O 0 1.3613478344609575e-08
gene O 0 5.4045969477556355e-08
with O 0 1.8003608603933685e-09
such O 0 1.3523822062211366e-09
extraordinarily O 0 2.2466767291007272e-07
high O 0 1.714221831150553e-08
sequence O 0 3.1500690056418534e-08
conservation O 0 3.211670263070232e-09
throughout O 0 9.635259257123607e-10
evolution O 0 3.4381548719153443e-09
, O 0 1.1625177487317728e-09
there O 0 1.2249489200755193e-09
are O 0 7.450992045576754e-10
presumed O 0 1.2788992762580165e-06
undiscovered O 0 3.152978024445474e-06
missense O 0 1.2496617273427546e-05
mutations O 0 6.035189130670915e-07
, O 0 1.69155345286498e-09
these O 0 4.169690426270023e-10
are O 0 3.882288934775602e-10
hypothesized O 0 9.357720642810818e-08
to O 0 1.523343584608483e-08
exist O 0 2.086580863647214e-08
in O 0 2.4273079102243855e-09
as O 0 5.893955901115078e-08
- O 0 1.8712231394601986e-05
yet O 0 1.815983523556497e-07
unidentified O 0 6.802818006690359e-07
phenotypes O 0 1.8038750795312808e-06
. O 0 1.649891068211673e-08
. O 0 1.121058303965583e-07

Genetic O 0 0.00039579285657964647
heterogeneity O 0 0.0001624237047508359
and O 0 9.192236234412121e-07
penetrance O 0 1.8851547793019563e-05
analysis O 0 4.595079161617832e-08
of O 0 3.995699771053296e-09
the O 0 2.3359058687333345e-08
BRCA1 O 0 6.726431456627324e-05
and O 0 1.1342528978275368e-06
BRCA2 O 0 3.8917860365472734e-05
genes O 0 2.8578390356415184e-06
in O 0 3.248771349717572e-07
breast B-Disease 1 0.6698527336120605
cancer I-Disease 0 0.0003482392057776451
families O 0 6.196081585585489e-07
. O 0 2.954553224299161e-07

The O 0 0.0001836155279306695
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Linkage O 0 0.001621910254471004
Consortium O 0 3.388519326108508e-05
. O 0 1.3903650142310653e-06

The O 0 1.9570462939100253e-07
contribution O 0 5.712018946724129e-08
of O 0 1.1141088052113446e-08
BRCA1 O 0 1.820205943658948e-05
and O 0 1.887000621536572e-06
BRCA2 O 0 0.00365442200563848
to O 0 0.00019441045878920704
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.00035539575037546456
assessed O 0 6.506665783945209e-08
by O 0 6.228470517122275e-10
linkage O 0 3.1856382065598154e-06
and O 0 4.735159109259257e-08
mutation O 0 3.2677096584166065e-08
analysis O 0 1.1887817397138178e-09
in O 0 4.609031212243764e-10
237 O 0 1.1333577631944536e-08
families O 0 2.923751463157487e-09
, O 0 3.333701092955721e-10
each O 0 1.9496408654173791e-10
with O 0 1.224526147147742e-09
at O 0 1.2601988785831963e-08
least O 0 6.8237998585019e-10
four O 0 1.6918341172456053e-09
cases O 0 1.5941219455584132e-09
of O 0 9.704723247239144e-09
breast B-Disease 0 0.21570870280265808
cancer I-Disease 0 1.8783781342790462e-05
, O 0 3.4822142946921986e-09
collected O 0 3.3948730493449375e-09
by O 0 2.9460307526818497e-09
the O 0 2.7433036393631482e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Linkage O 0 0.00016662752022966743
Consortium O 0 2.4741675588302314e-06
. O 0 3.921753659597016e-07

Families O 0 1.7031357856467366e-05
were O 0 1.2156330342349975e-07
included O 0 6.992930678961784e-09
without O 0 1.7667514118357985e-09
regard O 0 1.3214852545573308e-09
to O 0 6.54855558668288e-10
the O 0 1.1764299534533507e-09
occurrence O 0 1.36453806476311e-07
of O 0 4.4289254930163224e-08
ovarian B-Disease 0 0.001285904785618186
or I-Disease 0 1.9786013183420437e-07
other I-Disease 0 1.0564281893721272e-07
cancers I-Disease 0 0.0006120320176705718
. O 0 5.350048581931333e-07

Overall O 0 0.001311641652137041
, O 0 6.852768819953781e-06
disease O 0 0.00018061205628328025
was O 0 3.1194926464195305e-07
linked O 0 3.0745550816391187e-07
to O 0 6.540806563037904e-09
BRCA1 O 0 5.787777581645059e-07
in O 0 1.2529219883816722e-09
an O 0 5.702890382153214e-10
estimated O 0 7.979067184749056e-09
52 O 0 2.4397950326715545e-08
% O 0 4.4544465338525185e-10
of O 0 1.6185115747635592e-10
families O 0 3.1249931531363018e-09
, O 0 3.985057839273054e-10
to O 0 1.5630562399948644e-09
BRCA2 O 0 3.099969774211786e-07
in O 0 4.037467693507324e-09
32 O 0 3.063798104108173e-08
% O 0 3.7977992972670904e-10
of O 0 1.0833557662071058e-10
families O 0 6.59999521701593e-09
, O 0 1.5651893114920767e-09
and O 0 5.518342671706478e-09
to O 0 1.1726259963040775e-09
neither O 0 1.7206676083958428e-09
gene O 0 7.411408375901374e-09
in O 0 2.5746318410568847e-09
16 O 0 1.5263131203369085e-08
% O 0 6.635916260933072e-10
( O 0 5.535871760997679e-10
95 O 0 1.457446252572936e-08
% O 0 8.444065890955699e-09
confidence O 0 8.25535764192864e-08
interval O 0 1.382214236400614e-07
[ O 0 5.899253352481537e-08
CI O 0 2.9894247290940257e-06
] O 0 1.2663701909332303e-07
6 O 0 2.5266901459986002e-08
% O 0 2.8670479323977816e-09
- O 0 7.554359058303817e-07
28 O 0 5.169032988305844e-07
% O 0 1.6190775387059375e-09
) O 0 8.278259744365357e-10
, O 0 8.278054908217314e-10
suggesting O 0 1.3621321848233947e-08
other O 0 3.4923846037315798e-09
predisposition O 0 1.172506199509371e-05
genes O 0 2.2123142571217613e-06
. O 0 5.196657753003819e-07

The O 0 4.719110222595191e-07
majority O 0 1.407246372764348e-07
( O 0 3.584245789056695e-08
81 O 0 1.0415327267310204e-07
% O 0 2.625346828821762e-09
) O 0 4.199733338872136e-10
of O 0 9.249680466005827e-10
the O 0 1.0406427009002073e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.905395379253605e-07
were O 0 1.4574241369302854e-08
due O 0 1.324730658502915e-09
to O 0 2.1057546817360162e-09
BRCA1 O 0 1.1759625522245187e-06
, O 0 6.819288245196731e-09
with O 0 1.6650711920362937e-09
most O 0 7.30215754529695e-09
others O 0 1.7929631113133837e-08
( O 0 3.3734626203596463e-09
14 O 0 1.9251176652801405e-08
% O 0 1.334993338097945e-09
) O 0 1.2537442195537096e-09
due O 0 5.684735349120729e-09
to O 0 7.591177109134151e-08
BRCA2 O 0 7.098818605300039e-05
. O 0 6.554484457410581e-07

Conversely O 0 6.861221481813118e-05
, O 0 7.831086890064398e-08
the O 0 2.007685573346407e-09
majority O 0 3.15920756221999e-09
of O 0 3.738321041613091e-10
families O 0 7.173990290709753e-09
with O 0 7.71817809663844e-09
male B-Disease 0 7.706993528699968e-06
and I-Disease 0 3.903469689703343e-07
female I-Disease 0 7.803831067576539e-06
breast I-Disease 0 0.002248741453513503
cancer I-Disease 0 2.3150181732489727e-05
were O 0 1.607199493491862e-07
due O 0 1.1698028323792187e-08
to O 0 2.8040442856536174e-08
BRCA2 O 0 3.175633537466638e-05
( O 0 5.377573941700575e-08
76 O 0 2.4471196979902743e-07
% O 0 1.1809719424604737e-08
) O 0 2.2566180035710204e-08
. O 0 1.1535843214005581e-07

The O 0 2.8232548743289954e-07
largest O 0 6.030055743622142e-08
proportion O 0 2.5435749506641514e-08
( O 0 7.401914636773199e-09
67 O 0 8.329060108280828e-08
% O 0 2.4952997446092695e-09
) O 0 3.4269839743750197e-10
of O 0 2.6102614514300626e-10
families O 0 5.7558935395718436e-09
due O 0 1.1922263176700199e-09
to O 0 7.683216840526086e-10
other O 0 3.922901170572146e-10
genes O 0 1.3241280782949616e-07
was O 0 6.153896720206831e-06
found O 0 8.396368045282543e-09
in O 0 2.5210948884080153e-09
families O 0 2.465113890792736e-09
with O 0 4.884234128255116e-10
four O 0 7.446875560646049e-09
or O 0 2.6413540243908074e-09
five O 0 2.7298141525022857e-09
cases O 0 1.3890235628366554e-09
of O 0 2.078770044988687e-09
female O 0 2.0595884052454494e-05
breast B-Disease 0 0.0053296638652682304
cancer I-Disease 0 2.4023003788897768e-05
only O 0 8.296571962773669e-08
. O 0 1.2962973983121628e-07

These O 0 2.445862321565073e-07
estimates O 0 5.738915547226497e-07
were O 0 3.388896985256906e-08
not O 0 3.01191604989981e-09
substantially O 0 1.388844736993633e-07
affected O 0 3.1380142928583155e-09
either O 0 3.128361181214956e-10
by O 0 2.4031771017618553e-10
changing O 0 1.5427474409079878e-08
the O 0 3.7556180387809945e-09
assumed O 0 8.959498387639542e-08
penetrance O 0 1.8793090816870972e-07
model O 0 2.8346958558245205e-08
for O 0 2.2620942896622864e-09
BRCA1 O 0 1.0554427944953204e-06
or O 0 2.0882051643411614e-08
by O 0 4.002364273336667e-10
including O 0 8.761631975495732e-10
or O 0 2.71219064984507e-08
excluding O 0 2.0056432958881487e-07
BRCA1 O 0 6.016813131282106e-05
mutation O 0 1.5339676338044228e-06
data O 0 6.153271669973037e-07
. O 0 3.041307081730338e-07

Among O 0 1.0095119478137349e-06
those O 0 4.0535038436928517e-08
families O 0 3.083654931401725e-08
with O 0 2.8038840582667035e-08
disease O 0 2.8275894692342263e-06
due O 0 3.038666651633548e-09
to O 0 2.704069412828858e-09
BRCA1 O 0 1.7746538105711807e-06
that O 0 2.8554777031786216e-07
were O 0 5.394204549702408e-07
tested O 0 5.443807538085821e-08
by O 0 1.1886722162124386e-10
one O 0 5.71637237545275e-10
of O 0 4.386630989006157e-11
the O 0 1.8535915857764707e-10
standard O 0 1.7378184447025546e-09
screening O 0 1.4942292958508574e-09
methods O 0 3.285156147114776e-09
, O 0 1.0723966159531528e-09
mutations O 0 1.6685055115317482e-08
were O 0 1.877990873921931e-09
detected O 0 1.3066259185734452e-08
in O 0 3.3469785276629693e-10
the O 0 4.771619210863776e-10
coding O 0 2.3951878347361344e-07
sequence O 0 8.315916488754738e-08
or O 0 2.3641655300110642e-09
splice O 0 5.186310545468586e-07
sites O 0 7.861343576109903e-09
in O 0 6.272342645274875e-10
an O 0 3.834359496579509e-10
estimated O 0 5.103661937511106e-09
63 O 0 1.5735505343172917e-08
% O 0 8.239524618147698e-10
( O 0 4.055680513648241e-10
95 O 0 6.999055557344036e-09
% O 0 2.852065472680465e-09
CI O 0 2.2160770640766714e-06
51 O 0 5.370613394006796e-07
% O 0 5.9907669935910235e-09
- O 0 1.3783168242298416e-06
77 O 0 1.5588864243909484e-07
% O 0 9.520975119414743e-09
) O 0 1.537509852767016e-08
. O 0 1.0017507179327367e-07

The O 0 3.642572323769855e-07
estimated O 0 3.569680586679169e-07
sensitivity O 0 5.148846753399994e-07
was O 0 2.2249577114052954e-07
identical O 0 1.8263255796568956e-08
for O 0 4.620684945777498e-10
direct O 0 3.027201378458244e-09
sequencing O 0 4.81454520695479e-08
and O 0 6.228675353270319e-09
other O 0 8.273839946504324e-10
techniques O 0 3.7407431818792247e-07
. O 0 2.5242820811399724e-07

The O 0 1.0412809388071764e-06
penetrance O 0 3.123739952570759e-05
of O 0 7.379757960279676e-08
BRCA2 O 0 3.026904960279353e-05
was O 0 7.760908147247392e-07
estimated O 0 4.215971571852606e-09
by O 0 4.46046588553628e-10
maximizing O 0 3.330240616605806e-08
the O 0 5.910772316042312e-09
LOD O 0 7.293900853255764e-05
score O 0 1.372641946773001e-07
in O 0 4.8187969170498945e-09
BRCA2 O 0 1.2720127415377647e-05
- O 0 5.224010965321213e-05
mutation O 0 4.2238139030814636e-07
families O 0 1.0104951542189156e-08
, O 0 7.957193237650984e-10
over O 0 1.7970090970820252e-09
all O 0 1.6077896791699686e-09
possible O 0 1.347938027862483e-08
penetrance O 0 4.4277489905653056e-06
functions O 0 2.2480311656636331e-07
. O 0 6.639023126808752e-07

The O 0 2.890931511956296e-07
estimated O 0 1.612925188965164e-07
cumulative O 0 2.1991702681134484e-07
risk O 0 8.91376643608055e-08
of O 0 7.909759069946176e-09
breast B-Disease 0 0.0015502555761486292
cancer I-Disease 0 2.4284392566187307e-05
reached O 0 5.402885108196642e-07
28 O 0 8.768009962523138e-08
% O 0 1.1612590888887553e-09
( O 0 5.417006287977699e-10
95 O 0 5.904338351570004e-09
% O 0 1.288206874505704e-09
CI O 0 4.5814621785211784e-07
9 O 0 4.715789714282437e-08
% O 0 9.130521894107346e-10
- O 0 9.444759996313223e-08
44 O 0 3.35981873433866e-08
% O 0 3.8062547558226356e-10
) O 0 1.0231371305735593e-10
by O 0 8.581107352467754e-11
age O 0 3.6583545082180535e-09
50 O 0 1.799389304224519e-09
years O 0 1.0913764336706322e-09
and O 0 2.6785778040050445e-09
84 O 0 7.2231580716675126e-09
% O 0 4.700546063496347e-10
( O 0 3.7607628122771075e-10
95 O 0 3.835107342808897e-09
% O 0 2.0059400807070915e-09
CI O 0 8.067750627560599e-07
43 O 0 1.0004769990246132e-07
% O 0 1.3862604397729683e-09
- O 0 4.0996347649979725e-08
95 O 0 2.895035855488004e-08
% O 0 1.7996124590524687e-09
) O 0 5.276675762999616e-10
by O 0 4.2676029377020086e-10
age O 0 2.0501332187450316e-08
70 O 0 1.9020543362557873e-08
years O 0 2.2309318836732928e-08
. O 0 8.190426115106675e-08

The O 0 1.1762948815885466e-05
corresponding O 0 0.00230675982311368
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 7.136230851756409e-05
were O 0 7.918909972204347e-08
0 O 0 2.0151662738499e-07
. O 0 2.0443430059913226e-07

4 O 0 4.621016614692053e-06
% O 0 1.410812586755128e-07
( O 0 1.0615400114488693e-08
95 O 0 2.3173742036419753e-08
% O 0 4.6205026471568544e-09
CI O 0 9.200323347613448e-07
0 O 0 1.5450590140630993e-08
% O 0 2.319013425733374e-09
- O 0 1.0387968529812497e-07
1 O 0 1.0847257314594572e-08
% O 0 7.651657085716579e-10
) O 0 1.934767485112232e-10
by O 0 1.1499908664225345e-10
age O 0 4.322904256781612e-09
50 O 0 7.629913367779295e-10
years O 0 6.05686223398294e-10
and O 0 1.1569876168238125e-09
27 O 0 1.4939166348426625e-08
% O 0 4.552502541610437e-10
( O 0 3.6124159219497187e-10
95 O 0 2.92003976554156e-09
% O 0 1.6483552300883275e-09
CI O 0 2.1799159810598212e-07
0 O 0 1.0289956442477433e-08
% O 0 1.007411820630466e-09
- O 0 1.544928664998224e-07
47 O 0 2.2889048523211386e-07
% O 0 1.5446575130084739e-09
) O 0 3.249006064187654e-10
by O 0 5.014300086259027e-10
age O 0 2.9713705274048152e-08
70 O 0 1.2956715700340737e-08
years O 0 2.9594250605669004e-08
. O 0 9.524011801431698e-08

The O 0 6.397224296961213e-07
lifetime O 0 2.1338653368729865e-06
risk O 0 1.0822261629073182e-06
of O 0 5.4787758330121505e-08
breast B-Disease 1 0.9590386152267456
cancer I-Disease 0 0.0007573203183710575
appears O 0 7.274717859218072e-07
similar O 0 2.5423902982879554e-09
to O 0 4.248981610999181e-09
the O 0 4.4627403994468295e-09
risk O 0 1.4674267134751062e-08
in O 0 1.0393627070115485e-09
BRCA1 O 0 3.5534313269636186e-07
carriers O 0 2.1589428911283903e-08
, O 0 4.1409937701075705e-09
but O 0 4.6345447479723134e-09
there O 0 5.675677705596627e-09
was O 0 1.1480550909936937e-07
some O 0 1.7543763664029655e-10
suggestion O 0 3.5547167431815296e-09
of O 0 3.448293317553919e-10
a O 0 1.3105144525127344e-08
lower O 0 1.0627276481045556e-07
risk O 0 2.1331475252850396e-08
in O 0 1.6949380787778523e-09
BRCA2 O 0 7.521234124396869e-07
carriers O 0 3.2841239061554006e-08
< O 0 4.574311063265668e-08
50 O 0 7.764156428891056e-09
years O 0 2.0918238252676247e-09
of O 0 3.343362697805219e-09
age O 0 1.2698386342435697e-07
. O 0 1.0530685301546328e-07

Eye B-Disease 1 0.9998487234115601
movement I-Disease 0 0.0009078052244149148
abnormalities I-Disease 0 0.2279619425535202
correlate O 0 6.171469976834487e-06
with O 0 1.8225297537810548e-07
genotype O 0 0.0007862257189117372
in O 0 1.8343642977924901e-06
autosomal O 1 0.9999774694442749
dominant O 1 0.9543703198432922
cerebellar B-Disease 1 0.9995449185371399
ataxia I-Disease 1 0.9999991655349731
type I-Disease 0 0.11605553328990936
I I-Disease 0 0.02564852684736252
. O 0 1.3520949551093508e-06

We O 0 1.6818547010188922e-05
compared O 0 1.756680376274744e-06
horizontal O 0 0.0008784980163909495
eye O 1 0.846882700920105
movements O 0 3.2430987630505115e-05
( O 0 9.704245940156397e-08
visually O 0 3.0469331591120863e-07
guided O 0 2.6073141157212376e-07
saccades O 0 6.571589619852602e-05
, O 0 5.115212786677148e-08
antisaccades O 0 1.5579962564515881e-06
, O 0 1.4790034974510036e-08
and O 0 1.595698506662302e-08
smooth O 0 9.090542789635947e-07
pursuit O 0 5.437071877167909e-07
) O 0 4.569642886309566e-09
in O 0 1.466667565175328e-09
control O 0 1.551057948745438e-07
subjects O 0 8.859865374688525e-08
( O 0 7.0796133400108374e-09
n O 0 5.582616040555877e-07
= O 0 2.335782710360945e-06
14 O 0 1.6450997009087587e-07
) O 0 6.183658474157028e-09
and O 0 1.8237914289898072e-08
patients O 0 4.653029961332322e-09
with O 0 4.628049887767105e-10
three O 0 4.86430407065086e-09
forms O 0 1.5147703535944856e-08
of O 0 2.9345132546154673e-08
autosomal O 0 0.014374516904354095
dominant O 0 0.00014813973393756896
cerebellar B-Disease 0 0.00036501538124866784
ataxias I-Disease 0 0.00014510154142044485
type I-Disease 0 7.5843045124202035e-06
I I-Disease 0 1.943717143149115e-05
spinocerebellar B-Disease 0 0.0004521234077401459
ataxias I-Disease 0 1.775576311047189e-05
1 I-Disease 0 9.6406907346136e-08
and I-Disease 0 2.194782489084446e-08
2 I-Disease 0 2.2889960149541366e-08
( O 0 5.076303821738293e-09
SCA1 B-Disease 0 6.975747623982897e-07
, O 0 4.10974809739173e-09
n O 0 2.1127925720065832e-07
= O 0 3.556235128598928e-07
11 O 0 1.655097925379323e-08
; O 0 5.640087064051613e-09
SCA2 B-Disease 0 8.214752824642346e-07
, O 0 2.1624613211201904e-09
n O 0 1.1267110977541961e-07
= O 0 2.2059636251015036e-07
10 O 0 7.172717531034323e-09
) O 0 2.3955448735790696e-09
and O 0 6.367830707176836e-08
SCA3 B-Disease 1 1.0
/ O 0 3.409318742342293e-05
Machado B-Disease 0 1.4194179129844997e-05
- I-Disease 0 0.0001232667564181611
Joseph I-Disease 0 0.0002028041344601661
disease I-Disease 0 5.966259050182998e-05
( O 0 4.069104875270568e-08
MJD B-Disease 1 0.9999986886978149
) O 0 5.149131254711392e-08
( O 0 1.9180072641233892e-08
n O 0 1.1342582411089097e-06
= O 0 3.856866896967404e-06
16 O 0 2.095459308293357e-07
) O 0 4.596262215272873e-08
. O 0 1.777593183760473e-07

In O 0 1.2570860690175323e-06
SCA1 B-Disease 0 3.3202792110387236e-05
, O 0 4.396773434223178e-08
saccade O 0 4.49199296781444e-06
amplitude O 0 5.121510184835643e-07
was O 0 1.239832698729515e-07
significantly O 0 1.3800620024539967e-07
increased O 0 2.8248512862205644e-08
, O 0 1.4358465527664066e-09
resulting O 0 1.4788851032676575e-08
in O 0 1.569767427156421e-08
hypermetria B-Disease 0 8.237091242335737e-05
. O 0 5.218947762841708e-07

The O 0 1.469092467232258e-06
smooth O 0 4.724883183371276e-06
pursuit O 0 5.272906491882168e-06
gain O 0 9.57093379838625e-06
was O 0 6.7679529820452444e-06
decreased O 0 6.231581210158765e-06
. O 0 2.8808966590077034e-07

In O 0 2.0458576273085782e-06
SCA2 B-Disease 0 5.219419836066663e-05
, O 0 1.2985717035007838e-07
saccade O 0 1.6456235243822448e-05
velocity O 0 4.1724342736415565e-06
was O 0 9.087821126740891e-07
markedly O 0 2.2555681425728835e-05
decreased O 0 9.6270296126022e-06
. O 0 2.21758355678503e-07

The O 0 7.023275543360796e-07
percentage O 0 7.62171623591712e-07
of O 0 4.605421377590346e-09
errors O 0 1.829956062238125e-07
in O 0 7.122317402519229e-09
antisaccades O 0 2.667840089998208e-05
was O 0 1.6260188431260758e-06
greatly O 0 1.4200775666495247e-08
increased O 0 1.044297270880179e-08
and O 0 1.4250620239408818e-08
was O 0 8.740008894392304e-08
significantly O 0 2.7651141820683733e-08
correlated O 0 1.8926343159364478e-08
with O 0 5.1507589304833346e-09
age O 0 8.032591836126812e-08
at O 0 4.940559605870476e-08
disease O 0 4.385251031635562e-06
onset O 0 6.923852652107598e-06
. O 0 2.707862449824461e-07

In O 0 1.588329610058281e-07
addition O 0 1.1313145975577754e-08
, O 0 1.0190263077802797e-09
a O 0 9.433391845448114e-10
correlation O 0 1.1847852476876142e-07
between O 0 1.061631564880372e-07
smooth O 0 1.1380298928997945e-05
pursuit O 0 1.882596370705869e-05
gain O 0 2.3585836970596574e-05
and O 0 7.863326345614041e-08
the O 0 1.668650995156895e-09
number O 0 3.706939422087885e-09
of O 0 3.9395717799095564e-09
trinucleotide O 0 0.00011184745380887762
repeats O 0 0.0001345396594842896
was O 0 3.345602181070717e-06
found O 0 1.2549236316772294e-07
. O 0 1.7815543174037884e-07

In O 0 4.576231731334701e-06
SCA3 B-Disease 1 0.9999973773956299
, O 0 3.6245396017875464e-07
gaze B-Disease 0 7.787965296301991e-05
- I-Disease 0 0.00016105103713925928
evoked I-Disease 0 5.03728624607902e-05
nystagmus I-Disease 0 0.002229244215413928
was O 0 4.569410975818755e-06
often O 0 3.225625988534375e-08
present O 0 1.7012019570827874e-09
as O 0 2.4281878729937034e-09
was O 0 1.0446702702893162e-07
saccade O 0 2.8693525564449374e-06
hypometria O 0 5.535546279133996e-06
and O 0 1.2364921531116124e-07
smooth O 0 1.05145147699659e-06
pursuit O 0 1.6199854826481896e-06
gain O 0 3.772653599298792e-06
was O 0 2.9531347536249086e-06
markedly O 0 6.929844676051289e-05
decreased O 0 9.43479699344607e-06
. O 0 2.3780380331572815e-07

Three O 0 7.661221275157004e-07
major O 0 1.4718210650244146e-07
criteria O 0 7.373159149892672e-08
, O 0 8.651883653953973e-09
saccade O 0 1.9753406377276406e-06
amplitude O 0 1.3823117228639603e-07
, O 0 4.303357670210062e-09
saccade O 0 7.047698318274342e-07
velocity O 0 2.940349475011317e-07
, O 0 3.972485007608384e-09
and O 0 1.6833238136726436e-09
presence O 0 4.4729322468128885e-09
of O 0 1.8804855450582636e-09
gaze B-Disease 0 6.876090628793463e-05
- I-Disease 0 1.1482349691505078e-05
evoked I-Disease 0 3.778317477554083e-06
nystagmus I-Disease 0 9.760258762980811e-06
, O 0 2.116021358133935e-09
permitted O 0 7.246903632740498e-10
the O 0 5.917582535097665e-10
correct O 0 6.927987783456047e-08
assignment O 0 9.747558316064442e-09
of O 0 4.0342248985858475e-10
90 O 0 2.194864956450715e-09
% O 0 1.5629153526930395e-10
of O 0 5.833875743599393e-11
the O 0 1.8299859405601637e-09
SCA1 B-Disease 0 1.559893235025811e-06
, O 0 1.3929235542775587e-09
90 O 0 1.1876779559827355e-09
% O 0 1.6063114727238315e-10
of O 0 4.591138927367844e-11
the O 0 1.8693995240681716e-09
SCA2 B-Disease 0 5.10944846610073e-06
, O 0 2.8974596055775237e-09
and O 0 2.51417997532144e-09
93 O 0 4.570270384363084e-09
% O 0 2.572259627520168e-10
of O 0 3.957786529062979e-11
the O 0 4.597110692117212e-09
patients O 0 7.556316461432289e-09
with O 0 1.3390181408112767e-08
SCA3 B-Disease 1 1.0
to O 0 2.1706528130494007e-08
their O 0 3.575129081667683e-09
genetically O 0 1.440637475980111e-07
confirmed O 0 7.69513917475706e-07
patient O 0 2.7687934789355495e-07
group O 0 1.673610512398227e-07
and O 0 1.5721704826887617e-08
, O 0 2.4513246987822868e-09
therefore O 0 2.436538526495724e-09
, O 0 2.1528354654520854e-09
may O 0 1.1698229940293459e-08
help O 0 5.681938919366303e-09
orient O 0 9.51153765527124e-07
diagnoses O 0 4.470070507522905e-06
of O 0 1.4708642082084111e-09
SCA1 B-Disease 0 7.694956366322003e-06
, O 0 4.81176121169824e-09
SCA2 B-Disease 0 1.7011044519676943e-06
, O 0 8.288518316135196e-09
and O 0 5.9463040713580995e-08
SCA3 B-Disease 1 1.0
at O 0 3.478644572396661e-08
early O 0 3.044887719738654e-08
clinical O 0 4.425438149269212e-08
stages O 0 7.747118502265948e-08
of O 0 1.1153180601297663e-09
the O 0 4.2848824932661955e-08
diseases O 0 8.252519364759792e-06
. O 0 1.4964376404691393e-08
. O 0 9.245103171906521e-08

Genetic O 0 3.437506529735401e-05
basis O 0 5.971991754449846e-07
and O 0 2.952670286049397e-08
molecular O 0 4.205990364880563e-07
mechanism O 0 4.366671873867745e-06
for O 0 2.8064364414603915e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999998807907104
fibrillation I-Disease 1 1.0
. O 0 4.352321775513701e-05

Ventricular B-Disease 1 0.8889973163604736
fibrillation I-Disease 1 0.8900773525238037
causes O 0 6.885495622555027e-06
more O 0 7.817323677272725e-09
than O 0 2.010463795443229e-09
300 O 0 1.2571037544262254e-09
, O 0 2.6614802028923634e-10
000 O 0 5.1079664942221825e-09
sudden O 0 2.3103305935023855e-08
deaths O 0 2.2123934684259439e-07
each O 0 7.3891630592015645e-09
year O 0 1.1569132318811626e-08
in O 0 3.368852308227588e-09
the O 0 5.4921365233440156e-08
USA O 0 1.836820774769876e-05
alone O 0 1.5549695717709255e-06
. O 0 1.2002061566818156e-07

In O 0 2.4260231157313683e-07
approximately O 0 1.1183972503658879e-07
5 O 0 4.749169590922975e-08
- O 0 1.540514745101973e-06
12 O 0 8.212890634240466e-08
% O 0 9.059467065419824e-10
of O 0 6.945296421312364e-11
these O 0 2.480157468287558e-10
cases O 0 1.386746939502359e-09
, O 0 1.4511877255429795e-09
there O 0 1.1997358662085844e-09
are O 0 8.779832971761437e-10
no O 0 1.9118566285669658e-08
demonstrable O 0 0.00010159563680645078
cardiac O 0 4.137720316066407e-05
or O 0 1.7107898031554214e-07
non O 0 1.1466227789469485e-07
- O 0 0.0017981902929022908
cardiac O 0 0.00011655044363578781
causes O 0 1.621622516267962e-07
to O 0 2.539521037903114e-09
account O 0 7.81979903052843e-09
for O 0 4.690210997360111e-10
the O 0 4.243126294767308e-09
episode O 0 2.3175054593593813e-05
, O 0 5.381668088944025e-08
which O 0 3.959121031016366e-08
is O 0 4.2126999666436404e-09
therefore O 0 4.681106169357463e-09
classified O 0 2.676434860404697e-07
as O 0 1.8778053345158696e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999998807907104
fibrillation I-Disease 1 1.0
( O 0 5.273091665003449e-05
IVF B-Disease 1 1.0
) O 0 1.4448947922574007e-06
. O 0 6.917700829944806e-07

A O 0 2.51362598646665e-06
distinct O 0 6.366961997628096e-07
group O 0 2.389035387295735e-07
of O 0 1.5387829677138143e-08
IVF B-Disease 1 1.0
patients O 0 1.0966020454361569e-05
has O 0 4.157973307883367e-07
been O 0 1.6151886939042015e-08
found O 0 1.5393869512436709e-09
to O 0 6.008833985937656e-10
present O 0 2.0047850046722715e-09
with O 0 1.8180978944570825e-09
a O 0 5.194299390609558e-08
characteristic O 0 2.094277533615241e-06
electrocardiographic O 0 6.453372043324634e-05
pattern O 0 0.00013876376033294946
. O 0 5.874304065400793e-07

Because O 0 4.4157715706205636e-07
of O 0 1.6633888710870792e-09
the O 0 4.890349236674751e-10
small O 0 7.263619705710767e-10
size O 0 1.2892177991830067e-08
of O 0 6.639410132791568e-10
most O 0 2.2284003531325425e-09
pedigrees O 0 1.17762908757868e-06
and O 0 9.013280788394695e-09
the O 0 8.01466282229768e-10
high O 0 3.120158709180032e-08
incidence O 0 2.245203859274625e-06
of O 0 2.857286851565277e-09
sudden B-Disease 0 1.282830112359079e-06
death I-Disease 0 1.3783510439679958e-06
, O 0 1.6374160916043934e-09
however O 0 7.101695342903724e-10
, O 0 7.785205813348739e-11
molecular O 0 1.3337462245743836e-09
genetic O 0 9.558148050814452e-09
studies O 0 5.679064440933246e-10
of O 0 1.0005296591231172e-09
IVF B-Disease 1 1.0
have O 0 4.213275587972021e-06
not O 0 2.827805190008803e-08
yet O 0 2.0337289186045382e-08
been O 0 5.869051733498054e-08
done O 0 1.1775646413525465e-07
. O 0 9.775471454531726e-08

Because O 0 5.0561331590870395e-05
IVF B-Disease 1 0.9999994039535522
causes O 0 0.00022505233937408775
cardiac O 0 0.2542542815208435
rhythm O 1 0.5418563485145569
disturbance O 0 2.2639811504632235e-05
, O 0 2.0475656725693625e-08
we O 0 3.907154599858131e-09
investigated O 0 9.805327216838577e-09
whether O 0 3.0564188957526994e-09
malfunction O 0 8.967463145381771e-07
of O 0 5.644497091950029e-10
ion O 0 7.156090475746169e-08
channels O 0 3.0549570055882214e-06
could O 0 6.842652965133311e-06
cause O 0 1.4096022482590342e-07
the O 0 1.6350542253462663e-08
disorder O 0 1.4280857612902764e-05
by O 0 2.1911161773857657e-10
studying O 0 1.546688777054328e-09
mutations O 0 9.737694028899568e-08
in O 0 2.1612038825225e-09
the O 0 1.1888956485961444e-08
cardiac O 0 9.399413102073595e-06
sodium O 0 1.9654908101074398e-06
channel O 0 4.576825176627608e-06
gene O 0 3.860344804706983e-06
SCN5A O 0 8.13987644505687e-05
. O 0 1.1106632200608146e-06

We O 0 1.4568131518899463e-05
have O 0 6.048590250884445e-08
now O 0 1.0188324850446406e-08
identified O 0 1.5179287160549393e-08
a O 0 1.0511236325783102e-08
missense O 0 1.1303136489004828e-05
mutation O 0 3.3500896279292647e-07
, O 0 2.2149588829734057e-09
a O 0 5.976330097468008e-09
splice O 0 0.0001853080466389656
- O 0 4.791758328792639e-05
donor O 0 2.7012595182895893e-07
mutation O 0 2.4149730393219215e-07
, O 0 1.9206420898143506e-09
and O 0 2.5463018360483147e-09
a O 0 1.275462402361427e-08
frameshift O 0 3.233118695789017e-05
mutation O 0 1.4383174118393072e-07
in O 0 1.889509659847022e-09
the O 0 2.711894264706416e-09
coding O 0 5.404078365245368e-06
region O 0 1.771375792714025e-07
of O 0 4.023936739372402e-09
SCN5A O 0 1.3250266420072876e-05
in O 0 1.6140093705985237e-08
three O 0 6.888168968544051e-07
IVF B-Disease 1 1.0
families O 0 7.702723223701469e-07
. O 0 1.745560354038389e-07

We O 0 1.1797192200901918e-05
show O 0 7.027255151115241e-07
that O 0 2.0346706541829462e-09
sodium O 0 2.187560710353864e-08
channels O 0 2.5200481701403987e-08
with O 0 7.294664317036847e-10
the O 0 4.140756626469511e-09
missense O 0 3.96445966543979e-06
mutation O 0 4.3577341557465843e-07
recover O 0 9.748899998385241e-08
from O 0 1.3884117189277845e-09
inactivation O 0 2.3637639401385968e-07
more O 0 3.820838923029868e-10
rapidly O 0 5.580591100340371e-09
than O 0 5.360221710937196e-10
normal O 0 2.214549210677319e-09
and O 0 2.0572887837744247e-09
that O 0 5.412668646620489e-10
the O 0 6.4062142257625965e-09
frameshift O 0 2.2911923224455677e-05
mutation O 0 2.107479843971305e-07
causes O 0 1.8333686568894336e-08
the O 0 1.4608910747782033e-09
sodium O 0 3.522564639979464e-08
channel O 0 1.4209982737156679e-06
to O 0 1.4693030792045647e-08
be O 0 3.604750054009287e-09
non O 0 9.37413524582098e-09
- O 0 1.208093522109266e-06
functional O 0 7.277347435774573e-07
. O 0 2.2874995408983523e-07

Our O 0 8.232113941630814e-06
results O 0 4.970020199834835e-07
indicate O 0 6.380024331065215e-08
that O 0 2.8639106641747958e-09
mutations O 0 8.226435710412261e-08
in O 0 1.6437305960792514e-09
cardiac O 0 8.686525916346e-07
ion O 0 5.681924335476651e-07
- O 0 1.932798659254331e-05
channel O 0 1.2840349882026203e-05
genes O 0 6.856527079435182e-08
contribute O 0 3.2631366497781755e-09
to O 0 4.25607660226035e-10
the O 0 1.7267762775219353e-09
risk O 0 8.560861353146265e-09
of O 0 4.854893709271835e-10
developing O 0 6.189490164842937e-08
IVF B-Disease 1 0.9999997615814209
. O 0 9.777112097708596e-08
. O 0 1.27367727031924e-07

Molecular O 0 2.3345010049524717e-05
heterogeneity O 0 4.102179445908405e-05
in O 0 2.0239913567365875e-07
mucopolysaccharidosis B-Disease 0 2.507494173187297e-05
IVA I-Disease 0 0.005596627481281757
in O 0 4.647622233733273e-07
Australia O 0 1.390729380545963e-07
and O 0 1.7296779120101746e-08
Northern O 0 1.1263415444773273e-07
Ireland O 0 1.9041566190480808e-07
: O 0 6.156332332807324e-09
nine O 0 2.0003513512278914e-08
novel O 0 9.311003168477328e-08
mutations O 0 6.833757026925014e-08
including O 0 1.049316300516523e-09
T312S O 0 4.467179621769901e-07
, O 0 1.6975878480707252e-09
a O 0 1.762856860487716e-09
common O 0 1.047419129207583e-08
allele O 0 1.4317730290258623e-07
that O 0 5.2456208265994064e-09
confers O 0 4.145935861288308e-07
a O 0 3.965008659179148e-07
mild O 0 0.00019337059347890317
phenotype O 0 0.00031877783476375043
. O 0 8.586126796217286e-07

Mucopolysaccharidosis B-Disease 0 0.012643162161111832
IVA I-Disease 1 0.9997307658195496
( O 0 0.020283548161387444
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
) O 0 1.5669307913412922e-06
is O 0 4.60376377020566e-08
an O 0 6.923668394165361e-08
autosomal B-Disease 1 0.9999839067459106
recessive I-Disease 1 0.9999985694885254
lysosomal I-Disease 1 0.9999947547912598
storage I-Disease 1 0.9999735355377197
disorder I-Disease 1 0.9999983310699463
caused O 0 2.229295660072239e-06
by O 0 4.558578847735362e-09
a O 0 1.7976461776925134e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.1142240197159481e-07
N O 0 3.058623042306863e-05
- O 0 5.014993803342804e-05
acetylgalactosamine O 0 4.6491375542245805e-05
- O 0 3.1291543564293534e-05
6 O 0 1.3056327361482545e-06
- O 0 5.0825958169298247e-05
sulfate O 0 2.9809509214828722e-05
sulfatase O 0 0.0001058950656442903
( O 0 1.9974524434474006e-07
GALNS O 0 1.4006410310685169e-05
) O 0 1.3705621881854313e-07
. O 0 2.2895990525739762e-07

Previous O 0 1.318681938755617e-06
studies O 0 2.226642514813193e-08
of O 0 1.6190713214569996e-09
patients O 0 1.0669720218459133e-08
from O 0 3.903584400166693e-10
a O 0 3.5225629080315457e-09
British O 0 2.8032698651259125e-07
- O 0 4.714001261163503e-05
Irish O 0 1.042529902406386e-06
population O 0 2.7671072100332594e-09
showed O 0 3.64144661091359e-08
that O 0 1.9499123149469e-10
the O 0 1.0208432987823812e-09
I113F O 0 4.630306307262799e-07
mutation O 0 6.24237941337924e-08
is O 0 8.389832162336575e-10
the O 0 1.9631787862017802e-10
most O 0 4.852912516284391e-10
common O 0 1.8991423988978795e-09
single O 0 5.2861505395185304e-08
mutation O 0 1.7602592379262205e-06
among O 0 4.487260696350859e-07
MPS B-Disease 1 0.9999990463256836
IVA I-Disease 1 1.0
patients O 0 5.0527105486253276e-05
and O 0 9.450148041878492e-08
produces O 0 2.2532252330620395e-07
a O 0 7.598550411103133e-08
severe O 0 2.1669440684490837e-05
clinical O 0 4.3645854930218775e-06
phenotype O 0 0.00031379651045426726
. O 0 5.371197175918496e-07

We O 0 1.7113964076997945e-06
studied O 0 1.2991512221560697e-07
mutations O 0 3.17429766027999e-07
in O 0 1.870979593476818e-09
the O 0 1.88988469318474e-09
GALNS O 0 7.110090791684343e-07
gene O 0 6.570969901531498e-08
from O 0 3.956220684386835e-09
23 O 0 3.8322941264823385e-08
additional O 0 7.556118220009012e-08
MPS B-Disease 1 0.9999986886978149
IVA I-Disease 1 1.0
patients O 0 3.899119747075019e-06
( O 0 5.551926030022969e-09
15 O 0 4.217443283494049e-09
from O 0 6.9702627003565e-10
Australia O 0 2.792109654592423e-09
, O 0 9.154673685785042e-10
8 O 0 5.158703242358342e-09
from O 0 5.46153400282634e-10
Northern O 0 2.494634721017519e-08
Ireland O 0 1.1341194294800516e-07
) O 0 1.0248759618747272e-09
, O 0 2.169839308230337e-10
with O 0 1.8316891059466656e-10
various O 0 2.2508352959249578e-09
clinical O 0 4.656983492168365e-07
phenotypes O 0 4.2592029785737395e-05
( O 0 4.4189768289015774e-08
severe O 0 1.299921336794796e-06
, O 0 2.7978779293391653e-09
16 O 0 9.147783863738823e-09
cases O 0 1.8178101246490996e-09
; O 0 3.4908993473692362e-09
intermediate O 0 2.461670201014954e-09
, O 0 3.704845319418837e-10
4 O 0 4.658446961514073e-09
cases O 0 4.2629682006634084e-09
; O 0 6.301618782345031e-08
mild O 0 1.545712621009443e-06
, O 0 5.638839617461144e-09
3 O 0 2.7313364014958097e-08
cases O 0 1.472186905715489e-08
) O 0 3.485186184093436e-08
. O 0 1.7483110070770636e-07

We O 0 1.372635665575217e-06
found O 0 2.1314475517897336e-08
two O 0 2.06552197568044e-09
common O 0 6.587280498848713e-09
mutations O 0 7.418482539378601e-08
that O 0 1.560396256650165e-09
together O 0 1.1178209469164813e-08
accounted O 0 1.5235761097187606e-08
for O 0 4.4292589040928476e-10
32 O 0 4.372328987756191e-08
% O 0 3.51851853208629e-10
of O 0 4.734519720717145e-11
the O 0 1.03230157755263e-09
44 O 0 2.1245435632977205e-08
unrelated O 0 1.2121942560838761e-08
alleles O 0 7.414266889327337e-08
in O 0 1.173676000831847e-08
these O 0 3.4266477655364724e-08
patients O 0 2.4086247663035465e-07
. O 0 8.156441566598005e-08

One O 0 1.6992008795568836e-06
is O 0 2.4450313773627386e-08
the O 0 5.212031251033977e-09
T312S O 0 1.0687399480957538e-06
mutation O 0 3.6087286048314127e-07
, O 0 1.7919229433616124e-09
a O 0 3.4811520333022372e-09
novel O 0 1.8697092230013368e-07
mutation O 0 1.0738896349948845e-07
found O 0 6.5616867495066344e-09
exclusively O 0 5.1141273438304324e-09
in O 0 1.1822429257790645e-08
milder O 0 7.55290748202242e-05
patients O 0 2.0663505893026013e-06
. O 0 1.5383464813112369e-07

The O 0 4.918605327475234e-07
other O 0 1.231852042593573e-08
is O 0 3.608836784962932e-09
the O 0 1.737934463008628e-09
previously O 0 2.202144315788246e-07
described O 0 2.833185988038167e-07
I113F O 0 5.275051648823137e-07
that O 0 6.504095040327229e-09
produces O 0 4.4104048413373675e-08
a O 0 5.905017275154023e-08
severe O 0 2.65844319073949e-05
phenotype O 0 6.782818672945723e-05
. O 0 3.386048206266423e-07

The O 0 7.279062401721603e-07
I113F O 0 6.339500487229088e-06
and O 0 3.869813625101415e-08
T312S O 0 9.984008784158505e-07
mutations O 0 1.7103982941080176e-07
accounted O 0 2.50562646186836e-08
for O 0 5.682033177301093e-10
8 O 0 2.22249276760067e-08
( O 0 3.003110649046903e-09
18 O 0 1.2404483662464827e-08
% O 0 1.29126209724717e-09
) O 0 5.872774488935306e-10
and O 0 7.50068807064963e-09
6 O 0 3.829517680742356e-08
( O 0 2.7583333395142517e-09
14 O 0 1.7257795192904268e-08
% O 0 1.1889744744308928e-09
) O 0 3.8638209298724746e-10
of O 0 5.359669374982445e-10
44 O 0 1.895871548640571e-08
unrelated O 0 5.622239740432633e-08
alleles O 0 2.2970637303387775e-07
, O 0 2.244756913682977e-08
respectively O 0 4.305281322558585e-07
. O 0 2.8600263135558635e-07

The O 0 4.5733642650702677e-07
relatively O 0 1.0057538446517356e-07
high O 0 4.705789535819349e-08
residual O 0 8.382256737604621e-07
GALNS O 0 5.9415474424895365e-06
activity O 0 1.1391740173394282e-07
seen O 0 4.024138533509358e-08
when O 0 9.786506049991317e-10
the O 0 5.943894265669769e-10
T312S O 0 8.659646510977836e-08
mutant O 0 1.8258106138091534e-07
cDNA O 0 2.7801922897197073e-07
is O 0 1.6861877227825062e-08
overexpressed O 0 7.490439770663215e-07
in O 0 4.901389516476229e-09
mutant O 0 1.1163613180542598e-06
cells O 0 5.049865592354763e-08
provides O 0 1.7378913863552725e-09
an O 0 2.4052360103610226e-10
explanation O 0 2.165759349637142e-09
for O 0 5.70099800700774e-10
the O 0 1.4832354899851907e-08
mild O 0 1.8215430827694945e-05
phenotype O 0 1.2065785085724201e-05
in O 0 5.865960162054762e-09
patients O 0 1.9427011110906278e-08
with O 0 1.7769034021952734e-09
this O 0 1.7652062922479672e-08
mutation O 0 2.709316277105245e-06
. O 0 2.2254796760989848e-07

The O 0 2.8700566190309473e-07
distribution O 0 1.121978172591298e-07
and O 0 7.0801937646081115e-09
relative O 0 6.451362555282003e-09
frequencies O 0 9.493991370845833e-09
of O 0 2.257033449026835e-10
the O 0 1.8556017833404326e-09
I113F O 0 2.9391244993348664e-07
and O 0 8.974203602463149e-09
T312S O 0 1.0760670932086214e-07
mutations O 0 2.6735666125432545e-08
in O 0 9.272873580101759e-10
Australia O 0 1.823780015897114e-09
corresponded O 0 1.4074955423382107e-08
to O 0 1.8667305479169727e-09
those O 0 9.339454765111554e-10
observed O 0 4.901043126892546e-09
in O 0 7.876287955177474e-10
Northern O 0 1.7049457312623417e-07
Ireland O 0 2.966597776321578e-07
and O 0 2.868219972640418e-08
are O 0 2.1579608933119943e-10
unique O 0 4.487251681339899e-10
to O 0 1.3957053290880594e-09
these O 0 4.0314862559398534e-10
two O 0 8.102489235106702e-10
populations O 0 5.116488566159205e-09
, O 0 6.587892453779887e-10
suggesting O 0 4.2720191828493626e-09
that O 0 2.530705089931473e-10
both O 0 1.3681932253817308e-09
mutations O 0 6.624894410833804e-08
were O 0 4.201540448889318e-08
probably O 0 9.614592677564815e-09
introduced O 0 5.131265634616966e-09
to O 0 5.477205800019647e-09
Australia O 0 4.712172874121734e-09
by O 0 5.050110885029824e-10
Irish O 0 1.5821576937469217e-08
migrants O 0 3.476328336304846e-09
during O 0 1.0495665447862734e-09
the O 0 1.1890696205441031e-09
19th O 0 5.737197170674335e-07
century O 0 1.2254832881808397e-06
. O 0 1.9755319158321072e-07

Haplotype O 0 0.00020961250993423164
analysis O 0 7.769180001560017e-07
using O 0 1.2949024608133186e-07
6 O 0 1.6331334506958228e-07
RFLPs O 0 5.771534006271395e-07
provides O 0 2.4074036097943008e-09
additional O 0 1.0812776229940368e-09
data O 0 8.58800941472282e-09
that O 0 1.0823753004984837e-09
the O 0 4.169374623330668e-09
I113F O 0 1.1587725339268218e-06
mutation O 0 5.370235101054277e-08
originated O 0 1.6288041138068365e-08
from O 0 5.957707660542155e-10
a O 0 4.434764555583115e-09
common O 0 2.2829222956488593e-08
ancestor O 0 4.977068215339386e-07
. O 0 2.6913235728898144e-07

The O 0 1.7255992190712277e-07
other O 0 4.996840718973772e-09
9 O 0 7.728817053020975e-08
novel O 0 9.056434180365613e-08
mutations O 0 1.884048401734617e-07
identified O 0 2.0886114171503323e-08
in O 0 1.7945909203120891e-09
these O 0 3.0890161539787186e-09
23 O 0 1.2512202829384478e-07
patients O 0 1.1638096708566081e-08
were O 0 2.1581605835763185e-08
each O 0 1.2029897078491558e-09
limited O 0 3.0566402742238097e-09
to O 0 6.561586829434418e-09
a O 0 3.8592730788877816e-08
single O 0 4.7403008807123115e-07
family O 0 9.313967552770919e-07
. O 0 2.936384362328681e-07

These O 0 1.3698904410830437e-07
data O 0 2.2699138568782473e-08
provide O 0 1.1793528376102813e-09
further O 0 1.7166291721437688e-09
evidence O 0 9.561808012037432e-10
for O 0 4.170652712076617e-10
extensive O 0 2.2194175386403003e-08
allelic O 0 3.3507621992612258e-06
heterogeneity O 0 3.099186142208055e-05
in O 0 5.811245046061231e-06
MPS B-Disease 1 0.9999991655349731
IVA I-Disease 1 1.0
in O 0 9.101437967728998e-07
British O 0 1.1741186426661443e-05
- O 0 0.027988921850919724
Irish O 0 1.0771431334433146e-05
patients O 0 4.327063862774594e-08
and O 0 1.133627525184977e-09
provide O 0 4.667641273492507e-10
evidence O 0 5.000003189259417e-10
for O 0 1.9481352642181093e-10
their O 0 2.2614126127251666e-09
transmission O 0 7.372722166110179e-07
to O 0 3.974667706074797e-09
Australia O 0 1.2347611821894589e-09
by O 0 4.214546767133953e-10
British O 0 7.425858683518527e-08
- O 0 7.756824743410107e-06
Irish O 0 2.203715752102653e-07
migrants O 0 5.539964931244867e-08
. O 0 6.229020410586372e-09
. O 0 4.241736206722635e-08

Identification O 0 2.319856776011875e-06
of O 0 5.69169245068224e-08
constitutional O 0 7.47287344893266e-07
WT1 O 0 0.0004906679387204349
mutations O 0 3.591931817936711e-05
, O 0 5.31779020818135e-09
in O 0 4.719071799996755e-09
patients O 0 4.837825784420602e-08
with O 0 1.8542015922662358e-08
isolated O 0 0.0026366121601313353
diffuse B-Disease 1 0.998566210269928
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 6.572273747451618e-08
and O 0 2.04173833395771e-09
analysis O 0 8.842793164376417e-09
of O 0 7.0125247830787885e-09
genotype O 0 0.00015090689703356475
/ O 0 0.000208519515581429
phenotype O 0 1.8624996300786734e-05
correlations O 0 4.6043834345255163e-07
by O 0 8.918282223824292e-10
use O 0 2.3061865750406696e-09
of O 0 1.6344174902371833e-09
a O 0 2.5755811705607812e-08
computerized O 0 9.437425433134194e-06
mutation O 0 1.658769292589568e-06
database O 0 5.647835337185825e-07
. O 0 2.8782906724700297e-07

Constitutional O 0 7.036421720840735e-06
mutations O 0 1.4380625543708447e-05
of O 0 1.065963139978976e-08
the O 0 6.7314647189675725e-09
WT1 O 0 6.288366876106011e-06
gene O 0 2.875983113881375e-07
, O 0 4.529725039503774e-09
encoding O 0 3.979524620945085e-08
a O 0 2.4345129645553243e-07
zinc O 0 0.0015262402594089508
- O 0 0.00021670061687473208
finger O 0 0.00010998579091392457
transcription O 0 3.3789513054216513e-07
factor O 0 2.982067215384632e-08
involved O 0 1.1948152689456037e-08
in O 0 2.551611899548334e-08
renal O 0 0.00023113747010938823
and O 0 2.8327701784292003e-07
gonadal O 0 1.5024633285065647e-05
development O 0 9.171176706956885e-09
, O 0 4.188240421143519e-09
are O 0 3.828944106221144e-10
found O 0 2.6661204355349355e-09
in O 0 1.0736368460939616e-09
most O 0 3.864205844195112e-09
patients O 0 1.1831926549632499e-08
with O 0 4.664424224642971e-08
Denys B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.2055281786160776e-06
DDS B-Disease 1 1.0
) O 0 1.492837782279821e-07
, O 0 2.910766028207945e-08
or O 0 1.6236602959907032e-06
diffuse B-Disease 1 0.9983249306678772
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.3811320059176069e-05
DMS B-Disease 0 0.00519520090892911
) O 0 2.44693492135184e-08
associated O 0 3.0214515334137104e-08
with O 0 6.500203397763471e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 1.0035872946900781e-05
/ O 0 0.0002484457800164819
or O 0 5.93074582866393e-06
Wilms B-Disease 1 0.5690025091171265
tumor I-Disease 0 0.088124118745327
( O 0 1.8283283225173363e-06
WT B-Disease 1 0.9999969005584717
) O 0 2.988738572184957e-07
. O 0 4.051576070196461e-07

Most O 0 1.8366381482337601e-06
mutations O 0 6.792929343646392e-05
in O 0 4.967499194208358e-07
DDS B-Disease 1 1.0
patients O 0 0.0006927796639502048
lie O 0 5.377499746828107e-06
in O 0 4.081414761714086e-09
exon O 0 1.0506034868740244e-06
8 O 0 1.6207010844482284e-07
or O 0 7.695422965525722e-09
exon O 0 3.5456966429592285e-07
9 O 0 2.965432202017837e-07
, O 0 7.867148710261063e-09
encoding O 0 8.304930361191509e-07
zinc O 0 0.010747733525931835
finger O 0 0.2691090703010559
2 O 0 1.8731856243903167e-06
or O 0 6.191001489241899e-07
zinc O 0 0.0007029269472695887
finger O 0 0.025333911180496216
3 O 0 2.1255490878502314e-07
, O 0 7.879792818243914e-09
respectively O 0 1.962604301297688e-08
, O 0 7.723549577676181e-10
with O 0 9.787962662599625e-10
a O 0 6.796178553258869e-08
hot O 0 0.0008472249610349536
spot O 0 0.01745828054845333
( O 0 6.469836932865292e-08
R394W O 0 3.041640752599051e-07
) O 0 2.302960044886504e-09
in O 0 2.9975311122143466e-09
exon O 0 2.286981271026889e-06
9 O 0 1.8449117078489508e-06
. O 0 4.199056888865016e-07

We O 0 9.453245866097859e-07
analyzed O 0 9.109204057722309e-08
a O 0 5.941585001778549e-09
series O 0 4.0411983093235904e-08
of O 0 3.3623046569175585e-09
24 O 0 3.316096979233407e-07
patients O 0 1.8117949807106015e-08
, O 0 7.696975279358753e-10
10 O 0 3.0185642874158702e-09
with O 0 7.284990832800986e-09
isolated B-Disease 0 0.0006968589150346816
DMS I-Disease 1 0.9095728993415833
( O 0 5.371515499064117e-08
IDMS B-Disease 0 1.201191571453819e-05
) O 0 6.9802972291199694e-09
, O 0 1.5442598311210531e-09
10 O 0 5.095579069802625e-09
with O 0 1.904170510158565e-08
DDS B-Disease 1 1.0
, O 0 8.935842856772069e-07
and O 0 5.7090346672339365e-08
4 O 0 7.636385390696887e-08
with O 0 1.901336617038396e-07
urogenital B-Disease 0 0.07269512116909027
abnormalities I-Disease 1 0.999065101146698
and O 0 1.2810476164304418e-06
/ O 0 0.00017807967378757894
or O 0 9.8036007329938e-06
WT B-Disease 1 1.0
. O 0 1.8084275552610052e-06

We O 0 8.757596333452966e-06
report O 0 8.722595339349937e-07
WT1 O 0 4.422658457770012e-05
heterozygous O 0 7.6219143920752686e-06
mutations O 0 1.7667829297352e-06
in O 0 9.766409903022577e-09
16 O 0 1.2724606790470716e-07
patients O 0 5.1663764821796576e-08
, O 0 4.9121893219705726e-09
4 O 0 4.009979193142499e-08
of O 0 3.422008454379011e-09
whom O 0 1.1272027222730685e-06
presented O 0 2.30826771030479e-07
with O 0 3.0468376621684e-07
IDMS B-Disease 0 0.0020684211049228907
. O 0 9.522792083771492e-07

One O 0 6.713466518704081e-06
male O 0 1.1247329894104041e-05
and O 0 6.55350902434293e-08
two O 0 8.510460958177646e-08
female O 0 1.1223242836422287e-05
IDMS B-Disease 0 0.002072904957458377
patients O 0 1.6989529285638127e-06
with O 0 9.791482113996608e-08
WT1 O 0 0.004249777644872665
mutations O 0 0.00025161728262901306
underwent O 0 6.684975232928991e-05
normal O 0 5.357484951673541e-06
puberty O 0 0.00011891966278199106
. O 0 1.0621911314956378e-06

Two O 0 3.3557666938577313e-06
mutations O 0 3.683253453345969e-05
associated O 0 7.510497823659534e-08
with O 0 1.3915594010427412e-08
IDMS B-Disease 0 0.00020545892766676843
are O 0 2.8219149239561148e-09
different O 0 1.358584467148205e-09
from O 0 1.56133694861893e-09
those O 0 3.92193788556483e-09
described O 0 9.46094758091931e-07
in O 0 5.015654096496291e-07
DDS B-Disease 1 1.0
patients O 0 3.8695150578860193e-05
. O 0 4.898191150459752e-07

No O 0 7.218392511276761e-06
WT1 O 0 0.000338615762302652
mutations O 0 6.909935473231599e-05
were O 0 1.4473771159373428e-07
detected O 0 1.272624530201938e-07
in O 0 1.7743767566358315e-09
the O 0 5.057477547865119e-09
six O 0 5.076983811136415e-08
other O 0 2.9452907668314765e-08
IDMS B-Disease 0 0.001800566096790135
patients O 0 2.129282279383915e-07
, O 0 1.6422576631924812e-09
suggesting O 0 1.4182965024645e-08
genetic O 0 6.485713299753115e-08
heterogeneity O 0 4.63024889540975e-07
of O 0 1.1773756192212659e-08
this O 0 9.409122725401176e-08
disease O 0 4.586093200487085e-05
. O 0 4.2482707840463263e-07

We O 0 1.8584133840704453e-06
analyzed O 0 2.6685645480029052e-06
genotype O 0 2.7490061256685294e-05
/ O 0 4.4098302169004455e-05
phenotype O 0 7.660273695364594e-06
correlations O 0 2.62753815150063e-06
, O 0 2.63345256712455e-08
on O 0 2.0130821098973684e-07
the O 0 2.2999881998941873e-09
basis O 0 6.252171225185066e-09
of O 0 1.004035632412581e-09
the O 0 1.6852261808253388e-08
constitution O 0 4.055869951002933e-08
of O 0 1.0357985580355944e-09
a O 0 1.8761442177606114e-08
WT1 O 0 6.7212949943495914e-06
mutation O 0 6.064821178597413e-08
database O 0 1.2493692302939507e-08
of O 0 1.2233961621532785e-09
84 O 0 2.2749372163843873e-08
germ O 0 4.35956462752074e-06
- O 0 8.901248656911775e-05
line O 0 0.0006103796768002212
mutations O 0 1.624840990643861e-07
, O 0 3.6663019842286815e-10
to O 0 1.0215712997752036e-10
compare O 0 3.305886453475182e-09
the O 0 4.210914672508892e-10
distribution O 0 1.0030905883695596e-08
and O 0 6.078820558030884e-09
type O 0 7.134214108361903e-09
of O 0 5.79879977369302e-10
mutations O 0 8.760453340528329e-08
, O 0 1.1806536859282346e-09
according O 0 4.4867382031910097e-10
to O 0 6.188209389357269e-10
the O 0 4.1756296198514065e-09
different O 0 1.9174062515503465e-07
symptoms O 0 7.82339702709578e-06
. O 0 7.691611614291105e-08

This O 0 5.15323847594118e-07
demonstrated O 0 5.062074706074782e-07
( O 0 1.4100696610341856e-08
1 O 0 6.5747780553238044e-09
) O 0 2.4682991206503857e-09
the O 0 1.2468713839197676e-09
association O 0 2.0653723176167205e-09
between O 0 2.7623767717699366e-09
mutations O 0 1.2009549266167596e-07
in O 0 3.2763580737338316e-09
exons O 0 3.7364968648034846e-06
8 O 0 4.5335912091104547e-07
and O 0 5.7038750611582145e-08
9 O 0 1.3679583332759648e-07
and O 0 1.0963973551270101e-07
DMS B-Disease 0 0.00014593673404306173
; O 0 1.0114053594634242e-08
( O 0 1.0095315694513829e-09
2 O 0 5.864103425068379e-09
) O 0 2.139099120057608e-09
among O 0 2.0725228200291212e-09
patients O 0 4.316460966435898e-09
with O 0 4.812936271747503e-09
DMS B-Disease 0 0.0003333906061016023
, O 0 1.76496972592588e-09
a O 0 1.640316882323134e-09
higher O 0 1.284830464243214e-09
frequency O 0 8.04598965231662e-09
of O 0 3.9362796355746354e-10
exon O 0 2.13128743098423e-07
8 O 0 8.760637371096891e-08
mutations O 0 1.1729044047115167e-07
among O 0 3.202403231483686e-09
46 O 0 3.7672997166282585e-08
, O 0 6.3355298784983916e-09
XY O 0 8.445609273621812e-05
patients O 0 5.267279590270846e-08
with O 0 2.9958733271939764e-09
female O 0 1.2229510275574285e-06
phenotype O 0 2.884104333134019e-06
than O 0 2.107213070701164e-09
among O 0 1.354098611017207e-09
46 O 0 2.760071637908368e-08
, O 0 4.600742009586156e-09
XY O 0 1.9170263840351254e-05
patients O 0 1.5313402101924112e-08
with O 0 7.802721246896738e-10
sexual O 0 2.8674323360178278e-08
ambiguity O 0 1.2371455682114174e-07
or O 0 5.5538670551413816e-08
male O 0 1.2767227417498361e-06
phenotype O 0 1.083716779248789e-05
; O 0 2.5261117642116915e-08
and O 0 2.8020394893246703e-08
( O 0 5.769193123228433e-09
3 O 0 7.374857613484664e-09
) O 0 7.879293328905135e-10
statistically O 0 8.691529274074128e-09
significant O 0 7.750569630537996e-10
evidence O 0 3.0058211475392227e-09
that O 0 2.789171560380055e-09
mutations O 0 5.965319616052511e-08
in O 0 1.6461245699872507e-09
exons O 0 3.5520865822036285e-06
8 O 0 5.10336292336433e-07
and O 0 6.347797665284816e-08
9 O 0 1.1380881659306397e-07
preferentially O 0 1.314457875878361e-07
affect O 0 3.3211822625389686e-08
amino O 0 1.5837459343970295e-08
acids O 0 6.051299905607266e-09
with O 0 3.1344055129167714e-10
different O 0 7.012374014792044e-10
functions O 0 7.225679610201041e-09
. O 0 1.376339220371392e-08
. O 0 1.33123762680043e-07

The O 0 1.2694210909103276e-06
185delAG O 0 4.655840893974528e-05
BRCA1 O 0 4.555338455247693e-05
mutation O 0 1.8906193872680888e-06
originated O 0 1.4672048109787283e-07
before O 0 3.963448680366355e-09
the O 0 4.660284380619828e-10
dispersion O 0 2.415393751675765e-08
of O 0 2.90990287421522e-10
Jews O 0 1.7381575290187357e-08
in O 0 9.586004212636112e-10
the O 0 3.2880898004350456e-09
diaspora O 0 6.55665957083329e-08
and O 0 2.75067549182495e-07
is O 0 6.722162826378053e-09
not O 0 1.0829906971210335e-09
limited O 0 2.6668731667456314e-09
to O 0 1.0489426216508946e-08
Ashkenazim O 0 1.770859853422735e-05
. O 0 2.3494432355164463e-07

The O 0 1.080142283171881e-06
185delAG O 0 1.677864020166453e-05
mutation O 0 3.0947051072871545e-06
in O 0 3.115704316769552e-08
BRCA1 O 0 7.160675977502251e-06
is O 0 5.182088003152785e-08
detected O 0 2.0447058091122017e-07
in O 0 4.130848996197756e-09
Ashkenazi O 0 2.2594233541894937e-06
Jews O 0 3.0416778429298574e-08
both O 0 1.4066787734634545e-09
in O 0 1.859429055173223e-08
familial B-Disease 0 0.0413416288793087
breast I-Disease 1 0.9999973773956299
and I-Disease 1 0.9999843835830688
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 7.029306630101928e-07
in O 0 4.188256408355073e-09
the O 0 5.8522480195222215e-09
general O 0 1.3607142967941854e-08
population O 0 3.2289069196167475e-08
. O 0 1.3060085279903433e-07

All O 0 5.880138473912666e-07
tested O 0 7.741061835986329e-07
Ashkenazi O 0 1.8758385067485506e-06
mutation O 0 2.440999082864437e-07
carriers O 0 4.019413069045186e-08
share O 0 1.4830062511350661e-08
the O 0 1.2260007453690491e-09
same O 0 4.672836784180845e-09
allelic O 0 7.553869068033237e-07
pattern O 0 2.7923249945160933e-05
at O 0 3.927936376157959e-08
the O 0 5.032077865507745e-08
BRCA1 O 0 5.082876668893732e-05
locus O 0 6.559368193848059e-05
. O 0 3.002931862283731e-06

Our O 0 2.214013193224673e-06
previous O 0 1.0064793087849466e-07
study O 0 1.067926902464933e-08
showed O 0 1.20649957580099e-07
that O 0 5.035730721303366e-10
this O 0 7.585757022532391e-10
Ashkenazi O 0 4.439850727067096e-06
mutation O 0 1.8086018371832324e-07
also O 0 5.2285727747403143e-08
occurs O 0 3.948621429827881e-09
in O 0 9.88890080932947e-10
Iraqi O 0 9.689597391115967e-08
Jews O 0 8.763541892164994e-09
with O 0 3.1279911993919995e-10
a O 0 4.325271252270113e-09
similar O 0 4.383309004651892e-08
allelic O 0 1.6046178643591702e-05
pattern O 0 0.00041465924005024135
. O 0 1.0515236681385431e-06

We O 0 3.136210943921469e-05
extended O 0 4.129674096020608e-07
our O 0 1.1786315035067219e-08
analysis O 0 3.557117933539189e-09
to O 0 9.26619114771654e-10
other O 0 5.269062408608249e-10
non O 0 1.2159385498478059e-08
- O 0 5.599785595222784e-07
Ashkenazi O 0 6.633289331148262e-07
subsets O 0 4.162463440593456e-08
354 O 0 5.7701754485606216e-08
of O 0 4.3471778954362605e-10
Moroccan O 0 3.447738379236398e-07
origin O 0 6.8858412305417005e-09
, O 0 1.7791247364229434e-09
200 O 0 5.170139427690401e-09
Yemenites O 0 5.564787670664373e-07
and O 0 1.7542610919463186e-08
150 O 0 9.121527533295648e-09
Iranian O 0 5.737022590324159e-08
Jews O 0 1.5799072627942223e-07
. O 0 1.0015882168090684e-07

Heteroduplex O 0 0.0001252108922926709
analysis O 0 3.138093802590447e-07
complemented O 0 2.7443792305348325e-07
by O 0 1.610840683063941e-09
direct O 0 3.8900291876586834e-09
DNA O 0 3.6296164296345523e-08
sequencing O 0 4.527205632598452e-08
of O 0 2.3657580339175865e-09
abnormally O 0 2.382993926630661e-07
migrating O 0 4.405579190347453e-08
bands O 0 2.1276380834933661e-07
were O 0 3.73293111977091e-08
employed O 0 2.949423674181162e-07
. O 0 1.3542600640903402e-07

Four O 0 6.2466426697938e-07
of O 0 4.491372163073493e-09
Moroccan O 0 1.1557673360584886e-06
origin O 0 9.928196043063053e-09
( O 0 1.0556779894699275e-09
1 O 0 1.1227178076111954e-09
. O 0 4.631264260979151e-10
1 O 0 4.804039832606577e-09
% O 0 1.2444503205699675e-09
) O 0 4.638354145214407e-10
and O 0 2.5332237640895983e-08
none O 0 1.017498352240409e-08
of O 0 1.1577906688930995e-10
the O 0 5.160907701196038e-09
Yemenites O 0 2.791754923237022e-06
or O 0 6.927829332425972e-08
Iranians O 0 2.122385183156439e-07
was O 0 8.561877251622718e-08
a O 0 2.28916929856382e-09
carrier O 0 1.8511485677663586e-08
of O 0 4.1845413245589214e-10
the O 0 1.0102524150568115e-08
185delAG O 0 6.027030849509174e-06
mutation O 0 1.199278585772845e-06
. O 0 1.2981753627627768e-07

BRCA1 O 0 0.0008507083402946591
allelic O 0 9.901836892822757e-05
patterns O 0 0.00015366902516689152
were O 0 3.2359915280721907e-07
determined O 0 1.7458527068470175e-08
for O 0 8.23685342155045e-10
four O 0 1.1734723415202097e-08
of O 0 6.902129978669791e-10
these O 0 2.6827446930610677e-09
individuals O 0 6.988367107219062e-10
and O 0 7.702086191052615e-10
for O 0 2.8220048520211094e-10
12 O 0 3.041148444182795e-09
additional O 0 1.6593010299104094e-09
non O 0 1.348874256734689e-08
- O 0 3.939952875953168e-06
Ashkenazi O 0 4.042107320856303e-06
185delAG O 0 5.585651479123044e-07
mutation O 0 1.8016778824403445e-07
carriers O 0 4.181569224215309e-08
who O 0 1.1267573540862941e-07
had O 0 4.408400855027139e-05
breast B-Disease 1 0.9999723434448242
/ I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.242696948291268e-06

Six O 0 6.060524356144015e-06
non O 0 8.233922130784777e-07
- O 0 0.00012224614329170436
Ashkenazi O 0 0.00023690229863859713
individuals O 0 1.3582457825123129e-08
shared O 0 1.383453351877506e-08
the O 0 2.6318545121029047e-09
common O 0 3.6034663253303734e-08
Ashkenazi O 0 5.380736638471717e-06
haplotype O 0 1.3504786693374626e-05
, O 0 3.1825660329332095e-08
four O 0 2.54347796158072e-08
had O 0 2.6402329922348144e-07
a O 0 1.8101533605374698e-09
closely O 0 3.2263951510458355e-08
related O 0 1.147060935124955e-08
pattern O 0 0.0001596924994373694
, O 0 3.0059375433211244e-08
and O 0 1.7036056121355614e-08
the O 0 3.278026960984448e-09
rest O 0 1.9626003933126412e-08
( O 0 2.8217372882721747e-09
n O 0 1.7107554128870106e-07
= O 0 6.576298119398416e-07
6 O 0 4.8511960670793997e-08
) O 0 3.6808289749501455e-09
displayed O 0 4.09829787884064e-08
a O 0 2.430538259545756e-08
distinct O 0 6.502310725409188e-07
BRCA1 O 0 7.533630559919402e-05
allelic O 0 7.410810212604702e-05
pattern O 0 0.0004174124333076179
. O 0 1.187555994874856e-06

We O 0 4.168345640209736e-06
conclude O 0 2.0112631204938225e-07
that O 0 2.3211199629002977e-09
the O 0 3.5852083524190448e-09
185delAG O 0 4.1875823626469355e-06
BRCA1 O 0 2.6514908313401975e-05
mutation O 0 1.4571802466889494e-06
occurs O 0 9.54059053981382e-09
in O 0 3.7705885636007963e-10
some O 0 2.980392599383208e-10
non O 0 3.811632787176222e-09
- O 0 2.0732770735776285e-06
Ashkenazi O 0 1.564243348184391e-06
populations O 0 6.5219714073805335e-09
at O 0 1.679142158650393e-09
rates O 0 7.496941734075335e-09
comparable O 0 3.5139602339029352e-09
with O 0 7.20151493993626e-10
that O 0 1.3597329928671797e-09
of O 0 4.095670025350273e-09
Ashkenazim O 0 3.157692481181584e-05
. O 0 2.817305357893929e-07

The O 0 4.799518364961841e-07
majority O 0 7.475924945765655e-08
of O 0 2.1693851159909627e-09
Jewish O 0 9.710262816042814e-08
185delAG O 0 1.8886767065851018e-06
mutation O 0 2.1540651573559444e-07
carriers O 0 1.8788444577921837e-08
have O 0 1.1564935675778543e-09
a O 0 1.3775518503678086e-09
common O 0 7.465804863215908e-09
allelic O 0 1.359398765998776e-06
pattern O 0 0.0003522113838698715
, O 0 1.1520424614275271e-08
supporting O 0 2.4306261892093062e-08
the O 0 4.348905235929124e-09
founder O 0 2.3513980806910695e-07
effect O 0 7.755335040826594e-09
notion O 0 5.781044976060912e-09
, O 0 3.104390522423728e-09
but O 0 7.398580081918738e-10
dating O 0 2.3082868949586555e-08
the O 0 1.2949346039903276e-09
mutations O 0 1.5574801892626056e-08
origin O 0 7.293022297183427e-10
to O 0 3.4638766854833136e-10
an O 0 2.158150325115571e-10
earlier O 0 1.183346132194174e-08
date O 0 1.1474770644781529e-07
than O 0 2.3255333214677876e-09
currently O 0 1.1152228474031745e-08
estimated O 0 3.556332828225095e-08
. O 0 7.043277605589537e-08

However O 0 8.697534212842584e-07
, O 0 3.673310544627384e-09
the O 0 6.000095420510831e-10
different O 0 9.498678510411196e-10
allelic O 0 5.522662149815005e-07
pattern O 0 8.728648390388116e-05
at O 0 3.885255850377689e-08
the O 0 7.958988135214895e-09
BRCA1 O 0 2.175007921323413e-06
locus O 0 1.1202904488527565e-06
even O 0 3.5119718688747525e-08
in O 0 8.570659182360885e-10
some O 0 5.329403585108139e-10
Jewish O 0 2.2039358782421914e-08
mutation O 0 2.331130311006291e-08
carriers O 0 4.3820778117265036e-09
, O 0 7.59970308905622e-10
might O 0 4.6960675348373115e-09
suggest O 0 4.777741313688466e-09
that O 0 2.7069577135385714e-10
the O 0 9.042790405366929e-10
mutation O 0 9.629314234871345e-08
arose O 0 2.528396514378528e-08
independently O 0 5.989546991713723e-08
. O 0 1.9447625732027518e-08
. O 0 1.282398045532318e-07

Crystal O 0 0.0001283998863073066
structure O 0 7.851559189475665e-07
of O 0 1.1206046757195054e-08
the O 0 1.635235946650937e-07
hemochromatosis B-Disease 1 1.0
protein O 0 4.993404581909999e-05
HFE O 0 0.0022474313154816628
and O 0 2.644509322635713e-07
characterization O 0 4.3875917299374123e-07
of O 0 1.3347692950915757e-09
its O 0 3.515448154800538e-09
interaction O 0 1.095824053720662e-08
with O 0 1.4019279959143205e-08
transferrin O 0 5.970959591650171e-06
receptor O 0 2.9844454729754943e-06
. O 0 3.5230726780355326e-07

HFE O 0 0.06828726828098297
is O 0 1.76096432369377e-06
an O 0 2.9174916704732823e-08
MHC O 0 3.3039830213965615e-06
- O 0 1.6998816363411606e-06
related O 0 1.390333714823555e-08
protein O 0 4.378771834012696e-08
that O 0 1.2294477658159053e-09
is O 0 5.302271399720837e-10
mutated O 0 3.367652468000415e-08
in O 0 6.33203889321976e-09
the O 0 1.5016347276741726e-07
iron B-Disease 1 0.9996140599250793
- I-Disease 1 0.9999996423721313
overload I-Disease 1 0.9999942779541016
disease I-Disease 1 0.9994186162948608
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 4.9769510951591656e-05

HFE O 0 0.001715517370030284
binds O 0 3.119301618426107e-05
to O 0 3.3310701041955326e-07
transferrin O 0 1.2990268260182347e-05
receptor O 0 3.0386624985112576e-06
( O 0 1.387301296063015e-07
TfR O 0 0.0001504755491623655
) O 0 3.729280351194575e-08
and O 0 1.0474051848063937e-08
reduces O 0 2.7152964321430773e-08
its O 0 1.519173231656623e-09
affinity O 0 9.35846777849747e-09
for O 0 1.885999134643157e-09
iron O 0 4.104417530470528e-05
- O 0 7.039744104986312e-06
loaded O 0 3.925952114514075e-07
transferrin O 0 6.592813406314235e-07
, O 0 7.212777486387267e-09
implicating O 0 1.280414949178521e-06
HFE O 0 6.279373337747529e-05
in O 0 1.9154232688833872e-07
iron O 0 0.002993697067722678
metabolism O 0 2.6649388018995523e-05
. O 0 4.3204832422816253e-07

The O 0 2.4415630832663737e-06
2 O 0 3.49565334545332e-06
. O 0 8.471347996419354e-07

6 O 0 7.4454683272051625e-06
A O 0 3.512890316414996e-07
crystal O 0 1.886885002022609e-05
structure O 0 3.6813719361816766e-07
of O 0 1.0962903473910046e-08
HFE O 0 0.0007183453417383134
reveals O 0 4.966294454789022e-06
the O 0 2.0533921230025953e-09
locations O 0 7.586994144048731e-08
of O 0 7.784504418850702e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 0.00011831724259536713
and O 0 7.356456421803159e-08
a O 0 6.343706360212309e-08
patch O 1 0.9465062022209167
of O 0 1.1419440504312206e-08
histidines O 0 1.3717661204282194e-05
that O 0 3.363807365985849e-08
could O 0 1.0424668772657242e-07
be O 0 1.4441081663818522e-09
involved O 0 1.2879882715921553e-09
in O 0 4.011882381860232e-09
pH O 0 1.1631565939751454e-05
- O 0 2.977040367113659e-06
dependent O 0 2.7867116614288534e-07
interactions O 0 1.6774775701833278e-07
. O 0 1.72565847833539e-07

We O 0 2.9028797143837437e-05
also O 0 1.8878037622016564e-07
demonstrate O 0 6.722063261577205e-08
that O 0 1.769969948384187e-08
soluble O 0 7.24761434867105e-07
TfR O 0 0.0001895601162686944
and O 0 3.884255761477107e-08
HFE O 0 2.3656235498492606e-05
bind O 0 1.0706251032388536e-06
tightly O 0 8.049973985180259e-06
at O 0 3.8630730614386266e-08
the O 0 9.712310955478642e-10
basic O 0 1.4380178825490475e-08
pH O 0 3.0373593062904547e-07
of O 0 1.910454988651722e-10
the O 0 9.760632302402428e-10
cell O 0 7.116873916857003e-07
surface O 0 2.194332182625658e-06
, O 0 1.2500628088218946e-08
but O 0 3.4358080824858916e-09
not O 0 1.2887696465568865e-09
at O 0 2.2190818071976537e-09
the O 0 6.562487886441204e-09
acidic O 0 2.0228328594384948e-06
pH O 0 2.1609778286801884e-06
of O 0 4.670279718510528e-09
intracellular O 0 1.8104292394127697e-06
vesicles O 0 1.1103391443612054e-05
. O 0 7.0781032945888e-07

TfR O 1 0.7945749163627625
HFE O 0 0.006542840041220188
stoichiometry O 0 0.00011276285658823326
( O 0 2.00405747818877e-06
2 O 0 3.390200333797111e-07
1 O 0 7.848492344919578e-08
) O 0 2.2552111289542154e-08
differs O 0 1.601943040441256e-07
from O 0 2.503161589118008e-08
TfR O 0 4.825361247640103e-05
transferrin O 0 1.926388677020441e-06
stoichiometry O 0 4.492163157010509e-07
( O 0 1.0627211999292285e-08
2 O 0 8.318561839359973e-09
2 O 0 2.4533090225986598e-08
) O 0 4.2805021749359184e-09
, O 0 1.9043258081552494e-09
implying O 0 1.043459008087666e-08
a O 0 8.797450545827701e-10
different O 0 4.0960745906204465e-10
mode O 0 2.4872326420677382e-08
of O 0 2.904573803697019e-10
binding O 0 4.5119366021140195e-09
for O 0 1.464210752644135e-09
HFE O 0 1.795668140402995e-05
and O 0 3.5691829936013164e-08
transferrin O 0 2.0036223702390998e-07
to O 0 1.091331203184609e-08
TfR O 0 2.123403646692168e-05
, O 0 3.4983247410025342e-09
consistent O 0 1.0466403743691899e-08
with O 0 1.0145000395311854e-09
our O 0 1.0485985413311028e-08
demonstration O 0 4.9390802558946234e-08
that O 0 4.1836738517986305e-09
HFE O 0 5.947817498963559e-06
, O 0 1.3250851083057569e-08
transferrin O 0 4.257380226135865e-07
, O 0 1.6213526521369204e-08
and O 0 2.982317326427619e-08
TfR O 0 3.181626743753441e-05
form O 0 1.3241276519693201e-08
a O 0 2.4123506747741885e-08
ternary O 0 6.496707669612078e-07
complex O 0 1.131142994381662e-06
. O 0 5.895091135244002e-07

Identification O 0 6.358764608194178e-07
of O 0 9.42898914502166e-09
three O 0 8.581361399251364e-09
novel O 0 2.493774502454471e-07
mutations O 0 1.1980988574578078e-06
and O 0 3.1099332886697084e-08
a O 0 6.772586047532059e-09
high O 0 1.6720608897458078e-08
frequency O 0 2.0329455452383627e-08
of O 0 5.297439154006156e-10
the O 0 5.421257665005896e-09
Arg778Leu O 0 8.26202449388802e-06
mutation O 0 1.2239667057656334e-07
in O 0 5.1535402612046255e-09
Korean O 0 4.090153709057631e-07
patients O 0 5.796804458668703e-08
with O 0 1.7249535133601057e-08
Wilson B-Disease 0 6.076597128412686e-05
disease I-Disease 0 9.113180567510426e-06
. O 0 1.6868060015440278e-07

Four O 0 2.863385361706605e-06
mutations O 0 1.0770568223961163e-05
- O 0 1.214870917465305e-05
- O 0 3.2864776585483924e-05
R778L O 0 2.679698809515685e-06
, O 0 1.1796413623699209e-08
A874V O 0 1.57382132215389e-07
, O 0 2.3638273560777634e-09
L1083F O 0 1.0110624515391464e-07
, O 0 1.3459103831436892e-09
and O 0 2.051145253645359e-09
2304delC O 0 1.740397408411809e-07
- O 0 3.706966708705295e-06
- O 0 1.0039624612545595e-05
in O 0 7.148829972436488e-09
the O 0 4.769219241751443e-09
copper O 0 2.728816923536215e-07
- O 0 6.196991364504356e-08
transporting O 0 7.575191141029336e-09
enzyme O 0 1.0181565812672488e-08
, O 0 1.2255565451368966e-09
P O 0 2.0300922187743708e-07
- O 0 1.3563462175625318e-07
type O 0 5.4316828368428105e-08
ATPase O 0 7.154745276238828e-07
( O 0 1.563358154044181e-08
ATP7B O 0 1.8830689896276454e-06
) O 0 3.9376106819588585e-09
, O 0 1.7575589872365072e-09
were O 0 2.595077042144567e-09
identified O 0 1.524299975130816e-08
in O 0 3.6949179271772437e-09
Korean O 0 6.501468305941671e-07
Patients O 0 3.993858044282206e-08
with O 0 1.947542749292097e-08
Wilson B-Disease 0 6.795624358346686e-05
disease I-Disease 0 2.3311305994866416e-05
. O 0 1.273908054599815e-07

Arg778Leu O 0 0.0002760239294730127
, O 0 1.3288149602885824e-07
the O 0 3.4047686892080264e-09
most O 0 1.7957549891534086e-09
frequently O 0 1.0909798930924808e-07
reported O 0 2.935207454868305e-08
mutation O 0 8.450543376170572e-09
of O 0 1.1464910965042208e-10
this O 0 3.0669639050628916e-10
enzyme O 0 1.0604634503863508e-08
, O 0 8.614652102778564e-09
was O 0 2.7848466288560303e-07
found O 0 4.531125252782431e-09
in O 0 1.5482884974105104e-09
six O 0 6.004849950613789e-09
of O 0 4.586125923466966e-10
eight O 0 1.3428827827510759e-08
unrelated O 0 4.654852148178179e-08
patients O 0 1.207532829283764e-08
studied O 0 2.0904675768207426e-09
, O 0 4.787060747801775e-10
an O 0 1.8730460238369773e-10
allele O 0 2.7260639967607858e-08
frequency O 0 3.162790562782902e-08
of O 0 4.36088276600799e-09
37 O 0 7.406097211060114e-07
. O 0 1.8739167728654138e-07

5 O 0 5.1364222599659115e-06
% O 0 1.6317775930474454e-07
, O 0 5.0618687019721165e-09
which O 0 5.75442227201961e-09
is O 0 1.4169601048052982e-09
considerably O 0 7.232065968310053e-08
higher O 0 7.167575866162679e-09
than O 0 1.8857544414885297e-09
those O 0 3.821531424641478e-10
in O 0 2.763608786260363e-10
other O 0 7.423090475633387e-10
Asian O 0 1.78070074241532e-08
populations O 0 1.7315734623934986e-07
. O 0 1.5376600970284926e-07

The O 0 4.6744972337364743e-07
novel O 0 4.688457977408689e-07
single O 0 8.973557186209291e-08
nucleotide O 0 4.986522412764316e-07
deletion O 0 1.1252083140789182e-06
, O 0 2.050715863788355e-08
2304delC O 0 1.208191520163382e-06
, O 0 2.1277593020840868e-08
was O 0 1.3467743542605604e-07
found O 0 6.518401818311759e-09
in O 0 3.2640703473418853e-09
one O 0 5.7222472094053956e-08
patient O 0 8.215856723836623e-07
. O 0 3.769409886444919e-07

Since O 0 1.046672196025611e-06
a O 0 8.855540301055953e-08
mutation O 0 2.9553675062743423e-07
at O 0 1.9105625526094627e-08
cDNA O 0 1.2470691217458807e-06
nucleotide O 0 2.658601715666009e-06
2302 O 0 1.6322599549312145e-05
( O 0 1.6714549744278884e-08
2302insC O 0 3.766366205582017e-07
) O 0 1.9811082552223525e-08
had O 0 3.0403261916944757e-06
been O 0 2.1768849478576158e-07
previously O 0 3.626952889135282e-07
described O 0 6.370405571942683e-07
, O 0 7.072514129902174e-09
this O 0 2.985564295787668e-10
region O 0 7.377488397963816e-09
of O 0 2.1079959999781295e-10
the O 0 2.2552528733399413e-09
ATP7B O 0 3.6685762552224332e-06
gene O 0 2.9939076284790644e-07
may O 0 1.9999093581191119e-07
be O 0 3.0806373008118726e-09
susceptible O 0 5.8792362978010715e-08
to O 0 3.335451914665555e-09
gene O 0 1.4810848369961604e-06
rearrangements O 0 0.0007792695541866124
causing O 0 2.107285581587348e-05
Wilson B-Disease 0 0.0001255087845493108
disease I-Disease 0 8.211821841541678e-05
. O 0 3.7313864709176414e-07

Disruption O 0 4.894816083833575e-05
of O 0 2.9867237572034355e-08
splicing O 0 9.844681017057155e-07
regulated O 0 8.849225707763253e-08
by O 0 2.7639104338561538e-09
a O 0 1.7760402926114693e-08
CUG O 0 1.4242260476748925e-05
- O 0 3.052260126423789e-06
binding O 0 3.7015226439507387e-07
protein O 0 4.661841103370534e-06
in O 0 2.0804984615097055e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 7.076780093484558e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9970031380653381
DM B-Disease 1 1.0
) O 0 1.5173840438365005e-05
is O 0 5.263914815145654e-08
caused O 0 3.135221859906778e-08
by O 0 5.012932846604201e-10
a O 0 1.0979748665818079e-08
CTG O 0 2.3724298898741836e-06
expansion O 0 3.896878553177885e-08
in O 0 8.03441135843741e-09
the O 0 7.647036781577299e-09
3 O 0 8.684788355139972e-08
untranslated O 0 1.1077044291596394e-05
region O 0 2.0658782773352868e-07
of O 0 8.815225882585764e-09
the O 0 4.040998646814842e-07
DM B-Disease 1 1.0
gene O 0 3.819322228082456e-05
. O 0 1.6820541759443586e-06

One O 0 1.0367318736825837e-06
model O 0 5.420484399110137e-07
of O 0 7.918275457541313e-08
DM B-Disease 1 1.0
pathogenesis O 0 3.0106884878478013e-05
suggests O 0 5.703211058971647e-07
that O 0 4.431424560635833e-09
RNAs O 0 1.7118341588684416e-07
from O 0 7.081756847604481e-10
the O 0 5.370199285259503e-10
expanded O 0 1.1424276635807473e-08
allele O 0 5.3917986519991246e-08
create O 0 5.257881685594157e-09
a O 0 1.1076929595787988e-08
gain O 0 2.1783635872907325e-07
- O 0 2.889922143367585e-06
of O 0 2.281889566191353e-09
- O 0 1.8059508875012398e-06
function O 0 7.3098775921209835e-09
mutation O 0 1.229870605357064e-08
by O 0 1.5509922512979557e-10
the O 0 5.491994636841468e-10
inappropriate O 0 1.4408018778055975e-08
binding O 0 6.310095557182649e-09
of O 0 3.8276881664245366e-10
proteins O 0 2.073210714215179e-09
to O 0 1.7527483908708064e-09
the O 0 8.99588314950961e-09
CUG O 0 4.419188917381689e-05
repeats O 0 1.759164842951577e-05
. O 0 3.096810985425691e-07

Data O 0 1.8668030179469497e-06
presented O 0 3.8408930436162336e-07
here O 0 6.334892077575205e-08
indicate O 0 4.122759378333285e-08
that O 0 1.0335231559466251e-09
the O 0 1.89791116156357e-09
conserved O 0 1.860295100186704e-07
heterogeneous O 0 4.5363503886619583e-07
nuclear O 0 2.725030299188802e-07
ribonucleoprotein O 0 6.704252086819906e-07
, O 0 5.960381965763872e-09
CUG O 0 9.482374139224703e-07
- O 0 2.394080524936726e-07
binding O 0 3.4236293799949635e-08
protein O 0 7.947281233100512e-08
( O 0 6.20089046776684e-09
CUG O 0 2.866858267225325e-06
- O 0 0.00011379984789527953
BP O 0 4.9863767344504595e-05
) O 0 6.589404133450216e-09
, O 0 2.169579627064877e-09
may O 0 1.0381903337020049e-08
mediate O 0 1.3846459978594794e-06
the O 0 2.2661849286009783e-08
trans O 0 2.0669970126618864e-06
- O 0 0.00015751313185319304
dominant O 0 7.105711574695306e-07
effect O 0 1.9407789153547128e-08
of O 0 7.160234627434647e-10
the O 0 4.203598358287763e-09
RNA O 0 8.725898510419938e-07
. O 0 9.459218830443206e-08

CUG O 0 0.0029198674019426107
- O 1 0.9049362540245056
BP O 0 0.0008762935758568347
was O 0 4.331324987560947e-07
found O 0 5.814241532675624e-09
to O 0 8.503961979045016e-10
bind O 0 2.1622973633839138e-08
to O 0 1.4673867676506802e-09
the O 0 1.880765321260469e-09
human O 0 3.2728930676739765e-08
cardiac O 0 1.5162702766247094e-05
troponin O 0 0.00010426053631817922
T O 0 9.443920134799555e-05
( O 0 1.3126207676350532e-08
cTNT O 0 9.68780540233638e-08
) O 0 3.5565683731419995e-09
pre O 0 9.088968511150597e-08
- O 0 2.4392800241912482e-06
messenger O 0 5.188318823456939e-07
RNA O 0 1.4099840939252317e-07
and O 0 1.8386626665645167e-09
regulate O 0 5.812311965058825e-09
its O 0 4.290204191903513e-09
alternative O 0 3.929307723637976e-08
splicing O 0 3.541073965607211e-06
. O 0 5.397786253524828e-07

Splicing O 0 4.994114351575263e-05
of O 0 6.03287560352328e-07
cTNT O 0 1.8588938473840244e-05
was O 0 1.5982593595254002e-06
disrupted O 0 9.869452696875669e-06
in O 0 4.626722045486531e-07
DM B-Disease 1 1.0
striated O 1 0.5407843589782715
muscle O 0 0.0003733641642611474
and O 0 1.0519383408791327e-07
in O 0 6.1827973851791285e-09
normal O 0 1.4980760454363917e-07
cells O 0 1.9258342831562913e-07
expressing O 0 1.2971551832663408e-08
transcripts O 0 1.1573330738201548e-07
that O 0 4.6800261443991076e-09
contain O 0 1.5154731158872892e-07
CUG O 0 0.00010992455645464361
repeats O 0 4.725523467641324e-05
. O 0 3.855977297462232e-07

Altered O 0 0.00013165222480893135
expression O 0 1.8830078261089511e-06
of O 0 1.3987442315510634e-08
genes O 0 4.4439624957703927e-07
regulated O 0 1.1177425562891585e-07
posttranscriptionally O 0 2.4612966171844164e-06
by O 0 8.024594322364464e-09
CUG O 0 4.653932774090208e-05
- O 0 0.0028518331237137318
BP O 0 3.657321212813258e-05
therefore O 0 1.8146620206493935e-08
may O 0 9.674745449217426e-09
contribute O 0 6.363056748170948e-09
to O 0 3.469791920451826e-08
DM B-Disease 1 1.0
pathogenesis O 0 3.35304721374996e-05
. O 0 1.690084445726825e-07
. O 0 3.683457805436774e-07

Identification O 0 1.9417011571931653e-06
of O 0 2.1104963110474273e-08
a O 0 3.933956804758054e-08
novel O 0 8.387253842556674e-07
nonsense O 0 1.712244193186052e-05
mutation O 0 4.011961323158175e-07
and O 0 1.9210744106601396e-09
a O 0 4.555971155895122e-09
missense O 0 7.243012873914267e-07
substitution O 0 1.7759150594542916e-08
in O 0 3.5760159278197534e-09
the O 0 7.619011199722081e-09
vasopressin O 0 9.494897312833928e-07
- O 0 4.2150226363446563e-05
neurophysin O 0 1.5180410628090613e-05
II O 0 1.0884405128308572e-06
gene O 0 7.131414037075956e-08
in O 0 5.989853502086362e-09
two O 0 1.100098323547627e-08
Spanish O 0 4.4215278194315033e-07
kindreds O 0 1.2599782166944351e-05
with O 0 1.6498714217050292e-07
familial B-Disease 0 0.04207252338528633
neurohypophyseal I-Disease 1 0.9893876314163208
diabetes I-Disease 1 0.9982165694236755
insipidus I-Disease 1 0.7264527082443237
. O 0 7.624400950589916e-06

Familial B-Disease 1 0.9998149275779724
neurohypophyseal I-Disease 1 0.999976634979248
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9999978542327881
( O 0 0.006839004345238209
FNDI B-Disease 1 1.0
) O 0 6.29483167813305e-07
is O 0 2.1444231279588166e-08
an O 0 1.2611510946669569e-08
autosomal B-Disease 1 0.9996523857116699
dominant I-Disease 1 0.9990070462226868
disease I-Disease 1 0.997246503829956
caused O 0 2.1380461475928314e-05
by O 0 1.210788553862585e-07
deficiency O 0 0.01529056578874588
in O 0 6.078322289937432e-09
the O 0 4.781873741421805e-08
antidiuretic O 0 8.219483424909413e-05
hormone O 0 2.0079025944141904e-06
arginine O 0 2.1532159735215828e-06
vasopressin O 0 2.0292593490012223e-06
( O 0 4.605406545010737e-08
AVP O 0 1.4168858797347639e-06
) O 0 5.576526351802613e-09
encoded O 0 4.283752463862811e-09
by O 0 1.6955816750652275e-09
the O 0 9.560134905939321e-09
AVP O 0 3.1700510589871556e-05
- O 0 0.002419015858322382
neurophysin O 0 0.0002036229707300663
II O 0 1.595775938767474e-05
( O 0 2.4551253474669466e-08
AVP O 0 3.5049033613177016e-06
- O 0 2.101573954860214e-05
NPII O 0 8.54027530294843e-06
) O 0 6.925699125304163e-09
gene O 0 8.606969714719526e-08
on O 0 1.7211156944085815e-07
chromosome O 0 0.00020639707508962601
20p13 O 0 4.219398397253826e-05
. O 0 9.044917987921508e-07

In O 0 2.1218853873961052e-07
this O 0 2.4522786024050447e-09
study O 0 1.4524753622069397e-09
, O 0 1.6191238350060644e-09
we O 0 1.7502062021890197e-09
analyzed O 0 4.550976928641148e-09
two O 0 6.43241637732217e-09
families O 0 6.898080329165168e-09
with O 0 3.993993136219842e-09
FNDI B-Disease 1 0.9999850988388062
using O 0 3.919178759304032e-09
direct O 0 3.791837066557946e-09
automated O 0 4.0294072078950194e-08
fluorescent O 0 2.7030247906623117e-07
, O 0 4.594191693740868e-09
solid O 0 3.104812762444453e-08
phase O 0 2.2727299153757485e-08
, O 0 4.081251780974071e-09
single O 0 2.106780172539402e-08
- O 0 7.526817284997378e-07
stranded O 0 4.934993569349899e-08
DNA O 0 2.0183758664416018e-08
sequencing O 0 2.2534480947911106e-08
of O 0 2.7637154786930296e-09
PCR O 0 2.5901367735059466e-06
- O 0 2.801564278342994e-06
amplified O 0 4.631941465049749e-06
AVP O 0 1.7911530449055135e-05
- O 0 2.3590988348587416e-05
NPII O 0 3.862362791551277e-05
DNA O 0 4.9984628276433796e-06
. O 0 3.36773979370264e-07

In O 0 5.143713224242674e-07
one O 0 1.8479065388987692e-08
of O 0 3.744757837154111e-10
the O 0 2.104662222279785e-09
families O 0 1.2933408122250967e-08
, O 0 1.0021453666908542e-09
affected O 0 1.767118784634647e-09
individuals O 0 2.8821020570113376e-10
presented O 0 1.743505784190802e-09
a O 0 5.754312581984777e-09
novel O 0 1.0721536227720208e-06
nonsense O 0 3.229324647691101e-06
mutation O 0 3.256261749129408e-08
in O 0 5.447987616591377e-10
exon O 0 1.399118332301441e-07
3 O 0 5.016648785272082e-08
of O 0 6.052485734819868e-10
the O 0 2.0835810854435977e-09
gene O 0 3.735203080168503e-08
, O 0 2.035450918924653e-09
consisting O 0 6.134480146080534e-10
in O 0 6.49279907616318e-10
a O 0 1.6863582530390886e-08
G O 0 7.0834234975336585e-06
to O 0 1.4889099730908129e-08
T O 0 4.679056473833043e-06
transition O 0 2.3771486112877938e-08
at O 0 3.7247855910749195e-09
nucleotide O 0 6.134474261898504e-08
2101 O 0 5.631994781651883e-07
, O 0 1.2310105157453677e-09
which O 0 6.537298480324694e-10
produces O 0 7.850460836955619e-10
a O 0 8.461991107822087e-10
stop O 0 2.2469331284469263e-08
signal O 0 7.476424457308894e-08
in O 0 2.70619526787641e-09
codon O 0 1.285349071622477e-06
82 O 0 1.7094099291625753e-07
( O 0 1.8820724534407418e-08
Glu O 0 2.7040121494792402e-05
) O 0 2.048819602862295e-08
of O 0 1.6592132112691615e-08
NPII O 0 0.00018276280025020242
. O 0 4.0160037428904616e-07

The O 0 1.4162562820274616e-06
premature O 0 3.6478325000643963e-06
termination O 0 8.743040211811604e-07
eliminates O 0 2.6296388000446314e-07
part O 0 8.525272932047301e-09
of O 0 7.579928906764621e-10
the O 0 4.102127970639913e-09
C O 0 1.004053501674207e-06
- O 0 1.1745268011509324e-06
terminal O 0 6.573564803602494e-08
domain O 0 5.0760911030067746e-09
of O 0 7.51801509935035e-10
NPII O 0 4.064783752255607e-06
, O 0 5.091661536837933e-10
including O 0 5.27437919728424e-11
a O 0 6.985568234973982e-10
cysteine O 0 4.3437076158170385e-09
residue O 0 2.3328516007836697e-08
in O 0 5.078974463224029e-10
position O 0 1.4566965944595722e-07
85 O 0 1.2949377570237175e-08
, O 0 1.5966049593529874e-09
which O 0 1.0140903228261777e-08
could O 0 3.827370420594889e-08
be O 0 9.241974407991904e-10
involved O 0 6.551453823888664e-10
in O 0 1.1949946587819227e-09
the O 0 1.3525840891759344e-08
correct O 0 1.682806669123238e-06
folding O 0 2.1515245407499606e-06
of O 0 4.605087866593749e-09
the O 0 6.373103644818912e-08
prohormone O 0 7.291556539712474e-05
. O 0 4.011831151728984e-07

In O 0 1.0854438414753531e-06
the O 0 4.928597263642587e-08
second O 0 1.4094329969793762e-07
family O 0 2.998007175847306e-08
, O 0 7.440595917174164e-10
a O 0 6.856678003153149e-10
G279A O 0 3.225638423032251e-08
substitution O 0 3.952192795253495e-09
at O 0 8.110982108178177e-09
position O 0 5.183877149761429e-08
- O 0 3.513945898703241e-07
1 O 0 4.794721064627083e-09
of O 0 1.5592588331614365e-10
the O 0 1.9229993153402347e-09
signal O 0 8.23140908323694e-07
peptide O 0 2.200172488642238e-08
was O 0 2.351359285057697e-08
observed O 0 2.9356259645396676e-09
in O 0 8.354302249991008e-10
all O 0 1.3677182719717962e-09
affected O 0 1.81315016334338e-08
individuals O 0 5.535166991421647e-09
. O 0 3.299085093999565e-08

This O 0 9.092364052776247e-07
missense O 0 0.00012930553930345923
mutation O 0 1.0097660378960427e-05
, O 0 3.453391173025011e-08
which O 0 4.606873815760082e-08
replaces O 0 9.311328540206887e-06
Ala O 0 3.917702633771114e-05
with O 0 4.1188453536733505e-08
Thr O 0 0.00028580991784110665
, O 0 7.960991865729738e-09
is O 0 1.7477841396384974e-09
frequent O 0 4.302998846128503e-08
among O 0 7.511085442502008e-08
FNDI B-Disease 1 1.0
patients O 0 5.7292531892016996e-06
and O 0 1.564714580126747e-07
is O 0 8.0006152813894e-09
thought O 0 8.83197159851079e-09
to O 0 8.964858855264879e-10
reduce O 0 9.638756459651177e-09
the O 0 7.373869292948143e-10
efficiency O 0 6.298636279211678e-09
of O 0 3.158880379494633e-10
cleavage O 0 1.388989289807796e-06
by O 0 5.224831234329486e-09
signal O 0 1.0847804787772475e-06
peptidases O 0 1.6093144949991256e-06
. O 0 2.389649900180757e-08
. O 0 9.418100432867504e-08

Genetic O 0 0.00016880639304872602
heterogeneity O 0 5.651204992318526e-05
of O 0 3.9820611164032016e-07
Saethre B-Disease 1 0.5243149995803833
- I-Disease 1 0.9999983310699463
Chotzen I-Disease 1 0.9999955892562866
syndrome I-Disease 1 0.9999998807907104
, O 0 2.3251487846209784e-08
due O 0 5.420720317061978e-09
to O 0 4.194507852162133e-09
TWIST O 0 0.0001746012712828815
and O 0 1.0513110737520037e-06
FGFR O 0 0.0002206307544838637
mutations O 0 1.1505661859700922e-05
. O 0 2.675906500826386e-07

Thirty O 0 6.367186870193109e-05
- O 0 2.783009949780535e-05
two O 0 4.092884253736884e-08
unrelated O 0 2.803531913286861e-07
patients O 0 6.388730611206483e-08
with O 0 7.744599406223074e-10
features O 0 5.660966166942671e-07
of O 0 2.5936586212083057e-08
Saethre B-Disease 1 0.9869787693023682
- I-Disease 1 0.9999995231628418
Chotzen I-Disease 1 0.9999972581863403
syndrome I-Disease 1 0.999990701675415
, O 0 2.5133073400240846e-09
a O 0 1.0304569642016759e-08
common O 0 5.684574944098131e-07
autosomal B-Disease 0 0.24612553417682648
dominant I-Disease 0 0.029966318979859352
condition I-Disease 0 4.770429586642422e-05
of O 0 5.851224216257833e-08
craniosynostosis B-Disease 1 0.9596282839775085
and O 0 0.00011370873835403472
limb B-Disease 0 0.2308279573917389
anomalies I-Disease 0 0.0012255441397428513
, O 0 2.4254857677874497e-08
were O 0 1.4228892730727694e-08
screened O 0 1.212007418871508e-07
for O 0 1.888623257784161e-09
mutations O 0 2.1514311754344817e-07
in O 0 3.92540311366929e-09
TWIST O 0 5.1946317398687825e-05
, O 0 4.7892214638523e-08
FGFR2 O 0 8.098531907307915e-06
, O 0 1.4185508767639021e-08
and O 0 7.064899421038717e-08
FGFR3 O 0 3.0837290978524834e-05
. O 0 2.533475651489425e-07

Nine O 0 2.8873853807453997e-05
novel O 0 2.0217914880049648e-06
and O 0 7.482115904622333e-08
three O 0 1.2846423480539215e-08
recurrent O 0 6.049953299225308e-05
TWIST O 0 0.009419811889529228
mutations O 0 1.960918598342687e-05
were O 0 1.275284091661888e-07
found O 0 9.861198968508234e-09
in O 0 4.484610016675106e-09
12 O 0 8.972324394562747e-08
families O 0 4.5677023052803634e-08
. O 0 1.3915068564074318e-07

Seven O 0 3.1609017696609953e-06
families O 0 2.1825225360316836e-07
were O 0 1.950606076661643e-08
found O 0 4.345505733027721e-09
to O 0 4.015081600527992e-09
have O 0 1.402548477358323e-08
the O 0 2.5754618437900945e-09
FGFR3 O 0 3.924262728105532e-06
P250R O 0 2.7288922410662053e-07
mutation O 0 6.441675992618912e-08
, O 0 2.370554863517782e-09
and O 0 3.1194726801686556e-09
one O 0 7.860713857610335e-09
individual O 0 2.0796186994687105e-09
was O 0 1.339574737357907e-06
found O 0 5.352909226985503e-09
to O 0 2.5806248249438113e-09
have O 0 4.875431613982073e-09
an O 0 9.669944844858946e-10
FGFR2 O 0 3.1577146728523076e-06
VV269 O 0 8.158189075402333e-07
- O 0 1.0670167966964073e-06
270 O 0 3.9156020648078993e-07
deletion O 0 6.294858849287266e-06
. O 0 4.3772229219030123e-07

To O 0 3.2830163831931714e-07
date O 0 1.511633769268883e-07
, O 0 3.0280502549828725e-09
our O 0 1.7325297863024502e-09
detection O 0 7.472058527469017e-09
rate O 0 1.067008703614647e-08
for O 0 3.9837050325175483e-10
TWIST O 0 6.642368589382386e-06
or O 0 5.9190671919395754e-08
FGFR O 0 1.0527514859859366e-05
mutations O 0 3.9320670452980266e-07
is O 0 8.023110176225146e-09
68 O 0 5.999791596877913e-08
% O 0 1.1038748803926524e-09
in O 0 1.3137021470654986e-09
our O 0 1.5208100023755833e-07
Saethre B-Disease 0 0.027756720781326294
- I-Disease 1 0.9999071359634399
Chotzen I-Disease 1 0.9996416568756104
syndrome I-Disease 1 0.9999525547027588
patients O 0 9.246442544963429e-08
, O 0 9.027315006626679e-10
including O 0 1.1114764664199583e-09
our O 0 9.89447102028862e-09
five O 0 2.3469322485425437e-08
patients O 0 3.254821479004022e-08
elsewhere O 0 2.255357323122098e-08
reported O 0 3.495218336979633e-08
with O 0 8.727560896204523e-09
TWIST O 0 0.0003667965065687895
mutations O 0 2.3096901713870466e-05
. O 0 2.9783421950924094e-07

More O 0 1.3159328204892518e-07
than O 0 6.597603796620888e-09
35 O 0 8.596006573213799e-09
different O 0 2.1136739025706675e-09
TWIST O 0 1.5020305909274612e-05
mutations O 0 3.3037943012459436e-06
are O 0 9.697839864486468e-09
now O 0 9.630908515134706e-09
known O 0 9.439389714316349e-09
in O 0 1.8156133263502738e-09
the O 0 4.876919756924281e-09
literature O 0 3.797585890197297e-08
. O 0 9.858889171709961e-08

The O 0 1.6674245273406996e-07
most O 0 5.918623813272461e-09
common O 0 2.6642599237902687e-09
phenotypic O 0 9.006410550682631e-08
features O 0 5.040146788815036e-07
, O 0 1.434464991234563e-08
present O 0 1.113020786647212e-09
in O 0 6.743785530005653e-10
more O 0 9.748891693917017e-10
than O 0 1.4288826788444453e-09
a O 0 9.435501269194901e-09
third O 0 3.797977399244701e-07
of O 0 3.448071606015901e-09
our O 0 1.1157211332601946e-07
patients O 0 6.9208261344044786e-09
with O 0 1.8742121188353167e-09
TWIST O 0 3.648222627816722e-05
mutations O 0 1.1178699423908256e-06
, O 0 2.3796016268562425e-09
are O 0 1.5022020294352956e-09
coronal B-Disease 0 3.478145572444191e-06
synostosis I-Disease 0 8.790229003352579e-06
, O 0 1.5271604425493024e-08
brachycephaly B-Disease 0 6.661959560005926e-06
, O 0 9.083872498649725e-08
low B-Disease 0 9.163762297248468e-05
frontal I-Disease 1 0.9999938011169434
hairline I-Disease 1 1.0
, O 0 1.2905348967251484e-06
facial B-Disease 0 0.44116461277008057
asymmetry I-Disease 0 0.0005232943804003298
, O 0 3.7613196468555543e-07
ptosis B-Disease 0 0.001208891742862761
, O 0 1.63873764336131e-07
hypertelorism B-Disease 0 6.0308761021588e-05
, O 0 1.316083455549233e-07
broad B-Disease 0 1.0634981663315557e-05
great I-Disease 0 2.493786632840056e-05
toes I-Disease 1 0.9993982315063477
, O 0 5.891516963174581e-08
and O 0 4.329160674387822e-08
clinodactyly B-Disease 0 2.0646839402616024e-05
. O 0 3.3992134262916807e-07

Significant O 0 1.5735737406430417e-06
intra O 0 5.288987267704215e-06
- O 0 3.990012191934511e-05
and O 0 7.033826676661192e-08
interfamilial O 0 4.527310466073686e-06
phenotypic O 0 3.091982307523722e-06
variability O 0 3.742899571079761e-05
is O 0 1.4144063698040554e-08
present O 0 2.1627335478058285e-09
for O 0 9.22853349294428e-10
either O 0 2.5109034851311662e-08
TWIST O 0 0.0002684812934603542
mutations O 0 3.5707696952158585e-05
or O 0 1.5258349606028787e-07
FGFR O 0 0.00014863722026348114
mutations O 0 1.9810000594588928e-05
. O 0 5.082134180156572e-07

The O 0 1.1134273592006139e-07
overlap O 0 3.301380218090344e-07
in O 0 7.997000395221221e-09
clinical O 0 5.7812354015140954e-08
features O 0 1.9675496787385782e-06
and O 0 3.972116360273503e-07
the O 0 4.860344127166627e-09
presence O 0 7.71398660504019e-08
, O 0 5.9991371870182775e-09
in O 0 2.781896657477745e-10
the O 0 3.925999803033875e-10
same O 0 1.2023427808927067e-09
genes O 0 1.0103333281108462e-08
, O 0 5.264512159541823e-10
of O 0 1.4003123660621952e-10
mutations O 0 4.991372648532888e-09
for O 0 1.506809815809973e-10
more O 0 2.0586457538662728e-10
than O 0 8.87893925050065e-10
one O 0 8.059567235818577e-09
craniosynostotic B-Disease 0 9.841134669841267e-06
condition I-Disease 0 7.550758596153173e-08
- O 0 5.203164121780901e-08
such O 0 2.2235845109630503e-10
as O 0 4.244550488863297e-09
Saethre B-Disease 0 7.790926588313596e-07
- I-Disease 0 1.2412125443006516e-06
Chotzen I-Disease 0 2.1880505300941877e-06
, I-Disease 0 2.2172670366416014e-09
Crouzon I-Disease 0 2.187725982594202e-07
, I-Disease 0 2.3212569644215364e-09
and I-Disease 0 1.6902157895515302e-08
Pfeiffer I-Disease 0 0.0412108413875103
syndromes I-Disease 0 0.003298284253105521
- O 0 3.9698852560832165e-06
support O 0 8.874761370236683e-09
the O 0 1.9247714533321414e-09
hypothesis O 0 1.9585504773544926e-08
that O 0 2.5907054279628028e-09
TWIST O 0 3.752659722522367e-06
and O 0 3.168919349150201e-08
FGFRs O 0 9.513116197013005e-07
are O 0 6.56746823590737e-10
components O 0 2.886691996550894e-09
of O 0 1.1195844945577349e-10
the O 0 4.4884673755518634e-10
same O 0 4.508527717828059e-10
molecular O 0 3.6402432179727384e-09
pathway O 0 7.902385412705826e-09
involved O 0 7.154828396416235e-10
in O 0 3.008148452554593e-10
the O 0 1.585407249926618e-09
modulation O 0 2.508194825168175e-07
of O 0 3.550009708419566e-08
craniofacial O 1 0.9480301737785339
and O 0 5.8951238315785304e-05
limb O 0 0.00039583886973559856
development O 0 4.4512042940425545e-09
in O 0 4.30733226863822e-09
humans O 0 2.9466393769439492e-08
. O 0 2.40306956555969e-08
. O 0 1.0308151132676358e-07

Mutation O 0 0.00014956461382098496
analysis O 0 3.615343075580313e-06
of O 0 4.1224222968594404e-07
UBE3A O 1 0.691430389881134
in O 0 0.0012279850197955966
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0019473953871056437
. O 0 2.1767614271084312e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9723274111747742
AS B-Disease 1 0.9999967813491821
) O 0 1.387298596000619e-07
is O 0 1.767416435427549e-08
caused O 0 2.8779085781138747e-08
by O 0 2.8770286153445568e-09
chromosome O 0 3.427927731536329e-05
15q11 O 0 6.478063369286247e-06
- O 0 1.7448712242185138e-05
q13 O 0 2.9860111681045964e-06
deletions O 0 1.2526091950348928e-06
of O 0 4.863839997426567e-09
maternal O 0 1.101595330510463e-06
origin O 0 2.8148686936901868e-08
, O 0 4.8930384188849985e-09
by O 0 4.581669266201516e-09
paternal O 0 1.7542664863867685e-05
uniparental B-Disease 0 0.00614775437861681
disomy I-Disease 0 0.019741620868444443
( O 0 3.562794063327601e-06
UPD B-Disease 1 1.0
) O 0 4.8223665061186693e-08
15 O 0 2.931134446271244e-08
, O 0 1.167896113152267e-09
by O 0 2.596057369075311e-09
imprinting O 0 0.1224021315574646
defects O 1 0.9997995495796204
, O 0 1.3959030376042847e-08
and O 0 7.495111198352333e-09
by O 0 1.380002778716971e-09
mutations O 0 1.1787646769789717e-07
in O 0 2.62394506123087e-09
the O 0 2.955916045266349e-08
UBE3A O 0 7.405970973195508e-05
gene O 0 6.109391961217625e-06
. O 0 7.178550163189357e-07

UBE3A O 0 0.002522640395909548
encodes O 0 2.2607233404414728e-05
a O 0 4.534404070000164e-07
ubiquitin O 0 1.9003373381565325e-06
- O 0 1.1549816463229945e-06
protein O 0 1.5697501964950789e-07
ligase O 0 2.610349554288405e-07
and O 0 3.999278064270584e-08
shows O 0 3.6426386031962465e-06
brain O 0 4.600135525834048e-06
- O 0 1.1360693861206528e-06
specific O 0 6.187624990161567e-08
imprinting O 0 8.709508256288245e-05
. O 0 7.892368785178405e-07

Here O 0 9.873124326986726e-06
we O 0 3.2874868338694796e-07
describe O 0 5.152678568265401e-07
UBE3A O 0 5.1546416216297075e-05
coding O 0 6.671340088360012e-05
- O 0 0.00018785276915878057
region O 0 1.9681274352478795e-06
mutations O 0 2.1906143956584856e-06
detected O 0 8.046269073247458e-08
by O 0 6.113525241602247e-10
SSCP O 0 3.063757390009414e-07
analysis O 0 5.877820896671437e-09
in O 0 3.587876218347219e-09
13 O 0 6.020908358550514e-07
AS B-Disease 1 0.9999874830245972
individuals O 0 4.948280452055087e-09
or O 0 1.2079359734684658e-08
families O 0 6.801560203939516e-08
. O 0 8.457432443265134e-08

Two O 0 4.432011792232515e-06
identical O 0 3.3963988244067878e-06
de O 0 7.925246791273821e-06
novo O 0 7.30537476556492e-06
5 O 0 1.5297251820811653e-07
- O 0 3.2497086976945866e-06
bp O 0 9.13293149551464e-07
duplications O 0 4.3057985976702184e-07
in O 0 4.95387109111789e-09
exon O 0 4.4645051389125e-07
16 O 0 3.4671725757107197e-07
were O 0 6.269476671150187e-08
found O 0 9.781923893115163e-08
. O 0 1.8794830225488113e-07

Among O 0 5.256896997707372e-07
the O 0 4.82100315224443e-09
other O 0 9.540166434618413e-10
11 O 0 6.357330217809931e-09
unique O 0 4.227027172731823e-09
mutations O 0 1.299935803444896e-07
, O 0 2.5563602346068137e-09
8 O 0 1.5254807195219655e-08
were O 0 3.3032137025656994e-09
small O 0 1.4603895870379802e-09
deletions O 0 1.8002111801251885e-07
or O 0 2.006469124182786e-08
insertions O 0 2.3715433599136304e-06
predicted O 0 4.8222932491626125e-06
to O 0 1.2440973584659787e-08
cause O 0 7.733034834700447e-08
frameshifts O 0 6.7723626671067905e-06
, O 0 7.778118593648742e-09
1 O 0 5.410091485913426e-09
was O 0 1.4076060494971898e-07
a O 0 4.031035061302646e-09
mutation O 0 1.968332519197702e-08
to O 0 8.95518548205132e-10
a O 0 3.781508883804463e-09
stop O 0 4.500327221990119e-08
codon O 0 4.575375456283837e-08
, O 0 8.094997450136532e-10
1 O 0 1.4547237858764106e-09
was O 0 1.8604222162821316e-08
a O 0 6.193597190673472e-09
missense O 0 1.454862854188832e-06
mutation O 0 5.805180336437843e-08
, O 0 3.601506426420542e-09
and O 0 1.6781889655703708e-08
1 O 0 2.045239355652484e-08
was O 0 3.937713699997403e-06
predicted O 0 4.935059223498683e-07
to O 0 2.2363497720334635e-09
cause O 0 4.2075849471245874e-09
insertion O 0 1.2852355624204392e-08
of O 0 1.0977857511917932e-09
an O 0 4.950395204872393e-09
isoleucine O 0 0.0007359258597716689
in O 0 3.111913393638588e-09
the O 0 3.3160791890196606e-09
hect O 0 2.924409159277275e-07
domain O 0 8.261654471652946e-09
of O 0 5.792586965647217e-10
the O 0 4.067651548922413e-09
UBE3A O 0 2.6392135623609647e-06
protein O 0 4.432753897276598e-08
, O 0 1.3900174344882998e-09
which O 0 3.6603137187896095e-10
functions O 0 5.93167404083772e-10
in O 0 9.690309665799646e-10
E2 O 0 1.4079981269787822e-07
binding O 0 2.0511226495045776e-08
and O 0 6.4993823656323e-09
ubiquitin O 0 1.7214522074482375e-07
transfer O 0 8.918409122316007e-08
. O 0 1.7427991849672253e-07

Eight O 0 1.8109283246303676e-06
of O 0 3.477574894716895e-09
the O 0 2.073788030187984e-09
cases O 0 6.504020877429184e-09
were O 0 1.4286353433590193e-08
familial O 0 2.066853085125331e-06
, O 0 9.40049460496084e-08
and O 0 3.339126308787854e-08
five O 0 1.8492359643573764e-08
were O 0 5.5010161759128096e-08
sporadic O 0 2.2407704818760976e-05
. O 0 6.597285278076015e-07

In O 0 2.6557358978607226e-07
two O 0 2.943426480328526e-08
familial O 0 4.4287585296842735e-06
cases O 0 1.2716492392428336e-07
and O 0 1.6881861242268315e-08
one O 0 5.085355248013457e-09
sporadic O 0 1.475710291742871e-06
case O 0 4.166490796819744e-08
, O 0 6.913662087271177e-09
mosaicism O 0 2.520712541809189e-06
for O 0 5.678265857511633e-09
UBE3A O 0 2.34374929277692e-05
mutations O 0 1.1914493143194704e-06
was O 0 6.143355903986958e-07
detected O 0 9.720825744352624e-08
in O 0 1.755260825575533e-09
the O 0 1.071442401467948e-08
mother O 0 2.009182253459585e-06
of O 0 2.244096686254693e-09
three O 0 1.720837985885737e-06
AS B-Disease 1 1.0
sons O 0 0.0010967879788950086
, O 0 4.007301157571419e-09
in O 0 1.0619526369382015e-09
the O 0 7.982766447867107e-09
maternal O 0 9.306731385549938e-07
grandfather O 0 1.77607444129535e-06
of O 0 9.506054832186805e-10
two O 0 1.165427221394566e-07
AS B-Disease 1 1.0
first O 0 6.140444952507096e-07
cousins O 0 3.3665652154013515e-05
, O 0 6.310266797981967e-08
and O 0 3.298606898738399e-08
in O 0 8.522265559918196e-09
the O 0 4.964505606608327e-08
mother O 0 7.642133823537733e-06
of O 0 1.4256675839874333e-09
an O 0 3.43565247362676e-08
AS B-Disease 1 1.0
daughter O 0 0.014178110286593437
. O 0 6.767422746634111e-07

The O 0 8.646954086088954e-08
frequencies O 0 1.1238780217581734e-07
with O 0 3.493550559952041e-09
which O 0 1.1184565273936187e-08
we O 0 3.570413298348285e-09
detected O 0 1.9920056715250212e-08
mutations O 0 2.0105222375832454e-08
were O 0 1.72254932540028e-09
5 O 0 2.4116224572878764e-09
( O 0 1.1741433381118327e-09
14 O 0 7.166987447959627e-09
% O 0 6.701088572924618e-10
) O 0 2.1312990261534992e-10
of O 0 1.880699762590865e-10
35 O 0 5.174608741498332e-09
in O 0 4.8238241179277e-10
sporadic O 0 3.1550246148981387e-07
cases O 0 5.210281983636378e-09
and O 0 8.58486526311708e-09
8 O 0 1.5062108005281516e-08
( O 0 2.045807967476776e-09
80 O 0 3.2955238538079357e-09
% O 0 7.799269563513178e-10
) O 0 3.3159003320903935e-10
of O 0 1.7258895701477428e-10
10 O 0 3.3224354378802445e-09
in O 0 1.9026664688226447e-09
familial O 0 1.4550181504091597e-06
cases O 0 4.353347193841728e-08
. O 0 2.1749130496573343e-08
. O 0 1.4746858312264521e-07

The O 0 1.6263727957266383e-05
hemochromatosis B-Disease 1 0.9999994039535522
845 O 0 0.00024796632351353765
G O 0 0.00025548459962010384
- O 0 1.5704819816164672e-05
- O 0 8.129747584462166e-06
> O 0 9.02789167867013e-08
A O 0 1.147152772773552e-08
and O 0 2.2890822570786895e-09
187 O 0 1.1465403737531688e-08
C O 0 9.466727135531983e-08
- O 0 1.028521637636004e-06
- O 0 2.754196793830488e-05
> O 0 9.004372145682282e-07
G O 0 7.815261596988421e-06
mutations O 0 2.5271677372984414e-07
: O 0 5.591181295727665e-09
prevalence O 0 5.770372695224069e-07
in O 0 6.940271912725393e-09
non O 0 7.791307155002869e-08
- O 0 4.278556298231706e-05
Caucasian O 0 2.8643889891100116e-05
populations O 0 1.466298726882087e-06
. O 0 2.412401727269753e-07

Hemochromatosis B-Disease 1 0.9947500824928284
, O 0 1.5365563740488142e-05
the O 0 3.5851462598657236e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 1.888477356715157e-07
iron I-Disease 1 0.8896445631980896
metabolism I-Disease 0 1.5290896044461988e-05
, O 0 4.9257278256220616e-09
leads O 0 3.654931646224213e-08
, O 0 2.491913342339558e-09
if O 0 5.1493640462751955e-09
untreated O 0 2.3730629550300364e-07
, O 0 1.1808248823186318e-09
to O 0 1.0173217823705727e-08
progressive O 0 4.678833192883758e-06
iron B-Disease 1 0.8413804769515991
overload I-Disease 0 0.009593844413757324
and O 0 4.084844533736032e-07
premature B-Disease 0 1.6610487136858865e-06
death I-Disease 0 2.491894292688812e-06
. O 0 3.0646168625025894e-07

The O 0 6.261515409278218e-06
hemochromatosis B-Disease 1 0.9999998807907104
gene O 0 1.1042511687264778e-05
, O 0 9.18620060019748e-08
HFE O 0 6.485235644504428e-05
, O 0 3.889452671046456e-08
recently O 0 5.713075097446563e-07
has O 0 1.608521245088923e-07
been O 0 1.878772692975872e-08
identified O 0 7.601464346862485e-08
, O 0 2.428437895218849e-09
and O 0 1.8613904861908281e-09
characterization O 0 1.5356048876924433e-08
of O 0 2.6757374094188435e-10
this O 0 6.316848155663024e-10
gene O 0 7.643219390729428e-08
has O 0 2.4953997126431204e-05
shown O 0 1.6192426244288072e-07
that O 0 4.6225273608868633e-10
it O 0 4.216452187399966e-10
contains O 0 6.290576948231319e-10
two O 0 4.896605343418514e-09
mutations O 0 1.968945042563064e-07
that O 0 4.120682017827448e-09
result O 0 5.10042141854683e-09
in O 0 1.843783015154088e-09
amino O 0 1.373140268157158e-08
acid O 0 1.3028929934932876e-08
substitutions O 0 1.7743539970638267e-08
- O 0 3.641106260943161e-08
cDNA O 0 2.322195484794065e-07
nucleotides O 0 1.8406115032121306e-07
845 O 0 3.4615990784914175e-07
G O 0 1.985180006158771e-06
- O 0 1.3715116438106634e-06
- O 0 2.976526729980833e-06
> O 0 6.293739573948187e-08
A O 0 3.1185876991912664e-08
( O 0 4.826864241636031e-09
C282Y O 0 8.114034244499635e-08
) O 0 1.3835897982872325e-09
and O 0 7.957860481688783e-10
187 O 0 1.4456245089888853e-08
C O 0 1.6718956885597436e-07
- O 0 3.6170849853078835e-06
- O 0 5.7854107581079006e-05
> O 0 1.590952251717681e-06
G O 0 1.2838831025874242e-05
( O 0 3.8339610597404317e-08
H63D O 0 7.287241714948323e-06
) O 0 6.265830876373002e-08
. O 0 2.061265291786185e-07

Although O 0 0.00016591738676652312
hemochromatosis B-Disease 1 1.0
is O 0 1.0690767737742135e-07
common O 0 1.947732286566861e-08
in O 0 5.422022830714468e-09
Caucasians O 0 9.752635605764226e-07
, O 0 5.19561416112424e-09
affecting O 0 2.4463375325467496e-08
> O 0 3.775629764390942e-08
= O 0 8.926476624537827e-08
1 O 0 8.801566586669196e-09
/ O 0 3.225746354473813e-07
300 O 0 3.852710594998143e-09
individuals O 0 1.2796913528845266e-10
of O 0 6.502103022665295e-11
northern O 0 6.421579712423409e-09
European O 0 6.530248786162929e-09
origin O 0 4.0068730555731236e-09
, O 0 7.799764389915254e-09
it O 0 2.0238266174033015e-08
has O 0 2.6950786491397594e-07
not O 0 8.0331394869404e-09
been O 0 1.1965964219484704e-08
recognized O 0 1.5017894705593449e-09
in O 0 6.776277872155845e-10
other O 0 1.9553545449468857e-09
populations O 0 1.1993662951681472e-07
. O 0 1.3141546162387385e-07

The O 0 2.324683805454697e-07
present O 0 8.695426600979772e-09
study O 0 1.6832018001622373e-09
used O 0 3.342144783147205e-09
PCR O 0 7.670228114875499e-07
and O 0 2.891022976569957e-09
restriction O 0 9.37697830494244e-09
- O 0 6.506579097731446e-08
enzyme O 0 9.33160659855048e-09
digestion O 0 1.3423603562046083e-08
to O 0 6.272772856696918e-10
analyze O 0 6.661637907967588e-09
the O 0 1.044557773610677e-09
frequency O 0 1.595485521477258e-08
of O 0 3.2351854528656077e-10
the O 0 1.421529449707748e-09
845 O 0 1.147072339335864e-07
G O 0 3.527806939018774e-06
- O 0 1.2677249969783588e-06
- O 0 1.3141573163011344e-06
> O 0 2.7091145327062804e-08
A O 0 5.551523685198845e-09
and O 0 1.901788504454771e-09
187 O 0 8.52415205088164e-09
C O 0 5.424146110044603e-08
- O 0 1.9085725000422826e-07
- O 0 1.7785202999220928e-06
> O 0 1.2852727593326563e-07
G O 0 9.358413990412373e-07
mutations O 0 5.6009188398320475e-08
in O 0 1.5667753761050562e-09
HLA O 0 1.2533261042335653e-06
- O 0 3.921944369267294e-07
typed O 0 4.357626153250749e-07
samples O 0 1.610608180158124e-08
from O 0 9.099228037712237e-10
non O 0 5.251317158894153e-09
- O 0 1.0248861599393422e-06
Caucasian O 0 2.696829142223578e-06
populations O 0 2.9468079532080083e-08
, O 0 1.1123714172001087e-09
comprising O 0 1.2674201688156472e-09
Australian O 0 6.449222045290526e-09
Aboriginal O 0 2.5256877478341266e-08
, O 0 1.7558435816411588e-09
Chinese O 0 1.118319437054538e-09
, O 0 1.3181221669711363e-09
and O 0 1.2237258317782107e-08
Pacific O 0 1.0670681405144933e-07
Islanders O 0 2.542315087339375e-06
. O 0 4.959688340022694e-07

Results O 0 6.488347571576014e-05
showed O 0 3.195478711859323e-06
that O 0 5.631398680705502e-10
the O 0 8.834460385465093e-10
845 O 0 2.0381155252380267e-07
G O 0 3.600406898840447e-06
- O 0 2.1781111172458623e-06
- O 0 2.4539137939427746e-06
> O 0 4.2722412274542876e-08
A O 0 1.2099444113289337e-08
mutation O 0 1.5126447294733225e-07
was O 0 7.940613500068139e-08
present O 0 9.031724812480491e-10
in O 0 3.6787353718814586e-10
these O 0 3.9487096925583387e-10
populations O 0 4.099124595313697e-09
( O 0 6.948082664770538e-10
allele O 0 9.747874507581855e-09
frequency O 0 4.485482207883251e-09
0 O 0 2.1832287089296187e-09
. O 0 6.304125554912332e-10
32 O 0 1.5409828080237276e-08
% O 0 1.1733485294485035e-09
) O 0 4.3696732343612155e-10
, O 0 1.1817801182090193e-09
and O 0 2.9505311971433912e-08
, O 0 2.4162034595320847e-09
furthermore O 0 1.0130946748176939e-08
, O 0 1.0330899691268769e-08
it O 0 1.482616625025912e-07
was O 0 0.0003784473810810596
always O 0 1.827913536089909e-07
seen O 0 1.942727045900483e-08
in O 0 2.4416546562378016e-10
conjunction O 0 1.6323208340551787e-09
with O 0 3.14343551188756e-09
HLA O 0 1.9412515030126087e-05
haplotypes O 0 1.467823608436447e-06
common O 0 9.872113793107928e-09
in O 0 3.6383622781244185e-09
Caucasians O 0 3.6709732853523747e-07
, O 0 8.868090151104013e-10
suggesting O 0 4.2222163543215174e-09
that O 0 7.375430821632278e-10
845 O 0 7.711456362358149e-08
G O 0 1.069659560926084e-06
- O 0 1.0580449725239305e-06
- O 0 6.960012797208037e-06
> O 0 5.052486073964246e-08
A O 0 9.033799841517975e-08
may O 0 1.7700078558391397e-07
have O 0 4.738978098828284e-09
been O 0 2.6410165165913213e-09
introduced O 0 2.7731410501274922e-09
into O 0 1.7518225758905714e-09
these O 0 4.774222128745009e-10
populations O 0 4.909726403212744e-09
by O 0 1.9876058576784317e-09
Caucasian O 0 4.548264314507833e-06
admixture O 0 6.212225798662985e-06
. O 0 5.369343512029445e-07

187 O 0 1.431683176633669e-05
C O 0 5.816245902678929e-06
- O 0 3.606345217121998e-06
- O 0 1.0042708709079307e-05
> O 0 5.887713996344246e-07
G O 0 1.907645128085278e-05
was O 0 1.7843973409981118e-07
present O 0 2.06843941974455e-09
at O 0 1.4628764866131405e-09
an O 0 3.9135442109206053e-10
allele O 0 3.5313366453237904e-08
frequency O 0 5.897948085475946e-08
of O 0 5.24632115528334e-09
2 O 0 2.84160961427915e-07
. O 0 3.2365099400522013e-07

68 O 0 0.00011853814066853374
% O 0 2.633596523082815e-07
in O 0 2.4617075045085812e-09
the O 0 1.1861973625570954e-09
two O 0 4.368758244055471e-09
populations O 0 5.0613980562275174e-08
analyzed O 0 1.4777972978663456e-07
( O 0 9.376281084882976e-09
Australian O 0 2.2210350891782582e-08
Aboriginal O 0 1.418819266518767e-07
and O 0 6.371074334765581e-08
Chinese O 0 1.7030890475666638e-08
) O 0 2.836859636090594e-08
. O 0 6.876538805045129e-08

In O 0 7.965086297190282e-07
the O 0 3.5672158560373646e-08
Australian O 0 5.9420301568025025e-08
Aboriginal O 0 3.009804316889131e-08
samples O 0 6.109659000941292e-09
, O 0 7.302097815298225e-10
187 O 0 9.347514762225728e-09
C O 0 4.734472724976513e-08
- O 0 4.2273518374713603e-07
- O 0 3.9550413930555806e-06
> O 0 1.5859244228977332e-07
G O 0 7.397270110232057e-06
was O 0 1.950705268427555e-07
found O 0 2.153677458593961e-09
to O 0 1.0757603696731621e-09
be O 0 7.572385496423806e-10
associated O 0 2.4966946288174086e-09
with O 0 5.78587666666408e-09
HLA O 0 3.7085064832353964e-05
haplotypes O 0 2.3610948574059876e-06
common O 0 1.3427751355266082e-08
in O 0 4.67859795350023e-09
Caucasians O 0 5.973768679723435e-07
, O 0 3.8264782453723e-09
suggesting O 0 4.759552751920637e-08
that O 0 7.74690800398048e-09
it O 0 1.001077976070519e-08
was O 0 4.716212487210214e-08
introduced O 0 5.004662018137651e-09
by O 0 1.6192196472530895e-09
recent O 0 2.755216854666287e-08
admixture O 0 4.641466148314066e-06
. O 0 4.7254778223759786e-07

In O 0 4.67961797312455e-07
the O 0 1.0991670684745714e-08
Chinese O 0 6.260250096090658e-09
samples O 0 7.353115005770405e-09
analyzed O 0 1.6226458399160038e-08
, O 0 1.1190320892140448e-09
187 O 0 1.2918368597070184e-08
C O 0 4.560381228202459e-08
- O 0 1.4590797547953116e-07
- O 0 1.7096949704864528e-06
> O 0 3.2878728006835445e-07
G O 0 2.504461372154765e-05
was O 0 7.767253578094824e-07
present O 0 2.654126030066095e-09
in O 0 1.6579597694743597e-09
association O 0 3.266273085333893e-10
with O 0 2.6705215816491545e-10
a O 0 3.2298479446524198e-09
wide O 0 3.4026864881298025e-08
variety O 0 4.309477219521796e-09
of O 0 2.8976585575435365e-09
HLA O 0 7.869424734963104e-06
haplotypes O 0 1.4887957604514668e-06
, O 0 8.749361235516062e-09
showing O 0 5.2344397261094855e-08
this O 0 2.235278490081427e-10
mutation O 0 4.843851986180425e-09
to O 0 8.002031259835007e-10
be O 0 1.3750737215545428e-09
widespread O 0 3.938587234131319e-09
and O 0 3.957867633630485e-08
likely O 0 4.5387650970951654e-08
to O 0 2.119616482332276e-09
predate O 0 1.6763884502779547e-07
the O 0 1.0685294871137785e-09
more O 0 1.9770936277030415e-10
genetically O 0 6.31293683994727e-09
restricted O 0 4.515612772593158e-09
845 O 0 2.3682113692302664e-07
G O 0 8.657911166665144e-06
- O 0 7.140095476643182e-06
- O 0 9.46062027651351e-06
> O 0 1.962271625188805e-07
A O 0 8.88852156322173e-08
mutation O 0 1.0680683999453322e-06
. O 0 2.0094914532364783e-07

Genotype O 0 0.11721029877662659
- O 0 0.013213248923420906
phenotype O 0 0.0013214803766459227
correlations O 0 0.0002367740380577743
in O 0 5.119506113260286e-06
attenuated B-Disease 1 0.9995558857917786
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999992847442627
coli I-Disease 1 0.9999998807907104
. O 0 5.383768439060077e-05

Germ O 0 0.009701657108962536
- O 0 0.4227360188961029
line O 0 0.00018374934734310955
mutations O 0 8.863834750627575e-07
of O 0 2.007057631203679e-09
the O 0 2.399080578641133e-08
tumor B-Disease 0 1.4994143384683412e-05
suppressor O 0 9.956031863112003e-05
APC O 0 4.092356903129257e-06
are O 0 2.1788991944049485e-08
implicated O 0 2.8956383175682276e-06
in O 0 1.4937504602130502e-06
attenuated B-Disease 1 0.9998834133148193
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 1.0
( O 0 0.00046943427878431976
AAPC B-Disease 1 1.0
) O 0 2.943289700851892e-07
, O 0 8.175704557800145e-09
a O 0 3.996022357455331e-08
variant O 0 0.0002297690080013126
of O 0 1.1819534847745672e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.00017447462596464902
FAP B-Disease 0 0.0008016071515157819
) O 0 2.541054527682718e-06
. O 0 1.1205852388229687e-06

AAPC B-Disease 1 0.9999998807907104
is O 0 5.232540843280731e-06
recognized O 0 6.74694362601258e-08
by O 0 1.5242030970696874e-09
the O 0 8.344794300008118e-10
occurrence O 0 2.371985274862709e-08
of O 0 1.9144463792031274e-09
< O 0 2.872014590593608e-07
100 O 0 2.2807244093314694e-08
colonic B-Disease 0 3.974188075517304e-06
adenomas I-Disease 0 2.7564881747821346e-05
and O 0 2.804611298756754e-08
a O 0 1.3044943791840069e-08
later O 0 7.948309530547704e-07
onset O 0 6.514088454423472e-05
of O 0 3.243225728510879e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 7.732842988161792e-08
age O 0 3.6899336919304915e-08
> O 0 8.675235818600413e-08
40 O 0 2.948505972710791e-08
years O 0 2.1679467110402584e-08
) O 0 1.609932454016416e-08
. O 0 9.687232704891358e-08

The O 0 2.913205605636904e-07
aim O 0 2.2383103726042464e-07
of O 0 1.1924128351381569e-09
this O 0 6.475003311301464e-10
study O 0 1.7682078023995018e-09
was O 0 3.966188089066236e-08
to O 0 2.42245157267007e-09
assess O 0 3.676501876270777e-07
genotype O 0 3.283915066276677e-05
- O 0 0.0001819088211050257
phenotype O 0 7.166844443418086e-05
correlations O 0 1.9360195437911898e-05
in O 0 8.069104637797864e-07
AAPC B-Disease 1 1.0
families O 0 3.6198628095007734e-06
. O 0 6.739760465279687e-07

By O 0 4.90482420900662e-07
protein O 0 2.6252887437294703e-06
- O 0 2.9727084438491147e-06
truncation O 0 9.590137779014185e-06
test O 0 2.0790493238109775e-07
( O 0 2.5638570377850556e-08
PTT O 0 1.2581723751736718e-07
) O 0 1.7476309288610992e-09
assay O 0 2.4400371501087648e-08
, O 0 1.2574539187681921e-09
the O 0 4.555369137460019e-10
entire O 0 1.133264770913911e-08
coding O 0 9.994200809160247e-07
region O 0 5.4048957309760226e-08
of O 0 4.5391501668490264e-10
the O 0 2.4154018785083053e-09
APC B-Disease 0 1.3401530907231063e-07
gene O 0 8.646657789768142e-08
was O 0 1.2206531891933992e-06
screened O 0 2.0510373133220128e-07
in O 0 5.075325937298203e-09
affected O 0 1.9143815421784893e-08
individuals O 0 1.2758315515171148e-09
from O 0 3.736726039704763e-09
11 O 0 5.166219239072234e-07
AAPC B-Disease 1 0.9999997615814209
kindreds O 0 0.00017588838818483055
, O 0 3.8224463594360714e-08
and O 0 3.3122105058680518e-09
their O 0 2.0879851181376807e-09
phenotypic O 0 5.348094873625087e-07
differences O 0 1.1191339126526145e-06
were O 0 4.6078889681666624e-07
examined O 0 1.4507368177874014e-06
. O 0 2.653621891113289e-07

Five O 0 5.703489023289876e-06
novel O 0 2.557747848186409e-06
germ O 0 0.0001857781026046723
- O 0 0.0008583148592151701
line O 0 0.00018866680329665542
APC B-Disease 0 3.306807229819242e-06
mutations O 0 8.888103479876008e-07
were O 0 1.2772077617739797e-08
identified O 0 3.391729208601646e-08
in O 0 6.793220652667742e-09
seven O 0 1.2822903272535768e-07
kindreds O 0 4.9762682465370744e-05
. O 0 1.9115545057957206e-07

Mutations O 0 0.0004410996043588966
were O 0 5.699502594325168e-07
located O 0 1.6536400693212272e-08
in O 0 1.9352555113982817e-09
three O 0 6.7136549652957456e-09
different O 0 3.258049385834738e-09
regions O 0 1.011337857903527e-08
of O 0 5.256615698279177e-10
the O 0 5.074987097231087e-09
APC B-Disease 0 1.0961966268041579e-07
gene O 0 3.301514794884497e-08
( O 0 1.3962405676082312e-09
1 O 0 1.9492552016942e-09
) O 0 1.104418223540904e-09
at O 0 1.4152853333726512e-09
the O 0 1.1307920155800844e-09
5 O 0 2.089456252463151e-08
end O 0 2.0670726996740996e-07
spanning O 0 2.3450311914530175e-07
exons O 0 7.850630936445668e-07
4 O 0 9.460355698820422e-08
and O 0 7.351210484785042e-08
5 O 0 1.8002587864884845e-08
, O 0 2.610003768666047e-09
( O 0 8.746537383252928e-10
2 O 0 1.1750777018093572e-09
) O 0 2.1321445997646293e-10
within O 0 2.4132731923920403e-10
exon O 0 3.118867297757788e-08
9 O 0 2.8044357236467476e-07
, O 0 8.771250392669572e-09
and O 0 1.1345646200311421e-08
( O 0 1.0212639622864117e-09
3 O 0 4.753181404026918e-09
) O 0 1.3436917134512782e-09
at O 0 2.250096997613582e-09
the O 0 2.8519184791520047e-09
3 O 0 4.233588768443042e-08
distal O 0 2.7710939320968464e-06
end O 0 1.6702651919331402e-06
of O 0 1.3059973102969025e-09
the O 0 8.73352234975755e-09
gene O 0 7.693810744058283e-07
. O 0 2.981683735470142e-07

Variability O 0 0.0002384178078500554
in O 0 7.928960599201673e-08
the O 0 5.094199284627621e-09
number O 0 4.162518862926845e-08
of O 0 2.7757519092119765e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.13871486485004425
most O 0 9.86360682020404e-09
apparent O 0 6.800729579481413e-08
in O 0 2.450473823856214e-09
individuals O 0 5.702520677886014e-10
with O 0 8.981219656867268e-10
mutations O 0 3.64772404282121e-07
in O 0 3.763412692592283e-09
region O 0 2.4540608478673676e-07
1 O 0 9.342099360765133e-08
, O 0 4.1185938215448914e-08
and O 0 4.634078720755497e-07
upper O 0 2.2044117940822616e-05
- O 0 0.2857353687286377
gastrointestinal O 0 7.064263627398759e-05
manifestations O 0 4.1657446558929223e-07
were O 0 3.019544791982298e-08
more O 0 1.6572135885795092e-09
severe O 0 6.635339104832383e-07
in O 0 8.066857404287475e-09
them O 0 3.455302177712838e-08
. O 0 2.027571213147894e-07

In O 0 2.851317049135105e-07
individuals O 0 1.0097900293715156e-08
with O 0 2.624365613712598e-09
mutations O 0 2.768862259472371e-07
in O 0 5.281642678767184e-09
either O 0 2.3023858375381678e-08
region O 0 2.669562206847331e-07
2 O 0 2.0547415147120773e-07
or O 0 5.513789957944937e-08
region O 0 6.8277898890301e-08
3 O 0 8.388911965084844e-08
, O 0 2.202127813433208e-09
the O 0 8.98224772338807e-10
average O 0 8.982372179389131e-09
number O 0 5.670502956078849e-10
of O 0 3.627619871160448e-10
adenomas B-Disease 0 1.3026005944993813e-06
tended O 0 1.3305703987498418e-06
to O 0 6.9533889757167344e-09
be O 0 4.2925121235271035e-09
lower O 0 9.944457701749343e-09
than O 0 7.157872072838245e-10
those O 0 2.033176127458347e-10
in O 0 2.1548884898692222e-10
individuals O 0 2.0580215309706773e-10
with O 0 4.6558243371741526e-10
mutations O 0 6.459516299628376e-08
in O 0 1.0703653519072986e-09
region O 0 5.0279528096552895e-08
1 O 0 1.3852144320480875e-08
, O 0 4.765345895663131e-09
although O 0 4.040333401178486e-09
age O 0 9.632544539783794e-09
at O 0 1.1607570016280988e-08
diagnosis O 0 3.301287051726831e-06
was O 0 2.259372990920383e-07
similar O 0 3.8157665471771907e-08
. O 0 1.527478730167786e-07

In O 0 4.278147571312729e-06
all O 0 6.386123914126074e-07
AAPC B-Disease 1 0.9999991655349731
kindreds O 0 0.00045110072824172676
, O 0 2.5618431820362275e-08
a O 0 2.0041360571099176e-08
predominance O 0 6.160755674500251e-06
of O 0 8.928246586492605e-08
right O 0 0.08938770741224289
- O 1 0.9999995231628418
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.000192149993381463
rectal B-Disease 1 0.9970307350158691
polyp I-Disease 0 0.002368267858400941
sparing O 0 5.195981884753564e-06
was O 0 1.360073042633303e-06
observed O 0 8.7378060698029e-07
. O 0 2.3222685285873013e-07

No O 0 4.3217118218308315e-05
desmoid B-Disease 0 0.4497523009777069
tumors I-Disease 1 1.0
were O 0 1.0165186949961935e-06
found O 0 1.578914066158177e-08
in O 0 4.9787272082824074e-09
these O 0 3.0357778513234734e-08
kindreds O 0 7.51597763155587e-05
. O 0 3.7128859275981085e-07

Our O 0 1.7169858210763778e-06
data O 0 9.805124534523202e-08
suggest O 0 3.2327275079069295e-08
that O 0 1.7332040247453051e-09
, O 0 2.0042458803715135e-09
in O 0 3.4316052222038707e-08
AAPC B-Disease 1 1.0
families O 0 5.898077688470948e-07
, O 0 1.156008400116093e-09
the O 0 1.2728072762424603e-10
location O 0 1.7811252916999365e-08
of O 0 5.425113136503512e-10
the O 0 3.5471263259978514e-08
APC B-Disease 0 1.8396674931864254e-05
mutation O 0 2.614953928059549e-06
may O 0 1.7603670698917995e-07
partially O 0 4.4195422788106953e-07
predict O 0 7.620060671342799e-08
specific O 0 1.1694326396138877e-08
phenotypic O 0 2.7491385026223725e-06
expression O 0 2.225260004706797e-06
. O 0 6.296332912825164e-07

This O 0 3.537984980539477e-07
should O 0 2.8803905038898847e-08
help O 0 4.050966673219136e-09
in O 0 7.774614285693815e-10
the O 0 9.31557941896699e-10
design O 0 1.3850221591837908e-07
of O 0 1.86662041379293e-09
tailored O 0 5.677787157765124e-06
clinical O 0 3.3720272085702163e-07
- O 0 5.2517829317366704e-05
management O 0 2.25636416217867e-08
protocols O 0 1.6251703982561594e-08
in O 0 5.134767611103541e-10
this O 0 3.0121502514468546e-10
subset O 0 1.4697124406382045e-08
of O 0 7.231773846427814e-09
FAP B-Disease 0 8.167622581822798e-06
patients O 0 3.5046954849349277e-07
. O 0 2.497948692337104e-08
. O 0 1.5905578720776248e-07

Wilms B-Disease 0 0.037785615772008896
' I-Disease 0 0.0004178921808488667
tumor I-Disease 0 3.9410100725945085e-05
1 O 0 3.857665547002398e-07
and O 0 7.653883216107715e-08
Dax O 0 0.4029577672481537
- O 0 1.579035961185582e-05
1 O 0 3.35808927331982e-08
modulate O 0 2.945881760751945e-07
the O 0 6.369200722389223e-09
orphan O 0 8.349258564521733e-07
nuclear O 0 6.674485319990708e-08
receptor O 0 1.2717582364984992e-07
SF O 0 3.20335166179575e-05
- O 0 1.6538284626221866e-06
1 O 0 1.5546220311080106e-08
in O 0 1.2289975703794198e-09
sex O 0 3.119641078797031e-08
- O 0 1.3963789058379916e-07
specific O 0 2.488124550836801e-08
gene O 0 9.461751346862002e-07
expression O 0 1.0985257858919795e-06
. O 0 3.663027996481105e-07

Products O 0 5.967976903775707e-06
of O 0 1.0373870651392281e-07
steroidogenic O 0 1.9220658941776492e-05
factor O 0 3.492417022243899e-07
1 O 0 1.284736015350063e-07
( O 0 4.6761289951291474e-08
SF O 0 0.002289459342136979
- O 0 0.0001525419793324545
1 O 0 1.9590592614804336e-07
) O 0 1.9199251966028896e-08
and O 0 7.40163557111373e-08
Wilms B-Disease 0 0.0001511892187409103
tumor I-Disease 0 1.7173333617392927e-05
1 O 0 7.423464865041751e-08
( O 0 2.6328448754497913e-08
WT1 O 0 7.1353847488353495e-06
) O 0 1.4532270498079924e-08
genes O 0 3.95089863047815e-08
are O 0 1.024420548390026e-09
essential O 0 2.183482727957653e-09
for O 0 6.973959743028502e-10
mammalian O 0 1.3024573775055615e-07
gonadogenesis O 0 1.2297975899855373e-06
prior O 0 8.35511926311483e-09
to O 0 3.792770097987841e-09
sexual O 0 1.1314823211705516e-07
differentiation O 0 9.975271950679598e-07
. O 0 2.908222427322471e-07

In O 0 3.544448929915234e-07
males O 0 3.358015874255216e-07
, O 0 2.2504458740968403e-08
SF O 0 0.001295111607760191
- O 0 1.799439633032307e-05
1 O 0 2.594187975546447e-08
participates O 0 5.046531192931525e-09
in O 0 4.466697844929257e-10
sexual O 0 5.2975028808077695e-09
development O 0 2.586946490357178e-10
by O 0 2.247723951409597e-10
regulating O 0 1.633878987661319e-08
expression O 0 1.4634241374267276e-08
of O 0 6.660897389210163e-10
the O 0 1.6558525217647002e-08
polypeptide O 0 8.342688488482963e-06
hormone O 0 1.7255742932320572e-06
Mullerian O 0 2.983700869663153e-05
inhibiting O 0 3.821495283773402e-06
substance O 0 1.0668406957847765e-06
( O 0 2.604230360248039e-07
MIS O 0 0.0007800177554599941
) O 0 3.109572048742848e-07
. O 0 2.808533281495329e-07

Here O 0 7.36348602004e-06
, O 0 9.689098590115464e-08
we O 0 2.4122263297954305e-08
show O 0 2.117161557180225e-07
that O 0 1.3108369500969275e-08
WT1 O 0 0.00010494710295461118
- O 0 9.123088966589421e-05
KTS O 0 0.0001362627517664805
isoforms O 0 6.251929676182044e-07
associate O 0 9.611918727614466e-08
and O 0 1.1465555616041456e-08
synergize O 0 3.0967510156187927e-06
with O 0 7.920601774458191e-08
SF O 0 0.13705486059188843
- O 0 5.1887898735003546e-05
1 O 0 1.1964884549797716e-07
to O 0 2.4635454565213877e-08
promote O 0 8.406183837905701e-07
MIS O 0 0.053666505962610245
expression O 0 2.7354581106919795e-06
. O 0 5.558518978432403e-07

In O 0 2.144645577573101e-06
contrast O 0 3.830266905424651e-06
, O 0 1.6553686066345108e-07
WT1 O 0 0.0001684491289779544
missense O 0 0.00025440295576117933
mutations O 0 1.8452761651133187e-05
, O 0 1.077354383482998e-08
associated O 0 2.680081401251755e-08
with O 0 3.6321306851050394e-08
male B-Disease 0 7.904534868430346e-05
pseudohermaphroditism I-Disease 1 1.0
in O 0 2.446021198920789e-06
Denys B-Disease 1 0.9999964237213135
- I-Disease 1 0.9999997615814209
Drash I-Disease 1 0.9999926090240479
syndrome I-Disease 1 0.9999995231628418
, O 0 7.38829228907889e-08
fail O 0 1.85471520808278e-07
to O 0 3.78539821710433e-09
synergize O 0 8.226659701904282e-06
with O 0 2.065988695676424e-07
SF O 1 0.8809728026390076
- O 0 0.000986228114925325
1 O 0 5.73619047372631e-07
. O 0 2.782648493848683e-07

Additionally O 0 1.456610334571451e-05
, O 0 7.914863431324193e-08
the O 0 8.370719228878443e-09
X O 0 0.0006604515365324914
- O 0 0.015851914882659912
linked O 0 2.4554994524805807e-05
, O 0 1.1745449945976816e-08
candidate O 0 4.421438504209618e-08
dosage O 0 2.523911462049e-07
- O 0 4.2158416135862353e-07
sensitive O 0 1.4385081215095852e-07
sex O 0 1.1679796330099634e-07
- O 0 4.1574381270947924e-07
reversal O 0 1.2081783040684968e-07
gene O 0 4.129070774183674e-08
, O 0 5.3869029237318955e-09
Dax O 0 0.0008248982485383749
- O 0 1.3841284953741706e-06
1 O 0 1.9649002425126127e-08
, O 0 2.8283810848961366e-09
antagonizes O 0 6.444920472858939e-07
synergy O 0 2.0073770201634034e-07
between O 0 3.415150473529138e-08
SF O 0 0.000904719578102231
- O 0 1.0442382517794613e-05
1 O 0 4.8924164275376825e-08
and O 0 3.7890483639557715e-08
WT1 O 0 2.883336946979398e-06
, O 0 8.545379515112472e-09
most O 0 1.0774154901582733e-09
likely O 0 3.672525616948974e-09
through O 0 2.7498800458936046e-10
a O 0 7.503403454123259e-10
direct O 0 1.251930559220682e-09
interaction O 0 5.8416533832428286e-09
with O 0 2.0630032793178543e-08
SF O 1 0.9649848937988281
- O 0 0.000998970470391214
1 O 0 5.635707793771871e-07
. O 0 1.4494352740257455e-07

We O 0 2.5090564577112673e-06
propose O 0 7.119209044503805e-07
that O 0 1.1771779107050406e-08
WT1 O 0 8.4734683696297e-06
and O 0 3.837832025510579e-07
Dax O 1 0.8395183086395264
- O 0 1.3723510164709296e-05
1 O 0 2.921991359983167e-08
functionally O 0 8.343990742787355e-08
oppose O 0 6.98402624621508e-09
each O 0 7.834366488879141e-10
other O 0 3.4593605757748946e-10
in O 0 4.612480619670123e-09
testis O 0 9.102184890252829e-07
development O 0 2.2595585402740426e-09
by O 0 2.5066384523597662e-09
modulating O 0 1.4010398672326119e-06
SF O 0 0.09836864471435547
- O 0 4.522455492406152e-05
1 O 0 2.7182767325939494e-07
- O 0 1.3315858268470038e-05
mediated O 0 1.3402875083556864e-05
transactivation O 0 3.236598058720119e-05
. O 0 7.616427666334857e-08
. O 0 1.6703370420145802e-07

A O 0 4.339737188274739e-06
mouse O 0 4.1212399082724005e-05
model O 0 2.131811015715357e-06
for O 0 1.0431982673253515e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 0 0.004669331479817629
- O 0 0.01091363001614809
centre O 0 4.629604518413544e-05
mutations O 0 8.32888763397932e-05
. O 0 1.3087618526697042e-06

Imprinting O 0 0.0002219496527686715
in O 0 4.938006554766616e-07
the O 0 7.483143349418242e-08
15q11 O 0 4.691827143687988e-06
- O 0 1.7795768144424073e-05
q13 O 0 2.579455895102001e-06
region O 0 6.461696955284424e-08
involves O 0 6.1786598060109554e-09
an O 0 1.0820243590003997e-09
imprinting O 0 6.1014438870188314e-06
centre O 0 3.42842076861416e-06
( O 0 4.077371329458401e-08
IC O 0 5.651730248246167e-07
) O 0 3.365409950717435e-09
, O 0 4.6381418150609477e-10
mapping O 0 5.0198075030039035e-08
in O 0 2.329924475574785e-09
part O 0 6.4971512614420135e-09
to O 0 7.527747314384214e-09
the O 0 3.783153346148538e-09
promoter O 0 3.6103883758187294e-06
and O 0 4.8729333457231405e-08
first O 0 1.8007909829975688e-08
exon O 0 1.2771611181960907e-06
of O 0 7.531843948527239e-08
SNRPN O 0 0.0003741223190445453
. O 0 1.017907834466314e-06

Deletion O 0 6.033844329067506e-05
of O 0 6.11683148576958e-08
this O 0 2.297139722884367e-08
IC O 0 3.2406471746071475e-06
abolishes O 0 3.289188043709146e-06
local O 0 5.7298709776887335e-08
paternally O 0 1.536821287118073e-06
derived O 0 2.9800657941336794e-08
gene O 0 1.195163292777579e-07
expression O 0 9.22016667459502e-08
and O 0 1.800571070020851e-08
results O 0 1.3472175908191275e-07
in O 0 6.7406285779725295e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.808473800541833e-05
PWS B-Disease 1 0.9999998807907104
) O 0 2.049564272965654e-06
. O 0 1.0343064786866307e-06

We O 0 5.419629360403633e-06
have O 0 1.2701529605863016e-08
created O 0 8.085342173558274e-09
two O 0 4.038777312587172e-09
deletion O 0 1.989197699003853e-06
mutations O 0 8.9276829839946e-07
in O 0 8.970046039280533e-09
mice O 0 3.63240615115501e-05
to O 0 6.91263551289012e-07
understand O 0 8.041641194722615e-06
PWS B-Disease 1 1.0
and O 0 3.135563133582764e-07
the O 0 2.3772288582080137e-09
mechanism O 0 2.4044402024969713e-08
of O 0 1.5219865368010232e-09
this O 0 1.8092189080221033e-08
IC O 0 4.557408828986809e-06
. O 0 2.2749054551240988e-07

Mice O 0 0.05334711819887161
harbouring O 0 0.00012258351489435881
an O 0 8.888148528285456e-08
intragenic O 0 1.0623141861287877e-05
deletion O 0 4.598863142746268e-06
in O 0 3.501444112430363e-08
Snrpn O 0 2.2990147044765763e-05
are O 0 2.8434847365588212e-08
phenotypically O 0 2.862699830075144e-06
normal O 0 8.493368852668937e-08
, O 0 2.9168334414464425e-09
suggesting O 0 3.093168388090817e-08
that O 0 1.1386288578663084e-09
mutations O 0 3.911883794671667e-08
of O 0 6.596681534354332e-10
SNRPN O 0 1.4525486221828032e-05
are O 0 2.098193174759899e-09
not O 0 8.442725962787279e-10
sufficient O 0 3.7115874818027805e-09
to O 0 2.16076792014519e-08
induce O 0 2.3760532712913118e-05
PWS B-Disease 1 0.9999998807907104
. O 0 1.7819344293457107e-06

Mice O 0 0.0012337261578068137
with O 0 2.6455353463461506e-08
a O 0 8.11704836678473e-09
larger O 0 6.624108372932369e-09
deletion O 0 2.6560752530713216e-07
involving O 0 1.09026183636729e-08
both O 0 1.0347820378342476e-08
Snrpn O 0 2.656507058418356e-05
and O 0 3.5397661690694804e-08
the O 0 1.938740368245817e-08
putative O 0 0.00027826911536976695
PWS O 1 1.0
- O 1 0.8207125663757324
IC O 0 6.426399340853095e-05
lack O 0 6.237677752096715e-08
expression O 0 2.4914584173529875e-08
of O 0 8.785495109187025e-10
the O 0 6.783497319418075e-09
imprinted O 0 1.5252590856107417e-05
genes O 0 1.230839529853256e-06
Zfp127 O 0 1.382415575790219e-05
( O 0 2.4067389858828392e-08
mouse O 0 2.9541320145654026e-06
homologue O 0 5.29281669514603e-06
of O 0 1.436817065325613e-08
ZNF127 O 0 2.0345827579149045e-05
) O 0 1.1822451462251138e-08
, O 0 5.711732420365934e-09
Ndn O 0 4.3508512135304045e-06
and O 0 6.195570279032836e-09
Ipw O 0 7.48511240544758e-07
, O 0 3.0808681827920736e-08
and O 0 2.5131887682050547e-08
manifest O 0 6.459072920961262e-08
several O 0 3.1410141154708526e-09
phenotypes O 0 2.0227557797625195e-06
common O 0 1.328660346189281e-07
to O 0 1.2427476576704066e-06
PWS B-Disease 1 1.0
infants O 0 0.014026537537574768
. O 0 7.434786084559164e-07

These O 0 5.544426073811337e-08
data O 0 2.66594391007402e-08
demonstrate O 0 1.4817141291700864e-08
that O 0 1.3093470752068015e-09
both O 0 1.3766772166690089e-09
the O 0 6.309096800549696e-09
position O 0 5.684282200490998e-07
of O 0 1.2918361935732037e-09
the O 0 1.0461134181127818e-08
IC O 0 1.5420964700751938e-06
and O 0 3.090043065867576e-08
its O 0 2.2064583493630607e-09
role O 0 2.9663858036599322e-09
in O 0 8.881022028894847e-10
the O 0 3.616248689386481e-10
coordinate O 0 2.367835882921554e-08
expression O 0 1.1956382550692979e-08
of O 0 2.5704793849001817e-10
genes O 0 2.3096609069739316e-08
is O 0 1.221670653528406e-09
conserved O 0 5.893975529858153e-09
between O 0 7.391178780125074e-09
mouse O 0 0.00015296292258426547
and O 0 1.7880854841223481e-07
human O 0 6.849152356380728e-09
, O 0 4.021941890641756e-09
and O 0 1.754247769270023e-08
indicate O 0 3.8283197056898643e-08
that O 0 1.3644692042902307e-09
the O 0 2.4025090805679383e-09
mouse O 0 8.883289410732687e-05
is O 0 3.860920472220641e-09
a O 0 8.283045915824516e-10
suitable O 0 3.145174565233333e-09
model O 0 3.3179659908455506e-08
system O 0 9.021760227767572e-09
in O 0 3.531678505197533e-09
which O 0 1.5034382627732157e-08
to O 0 7.976065363735074e-10
investigate O 0 2.2626724938135112e-09
the O 0 5.580865214405151e-10
molecular O 0 5.286581394869927e-09
mechanisms O 0 1.0412800399706157e-08
of O 0 4.3273071237415195e-10
imprinting O 0 7.405896212731022e-06
in O 0 5.1413785229215136e-08
this O 0 3.122365921370829e-09
region O 0 3.8975695559884116e-08
of O 0 9.837636261167404e-10
the O 0 4.9467332452479695e-09
genome O 0 1.6839290140069352e-07
. O 0 1.857461739973587e-08
. O 0 9.013490398501744e-08

Mutations O 0 5.842360042151995e-05
of O 0 1.77748393781485e-08
the O 0 5.9997322665594766e-09
ATM O 0 7.143835887291061e-07
gene O 0 3.624919600042631e-07
detected O 0 3.879303278608859e-07
in O 0 3.606787402077316e-08
Japanese O 0 0.00011189396172994748
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 3.19565660902299e-05
: O 0 4.7628918586895e-09
possible O 0 2.9569691140096666e-09
preponderance O 0 1.5203428915810946e-07
of O 0 7.492048648138905e-10
the O 0 4.436634171156584e-09
two O 0 4.2277306988580676e-08
founder O 0 7.1168797148857266e-06
mutations O 0 1.7474470723755076e-06
4612del165 O 0 1.140857534664974e-06
and O 0 8.655403149759877e-08
7883del5 O 0 7.038441708573373e-06
. O 0 3.240812418425776e-07

The O 0 7.506566248594027e-07
ATM O 0 2.736947135417722e-05
( O 0 1.513327106295037e-06
A O 1 0.9999716281890869
- O 1 0.9999997615814209
T O 1 1.0
, O 0 3.0746221568733745e-08
mutated O 0 2.575370672275312e-07
) O 0 4.572433098815054e-09
gene O 0 5.59240014297302e-08
on O 0 1.0921437620936558e-07
human O 0 1.5231032080009754e-07
chromosome O 0 0.00012615023297257721
11q22 O 0 2.1563768314081244e-05
. O 0 8.069089290074771e-07

3 O 0 4.250308484188281e-05
has O 0 1.3985754776513204e-06
recently O 0 6.434100328078785e-07
been O 0 2.8302766352794606e-08
identified O 0 1.6646401590492133e-08
as O 0 7.797365531025946e-10
the O 0 2.3483359701259587e-10
gene O 0 1.7147712583209795e-08
responsible O 0 4.985369006504925e-09
for O 0 2.9973465376365027e-10
the O 0 1.4835467077034536e-08
human O 0 6.387759185599862e-06
recessive B-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999992847442627
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.03548711538314819
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 7.378060900009586e-07
. O 0 3.8392010992538417e-07

In O 0 5.587622808889137e-07
order O 0 4.108785844891827e-08
to O 0 1.5170189548996404e-09
define O 0 2.3936141957392465e-08
the O 0 2.2407220523490423e-09
types O 0 2.3644780355880357e-08
of O 0 1.0296789199060186e-08
disease O 0 6.681014838250121e-06
- O 0 6.76686840961338e-06
causing O 0 1.6039732031458698e-07
ATM O 0 6.810308832427836e-07
mutations O 0 3.348307302530884e-07
in O 0 4.731545377723023e-09
Japanese O 0 8.6564074308626e-07
A B-Disease 1 0.9999991655349731
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.0909773209277773e-06
as O 0 2.8749442826381255e-09
well O 0 1.2219713019234746e-09
as O 0 1.3033844004084472e-09
to O 0 4.4706868762567353e-10
look O 0 4.791183449981418e-09
for O 0 4.440187106879989e-10
possible O 0 7.1746200092093204e-09
mutational O 0 1.1825653700725525e-06
hotspots O 0 2.2615142825088697e-06
, O 0 1.1150931733538982e-08
reverse O 0 5.246079126663972e-07
- O 0 3.4295096611458575e-06
transcribed O 0 1.2686235777437105e-06
RNA O 0 2.560121856731712e-07
derived O 0 8.828838993224508e-09
from O 0 1.0553879992158954e-09
ten O 0 7.272454194406919e-09
patients O 0 5.767476718432363e-09
belonging O 0 1.843754926511565e-09
to O 0 7.859690120959328e-10
eight O 0 8.415670826877886e-09
unrelated O 0 2.66857416164612e-08
Japanese O 0 3.5279916232866526e-07
A B-Disease 1 0.9999890327453613
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
families O 0 1.2140804983573616e-07
was O 0 2.3227995527008716e-08
analyzed O 0 6.022708998187909e-09
for O 0 5.360027421907887e-10
mutations O 0 1.7285730180560677e-08
by O 0 1.289732903808627e-10
the O 0 1.10582198953324e-09
restriction O 0 3.9934086260018375e-08
endonuclease O 0 8.349895779247163e-07
fingerprinting O 0 4.864733682552469e-07
method O 0 5.075339117865951e-07
. O 0 1.3945650323421432e-07

As O 0 1.7463958101870958e-06
has O 0 2.3272812654795416e-07
been O 0 3.673795845315908e-08
reported O 0 4.2648490961028074e-08
by O 0 3.9586189881646305e-10
others O 0 1.0206258060918572e-08
, O 0 1.2413162719937532e-09
mutations O 0 3.2285129236697685e-08
that O 0 9.974200354534446e-10
lead O 0 1.6341127562213842e-08
to O 0 1.5953386389711e-09
exon O 0 4.250240124292759e-07
skipping O 0 1.8590089894132689e-06
or O 0 2.512647938601731e-07
premature O 0 1.2013032346658292e-07
protein O 0 4.866552316684647e-08
truncation O 0 2.336286343052052e-06
were O 0 4.068542693858035e-07
also O 0 9.83745707117123e-08
predominant O 0 2.0272425160783314e-07
in O 0 1.8720264449711976e-08
our O 0 1.5940352682264347e-07
mutants O 0 1.118541695177555e-05
. O 0 1.82613462129666e-07

Six O 0 8.380633857996145e-07
different O 0 2.1746723533055956e-08
mutations O 0 5.837779895045969e-07
were O 0 1.0469637601318027e-08
identified O 0 4.7449233875340724e-08
on O 0 4.56584700714302e-07
12 O 0 6.30885850227969e-08
of O 0 7.522863998410401e-10
the O 0 9.619068208621684e-09
16 O 0 8.932045858500715e-08
alleles O 0 4.062017637807003e-07
examined O 0 2.4171743007173063e-06
. O 0 6.942219670236227e-07

Four O 0 1.7051260101652588e-06
were O 0 2.6466102198696717e-08
deletions O 0 1.877662754168341e-07
involving O 0 2.5747068477244284e-08
a O 0 3.1363947528006975e-07
loss O 0 7.06585581156105e-07
of O 0 2.068546001154914e-09
a O 0 2.9176975502309688e-08
single O 0 8.564719422565759e-08
exon O 0 1.5697530670877313e-06
exon O 0 4.461391199583886e-06
7 O 0 5.803906333312625e-07
, O 0 1.913334024550295e-08
exon O 0 1.0071472615891253e-06
16 O 0 1.5581640866457747e-07
, O 0 1.0585901044635193e-08
exon O 0 7.728373816462408e-07
33 O 0 5.809948788737529e-07
or O 0 4.30689901520509e-08
exon O 0 3.382308705113246e-06
35 O 0 2.256219431728823e-06
. O 0 6.31175907983561e-07

The O 0 1.0388479267930961e-06
others O 0 4.333233789566293e-07
were O 0 1.3296346246249868e-08
minute O 0 3.408382909242391e-08
deletions O 0 2.4200519987971347e-07
, O 0 2.4376125562497464e-09
4649delA O 0 9.859866878514367e-08
in O 0 2.3896942202839e-09
exon O 0 5.415275836639921e-07
33 O 0 3.915968420642457e-07
and O 0 1.407329008884517e-08
7883del5 O 0 3.488911772819847e-07
in O 0 9.899322250817022e-09
exon O 0 3.439545480432571e-06
55 O 0 1.0877339491344173e-06
. O 0 3.4932065773318755e-07

The O 0 6.301029884525633e-07
mutations O 0 2.7836088065669173e-06
4612del165 O 0 1.7844563444668893e-06
and O 0 2.9073261131884465e-08
7883del5 O 0 5.345382305677049e-07
were O 0 2.2022717871550412e-08
found O 0 1.364357182787046e-09
in O 0 4.213976112499296e-10
more O 0 1.5837260669560038e-10
than O 0 1.0345876239048479e-10
two O 0 1.6435698635408613e-10
unrelated O 0 2.2522523845935893e-09
families O 0 1.1778465980327724e-09
; O 0 6.567981714056259e-10
44 O 0 4.8688519882489345e-09
% O 0 4.1992287425074437e-10
( O 0 2.101047669178513e-10
7 O 0 2.639178653396357e-09
of O 0 3.190439856748384e-10
16 O 0 8.941589868527444e-08
) O 0 7.886299946413544e-10
of O 0 1.213280170775377e-10
the O 0 1.0130594141344318e-09
mutant O 0 2.9691723284486216e-06
alleles O 0 4.025159796583466e-07
had O 0 0.0020428423304110765
one O 0 1.1902548280318115e-08
of O 0 2.9604213525047385e-10
the O 0 1.6511242373340451e-09
two O 0 1.1489379403428757e-07
mutations O 0 4.379604888526956e-06
. O 0 2.113151253979595e-07

The O 0 2.398577976236993e-07
4612del165 O 0 1.9535830233508023e-06
mutations O 0 3.8510933109137113e-07
in O 0 1.480334965719976e-09
three O 0 1.3095093898130017e-09
different O 0 1.4044430063364644e-09
families O 0 2.3126759174374456e-08
were O 0 4.18555927694797e-08
all O 0 5.061663310712561e-10
ascribed O 0 4.3593217924353667e-08
to O 0 2.620344163872801e-09
the O 0 1.5681984599780208e-09
same O 0 2.063998927326338e-08
T O 0 9.240849067282397e-06
- O 0 5.371171596380009e-07
- O 0 4.828689839087019e-07
> O 0 1.052166620496564e-08
A O 0 2.329204606965618e-09
substitution O 0 5.825075088949916e-09
at O 0 1.9279164931162995e-09
the O 0 2.8609081770269995e-09
splice O 0 2.788848860291182e-06
donor O 0 8.885182012363657e-08
site O 0 1.937783622452116e-07
in O 0 2.0138649858836288e-08
intron O 0 0.00013247771130409092
33 O 0 6.802053121646168e-06
. O 0 3.984119700817246e-07

Microsatellite O 0 0.0006323899142444134
genotyping O 0 0.00012130348477512598
around O 0 5.44749354958185e-07
the O 0 1.2793045733872077e-08
ATM O 0 5.583009965448582e-07
locus O 0 2.6278689801984e-06
also O 0 4.6344942461473693e-07
indicated O 0 7.643087940323312e-08
that O 0 4.214739668384482e-10
a O 0 3.311579011011645e-09
common O 0 2.427137957283776e-08
haplotype O 0 0.00010485726670594886
was O 0 1.9986935512861237e-05
shared O 0 1.1326209303774704e-08
by O 0 5.723747587005334e-10
the O 0 1.6272941882888858e-09
mutant O 0 7.672546757930832e-07
alleles O 0 1.333553996119008e-07
in O 0 1.0103275549511181e-08
both O 0 1.184177449431445e-07
mutations O 0 9.956766007235274e-06
. O 0 2.592336159068509e-07

This O 0 2.000806063051641e-07
suggests O 0 1.2479955557864741e-07
that O 0 2.1757915469322597e-09
these O 0 3.276900140125605e-10
two O 0 3.243460167112744e-09
founder O 0 5.8167897805105895e-06
mutations O 0 4.489440470933914e-06
may O 0 2.1384887816111586e-07
be O 0 2.047135128080413e-09
predominant O 0 9.247007426438358e-08
among O 0 5.332833286075811e-09
Japanese O 0 1.6202646335727877e-08
ATM O 0 5.775327167611977e-07
mutant O 0 4.754734618472867e-06
alleles O 0 3.61503634849214e-06
. O 0 7.590075483676628e-07

W474C O 0 0.00020090241741854697
amino O 0 1.0038744221674278e-05
acid O 0 7.730894822088885e-07
substitution O 0 1.0900190261509124e-07
affects O 0 8.743209889416903e-08
early O 0 5.540057301800516e-09
processing O 0 2.7837079308312696e-09
of O 0 1.6403253755292724e-10
the O 0 3.557910077667259e-10
alpha O 0 3.7540570652083716e-09
- O 0 6.0017351088959e-09
subunit O 0 4.2749128681407456e-09
of O 0 4.955645893645055e-10
beta O 0 4.8186312717746205e-09
- O 0 2.572287485236302e-07
hexosaminidase O 0 4.278030871773808e-07
A O 0 4.6002877951423216e-08
and O 0 3.202117682121752e-08
is O 0 3.606077214612924e-09
associated O 0 1.3463963277615676e-08
with O 0 3.2442102337881806e-08
subacute O 0 0.001712003955617547
G B-Disease 0 0.0009937926661223173
( I-Disease 0 1.6131158986354421e-07
M2 I-Disease 0 3.7077144952490926e-05
) I-Disease 0 2.627382684750046e-07
gangliosidosis I-Disease 0 3.177105463691987e-05
. O 0 1.355225549559691e-06

Mutations O 0 0.00036680142511613667
in O 0 7.082925890244951e-08
the O 0 4.638774697696135e-08
HEXA O 0 6.38712735963054e-05
gene O 0 6.571965514012845e-07
, O 0 5.662291968633326e-09
encoding O 0 2.5117943280861255e-08
the O 0 3.3892186834805216e-09
alpha O 0 1.3364946482852247e-08
- O 0 1.568663066109366e-08
subunit O 0 8.642300208805409e-09
of O 0 8.226710423997474e-10
beta O 0 1.6521015666626226e-08
- O 0 5.722770879401651e-07
hexosaminidase O 0 1.2737382348859683e-06
A O 0 8.492688863270814e-08
( O 0 7.256063305760563e-09
Hex O 0 1.4700818837809493e-06
A O 0 7.192804929445629e-08
) O 0 2.9822422309422336e-09
, O 0 8.042027044297129e-10
that O 0 7.526781420352791e-10
abolish O 0 9.253112409624009e-08
Hex O 0 4.696088581113145e-06
A O 0 1.8336239193672554e-08
enzyme O 0 2.940806780316052e-07
activity O 0 7.288800816240837e-07
cause O 0 2.0725630747620016e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.055774904787540436
( O 0 2.9251921773720824e-08
TSD B-Disease 0 6.257737823034404e-06
) O 0 8.835678855234619e-09
, O 0 3.4066784948549866e-09
the O 0 1.558014872671265e-08
fatal O 0 1.683496157056652e-05
infantile B-Disease 0 0.0007836796576157212
form I-Disease 0 7.08392491333143e-08
of I-Disease 0 1.7754034686845444e-08
G I-Disease 0 0.00015917608106974512
( I-Disease 0 2.6780325512731906e-08
M2 I-Disease 0 5.759383839176735e-06
) I-Disease 0 2.7711383410178314e-08
gangliosidosis I-Disease 0 1.262940372726007e-06
, I-Disease 0 6.608321445611409e-09
Type I-Disease 0 6.882850556166886e-08
1 I-Disease 0 6.104850314159194e-08
. O 0 2.5051946295207017e-07

Less O 0 2.0421915905899368e-05
severe O 0 0.00018472816736903042
, O 0 1.3481404437243327e-07
subacute O 0 0.0007939140778034925
( O 0 3.4647828783818113e-07
juvenile O 0 0.00016787205822765827
- O 1 0.8710582256317139
onset O 0 0.14381366968154907
) O 0 2.4753660454734927e-07
and O 0 1.272895474357938e-06
chronic O 0 0.017052989453077316
( O 0 2.8631912840637597e-08
adult O 0 1.7158776017822674e-06
- O 0 0.029594985768198967
onset O 0 0.00010174240014748648
) O 0 3.232571765821035e-09
variants O 0 4.6570988843086525e-08
are O 0 1.5160008803860592e-09
characterized O 0 1.9932635098030005e-08
by O 0 1.5432313760221916e-10
a O 0 1.9191848110722276e-09
broad O 0 7.464269913270982e-08
spectrum O 0 5.270042890970217e-08
of O 0 4.378992723985675e-10
clinical O 0 3.739601339702858e-08
manifestations O 0 1.5074343195919937e-07
and O 0 2.0269634859459984e-08
are O 0 8.028203102306009e-10
associated O 0 4.5288870431647865e-09
with O 0 2.978052693336508e-09
residual O 0 3.3784465358621674e-06
levels O 0 4.410186349446121e-08
of O 0 1.3808927334935106e-09
Hex O 0 7.431422545778332e-06
A O 0 4.305707790308588e-08
enzyme O 0 2.117187705152901e-07
activity O 0 3.1350728590950894e-07
. O 0 7.032471671664098e-08

We O 0 5.364207936509047e-06
identified O 0 3.627485511970008e-07
a O 0 7.50140713989822e-08
1422 O 0 7.68119662097888e-06
G O 0 3.7628044083248824e-05
- O 0 1.91611052287044e-05
- O 0 3.9116777770686895e-05
> O 0 1.0918745374510763e-06
C O 0 1.0882880587814725e-06
( O 0 9.281247770331902e-09
amino O 0 1.6525397938949027e-08
acid O 0 2.1793146842696842e-08
W474C O 0 4.965168542980791e-08
) O 0 5.830340654711108e-10
substitution O 0 1.5450052348597865e-09
in O 0 8.115156324706163e-10
the O 0 2.0870256633997997e-09
first O 0 2.1563215213404874e-08
position O 0 3.876077769859876e-08
of O 0 4.510118944978103e-10
exon O 0 2.861559664779634e-07
13 O 0 1.1377506581311536e-07
of O 0 1.5101049299914848e-09
HEXA O 0 3.678987923194654e-05
of O 0 1.961484308310446e-09
a O 0 1.4618255939069513e-08
non O 0 3.320346309010347e-08
- O 0 4.23475421484909e-06
Jewish O 0 1.1098096592832007e-06
proband O 0 4.6679022489115596e-05
who O 0 1.4668580661236774e-06
manifested O 0 3.966669055444072e-07
a O 0 1.8155068559622123e-08
subacute O 0 2.8705992008326575e-05
variant O 0 3.877049493894447e-06
of O 0 7.381559896657564e-08
G B-Disease 0 0.0006663103704340756
( I-Disease 0 1.1783431830281188e-07
M2 I-Disease 0 4.335631456342526e-05
) I-Disease 0 3.0178870247254963e-07
gangliosidosis I-Disease 0 2.7339423468220048e-05
. O 0 8.349131235263485e-07

On O 0 4.546707714325748e-06
the O 0 5.1890612695615346e-08
second O 0 1.1343956884957151e-06
maternally O 0 4.001378329121508e-05
inherited O 0 2.5483603167231195e-05
allele O 0 2.7446642434370006e-06
, O 0 1.4740695775117274e-08
we O 0 3.5384413177297347e-09
identified O 0 1.7271659658035787e-08
the O 0 4.620617222172996e-09
common O 0 7.46999432976736e-07
infantile O 1 0.7166349291801453
disease O 0 0.00012208480620756745
- O 0 2.2328733393806033e-05
causing O 0 3.488678714802518e-07
4 O 0 9.352046959065774e-08
- O 0 3.472484650046681e-06
bp O 0 1.0845653832802782e-06
insertion O 0 2.7687880788107577e-07
, O 0 1.3537377441252829e-08
+ O 0 4.0417387481284095e-07
TATC O 0 6.990798283368349e-06
1278 O 0 4.781066763825947e-06
, O 0 8.413488572500682e-09
in O 0 5.834682514915812e-09
exon O 0 3.542357490005088e-06
11 O 0 1.5596820048813242e-06
. O 0 3.6891316312903655e-07

Pulse O 0 0.0012622452341020107
- O 0 8.638638246338814e-05
chase O 0 6.86017619955237e-06
analysis O 0 8.917967164734364e-08
using O 0 3.194461939415305e-08
proband O 0 5.111427526571788e-06
fibroblasts O 0 1.8739252709565335e-06
revealed O 0 1.7736083464114927e-06
that O 0 2.4354886996036385e-09
the O 0 1.688909900821045e-09
W474C O 0 2.584003482297703e-07
- O 0 1.0072820799678084e-07
containing O 0 5.4129194460017516e-09
alpha O 0 8.368021831017813e-09
- O 0 8.370943049840207e-09
subunit O 0 1.1938448452042394e-08
precursor O 0 1.9013107532828144e-08
was O 0 2.2283255418642511e-07
normally O 0 3.4367386714251325e-09
synthesized O 0 9.089242247739548e-09
, O 0 1.5633007111048869e-09
but O 0 8.252767913496939e-10
not O 0 2.2375007402430924e-10
phosphorylated O 0 4.923558449831944e-09
or O 0 2.863883574732995e-09
secreted O 0 2.3014331773651975e-08
, O 0 5.632637467556378e-09
and O 0 5.095705635227432e-09
the O 0 3.9858352174348965e-09
mature O 0 1.9676905438359427e-08
lysosomal O 0 1.042832735720367e-07
alpha O 0 1.9404014395263403e-08
- O 0 3.429236983265582e-08
subunit O 0 4.3433370677803396e-08
was O 0 5.065450068286736e-07
not O 0 1.1591330562055191e-08
detected O 0 4.0398737155555864e-07
. O 0 1.1811535927108707e-07

When O 0 7.876879521973024e-07
the O 0 1.6582324846581287e-08
W474C O 0 4.7606741304662137e-07
- O 0 1.4078705135034397e-07
containing O 0 2.1929414728560914e-08
alpha O 0 4.1740154443914435e-08
- O 0 5.348370279989467e-08
subunit O 0 7.543705748958018e-08
was O 0 2.507757130842947e-07
transiently O 0 6.264241960707295e-07
co O 0 5.725390792576945e-07
- O 0 3.970331817981787e-06
expressed O 0 8.371453752431535e-09
with O 0 5.12776043848362e-10
the O 0 6.837401755888095e-10
beta O 0 2.820542466253073e-09
- O 0 7.236299115476186e-09
subunit O 0 4.585096302633929e-09
to O 0 2.522614783728727e-09
produce O 0 3.5236715767439364e-09
Hex O 0 1.3218813137427787e-06
A O 0 3.7590599077930165e-08
( O 0 4.495777528035205e-09
alphabeta O 0 2.3821372963084286e-07
) O 0 2.760064843343457e-09
in O 0 1.586121123331452e-09
COS O 0 0.00011899726086994633
- O 0 1.0127991117769852e-05
7 O 0 9.650404564354176e-08
cells O 0 1.3844432267262619e-08
, O 0 3.1918029330668674e-10
the O 0 5.526356039453617e-10
mature O 0 3.6682203941040825e-09
alpha O 0 1.7189356604774275e-09
- O 0 5.822675674949096e-09
subunit O 0 6.289512466395308e-09
was O 0 1.687156725438399e-07
present O 0 1.2741705468499731e-09
, O 0 8.958192521113517e-10
but O 0 7.737069873670066e-10
its O 0 1.7743971847394846e-09
level O 0 1.3920265828915035e-08
was O 0 1.7780678263079608e-07
much O 0 1.0409478834461083e-09
lower O 0 4.113551277384886e-09
than O 0 2.939226917408888e-10
that O 0 1.984922504139064e-10
from O 0 1.7011848874037838e-10
normal O 0 1.1488666684655868e-09
alpha O 0 3.07285596967688e-09
- O 0 6.222453663440319e-09
subunit O 0 6.568172672416495e-09
transfections O 0 1.0462854049819725e-07
, O 0 6.067593094627455e-10
although O 0 4.0840761328375663e-10
higher O 0 2.4324514624751714e-10
than O 0 1.7317623723922537e-10
in O 0 6.095827176366697e-10
those O 0 3.5797689257321963e-09
cells O 0 1.1670950428310789e-08
transfected O 0 4.626483871561504e-07
with O 0 1.2383768455137556e-09
an O 0 8.224984582305694e-10
alpha O 0 3.326050901364397e-08
- O 0 1.130521312120436e-07
subunit O 0 2.1163377539323847e-07
associated O 0 9.776701404007326e-08
with O 0 1.4746578358426632e-07
infantile O 0 0.026604924350976944
TSD B-Disease 0 0.0019254385260865092
. O 0 2.6959189654007787e-06

Furthermore O 0 9.79546985035995e-06
, O 0 2.4224529937555417e-08
the O 0 2.052154668419348e-09
precursor O 0 1.8577026139610098e-08
level O 0 3.791540414965766e-09
of O 0 2.4411658805512104e-10
the O 0 1.050940667823852e-09
W474C O 0 7.206330820963558e-08
alpha O 0 7.503722088131326e-09
- O 0 1.0575487152664209e-08
subunit O 0 7.666094425928804e-09
was O 0 2.0596756655777426e-07
found O 0 1.5952594800694442e-09
to O 0 5.506669009669451e-10
accumulate O 0 2.1539289463134992e-08
in O 0 2.4368629336635195e-10
comparison O 0 3.5835536760231435e-09
to O 0 1.7438614996478918e-09
the O 0 2.4756450223151205e-09
normal O 0 1.4288042748944463e-08
alpha O 0 1.7133784169232058e-08
- O 0 4.287809574066159e-08
subunit O 0 7.125975542976448e-08
precursor O 0 2.8333238333289046e-07
levels O 0 9.67152118391823e-08
. O 0 1.1419935219691979e-07

We O 0 8.110218004730996e-06
conclude O 0 2.3672673421515356e-07
that O 0 3.4697831274854707e-09
the O 0 2.445543101359249e-09
1422 O 0 8.922609708861273e-07
G O 0 9.3672515504295e-06
- O 0 3.8133041471155593e-06
- O 0 1.1907486623385921e-05
> O 0 3.4601865195327264e-07
C O 0 2.470180220370821e-07
mutation O 0 5.1657757182965724e-08
is O 0 1.2542800131853937e-09
the O 0 9.789344890265284e-10
cause O 0 1.0008049500243033e-08
of O 0 1.6572420102889396e-09
Hex B-Disease 1 0.5767491459846497
A I-Disease 0 0.00045894767390564084
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.3109044516568247e-08
the O 0 4.493585592513227e-08
proband O 0 5.375539694796316e-05
. O 0 4.327976341755857e-07

The O 0 3.099239620496519e-07
resulting O 0 2.806996235449333e-07
W474C O 0 1.4107281458564103e-06
substitution O 0 3.254101841321244e-07
clearly O 0 2.0620832685835921e-07
interferes O 0 2.0186939764244016e-07
with O 0 4.980208689886467e-09
alpha O 0 1.5306452993968378e-08
- O 0 1.7626257786673705e-08
subunit O 0 8.621753977422486e-09
processing O 0 6.1240790216743335e-09
, O 0 1.5360492877647403e-09
but O 0 4.89527696156955e-10
because O 0 8.060481448968204e-11
the O 0 1.0483974799413431e-10
base O 0 4.1869703260033475e-09
substitution O 0 4.463310609992277e-09
falls O 0 6.836821739852894e-06
at O 0 6.1633116388293274e-09
the O 0 8.920902350162407e-10
first O 0 9.547744816984505e-09
position O 0 3.799172532126249e-08
of O 0 5.993941454285334e-10
exon O 0 2.7311469352753193e-07
13 O 0 3.286423932991056e-08
, O 0 1.0855427667877393e-09
aberrant O 0 3.6624683730224206e-08
splicing O 0 6.586441259059939e-07
may O 0 1.6033492329370347e-06
also O 0 3.3611136984745826e-08
contribute O 0 2.9288083069900495e-09
to O 0 6.501676086401176e-09
Hex B-Disease 0 0.05848627910017967
A I-Disease 0 1.3818711522617377e-05
deficiency I-Disease 0 8.596580300945789e-05
in O 0 9.890994689953914e-10
this O 0 2.32611907513558e-09
proband O 0 2.5465735689067515e-06
. O 0 2.375036523005747e-08
. O 0 1.0296400176912357e-07

Two O 0 3.2782340895209927e-06
frequent O 0 3.329046376165934e-05
missense O 0 0.0024680497590452433
mutations O 0 0.0010473860893398523
in O 0 3.1396793929161504e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 7.654373803234193e-06

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.00010511877189856023
an O 0 0.00010723292507464066
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.1198354959487915
by O 0 1.7733280799347995e-07
early O 0 2.8359014322631992e-05
childhood O 1 0.9992233514785767
deafness B-Disease 1 1.0
and O 1 0.6894752383232117
goiter B-Disease 1 1.0
. O 0 1.126070310419891e-05

A O 0 6.440290690079564e-06
century O 0 8.079978215391748e-07
after O 0 2.624191708378021e-08
its O 0 2.095010165348299e-09
recognition O 0 6.953561726419366e-09
as O 0 5.3258325749538926e-08
a O 0 3.217787025278085e-06
syndrome O 1 0.973186194896698
by O 0 2.7956799097950125e-09
Vaughan O 0 6.649808028669213e-07
Pendred O 0 1.3564409755417728e-06
, O 0 3.4735512244310485e-09
the O 0 8.542674123646066e-09
disease O 0 1.8106295556208352e-06
gene O 0 4.1668889139145904e-07
( O 0 8.342001223127227e-08
PDS O 0 1.3140660485078115e-05
) O 0 1.5668687680658877e-08
was O 0 2.941289096725086e-07
mapped O 0 5.256648819340626e-06
to O 0 8.78466579479209e-08
chromosome O 0 0.00010970173025270924
7q22 O 0 1.1337683645251673e-05
- O 0 6.828604819020256e-05
q31 O 0 3.699700755532831e-05
. O 0 6.4991616000043e-07

1 O 0 7.937484951980878e-06
and O 0 6.777343060093699e-07
, O 0 2.004155241763783e-08
recently O 0 2.163888552786375e-07
, O 0 3.5658944685934557e-09
found O 0 3.0139963858033525e-09
to O 0 1.4314113228053316e-09
encode O 0 9.296204694919652e-08
a O 0 6.61160228787594e-08
putative O 0 1.2123478882131167e-05
sulfate O 0 1.200634960696334e-05
transporter O 0 0.00010432150156702846
. O 0 1.1506961072882405e-06

We O 0 6.3479706113867e-06
performed O 0 2.375254695152762e-07
mutation O 0 7.019137626684824e-08
analysis O 0 4.1678638318387584e-09
of O 0 3.422326588786717e-10
the O 0 3.680744598000274e-09
PDS B-Disease 0 1.9594101559050614e-06
gene O 0 7.563731685422681e-08
in O 0 1.1878892536287822e-08
patients O 0 2.7134118951721575e-08
from O 0 1.0650663684330652e-09
14 O 0 2.030430401589456e-08
Pendred B-Disease 0 6.561401164617564e-07
families O 0 3.965111794457243e-09
originating O 0 4.988793378402079e-09
from O 0 9.773840625726393e-10
seven O 0 3.6082585808117074e-09
countries O 0 6.381843942193655e-10
and O 0 5.908394218323565e-09
identified O 0 3.781604718255949e-08
all O 0 6.038295197186017e-09
mutations O 0 1.2275080507606617e-06
. O 0 1.7252865802674933e-07

The O 0 2.9569858384093095e-07
mutations O 0 5.376578542382049e-07
include O 0 3.5668874520666805e-09
three O 0 1.3111045582547831e-08
single O 0 1.0599643474051845e-07
base O 0 1.795350641486948e-07
deletions O 0 9.7505062512937e-07
, O 0 5.26637267128649e-09
one O 0 2.4560233846671053e-09
splice O 0 2.053898606391158e-05
site O 0 1.519283387096948e-06
mutation O 0 3.752026316306001e-07
and O 0 1.082801226459651e-08
10 O 0 4.629485061968808e-08
missense O 0 2.1242098227958195e-05
mutations O 0 8.883705959306099e-06
. O 0 5.130607405590126e-07

One O 0 2.6993611754733138e-06
missense O 0 0.0001194396973005496
mutation O 0 9.34483887249371e-06
( O 0 8.884470759085161e-08
L236P O 0 1.8367938992014388e-06
) O 0 4.128023434191164e-08
was O 0 2.4438219270450645e-07
found O 0 4.986177248866852e-09
in O 0 6.421331244510498e-10
a O 0 7.870960772038416e-09
homozygous O 0 3.412423268400744e-07
state O 0 6.351267844983965e-10
in O 0 8.951821506286706e-10
two O 0 8.695874242903301e-09
consanguineous O 0 3.7631095892720623e-06
families O 0 6.743315594803789e-08
and O 0 2.857047265436563e-09
in O 0 5.770422473183601e-10
a O 0 5.780185219350642e-09
heterozygous O 0 7.930881196216433e-08
state O 0 1.3850077751342837e-09
in O 0 1.260090032317862e-09
five O 0 3.6342839848657604e-09
additional O 0 5.490154109111245e-09
non O 0 6.533913676776137e-08
- O 0 2.5211327738361433e-05
consanguineous O 0 5.873788904864341e-05
families O 0 5.666388460667804e-07
. O 0 2.212655232369798e-07

Another O 0 9.849331036093645e-06
missense O 0 0.00033125426853075624
mutation O 0 8.626643648312893e-06
( O 0 8.325390865593363e-08
T416P O 0 1.1886234005942242e-06
) O 0 3.535508596996806e-08
was O 0 2.5906138034770265e-07
found O 0 4.1753986934622844e-09
in O 0 4.3865075460836067e-10
a O 0 6.62265531303774e-09
homozygous O 0 2.498740343526151e-07
state O 0 7.955128777936693e-10
in O 0 6.485513015519473e-09
one O 0 8.505040938189268e-08
family O 0 1.3681083999017574e-07
and O 0 1.996025567052584e-08
in O 0 9.884394414072517e-10
a O 0 6.5087113476636205e-09
heterozygous O 0 5.6396920911083726e-08
state O 0 8.256089700786617e-10
in O 0 3.5310587787051873e-09
four O 0 7.226591947073757e-08
families O 0 1.240662896861977e-07
. O 0 1.4872276210553537e-07

Pendred B-Disease 0 0.003485810710117221
patients O 0 2.8753283913829364e-05
in O 0 2.5038444206870736e-08
three O 0 1.3607351689870484e-08
non O 0 2.4714568169770246e-08
- O 0 2.2772851480112877e-06
consanguineous O 0 1.5111569155124016e-05
families O 0 3.590644155337941e-07
were O 0 4.6873715575657116e-08
shown O 0 1.3904609907910981e-08
to O 0 1.1176136682777837e-09
be O 0 9.83707337809392e-10
compound O 0 4.76024268891706e-08
heterozygotes O 0 2.3857612063693523e-07
for O 0 2.5001398729074253e-09
L236P O 0 1.3319162235347903e-06
and O 0 7.321880701738337e-08
T416P O 0 3.725104079421726e-06
. O 0 1.811190912803795e-07

In O 0 3.688491574393993e-07
total O 0 1.0309684483900128e-07
, O 0 5.200988084652636e-09
one O 0 5.9799560858664336e-09
or O 0 9.779532739173646e-09
both O 0 5.667518121477144e-10
of O 0 3.75783015815756e-10
these O 0 1.614815281492099e-09
mutations O 0 6.13319954823055e-08
were O 0 3.0223219482650165e-08
found O 0 8.209910973278056e-09
in O 0 1.0882963863423356e-08
nine O 0 1.251815859859562e-07
of O 0 2.492663020436936e-10
the O 0 4.101932571387579e-09
14 O 0 5.3036728786537424e-08
families O 0 1.2615817723826694e-08
analyzed O 0 2.3731060139198235e-07
. O 0 1.678570669128021e-07

The O 0 1.494311874239429e-07
identification O 0 7.889617137379901e-08
of O 0 1.7709518296271654e-09
two O 0 1.3438820722910805e-08
frequent O 0 2.33404352911748e-06
PDS B-Disease 0 0.00028899990138597786
mutations O 0 1.054356289387215e-06
will O 0 4.4510857222235245e-09
facilitate O 0 5.877540676380022e-09
the O 0 7.612895203124026e-09
molecular O 0 2.996226157847559e-06
diagnosis O 0 0.008791215717792511
of O 0 1.4703982742503285e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 4.404782430356136e-06

Insertional O 0 0.0005969702615402639
mutation O 0 4.0439328586217016e-05
by O 0 4.7198930985814513e-08
transposable O 0 1.69958257174585e-05
element O 0 5.269078542369243e-07
, O 0 2.0367838970969387e-08
L1 O 0 3.412525984458625e-05
, O 0 1.4724059305137871e-08
in O 0 3.6561360605702475e-09
the O 0 3.440807105903332e-08
DMD B-Disease 1 1.0
gene O 0 2.092105660267407e-06
results O 0 2.409642547718249e-07
in O 0 1.1090801166346864e-07
X B-Disease 1 0.9999923706054688
- I-Disease 1 1.0
linked I-Disease 1 0.9999978542327881
dilated I-Disease 1 0.9998582601547241
cardiomyopathy I-Disease 1 1.0
. O 0 7.532930794695858e-06

X B-Disease 1 0.9999790191650391
- I-Disease 1 0.9999991655349731
linked I-Disease 1 0.9999849796295166
dilated I-Disease 1 0.9999984502792358
cardiomyopathy I-Disease 1 1.0
( O 0 9.227992450178135e-06
XLDCM B-Disease 0 0.0002995218092110008
) O 0 2.291651846064724e-08
is O 0 2.0258146271601163e-09
a O 0 9.689224533815377e-09
clinical O 0 6.439956337089825e-07
phenotype O 0 9.220444553648122e-06
of O 0 5.430654592686324e-09
dystrophinopathy B-Disease 0 0.00017880754603538662
which O 0 3.878911059018719e-07
is O 0 1.2047744135657013e-08
characterized O 0 8.673366380662628e-08
by O 0 2.769234841437651e-09
preferential O 0 8.072768764577631e-07
myocardial B-Disease 0 0.0004070392460562289
involvement I-Disease 0 2.384246329256712e-07
without O 0 4.962003696817874e-09
any O 0 1.783099445873404e-09
overt O 0 2.9585402216980583e-07
clinical O 0 1.4847505553916562e-06
signs O 0 1.5677673218306154e-05
of O 0 9.988312967834645e-07
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 4.475920650293119e-05

To O 0 3.889772131060454e-07
date O 0 2.3536054527539818e-07
, O 0 3.6234586442418504e-09
several O 0 2.231624440796054e-09
mutations O 0 2.9751171837233414e-07
in O 0 1.4596746922279635e-08
the O 0 2.30364366871072e-06
Duchenne B-Disease 1 0.9999998807907104
muscular I-Disease 1 0.9898650050163269
dystrophy I-Disease 0 0.21422049403190613
gene O 0 9.655163921706844e-06
, O 0 4.3400041249697097e-07
DMD O 1 1.0
, O 0 1.0222335333764931e-07
have O 0 3.076551990943699e-08
been O 0 1.8127421341773697e-08
identified O 0 4.7528395441531757e-08
in O 0 6.704863775297554e-09
patients O 0 1.4036135809192274e-08
with O 0 2.6071926839676962e-09
XLDCM B-Disease 0 4.422375786816701e-05
, O 0 4.888952798154378e-09
but O 0 3.8526645762537726e-10
a O 0 7.757727793489266e-10
pathogenic O 0 9.784831611625577e-09
correlation O 0 9.239705001107268e-09
of O 0 5.067420927318267e-10
these O 0 3.6059122354714646e-09
cardiospecific O 0 4.947395609633531e-06
mutations O 0 8.849441996972018e-07
in O 0 3.9091315073847e-08
DMD O 1 1.0
with O 0 4.48966197552636e-08
the O 0 6.2303534775765e-08
XLDCM B-Disease 0 0.023101625964045525
phenotype O 0 0.0012336188228800893
has O 0 5.2899099500791635e-06
remained O 0 8.527226214027905e-07
to O 0 5.302354999514591e-09
be O 0 1.857029552354561e-08
elucidated O 0 1.1579657439142466e-05
. O 0 2.417394568965392e-07

We O 0 9.049818800122011e-06
report O 0 4.6083762583748467e-08
here O 0 1.7756802694890439e-09
the O 0 2.6105403949649997e-10
identification O 0 2.351380423704086e-09
of O 0 3.18073650751316e-10
a O 0 7.097149090640187e-09
unique O 0 3.009798632547245e-08
de O 0 2.5258862024202244e-06
novo O 0 2.2767142127122497e-06
L1 O 0 1.5051315358505235e-06
insertion O 0 1.6432683480616106e-07
in O 0 5.2447504117481e-09
the O 0 4.744214798790836e-09
muscle O 0 1.8510556287765212e-07
exon O 0 1.7397006502051227e-07
1 O 0 5.8525412072185645e-08
in O 0 1.2907609914236673e-07
DMD O 1 1.0
in O 0 9.996472982720661e-08
three O 0 1.7213044145591994e-07
XLDCM B-Disease 0 0.0001500462822150439
patients O 0 5.1759734276402014e-08
from O 0 8.085908609345438e-10
two O 0 2.5592776786709237e-09
unrelated O 0 9.025395542039405e-08
Japanese O 0 2.46561910444143e-07
families O 0 7.371738774963887e-08
. O 0 7.954317027270008e-08

The O 0 3.846130880447163e-07
insertion O 0 3.036107500520302e-06
was O 0 9.237961648977944e-07
a O 0 2.3633823786894936e-08
5 O 0 3.9272769924991735e-08
- O 0 7.25315999261511e-07
truncated O 0 2.8947056307515595e-07
form O 0 9.438813286521963e-09
of O 0 1.0321087318132527e-09
human O 0 8.570043341649125e-09
L1 O 0 4.333835022407584e-06
inversely O 0 3.144504887586663e-07
integrated O 0 9.597574290864941e-08
in O 0 5.196129748696876e-09
the O 0 1.53575712147358e-08
5 O 0 1.2984230579604628e-07
- O 0 2.720005977607798e-05
untranslated O 0 6.019499051035382e-05
region O 0 5.613377425106592e-07
in O 0 5.000244218678063e-09
the O 0 5.486113785480029e-09
muscle O 0 9.716043081198222e-08
exon O 0 9.154909008657341e-08
1 O 0 3.364346312650923e-08
, O 0 3.549615268383377e-09
which O 0 6.279815334409022e-09
affected O 0 9.714590243348198e-10
the O 0 2.89331614222732e-10
transcription O 0 3.209229362255428e-07
or O 0 1.4650026969320606e-07
the O 0 1.5315768209234193e-08
stability O 0 3.3521862974339456e-07
of O 0 6.136072205897847e-10
the O 0 1.4699534922613111e-08
muscle O 0 3.2923628623393597e-07
form O 0 9.161363889731433e-10
of O 0 5.158169447128103e-10
dystrophin O 0 9.827405023088431e-08
transcripts O 0 1.9718744681540556e-07
but O 0 1.666050408744013e-08
not O 0 1.4341304810372435e-09
that O 0 2.7537533364707656e-10
of O 0 1.9974365217390044e-10
the O 0 1.696682438989683e-08
brain O 0 3.1550687253911747e-06
or O 0 1.8816416869071872e-08
Purkinje O 0 8.207429345929995e-06
cell O 0 1.5331280565078487e-06
form O 0 4.480038384713225e-08
, O 0 2.5485380916734357e-08
probably O 0 5.663335969074978e-07
due O 0 2.5780471091252366e-09
to O 0 2.926251019275128e-09
its O 0 2.871414883642842e-09
unique O 0 5.1313437943179e-09
site O 0 6.353866410790943e-08
of O 0 1.604903543395153e-09
integration O 0 2.0070362438673328e-07
. O 0 2.579930651336326e-07

We O 0 1.5122463992156554e-06
speculate O 0 1.7086129844301468e-07
that O 0 1.4274607051945054e-09
this O 0 2.1101682901036867e-10
insertion O 0 1.6352290188592633e-08
of O 0 4.6148543320079227e-10
an O 0 1.0878516976120522e-09
L1 O 0 1.335171782557154e-05
sequence O 0 9.26547158996982e-07
in O 0 5.373636327021813e-07
DMD O 1 1.0
is O 0 1.399960467551864e-07
responsible O 0 9.914628229523714e-09
for O 0 4.783656248896762e-10
some O 0 2.2047406955660875e-10
of O 0 1.0025692775972317e-10
the O 0 8.397788575642551e-10
population O 0 5.521993418078353e-10
of O 0 1.328895465890767e-10
Japanese O 0 2.67348525540001e-08
patients O 0 6.0367169041342095e-09
with O 0 3.0209028611949407e-09
XLDCM B-Disease 0 2.3031096134218387e-05
. O 0 3.0974426579177816e-08
. O 0 1.7189209700063657e-07

Severe O 0 0.003764115506783128
early O 0 4.87535044157994e-06
- O 0 0.03651556745171547
onset O 1 0.714843213558197
obesity B-Disease 1 1.0
, O 0 6.982727791182697e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 2.088718429149594e-05
red O 0 0.0005377928027883172
hair O 1 0.99997878074646
pigmentation O 1 0.9737981557846069
caused O 0 2.595326805021614e-06
by O 0 2.291337253268466e-08
POMC O 0 0.0004480995994526893
mutations O 0 7.0209043769864365e-06
in O 0 6.58205863146577e-08
humans O 0 4.4803886112276814e-07
. O 0 3.88949388252513e-07

Sequential O 0 4.585664646583609e-05
cleavage O 0 0.0002629042137414217
of O 0 5.761706844964465e-08
the O 0 8.837566234376482e-09
precursor O 0 7.427685488892166e-08
protein O 0 1.2401460480759852e-07
pre O 0 6.194238153511833e-07
- O 0 3.4090782719431445e-05
pro O 0 8.06271236797329e-06
- O 0 0.0001851339329732582
opiomelanocortin O 0 9.126316581387073e-05
( O 0 1.0802870065163006e-07
POMC O 0 1.0719250894908328e-05
) O 0 2.3297745954664606e-08
generates O 0 4.848790879918852e-08
the O 0 1.3103795382107819e-08
melanocortin O 0 2.1864818336325698e-05
peptides O 0 2.4602265966677805e-06
adrenocorticotrophin O 0 2.8257833037059754e-05
( O 0 1.918651832966134e-07
ACTH O 0 1.1290649126749486e-05
) O 0 1.231816693092469e-08
, O 0 3.991487584897868e-09
melanocyte O 0 2.8533320346468827e-06
- O 0 1.5920517398626544e-05
stimulating O 0 1.5269355344571522e-06
hormones O 0 8.794638119979936e-07
( O 0 1.8688940173205992e-08
MSH O 0 3.062558789679315e-06
) O 0 3.531820169655475e-09
alpha O 0 9.034072157021455e-09
, O 0 7.265726353899993e-10
beta O 0 2.2856398995685367e-09
and O 0 7.747051888884471e-10
gamma O 0 8.284282593251646e-09
as O 0 1.8896106901422627e-09
well O 0 1.3499906748037915e-09
as O 0 6.498139248911627e-10
the O 0 9.563558833747265e-10
opioid O 0 3.489915911814023e-08
- O 0 1.0876410527771441e-07
receptor O 0 1.578104757982146e-07
ligand O 0 2.0664398903136316e-07
beta O 0 6.182104925755993e-07
- O 0 2.686405787244439e-05
endorphin O 0 0.00022577425988856703
. O 0 1.1780020940932445e-06

While O 0 4.65905401370037e-07
a O 0 2.7981942096744206e-08
few O 0 1.3474548588021662e-08
cases O 0 3.859800923322609e-09
of O 0 8.397040396346256e-09
isolated O 0 0.11099046468734741
ACTH B-Disease 1 0.9987956285476685
deficiency I-Disease 0 0.03702633082866669
have O 0 3.12644345967783e-08
been O 0 3.880634835695673e-08
reported O 0 2.2544612932051677e-07
( O 0 1.9319887911706246e-08
OMIM O 0 4.735226684715599e-05
201400 O 0 7.682995715185825e-07
) O 0 3.2528584270608008e-09
, O 0 1.2813111682774547e-09
an O 0 3.937941528420197e-09
inherited O 0 0.0007292780210264027
POMC O 0 0.3245137929916382
defect O 0 0.0009405870805494487
has O 0 1.6668726630086894e-06
not O 0 1.3253859343365093e-08
been O 0 4.144733267708034e-08
described O 0 2.3695666584444552e-07
so O 0 2.0225995100986438e-08
far O 0 3.5694348810011434e-08
. O 0 8.829533726384398e-08

Recent O 0 2.1082046259834897e-06
studies O 0 8.057157430130246e-08
in O 0 3.810673554482946e-09
animal O 0 6.089720017143918e-08
models O 0 1.1390002896405349e-07
elucidated O 0 7.18148100986582e-07
a O 0 1.3625791162041878e-08
central O 0 6.988757128567613e-09
role O 0 5.472945208140345e-09
of O 0 8.102180593105857e-10
alpha O 0 4.225134730972968e-08
- O 0 3.2654845654178644e-06
MSH O 0 8.704747415322345e-06
in O 0 2.9539419799107236e-09
the O 0 8.630254844099738e-10
regulation O 0 6.37240882284118e-09
of O 0 1.8045989702564214e-10
food O 0 3.3932612275577867e-09
intake O 0 1.091464518765406e-08
by O 0 9.885407076248853e-11
activation O 0 2.4640374185480596e-09
of O 0 3.1750993501056257e-10
the O 0 5.99388760846864e-09
brain O 0 7.612504759890726e-07
melanocortin O 0 1.2189152585051488e-06
- O 0 1.8632653109307284e-06
4 O 0 7.545345681592153e-08
- O 0 5.039128154749051e-07
receptor O 0 1.814231751495754e-07
( O 0 1.3147881894326474e-08
MC4 O 0 1.7898149735628976e-06
- O 0 8.785357863416721e-07
R O 0 1.376897898808238e-06
; O 0 5.3228030871821375e-09
refs O 0 4.0447076798955095e-07
3 O 0 3.748098720279813e-08
- O 0 2.437175680825021e-06
5 O 0 7.828533199472076e-08
) O 0 1.3796528364196092e-09
and O 0 2.3412485283813567e-09
the O 0 8.622768055133179e-10
linkage O 0 7.964486599121301e-07
of O 0 3.2596156884778793e-09
human O 0 1.8176243088419142e-07
obesity B-Disease 1 0.9999998807907104
to O 0 5.146225134922133e-08
chromosome O 0 8.70024086907506e-06
2 O 0 3.78551590074494e-08
in O 0 1.5596731683942266e-09
close O 0 2.7105411248840028e-08
proximity O 0 3.7271966846219584e-08
to O 0 2.246697405894338e-08
the O 0 1.2134896643090087e-08
POMC O 0 2.6497338694753125e-05
locus O 0 1.3465320307659567e-06
, O 0 2.7574879268854602e-08
led O 0 2.0275667367286587e-08
to O 0 3.1795428512282342e-09
the O 0 1.4967337369498068e-09
proposal O 0 1.9822989472118024e-08
of O 0 9.356553309913807e-10
an O 0 2.222063644197192e-09
association O 0 3.807534731947726e-09
of O 0 2.54067411553649e-09
POMC O 0 7.73773790569976e-05
with O 0 7.58770326569902e-08
human O 0 1.5441980849573156e-06
obesity B-Disease 1 0.9999998807907104
. O 0 1.1901025800398202e-06

The O 0 2.3050448305639293e-07
dual O 0 3.548730660440924e-07
role O 0 1.234463127275376e-07
of O 0 3.5586378288599008e-09
alpha O 0 1.1357147400303802e-07
- O 0 1.1782058209064417e-05
MSH O 0 1.3284049600770231e-05
in O 0 5.0016843999856064e-09
regulating O 0 7.117743194839932e-08
food O 0 4.309816148406753e-08
intake O 0 1.5435192324275704e-07
and O 0 1.0019986618203802e-08
influencing O 0 1.7427741738629265e-07
hair O 0 0.01962524652481079
pigmentation O 0 0.00021251864382065833
predicts O 0 6.888037660246482e-06
that O 0 2.6698352417753313e-09
the O 0 2.3424990835962944e-09
phenotype O 0 6.1453579291992355e-06
associated O 0 6.697514098874535e-09
with O 0 1.916269587454167e-09
a O 0 1.9258820316281344e-07
defect O 0 3.12697738991119e-05
in O 0 2.013592315108781e-08
POMC O 0 4.543810791801661e-05
function O 0 7.642315580369541e-08
would O 0 4.513358931035327e-08
include O 0 5.3211209660730674e-08
obesity B-Disease 1 1.0
, O 0 2.1755850454496795e-08
alteration O 0 1.2520931704784743e-06
in O 0 1.9489182534471183e-07
pigmentation O 1 0.9951260685920715
and O 0 0.01760946959257126
ACTH B-Disease 1 0.9998345375061035
deficiency I-Disease 1 0.5978223085403442
. O 0 4.959972557116998e-07

The O 0 1.7614637215501716e-07
observation O 0 4.7152053639365477e-07
of O 0 3.4375122748286913e-09
these O 0 1.8567002157965362e-08
symptoms O 0 6.356187327583029e-07
in O 0 7.290880676968925e-10
two O 0 5.933216140618924e-09
probands O 0 2.9219606858532643e-06
prompted O 0 3.300809581219255e-08
us O 0 3.7874281488825545e-09
to O 0 1.9021938191254861e-10
search O 0 6.897908910730166e-09
for O 0 3.0842297604749547e-09
mutations O 0 2.611833451737766e-07
within O 0 9.209477624949614e-09
their O 0 3.74026463134669e-08
POMC O 0 0.00016627104196231812
genes O 0 6.073960321373306e-06
. O 0 6.872827498227707e-07

Patient O 0 0.000624559004791081
1 O 0 2.5128254037554143e-06
was O 0 3.7033021271781763e-07
found O 0 5.959892579454618e-09
to O 0 2.0230885855454517e-09
be O 0 1.1045109271634601e-09
a O 0 2.2243067387961446e-09
compound O 0 7.026746828842079e-08
heterozygote O 0 2.575365840584709e-07
for O 0 1.0016371065901808e-09
two O 0 6.581264866412084e-09
mutations O 0 9.937786416003291e-08
in O 0 2.8903612836472803e-09
exon O 0 6.23531036580971e-07
3 O 0 1.1050723713879052e-07
( O 0 1.5070959591412247e-08
G7013T O 0 2.7907753974432126e-07
, O 0 5.578292494590187e-09
C7133delta O 0 1.1602332961047068e-06
) O 0 4.107232776107139e-09
which O 0 2.458047765330207e-09
interfere O 0 3.963123607064745e-09
with O 0 1.092684387415943e-09
appropriate O 0 6.451141398855498e-09
synthesis O 0 3.148825555854273e-08
of O 0 1.2897958256985476e-08
ACTH O 0 1.7981290511670522e-05
and O 0 6.378807881901594e-08
alpha O 0 6.217147188181116e-07
- O 0 4.398687815410085e-05
MSH O 0 0.0002725771046243608
. O 0 7.430065807056963e-07

Patient O 0 0.0005178851424716413
2 O 0 2.8406118417478865e-06
was O 0 1.3166507528694638e-07
homozygous O 0 2.451967304750724e-07
for O 0 1.1670010513498141e-09
a O 0 7.392376932813249e-09
mutation O 0 8.725084654770399e-08
in O 0 4.528049490915009e-09
exon O 0 1.5382157698695664e-06
2 O 0 1.2433438314474188e-06
( O 0 5.8393613500129504e-08
C3804A O 0 3.4334036627114983e-06
) O 0 6.291914900202755e-08
which O 0 9.401803424680111e-08
abolishes O 0 7.52708874642849e-05
POMC O 0 0.0007466648239642382
translation O 0 1.1651148270175327e-05
. O 0 1.359917405352462e-06

These O 0 1.4186109353886422e-07
findings O 0 3.019014727101421e-08
represent O 0 2.3235160462320437e-09
the O 0 5.768815980466968e-10
first O 0 1.8501733478615279e-09
examples O 0 2.3191415454704156e-09
of O 0 1.3271054255525883e-09
a O 0 5.097388566355221e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 9.138924284002314e-09
the O 0 2.680111022002052e-09
POMC O 0 8.011619684111793e-06
gene O 0 2.1884876844069368e-07
and O 0 1.098812862920795e-08
define O 0 8.548659735652109e-08
a O 0 3.6506957457049793e-08
new O 0 1.265092123503564e-06
monogenic B-Disease 1 0.8126342296600342
endocrine I-Disease 1 0.9574044942855835
disorder I-Disease 0 0.003049929393455386
resulting O 0 6.582761358231437e-08
in O 0 4.1704639741624305e-09
early O 0 5.848244768458244e-07
- O 1 0.802960216999054
onset O 1 0.9874083995819092
obesity B-Disease 1 1.0
, O 0 5.446972500067204e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.4079543689149432e-05
red O 0 0.0001688989723334089
hair O 1 0.9968671202659607
pigmentation O 0 0.10819106549024582
. O 0 1.978407198066634e-07
. O 0 3.3226848472622805e-07

A O 0 5.300818429532228e-06
European O 0 7.956120953167556e-07
multicenter O 0 2.6883020836976357e-05
study O 0 2.2993233983470418e-07
of O 0 8.593008260504575e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 3.7450476497724594e-08
classification O 0 6.801806762268825e-08
of O 0 8.884326607727644e-10
105 O 0 1.030620495612311e-07
mutations O 0 6.119341264820832e-07
and O 0 1.2835843499203747e-08
a O 0 6.145878916896663e-09
general O 0 1.8163406334537058e-09
system O 0 6.949557374014148e-09
for O 0 1.5260387398186026e-09
genotype O 0 5.150811261955823e-07
- O 0 5.08178800373571e-06
based O 0 1.3804331899791578e-07
prediction O 0 1.8002642718784045e-06
of O 0 2.3151608630200826e-08
metabolic O 0 0.0006924743065610528
phenotype O 0 0.0001742358726914972
. O 0 7.577397695968102e-07

Phenylketonuria B-Disease 1 0.9746229648590088
( O 0 4.732765955850482e-05
PKU B-Disease 0 0.00040363986045122147
) O 0 1.2435349390216288e-06
and O 0 9.675179626356112e-07
mild B-Disease 0 0.16598129272460938
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.0029397220350801945
MHP B-Disease 1 1.0
) O 0 3.1733532068756176e-07
are O 0 1.1432215529794121e-07
allelic B-Disease 0 0.3046762943267822
disorders I-Disease 1 0.9992882609367371
caused O 0 2.7210001007915707e-07
by O 0 1.784140502003595e-09
mutations O 0 2.36729007951908e-07
in O 0 1.8957693193044634e-09
the O 0 1.7439688804188336e-08
gene O 0 7.768129762553144e-06
encoding O 0 0.00023522909032180905
phenylalanine O 1 0.6169822812080383
hydroxylase O 0 0.46860015392303467
( O 0 1.4749630281585269e-06
PAH O 0 0.00018187864043284208
) O 0 3.2098628821586317e-07
. O 0 5.411827146417636e-07

Previous O 0 3.949704023398226e-06
studies O 0 6.252579254351076e-08
have O 0 1.4272490744815514e-08
suggested O 0 1.1603076721655725e-08
that O 0 5.786977563815299e-10
the O 0 1.7006601682467704e-09
highly O 0 1.6701516614148204e-08
variable O 0 9.935869229593663e-07
metabolic O 0 0.00028978483169339597
phenotypes O 0 0.00017487751028966159
of O 0 1.2206346582388505e-06
PAH B-Disease 1 0.9973227381706238
deficiency I-Disease 0 0.09313945472240448
correlate O 0 1.2206661267555319e-05
with O 0 7.40904340545967e-07
PAH O 0 0.00551977613940835
genotypes O 0 0.0005097027751617134
. O 0 3.3116041322500678e-06

We O 0 2.30462364925188e-06
identified O 0 3.002144808306184e-07
both O 0 9.050836524693295e-09
causative O 0 2.1369323803810403e-06
mutations O 0 1.9878816601703875e-06
in O 0 1.361947710165623e-08
686 O 0 4.7734442887303885e-06
patients O 0 2.593414194507204e-07
from O 0 4.377399775989943e-09
seven O 0 2.467735704669849e-08
European O 0 2.7157108561937093e-08
centers O 0 1.9724444655366824e-07
. O 0 2.3665360515678913e-07

On O 0 2.2893859750183765e-06
the O 0 4.83738027412528e-09
basis O 0 4.10735001565854e-09
of O 0 2.39478520347447e-10
the O 0 1.1776219999148907e-09
phenotypic O 0 4.2154997004217876e-07
characteristics O 0 1.3667717269072455e-07
of O 0 4.6686943200313635e-09
297 O 0 6.66840264784696e-07
functionally O 0 3.121241206827108e-06
hemizygous O 0 7.2603547778271604e-06
patients O 0 9.090667418831799e-08
, O 0 7.155374071032838e-10
105 O 0 3.937881132287657e-09
of O 0 2.051766256894183e-10
the O 0 2.281915545410129e-09
mutations O 0 2.1433562835682096e-07
were O 0 1.272929939233336e-08
assigned O 0 1.4717910445938287e-08
to O 0 1.4035814288604342e-08
one O 0 4.8337276403742635e-09
of O 0 3.40612454907685e-10
four O 0 6.153068721204136e-09
arbitrary O 0 9.09906873403088e-07
phenotype O 0 2.3749069441691972e-05
categories O 0 2.940915919680265e-07
. O 0 2.6409557563056296e-07

We O 0 2.1545718027482508e-06
proposed O 0 5.6166342687902215e-08
and O 0 4.0872752293807935e-08
tested O 0 2.8121856843199566e-08
a O 0 9.07454777987482e-10
simple O 0 2.35101271783833e-09
model O 0 3.203478149416128e-09
for O 0 2.1019094798013782e-10
correlation O 0 1.796187376612579e-08
between O 0 1.531489246531237e-08
genotype O 0 6.899134632476489e-07
and O 0 8.467452516924823e-09
phenotypic O 0 9.725255267767352e-07
outcome O 0 6.328454560389218e-07
. O 0 5.545800263462297e-07

The O 0 9.011820907289803e-07
observed O 0 2.122341811627848e-06
phenotype O 0 9.848119589150883e-06
matched O 0 1.695720470706874e-06
the O 0 9.318533500390913e-09
predicted O 0 1.164591026281414e-06
phenotype O 0 7.440020226567867e-07
in O 0 3.5132896591960616e-09
79 O 0 9.722550231572313e-08
% O 0 1.0115321913417574e-09
of O 0 6.524340789848537e-11
the O 0 3.8881307062865744e-09
cases O 0 1.0379250348080404e-08
, O 0 1.25678791818018e-08
and O 0 2.910538476896818e-08
in O 0 3.864235598172172e-09
only O 0 2.4611770399474153e-09
5 O 0 1.0134942884931775e-09
of O 0 1.9232658521328716e-10
184 O 0 1.1753471973463547e-08
patients O 0 8.16562106820129e-09
was O 0 3.263623682414618e-08
the O 0 5.155592064376435e-10
observed O 0 2.800479315112625e-08
phenotype O 0 7.32878291387351e-08
more O 0 5.561238691775827e-10
than O 0 3.923320002208186e-10
one O 0 1.2062224552522594e-09
category O 0 2.3699277207356317e-08
away O 0 2.150177778048601e-07
from O 0 2.7349738029869286e-09
that O 0 2.3765986956192364e-09
expected O 0 2.533049681119337e-08
. O 0 8.806776463643473e-08

Among O 0 5.350748324417509e-07
the O 0 8.43955838547572e-09
seven O 0 6.985758194133496e-09
contributing O 0 4.619312932163666e-09
centers O 0 6.381409178857211e-09
, O 0 1.845038899439544e-09
the O 0 7.206791829972303e-10
proportion O 0 2.9569182657951387e-09
of O 0 2.407287424954774e-10
patients O 0 5.0945199170371325e-09
for O 0 2.4584406732586217e-10
whom O 0 2.8266189389114516e-08
the O 0 1.7755888981341172e-09
observed O 0 1.6620408871403924e-07
phenotype O 0 2.422220859443769e-06
did O 0 2.866399597678537e-07
not O 0 2.8653424077873524e-09
match O 0 9.519704136096152e-09
the O 0 8.393101325054886e-09
predicted O 0 4.104645540792262e-06
phenotype O 0 8.143629770529515e-07
was O 0 4.063117486907686e-08
4 O 0 4.480232629333614e-09
% O 0 8.307063370516232e-10
- O 0 2.456313268339727e-07
23 O 0 9.1697806681168e-08
% O 0 2.050390301988614e-09
( O 0 2.382358088581782e-09
P O 0 1.0679401611923822e-06
< O 0 7.953194369747507e-08
. O 0 1.5364741701162643e-09
0001 O 0 8.871921863828902e-08
) O 0 8.541578000453853e-10
, O 0 2.273677079944747e-10
suggesting O 0 2.926932030078433e-09
that O 0 1.7313463163137754e-10
differences O 0 3.314801766407527e-09
in O 0 1.5730718117001885e-10
methods O 0 1.0241353320949997e-09
used O 0 1.1642620201257614e-09
for O 0 1.9108922777455462e-10
mutation O 0 2.1842668118665642e-08
detection O 0 2.763669471050889e-08
or O 0 4.3524423176677374e-08
phenotype O 0 1.0072231816593558e-05
classification O 0 6.535721581713005e-07
may O 0 3.5291526501168846e-07
account O 0 5.8606035580055504e-09
for O 0 3.571624107578941e-10
a O 0 2.244807228990453e-09
considerable O 0 3.3816633937533425e-09
proportion O 0 1.065160315505409e-08
of O 0 3.4706901796965894e-09
genotype O 0 4.899505074718036e-05
- O 0 0.004486940335482359
phenotype O 0 0.00041773365228436887
inconsistencies O 0 7.281446596607566e-05
. O 0 8.305769370053895e-07

Our O 0 2.195520892200875e-06
data O 0 2.1635645452988683e-07
indicate O 0 1.6914066236495273e-07
that O 0 2.1205304179261475e-09
the O 0 9.52918721708329e-09
PAH O 0 4.146504943491891e-05
- O 0 3.2869291317183524e-05
mutation O 0 2.4538717298128176e-06
genotype O 0 1.7546443586979876e-06
is O 0 4.219044669184768e-09
the O 0 9.698908343125368e-10
main O 0 1.8363925491371447e-08
determinant O 0 4.949316689817351e-07
of O 0 1.439228025645889e-08
metabolic O 0 0.0002782977535389364
phenotype O 0 1.0636726074153557e-05
in O 0 1.2790289716235748e-08
most O 0 6.364223992250118e-08
patients O 0 5.081576546217548e-07
with O 0 1.6781077647465281e-06
PAH B-Disease 1 0.9994811415672302
deficiency I-Disease 0 0.21908371150493622
. O 0 5.942295615568582e-07

In O 0 4.933732498102472e-07
the O 0 9.271339251881727e-09
present O 0 2.5090494126800422e-09
study O 0 9.874990825053942e-10
, O 0 5.088078847137467e-10
the O 0 4.3152736939333636e-10
classification O 0 2.6130985375516502e-08
of O 0 1.976604435682816e-09
105 O 0 6.864259489702818e-07
PAH O 0 1.7154869055957533e-05
mutations O 0 4.817246122001961e-07
may O 0 1.5796761232422796e-08
allow O 0 5.889556065064028e-10
the O 0 7.501342880189554e-10
prediction O 0 1.1445808212329212e-07
of O 0 1.4102403966820276e-10
the O 0 9.960360314309469e-10
biochemical O 0 8.371886792701844e-07
phenotype O 0 6.554784590662166e-07
in O 0 1.2559677742274289e-09
> O 0 2.209040594891576e-08
10 O 0 2.049021841088461e-09
, O 0 8.069146462119647e-10
000 O 0 8.165543796678776e-09
genotypes O 0 4.0501811326976167e-07
, O 0 1.9006654028430603e-08
which O 0 2.4739898663028725e-07
may O 0 1.176177448769522e-07
be O 0 2.391352671438085e-10
useful O 0 3.5101532791514956e-10
for O 0 1.4615174348531212e-10
the O 0 2.7561193327585443e-09
management O 0 2.2195360216414883e-08
of O 0 5.7236304584762365e-09
hyperphenylalaninemia B-Disease 1 0.9999998807907104
in O 0 5.953504569333745e-07
newborns O 0 2.764646524155978e-05
. O 0 1.3688899969110935e-07

Somatic O 0 0.00014406713307835162
instability O 0 1.5687723134760745e-05
of O 0 2.185979752766798e-08
the O 0 2.161336709605166e-08
CTG O 0 2.874812707887031e-05
repeat O 0 8.817968364382978e-07
in O 0 6.127549134760102e-09
mice O 0 8.712028147783712e-07
transgenic O 0 2.1104847292008344e-07
for O 0 9.574222303854185e-09
the O 0 6.866426360829792e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 5.25988298250013e-06
is O 0 2.4164906520240947e-08
age O 0 7.1008585678100644e-09
dependent O 0 4.88539164678059e-09
but O 0 2.300146295652894e-09
not O 0 3.405474791051688e-10
correlated O 0 3.806460036059889e-09
to O 0 1.213982137038272e-09
the O 0 1.21006371589516e-09
relative O 0 4.355041482995148e-08
intertissue O 0 1.5722612261015456e-06
transcription O 0 1.3360278217078303e-06
levels O 0 1.015986157426596e-07
and O 0 5.5929014308730984e-08
proliferative O 0 0.0006060274317860603
capacities O 0 5.9447556850500405e-06
. O 0 4.088055902684573e-07

A O 0 6.297026629908942e-06
( O 0 9.850202786765294e-07
CTG O 0 1.414258895238163e-05
) O 0 5.043550999062063e-08
nexpansion O 0 1.7052137764039799e-06
in O 0 1.6537725855414465e-08
the O 0 2.198721027468764e-08
3 O 0 8.132670927807339e-07
- O 0 0.01311282068490982
untranslated O 0 0.04781961068511009
region O 0 4.462286233319901e-05
( O 0 1.0531227445653712e-07
UTR O 0 9.108349331654608e-06
) O 0 1.4245483903607692e-08
of O 0 2.607948523802861e-09
the O 0 1.2529409332273644e-07
DM O 1 1.0
protein O 0 3.890449988830369e-06
kinase O 0 9.909601430990733e-06
gene O 0 1.5755483673274284e-06
( O 0 4.503633022068243e-08
DMPK O 0 9.227693226421252e-06
) O 0 8.29206037167296e-09
is O 0 3.1397444644198913e-09
responsible O 0 2.2760744400329713e-08
for O 0 5.446715789503287e-08
causing O 0 0.0006281167734414339
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00012509655789472163
DM B-Disease 1 1.0
) O 0 3.2872626434254926e-06
. O 0 9.442306918572285e-07

Major O 0 6.64736217004247e-06
instability O 0 1.0931000360869803e-05
, O 0 1.4329062381079893e-08
with O 0 7.628487286304164e-10
very O 0 8.649205796018578e-10
large O 0 3.972217832437508e-10
expansions O 0 5.8658400803324184e-08
between O 0 5.7988280843801476e-08
generations O 0 1.9511182358655788e-07
and O 0 1.3042257052120476e-08
high O 0 1.1967197899309667e-08
levels O 0 2.096097295734012e-09
of O 0 3.356907252172192e-10
somatic O 0 1.428154945415372e-07
mosaicism O 0 1.3704062439501286e-05
, O 0 7.564059600895234e-09
is O 0 3.504435408530071e-09
observed O 0 1.694392715023696e-08
in O 0 1.0299538999447577e-08
patients O 0 2.525679008158477e-07
. O 0 1.1421514756193574e-07

There O 0 1.1023068964277627e-06
is O 0 1.515518910366609e-08
a O 0 6.618046555217916e-09
good O 0 1.0764341418223466e-08
correlation O 0 2.9012657165594646e-08
between O 0 2.1382721371310254e-08
repeat O 0 4.255512635609193e-07
size O 0 2.0599978256541362e-07
( O 0 7.36823535518738e-09
at O 0 2.9774622767320125e-09
least O 0 7.25127291545391e-10
in O 0 7.37201300005097e-10
leucocytes O 0 1.1638783234957373e-06
) O 0 2.4622006655761197e-09
, O 0 1.3397967180139858e-09
clinical O 0 2.5328374064770287e-08
severity O 0 1.5418772818520665e-06
and O 0 3.756049693492969e-08
age O 0 2.60257841944167e-08
of O 0 4.7690917881482164e-09
onset O 0 2.1298163119354285e-05
. O 0 3.287762808668049e-07

The O 0 3.924131760868477e-06
trinucleotide O 0 0.00041290593799203634
repeat O 0 2.1840040062670596e-05
instability O 0 4.0205968616646715e-06
mechanisms O 0 1.6711862826923607e-07
involved O 0 2.4090354600048158e-08
in O 0 9.800786671121386e-08
DM B-Disease 1 1.0
and O 0 3.743216154816764e-07
other O 0 1.163205975984738e-08
human O 0 9.46477427987702e-07
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.0396257127686113e-08
unknown O 0 2.54021614409794e-07
. O 0 2.18454857758843e-07

We O 0 2.6237621568725444e-06
studied O 0 3.554851559783856e-07
somatic O 0 1.086174847841903e-06
instability O 0 6.053305696696043e-07
by O 0 2.4353909999774714e-09
measuring O 0 1.872487587206706e-07
the O 0 4.7770485345211e-09
CTG O 0 4.604150944942376e-06
repeat O 0 1.648229385864397e-06
length O 0 8.026379418879515e-07
at O 0 4.158692057387725e-09
several O 0 1.4527247182982705e-09
ages O 0 2.5549919513423447e-08
in O 0 2.994386683052852e-10
various O 0 9.098499731408083e-10
tissues O 0 2.247147357081758e-08
of O 0 4.035733136564801e-10
transgenic O 0 5.837050593981985e-07
mice O 0 1.049823254106741e-06
carrying O 0 7.295085424630088e-09
a O 0 1.2825075224043303e-08
( O 0 1.0145372542069708e-08
CTG O 0 9.846971806837246e-07
) O 0 3.119080105307148e-09
55expansion O 0 2.2903418539499398e-07
surrounded O 0 5.699155636307296e-08
by O 0 9.386207366901544e-10
45 O 0 6.535531671403305e-09
kb O 0 4.442542831384344e-07
of O 0 1.3673765453248166e-09
the O 0 3.754459498850338e-08
human O 0 1.6196518117794767e-06
DM B-Disease 1 1.0
region O 0 1.2267029205759172e-06
, O 0 9.6276531191819e-10
using O 0 2.355114769869715e-09
small O 0 1.1798843679855509e-08
- O 0 7.4992199188272934e-06
pool O 0 1.6721776319172932e-06
PCR O 0 2.4803126507322304e-05
. O 0 2.869725506116083e-07

These O 0 6.679617854388198e-07
mice O 0 7.805929271853529e-06
have O 0 2.545584187885197e-08
been O 0 1.4642560941524607e-08
shown O 0 1.5177057832715946e-08
to O 0 1.0901822777853454e-09
reproduce O 0 6.563353736055433e-07
the O 0 2.3872843701866486e-09
intergenerational O 0 7.671288813071442e-07
and O 0 1.8479136443261268e-08
somatic O 0 1.5093317529135675e-07
instability O 0 1.4961099736865435e-07
of O 0 4.778969442398306e-10
the O 0 3.361509515187322e-09
55 O 0 3.994879094193493e-08
CTG O 0 1.1632491805357859e-06
repeat O 0 1.8981678806540003e-07
suggesting O 0 2.7630582266624515e-08
that O 0 5.999214458540791e-10
surrounding O 0 4.470603887085645e-09
sequences O 0 7.479604846594157e-08
and O 0 4.760539962234134e-09
the O 0 5.9675336894216e-10
chromatin O 0 5.407762415643447e-08
environment O 0 3.3987230807497326e-08
are O 0 7.422070735785269e-10
involved O 0 1.0679142015135312e-09
in O 0 3.9968890419572745e-09
instability O 0 2.3010877612250624e-06
mechanisms O 0 5.874035196029581e-07
. O 0 1.8413963687180512e-07

As O 0 1.0913623782471404e-06
observed O 0 2.860429901829775e-07
in O 0 1.399197091522808e-09
some O 0 3.4452954378316747e-10
of O 0 1.1219380285920622e-10
the O 0 4.3202170729728095e-09
tissues O 0 3.0620341817666485e-07
of O 0 3.614735177848161e-08
DM B-Disease 1 1.0
patients O 0 2.8395013487170218e-06
, O 0 4.179502077761299e-09
there O 0 1.0383343074238383e-09
is O 0 4.662400465704764e-10
a O 0 1.8359117559541005e-09
tendency O 0 4.596700620140837e-08
for O 0 1.2063443577403632e-09
repeat O 0 7.43577174944221e-07
length O 0 1.2498146588768577e-06
and O 0 6.7259340319481e-09
somatic O 0 3.623640409955442e-08
mosaicism O 0 7.995735131771653e-07
to O 0 5.148892867623545e-09
increase O 0 3.437092832569988e-09
with O 0 3.4566185469486754e-09
the O 0 2.443208479974146e-08
age O 0 3.578077922838929e-08
of O 0 3.9302930354701004e-10
the O 0 9.845225079629927e-09
mouse O 0 0.00028011910035274923
. O 0 9.299997145717498e-07

Furthermore O 0 1.204864020110108e-05
, O 0 1.325140033259231e-07
we O 0 1.5576226530811255e-08
observed O 0 7.0706120958163865e-09
no O 0 4.5706866069750163e-10
correlation O 0 1.249676717662851e-08
between O 0 3.5663296760191088e-09
the O 0 3.6460037211583085e-09
somatic O 0 2.740056288530468e-07
mutation O 0 6.044185170139826e-07
rate O 0 5.186429348214006e-07
and O 0 6.84215706314717e-08
tissue O 0 3.3688977509882534e-06
proliferation O 0 1.124340542446589e-06
capacity O 0 1.0729130650588559e-07
. O 0 9.220799768172583e-08

The O 0 3.0663474603898067e-07
somatic O 0 2.5152135094685946e-06
mutation O 0 2.0259044504200574e-06
rates O 0 1.4869863207422895e-07
in O 0 8.529042472282811e-10
different O 0 2.6529518581952516e-09
tissues O 0 3.151529881506576e-07
were O 0 1.4109150470176246e-07
also O 0 5.73549066018586e-08
not O 0 1.709545172090543e-09
correlated O 0 1.8178734961793452e-08
to O 0 2.7163049587386467e-09
the O 0 1.883716294059923e-09
relative O 0 5.927506663283566e-08
inter O 0 9.767863957677037e-07
- O 0 4.727848863694817e-05
tissue O 0 8.133911819641071e-07
difference O 0 5.4196758192404104e-09
in O 0 3.728430064686705e-10
transcriptional O 0 6.765255022855854e-08
levels O 0 7.52272377724239e-09
of O 0 1.887038164616328e-10
the O 0 6.406430941297003e-10
three O 0 4.715688284306907e-09
genes O 0 9.679106227622469e-08
( O 0 6.720983325436691e-09
DMAHP O 0 9.873846238406259e-07
, O 0 7.527862777578775e-09
DMPK O 0 3.595109319576295e-06
and O 0 4.666657815732833e-08
59 O 0 3.698960426845588e-08
) O 0 4.941185793860825e-10
surrounding O 0 2.8492923576095563e-09
the O 0 7.916988842282535e-09
repeat O 0 1.969096274478943e-06
. O 0 3.015044214293994e-08
. O 0 1.1815174616458535e-07

A O 0 3.858474883600138e-06
novel O 0 8.372944648726843e-06
missense O 0 0.00011588540655793622
mutation O 0 4.6664540604979265e-06
in O 0 1.0449269005619044e-08
patients O 0 3.7133382591036934e-08
from O 0 1.8218401232061865e-09
a O 0 1.871726418301023e-08
retinoblastoma B-Disease 0 2.5942355932784267e-05
pedigree O 0 0.00019033289572689682
showing O 0 9.91999331745319e-06
only O 0 3.5057407643535043e-08
mild O 0 5.5726951586621e-07
expression O 0 2.6141455222727927e-08
of O 0 1.0613998568942407e-09
the O 0 4.577933054861205e-08
tumor B-Disease 0 0.00016619068628642708
phenotype O 0 5.599523865384981e-05
. O 0 7.179783096944448e-07

We O 0 5.253847120911814e-06
have O 0 9.537624023892022e-09
used O 0 3.834339512565066e-09
single O 0 1.7805650287527897e-08
strand O 0 1.4554026392943342e-06
conformation O 0 3.1380821496895805e-07
polymorphism O 0 6.552259179670727e-08
analysis O 0 3.655438840510783e-09
to O 0 8.344126500858806e-10
study O 0 6.982637801300484e-10
the O 0 2.0265760181104042e-09
27 O 0 6.726102697030001e-08
exons O 0 1.8565219761512708e-07
of O 0 8.483613811449686e-10
the O 0 5.382548184940106e-09
RB1 O 0 2.824934654199751e-06
gene O 0 2.22031921737198e-08
in O 0 1.7765305893036043e-09
individuals O 0 3.944366500086005e-10
from O 0 2.402324450478943e-10
a O 0 9.552479696139926e-09
family O 0 3.747909715912101e-07
showing O 0 8.994375093607232e-06
mild O 0 1.8422921357341693e-06
expression O 0 1.6390197643545434e-08
of O 0 1.2486968126168563e-09
the O 0 3.051521701991078e-08
retinoblastoma B-Disease 0 0.00013063146616332233
phenotype O 0 0.00014524399011861533
. O 0 6.49154912935046e-07

In O 0 2.6187046842096606e-07
this O 0 1.215458667047642e-08
family O 0 9.042988580176825e-08
affected O 0 3.4163495143957334e-08
individuals O 0 2.409236365963352e-09
developed O 0 1.0603282873944408e-07
unilateral B-Disease 0 0.04099951311945915
tumors I-Disease 1 1.0
and O 0 1.283356687054038e-05
, O 0 8.528233230720161e-09
as O 0 1.8550108116244246e-09
a O 0 5.741814135262757e-09
result O 0 3.8042897720913516e-09
of O 0 6.190888912627202e-10
linkage O 0 8.565974667362752e-07
analysis O 0 1.8124724832091488e-08
, O 0 4.738770265078074e-09
unaffected O 0 1.4783189783429407e-07
mutation O 0 5.626240806577698e-08
carriers O 0 1.593295984037013e-08
were O 0 1.7542911123769045e-08
also O 0 2.77896141653855e-08
identified O 0 5.871000041679508e-08
within O 0 2.5437290052110484e-09
the O 0 1.2037729923974894e-08
pedigree O 0 7.098513742676005e-05
. O 0 4.171429850430286e-07

A O 0 5.6069429774652235e-06
single O 0 1.4952041738069966e-06
band O 0 1.050576315719809e-06
shift O 0 2.1765529822914687e-07
using O 0 2.3960668116274064e-08
SSCP O 0 2.1556696083280258e-05
was O 0 1.9092479419668962e-07
identified O 0 1.2014951700223264e-08
in O 0 1.4581795770851613e-09
exon O 0 5.83160897349444e-07
21 O 0 9.057338843376783e-07
which O 0 2.4107269069872928e-08
resulted O 0 7.88931320272468e-09
in O 0 1.4219578847729508e-09
a O 0 3.133380488407056e-08
missense O 0 9.701267117634416e-06
mutation O 0 1.7837184884683666e-07
converting O 0 3.7284053178154863e-08
a O 0 4.9467452356566355e-08
cys O 0 5.2221679652575403e-05
- O 0 1.5420671843457967e-05
- O 0 1.1598711353144608e-05
> O 0 1.933751718752319e-07
arg O 0 4.5618295985150326e-07
at O 0 1.1644712749614428e-08
nucleotide O 0 1.5927163588003168e-07
position O 0 1.6407470582180395e-07
28 O 0 4.7850942763716375e-08
in O 0 1.571063612537671e-09
the O 0 1.1563397350755622e-08
exon O 0 9.27275323192589e-06
. O 0 1.1742512242562952e-06

The O 0 5.067049073659291e-07
mutation O 0 2.5886181447276613e-06
destroyed O 0 2.967888121929718e-07
an O 0 6.975665822750443e-09
NdeI O 0 2.9331004043342546e-06
restriction O 0 1.5819863108390564e-07
enzyme O 0 9.790143167265342e-07
site O 0 2.41311590798432e-06
. O 0 5.292445734994544e-07

Analysis O 0 1.740901780067361e-06
of O 0 1.616884048871725e-08
all O 0 5.731069840919645e-09
family O 0 2.0208563711321403e-08
members O 0 4.6031995992734664e-09
demonstrated O 0 1.67054974298253e-08
that O 0 5.883875053847021e-10
the O 0 2.942111221315713e-09
missense O 0 4.314465058996575e-06
mutation O 0 3.881819736761827e-07
co O 0 3.369015075804782e-07
- O 0 8.032956770875899e-07
segregated O 0 1.8337854612582305e-07
with O 0 4.138311027190866e-08
patients O 0 1.977469565872525e-07
with O 0 3.7048849321763555e-07
tumors B-Disease 1 1.0
or O 0 9.411081919097342e-06
who O 0 4.195932706352323e-05
, O 0 2.5789028690326177e-09
as O 0 1.7089324400032524e-09
a O 0 5.095024846468732e-09
result O 0 1.624822276724558e-09
of O 0 2.3239538071706534e-10
linkage O 0 2.9773849519187934e-07
analysis O 0 4.4354770523113984e-08
had O 0 7.199871561169857e-06
been O 0 1.722731610698247e-07
predicted O 0 1.5051230661811132e-07
to O 0 8.832337639042009e-10
carry O 0 7.727958717396177e-09
the O 0 1.2099213186900215e-08
predisposing O 0 1.6909156329347752e-05
mutation O 0 5.752083325205604e-06
. O 0 4.315072317240265e-07

These O 0 1.77559741132427e-07
observations O 0 2.751488921148848e-07
point O 0 4.513427995789243e-07
to O 0 7.9845019484992e-09
another O 0 1.484395806272687e-08
region O 0 3.1710175818489006e-08
of O 0 7.690136860638574e-10
the O 0 6.6858230063360224e-09
RB1 O 0 7.462926987500396e-06
gene O 0 1.0662909488701189e-07
where O 0 1.9627053760018498e-08
mutations O 0 6.958273957025085e-08
only O 0 8.56709592156335e-10
modify O 0 1.2145594752155375e-08
the O 0 1.3461542991421993e-09
function O 0 1.23310661681586e-09
of O 0 9.33973454131376e-11
the O 0 8.686734664919982e-10
gene O 0 3.2171101338462904e-08
and O 0 2.1279298323406692e-08
raise O 0 3.422994110380273e-09
important O 0 3.98040128635202e-10
questions O 0 8.408447826901977e-10
for O 0 1.5807262443434666e-10
genetic O 0 3.114427116202023e-08
counseling O 0 1.657277692856951e-08
in O 0 1.1495374652170653e-09
families O 0 2.6541666642287964e-09
with O 0 4.944070708390313e-10
these O 0 2.0160662028700926e-09
distinctive O 0 6.144861686152581e-07
phenotypes O 0 3.847389052680228e-06
. O 0 2.8192264522886035e-08
. O 0 7.49204076555543e-08

Maternal B-Disease 0 0.005010426510125399
disomy I-Disease 0 0.039537519216537476
and O 0 0.0007040072814561427
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 2.703826339711668e-06
with O 0 2.0678248446870384e-08
gamete O 0 3.2473728879267583e-06
complementation O 0 1.3538338862417731e-05
in O 0 6.050757672682039e-09
a O 0 7.13546599584447e-09
case O 0 9.839893344576467e-09
of O 0 2.1904444924558675e-09
familial O 0 2.905984501921921e-06
translocation O 0 1.9264167349319905e-05
( O 0 2.250896535826996e-08
3 O 0 1.3559602329848985e-08
; O 0 1.091884982429292e-08
15 O 0 2.126793674506189e-08
) O 0 3.104834611633578e-09
( O 0 2.347186223161657e-09
p25 O 0 1.0942058992213788e-07
; O 0 6.937280527807843e-09
q11 O 0 1.5974654843375902e-07
. O 0 3.3465270554700055e-09
2 O 0 2.3642119373334936e-08
) O 0 3.0320222776936134e-08
. O 0 1.3296744327817578e-07

Maternal B-Disease 0 0.058928053826093674
uniparental I-Disease 1 0.9758815169334412
disomy I-Disease 1 0.711224377155304
( I-Disease 0 0.00011297078162897378
UPD I-Disease 1 0.9999998807907104
) I-Disease 0 8.748981628059482e-08
for I-Disease 0 2.6804432007310197e-09
chromosome I-Disease 0 0.00013652091729454696
15 I-Disease 0 2.895086765875021e-07
is O 0 2.511845842434468e-09
responsible O 0 9.647836973769586e-10
for O 0 1.5038181810922424e-10
an O 0 4.305999168341401e-10
estimated O 0 1.4003618709068633e-08
30 O 0 3.8806695634718835e-09
% O 0 1.6138383684971558e-10
of O 0 1.4021672711805877e-10
cases O 0 1.4021820149423547e-08
of O 0 1.2633149708562996e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.1278976419125684e-05
PWS B-Disease 1 0.9999996423721313
) O 0 1.2077260862497496e-06
. O 0 7.48003230910399e-07

We O 0 2.147028317267541e-05
report O 0 2.5810743764509425e-08
on O 0 3.3134111010468814e-09
an O 0 2.1371120151325584e-10
unusual O 0 1.3344053639841036e-09
case O 0 3.5473748383196835e-09
of O 0 4.77325734493661e-10
maternal B-Disease 0 2.949783777239645e-07
disomy I-Disease 0 3.60079843630956e-06
15 I-Disease 0 1.2089793699487927e-07
in O 0 4.379515061714301e-08
PWS B-Disease 1 1.0
that O 0 6.140386972219858e-07
is O 0 1.0697740471243833e-08
most O 0 9.315970217471659e-10
consistent O 0 1.2026966089706548e-08
with O 0 5.788125534422761e-10
adjacent O 0 6.935999152801742e-08
- O 0 4.229571914038388e-06
1 O 0 1.6966305693699724e-08
segregation O 0 3.23388711365169e-08
of O 0 3.2988867193495253e-10
a O 0 9.900228192805116e-09
paternal O 0 4.083265594090335e-06
t O 0 1.9690645785885863e-05
( O 0 3.07319591996702e-09
3 O 0 2.999132497905066e-09
; O 0 3.2872873312328466e-09
15 O 0 6.408952035741322e-09
) O 0 1.5022708632628223e-09
( O 0 1.5398274877398421e-09
p25 O 0 1.0189689447770434e-07
; O 0 4.730886349335606e-09
q11 O 0 1.069195008085444e-07
. O 0 1.9291745978478048e-09
2 O 0 2.464987103323324e-09
) O 0 2.475719351746619e-10
with O 0 1.8497138543072111e-10
simultaneous O 0 5.487079235422243e-08
maternal O 0 1.0953643823086168e-06
meiotic O 0 5.099367172078928e-06
nondisjunction O 0 3.0317269192892127e-06
for O 0 1.3756070060821912e-08
chromosome O 0 2.898992897826247e-05
15 O 0 3.259437733049708e-07
. O 0 2.1858510024230782e-07

The O 0 1.0156292091778596e-06
patient O 0 6.77505067869788e-06
( O 0 1.5590886448535457e-07
J O 0 2.6593053917167708e-05
. O 0 1.2040645813726769e-08
B O 0 1.2519745951067307e-07
. O 0 1.3253927955148015e-09
) O 0 5.718105988705702e-10
, O 0 1.9777310344970545e-10
a O 0 2.9788367328364984e-09
17 O 0 5.114608114809016e-08
- O 0 1.9681463072629413e-06
year O 0 2.9199966888882045e-08
- O 0 8.218755283451173e-06
old O 0 0.00014955918595660478
white O 0 3.941861905332189e-06
male O 0 5.200654413783923e-07
with O 0 6.72506388355032e-08
PWS B-Disease 1 1.0
, O 0 8.984243748955123e-08
was O 0 2.840130264303298e-07
found O 0 3.2580991238262413e-09
to O 0 2.2194754922821858e-09
have O 0 4.63017135743371e-09
47 O 0 2.8025047171809092e-08
chromosomes O 0 1.3063460357898293e-07
with O 0 5.854335682897727e-09
a O 0 6.267396912562617e-08
supernumerary O 0 0.0002209277736255899
, O 0 1.0430296271124462e-07
paternal O 0 2.0855259208474308e-05
der O 0 0.05943842977285385
( O 0 1.7562999943265822e-08
15 O 0 1.0742313705236484e-08
) O 0 6.501275628956193e-10
consisting O 0 8.867024892111885e-10
of O 0 2.187993564106705e-09
the O 0 5.079444918010267e-07
short O 0 0.008252792991697788
arm O 0 0.07385150343179703
and O 0 1.2786537695319566e-07
the O 0 1.279155803501908e-08
proximal O 0 1.5332596376538277e-05
long O 0 9.870262147160247e-06
arm O 0 8.059912943281233e-06
of O 0 1.9596444467140373e-09
chromosome O 0 5.674133717548102e-06
15 O 0 7.358014642022681e-08
, O 0 6.130518315217159e-09
and O 0 8.188161615407807e-08
distal O 0 0.0005148944910615683
chromosome O 1 0.672220766544342
arm O 0 0.007130510173738003
3p O 0 0.0007056301110424101
. O 0 2.4733581085456535e-06

The O 0 7.629832339262066e-07
t O 0 8.272952072729822e-06
( O 0 1.0070396072592303e-08
3 O 0 1.0415202922331446e-08
; O 0 5.447574835670821e-09
15 O 0 4.394786401462625e-08
) O 0 3.5097065254063864e-09
was O 0 7.121817020561139e-07
present O 0 1.4960029881549985e-09
in O 0 1.2182245212599696e-09
the O 0 2.6506352668320687e-09
balanced O 0 1.683478600966737e-08
state O 0 5.830296800901635e-10
in O 0 2.925865771885583e-09
the O 0 5.445199136033807e-08
patients O 0 1.0874482114786588e-07
father O 0 3.055604906876397e-07
and O 0 3.1981809200942735e-08
a O 0 6.177318567779366e-08
sister O 0 2.2375010303221643e-05
. O 0 7.811810860403057e-07

Fluorescent O 0 3.507623478071764e-05
in O 0 1.5495145078148198e-07
situ O 0 6.393680109795241e-07
hybridization O 0 1.618702185623988e-07
analysis O 0 4.635431594124384e-08
demonstrated O 0 6.840825506060355e-08
that O 0 2.8944660002139244e-09
the O 0 7.174786276209488e-08
PWS B-Disease 1 1.0
critical O 0 6.294375225479598e-07
region O 0 5.141868655300641e-07
resided O 0 1.6768250077348057e-07
on O 0 2.320443925896143e-08
the O 0 1.3220373684674769e-09
derivative O 0 4.2820065715432065e-08
chromosome O 0 2.2244259980652714e-06
3 O 0 7.667676982237026e-08
and O 0 1.026712084239989e-07
that O 0 2.4951106070147944e-08
there O 0 1.1437751190612744e-08
was O 0 7.301338200704777e-07
no O 0 1.0440418529711337e-09
deletion O 0 6.257017304278634e-08
of O 0 5.679543946257581e-09
the O 0 5.327732424120768e-07
PWS B-Disease 1 1.0
region O 0 3.532951268425677e-06
on O 0 1.962020633072825e-06
the O 0 1.4178691998267823e-08
normal O 0 4.137600839726474e-08
pair O 0 1.5580393153413752e-07
of O 0 1.1186565007648142e-09
15s O 0 1.1475285788264955e-07
present O 0 7.861568285250087e-09
in O 0 4.120212437896953e-08
J O 0 0.00025792032829485834
. O 0 4.56121199476911e-07

B O 0 0.0011188623029738665
. O 0 1.5324761989177205e-05

Methylation O 0 9.559621503285598e-06
analysis O 0 2.4044845758908195e-07
at O 0 2.8755819059256282e-08
exon O 0 4.653396672438248e-07
alpha O 0 7.119250966525215e-08
of O 0 9.073267137615915e-10
the O 0 1.0237446446126341e-09
small O 0 4.845256640351181e-09
nuclear O 0 5.994976248757666e-08
ribonucleoprotein O 0 8.719442803339916e-07
- O 0 8.837702694108884e-07
associated O 0 6.116446371606798e-08
polypeptide O 0 9.822446145335562e-07
N O 0 7.225454510262352e-07
( O 0 4.2350647433408994e-09
SNRPN O 0 3.7883768300162046e-07
) O 0 1.425493501017172e-09
gene O 0 3.445956409109385e-08
showed O 0 2.23400249410588e-07
a O 0 7.698681692147602e-09
pattern O 0 3.502649633446708e-05
characteristic O 0 2.036384501025168e-07
of O 0 6.837036492512993e-10
only O 0 2.426770784325072e-09
the O 0 2.0963852875865996e-09
maternal O 0 2.3687873351718736e-07
chromosome O 0 8.07953801995609e-06
15 O 0 5.266887725952074e-08
in O 0 4.3643630931455846e-08
J O 0 0.0007376861176453531
. O 0 6.866695230201003e-07

B O 0 0.0011521094711497426
. O 0 1.5356070434791036e-05

Maternal B-Disease 0 0.0022545165847986937
disomy I-Disease 0 0.002971145324409008
was O 0 3.917435151379323e-06
confirmed O 0 1.902351876026387e-08
by O 0 4.239410766881946e-10
polymerase O 0 1.1102696362286224e-07
chain O 0 4.185216084806598e-07
reaction O 0 9.065141526320986e-09
analysis O 0 4.3331898069709496e-09
of O 0 1.2477325839199693e-09
microsatellite O 0 8.177552444976754e-06
repeats O 0 1.0530618055781815e-05
at O 0 8.570892440218358e-09
the O 0 2.4017623445615754e-09
gamma O 0 1.2955558759131236e-07
- O 0 1.5693206023570383e-06
aminobutyric O 0 3.1171960017672973e-06
acid O 0 2.2867492077693896e-07
receptor O 0 1.720574118735385e-07
beta3 O 0 7.922624263301259e-07
subunit O 0 2.3892903300293256e-07
( O 0 4.0560095726505097e-08
GABRB3 O 0 5.41946883458877e-06
) O 0 7.85322455953974e-08
locus O 0 9.463859896641225e-06
. O 0 1.5699073401265196e-06

A O 0 6.529057372972602e-06
niece O 0 0.00040592398727312684
( O 0 5.858426561644592e-07
B O 0 5.664692253048997e-07
. O 0 5.2533808414523264e-09
B O 0 4.457434243931857e-08
. O 0 3.798031056323481e-10
) O 0 1.850560815697122e-10
with O 0 5.298045890889114e-10
45 O 0 8.34454461084988e-09
chromosomes O 0 7.516990052636174e-08
and O 0 9.788919896891457e-09
the O 0 4.3374048797062414e-10
derivative O 0 1.7215810999005043e-08
3 O 0 4.74216363954838e-08
but O 0 8.372763815600592e-09
without O 0 1.7962551446260022e-09
the O 0 2.3916093550013784e-09
der O 0 1.9764147509704344e-05
( O 0 1.835460117227683e-09
15 O 0 2.5520341395690593e-09
) O 0 1.1192498039491738e-09
demonstrated O 0 1.0878604683739468e-08
a O 0 1.796365722839255e-08
phenotype O 0 6.4585456129861996e-06
consistent O 0 5.582882778298881e-08
with O 0 2.131869347721249e-09
that O 0 1.0420269980215835e-08
reported O 0 6.781055361670951e-08
for O 0 5.150727067082528e-10
haploinsufficiency O 0 6.7330086039874e-07
of O 0 2.7598650031990246e-09
distal O 0 1.336820514552528e-05
3 O 0 1.3849854667569161e-06
p O 0 5.064887227490544e-05
. O 0 3.544357696227962e-07

Uniparental B-Disease 1 0.9999996423721313
disomy I-Disease 1 0.9999994039535522
associated O 0 2.0413541278685443e-05
with O 0 1.4521594948746497e-07
unbalanced O 0 6.630698771914467e-05
segregation O 0 3.090301788688521e-06
of O 0 4.805506659266712e-09
non O 0 1.7311631239635972e-08
- O 0 1.6666263036313467e-06
Robertsonian O 0 5.0584148993948475e-06
translocations O 0 1.2879030691692606e-05
has O 0 6.927028834979865e-07
been O 0 6.875201563616429e-08
reported O 0 9.704134384946883e-08
previously O 0 1.5105298700746062e-07
but O 0 3.9174018695575796e-08
has O 0 1.4561771877197316e-07
not O 0 2.9334206175235522e-09
, O 0 1.180216924190347e-09
to O 0 1.9424890584929244e-09
our O 0 3.993338104635313e-09
knowledge O 0 1.109747849170617e-09
, O 0 1.3840358858985269e-09
been O 0 3.4645524227272517e-09
observed O 0 2.8188484879621e-09
in O 0 3.30364069434097e-10
a O 0 5.1848734194948065e-09
case O 0 5.1270610867959476e-08
of O 0 8.04465827286549e-08
PWS B-Disease 1 0.9999998807907104
. O 0 1.8591047137306305e-06

Furthermore O 0 1.1753854778362438e-05
, O 0 7.274288549297125e-08
our O 0 4.4025298961969384e-08
findings O 0 1.555538631237141e-08
are O 0 1.6212097220247301e-09
best O 0 5.596390906248416e-08
interpreted O 0 4.2252960241739856e-08
as O 0 6.19860784922821e-09
true O 0 5.489005161507521e-08
gamete O 0 1.7968611700780457e-06
complementation O 0 1.4116396414465271e-05
resulting O 0 2.7522972345650487e-07
in O 0 7.462988804718407e-08
maternal B-Disease 0 0.0005772226140834391
UPD I-Disease 1 1.0
15 I-Disease 0 1.797501499822829e-05
and O 0 1.1330744200677145e-05
PWS B-Disease 1 0.9999997615814209

Schwartz B-Disease 1 0.5174298882484436
- I-Disease 1 0.9998295307159424
Jampel I-Disease 1 0.9980136156082153
syndrome I-Disease 1 0.999981164932251
type I-Disease 0 1.139582991527277e-06
2 I-Disease 0 3.186198682669783e-07
and O 0 2.1658746618413716e-07
Stuve B-Disease 1 0.6795756220817566
- I-Disease 1 0.9999998807907104
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.999994158744812
: O 0 6.404088814804254e-09
a O 0 4.6999564240479685e-09
case O 0 1.518009717926816e-08
for O 0 1.9792454342137944e-09
" O 0 1.98842641907504e-07
lumping O 0 2.577985242169234e-06
" O 0 2.1699054286727915e-06
. O 0 3.229008882499329e-07

Recent O 0 3.196536454197485e-06
studies O 0 2.2760100648611115e-07
demonstrated O 0 1.354341350179311e-07
the O 0 1.2080321187823984e-09
existence O 0 2.4449926527836396e-09
of O 0 2.2773272156939584e-10
a O 0 8.108785642946259e-09
genetically O 0 3.0604869039052573e-07
distinct O 0 1.592505185499249e-07
, O 0 1.7565813692499432e-08
usually O 0 5.2857949128792825e-09
lethal O 0 4.180339185921866e-09
form O 0 5.025052041141009e-10
of O 0 3.1810640233054244e-10
the O 0 2.25270913034592e-08
Schwartz B-Disease 1 0.8232260346412659
- I-Disease 1 0.9999994039535522
Jampel I-Disease 1 0.9999943971633911
syndrome I-Disease 1 0.9999977350234985
( O 0 1.238347238086135e-07
SJS B-Disease 0 0.00030439149122685194
) O 0 2.4283927757551282e-08
of O 0 1.6383197021241358e-08
myotonia B-Disease 1 0.9254008531570435
and O 0 1.0161107638850808e-05
skeletal B-Disease 1 0.929660439491272
dysplasia I-Disease 1 0.9999605417251587
, O 0 2.137187919970529e-07
which O 0 7.084181419259039e-08
we O 0 1.395125881487047e-08
called O 0 2.1107987890900404e-07
SJS B-Disease 0 0.00014977411774452776
type I-Disease 0 5.214609473114251e-07
2 I-Disease 0 3.4706826568253746e-07
. O 0 2.535438454742689e-07

This O 0 1.4887452380207833e-05
disorder O 0 0.46760091185569763
is O 0 3.5601875225665935e-08
reminiscent O 0 1.2282750958547695e-06
of O 0 1.5800579733493691e-09
another O 0 5.703755334707239e-08
rare O 0 9.578537429888456e-08
condition O 0 4.93949983138009e-07
, O 0 2.2797490561998757e-09
the O 0 1.0762575719525103e-08
Stuve B-Disease 1 0.6736078262329102
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 4.0489067032467574e-07
SWS B-Disease 0 0.007540739607065916
) O 0 1.7298757981620838e-08
, O 0 3.645211243963331e-09
which O 0 4.218384752618931e-09
comprises O 0 5.744399178553294e-09
campomelia B-Disease 0 2.75253069048631e-06
at O 0 3.3073892069523936e-08
birth O 0 4.823028803002671e-07
with O 0 1.2584291653183755e-07
skeletal B-Disease 1 0.8808791637420654
dysplasia I-Disease 1 0.9999138116836548
, O 0 1.6053826357165235e-07
contractures B-Disease 0 7.307936175493523e-05
, O 0 1.822897566228221e-08
and O 0 2.09912691673253e-08
early B-Disease 0 1.8467866880200745e-07
death I-Disease 0 2.7783762561739422e-06
. O 0 1.9152076902173576e-07

To O 0 2.9994546935085964e-07
test O 0 2.9425057945786648e-08
for O 0 3.552539373785635e-10
possible O 0 3.321503960762584e-09
nosologic O 0 1.1117695066786837e-06
identity O 0 1.1655917120378945e-07
between O 0 6.746004288515906e-08
these O 0 4.56573374663094e-08
disorders O 0 4.4104443077230826e-05
, O 0 2.345861505048674e-09
we O 0 1.9479209356632055e-09
reviewed O 0 7.674272772817403e-09
the O 0 2.3572224172596634e-09
literature O 0 2.508795837741218e-09
and O 0 1.8063698314918497e-09
obtained O 0 5.187957285990308e-10
a O 0 2.176596902714323e-09
follow O 0 9.042346427179382e-09
- O 0 1.3516732906282414e-06
up O 0 6.405508656825987e-07
of O 0 2.062450210615907e-10
the O 0 4.591254876284978e-10
only O 0 1.384474201948649e-09
two O 0 3.0719828902903146e-09
surviving O 0 4.077955111370102e-07
patients O 0 6.659833573507967e-09
, O 0 1.6006716785366137e-10
one O 0 1.762519713510713e-10
with O 0 6.523522833035145e-10
SJS B-Disease 0 3.0377004804904573e-06
type I-Disease 0 9.896282904264808e-09
2 I-Disease 0 7.83072451326916e-09
at O 0 7.067322282949817e-09
age O 0 1.3310505586616728e-08
10 O 0 1.9877270940327207e-09
years O 0 1.0013314621915015e-09
and O 0 1.3141683297135387e-09
another O 0 2.1175152742358705e-09
with O 0 8.722567557128968e-09
SWS B-Disease 0 0.0011854112381115556
at O 0 5.78929046923804e-08
age O 0 4.3381540137943375e-08
7 O 0 2.955386158021156e-08
years O 0 3.84815912468639e-08
. O 0 1.0466506950024268e-07

Patients O 0 0.0013140386436134577
reported O 0 5.12139104102971e-06
as O 0 2.0928704103084783e-08
having O 0 6.653779394127923e-08
either O 0 2.8598952894753893e-07
neonatal O 1 0.9999414682388306
SJS B-Disease 1 0.99994957447052
or O 0 5.234946911514271e-06
SWS B-Disease 0 0.150421142578125
presented O 0 8.141085316992758e-08
a O 0 9.336306838747532e-09
combination O 0 3.7460903712371874e-08
of O 0 1.1223967311124738e-09
a O 0 4.2984950709978875e-08
severe O 0 6.203120847203536e-06
, O 0 1.2049514275247475e-08
prenatal O 0 0.00026677429559640586
- O 1 0.999858021736145
onset O 1 0.9997696280479431
neuromuscular B-Disease 1 0.9999996423721313
disorder I-Disease 1 0.9997865557670593
( O 0 1.1626707419054583e-07
with O 0 6.258425173655269e-07
congenital B-Disease 1 1.0
joint I-Disease 0 7.664001896046102e-05
contractures I-Disease 1 0.9998626708984375
, O 0 4.46988315161434e-06
respiratory O 0 0.13713186979293823
and O 0 5.270500764709141e-07
feeding O 0 7.318533789657522e-06
difficulties O 0 3.013351772551687e-07
, O 0 3.5088030259089464e-09
tendency O 0 6.981551337048586e-08
to O 0 3.3310396663210895e-09
hyperthermia B-Disease 0 3.655574255390093e-05
, O 0 9.172960169223643e-09
and O 0 1.0651197257516287e-08
frequent O 0 1.4851214302780136e-07
death O 0 2.833188091244665e-06
in O 0 2.726090109206325e-08
infancy O 0 5.32549438503338e-06
) O 0 1.6336195729493852e-09
with O 0 4.628076533119696e-10
a O 0 1.925477377540119e-08
distinct O 0 6.651793000855832e-07
campomelic B-Disease 0 0.0004510733997449279
- I-Disease 0 0.30836448073387146
metaphyseal I-Disease 0 0.11332300305366516
skeletal I-Disease 0 0.39425623416900635
dysplasia I-Disease 1 0.9995771050453186
. O 0 4.3427180571598e-06

The O 0 2.3510213509325695e-07
similarity O 0 3.98329916606599e-07
of O 0 2.802813314772834e-09
the O 0 2.7027338145302338e-09
clinical O 0 7.990264094814847e-08
and O 0 2.412272337437571e-08
radiographic O 0 9.013127055368386e-06
findings O 0 1.945768559608041e-07
is O 0 7.392771728120806e-09
so O 0 6.331190016695132e-10
extensive O 0 4.7227270982830305e-09
that O 0 1.2793851311698745e-08
these O 0 2.147795896689786e-08
disorders O 0 3.424575334065594e-05
appear O 0 2.695728937851527e-07
to O 0 1.2437460839009873e-08
be O 0 4.734903580327909e-09
a O 0 1.0759539037508148e-08
single O 0 2.3208139054986532e-07
entity O 0 1.7952955886357813e-06
. O 0 5.317621116773807e-07

The O 0 4.379924405384372e-07
follow O 0 1.508090008428553e-07
- O 0 3.219714926672168e-06
up O 0 2.647133499067422e-07
observation O 0 1.693524467327734e-07
of O 0 3.677563809034723e-10
an O 0 8.739183821049323e-10
identical O 0 1.6783049261448468e-07
and O 0 2.2811248001630702e-08
unique O 0 1.3708792323541275e-08
pattern O 0 0.0010399548336863518
of O 0 1.2213456557219615e-07
progressive O 0 0.004006329458206892
bone B-Disease 1 0.9710864424705505
dysplasia I-Disease 1 0.9994707703590393
in O 0 7.140220503742967e-08
the O 0 3.0712929088849705e-08
two O 0 1.1232291399210226e-06
patients O 0 1.7256682838251436e-07
( O 0 1.5091403682276905e-09
one O 0 1.923842862794345e-09
with O 0 1.2552858308367831e-08
SJS B-Disease 0 0.00015731276653241366
type I-Disease 0 7.650234579159587e-08
2 I-Disease 0 2.6246571138699437e-08
, O 0 3.0925060290343254e-09
one O 0 4.653607277305127e-09
with O 0 4.385157126307604e-08
SWS B-Disease 0 0.4538658559322357
) O 0 1.2002629112828345e-08
surviving O 0 1.5337158743022883e-07
beyond O 0 5.750695208917023e-08
infancy O 0 1.7147850428500533e-07
adds O 0 3.8124493784152946e-08
to O 0 9.498225539417149e-10
the O 0 6.484321968258655e-10
evidence O 0 1.0639374936616264e-09
in O 0 9.242502874151626e-10
favor O 0 5.126647995012945e-09
of O 0 4.226954342101408e-09
identity O 0 1.3536689493776066e-06
. O 0 2.2783163444728416e-07

The O 0 7.43305633932323e-07
hypothesis O 0 2.145697180822026e-06
that O 0 9.921157584358298e-08
SWS B-Disease 0 0.002511140890419483
and O 0 9.791332189479363e-08
SJS B-Disease 0 6.958478479646146e-05
type I-Disease 0 8.465486445174975e-08
2 I-Disease 0 2.150517808274799e-08
are O 0 8.161195608202831e-10
the O 0 2.54853693704149e-09
same O 0 9.774843192644767e-07
disorder O 0 0.0016282526776194572
should O 0 1.2905267077201188e-08
be O 0 7.788685252307914e-10
testable O 0 8.392973427362449e-09
by O 0 1.4026646510956198e-10
molecular O 0 6.1427032349570254e-09
methods O 0 2.048737535176315e-08
. O 0 2.4176294743938342e-08
. O 0 1.2298147566980333e-07

A O 0 4.375433945824625e-06
mouse O 0 2.1535861378652044e-05
model O 0 2.362292889301898e-06
of O 0 2.1700738273011666e-07
severe O 1 0.7001508474349976
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 7.447769894497469e-05
defects O 1 0.9958237409591675
in O 0 2.8945095209564897e-07
hemostasis O 0 0.011980870738625526
and O 0 2.640566890477203e-05
thrombosis B-Disease 0 0.0027102536987513304
. O 0 2.6721756967162946e-06

von B-Disease 1 0.991769552230835
Willebrand I-Disease 1 0.962045431137085
factor I-Disease 0 5.797273479402065e-05
( I-Disease 0 5.835492174810497e-06
vWf I-Disease 0 0.0028376844711601734
) I-Disease 0 5.0255785026820377e-05
deficiency I-Disease 1 0.9995276927947998
causes O 0 0.0002836745115928352
severe O 1 0.9990492463111877
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 4.6750591309319134e-07
humans O 0 1.459171699025319e-06
. O 0 5.205492357163166e-07

We O 0 1.133820319410006e-06
generated O 0 5.967630301029203e-08
a O 0 5.755169230070578e-09
mouse O 0 1.513435336164548e-06
model O 0 1.23204387136866e-07
for O 0 3.186609864869183e-09
this O 0 7.3245596254878365e-09
disease O 0 9.871627781876668e-08
by O 0 1.7061305146448547e-10
using O 0 1.1290921975160018e-08
gene O 0 4.075241406553687e-07
targeting O 0 4.565661129163345e-06
. O 0 8.537316489309887e-07

vWf B-Disease 0 0.008841770701110363
- I-Disease 1 0.9733681082725525
deficient I-Disease 0 0.014105959795415401
mice O 0 0.00038986431900411844
appeared O 0 5.835347565152915e-06
normal O 0 4.7670297931290406e-08
at O 0 7.615901687074711e-09
birth O 0 5.792946922156261e-08
; O 0 8.501273462968584e-09
they O 0 5.632497579455276e-09
were O 0 8.664317263651355e-09
viable O 0 6.652955164554442e-08
and O 0 4.159415922799781e-08
fertile O 0 2.3777665774105117e-06
. O 0 2.8520946671051206e-07

Neither O 0 0.0002902015403378755
vWf O 0 0.0018236995674669743
nor O 0 5.83842811465729e-05
vWf O 0 0.0006022507441230118
propolypeptide O 0 0.00042488801409490407
( O 0 2.7861851776833646e-06
von B-Disease 0 0.01259739138185978
Willebrand I-Disease 0 0.2594989240169525
antigen O 0 9.893748938338831e-05
II O 0 5.502222484210506e-05
) O 0 3.615183530314425e-08
were O 0 2.4977104828849406e-08
detectable O 0 1.9231234205108194e-07
in O 0 2.0779058473863188e-09
plasma O 0 2.700293748603144e-07
, O 0 1.8354398889641743e-08
platelets O 0 4.608433812336443e-07
, O 0 2.2592441251134687e-09
or O 0 4.160548350284898e-09
endothelial O 0 3.97792341289005e-08
cells O 0 2.047573488539456e-08
of O 0 5.010667436522453e-10
the O 0 7.124790535328884e-09
homozygous O 0 7.502832886530086e-06
mutant O 0 3.6637618904933333e-05
mice O 0 0.00010750916408142075
. O 0 4.860772833126248e-07

The O 0 1.1484793276395067e-06
mutant O 0 6.998213211772963e-05
mice O 0 0.235274538397789
exhibited O 0 0.00032113573979586363
defects O 0 0.42014801502227783
in O 0 2.016186329001357e-08
hemostasis O 0 5.843422059115255e-06
with O 0 1.73216729848491e-08
a O 0 9.003250767136706e-08
highly O 0 3.278742042311933e-07
prolonged O 0 8.520061237504706e-05
bleeding O 1 0.5074945688247681
time O 0 8.083895863819635e-08
and O 0 4.0743081797245395e-08
spontaneous O 0 1.3821694722082611e-07
bleeding O 0 4.763933247886598e-05
events O 0 9.703483350165243e-09
in O 0 2.9444355842400682e-09
approximately O 0 5.814651871105525e-09
10 O 0 6.131313678992001e-09
% O 0 3.2171574293471394e-09
of O 0 3.75009223674283e-09
neonates O 0 3.5540826502256095e-05
. O 0 2.799342553316819e-07

As O 0 4.64382964082688e-07
in O 0 1.0380378334673424e-08
the O 0 2.576336477488894e-09
human O 0 1.5948648623975714e-08
disease O 0 8.151306474246667e-07
, O 0 4.5281506322325527e-10
the O 0 3.520438662807379e-10
factor O 0 7.48875184086728e-09
VIII O 0 9.942060387402307e-06
level O 0 3.694116657015911e-08
in O 0 1.6647060396834945e-09
these O 0 4.028967381941584e-09
mice O 0 3.596172291508992e-06
was O 0 1.3676274193130666e-06
reduced O 0 1.3125307063432956e-08
strongly O 0 4.8896056092928575e-09
as O 0 1.0786944670826415e-09
a O 0 3.1560094537752548e-09
result O 0 2.263034870608749e-09
of O 0 3.471065934679274e-10
the O 0 4.342531223500146e-09
lack O 0 8.65903171387572e-09
of O 0 6.763249404961869e-10
protection O 0 1.660884940690721e-08
provided O 0 6.347371073189834e-09
by O 0 5.560965909978677e-09
vWf O 0 1.0351084711146541e-05
. O 0 3.6863676200482587e-07

Defective O 0 0.019178057089447975
thrombosis B-Disease 0 0.008753771893680096
in O 0 3.2810535799399076e-07
mutant O 0 4.23615456384141e-05
mice O 0 0.47847363352775574
was O 0 0.0002864957496058196
also O 0 1.3895935353502864e-06
evident O 0 1.1875204108946491e-07
in O 0 9.509971699017683e-10
an O 0 8.793022421293983e-10
in O 0 7.17171921849058e-09
vivo O 0 8.5259091520129e-07
model O 0 1.9260015449162893e-07
of O 0 7.29175013702843e-08
vascular B-Disease 0 0.12108011543750763
injury I-Disease 0 0.002251056721433997
. O 0 1.4010051927471068e-06

In O 0 3.3575966540411173e-07
this O 0 4.197837633057588e-09
model O 0 4.380693141570191e-08
, O 0 2.1753767676102598e-09
the O 0 3.9778149663050044e-09
exteriorized O 0 6.561290774698136e-06
mesentery O 0 6.0076687077526e-05
was O 0 1.7537444136905833e-06
superfused O 0 2.735351245064521e-06
with O 0 2.5369082834458823e-08
ferric O 0 5.366853656596504e-06
chloride O 0 8.33660806165426e-07
and O 0 9.709373927080378e-08
the O 0 4.9094732723631296e-09
accumulation O 0 9.857629379439459e-08
of O 0 4.334562042629386e-09
fluorescently O 0 2.741861499089282e-05
labeled O 0 2.5276807718910277e-05
platelets O 0 8.616973900643643e-06
was O 0 3.6459121588450216e-07
observed O 0 3.353883570866856e-08
by O 0 2.3002340032718394e-09
intravital O 0 1.5511852780036861e-06
microscopy O 0 8.633455195194983e-07
. O 0 3.3745075711522077e-07

We O 0 3.392685357539449e-06
conclude O 0 1.0498477109877058e-07
that O 0 2.375619923000727e-09
these O 0 1.8444689109387014e-09
mice O 0 3.4490185498725623e-06
very O 0 1.1147422540602747e-08
closely O 0 1.4037736946193036e-06
mimic O 0 0.0002008520532399416
severe O 0 9.700618829810992e-05
human O 0 1.2196967873023823e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 6.16912211626186e-06
will O 0 1.0881286982566962e-07
be O 0 2.322350978190002e-09
very O 0 1.3500620066331237e-10
useful O 0 1.7048554235010727e-10
for O 0 5.87594278789183e-11
investigating O 0 8.233680404146071e-10
the O 0 2.618923689023944e-10
role O 0 3.6323020147221996e-09
of O 0 7.162365700530415e-10
vWf O 0 2.3258303372131195e-07
in O 0 1.1742717020979399e-08
normal O 0 9.20491487477193e-08
physiology O 0 6.068628266575615e-08
and O 0 4.2671352673551155e-08
in O 0 3.391444636235974e-08
disease O 0 7.374550818894932e-07
models O 0 8.519003102946954e-08
. O 0 1.1598253024658334e-08
. O 0 1.0346561651886077e-07

Oral O 0 9.11552197067067e-05
contraceptives O 0 0.002467148471623659
and O 0 4.975730121259403e-07
the O 0 3.5452391244916726e-08
risk O 0 9.665736797614954e-07
of O 0 4.406205391660478e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.451407337706769e-06

Hereditary B-Disease 1 0.9999997615814209
Ovarian I-Disease 1 0.9999992847442627
Cancer I-Disease 1 0.8096602559089661
Clinical O 0 1.6037609384511597e-05
Study O 0 4.820224148716079e-07
Group O 0 1.5270840094672167e-06
. O 0 4.248716436450195e-07

BACKGROUND O 0 6.752447370672598e-05
Women O 0 8.330885634677543e-07
with O 0 5.974917005602265e-09
mutations O 0 3.3227576068384224e-07
in O 0 2.5015518545501436e-09
either O 0 7.2876313872427545e-09
the O 0 1.1189259296884302e-08
BRCA1 O 0 4.756476300826762e-06
or O 0 2.7252323064885786e-08
the O 0 6.744766523070211e-09
BRCA2 O 0 1.4987506347097224e-06
gene O 0 6.700660293290639e-08
have O 0 1.4620346711069487e-08
a O 0 6.3952878548434455e-09
high O 0 6.501964122662685e-08
lifetime O 0 1.3206233973050985e-07
risk O 0 5.131939246894035e-07
of O 0 6.821176725679834e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.913522944771103e-07

Oral O 0 0.00018566760991234332
contraceptives O 0 0.012320604175329208
protect O 0 0.00018348445883020759
against O 0 0.007531135343015194
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 9.863799022014064e-08
general O 0 8.746941837500799e-09
, O 0 2.0157328251002582e-08
but O 0 2.235587537313677e-08
it O 0 1.2464916210319643e-08
is O 0 4.210988890918088e-09
not O 0 6.786508577327766e-10
known O 0 1.6212344799981793e-09
whether O 0 1.6751754428057097e-09
they O 0 8.87554030271076e-09
also O 0 4.278871656993033e-08
protect O 0 3.5589110325418005e-08
against O 0 3.601384435114596e-08
hereditary B-Disease 0 0.0001009814441204071
forms I-Disease 0 5.308297659212258e-07
of I-Disease 0 6.694830062770052e-06
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.1092162114655366e-06

METHODS O 0 4.061269009980606e-06
We O 0 1.2720978759261925e-07
enrolled O 0 6.106981231823738e-08
207 O 0 7.274052222783212e-07
women O 0 5.769822450929496e-07
with O 0 4.8614774641464464e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.4365661488445767e-07
161 O 0 3.462182363023203e-08
of O 0 1.4148077154274574e-09
their O 0 1.6922844281452853e-07
sisters O 0 0.00023082693223841488
as O 0 2.074564520171407e-08
controls O 0 1.268223172701255e-06
in O 0 2.8514506311694277e-09
a O 0 5.914290834851954e-09
case O 0 2.5398954051070177e-08
- O 0 1.0034734259534162e-05
control O 0 2.5387098503415473e-06
study O 0 5.513989975725053e-08
. O 0 1.1679662748065311e-07

All O 0 2.5701689310153597e-07
the O 0 2.43211957240419e-08
patients O 0 6.178520095545537e-08
carried O 0 2.291346135052663e-08
a O 0 8.368244763801158e-09
pathogenic O 0 1.9903066572624084e-07
mutation O 0 9.369061615416285e-08
in O 0 2.5704804951232063e-09
either O 0 1.9709432308445685e-08
BRCA1 O 0 3.276693178122514e-06
( O 0 2.49743408176073e-08
179 O 0 5.84846802098582e-08
women O 0 5.694233706776686e-08
) O 0 1.2129667048554893e-08
or O 0 1.016185748881071e-07
BRCA2 O 0 5.757127655670047e-05
( O 0 1.4539222092935233e-07
28 O 0 7.466219926755002e-07
women O 0 2.3203382681913354e-07
) O 0 4.7515431589317814e-08
. O 0 1.7807730046115466e-07

The O 0 2.1749488610112166e-07
control O 0 7.564805173387867e-07
women O 0 1.9195853440123756e-07
were O 0 1.638310287432887e-08
enrolled O 0 5.564043004113728e-09
regardless O 0 2.123760500793992e-09
of O 0 2.816998301291562e-10
whether O 0 5.861654273076056e-09
or O 0 5.318604934245741e-08
not O 0 3.0892060465248505e-08
they O 0 1.0991628940359988e-08
had O 0 1.752995757442477e-07
either O 0 1.954941453163883e-08
mutation O 0 5.221247647568816e-07
. O 0 1.253595911521188e-07

Lifetime O 0 2.5810753868427128e-05
histories O 0 1.7824273754740716e-06
of O 0 1.359578050141863e-08
oral O 0 9.861710026370929e-08
- O 0 5.271420491226309e-07
contraceptive O 0 2.826748641382437e-06
use O 0 2.022965972514612e-08
were O 0 2.080651206881612e-08
obtained O 0 1.1537351074508706e-09
by O 0 4.3707315544594394e-10
interview O 0 6.920696478118771e-07
or O 0 6.324917478650605e-09
by O 0 3.216708011066771e-10
written O 0 3.651244195879144e-09
questionnaire O 0 2.3834319407001203e-08
and O 0 5.991121376780484e-09
were O 0 8.84503670306458e-09
compared O 0 5.835194549774769e-09
between O 0 9.891414798346432e-09
patients O 0 1.0241709702540902e-08
and O 0 1.739149091406489e-08
control O 0 8.512066074217728e-07
women O 0 9.593858862899651e-08
, O 0 1.589883003028092e-09
after O 0 2.261740350562036e-09
adjustment O 0 1.2955380768175928e-08
for O 0 4.3617459644096357e-10
year O 0 2.8387092676496195e-09
of O 0 5.887826337591662e-10
birth O 0 2.5223039301636163e-07
and O 0 4.6790287200337843e-08
parity O 0 2.1669584384653717e-06
. O 0 1.9487194435896527e-07

RESULTS O 0 8.849494406604208e-06
The O 0 9.09281752115021e-08
adjusted O 0 4.8303707444574684e-05
odds O 0 3.630657374742441e-05
ratio O 0 2.8325661332928576e-05
for O 0 2.2545746105606668e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.3167588974738464e-07
with O 0 1.9138148843467206e-09
any O 0 2.251663966390538e-09
past O 0 1.2784825642597752e-08
use O 0 2.873343563081221e-09
of O 0 1.003289118450823e-09
oral O 0 5.440745454166063e-08
contraceptives O 0 0.00012835641973651946
was O 0 4.301860371924704e-06
0 O 0 1.5421832699757942e-07
. O 0 1.0699927344148819e-07

5 O 0 5.071717623650329e-06
( O 0 1.70157520074099e-07
95 O 0 2.099011453537969e-07
percent O 0 6.226278514986916e-07
confidence O 0 1.7797289331156207e-07
interval O 0 5.158351612521983e-08
, O 0 4.2426140378637456e-10
0 O 0 7.919325750727069e-10
. O 0 1.5339463033114953e-10
3 O 0 1.1221569229391548e-09
to O 0 8.454441036143123e-10
0 O 0 3.960690442283976e-09
. O 0 1.6627480503572656e-09
8 O 0 4.29399662493779e-08
) O 0 2.478925509308283e-08
. O 0 1.131289195654972e-07

The O 0 1.1068881349274307e-06
risk O 0 1.0802906444951077e-06
decreased O 0 5.597821086666954e-07
with O 0 1.741780608632837e-09
increasing O 0 5.479609210823355e-09
duration O 0 1.5049531398858562e-08
of O 0 1.542807548382541e-10
use O 0 1.928681658824871e-09
( O 0 3.2780582692737426e-09
P O 0 2.7971009330940433e-07
for O 0 7.062037066241089e-10
trend O 0 5.7279692100564716e-08
, O 0 5.501535893515097e-10
< O 0 4.063301695111932e-09
0 O 0 8.336840662259704e-10
. O 0 2.2680463063196044e-10
001 O 0 8.820103758466757e-09
) O 0 3.774603685169353e-10
; O 0 1.3398700204891867e-10
use O 0 1.1095398905203169e-10
for O 0 3.851518548536603e-10
six O 0 1.2407133986869212e-08
or O 0 7.4270594119241196e-09
more O 0 2.033281987223745e-09
years O 0 4.2130075428303826e-08
was O 0 4.420502719426622e-08
associated O 0 5.184999096741194e-10
with O 0 1.3470989601582772e-10
a O 0 6.743892111416017e-09
60 O 0 2.3199923759875674e-08
percent O 0 1.8703419257803944e-08
reduction O 0 1.668594507009402e-08
in O 0 8.494078329590593e-09
risk O 0 4.91313869588339e-07
. O 0 1.2847408470406663e-07

Oral O 0 7.716111576883122e-05
- O 0 6.219753413461149e-05
contraceptive O 0 6.41435690340586e-05
use O 0 5.49782669168053e-07
protected O 0 4.6795707021374255e-05
against O 0 0.002092994749546051
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 7.749391350841961e-09
for O 0 4.6448259127807034e-10
carriers O 0 2.6584019430231365e-09
of O 0 2.780554397840973e-10
the O 0 9.319724547651731e-09
BRCA1 O 0 1.5891257135081105e-05
mutation O 0 9.228257908944215e-07
( O 0 6.785283002130882e-09
odds O 0 1.8316933392270585e-07
ratio O 0 3.121908775938209e-08
, O 0 6.121179674245525e-10
0 O 0 5.849521977907557e-10
. O 0 1.2589483622260644e-10
5 O 0 1.269033655937335e-09
; O 0 1.4152853333726512e-09
95 O 0 1.6095762944701164e-08
percent O 0 2.4050763158811606e-07
confidence O 0 1.4249633295548847e-07
interval O 0 1.7697304954822357e-08
, O 0 1.9163817754908052e-10
0 O 0 3.4333630383187597e-10
. O 0 8.318537525475733e-11
3 O 0 3.660907410552028e-10
to O 0 3.5985453505915643e-10
0 O 0 1.6821457560212139e-09
. O 0 1.3020500233551502e-09
9 O 0 1.649998004893405e-08
) O 0 6.670343721815186e-10
and O 0 1.190699205899648e-09
for O 0 1.2124889980924536e-10
carriers O 0 1.5710395206980365e-09
of O 0 2.8731228507439255e-10
the O 0 1.694353990444597e-08
BRCA2 O 0 2.539006709412206e-05
mutation O 0 4.43080153900155e-07
( O 0 5.34269872787263e-09
odds O 0 1.622676109036547e-07
ratio O 0 4.1548407381242214e-08
, O 0 1.167686836112125e-09
0 O 0 1.0041045772624102e-09
. O 0 1.7052619039059635e-10
4 O 0 1.5026547783847377e-09
; O 0 1.8482371189065816e-09
95 O 0 2.6908789863000493e-08
percent O 0 1.757919392275653e-07
confidence O 0 9.525174249347401e-08
interval O 0 1.9766392966857893e-08
, O 0 4.475763371036834e-10
0 O 0 5.95458349295086e-10
. O 0 2.768731910407496e-10
2 O 0 1.418755779525327e-09
to O 0 1.5016549115287603e-09
1 O 0 7.665450496574522e-09
. O 0 3.0768498859856663e-09
1 O 0 1.4754281352225007e-08
) O 0 2.5394401248490794e-08
. O 0 1.1237128916263828e-07

CONCLUSIONS O 0 1.5786970834597014e-05
Oral O 0 2.30924820243672e-06
- O 0 2.7324674647388747e-06
contraceptive O 0 1.0419184945931192e-05
use O 0 8.045103072618076e-08
may O 0 6.615007208665702e-08
reduce O 0 7.484968200799358e-09
the O 0 3.902410394829303e-09
risk O 0 1.5393283092635102e-07
of O 0 3.7557634868790046e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.6721393098227963e-08
women O 0 1.2412624705859798e-08
with O 0 2.6059596702765475e-09
pathogenic O 0 1.828806261983118e-07
mutations O 0 1.7410914665560995e-07
in O 0 4.351427662641072e-09
the O 0 6.053102907799257e-08
BRCA1 O 0 0.00012410282215569168
or O 0 4.30113004767918e-06
BRCA2 O 0 0.001047623693011701
gene O 0 0.0004886499955318868

A O 0 8.203586730815005e-06
Japanese O 0 2.2288131731329486e-06
family O 0 1.8407975233003526e-07
with O 0 8.848127919236504e-08
adrenoleukodystrophy B-Disease 1 1.0
with O 0 2.4957675037740046e-08
a O 0 6.483338665930205e-08
codon O 0 1.9241231257183244e-06
291 O 0 2.0455580340694723e-07
deletion O 0 1.0652049695636379e-06
: O 0 9.291663438659725e-09
a O 0 7.64158247790192e-09
clinical O 0 7.652043620964832e-08
, O 0 2.7996074347669264e-09
biochemical O 0 2.570134540746949e-07
, O 0 4.6935242359325e-09
pathological O 0 4.108567281946307e-07
, O 0 7.989544137387838e-09
and O 0 2.132968468515628e-08
genetic O 0 1.4685992937302217e-06
report O 0 5.279671881908143e-07
. O 0 2.058648647107475e-07

We O 0 5.46506862519891e-06
report O 0 3.371116719108613e-08
a O 0 9.065280082154459e-09
Japanese O 0 7.442391591894193e-08
family O 0 2.473032338912162e-07
with O 0 2.1102523533045314e-06
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.0001134336635004729
ALD B-Disease 1 1.0
) O 0 4.547820964262428e-08
with O 0 2.041006252895272e-09
a O 0 1.4870709108549818e-08
three O 0 3.4818771865730014e-08
base O 0 2.927967273080867e-07
pair O 0 6.870887432341988e-07
deletion O 0 3.675359494081931e-06
( O 0 2.8566127241447248e-08
delGAG O 0 6.847090503470099e-07
291 O 0 1.7364716597967345e-07
) O 0 4.0011300939113426e-09
in O 0 5.871758634867774e-09
the O 0 4.639013582163898e-07
ALD B-Disease 1 1.0
gene O 0 7.454094884451479e-05
. O 0 1.6748462030591327e-06

A O 0 8.310024099955626e-07
variety O 0 1.107657396914874e-07
of O 0 8.973588094818297e-09
phenotypes O 0 5.317881004884839e-06
were O 0 1.1309138159276699e-07
observed O 0 5.2374758752193884e-08
within O 0 2.244884278468362e-09
this O 0 2.335312387913291e-09
family O 0 2.5563306849107903e-07
. O 0 2.5656581215116603e-07

While O 0 1.4371522638612078e-06
the O 0 4.2507263486868396e-08
proband O 0 4.274868842912838e-06
( O 0 4.283975485463998e-08
patient O 0 1.870970436357311e-07
1 O 0 2.7020497839203017e-08
) O 0 8.268149720436213e-09
was O 0 5.030528313909599e-07
classified O 0 4.268389020012364e-08
as O 0 4.488925142709377e-08
having O 0 1.2262585613598276e-08
a O 0 2.451427505434367e-09
rare O 0 4.424127730828786e-09
intermediate O 0 2.0171202486096718e-09
type O 0 7.787382294566214e-09
of O 0 1.4391338121200192e-09
adult O 0 1.3070592785879853e-06
cerebral O 0 3.124336217297241e-05
and O 0 2.2988652403910237e-07
cerebello O 0 0.0008516029338352382
- O 0 0.2558353841304779
brain O 0 2.1602631022688e-05
stem O 0 1.5390200758247374e-07
forms O 0 1.4471639886437515e-08
, O 0 1.914432878891148e-08
his O 0 5.129815008331207e-07
younger O 0 5.063337994215544e-06
brother O 0 1.6634980966045987e-06
( O 0 9.908900366895068e-09
patient O 0 6.532206242582106e-08
2 O 0 4.447829127229852e-08
) O 0 8.291205944033209e-09
and O 0 5.0385029481958554e-08
nephew O 0 0.0002078434481518343
( O 0 5.159542126875749e-08
patient O 0 2.3122399284147832e-07
3 O 0 9.164779868342521e-08
) O 0 1.827541673549149e-08
had O 0 2.182463276767521e-06
a O 0 6.308280831035518e-07
childhood O 0 0.0004512045707087964
ALD B-Disease 1 1.0
type O 0 2.919576218118891e-05
. O 0 1.3441803048408474e-06

Another O 0 4.9973377826972865e-06
nephew O 0 0.00012354293721728027
( O 0 2.4776073814791744e-07
patient O 0 4.61115490679731e-07
4 O 0 5.776077571795213e-08
) O 0 4.281204279976691e-09
of O 0 1.528211668322399e-09
patient O 0 1.4014835869602393e-06
1 O 0 3.1286481316783465e-07
was O 0 1.1058562449761666e-05
classified O 0 1.3493919936991006e-07
as O 0 1.8947243063394126e-07
having O 0 3.852595398257108e-08
an O 0 6.807307162404186e-09
adolescent O 0 4.1679004425532185e-06
form O 0 2.375789449615695e-07
. O 0 3.837444069176854e-07

The O 0 5.538590812648181e-07
tau O 0 4.627706289284106e-07
level O 0 5.448087136983304e-08
in O 0 6.922490136673787e-09
the O 0 4.122712127241357e-08
cerebrospinal O 0 0.0005953225190751255
fluid O 0 4.6509601816069335e-05
( O 0 2.456887386870221e-07
CSF O 0 0.0008043709676712751
) O 0 6.6148664323861794e-09
in O 0 4.7425952054425125e-09
patient O 0 4.303885532408458e-07
1 O 0 3.050410555260896e-07
was O 0 0.0009783155983313918
as O 0 3.050363517331789e-08
high O 0 5.1167745596103487e-08
as O 0 5.397619684543997e-09
that O 0 1.4622570931877021e-09
of O 0 1.4310017615315473e-09
patients O 0 5.1186287208793146e-08
with O 0 1.7741805891091644e-07
Alzheimers B-Disease 1 0.9999986886978149
disease I-Disease 0 0.0013929966371506453
( O 0 2.565123935482916e-08
AD B-Disease 0 2.9571169761766214e-06
) O 0 9.303477099820157e-08
. O 0 1.9171118026406475e-07

His O 0 1.859766234701965e-05
brain O 0 7.242445281008258e-05
magnetic O 0 2.3444235921488144e-06
resonance O 0 2.287116330990102e-06
image O 0 6.70520676067099e-05
( O 0 2.5743688070178905e-07
MRI O 0 3.2455216569360346e-05
) O 0 3.5527096997611807e-07
showed O 0 4.782655378221534e-05
abnormalities B-Disease 0 0.023824483156204224
in I-Disease 0 5.446972206613054e-09
the I-Disease 0 2.5476291298787146e-08
bilateral I-Disease 0 2.701076255107182e-06
cerebellar I-Disease 0 0.05483832582831383
hemispheres I-Disease 0 0.0024208067916333675
and O 0 2.6585460091155255e-06
brain O 0 2.6880281438934617e-05
stem O 0 9.364637207909254e-07
, O 0 1.1054851256631082e-08
but O 0 4.888840887673496e-09
not O 0 9.138710344025469e-10
in O 0 6.285659770455254e-10
the O 0 2.1644595449288317e-08
cerebral O 0 5.499439339473611e-06
white O 0 1.569784672028618e-06
matter O 0 7.003421842455282e-09
, O 0 8.736050216562319e-10
where O 0 1.0889187329610195e-09
marked O 0 1.4807027604035738e-08
reductions O 0 1.2725366538290928e-08
of O 0 2.804854404292456e-10
the O 0 1.640833957594623e-08
cerebral O 0 5.4420802371168975e-06
blood O 0 2.492062662895478e-07
flow O 0 1.526977655430528e-07
and O 0 1.811307903665238e-08
oxygen O 0 1.7492524762019457e-08
metabolism O 0 4.571406364561881e-08
were O 0 1.4397303793600713e-08
clearly O 0 2.5282325566422514e-08
demonstrated O 0 3.417416571949161e-09
by O 0 2.951597577460774e-10
positron O 0 1.681145107568227e-07
emission O 0 1.0003091688304266e-07
tomography O 0 5.359048373065889e-06
( O 0 7.904137078185158e-08
PET O 0 2.746334757830482e-06
) O 0 1.0875705669377567e-07
. O 0 1.453005893381487e-07

In O 0 1.0937766319329967e-06
patients O 0 1.3880530786991585e-06
2 O 0 1.4392105640581576e-07
and O 0 2.7964281557046888e-08
3 O 0 2.652740604958126e-08
, O 0 1.1140020017563756e-09
the O 0 1.0617318135786036e-09
autopsy O 0 6.213796041265596e-06
findings O 0 2.1183812748404307e-07
showed O 0 3.854554051940795e-06
massive O 0 3.141187221444852e-07
demyelination B-Disease 1 1.0
of I-Disease 0 1.845620545282145e-08
the I-Disease 0 2.988097378420207e-07
cerebral I-Disease 0 0.00010692732757888734
white I-Disease 0 2.1459591152961366e-06
matter I-Disease 0 2.7090201193402663e-09
with O 0 6.311452471763346e-10
sparing O 0 5.137307468316976e-09
of O 0 1.081570499827933e-09
the O 0 1.64414846182126e-08
U O 0 0.00013363761536311358
- O 0 0.27448517084121704
fibers O 0 0.00023094008793123066
, O 0 8.712704446800501e-10
compatible O 0 1.475729227706779e-08
with O 0 1.8421028036286202e-09
the O 0 5.100285083159406e-09
findings O 0 6.193091905970505e-08
of O 0 3.400175785372994e-08
childhood O 0 0.00034110830165445805
ALD B-Disease 1 1.0
. O 0 2.5946685582312057e-06

Oleic O 1 0.8809458613395691
and O 0 1.1413426364015322e-05
erucic O 0 0.001718405750580132
acids O 0 4.36303753303946e-06
( O 0 7.882487551569284e-08
Lorenzos O 0 2.507872295609559e-06
Oil O 0 6.269363552746654e-07
) O 0 4.0783332266869365e-09
were O 0 1.1795148191495741e-09
administered O 0 8.426268571781748e-10
to O 0 1.7245809225130415e-09
patients O 0 4.716174117902483e-09
1 O 0 3.1662412691702002e-09
and O 0 2.998018544531078e-08
4 O 0 3.736186471314795e-08
, O 0 4.200849001989582e-09
but O 0 2.871086257627553e-09
sufficient O 0 1.8624450870419196e-09
effectiveness O 0 3.021953176585157e-08
was O 0 4.1750070067791967e-07
not O 0 5.164737970630995e-09
obtained O 0 3.408824866824034e-08
. O 0 1.4927023528343852e-07

The O 0 1.7756616443875828e-07
findings O 0 6.443433164804446e-08
in O 0 1.5510994710865589e-09
this O 0 6.838288824084771e-10
family O 0 1.0255823745808357e-08
suggest O 0 9.022810054659658e-09
that O 0 1.876995225913447e-09
delGAG291 O 0 6.228642632777337e-07
is O 0 3.363176848125704e-09
part O 0 1.0543498296655684e-09
of O 0 3.1272276435068136e-10
the O 0 4.5207659837842584e-09
cause O 0 3.124154446254579e-08
of O 0 2.4103579132628283e-09
Japanese O 0 1.957842869160231e-06
ALD B-Disease 1 1.0
with O 0 2.065613635693353e-08
phenotypic O 0 4.291861387173412e-06
variations O 0 2.0741685148095712e-05
. O 0 6.874184350635915e-07

Moreover O 0 8.327888281201012e-06
, O 0 3.9334469903451463e-08
although O 0 1.1094599683403317e-09
the O 0 2.3628660139607405e-10
scale O 0 2.927938425045795e-08
of O 0 3.3249378250665984e-10
the O 0 2.0393018385078676e-09
study O 0 2.558047773604244e-09
is O 0 6.647840944395966e-09
limited O 0 2.494528583696365e-09
, O 0 3.68881281076483e-09
there O 0 5.350854204166922e-10
is O 0 1.841898022991728e-10
a O 0 2.699873102862682e-10
possibility O 0 1.1585776782396806e-09
that O 0 2.5179136553532544e-09
PET O 0 2.30401639100819e-07
can O 0 1.4571961415299484e-08
detect O 0 1.328453862470269e-07
an O 0 2.8830768883381097e-09
insidious B-Disease 0 4.648570029530674e-05
lesion I-Disease 0 0.027410639449954033
which O 0 2.247816865974528e-07
is O 0 4.653802676557461e-09
undetectable O 0 5.67613547275414e-08
by O 0 7.965362258666175e-10
computed O 0 1.5282977017250232e-07
tomogram O 0 2.582475872259238e-06
( O 0 1.4081104282581691e-08
CT O 0 3.730835260284948e-06
) O 0 8.832931719382486e-09
or O 0 3.986390328947209e-09
MRI O 0 1.8549840774539916e-07
analysis O 0 7.449944217086113e-09
, O 0 4.749819648708353e-09
and O 0 8.074769297650164e-09
that O 0 1.5397980668296896e-09
the O 0 1.3398938625286405e-09
higher O 0 7.481713915069577e-09
level O 0 2.4077158045088254e-09
of O 0 1.974425484219111e-10
tau O 0 3.911747814555611e-09
reflects O 0 4.217950433371698e-09
the O 0 2.790112030304215e-10
process O 0 2.1894794866028633e-09
of O 0 5.0020276809448205e-09
neuronal B-Disease 0 0.0001775662531144917
degeneration I-Disease 1 0.542002260684967
in O 0 3.577878032956505e-06
ALD B-Disease 1 1.0
. O 0 1.0062304681923706e-05

Lorenzos O 0 0.0006382621359080076
Oil O 0 7.014803122729063e-05
should O 0 5.696069393934522e-08
be O 0 4.5669221182542685e-10
given O 0 2.1948641515390221e-10
in O 0 1.8802621959412846e-10
the O 0 1.928394777195308e-09
early O 0 1.0099022063059238e-07
stage O 0 2.382946831858135e-06
. O 0 2.5651042179219985e-08
. O 0 1.3968303846922936e-07

Nonsense O 0 0.0008593884413130581
mutation O 0 2.005010719585698e-05
in O 0 4.098446382272414e-08
exon O 0 9.010273629428411e-07
4 O 0 1.453260978223625e-07
of O 0 3.924594427218153e-09
human O 0 1.8354329611725007e-08
complement O 0 1.970011851426534e-07
C9 O 0 5.065985078545054e-06
gene O 0 6.362500926115899e-07
is O 0 1.3688673305978227e-08
the O 0 1.4454114571904597e-09
major O 0 7.720474926031784e-09
cause O 0 5.9578727729103775e-08
of O 0 4.534946640433191e-09
Japanese O 0 2.552769274188904e-06
complement B-Disease 0 3.8578640669584274e-05
C9 I-Disease 0 0.031437914818525314
deficiency I-Disease 0 0.012546793557703495
. O 0 8.199021408472618e-07

Deficiency B-Disease 1 0.9999728202819824
of I-Disease 0 1.0657298332716891e-07
the I-Disease 0 4.1019422525323535e-08
ninth I-Disease 0 1.0777190482258447e-06
component I-Disease 0 5.344067233181704e-08
of I-Disease 0 1.128043214393415e-09
human I-Disease 0 8.818168417690231e-09
complement I-Disease 0 1.5941812137043598e-07
( O 0 2.4959579292271883e-08
C9 O 0 1.4994167258919333e-06
) O 0 4.435119382861785e-09
is O 0 6.190168932995732e-10
the O 0 3.655687974557509e-10
most O 0 3.4162044304508754e-09
common O 0 8.893012477528828e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.847190654937549e-08
Japan O 0 3.2264603078147047e-07
but O 0 1.1881815531467055e-08
is O 0 1.4419612170968321e-09
rare O 0 8.129765749487206e-10
in O 0 4.754638904813646e-10
other O 0 1.022296913788523e-09
countries O 0 7.585630790174491e-09
. O 0 8.129431705583556e-08

We O 0 1.7008708255161764e-06
studied O 0 2.9535717871453926e-08
the O 0 9.724618887929637e-10
molecular O 0 2.8105983318482686e-08
basis O 0 6.618175518724456e-08
of O 0 7.882096753064616e-08
C9 B-Disease 1 0.982637345790863
deficiency I-Disease 0 0.07408278435468674
in O 0 1.0945957917840587e-08
four O 0 3.8058740159385707e-08
Japanese O 0 3.9010808450257173e-07
C9 B-Disease 0 5.5309250456048176e-05
- I-Disease 0 0.00031510565895587206
deficient I-Disease 0 0.00013641927216667682
patients O 0 8.214250897253805e-07
who O 0 1.2313913657635567e-06
had O 0 4.4486307160696015e-05
suffered O 0 0.0036107085179537535
from O 0 7.241962975967908e-07
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.5003550970504875e-06

Direct O 0 1.603129021532368e-06
sequencing O 0 2.6184875423496123e-06
of O 0 6.249408102121379e-08
amplified O 0 2.401480742264539e-06
C9 O 0 7.312247817026218e-06
cDNA O 0 2.1792748157167807e-06
and O 0 1.4983731944084866e-07
DNA O 0 4.922026164422277e-07
revealed O 0 3.5292163147460087e-07
a O 0 1.8714693794663617e-08
nonsense O 0 2.577001794179523e-07
substitution O 0 2.368025420196318e-08
( O 0 8.898559222814129e-09
CGA O 0 7.487283255613875e-07
- O 0 3.866320639644982e-06
- O 0 5.241231519903522e-06
> O 0 1.0938782679659198e-07
TGA O 0 6.722024750160926e-07
) O 0 2.9469076068266986e-09
at O 0 1.1292509149996022e-09
codon O 0 3.8488565223815385e-08
95 O 0 5.397599256440344e-09
in O 0 5.986560691617626e-10
exon O 0 1.48178543213362e-07
4 O 0 1.2621465828033251e-07
in O 0 7.299385984538276e-09
the O 0 1.2203856591952444e-08
four O 0 4.3211548472754657e-07
C9 B-Disease 0 0.0003050091036129743
- I-Disease 0 0.2024761140346527
deficient I-Disease 0 0.0004959862562827766
individuals O 0 4.618504689801739e-08
. O 0 7.006831737044195e-08

An O 0 3.5752373150899075e-07
allele O 0 3.1568893064104486e-06
- O 0 3.965927817262127e-07
specific O 0 1.687606676625819e-08
polymerase O 0 5.175095338927349e-07
chain O 0 1.3921813888373435e-06
reaction O 0 1.9534915907115646e-08
system O 0 4.285337862341976e-09
designed O 0 3.262752201749208e-08
to O 0 3.0627271829786196e-09
detect O 0 1.8749179275800998e-07
exclusively O 0 8.990753919135841e-09
only O 0 5.519079415705619e-09
one O 0 1.2181851083425954e-09
of O 0 1.2213136058036866e-10
the O 0 8.294666065111755e-10
normal O 0 6.731966095685493e-09
and O 0 2.148864419737606e-09
mutant O 0 1.2764120072006335e-07
alleles O 0 2.9025832404272478e-08
indicated O 0 1.4565077322004072e-07
that O 0 5.282949633311773e-10
all O 0 1.440586122614107e-10
the O 0 5.562968419248193e-10
four O 0 7.458375250735116e-09
patients O 0 3.010675264647489e-09
were O 0 2.5878903464615632e-09
homozygous O 0 2.041599067581501e-08
for O 0 1.30930891129033e-10
the O 0 7.19651727099091e-10
mutation O 0 7.584820771455725e-09
in O 0 3.5602928938338607e-10
exon O 0 7.556349146398134e-08
4 O 0 7.587831873934192e-07
and O 0 3.5642037232719304e-07
that O 0 1.0051897092466788e-08
the O 0 2.9419204850000824e-09
parents O 0 3.766019052164893e-09
of O 0 3.5895100780614086e-10
patient O 0 4.5696712192011546e-08
2 O 0 3.7768398186699415e-08
were O 0 9.782763754628832e-08
heterozygous O 0 2.6567793156573316e-06
. O 0 2.521606461414194e-07

The O 0 3.127141781078535e-07
common O 0 5.894686694318807e-08
mutation O 0 1.5412540221859672e-07
at O 0 2.911575203157213e-09
codon O 0 7.867331675015521e-08
95 O 0 9.785689591979008e-09
in O 0 1.6778616274137903e-09
exon O 0 2.66770456391896e-07
4 O 0 4.93562424708216e-07
might O 0 2.4389188979512255e-07
be O 0 4.684616250472118e-09
responsible O 0 6.737180591187553e-09
for O 0 1.14986409283091e-09
most O 0 1.643766012193737e-08
Japanese O 0 1.2875882475782419e-06
C9 B-Disease 0 0.0008833529427647591
deficiency I-Disease 0 6.483992910943925e-05
. O 0 1.6007557945840745e-08
. O 0 1.3160997980321554e-07

BRCA1 O 0 0.0006544679636135697
required O 0 6.175740736580337e-07
for O 0 1.191654064314207e-08
transcription O 0 8.296448868350126e-06
- O 0 0.0011355404276400805
coupled O 0 2.7976129786111414e-05
repair O 0 9.368091014039237e-06
of O 0 9.889490115710942e-09
oxidative O 0 1.970948687812779e-06
DNA O 0 7.180232842074474e-06
damage O 0 7.134228326322045e-06
. O 0 5.467188088914554e-07

The O 0 1.4202437341737095e-05
breast B-Disease 1 0.9998749494552612
and I-Disease 1 0.8483854532241821
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
susceptibility O 0 0.0004284887691028416
gene O 0 1.2909502402180806e-05
BRCA1 O 0 5.1446331781335175e-05
encodes O 0 1.700008760963101e-05
a O 0 6.765042598999571e-06
zinc O 0 0.3889284133911133
finger O 0 0.003995472099632025
protein O 0 3.222127986646228e-07
of O 0 4.107279849563383e-09
unknown O 0 1.7959567344405514e-07
function O 0 2.1923207782492682e-07
. O 0 3.063351527998748e-07

Association O 0 5.632485681417165e-06
of O 0 1.6802514934965984e-08
the O 0 9.130770806109467e-09
BRCA1 O 0 1.1759345852624392e-06
protein O 0 5.389012613932209e-08
with O 0 1.1667117272295968e-09
the O 0 2.0423769342414744e-09
DNA O 0 1.689588060571623e-07
repair O 0 9.076483138414915e-07
protein O 0 9.004967438386302e-08
Rad51 O 0 2.2926676592760487e-06
and O 0 1.0491967294967708e-08
changes O 0 1.1246338305070935e-09
in O 0 1.4134422798850466e-10
the O 0 2.110144003975023e-10
phosphorylation O 0 5.129621616362101e-09
and O 0 5.046184803347842e-09
cellular O 0 2.847788849180688e-08
localization O 0 3.432587192264691e-08
of O 0 2.9706703763565656e-10
the O 0 8.956962394002232e-10
protein O 0 1.193496501628033e-08
after O 0 3.809227600015674e-09
exposure O 0 6.82571688059852e-09
to O 0 7.356337761166287e-10
DNA O 0 3.552156613295665e-08
- O 0 1.6413919468050153e-07
damaging O 0 3.605185128208177e-08
agents O 0 5.943500358540632e-09
are O 0 4.4653009068085225e-10
consistent O 0 6.0827405334862306e-09
with O 0 4.3271916605469585e-10
a O 0 1.7367383087218968e-09
role O 0 1.1482955031283382e-08
for O 0 2.2647534958508686e-09
BRCA1 O 0 8.445453545391501e-07
in O 0 3.469805065492437e-08
DNA O 0 7.3116066232614685e-06
repair O 0 9.41832477110438e-05
. O 0 9.341882218905084e-07

Here O 0 6.517933343275217e-06
, O 0 2.0192537419916334e-08
it O 0 3.4772762447232708e-09
is O 0 3.559724293111799e-09
shown O 0 1.600691668102172e-08
that O 0 2.9244486832169514e-09
mouse O 0 7.899968477431685e-05
embryonic O 0 3.7570707718259655e-06
stem O 0 2.5507179088890553e-06
cells O 0 1.1027221944459598e-06
deficient B-Disease 0 1.582938580213522e-06
in I-Disease 0 7.787114952861884e-09
BRCA1 I-Disease 0 2.1661217033397406e-06
are O 0 7.839542348619943e-09
defective O 0 8.87318890363531e-07
in O 0 1.841959651471825e-08
the O 0 2.4754763572332195e-08
ability O 0 4.3665281168614456e-08
to O 0 3.8334908580850424e-09
carry O 0 5.426626703552984e-09
out O 0 1.291829487826135e-08
transcription O 0 2.6739934355646255e-07
- O 0 7.717775588389486e-06
coupled O 0 1.0997542858603992e-06
repair O 0 4.369586008579063e-07
of O 0 9.456594396439755e-10
oxidative O 0 9.209797013909338e-08
DNA O 0 6.847351983196859e-07
damage O 0 1.8253039115734282e-06
, O 0 1.0183196508251058e-08
and O 0 1.7291897691507074e-08
are O 0 6.223379145353647e-09
hypersensitive O 0 3.6080236895941198e-06
to O 0 7.414040936737365e-08
ionizing O 0 5.627084192383336e-06
radiation O 0 2.215878339484334e-06
and O 0 1.6066653785173912e-08
hydrogen O 0 1.0071782696741138e-07
peroxide O 0 5.379818048822926e-06
. O 0 2.4551704314035305e-07

These O 0 3.1149710366662475e-07
results O 0 1.5273622011591215e-07
suggest O 0 6.122539986108677e-08
that O 0 4.721007140773281e-09
BRCA1 O 0 1.0960749250443769e-06
participates O 0 2.9426066916471427e-08
, O 0 6.159597720767351e-09
directly O 0 8.88697471168598e-09
or O 0 1.1856912784935503e-08
indirectly O 0 5.44269660451846e-08
, O 0 1.4310127527394911e-09
in O 0 1.3239097595985072e-09
transcription O 0 2.6751283712656004e-06
- O 0 0.00026451313169673085
coupled O 0 8.263774361694232e-06
repair O 0 3.757465037779184e-06
of O 0 4.573514456041039e-09
oxidative O 0 3.1523987331638637e-07
DNA O 0 1.3972796750749694e-06
damage O 0 1.804004000405257e-06
. O 0 4.191718971924274e-08
. O 0 1.439610173292749e-07

Truncation O 0 0.000428318657213822
mutations O 0 0.0001843679929152131
in O 0 3.426608330414638e-08
the O 0 1.2907753088597929e-08
transactivation O 0 1.1182878552062903e-05
region O 0 2.8033070975652663e-07
of O 0 5.331175501055441e-09
PAX6 O 0 1.8644330339157023e-05
result O 0 3.408824866824034e-08
in O 0 1.0450246001880714e-08
dominant O 0 3.3333151350234402e-06
- O 0 0.0001670512865530327
negative O 0 4.1483344830339774e-06
mutants O 0 2.5831513994489796e-05
. O 0 3.674125537145301e-07

PAX6 O 0 0.0023072627373039722
is O 0 5.300614134284842e-07
a O 0 3.3807364019367014e-08
transcription O 0 1.5854057267006283e-07
factor O 0 1.8401511425736317e-08
with O 0 1.2144755201504154e-09
two O 0 4.0381915589193795e-09
DNA O 0 1.3192953929319629e-07
- O 0 7.179755812103394e-07
binding O 0 7.101755272742594e-08
domains O 0 1.5101552719443134e-07
( O 0 9.086641661326667e-09
paired O 0 7.947112408146495e-07
box O 0 3.408038173802197e-05
and O 0 4.823378390028665e-07
homeobox O 0 2.147400209651096e-06
) O 0 8.175065069337961e-09
and O 0 5.878616704535489e-09
a O 0 1.1311722225570975e-08
proline O 0 8.110349654089077e-07
- O 0 2.9018719942541793e-06
serine O 0 1.5385473943752004e-06
- O 0 5.734107162425062e-06
threonine O 0 1.1242482287343591e-05
( O 0 5.2192962840535984e-08
PST O 0 4.929452188662253e-06
) O 0 4.2211237172296023e-08
- O 0 1.5219879969663452e-06
rich O 0 2.875133020552312e-07
transactivation O 0 1.157104634330608e-05
domain O 0 1.216677219417761e-06
. O 0 4.5229202783048095e-07

PAX6 O 0 0.008706211112439632
regulates O 0 8.732260903343558e-05
eye O 0 0.0009934930130839348
development O 0 6.437966959538244e-08
in O 0 2.9947651025707955e-09
animals O 0 2.3513937463803813e-09
ranging O 0 5.7960827248848545e-09
from O 0 1.269098937051183e-09
jellyfish O 0 3.4395078785109945e-08
to O 0 2.0027326463889494e-09
Drosophila O 0 5.715015660712197e-08
to O 0 5.893357357678042e-09
humans O 0 4.4017241407345864e-08
. O 0 7.832759507664377e-08

Heterozygous O 0 0.0006627776892855763
mutations O 0 8.294987492263317e-05
in O 0 2.3224362877272142e-08
the O 0 7.361057541288574e-09
human O 0 2.3960396333677636e-08
PAX6 O 0 8.196103408408817e-06
gene O 0 9.235001812157861e-07
result O 0 1.2722211728544153e-08
in O 0 1.5263589281389045e-09
various O 0 3.3136324795179917e-09
phenotypes O 0 3.0368778425327037e-06
, O 0 1.392964144031339e-08
including O 0 2.3733338849751817e-08
aniridia B-Disease 1 1.0
, O 0 2.3020840671961196e-05
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 7.753473596494587e-07
autosomal B-Disease 0 0.16270387172698975
dominant I-Disease 0 0.00032123096752911806
keratitis I-Disease 1 0.5379554629325867
, O 0 2.570296544490702e-07
and O 0 6.966400292185426e-07
familial B-Disease 0 0.03403428941965103
foveal I-Disease 1 0.9811635613441467
dysplasia I-Disease 1 0.9999934434890747
. O 0 8.260291906481143e-06

It O 0 2.8508377454272704e-06
is O 0 2.1577283959572924e-08
believed O 0 1.272405558694345e-08
that O 0 3.031463691183234e-10
the O 0 7.337546126251482e-10
mutated O 0 5.606689796877617e-07
allele O 0 6.373699648065667e-07
of O 0 4.5641033175058965e-09
PAX6 O 0 1.779056037776172e-05
produces O 0 1.055499652125036e-07
an O 0 1.3687204702961253e-09
inactive O 0 5.7604104597430705e-08
protein O 0 1.8470632312528323e-07
and O 0 5.720244189433288e-07
aniridia B-Disease 1 1.0
is O 0 2.202154689712188e-07
caused O 0 6.382531125836977e-08
due O 0 2.5898803102109014e-09
to O 0 4.175542134277066e-09
genetic O 0 1.5399331232401892e-06
haploinsufficiency O 0 7.473054574802518e-05
. O 0 1.796708914980627e-07

However O 0 1.7878428479889408e-06
, O 0 9.191525762730635e-09
several O 0 1.6920699286160357e-09
truncation O 0 9.933008868756588e-07
mutations O 0 2.365173941143439e-06
have O 0 1.412228840536045e-07
been O 0 2.2265661314690988e-08
found O 0 7.532343637706163e-09
to O 0 2.088029082969456e-09
occur O 0 1.2603448285020136e-09
in O 0 3.601380860196457e-10
the O 0 4.1908294612369446e-09
C O 0 1.1379236184438923e-06
- O 0 4.58352587884292e-06
terminal O 0 2.595245121028711e-07
half O 0 2.0444591797286193e-08
of O 0 9.982725757140543e-10
PAX6 O 0 1.032512727761059e-06
in O 0 5.986951823189202e-09
patients O 0 2.403078624979571e-08
with O 0 1.366597679464121e-08
Aniridia B-Disease 1 1.0
resulting O 0 5.772762534661524e-08
in O 0 6.749807934802732e-10
mutant O 0 1.1564614510461979e-07
proteins O 0 7.982293936947826e-09
that O 0 1.3887162531034392e-09
retain O 0 4.276984544304696e-09
the O 0 3.626900446640491e-10
DNA O 0 1.1876966965473912e-08
- O 0 4.6642817608244513e-08
binding O 0 1.4262802494613425e-08
domains O 0 3.153742511585733e-08
but O 0 1.969635476939402e-08
have O 0 3.4751035826730003e-08
lost O 0 4.794339929503622e-07
most O 0 6.959847698162491e-10
of O 0 5.772117783742203e-10
the O 0 1.1483983541893394e-08
transactivation O 0 7.834887583157979e-06
domain O 0 1.014444364955125e-06
. O 0 2.6892223559116246e-07

It O 0 2.00953877538268e-06
is O 0 1.7753832182165752e-08
not O 0 8.312039390112602e-10
clear O 0 1.3932610620770447e-09
whether O 0 5.5459536962843e-10
such O 0 1.0615982537487412e-09
mutants O 0 3.5412198485573754e-05
really O 0 4.855602128372993e-06
behave O 0 5.1066248119013835e-08
as O 0 2.705467405661466e-09
loss O 0 8.433861609091764e-09
- O 0 3.48206413036678e-07
of O 0 2.8179829580921023e-09
- O 0 2.7421212962508434e-06
function O 0 1.1614657680070195e-08
mutants O 0 5.305438435243559e-07
as O 0 1.0621456603132629e-08
predicted O 0 1.271646823397532e-07
by O 0 5.030539984574034e-09
haploinsufficiency O 0 1.2249504834471736e-05
. O 0 2.267640439868046e-07

Contrary O 0 7.5164543886785395e-06
to O 0 1.5339420400550807e-08
this O 0 1.1441869673944893e-09
theory O 0 3.027426531687638e-09
, O 0 1.3887905270237866e-09
our O 0 1.565810370252052e-09
data O 0 3.469983766990481e-08
showed O 0 7.104234214239113e-07
that O 0 4.384742846585965e-10
these O 0 3.1339034145538847e-10
mutants O 0 1.2512059299751854e-07
are O 0 4.893540572759036e-10
dominant O 0 3.401712689310443e-08
- O 0 9.937518825609004e-07
negative O 0 4.7236397904271143e-08
in O 0 9.76029701504899e-10
transient O 0 4.5695145445279195e-08
transfection O 0 7.99262465989159e-07
assays O 0 4.659533772155555e-07
when O 0 2.5257119062871425e-08
they O 0 2.639334750753619e-09
are O 0 2.8546709440746554e-10
coexpressed O 0 1.1849365932903311e-07
with O 0 2.6187303436842058e-09
wild O 0 3.951509484068083e-07
- O 0 0.0002917559177149087
type O 0 3.5344542084203567e-06
PAX6 O 0 0.00010213171481154859
. O 0 8.912379598768894e-07

We O 0 5.389276338974014e-06
found O 0 2.5880989795723508e-08
that O 0 1.3174259461123938e-09
the O 0 1.439899977029313e-09
dominant O 0 3.156143861815508e-07
- O 0 2.1751680833403952e-05
negative O 0 4.4047223468623997e-07
effects O 0 2.47404187803113e-07
result O 0 2.7666953172911235e-09
from O 0 4.471428782792941e-10
the O 0 3.472939713589085e-10
enhanced O 0 1.931089954609888e-08
DNA O 0 7.138395829997535e-08
binding O 0 2.2853621217677755e-08
ability O 0 2.7322011320052297e-08
of O 0 8.596166001240135e-10
these O 0 8.221130443075708e-09
mutants O 0 4.7402645577676594e-06
. O 0 2.206321170206138e-07

Kinetic O 0 1.6725154637242667e-05
studies O 0 3.177744360982615e-07
of O 0 7.511253841130383e-09
binding O 0 1.217070320080893e-07
and O 0 1.5376600970284926e-07
dissociation O 0 3.340972398291342e-06
revealed O 0 7.682475597903249e-07
that O 0 7.85816134385442e-10
various O 0 6.25177465352067e-10
truncation O 0 6.856931804577471e-07
mutants O 0 2.5557314984325785e-06
have O 0 1.922545322941005e-08
3 O 0 1.34710020915918e-08
- O 0 6.922003308318381e-07
5 O 0 4.547725396264468e-08
- O 0 2.0251857222319813e-06
fold O 0 3.6858862131339265e-06
higher O 0 2.9329449979798028e-09
affinity O 0 1.936016236214755e-09
to O 0 9.84386253066738e-11
various O 0 1.0879030315491534e-10
DNA O 0 5.800329549998651e-09
- O 0 9.782667120816768e-09
binding O 0 2.9200564188869294e-09
sites O 0 8.093858916424779e-09
when O 0 4.5207833032634426e-09
compared O 0 1.691756734700789e-09
with O 0 1.6442659733773013e-10
the O 0 1.843818098201666e-09
wild O 0 2.8891838610434206e-07
- O 0 7.264787564054132e-05
type O 0 1.9447811610007193e-06
PAX6 O 0 7.42652264307253e-05
. O 0 8.993413302960107e-07

These O 0 2.931733718014584e-07
results O 0 4.513643148129631e-08
provide O 0 2.7105395705717683e-09
a O 0 4.3999168752861806e-09
new O 0 1.2143601679781568e-08
insight O 0 6.308269462351745e-08
into O 0 1.1358394225169377e-09
the O 0 1.2978473851177341e-09
role O 0 7.891871156573416e-09
of O 0 1.4717734808655791e-09
mutant O 0 1.7898456690090825e-06
PAX6 O 0 5.661501745635178e-06
in O 0 4.228730432487282e-08
causing O 0 2.00426006813359e-06
aniridia B-Disease 1 0.9999997615814209
. O 0 2.022287617364782e-07
. O 0 2.432489054626785e-07

Reversal O 0 0.00018787317094393075
of O 0 1.0510804031582666e-06
severe O 0 0.016007952392101288
hypertrophic B-Disease 1 0.9999914169311523
cardiomyopathy I-Disease 1 1.0
and O 0 4.650343907997012e-05
excellent O 0 1.9167659957020078e-06
neuropsychologic O 0 2.1718224161304533e-05
outcome O 0 1.4121292224444915e-07
in O 0 2.6432603661419307e-08
very B-Disease 0 1.0912358305859016e-07
- I-Disease 0 0.010745554231107235
long I-Disease 0 2.430288259347435e-05
- I-Disease 0 0.00011358974006725475
chain I-Disease 0 1.9149760191794485e-05
acyl I-Disease 0 7.330865514632023e-07
- I-Disease 0 8.058738103500218e-07
coenzyme I-Disease 0 6.32191586191766e-07
A I-Disease 0 1.5875162944212207e-06
dehydrogenase I-Disease 0 0.0015375013463199139
deficiency I-Disease 0 0.16483590006828308
. O 0 8.995111784315668e-07

Very B-Disease 0 2.1279362044879235e-05
- I-Disease 0 0.0030331911984831095
long I-Disease 0 1.1334061127854511e-05
- I-Disease 0 4.03373378503602e-05
chain I-Disease 0 3.3070189147110796e-06
acyl I-Disease 0 2.707914177335624e-07
- I-Disease 0 1.453748836865998e-07
coenzyme I-Disease 0 5.7631030614402334e-08
A I-Disease 0 3.459139819028678e-08
dehydrogenase I-Disease 0 2.0744735138578108e-06
( I-Disease 0 1.498966355484299e-07
VLCAD I-Disease 0 0.0003046246129088104
) I-Disease 0 1.2550113979159505e-06
deficiency I-Disease 0 0.00022138236090540886
is O 0 9.959851610119586e-09
a O 0 9.163188963157154e-08
disorder O 0 0.0002935930388048291
of O 0 3.968236850226958e-09
fatty O 0 1.6844909396240837e-06
acid O 0 1.2214992750614329e-07
beta O 0 1.3707039947519206e-08
oxidation O 0 1.5375977824305664e-08
that O 0 3.6075704645810447e-09
reportedly O 0 4.400179420827044e-07
has O 0 3.0522841143465484e-08
high O 0 1.4054674757346675e-08
rates O 0 4.284294163880986e-08
of O 0 2.8492868064944332e-09
morbidity O 0 0.014537402428686619
and O 0 8.586004014432547e-07
mortality O 0 4.7018882469274104e-05
. O 0 4.104995525722188e-07

We O 0 1.0423251524116495e-06
describe O 0 6.589507250964743e-08
the O 0 2.720157210589491e-09
outcome O 0 5.0155750663805065e-09
of O 0 4.454420998722952e-10
a O 0 1.532865745446088e-08
5 O 0 5.571808614490692e-08
- O 0 3.3792264275689377e-06
year O 0 2.6190413393578638e-08
- O 0 2.146278347936459e-06
old O 0 1.939567482622806e-05
girl O 0 0.0035430791322141886
with O 0 7.6227433964959346e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 1.8557799194240943e-05
was O 0 5.972538588139287e-07
first O 0 7.197001661296554e-09
seen O 0 9.87256925100155e-08
at O 0 2.608943727722135e-09
5 O 0 4.068303471882473e-09
months O 0 3.5565954625838003e-09
of O 0 5.266660996205985e-10
age O 0 2.949225752502116e-08
with O 0 1.640160434135396e-07
severe O 0 0.1972876340150833
hypertrophic B-Disease 1 0.9999867677688599
cardiomyopathy I-Disease 1 1.0
, O 0 0.0002436641079839319
hepatomegaly B-Disease 1 1.0
, O 0 2.557538937253412e-05
encephalopathy B-Disease 0 0.20470578968524933
, O 0 4.0743703522139185e-08
and O 0 2.3627698908512684e-07
hypotonia B-Disease 0 0.036837201565504074
. O 0 9.229402166965883e-07

Biochemical O 0 0.0004142375255469233
studies O 0 5.879567106603645e-05
indicated O 1 0.7364928722381592
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 6.5458657445560675e-06
by O 0 4.890817972835748e-09
a O 0 5.89189923516642e-08
stable O 0 5.813223651784938e-06
yet O 0 1.0924395610345528e-07
inactive O 0 8.62952788338589e-07
enzyme O 0 1.5325229014706565e-06
. O 0 2.407722377029131e-07

Molecular O 0 7.729561730229761e-06
genetic O 0 2.6690124741435284e-06
analysis O 0 7.814464453304026e-08
of O 0 5.504288136393143e-09
her O 0 1.0978910722769797e-06
VLCAD O 0 0.00033340140362270176
gene O 0 1.4040547284821514e-06
revealed O 0 1.6637313819956034e-06
a O 0 6.435486454847705e-08
T1372C O 0 3.521534608807997e-06
( O 0 4.08731430923126e-08
F458L O 0 1.6028767504394636e-06
) O 0 3.362973188814067e-08
missense O 0 1.1228468792978674e-05
mutation O 0 1.3300489172252128e-06
and O 0 3.4620441624610976e-08
a O 0 1.577445658540455e-07
1668 O 0 0.00043456998537294567
ACAG O 0 0.00013699260307475924
1669 O 0 1.5819812688278034e-05
splice O 0 0.00032959136296994984
site O 0 2.756619687716011e-05
mutation O 0 2.8618362193810754e-05
. O 0 1.0709763955674134e-06

After O 0 1.2357052128209034e-06
initial O 0 1.438704373413202e-07
treatment O 0 1.0399387662118897e-07
with O 0 5.592546425958744e-09
intravenous O 0 1.6668296893840306e-06
glucose O 0 3.1461953767575324e-05
and O 0 2.9087237507496866e-08
carnitine O 0 3.2566009622314596e-07
, O 0 3.620101551859989e-09
the O 0 2.8525386497335603e-09
patient O 0 1.2924559200655494e-07
has O 0 6.523092821453247e-08
thrived O 0 1.3448813263039483e-07
on O 0 2.7132047719646835e-08
a O 0 1.8919990907306783e-08
low O 0 1.0319103012079722e-06
- O 0 5.150249307916965e-06
fat O 0 1.6830763343023136e-06
diet O 0 3.1531047994803885e-08
supplemented O 0 1.4053547658932075e-08
with O 0 1.6912728995066573e-09
medium O 0 9.550225144039359e-08
- O 0 2.379758143433719e-06
chain O 0 3.710245209731511e-06
triglyceride O 0 5.841004053763754e-07
oil O 0 1.1227038498873299e-07
and O 0 4.948856435760263e-09
carnitine O 0 1.536918148303812e-07
and O 0 3.993247066347294e-09
avoidance O 0 1.701495619954585e-07
of O 0 1.6101841637805592e-08
fasting O 0 2.146637052646838e-05
. O 0 3.580054794838361e-07

Her O 0 0.0007164159906096756
ventricular O 0 0.012288122437894344
hypertrophy O 0 0.0014289068058133125
resolved O 0 3.4496633816161193e-06
significantly O 0 3.846567437904014e-07
over O 0 1.4540588288980416e-08
1 O 0 2.4961673616985536e-08
year O 0 2.3169057783434255e-08
, O 0 6.6371597107206526e-09
and O 0 2.395498768237303e-07
cognitively O 0 3.084666104768985e-06
, O 0 2.4834497125425514e-08
she O 0 1.5065288607729599e-06
is O 0 3.275370863420335e-09
in O 0 8.732884970719113e-10
the O 0 2.0169164116623506e-09
superior O 0 1.9414231999803633e-08
range O 0 4.35229274842186e-08
for O 0 3.882202559424286e-09
age O 0 1.0795372418215265e-07
. O 0 1.00156917426375e-07

Clinical O 0 4.775308843818493e-05
recognition O 0 5.5094133131206036e-06
of O 0 1.6997219063341618e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.1008711453541764e-07
important O 0 4.298156941473508e-09
because O 0 5.932616176096417e-09
it O 0 1.319448372782972e-08
is O 0 2.458488745915588e-09
one O 0 5.64667201885527e-10
of O 0 1.1230899543690498e-10
the O 0 4.64169280789406e-09
few O 0 1.5624050320184324e-07
directly O 0 4.2324225546508387e-07
treatable O 0 9.187720934278332e-06
causes O 0 8.647811711171016e-08
of O 0 1.26638424191583e-08
cardiomyopathy B-Disease 1 1.0
in O 0 6.663456701971882e-07
children O 0 2.654940544744022e-06
. O 0 4.0592830430341564e-08
. O 0 1.9505935711094935e-07

Cloning O 0 5.233369392954046e-06
of O 0 6.043551081802434e-08
a O 0 7.109467503596534e-08
novel O 0 7.513648938584083e-07
member O 0 1.9547924168250574e-08
of O 0 1.3930829823038948e-09
the O 0 7.2933743489045355e-09
low O 0 2.8637759896810167e-06
- O 0 7.522291980421869e-06
density O 0 4.373763715648238e-07
lipoprotein O 0 6.221705916686915e-06
receptor O 0 7.862086590648687e-07
family O 0 9.262732305614918e-07
. O 0 3.189691994975874e-07

A O 0 1.9348487967363326e-06
gene O 0 1.9214530766475946e-06
encoding O 0 5.686863460141467e-07
a O 0 8.27627886224036e-08
novel O 0 5.904431077397021e-07
transmembrane O 0 6.261900580284419e-07
protein O 0 4.2442857761670894e-07
was O 0 3.1311466841543734e-07
identified O 0 1.0411270956467433e-08
by O 0 1.2373421731659562e-10
DNA O 0 1.0746596501576278e-08
sequence O 0 1.2651021563669929e-08
analysis O 0 3.2304328101417923e-09
within O 0 1.947794592283003e-09
the O 0 1.095809487594579e-08
insulin B-Disease 0 0.001493117306381464
- I-Disease 1 0.9935833811759949
dependent I-Disease 1 0.6160438656806946
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 6.328992299131642e-07
IDDM B-Disease 0 2.9456803531502374e-05
) O 0 2.313717395452386e-08
locus O 0 1.3634678452945082e-06
IDDM4 O 0 1.8788727174978703e-05
on O 0 8.019714528018085e-07
chromosome O 0 0.0002204175543738529
11q13 O 0 2.3060303647071123e-05
. O 0 6.406217494259181e-07

Based O 0 1.03935519746301e-06
on O 0 1.5124528829346673e-07
its O 0 9.41071665039317e-09
chromosomal O 0 8.536098903277889e-05
position O 0 2.7358860279491637e-06
, O 0 3.051264130249365e-09
this O 0 2.9496166620290865e-10
gene O 0 1.1262701882230886e-08
is O 0 1.898939672173583e-09
a O 0 2.284990419099131e-09
candidate O 0 1.6338541186655675e-08
for O 0 1.1219107864945954e-09
conferring O 0 1.4942092718683853e-07
susceptibility O 0 2.8530590498121455e-05
to O 0 1.3985687701278948e-06
diabetes B-Disease 0 0.03043617308139801
. O 0 9.489212402513658e-07

The O 0 5.167618724044587e-07
gene O 0 1.7729216779116541e-06
, O 0 3.077133214901551e-08
termed O 0 4.879248649558576e-07
low O 0 7.506916404054209e-07
- O 0 2.9889629331592005e-06
density O 0 2.8083138658985263e-07
lipoprotein O 0 1.3167178849471384e-06
receptor O 0 9.682983659331512e-08
related O 0 1.3179241697969246e-08
protein O 0 1.9419960040067963e-07
5 O 0 5.801184599363296e-08
( O 0 1.606671595766329e-08
LRP5 O 0 8.794404493528418e-06
) O 0 3.7020497778428307e-09
, O 0 5.224938259829059e-10
encodes O 0 1.0977445619175796e-08
a O 0 4.541785170175672e-09
protein O 0 2.8027772103200732e-08
of O 0 2.3539337146161188e-09
1615 O 0 9.266372558158764e-07
amino O 0 2.1962522467333656e-08
acids O 0 3.774130341582804e-09
that O 0 1.0249379817084403e-10
contains O 0 1.5561185673362843e-10
conserved O 0 5.570679473265727e-09
modules O 0 2.3854239472598238e-08
which O 0 1.1588721982036532e-08
are O 0 5.762723076507825e-10
characteristic O 0 1.6761767085426982e-08
of O 0 2.955822808736741e-10
the O 0 4.173201340051946e-09
low O 0 1.1367403658368858e-06
- O 0 2.1532554455916397e-05
density O 0 2.3478380626329454e-06
lipoprotein O 0 2.8828457288909703e-05
( O 0 3.9827519060509076e-08
LDL O 0 4.175618869339814e-06
) O 0 1.6163321348017234e-08
receptor O 0 1.5107791284663108e-07
family O 0 4.6118057639432664e-07
. O 0 2.95533368444012e-07

These O 0 1.775130016312687e-07
modules O 0 1.9518627425441082e-07
include O 0 1.1057466053898679e-08
a O 0 2.004395938115522e-08
putative O 0 3.936354914912954e-06
signal O 0 3.751071062652045e-06
peptide O 0 5.9221502368700385e-08
for O 0 4.217224347513593e-10
protein O 0 9.445855653211765e-09
export O 0 5.313339546120233e-09
, O 0 1.1828964474602799e-09
four O 0 2.8805429153067053e-09
epidermal O 0 3.8816307323941146e-07
growth O 0 1.0748200196530888e-07
factor O 0 1.7388538608997806e-08
( O 0 8.331693557295239e-09
EGF O 0 9.725551990413805e-07
) O 0 1.3185528224823884e-08
repeats O 0 7.35268258722499e-07
with O 0 3.889888411379161e-09
associated O 0 3.9539063578786227e-08
spacer O 0 2.004026282520499e-05
domains O 0 1.0187391126237344e-06
, O 0 3.6193419372665403e-09
three O 0 6.448779288348305e-09
LDL O 0 2.2054343844502e-06
- O 0 2.074048325084732e-06
receptor O 0 3.217696757928934e-07
( O 0 1.2406068172765572e-08
LDLR O 0 1.910017772388528e-06
) O 0 8.79732020564461e-09
repeats O 0 8.600895284871513e-07
, O 0 3.4308180740794114e-09
a O 0 5.513209000440611e-09
single O 0 1.388082040421068e-07
transmembrane O 0 1.8241328803014767e-07
spanning O 0 1.9717974453214993e-07
domain O 0 7.900263199189794e-08
, O 0 4.082209237310508e-09
and O 0 3.114205782139834e-09
a O 0 1.3212162919273851e-08
cytoplasmic O 0 1.828506128731533e-06
domain O 0 2.2507649646286154e-06
. O 0 4.993256652596756e-07

The O 0 1.697307823178562e-07
encoded O 0 1.9521976923897455e-07
protein O 0 6.551515525643481e-07
has O 0 2.7300863791879237e-08
a O 0 3.7850589329480044e-09
unique O 0 9.80848824383429e-09
organization O 0 6.86555390316812e-09
of O 0 1.4616409194090352e-09
EGF O 0 2.058604877674952e-06
and O 0 1.1168772573455499e-07
LDLR O 0 3.271830064477399e-05
repeats O 0 5.806901754112914e-06
; O 0 1.5056219382358904e-08
therefore O 0 1.837894836320686e-09
, O 0 4.511288842490302e-10
LRP5 O 0 8.86338739292114e-07
likely O 0 2.9612204244244822e-08
represents O 0 1.802828109020993e-09
a O 0 1.5054316682139302e-09
new O 0 5.167792860305553e-09
category O 0 2.575984048291957e-08
of O 0 1.1160351531813717e-09
the O 0 1.3576061164144448e-08
LDLR O 0 6.374008808052167e-05
family O 0 8.749113362682692e-07
. O 0 2.1696145324767713e-07

Both O 0 4.880668029727531e-07
human O 0 5.946542458445947e-08
and O 0 4.329746872144824e-08
mouse O 0 4.7117988287936896e-05
LRP5 O 0 2.5212166292476468e-05
cDNAs O 0 4.288752279535402e-06
have O 0 2.1536523320264678e-07
been O 0 1.4544582427333808e-08
isolated O 0 1.373442017893467e-07
and O 0 5.424463989101014e-09
the O 0 5.193263596936504e-10
encoded O 0 9.539298240213157e-09
mature O 0 3.890103794645938e-09
proteins O 0 1.0428775620852093e-09
are O 0 3.4766645118367023e-10
95 O 0 4.216389903888285e-09
% O 0 7.478599406418596e-10
identical O 0 1.558752060759616e-08
, O 0 9.717893156846458e-09
indicating O 0 6.359746862472093e-08
a O 0 1.7567019838793385e-08
high O 0 8.762793157757187e-08
degree O 0 2.8412496799745668e-09
of O 0 2.3116682179580295e-10
evolutionary O 0 3.749471488845302e-08
conservation O 0 1.4779939050413304e-08
. O 0 6.807073127390595e-09
. O 0 6.747612957269666e-08

The O 0 1.0753485639725113e-06
APC B-Disease 0 5.62182822250179e-06
variants O 0 1.4332719047160936e-06
I1307K O 0 3.358709136591642e-06
and O 0 2.2385616915698847e-08
E1317Q O 0 4.053647444379749e-07
are O 0 5.8365858812692295e-09
associated O 0 3.6928773283761984e-07
with O 0 0.41656187176704407
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.00017917876539286226
but O 0 3.4163957707278314e-07
not O 0 4.125386610098758e-08
always O 0 6.674409291917982e-08
with O 0 9.474052653501985e-10
a O 0 3.2733613153368424e-08
family O 0 2.4934391262831923e-07
history O 0 1.3912307395003154e-07
. O 0 3.4851336749852635e-07

Classical O 0 0.008106430992484093
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
( O 0 0.0019204160198569298
FAP B-Disease 0 0.0005007752915844321
) O 0 4.971660132468969e-07
is O 0 1.311744846077545e-08
a O 0 2.2562867130204722e-08
high O 0 7.968688805704005e-06
- O 1 0.9999982118606567
penetrance O 1 0.9999860525131226
autosomal B-Disease 1 0.9998469352722168
dominant I-Disease 0 0.24220292270183563
disease I-Disease 0 0.00021478140843100846
that O 0 6.321660528385564e-09
predisposes O 0 5.841973234055331e-07
to O 0 3.5395888442479873e-09
hundreds O 0 5.4151501061028284e-09
or O 0 3.774454082616785e-09
thousands O 0 1.544823291510511e-08
of O 0 4.772092779603554e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9805117249488831
carcinoma I-Disease 1 1.0
and O 0 7.766226190142334e-06
that O 0 2.120389908100151e-08
results O 0 1.635297586233264e-08
from O 0 2.7536601887589995e-09
truncating O 0 1.102705368793977e-06
mutations O 0 7.938287467368355e-07
in O 0 3.5767524497742897e-09
the O 0 1.5599981750824554e-08
APC B-Disease 0 3.354349246365018e-06
gene O 0 3.8234347812249325e-06
. O 0 6.727950676577166e-07

A O 0 8.744010301597882e-06
variant O 0 4.506195182329975e-05
of O 0 5.32230842509307e-07
FAP B-Disease 0 0.00019047233217861503
is O 0 2.9484156129910843e-06
attenuated B-Disease 1 0.8035734295845032
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999988079071045
coli I-Disease 1 1.0
, O 0 4.26153150101527e-07
which O 0 1.8626378661679155e-08
results O 0 5.529521729386033e-09
from O 0 1.6008191439098596e-09
germ O 0 1.5682666344218887e-05
- O 0 7.374082633759826e-05
line O 0 0.00024893588852137327
mutations O 0 1.0377788584037262e-07
in O 0 1.2777968683153063e-09
the O 0 3.0765916481101385e-09
5 O 0 2.1212313683349748e-08
and O 0 3.378454493940808e-08
3 O 0 1.4422838034988672e-08
regions O 0 6.430895371778433e-09
of O 0 6.588043444111236e-10
the O 0 9.571265557895003e-09
APC B-Disease 0 1.4410486528504407e-06
gene O 0 1.677115847087407e-06
. O 0 5.060086323283031e-07

Attenuated B-Disease 1 0.999842643737793
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999985694885254
coli I-Disease 1 1.0
patients O 0 0.0438004694879055
have O 0 2.7904691251023905e-06
" O 0 2.3938891899888404e-06
multiple O 0 4.189583705738187e-05
" O 1 0.9988527297973633
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 5.921862111790688e-07
typically O 0 2.9208267804392563e-08
fewer O 0 5.397949198737706e-09
than O 0 1.4426765337915981e-09
100 O 0 3.888397603901694e-09
) O 0 1.6586175766164502e-09
without O 0 1.6583772133316188e-09
the O 0 4.442231027468324e-09
florid O 0 0.0002886826987378299
phenotype O 0 8.053690180531703e-06
of O 0 7.654858080741178e-09
classical O 0 5.275101671031734e-07
FAP B-Disease 0 2.9136575903976336e-05
. O 0 4.150145116454951e-07

Another O 0 1.2683829027082538e-06
group O 0 1.9653543859021738e-07
of O 0 2.6401503205875088e-09
patients O 0 3.876957421766747e-08
with O 0 3.2309319664136638e-09
multiple O 0 8.052922453316569e-07
adenomas B-Disease 0 0.002426719991490245
has O 0 3.6823867048951797e-06
no O 0 1.596773202550139e-08
mutations O 0 1.045375839225926e-07
in O 0 6.968162713505421e-10
the O 0 1.945455352370118e-09
APC B-Disease 0 1.3953979305370012e-07
gene O 0 5.923573453969766e-08
, O 0 9.371864173601807e-09
and O 0 1.865574716930496e-08
their O 0 1.3113496066807784e-08
phenotype O 0 3.611128931879648e-06
probably O 0 1.7557765374931478e-07
results O 0 5.056088880905918e-09
from O 0 7.609072816272544e-10
variation O 0 5.169462014009696e-08
at O 0 7.579123106893348e-09
a O 0 1.2123468451363806e-08
locus O 0 1.2811991609851248e-06
, O 0 2.5470898279422727e-08
or O 0 1.1092426532854915e-08
loci O 0 9.635855491296752e-08
, O 0 2.6690407661789095e-09
elsewhere O 0 6.4145044831320774e-09
in O 0 9.92478432770838e-10
the O 0 1.405059979475709e-08
genome O 0 1.9570140921132406e-06
. O 0 2.4400006282121467e-07

Recently O 0 7.244711014209315e-05
, O 0 4.327377567392432e-08
however O 0 3.858137809231721e-09
, O 0 5.552473480996412e-10
a O 0 3.0625111335780275e-09
missense O 0 1.6005228644644376e-06
variant O 0 1.7496648752057808e-06
of O 0 1.3253252717504438e-08
APC B-Disease 0 4.641669875127263e-06
( O 0 2.9631529230300657e-08
I1307K O 0 7.754553053018753e-07
) O 0 2.2444744729455124e-08
was O 0 4.1912434767255036e-07
described O 0 6.100810878706397e-08
that O 0 1.342577382601462e-09
confers O 0 1.9384780003406377e-08
an O 0 1.9149468677426285e-09
increased O 0 1.8747533658824977e-07
risk O 0 1.1228104312976939e-06
of O 0 0.00019462969794403762
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.6909115174712497e-07
including O 0 6.455720402698262e-09
multiple O 0 7.148191230044176e-07
adenomas B-Disease 0 0.0003486668865662068
, O 0 5.3809703359775085e-08
in O 0 9.036040182763827e-08
Ashkenazim O 0 0.00032564220600761473
. O 0 6.879227498757245e-07

We O 0 1.4193177776178345e-05
have O 0 1.5033435829536757e-08
studied O 0 3.9214067548698495e-09
a O 0 2.3469801657682865e-09
set O 0 1.132171600914944e-08
of O 0 7.66869290291794e-10
164 O 0 2.425888965262857e-07
patients O 0 4.1131375638769896e-08
with O 0 6.542406083553942e-08
multiple O 1 0.9758940935134888
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.007966124452650547
/ I-Disease 1 0.786149799823761
or I-Disease 0 0.0004857157473452389
carcinoma I-Disease 1 1.0
and O 0 2.171739652112592e-06
analyzed O 0 1.8864482171920827e-06
codons O 0 1.141760640166467e-05
1263 O 0 2.638022488099523e-05
- O 0 2.547461372159887e-05
1377 O 0 1.258244265045505e-05
( O 0 6.484056314093323e-08
exon O 0 1.6866947589733172e-06
15G O 0 1.5003626685938798e-05
) O 0 7.261546031145372e-09
of O 0 6.751095238399785e-10
the O 0 3.6129412794849713e-09
APC B-Disease 0 1.4895896072175674e-07
gene O 0 5.4541690275300425e-08
for O 0 4.7615658083088874e-09
germ O 0 2.1403799109975807e-05
- O 0 6.498565198853612e-05
line O 0 2.710784610826522e-05
variants O 0 1.726960476844397e-06
. O 0 4.2002102418337017e-07

Three O 0 2.3197483187686885e-06
patients O 0 1.9421682395659445e-07
with O 0 1.3760601547119222e-09
the O 0 3.5609124537927528e-09
I1307K O 0 6.826135745541251e-07
allele O 0 4.4723887526743056e-07
were O 0 4.375089801555987e-08
detected O 0 3.923907954117567e-08
, O 0 6.997116219764621e-10
each O 0 9.864542516169195e-10
of O 0 2.981326296946918e-09
Ashkenazi O 0 5.367098856368102e-05
descent O 0 7.26007738194312e-06
. O 0 4.109358826553944e-07

Four O 0 4.88782643515151e-06
patients O 0 9.231496846950904e-07
had O 0 5.306890926704e-08
a O 0 1.1686098311258775e-08
germ O 0 5.765186870121397e-05
- O 0 0.0007933279848657548
line O 0 5.4676434956490993e-05
E1317Q O 0 1.4025519021743094e-06
missense O 0 2.0669594960054383e-06
variant O 0 3.590996868751972e-07
of O 0 4.059660163591161e-09
APC O 0 5.83199266657175e-07
that O 0 4.9088484388448705e-08
was O 0 1.3308597317518434e-06
not O 0 1.8739225726704944e-09
present O 0 2.6016624965485846e-10
in O 0 6.175322475598932e-10
controls O 0 6.672755716863321e-06
; O 0 5.5578301072500835e-08
one O 0 2.2451112080545954e-09
of O 0 1.276548866613325e-10
these O 0 1.061590038098359e-09
individuals O 0 5.427648885891756e-10
had O 0 8.278441043785278e-08
an O 0 5.623359555784191e-10
unusually O 0 7.351123709753438e-09
large O 0 7.022774584086733e-10
number O 0 1.4156256167296988e-09
of O 0 1.4113389346093186e-09
metaplastic B-Disease 0 2.0537281670840457e-05
polyps I-Disease 0 7.800095772836357e-06
of I-Disease 0 2.2978439151444263e-09
the I-Disease 0 1.537709160004397e-08
colorectum I-Disease 0 2.0451419914024882e-05
. O 0 2.558376763772685e-07

There O 0 1.3194733128329972e-06
is O 0 1.0584022547277527e-08
increasing O 0 1.5349305160228255e-09
evidence O 0 8.659159500545854e-10
that O 0 6.395796670055631e-10
there O 0 1.9179258181623027e-09
exist O 0 1.106877700607356e-08
germ O 0 6.706619842589134e-06
- O 0 4.342359898146242e-05
line O 0 1.1488426935102325e-05
variants O 0 3.057901665215468e-08
of O 0 3.1728292215760234e-10
the O 0 1.345897615578906e-09
APC B-Disease 0 7.157564851922871e-08
gene O 0 2.9603507201159118e-08
that O 0 5.717749385070192e-09
predispose O 0 1.0410957429485279e-07
to O 0 9.31637877954472e-10
the O 0 4.513173446074603e-10
development O 0 1.4808799742027645e-09
of O 0 8.717063515462087e-09
multiple O 1 0.9970744848251343
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9989598989486694
carcinoma I-Disease 1 1.0
, O 0 9.028853469317255e-07
but O 0 1.4864726338714718e-08
without O 0 1.6105182742975899e-09
the O 0 1.8948040914068542e-09
florid O 0 0.00023924349807202816
phenotype O 0 1.0108931746799499e-05
of O 0 1.9979138343728664e-09
classical O 0 2.3043629227004203e-08
FAP B-Disease 0 1.150918819803337e-06
, O 0 4.744640236253872e-09
and O 0 3.1265612321362823e-09
possibly O 0 2.9163218506766952e-09
with O 0 8.127238326771646e-10
importance O 0 8.775622717394072e-08
for O 0 0.00021639255282934755
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 2.696834371818113e-06
in O 0 2.3396504733597112e-09
the O 0 2.1218815593471163e-09
general O 0 5.7242419693182e-09
population O 0 4.259968822140081e-09
. O 0 8.643586291157135e-09
. O 0 1.1182287096289656e-07

Genomic O 0 2.407648935331963e-05
structure O 0 1.3139078873791732e-06
of O 0 1.0674503947427638e-08
the O 0 7.902689702632415e-08
human O 0 3.938200097763911e-05
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999933242797852
diarrhea I-Disease 1 1.0
( O 0 1.149136369349435e-05
CLD B-Disease 0 0.0024099512957036495
) O 0 2.0276466727864317e-07
gene O 0 8.676452125655487e-06
. O 0 1.254715925824712e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.999998927116394
diarrhea I-Disease 1 1.0
( O 0 0.0006906803464516997
CLD B-Disease 1 0.9642128944396973
) O 0 9.006777190734283e-07
is O 0 5.713609851909496e-08
caused O 0 7.107013288987218e-08
by O 0 1.3495683459652241e-09
mutations O 0 2.5867771569210163e-07
in O 0 1.7622046044607487e-09
a O 0 1.9899056624694822e-08
gene O 0 7.228721301544283e-07
which O 0 1.540228424801171e-07
encodes O 0 1.0204621503362432e-06
an O 0 9.371331799457039e-08
intestinal O 0 0.00023548626631963998
anion O 0 1.5991885447874665e-05
transporter O 0 0.00018822730635292828
. O 0 1.925395054058754e-06

We O 0 1.8879327399190515e-05
report O 0 1.4923166702374147e-07
here O 0 2.955463651588275e-09
the O 0 8.372790794020091e-10
complete O 0 9.543156487268334e-09
genomic O 0 1.1997987314771308e-07
organization O 0 7.836955973061777e-09
of O 0 3.555908623109616e-10
the O 0 1.7034033072960142e-09
human O 0 2.8559698606045458e-08
CLD B-Disease 0 1.4845373698335607e-05
gene O 0 3.164806514632801e-07
which O 0 7.224800668836906e-08
spans O 0 7.495699492210406e-07
approximately O 0 1.0278932371932115e-08
39kb O 0 1.4069446478970349e-06
, O 0 1.5373748496472217e-08
and O 0 9.957800806148498e-09
comprises O 0 1.7495560555857992e-08
21 O 0 1.270858689395027e-07
exons O 0 1.8966124116559513e-05
. O 0 1.4579350136045832e-06

All O 0 8.801300168670423e-07
exon O 0 3.01725922327023e-05
/ O 0 2.8744234441546723e-05
intron O 0 0.0002084930893033743
boundaries O 0 2.51274877882679e-06
conform O 0 4.31661192124011e-07
to O 0 7.68826335928452e-09
the O 0 8.830220110667142e-09
GT O 0 3.7234492538118502e-06
/ O 0 4.800164242624305e-05
AG O 0 0.0395844466984272
rule O 0 1.0269426411468885e-06
. O 0 1.3450198821374215e-07

An O 0 1.5042046186408697e-07
analysis O 0 5.100278244185574e-08
of O 0 1.947735084328883e-09
the O 0 3.591806407854392e-09
putative O 0 5.55286021608481e-07
promoter O 0 4.7986259232857265e-06
region O 0 1.0607086409208932e-07
sequence O 0 1.0324876598133415e-07
shows O 0 3.919155062703794e-07
a O 0 3.6926021351746385e-08
putative O 0 1.0609675882733427e-05
TATA O 0 1.5041493497847114e-05
box O 0 4.119837740290677e-06
and O 0 1.536135698643193e-07
predicts O 0 4.4396415432856884e-07
multiple O 0 1.7245717742753186e-08
transcription O 0 3.093746840931999e-07
factor O 0 4.7798671687360184e-08
binding O 0 6.32366479180746e-08
sites O 0 4.891762728220783e-07
. O 0 2.6728716306934075e-07

The O 0 2.0732124994538026e-07
genomic O 0 1.4926711173757212e-06
structure O 0 6.598021400350262e-07
was O 0 6.746326164375205e-08
determined O 0 3.793847902500147e-09
using O 0 2.2624997431108795e-09
DNA O 0 2.933192710941057e-08
from O 0 2.944321730868893e-10
several O 0 1.9799238637485672e-10
sources O 0 2.343973071194938e-10
including O 0 6.948516761973167e-11
multiple O 0 3.983965157772218e-09
large O 0 6.46464126674573e-09
- O 0 2.8647798899328336e-05
insert O 0 5.6903900258475915e-05
libaries O 0 6.042138011252973e-06
and O 0 6.944283814647179e-09
genomic O 0 1.6980850148229365e-07
DNA O 0 4.3757580669989693e-07
from O 0 1.4920827240416656e-08
Finnish O 0 5.557110853260383e-05
CLD B-Disease 0 0.0029237596318125725
patients O 0 1.9161645923304604e-06
and O 0 5.1408193257884705e-08
controls O 0 1.2724374755634926e-05
. O 0 6.898134756738727e-07

Exon O 0 4.259130218997598e-05
- O 0 5.49606329514063e-06
specific O 0 2.987213676419742e-08
primers O 0 2.63360925600864e-06
developed O 0 6.812751962570474e-08
in O 0 1.2291945239439883e-09
this O 0 2.44147785322113e-10
study O 0 5.495924271237129e-10
will O 0 3.6873409881010843e-10
facilitate O 0 2.0438462033922633e-09
mutation O 0 2.045313429732687e-08
screening O 0 6.5705036966789976e-09
studies O 0 1.1359976292979468e-09
of O 0 4.922448004762714e-10
patients O 0 1.6905930877442188e-08
with O 0 5.161124416730445e-09
the O 0 3.258567460306949e-07
disease O 0 5.923762728343718e-05
. O 0 2.225764177410383e-07

Genomic O 0 1.1536646525200922e-05
sequencing O 0 2.5556264517945237e-06
of O 0 2.479298899515925e-08
a O 0 9.610580065100294e-08
BAC O 0 5.597494964604266e-05
clone O 0 0.0006234402535483241
H O 1 1.0
_ O 0 1.510204441501628e-07
RG364P16 O 0 6.599229323001055e-07
revealed O 0 2.0118540078328806e-07
the O 0 6.03707084323446e-10
presence O 0 2.174061597415289e-09
of O 0 1.4588660834924383e-10
another O 0 4.347412208005608e-09
, O 0 7.652402045366102e-10
highly O 0 1.2095998647154715e-09
homologous O 0 1.5304323142117937e-08
gene O 0 4.3281698225428045e-08
3 O 0 1.1993360971018774e-08
of O 0 8.768386017266039e-10
the O 0 2.695399281549271e-08
CLD B-Disease 0 4.462405922822654e-05
gene O 0 1.6196055696582334e-07
, O 0 2.6814503950589597e-09
with O 0 2.679629018675911e-10
a O 0 1.791608639223341e-09
similar O 0 3.814017990322327e-09
genomic O 0 2.2696980295222602e-07
structure O 0 3.067008549351158e-07
, O 0 5.8626827836860684e-09
recently O 0 9.675838441580709e-08
identified O 0 1.1345380812599615e-07
as O 0 3.591253161516761e-08
the O 0 4.785486908076564e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 4.98132903885562e-05
( O 0 2.968748731291271e-07
PDS B-Disease 0 1.2042977687087841e-05
) O 0 3.16729398264215e-08
. O 0 2.4879062365812388e-08
. O 0 1.8805228307883226e-07

The O 0 1.5019270449556643e-06
APCI1307K O 0 0.00014825433026999235
allele O 0 5.163142486708239e-05
and O 0 5.92783976571809e-07
cancer B-Disease 0 1.0950459909508936e-05
risk O 0 7.722819361788424e-08
in O 0 1.5619177062831113e-09
a O 0 1.6377011746726566e-08
community O 0 1.1213059813997006e-08
- O 0 2.046919462372898e-06
based O 0 1.3941097165570682e-08
study O 0 2.2929231846546827e-09
of O 0 2.0692167979063925e-09
Ashkenazi O 0 5.4509519031853415e-06
Jews O 0 2.581271871804347e-07
. O 0 8.805265139244511e-08

Mutations O 0 0.0007146038697101176
in O 0 6.709983040309453e-07
APC O 0 1.0957593985949643e-05
are O 0 5.803995506425963e-08
classically O 0 6.67960339342244e-05
associated O 0 2.223497176601086e-06
with O 0 2.3356033125310205e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.00011012789764208719
FAP B-Disease 0 6.691334419883788e-05
) O 0 4.404503428645512e-08
, O 0 8.00805111111913e-09
a O 0 1.438704373413202e-07
highly O 0 0.00018991163233295083
penetrant O 1 0.9999990463256836
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.00010852176637854427
by O 0 5.570023375867095e-08
multiple O 0 6.918442522874102e-05
intestinal O 1 0.8755625486373901
polyps B-Disease 1 0.6144197583198547
and O 0 8.476777679788938e-07
, O 0 9.44003808456273e-09
without O 0 1.5359145066895508e-09
surgical O 0 5.541163545785821e-07
intervention O 0 5.8641283828819724e-08
, O 0 1.1170893099432533e-09
the O 0 7.082378572498271e-10
development O 0 1.567685004033592e-08
of O 0 1.1314783478155732e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.5679128182455315e-06
CRC B-Disease 0 9.735221101436764e-05
) O 0 2.276795925126862e-07
. O 0 3.692003929245402e-07

APC B-Disease 0 0.000284177454886958
is O 0 4.28508286631768e-07
a O 0 4.537518805136642e-07
tumour O 1 0.9999998807907104
- O 0 8.393807365791872e-05
suppressor O 0 0.00010080354695674032
gene O 0 1.5045762893350911e-06
, O 0 2.7656204437676024e-08
and O 0 1.4036135809192274e-08
somatic O 0 1.404194108545198e-06
loss O 0 7.25936729395471e-07
occurs O 0 2.5299627282038273e-07
in O 0 4.6487036797771e-07
tumours B-Disease 1 1.0
. O 0 3.1748957098898245e-06

The O 0 1.03814966223581e-06
germline O 0 2.210173443017993e-05
T O 0 3.218650090275332e-05
- O 0 9.439642099096091e-07
to O 0 1.2614878919237071e-08
- O 0 6.669445724583056e-07
A O 0 2.604391013960594e-08
transversion O 0 8.686674846103415e-07
responsible O 0 1.3033726986577676e-08
for O 0 3.667512127325523e-10
the O 0 3.763297673486932e-09
APC O 0 1.9368856385426625e-07
I1307K O 0 2.2595689586069057e-07
allele O 0 4.7010704662397984e-08
converts O 0 1.1370755892414763e-08
the O 0 8.277692420399774e-10
wild O 0 8.338052914780292e-09
- O 0 2.315993867796351e-07
type O 0 1.0565688768338077e-08
sequence O 0 2.414491007129982e-08
to O 0 4.167315381664594e-09
a O 0 1.4885387145113782e-07
homopolymer O 0 0.18154242634773254
tract O 0 0.057664673775434494
( O 0 5.6015380778262625e-08
A8 O 0 3.797787576331757e-05
) O 0 1.209789779466064e-08
that O 0 4.630444916386978e-09
is O 0 1.249652825663361e-08
genetically O 0 1.3209564713179134e-06
unstable O 0 0.001036096247844398
and O 0 1.6133096778503386e-06
prone O 0 5.545764906855766e-06
to O 0 1.4752507659920866e-08
somatic O 0 1.9478197827993426e-06
mutation O 0 2.1958057914162055e-06
. O 0 1.9683517393787042e-07

The O 0 1.5058164990477962e-06
I1307K O 0 1.730691838019993e-05
allele O 0 9.46076397667639e-06
was O 0 1.1415659173508175e-06
found O 0 2.1909388081553516e-08
in O 0 1.1641826169750402e-08
6 O 0 4.991546802557423e-07
. O 0 3.5033286849284195e-07

1 O 0 2.727494802456931e-06
% O 0 1.297920420029186e-07
of O 0 4.9838480009611885e-09
unselected O 0 1.632773819437716e-05
Ashkenazi O 0 0.0002733276633080095
Jews O 0 1.9423328012635466e-06
and O 0 2.9999007722381066e-08
higher O 0 5.162246630163736e-09
proportions O 0 1.0643524461784182e-07
of O 0 1.6288219661930725e-09
Ashkenazim O 0 6.215017037902726e-06
with O 0 1.610276356700524e-08
family O 0 5.230497777120036e-07
or O 0 1.3474806159763375e-08
personal O 0 8.303268117515472e-08
histories O 0 1.177414674202737e-06
of O 0 1.207026212313167e-08
CRC B-Disease 0 0.0002016393409576267
( O 0 4.1244582860144874e-08
ref O 0 0.00010489307896932587
. O 0 1.1237724528712079e-08
2 O 0 5.6605021114819465e-08
) O 0 3.7699233956800526e-08
. O 0 7.460057815933396e-08

To O 0 4.0903410081227776e-07
evaluate O 0 1.1285047918363489e-07
the O 0 2.6466140390368764e-09
role O 0 1.1192503812651466e-08
of O 0 1.6573272754172308e-09
I1307K O 0 5.569800123339519e-07
in O 0 1.1757956386304613e-08
cancer B-Disease 0 5.526518975784711e-07
, O 0 7.708056415367537e-09
we O 0 1.141240790758502e-08
genotyped O 0 6.702372274958179e-07
5 O 0 3.869776676879155e-08
, O 0 1.09933697700626e-08
081 O 0 3.090449126830208e-06
Ashkenazi O 0 4.813476152776275e-06
volunteers O 0 4.17787049400431e-08
in O 0 1.8383541355859734e-09
a O 0 1.1568338287304414e-08
community O 0 8.521798378069434e-08
survey O 0 6.49332548618986e-07
. O 0 1.6337659758391965e-07

Risk O 0 3.878325878758915e-05
of O 0 1.1346548944857204e-07
developing O 0 3.739780140676885e-06
colorectal B-Disease 1 1.0
, I-Disease 0 6.733253485435853e-06
breast I-Disease 0 0.01758577674627304
and I-Disease 0 9.190369496536732e-07
other I-Disease 0 1.8150117853110714e-08
cancers I-Disease 0 0.0001605788856977597
were O 0 5.259248680999917e-08
compared O 0 2.654117281508661e-08
between O 0 1.2934591175906007e-08
genotyped O 0 2.207313400504063e-06
I1307K O 0 3.764735936329089e-07
carriers O 0 2.5553234195285768e-08
and O 0 3.772359757903132e-09
non O 0 2.7263227231344445e-09
- O 0 3.5321392033438315e-07
carriers O 0 3.9098551951610716e-08
and O 0 3.419978966689996e-09
their O 0 1.7738320812199504e-09
first O 0 1.70105689534239e-08
- O 0 2.0123502508795355e-06
degree O 0 3.725654451613991e-08
relatives O 0 2.2714368697052123e-07
. O 0 1.0429660335375956e-07

Sperm O 0 2.733629480644595e-05
DNA O 0 2.1059299797343556e-06
analysis O 0 1.474638082754609e-07
in O 0 1.5981047596369535e-08
a O 0 3.231146763482684e-07
Friedreich B-Disease 1 0.9966052770614624
ataxia I-Disease 1 0.9999208450317383
premutation O 0 0.0015477999113500118
carrier O 0 3.947181085095508e-06
suggests O 0 1.8740526286364911e-07
both O 0 4.01144584216695e-09
meiotic O 0 1.604150725142972e-06
and O 0 1.0966145325141952e-08
mitotic O 0 1.6777160283254489e-07
expansion O 0 3.978636442525385e-08
in O 0 3.8147893732798366e-09
the O 0 1.0177079623474583e-08
FRDA B-Disease 0 1.6950745703070424e-05
gene O 0 3.2623097467876505e-06
. O 0 6.909689318490564e-07

Friedreich B-Disease 1 0.9999786615371704
ataxia I-Disease 1 0.9999996423721313
is O 0 0.00016436997975688428
usually O 0 5.620852334686788e-06
caused O 0 9.708744386216495e-08
by O 0 2.075801475154293e-10
an O 0 2.0382937004903567e-10
expansion O 0 8.250553129585114e-09
of O 0 2.3986264086062192e-09
a O 0 1.871655683771678e-07
GAA O 0 1.704690839687828e-05
trinucleotide O 0 1.641604831092991e-05
repeat O 0 1.1374668247299269e-06
in O 0 7.13733117052584e-09
intron O 0 8.659349077788647e-06
1 O 0 3.603521392392395e-08
of O 0 1.3899406070549958e-09
the O 0 1.0337444678043539e-08
FRDA B-Disease 0 2.039186620095279e-05
gene O 0 2.483597654645564e-06
. O 0 4.7466610908486473e-07

Occasionally O 0 3.5041226510657e-05
, O 0 2.8820942077345535e-08
a O 0 1.3534150689054059e-08
fully O 0 9.08594799398088e-09
expanded O 0 1.4723665842097944e-08
allele O 0 1.5842329048609827e-07
has O 0 1.8262772982780007e-07
been O 0 8.718659572082288e-09
found O 0 2.5898654332223714e-09
to O 0 1.7905631422010515e-09
arise O 0 4.0953578306357485e-09
from O 0 2.0282918400393868e-10
a O 0 1.312064457081874e-09
premutation O 0 1.9837764853036788e-07
of O 0 8.088792413651902e-10
100 O 0 7.219039588335363e-09
or O 0 9.313060544968721e-09
less O 0 1.4537871351194553e-08
triplet O 0 0.0001258807023987174
repeats O 0 7.690400525461882e-05
. O 0 5.273900001157017e-07

We O 0 7.504736004193546e-06
have O 0 3.760551336995377e-08
examined O 0 2.86049477438155e-08
the O 0 1.5299906896970583e-09
sperm O 0 1.6649003953261854e-08
DNA O 0 2.5623855037792964e-08
of O 0 1.0588258048116472e-09
a O 0 2.2086151574285395e-08
premutation O 0 1.9641845938167535e-05
carrier O 0 1.3831863725499716e-06
. O 0 2.9104063514751033e-07

This O 0 3.5760149330599234e-07
mans O 0 5.983032679068856e-06
leucocyte O 0 6.2530248214898165e-06
DNA O 0 1.2855808790845913e-06
showed O 0 1.2041332411172334e-06
one O 0 5.611287878792837e-09
normal O 0 2.0930860600287815e-08
allele O 0 9.485958685218066e-08
and O 0 6.349623493662193e-09
one O 0 1.7637445948182062e-09
allele O 0 2.83661059086171e-08
of O 0 8.868157874708515e-10
approximately O 0 1.1968748658830464e-08
100 O 0 2.3392766834717804e-08
repeats O 0 5.121732556290226e-06
. O 0 2.2365541951785417e-07

His O 0 3.4946501727972645e-06
sperm O 0 2.0431923530850327e-06
showed O 0 2.95380630177533e-07
an O 0 6.60641485961122e-10
expanded O 0 1.4141636306419514e-08
allele O 0 2.3909544211164757e-07
in O 0 5.937212055329155e-09
a O 0 6.304853172878211e-08
tight O 0 2.8257511075935327e-05
range O 0 9.782801413393827e-08
centering O 0 1.6608873920631595e-07
on O 0 5.5314227864755594e-08
a O 0 3.327838893341095e-09
size O 0 9.105934672959393e-09
of O 0 1.233294799618534e-09
approximately O 0 2.3592162889940482e-08
320 O 0 3.455322428180807e-07
trinucleotide O 0 4.649035690817982e-05
repeats O 0 6.0684782511089e-05
. O 0 8.585856789977697e-07

His O 0 1.8674367311177775e-05
affected O 0 1.4922441096132388e-06
son O 0 7.739577995380387e-06
has O 0 1.8606837670631649e-07
repeat O 0 2.464894919285143e-07
sizes O 0 3.6370948919284274e-07
of O 0 9.005925782901159e-09
1040 O 0 1.5880553974056966e-06
and O 0 5.429673421986081e-08
540 O 0 1.375039801132516e-06
. O 0 2.6917780360236065e-07

These O 0 9.221644603485402e-08
data O 0 4.0003691026413435e-08
suggest O 0 1.5704861411336424e-08
that O 0 3.954362670643974e-10
expansion O 0 4.53486004303727e-09
occurs O 0 3.579420759791674e-09
in O 0 2.944939569982097e-10
two O 0 8.372380122523282e-09
stages O 0 3.233289191939548e-07
, O 0 1.5534622477275661e-09
the O 0 5.29927879355796e-10
first O 0 5.042355422091305e-09
during O 0 8.319005928569823e-09
meiosis O 0 2.8038520838435943e-08
followed O 0 9.043312765300016e-09
by O 0 3.0312732879345106e-10
a O 0 3.532385939308824e-09
second O 0 4.5612509325110295e-08
mitotic O 0 1.316526891059766e-06
expansion O 0 1.0140680615222664e-06
. O 0 6.566208980984811e-07

We O 0 3.64193765562959e-05
also O 0 3.189624919741618e-07
show O 0 5.714115332011716e-07
that O 0 8.28674351360803e-10
in O 0 4.636691308679275e-10
all O 0 2.8019031539372463e-10
informative O 0 3.980686003046685e-08
carrier O 0 1.2114884384573088e-07
father O 0 2.7292220039498716e-08
to O 0 1.4621455157737273e-09
affected O 0 3.6868150754543194e-09
child O 0 6.817899844691055e-08
transmissions O 0 4.645934495783877e-06
, O 0 3.3125011622558986e-09
with O 0 8.240405025006226e-10
the O 0 2.4656454655769267e-09
notable O 0 4.984941348595839e-09
exception O 0 3.930242797878236e-09
of O 0 4.1669953598777454e-10
the O 0 8.432848197514886e-09
premutation O 0 5.3156400099396706e-06
carrier O 0 9.672240963709555e-08
, O 0 6.464144775009117e-10
the O 0 2.755839445534036e-10
expansion O 0 8.898491721254231e-09
size O 0 6.983309930319592e-08
decreases O 0 1.871737822511932e-07
. O 0 1.660938941938639e-08
. O 0 1.0017143381446658e-07

The O 0 9.048920901477686e-07
R496H O 0 1.1847590030811261e-05
mutation O 0 1.201608370138274e-06
of O 0 6.613958269952036e-09
arylsulfatase O 0 2.3965937998582376e-06
A O 0 2.862880990051053e-07
does O 0 6.694464218526264e-07
not O 0 1.7797509599404293e-07
cause O 0 4.700596036855131e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 7.1359772846335545e-06

Deficiency B-Disease 1 0.9999110698699951
of I-Disease 0 3.495345879400702e-07
arylsulfatase I-Disease 0 4.837340384256095e-05
A I-Disease 0 1.5739429954919615e-06
( O 0 4.981660026714962e-07
ARSA O 0 0.00031144553213380277
) O 0 7.1084912178776e-08
enzyme O 0 1.123659785662312e-06
activity O 0 2.3899658572190674e-06
causes O 0 3.15127290377859e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 6.443569145631045e-05
MLD B-Disease 1 0.9999998807907104
) O 0 1.6727678939787438e-06
. O 0 7.356259743573901e-07

A O 0 2.4573282644269057e-06
number O 0 7.804366219943404e-08
of O 0 3.1192957550274514e-08
ARSA O 0 0.0009742638212628663
gene O 0 5.391692866396625e-06
mutations O 0 6.411328740796307e-06
responsible O 0 1.7127895546309446e-07
for O 0 6.133151941867254e-08
MLD B-Disease 1 1.0
have O 0 3.686824811666156e-06
been O 0 3.629562002060993e-07
identified O 0 1.0662537306416198e-06
. O 0 1.9461043621049612e-07

Recently O 0 1.8985705537488684e-05
, O 0 2.69631446059293e-08
the O 0 4.92507989946489e-09
R496H O 0 5.125365305502783e-07
mutation O 0 1.5983249568307656e-07
of O 0 4.714806767225355e-09
ARSA O 0 0.00020033946202602237
was O 0 2.885301739752322e-07
proposed O 0 2.138246468774696e-09
to O 0 3.6509444356624954e-09
be O 0 2.2429540447177487e-09
a O 0 8.73203997997507e-09
cause O 0 8.946622642724833e-08
of O 0 2.96439655045333e-08
MLD B-Disease 1 1.0
( O 0 1.246571628144011e-07
Draghia O 0 1.8826303858077154e-05
et O 0 2.4541675884393044e-05
al O 0 4.5739685447188094e-05
. O 0 5.4362022439136126e-08
, O 0 1.5687318111190507e-08
1997 O 0 2.89815194065568e-08
) O 0 4.081806181943648e-08
. O 0 1.1987900450094457e-07

We O 0 2.2346107471094e-06
have O 0 2.107411134488757e-08
investigated O 0 3.539853921097347e-08
the O 0 1.3996696024420885e-09
R496H O 0 2.680823456557846e-07
mutation O 0 5.45527214512731e-08
and O 0 2.739045656952044e-09
found O 0 1.7880240621437338e-09
this O 0 3.4361405387706156e-10
mutation O 0 6.010005826340148e-09
at O 0 1.2091408985170915e-09
a O 0 2.1883941325739897e-09
relatively O 0 1.5062876501659161e-09
high O 0 3.0035172127185206e-09
frequency O 0 1.8174020510741684e-08
in O 0 6.980334088524387e-10
an O 0 6.204803337794829e-10
African O 0 3.4678580007607707e-09
American O 0 4.964105571048094e-09
population O 0 2.4173743007338544e-09
( O 0 1.1134624333664078e-09
f O 0 8.582610178109462e-08
= O 0 1.1548942069339319e-07
0 O 0 9.097081310471822e-09
. O 0 1.4514976998114548e-09
09 O 0 2.673280974363479e-08
, O 0 5.675504510804785e-09
n O 0 7.668567718610575e-07
= O 0 3.447887365837232e-06
61 O 0 3.9131754192567314e-07
subjects O 0 8.059232214918666e-08
) O 0 7.767137333303253e-08
. O 0 1.2346163202892058e-07

The O 0 1.6510375644429587e-06
ARSA O 0 0.00016857124865055084
enzyme O 0 9.359681598652969e-07
activity O 0 2.163321113357597e-07
in O 0 2.8143249952705673e-09
subjects O 0 4.361242744721494e-08
with O 0 1.0956527241035019e-08
and O 0 2.6004059350270836e-07
without O 0 1.457234222179693e-09
the O 0 1.760571910480735e-09
R496H O 0 4.044376282763551e-07
mutation O 0 1.4902857969900651e-07
was O 0 3.802203139002813e-07
determined O 0 4.504835970919885e-08
and O 0 2.3067199705906205e-08
found O 0 1.2346370148463848e-08
to O 0 5.913941336643802e-09
be O 0 8.526867212310663e-09
normal O 0 8.61651301420352e-08
. O 0 1.3695769496280263e-07

It O 0 2.7123023755848408e-06
is O 0 3.180302599048446e-08
therefore O 0 5.472047259758028e-09
concluded O 0 5.672582847893182e-09
that O 0 5.476795128522838e-10
the O 0 1.2954262107456316e-09
R496H O 0 4.708101073447324e-07
mutation O 0 5.557777527087637e-08
of O 0 2.187492853522599e-09
ARSA O 0 0.00014187299530021846
does O 0 2.342576834735155e-07
not O 0 2.1493520296900215e-09
negatively O 0 5.5923652375611255e-09
influence O 0 4.5969703599269e-09
the O 0 1.3208375504447645e-09
activity O 0 1.9447401911065754e-08
of O 0 1.7948920127963675e-09
ARSA O 0 0.010789833031594753
and O 0 6.098345011196216e-07
is O 0 6.032216948170799e-09
not O 0 1.6261524349303613e-09
a O 0 1.6122003287932785e-08
cause O 0 2.782332728656911e-07
of O 0 2.6160066113334324e-07
MLD B-Disease 1 0.9999997615814209

Down O 0 0.0005589893553406
- O 0 2.3924876586534083e-05
regulation O 0 3.51899615225193e-07
of O 0 1.4820166427398362e-08
transmembrane O 0 5.786127530882368e-06
carbonic O 0 2.5049988835235126e-05
anhydrases O 0 5.059605973656289e-05
in O 0 1.372470705973683e-06
renal B-Disease 1 0.9992520213127136
cell I-Disease 1 0.9995073080062866
carcinoma I-Disease 1 1.0
cell O 0 0.32825466990470886
lines O 0 0.00019686095765791833
by O 0 6.631263538281473e-09
wild O 0 4.101989929949923e-07
- O 0 0.00016838456213008612
type O 0 1.2343080925347749e-05
von B-Disease 1 0.9928748607635498
Hippel I-Disease 1 0.9827422499656677
- I-Disease 0 0.35091033577919006
Lindau I-Disease 0 0.01625356450676918
transgenes O 0 0.001114228623919189
. O 0 5.956979293841869e-06

To O 0 4.271280431566993e-07
discover O 0 8.506207223035744e-07
genes O 0 3.010528075719776e-07
involved O 0 2.4248798524695303e-08
in O 0 5.0964658271368535e-08
von B-Disease 1 0.9999357461929321
Hippel I-Disease 1 0.9999961853027344
- I-Disease 1 0.9999961853027344
Lindau I-Disease 1 0.9999749660491943
( O 0 1.2668028830375988e-06
VHL B-Disease 0 0.0002041743282461539
) O 0 1.2136661098338664e-07
- O 0 1.1993189218628686e-05
mediated O 0 5.3009014663985e-05
carcinogenesis O 0 0.0003307159640826285
, O 0 1.1358144291762073e-07
we O 0 6.053784318282851e-08
used O 0 1.4935767467250116e-06
renal B-Disease 1 0.9470514059066772
cell I-Disease 1 0.9986506104469299
carcinoma I-Disease 1 1.0
cell O 0 0.38004738092422485
lines O 0 0.04027639329433441
stably O 0 0.00011137629189761356
transfected O 0 4.3978616304229945e-05
with O 0 5.354310417260422e-08
wild O 0 1.0599922006804263e-06
- O 0 0.0005014559137634933
type O 0 7.830540198483504e-06
VHL O 0 0.0007191628101281822
- O 0 0.0006461440934799612
expressing O 0 2.9480136163329007e-06
transgenes O 0 8.84633045643568e-05
. O 0 1.8312389329366852e-06

Large O 0 8.033470066948212e-07
- O 0 2.1634459699271247e-06
scale O 0 3.143473747968528e-07
RNA O 0 2.0283680157717754e-07
differential O 0 1.0469961608805534e-07
display O 0 3.0474502921151725e-08
technology O 0 1.4055531849521685e-08
applied O 0 1.108639846592041e-08
to O 0 1.3450789371205474e-09
these O 0 9.238431686320325e-10
cell O 0 2.597555237571214e-07
lines O 0 3.870334239763906e-06
identified O 0 5.236796596364002e-08
several O 0 4.979353818157506e-09
differentially O 0 9.93208118416078e-07
expressed O 0 8.632975223576977e-09
genes O 0 2.6617012593987965e-08
, O 0 1.2070393573537785e-09
including O 0 5.482000409173793e-10
an O 0 1.9691162034263243e-09
alpha O 0 2.1947055017790262e-07
carbonic O 0 1.5745389418952982e-06
anhydrase O 0 1.1925678791158134e-06
gene O 0 1.3173001889299485e-07
, O 0 2.5862632924145146e-08
termed O 0 8.673785600876727e-07
CA12 O 0 8.729397814022377e-05
. O 0 6.613152550016821e-07

The O 0 4.451525228432729e-07
deduced O 0 1.153570451606356e-06
protein O 0 3.2210616041083995e-07
sequence O 0 4.6423241428783513e-07
was O 0 1.4917560520189e-07
classified O 0 1.0982701859063582e-08
as O 0 6.0929470357962145e-09
a O 0 1.4214976751247832e-08
one O 0 1.190765033243224e-07
- O 0 0.0008632412063889205
pass O 0 5.835998308612034e-06
transmembrane O 0 1.5241405435517663e-06
CA O 0 1.0566835726422141e-06
possessing O 0 1.4593657837735918e-08
an O 0 1.231945323532102e-09
apparently O 0 3.20199603720539e-07
intact O 0 2.169419488495805e-08
catalytic O 0 2.2461533077944296e-08
domain O 0 4.0242767340714636e-08
in O 0 4.1399039751865985e-09
the O 0 9.653235544249128e-09
extracellular O 0 2.1867028863198357e-06
CA O 0 6.005153773003258e-05
module O 0 7.146724328777054e-06
. O 0 4.472166779123654e-07

Reintroduced O 0 6.341355037875473e-05
wild O 0 9.061702257895377e-06
- O 0 0.0001778556761564687
type O 0 4.215940407448215e-06
VHL B-Disease 0 0.00010462605132488534
strongly O 0 5.058995498075092e-07
inhibited O 0 2.958508957817685e-07
the O 0 3.2603992838886597e-09
overexpression O 0 2.2849943093206093e-07
of O 0 1.3548349109271385e-09
the O 0 3.787276270372786e-09
CA12 O 0 2.4673790903761983e-06
gene O 0 1.4500048450827308e-07
in O 0 1.0810739858868601e-08
the O 0 1.819594643848177e-07
parental O 0 0.023383403196930885
renal B-Disease 1 0.9998874664306641
cell I-Disease 1 0.999988317489624
carcinoma I-Disease 1 1.0
cell O 1 0.8476710915565491
lines O 0 0.019539697095751762
. O 0 2.1298174033290707e-06

Similar O 0 1.6078018916232395e-06
results O 0 3.9326221212832024e-07
were O 0 1.82064958664796e-08
obtained O 0 6.8519221407825626e-09
with O 0 6.786927020385747e-09
CA9 O 0 6.904145993757993e-05
, O 0 8.703108456131758e-09
encoding O 0 9.227749586671052e-08
another O 0 4.834753326576902e-07
transmembrane O 0 6.366686193359783e-06
CA O 0 5.864061677129939e-06
with O 0 1.2820225991916345e-09
an O 0 2.1066746125342206e-09
intact O 0 1.713362962618703e-07
catalytic O 0 2.1469077182700858e-07
domain O 0 1.065885726347915e-06
. O 0 2.889922825488611e-07

Although O 0 1.1923631291210768e-06
both O 0 1.5361672822677974e-08
domains O 0 4.528820340965467e-08
of O 0 1.146648997973898e-09
the O 0 3.0432953934678153e-09
VHL B-Disease 0 3.718467041835538e-06
protein O 0 5.7866081704105454e-08
contribute O 0 2.727055914419907e-09
to O 0 7.691427494904701e-10
regulation O 0 7.34083949183173e-09
of O 0 1.6003611769122017e-09
CA12 O 0 2.0262219550204463e-05
expression O 0 5.3536055588665477e-08
, O 0 1.1588030535136795e-09
the O 0 5.710487638310724e-10
elongin O 0 1.361449477599308e-07
binding O 0 1.1323617599146019e-08
domain O 0 1.15755710794474e-07
alone O 0 3.672927277875715e-07
could O 0 3.290412919909613e-08
effectively O 0 2.3271547888725763e-07
regulate O 0 6.695868819406314e-07
CA9 O 0 0.00021524554176721722
expression O 0 4.050933512189658e-06
. O 0 6.031155521668552e-07

We O 0 1.3971191037853714e-05
mapped O 0 3.643389936769381e-05
CA12 O 0 0.000137077528052032
and O 0 2.70539203484077e-07
CA9 O 0 9.379266703035682e-05
loci O 0 3.5262528399471194e-06
to O 0 4.791030505657545e-08
chromosome O 0 2.079722617054358e-05
bands O 0 3.2784339509817073e-06
15q22 O 0 6.9449479269678704e-06
and O 0 1.7493718473815534e-07
17q21 O 0 9.75610782916192e-06
. O 0 6.687661766591191e-07

2 O 0 4.9236263294005767e-05
respectively O 0 2.5704262043291237e-06
, O 0 4.253224261674404e-08
regions O 0 3.014636433817941e-07
prone O 0 6.288606982707279e-06
to O 0 5.362934096808658e-09
amplification O 0 7.857387345211464e-07
in O 0 4.581765633560053e-09
some O 0 6.781272432476726e-09
human O 0 3.182323951023136e-07
cancers B-Disease 0 0.0006008621421642601
. O 0 3.32312197315332e-07

Additional O 0 4.2404747091495665e-07
experiments O 0 2.1988935827721434e-07
are O 0 5.776514822031231e-09
needed O 0 7.217470177067753e-09
to O 0 8.23515644565731e-10
define O 0 4.5250040159316995e-08
the O 0 1.7250250117228916e-09
role O 0 1.605167554430409e-08
of O 0 8.535621098815227e-09
CA O 0 6.746686722181039e-06
IX O 0 1.763713953550905e-05
and O 0 2.0172883523628116e-06
CA O 0 2.9616553547384683e-06
XII O 0 5.337425363904913e-07
enzymes O 0 1.1653555453960962e-08
in O 0 3.036417228763355e-10
the O 0 4.303650769088563e-10
regulation O 0 9.586465843369751e-09
of O 0 5.962186300223493e-10
pH O 0 1.8629880287335254e-06
in O 0 1.0210186029979695e-09
the O 0 1.3044961777453068e-09
extracellular O 0 7.283382075229383e-08
microenvironment O 0 6.950685929041356e-06
and O 0 1.8650162303401885e-08
its O 0 1.499288027062562e-09
potential O 0 3.1754219254054306e-09
impact O 0 1.3494352302245716e-08
on O 0 5.570288408307533e-07
cancer B-Disease 0 1.7479370626460877e-06
cell O 0 2.1118530639796518e-06
growth O 0 5.863211072210106e-07
. O 0 8.739942103375142e-08

A O 0 1.6851222426339518e-06
gene O 0 1.6302764151987503e-06
encoding O 0 6.137816512818972e-07
a O 0 9.933579292464856e-08
transmembrane O 0 5.316535407473566e-07
protein O 0 1.373402653825906e-07
is O 0 3.981443619238689e-09
mutated O 0 5.572935037889692e-07
in O 0 5.991878282429752e-08
patients O 0 1.096104256248509e-06
with O 0 4.768273720401339e-05
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.6848216652870178
optic B-Disease 1 1.0
atrophy I-Disease 1 0.999971866607666
( O 0 0.0001433816214557737
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 6.250850219657877e-07
. O 0 5.02343823427509e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0004898050683550537
WFS B-Disease 0 0.029831884428858757
; O 0 1.075554064300377e-05
OMIM O 0 0.005638699512928724
222300 O 0 3.602844299166463e-05
) O 0 1.588485503134507e-07
is O 0 2.2329624371764112e-08
an O 0 8.096625947473512e-08
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999980926513672
defined O 0 2.786971890600398e-06
by O 0 1.8575963878220136e-08
young O 0 9.89018872132874e-07
- O 0 0.0009405109449289739
onset O 0 0.0004900266067124903
non O 0 8.101189337139658e-07
- O 0 0.000619626312982291
immune O 0 3.572595596779138e-05
insulin B-Disease 0 0.0004262275469955057
- I-Disease 0 0.46035581827163696
dependent I-Disease 0 0.004029085859656334
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.00010633969941409305
progressive O 0 0.0006909061339683831
optic B-Disease 1 0.9999895095825195
atrophy I-Disease 0 0.025419535115361214
. O 0 2.8928284336871e-06

Linkage O 0 4.537934000836685e-05
to O 0 1.270601757141776e-07
markers O 0 4.763326160173165e-06
on O 0 1.5062530565046472e-06
chromosome O 0 0.004924415145069361
4p O 0 0.4546491205692291
was O 0 2.3465048798243515e-05
confirmed O 0 1.8691761738409696e-07
in O 0 6.807579389089824e-09
five O 0 5.585023643561726e-08
families O 0 1.4342781184950582e-07
. O 0 1.4523050140269333e-07

On O 0 1.97712552107987e-06
the O 0 6.885579217907889e-09
basis O 0 9.470443096404324e-09
of O 0 4.2502703578861656e-09
meiotic O 0 6.19584898231551e-05
recombinants O 0 0.001797979581169784
and O 0 4.804510354006197e-06
disease O 0 1.4773797374800779e-05
- O 0 7.416568223561626e-06
associated O 0 3.634528695783956e-07
haplotypes O 0 5.751721346314298e-06
, O 0 8.118225203190832e-09
the O 0 3.6954748150463956e-09
WFS B-Disease 0 1.7175365428556688e-05
gene O 0 3.0613918511335214e-07
was O 0 1.0690686025327523e-07
localized O 0 1.020986388766687e-07
to O 0 5.147645865122286e-09
a O 0 3.72345922983186e-08
BAC O 0 1.806649197533261e-05
/ O 0 4.161625383858336e-06
P1 O 0 5.655253062286647e-06
contig O 0 1.2153493571531726e-06
of O 0 1.2992046327653384e-09
less O 0 2.88485368926672e-09
than O 0 2.2109196695652145e-09
250 O 0 2.1696841656648758e-08
kb O 0 1.836305636970792e-05
. O 0 5.127316171638086e-07

Mutations O 0 0.0003458303108345717
in O 0 3.1500810848683614e-08
a O 0 3.78798610256581e-08
novel O 0 3.8367340948752826e-07
gene O 0 3.390075335119036e-06
( O 0 8.834435050175671e-08
WFS1 O 0 5.3005001063866075e-06
) O 0 4.5240091672837934e-09
encoding O 0 2.23855742831347e-08
a O 0 1.2436655261183205e-08
putative O 0 6.527897653541004e-07
transmembrane O 0 1.0578497011692889e-07
protein O 0 1.0269705796872586e-07
were O 0 3.04469054412948e-08
found O 0 2.691303402357903e-09
in O 0 6.649358841315234e-10
all O 0 1.207343336417921e-09
affected O 0 3.462795161723875e-09
individuals O 0 1.6960820248268504e-10
in O 0 6.956184517292741e-10
six O 0 9.71172653407848e-08
WFS B-Disease 0 4.7396039008162916e-05
families O 0 4.4756568229331606e-08
, O 0 1.117858805521621e-09
and O 0 5.350752618760168e-10
these O 0 2.5201177256128915e-10
mutations O 0 4.8483467907090017e-08
were O 0 6.665552554352416e-09
associated O 0 6.373696681549745e-09
with O 0 6.091552595677285e-09
the O 0 3.4322081887694367e-07
disease O 0 0.0002703255449887365
phenotype O 0 4.403204002301209e-05
. O 0 4.1351401591782633e-07

WFS1 O 0 0.0017914667259901762
appears O 0 3.197296609869227e-05
to O 0 1.8012856983773418e-08
function O 0 1.9132208706196252e-08
in O 0 5.9774474259199906e-09
survival O 0 2.487328629285912e-06
of O 0 8.999177403268277e-09
islet O 0 8.625022928754333e-06
beta O 0 3.913944510713918e-07
- O 0 6.285430572461337e-05
cells O 0 7.612142098878394e-07
and O 0 4.707836254169706e-08
neurons O 0 1.5939622244331986e-07
. O 0 1.2713940122921485e-08
. O 0 7.782410449408417e-08

Stable O 0 5.535368109121919e-05
interaction O 0 3.5073736626145546e-07
between O 0 3.1449243209635824e-08
the O 0 1.866004462058868e-09
products O 0 1.1563772162048735e-08
of O 0 9.09253172753921e-10
the O 0 1.6988161988251704e-08
BRCA1 O 0 6.973371637286618e-05
and O 0 2.0439581476239255e-06
BRCA2 O 0 0.00019689586770255119
tumor B-Disease 0 8.193290341296233e-06
suppressor O 0 1.0001725058828015e-05
genes O 0 4.775629918185587e-07
in O 0 1.3765255602038451e-08
mitotic O 0 9.43596660363255e-06
and O 0 6.826955996075412e-07
meiotic O 0 0.00015580101171508431
cells O 0 2.010271964536514e-05
. O 0 6.005138857290149e-07

BRCA1 O 0 0.004854136612266302
and O 0 4.850705408898648e-06
BRCA2 O 0 6.069126902730204e-05
account O 0 1.0330155930660112e-07
for O 0 6.435357802203612e-10
most O 0 4.376729811905733e-10
cases O 0 3.6834607586300194e-10
of O 0 3.3315336600558965e-10
familial O 0 1.0897171023316332e-06
, O 0 7.461605555647566e-09
early O 0 4.1502314473973456e-08
onset O 0 7.987649041751865e-06
breast B-Disease 0 0.0001370558311464265
and I-Disease 0 2.402983227511868e-05
/ I-Disease 1 0.9894577264785767
or I-Disease 1 0.9170572757720947
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.6375245099075073e-08
encode O 0 3.922470881434492e-08
products O 0 1.538727900651793e-07
that O 0 2.962462053446302e-09
each O 0 1.9302530684939256e-09
interact O 0 8.347886826243212e-09
with O 0 9.891641283843455e-09
hRAD51 O 0 1.9400966266402975e-05
. O 0 3.6002106185151206e-07

Results O 0 5.643529220833443e-06
presented O 0 4.3667449745043996e-07
here O 0 4.6795907593377706e-08
show O 0 8.058461844484555e-07
that O 0 8.655926642120448e-09
BRCA1 O 0 2.4287124688271433e-05
and O 0 9.255844588551554e-07
BRCA2 O 0 7.324618491111323e-05
coexist O 0 1.5091345630935393e-06
in O 0 9.69387792260079e-10
a O 0 3.0614597523737075e-09
biochemical O 0 1.2227266665831849e-07
complex O 0 1.1197522020722772e-08
and O 0 1.9418751051603067e-08
colocalize O 0 1.410528966516722e-06
in O 0 5.331419750120858e-09
subnuclear O 0 2.4227547328337096e-06
foci O 0 2.538349008318619e-06
in O 0 2.2033632696150107e-09
somatic O 0 1.562185900638724e-07
cells O 0 3.0103817039162095e-07
and O 0 2.7339842390006197e-08
on O 0 4.273741183169477e-08
the O 0 3.931862391226559e-09
axial O 0 8.088800029781851e-08
elements O 0 2.3814143546019295e-08
of O 0 5.00368857458966e-09
developing O 0 9.263565914352512e-08
synaptonemal O 0 3.588039817259414e-06
complexes O 0 1.9443027667875867e-06
. O 0 3.409797670883563e-07

Like O 0 7.009638466115575e-06
BRCA1 O 0 0.00020329297694843262
and O 0 6.780161925235006e-07
RAD51 O 0 0.0001823429629439488
, O 0 1.0160519536839274e-07
BRCA2 O 0 8.94104323378997e-06
relocates O 0 4.520303718891228e-06
to O 0 6.381301886904112e-08
PCNA O 0 2.209159720223397e-05
+ O 0 3.061123265979404e-07
replication O 0 1.7667025531409308e-07
sites O 0 2.2351185791080752e-08
following O 0 3.592985020617334e-09
exposure O 0 4.311674572932134e-08
of O 0 2.416406408300986e-09
S O 0 6.502908036054578e-06
phase O 0 1.0761780089296735e-07
cells O 0 5.483187592858485e-08
to O 0 8.10167399833972e-09
hydroxyurea O 0 3.1814151952858083e-06
or O 0 1.5673775521918287e-07
UV O 0 1.3862428204447497e-05
irradiation O 0 2.959475523311994e-06
. O 0 2.7693928927874367e-07

Thus O 0 2.8566510081873275e-06
, O 0 4.552281396286162e-08
BRCA1 O 0 4.527146302280016e-06
and O 0 1.64698178650724e-07
BRCA2 O 0 7.094225566106616e-06
participate O 0 2.2027842661032082e-08
, O 0 1.0410060369281382e-08
together O 0 6.3414688611374e-08
, O 0 2.041488977866379e-09
in O 0 6.516669981415646e-10
a O 0 1.365685697862773e-08
pathway O 0 2.3738371623949206e-07
( O 0 2.1675084838079783e-08
s O 0 4.675001946452539e-06
) O 0 6.667332463905495e-09
associated O 0 3.1241529363512655e-09
with O 0 4.226944350094186e-10
the O 0 6.73861688671451e-10
activation O 0 8.275027774118371e-09
of O 0 8.642922488810711e-10
double O 0 8.476616812913562e-07
- O 0 0.000207120378036052
strand O 0 0.000461117917438969
break O 0 1.5219230590446386e-05
repair O 0 2.334587770747021e-05
and O 0 2.576209823246245e-08
/ O 0 3.2194370191973576e-07
or O 0 1.5375830386687994e-08
homologous O 0 5.754260428147973e-07
recombination O 0 3.608601900850772e-06
. O 0 9.659958095653565e-07

Dysfunction O 0 0.03483680635690689
of O 0 3.8892821407898737e-08
this O 0 6.731144086558061e-09
pathway O 0 1.694068743063326e-07
may O 0 3.2159604756998306e-07
be O 0 9.332865591460404e-10
a O 0 2.4438411294624984e-09
general O 0 4.0387306832201375e-09
phenomenon O 0 1.5982288914528908e-07
in O 0 2.7907838262564155e-09
the O 0 1.8850030425454634e-09
majority O 0 1.3908156848430053e-09
of O 0 1.9506785076117694e-10
cases O 0 1.780530056727514e-09
of O 0 5.434757976985338e-09
hereditary B-Disease 1 0.9611620306968689
breast I-Disease 0 0.4308563768863678
and I-Disease 0 0.00041050167055800557
/ I-Disease 1 0.8720185160636902
or I-Disease 0 0.39320462942123413
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.7992483947182336e-07
. O 0 2.2817779665729176e-07

A O 0 4.616466412699083e-06
novel O 0 3.782712383326725e-06
Arg362Ser O 0 2.8605973056983203e-05
mutation O 0 8.392013910452079e-07
in O 0 7.537257928902363e-09
the O 0 5.136651104464818e-09
sterol O 0 1.8948034039567574e-06
27 O 0 7.786388209751749e-07
- O 0 3.7931736187601928e-06
hydroxylase O 0 2.026125366683118e-05
gene O 0 1.2758074490193394e-06
( O 0 3.1737279471144575e-08
CYP27 O 0 5.635215075017186e-06
) O 0 8.305276466558098e-09
: O 0 1.143447336815484e-09
its O 0 1.6964324389689978e-09
effects O 0 3.7730309543348994e-08
on O 0 4.641677975314451e-08
pre O 0 3.174006906192517e-07
- O 0 5.870540462638019e-07
mRNA O 0 6.431559995689895e-08
splicing O 0 2.2219784057142533e-07
and O 0 9.485882301873971e-09
enzyme O 0 5.507525813186476e-08
activity O 0 1.3281980670853955e-07
. O 0 1.1836873881065912e-07

A O 0 2.7856751785293454e-06
novel O 0 1.2486626701502246e-06
C O 0 9.730542842589784e-07
to O 0 3.83178067053791e-09
A O 0 1.628903589789843e-08
mutation O 0 7.004226176832162e-08
in O 0 9.69276880979919e-10
the O 0 3.606545284640106e-09
sterol O 0 1.5018725889603957e-06
27 O 0 8.421469601671561e-07
- O 0 3.186471076332964e-06
hydroxylase O 0 1.1905488463526126e-05
gene O 0 5.496427206708177e-07
( O 0 2.875499660603964e-08
CYP27 O 0 1.0529342034715228e-05
) O 0 1.2717092268133001e-08
was O 0 3.715676299975712e-08
identified O 0 5.3580575531952945e-09
by O 0 2.1366962366098363e-10
sequencing O 0 2.4018689259719395e-08
amplified O 0 2.5195586772497336e-07
CYP27 O 0 5.071908049103513e-07
gene O 0 3.967194217580072e-08
products O 0 2.113566033301595e-08
from O 0 1.7628096760091694e-09
a O 0 2.800153531268279e-08
patient O 0 1.1060166116294567e-06
with O 0 4.028993032534345e-07
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 1.6538693898837664e-06
CTX B-Disease 0 0.0007505742833018303
) O 0 4.828777377952065e-07
. O 0 5.564214689002256e-07

The O 0 4.2619541318345e-07
mutation O 0 2.0741551907121902e-06
changed O 0 1.430997684792601e-07
the O 0 6.457493650913193e-09
adrenodoxin O 0 6.05234731665405e-07
cofactor O 0 2.3648665603559493e-07
binding O 0 8.090004399718964e-08
residue O 0 3.702437254560209e-07
362Arg O 0 7.633296377207444e-07
to O 0 2.3170384721993287e-08
362Ser O 0 3.931665105483262e-06
( O 0 6.204039948443096e-08
CGT O 0 4.0618192542751785e-06
362Arg O 0 7.546993288087833e-07
to O 0 1.0901890945547166e-08
AGT O 0 3.5848931929649552e-06
362Ser O 0 1.0617485486363876e-06
) O 0 7.41458983100074e-09
, O 0 2.7403939117931486e-09
and O 0 1.925767634247677e-08
was O 0 9.161858542938717e-07
responsible O 0 3.52136879655518e-08
for O 0 1.3908853624400308e-08
deficiency O 0 6.035112164681777e-06
in O 0 5.419931170536074e-10
the O 0 1.9833115150191816e-09
sterol O 0 8.185591013898375e-07
27 O 0 3.0050208010834467e-07
- O 0 3.9928684714141127e-07
hydroxylase O 0 1.1919266853510635e-06
activity O 0 4.044668600045043e-08
, O 0 9.369196529718238e-10
as O 0 7.889203734734451e-10
confirmed O 0 1.0089197921558934e-08
by O 0 1.724142495440617e-10
expression O 0 4.243497997435952e-09
of O 0 3.420701777390178e-10
mutant O 0 1.0572263420272066e-07
cDNA O 0 1.424127873406178e-07
into O 0 6.08709527227802e-08
COS O 0 0.0007091707666404545
- O 0 3.5157274396624416e-05
1 O 0 2.622315946609888e-07
cells O 0 6.40068435586727e-07
. O 0 9.941825140913352e-08

Quantitative O 0 9.927317478286568e-06
analysis O 0 8.004120104487811e-07
showed O 0 6.170022061269265e-06
that O 0 2.74460987270686e-09
the O 0 1.128568460906365e-09
expression O 0 1.772081326123498e-08
of O 0 5.758482024553757e-10
CYP27 O 0 5.064459855930181e-07
gene O 0 3.0462473432635306e-08
mRNA O 0 2.900446993692185e-08
in O 0 1.8307784177551412e-09
the O 0 5.597455832173637e-09
patient O 0 1.6047030726440425e-07
represented O 0 6.342798997138743e-08
52 O 0 9.349137144454289e-07
. O 0 2.579362217147718e-07

5 O 0 1.2748423614539206e-05
% O 0 1.7242980732135038e-07
of O 0 2.9255979860920434e-09
the O 0 9.224280006492336e-09
normal O 0 2.0980348836019402e-07
level O 0 1.9624775404736283e-07
. O 0 3.1632131936021324e-07

As O 0 1.7744547164966207e-07
the O 0 8.019712893769793e-09
mutation O 0 1.0648194859186333e-07
occurred O 0 8.134752249588928e-08
at O 0 3.576834384233507e-09
the O 0 1.5229129068927705e-09
penultimate O 0 4.1561892771824205e-07
nucleotide O 0 7.65694920801252e-08
of O 0 9.83861214720605e-10
exon O 0 2.5867819886116195e-07
6 O 0 2.4072861037893745e-07
( O 0 8.812619967102364e-09
- O 0 2.1530147478188155e-06
2 O 0 1.1504992158961613e-07
position O 0 9.994489857945155e-08
of O 0 4.012830956412472e-09
exon O 0 7.663537644475582e-07
6 O 0 2.437849104808265e-07
- O 0 3.392472081031883e-06
intron O 0 3.0250695999711752e-05
6 O 0 2.334639503942526e-07
splice O 0 6.994352588662878e-06
site O 0 1.530090003143414e-06
) O 0 1.6547719861037535e-09
of O 0 5.973042199736156e-11
the O 0 6.86586454357041e-10
gene O 0 3.4639196400121364e-08
, O 0 1.2048825048793788e-08
we O 0 4.439435929981528e-09
hypothesized O 0 1.3051613123593597e-08
that O 0 5.076882247934122e-10
the O 0 3.956416971817589e-09
mutation O 0 1.4059280601941282e-06
may O 0 2.8624222636608465e-07
partially O 0 1.64662850465902e-07
affect O 0 5.023713001151009e-09
the O 0 8.461539247051064e-10
normal O 0 5.867582864027554e-09
splicing O 0 5.154142712626708e-08
efficiency O 0 1.784376202351723e-08
in O 0 7.533604295950624e-10
exon O 0 3.857904857795802e-07
6 O 0 3.415913738535892e-07
and O 0 3.629021350093353e-08
cause O 0 4.4479282479414906e-09
alternative O 0 2.0854975524287056e-09
splicing O 0 1.4522939295602555e-07
elsewhere O 0 1.7613662350868253e-07
, O 0 1.0892926560757132e-09
which O 0 1.6149878101501258e-09
resulted O 0 5.3178714765067525e-09
in O 0 1.7621542003354307e-09
decreased O 0 2.8197757728776196e-07
transcript O 0 1.6264932582998881e-06
in O 0 1.506828617436895e-08
the O 0 1.1391708198971173e-07
patient O 0 4.9285499699180946e-06
. O 0 3.310131830858154e-07

Transfection O 0 0.0003650021681096405
of O 0 1.6494779231379653e-07
constructed O 0 9.224262953466678e-07
minigenes O 0 1.4422857930185273e-05
, O 0 1.763483226113749e-08
with O 0 4.828309752014093e-09
or O 0 5.464780272745884e-08
without O 0 2.8805922092089986e-09
the O 0 1.5529763031096877e-09
mutation O 0 4.246625806558768e-08
, O 0 1.1011410672168154e-09
into O 0 8.552145658313748e-09
COS O 0 0.00015990626707207412
- O 0 4.593589892465388e-06
1 O 0 2.103620033722109e-08
cells O 0 2.5361291733361213e-08
confirmed O 0 6.446614797539496e-09
that O 0 2.567965562416674e-10
the O 0 8.260925277170372e-10
mutant O 0 1.118336967920186e-06
minigene O 0 1.3756362022832036e-05
was O 0 7.724144097664976e-07
responsible O 0 4.29877156093994e-09
for O 0 1.1750860007264663e-10
a O 0 9.506326836827839e-10
mRNA O 0 2.5572493456138545e-08
species O 0 2.028416545840628e-09
alternatively O 0 3.1746544948418887e-08
spliced O 0 4.9796570237958804e-05
at O 0 7.461024864596766e-08
an O 0 5.134290770314465e-09
activated O 0 7.340407819356187e-07
cryptic O 0 1.290581622015452e-06
5 O 0 2.756404704484794e-08
splice O 0 3.817532160610426e-06
site O 0 9.755873406902538e-07
88 O 0 1.5505922590364207e-07
bp O 0 7.527132197537867e-07
upstream O 0 7.2322457356222e-08
from O 0 1.1578266123635217e-09
the O 0 8.568664666697146e-10
3 O 0 1.1337793814902852e-08
end O 0 3.123052394471415e-08
of O 0 1.982388697641113e-09
exon O 0 1.9191400042473106e-06
6 O 0 1.3448303661789396e-06
. O 0 3.167856164054683e-07

Our O 0 1.4483853192359675e-06
data O 0 7.721465067334066e-08
suggest O 0 1.7446474487314845e-08
that O 0 3.3665509269198424e-10
the O 0 3.0704638831480224e-10
C O 0 2.0910070119839475e-08
to O 0 3.785237956410725e-10
A O 0 6.917421746521768e-09
mutation O 0 1.4958811078713552e-08
at O 0 1.460058074442827e-09
the O 0 5.602910913005132e-10
penultimate O 0 1.517293952701948e-07
nucleotide O 0 2.966987189267911e-08
of O 0 4.77801243015108e-10
exon O 0 7.624566933372989e-08
6 O 0 1.6948581205156188e-08
of O 0 2.1152939122526249e-10
the O 0 8.628823211509484e-10
CYP27 O 0 1.0962589840346482e-06
gene O 0 3.6654245860745505e-08
not O 0 6.346717817962144e-09
only O 0 5.572911021545224e-09
causes O 0 4.555547405971083e-08
the O 0 3.885937971404019e-08
deficiency B-Disease 0 1.1030809218937065e-05
in I-Disease 0 9.417049362525631e-10
the I-Disease 0 2.1283914630743084e-09
sterol I-Disease 0 4.2324708715568704e-07
27 I-Disease 0 2.5233771339117084e-07
- I-Disease 0 4.674925264680496e-07
hydroxylase I-Disease 0 1.911417257360881e-06
activity I-Disease 0 8.669677953321298e-08
, O 0 4.676795395397448e-09
but O 0 6.181123168857994e-09
also O 0 1.3408984500529186e-07
partially O 0 4.353123586042784e-07
leads O 0 1.9509185378296934e-08
to O 0 1.0058814892133228e-09
alternative O 0 4.279856913314006e-09
pre O 0 7.752957031925689e-08
- O 0 2.2549880895894603e-07
mRNA O 0 2.69382667283935e-08
splicing O 0 4.833702504924986e-08
of O 0 9.925786859099617e-10
the O 0 4.610299253471339e-09
gene O 0 5.982114998914767e-07
. O 0 2.816032065311447e-07

To O 0 9.108263157031615e-07
our O 0 5.6244061852339655e-08
knowledge O 0 7.990047734551808e-09
, O 0 4.319071766900606e-09
this O 0 5.370701106066633e-10
is O 0 1.1618439543781278e-09
the O 0 5.608449260563475e-10
first O 0 1.9326042988154768e-08
report O 0 8.505425697080682e-09
regarding O 0 2.165139845189401e-09
effects O 0 6.127306306780156e-08
on O 0 1.6415202708230936e-07
pre O 0 1.9395103834085603e-07
- O 0 1.238947362480758e-07
mRNA O 0 1.3696612732871927e-08
splicing O 0 2.1786330961504063e-08
of O 0 3.4919431235458376e-10
a O 0 1.8218365704925077e-09
mutation O 0 1.6451867423938893e-08
at O 0 2.3292578976708e-09
the O 0 3.2502165403514027e-09
- O 0 6.412319180526538e-06
2 O 0 2.593837393760623e-07
position O 0 2.088713699777145e-07
of O 0 1.5556147481277094e-09
a O 0 3.6983042406291133e-08
5 O 0 4.347530691006796e-08
splice O 0 2.472038431733381e-05
site O 0 7.492935765185393e-06
. O 0 5.82367817969498e-07

ATM O 0 0.0014303411589935422
germline O 0 0.0025662891566753387
mutations O 0 0.0003088387893512845
in O 0 7.403484687529271e-07
classical O 0 0.00118688412476331
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.0011295074364170432
in O 0 2.082012784399012e-08
the O 0 1.0764505731231111e-08
Dutch O 0 4.827704742638161e-06
population O 0 3.4594499709328375e-08
. O 0 1.4575776674519147e-07

Germline O 0 0.0026277771685272455
mutations O 0 9.903272439260036e-05
in O 0 2.483847616474577e-08
the O 0 3.2559623885930478e-09
ATM O 0 1.9757352731630817e-07
gene O 0 1.2736784071876173e-07
are O 0 2.2865469517796555e-09
responsible O 0 8.500787629373008e-09
for O 0 2.2160460133591187e-08
the O 0 0.034665849059820175
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.37844419479370117
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.746916826865345e-07
. O 0 2.5212412424480135e-07

In O 0 5.896918651160377e-07
our O 0 4.913035311915337e-08
study O 0 8.158616005005115e-09
, O 0 2.3086335065869434e-09
we O 0 2.051657732593526e-09
have O 0 1.2763329282350355e-09
determined O 0 1.9669765816132667e-09
the O 0 3.9341932489556086e-10
ATM O 0 1.7788939032925555e-07
mutation O 0 4.541874076835484e-08
spectrum O 0 2.606050486519962e-08
in O 0 1.4075806076263575e-09
19 O 0 6.039368116717014e-08
classical O 0 2.1126676585936366e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 4.3468801891322073e-07
, O 0 1.3361772799314053e-10
including O 0 4.883300014357772e-11
some O 0 1.0001341421705945e-10
immigrant O 0 1.0202170663831112e-08
populations O 0 7.840109894630132e-09
, O 0 1.0250206239348358e-09
as O 0 2.957640354850355e-09
well O 0 1.8801626922027026e-09
as O 0 4.957822152817926e-09
12 O 0 6.580712419435031e-09
of O 0 4.257976193855484e-10
Dutch O 0 2.980799536089762e-07
ethnic O 0 7.83386511216122e-08
origin O 0 5.508786315999714e-08
. O 0 8.221009295539261e-08

Both O 0 5.114267196404398e-07
the O 0 3.0536465800423684e-08
protein O 0 2.3362495937817584e-07
truncation O 0 3.46165234077489e-06
test O 0 2.14870183867788e-07
( O 0 2.8297476362126872e-08
PTT O 0 1.8252397637752438e-07
) O 0 2.561646228471659e-09
and O 0 3.716267849007693e-10
the O 0 4.030094868934242e-10
restriction O 0 1.1942388411512184e-08
endonuclease O 0 5.553612254516338e-07
fingerprinting O 0 3.3814885114225035e-07
( O 0 8.178496102573263e-09
REF O 0 1.5832180224606418e-06
) O 0 7.146535585533798e-10
method O 0 3.4171103724389695e-09
were O 0 4.1746819334775864e-09
used O 0 5.38117239656799e-09
and O 0 1.958173179161804e-08
compared O 0 2.980899971305462e-09
for O 0 6.143013181469925e-11
their O 0 2.1703773500636458e-10
detection O 0 4.9389079492812016e-09
efficiency O 0 3.2510223402226757e-09
, O 0 1.4518623803194686e-10
identifying O 0 2.787692965355859e-09
76 O 0 7.162505255564611e-09
% O 0 4.198331959859303e-10
and O 0 8.092110315160994e-10
60 O 0 3.427155670365778e-09
% O 0 2.7872876229295684e-10
of O 0 1.1342454753204834e-10
the O 0 7.833802051493421e-09
mutations O 0 4.586069337619847e-07
, O 0 2.1048883525054407e-08
respectively O 0 1.8678611013456248e-07
. O 0 2.0145013479577756e-07

Most O 0 9.711862958283746e-07
patients O 0 9.216314538207371e-07
were O 0 2.1840003583406542e-08
found O 0 5.725191876138069e-09
to O 0 4.315127810627928e-09
be O 0 8.807949036793161e-09
compound O 0 1.1956357184317312e-06
heterozygote O 0 4.070901559316553e-05
. O 0 6.987319807194581e-07

Seventeen O 0 3.5489953006617725e-05
mutations O 0 1.6141704691108316e-05
were O 0 3.8908698485329296e-08
distinct O 0 2.153431921669835e-08
, O 0 4.442044510000187e-09
of O 0 8.133146933708701e-10
which O 0 1.5912299033971067e-07
10 O 0 1.9282191843217333e-08
were O 0 1.058174632362352e-07
not O 0 3.43118635726114e-08
reported O 0 4.206154926578165e-07
previously O 0 4.4557387468557863e-07
. O 0 3.241158594846638e-07

Mutations O 0 0.00018607826496008784
are O 0 2.64624180346118e-08
small O 0 1.9117326388595757e-08
deletions O 0 3.7320521641959203e-06
or O 0 2.2297562907169777e-07
point O 0 2.313663571840152e-06
mutations O 0 8.906813491194043e-06
frequently O 0 7.089723226272326e-07
affecting O 0 1.406460228281503e-07
splice O 0 0.0001555596390971914
sites O 0 7.119329893612303e-06
. O 0 1.4293951835497865e-06

Moreover O 0 2.7733658498618752e-05
, O 0 1.8667802237359865e-07
a O 0 7.72037509477741e-08
16 O 0 5.687698489964532e-07
. O 0 3.035016788999201e-07

7 O 0 2.012821460084524e-05
- O 0 8.669412636663765e-06
kb O 0 9.015963769343216e-06
genomic O 0 1.094831759473891e-06
deletion O 0 1.143198005593149e-06
of O 0 2.5641295753331406e-09
the O 0 1.6212189368758345e-09
3 O 0 6.091613613534719e-08
end O 0 1.0427810792634773e-07
of O 0 2.0560794733448517e-10
the O 0 4.780983942076489e-10
gene O 0 2.7127494917067452e-08
, O 0 6.077696124151544e-09
most O 0 8.40347735842073e-10
likely O 0 5.589667395611286e-09
a O 0 8.475041779476555e-10
result O 0 3.2602109900636833e-10
of O 0 4.5088606459575686e-11
recombination O 0 2.987987191005459e-09
between O 0 1.6945220338016043e-08
two O 0 2.1557751495038247e-07
LINE O 1 0.6607850790023804
elements O 0 1.4042703924133093e-06
, O 0 2.0462994143599644e-07
was O 0 4.274403636372881e-06
identified O 0 7.619724442520237e-07
. O 0 1.8913935662112635e-07

The O 0 2.8912236871292407e-07
most O 0 1.5540646103318068e-08
frequently O 0 1.5204589942641178e-07
found O 0 1.3778862495428257e-08
mutation O 0 8.671000983895283e-08
, O 0 1.2481801148211957e-09
identified O 0 1.0438611752761062e-08
in O 0 8.061992740060475e-10
three O 0 3.21203175168705e-09
unrelated O 0 3.3260700860182624e-08
Turkish O 0 2.484422111592721e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 2.8590001477368787e-08
, O 0 4.5005394966324275e-09
was O 0 4.453160045159166e-07
previously O 0 6.12697874657897e-08
described O 0 1.2128214166295948e-07
to O 0 1.082780531902472e-08
be O 0 2.390642572791535e-09
a O 0 9.118901189708595e-09
Turkish O 0 1.2019739870083868e-06
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
founder O 0 2.362969462410547e-05
mutation O 0 2.482425543348654e-06
. O 0 1.2088732148640702e-07

The O 0 3.8454743389593204e-07
presence O 0 1.2470295018829347e-07
of O 0 4.7621107057693735e-09
a O 0 2.5235497247422245e-08
founder O 0 2.7584617328102468e-06
mutation O 0 5.054009193372622e-07
among O 0 2.6427195987110963e-09
relatively O 0 9.705347636668193e-10
small O 0 4.0936454226425667e-10
ethnic O 0 1.3339785276400562e-08
population O 0 1.0242409143046416e-09
groups O 0 4.6208525894542163e-10
in O 0 2.2673196653499872e-10
Western O 0 8.732588874238445e-09
Europe O 0 1.607898525435303e-07
could O 0 2.7825945991821754e-08
indicate O 0 4.132606701290342e-09
a O 0 1.3229354278720962e-09
high O 0 1.1595465920777315e-08
carrier O 0 1.3269136900362355e-08
frequency O 0 9.49192724419845e-09
in O 0 9.43186195812018e-10
such O 0 1.933042170776389e-09
communities O 0 1.10448233670013e-07
. O 0 2.1515543835448625e-07

In O 0 7.540855904153432e-07
patients O 0 3.693739927257411e-07
of O 0 2.318770064846376e-09
Dutch O 0 5.145400905348652e-07
ethnic O 0 8.559689490539313e-08
origin O 0 2.6109512774041832e-08
, O 0 7.545112090667772e-09
however O 0 4.7085340071362225e-09
, O 0 2.436129742378057e-09
no O 0 1.7658383644203468e-09
significant O 0 1.0606470146612423e-09
founder O 0 1.6206654152028932e-07
effect O 0 8.798163975143325e-08
could O 0 1.299974172752627e-07
be O 0 5.752710308115638e-09
identified O 0 1.9607470846949582e-07
. O 0 9.662320366032873e-08

The O 0 6.79721438245906e-07
observed O 0 6.955712592571217e-07
genetic O 0 2.637067098021362e-07
heterogeneity O 0 4.806205424756627e-07
including O 0 9.427425062824568e-09
the O 0 4.7082289178490555e-09
relative O 0 1.220958978365161e-07
high O 0 1.950675425632653e-07
percentage O 0 2.0368777597923327e-07
of O 0 6.74834077507569e-10
splice O 0 7.880737393861637e-05
- O 0 2.6671761588659137e-05
site O 0 2.9028653898421908e-06
mutations O 0 1.3186103160478524e-06
had O 0 9.007851531350752e-07
no O 0 1.214851330644251e-08
reflection O 0 1.7170556532164483e-08
on O 0 5.70861011794932e-08
the O 0 8.458351885565207e-08
phenotype O 0 6.516777648357674e-05
. O 0 4.2651217313505185e-07

All O 0 1.4583314396077185e-06
patients O 0 2.386130518061691e-06
manifested O 0 1.4268578070186777e-06
classical O 0 7.461678706022212e-07
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
and O 0 4.809506748415515e-08
increased O 0 1.873426569432013e-08
cellular O 0 2.8953104447282385e-07
radioresistant O 0 1.9789345060416963e-06
DNA O 0 6.634136866523477e-07
synthesis O 0 1.0781169521578704e-06
. O 0 1.5987883728030283e-07

Determination O 0 1.3781268535240088e-05
of O 0 1.0440244224696471e-08
the O 0 3.440936646725845e-09
genomic O 0 1.2622393796846154e-07
structure O 0 5.177898998454111e-08
of O 0 8.028570586127159e-10
the O 0 4.038954504181902e-09
COL4A4 O 0 4.235614596836967e-06
gene O 0 7.642680088792986e-08
and O 0 5.128526048281401e-09
of O 0 1.8122537914777581e-09
novel O 0 2.2706193703925237e-05
mutations O 0 0.06114741414785385
causing O 0 0.00017640924488659948
autosomal B-Disease 1 0.9999991655349731
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 7.724926035734825e-06

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 2.742435071922955e-06
a O 0 1.1969979141213116e-06
progressive O 0 0.00018208721303381026
hematuric B-Disease 1 0.6107718348503113
glomerulonephritis I-Disease 1 1.0
characterized O 0 5.690514808520675e-05
by O 0 5.943945780018112e-08
glomerular B-Disease 0 0.017069123685359955
basement I-Disease 1 0.9845888018608093
membrane I-Disease 0 0.023710180073976517
abnormalities I-Disease 1 0.9999703168869019
and O 0 1.51400257664136e-07
associated O 0 1.7205110225404496e-08
with O 0 5.519468881942657e-09
mutations O 0 1.0534517969063018e-06
in O 0 3.944955473400569e-09
either O 0 1.483444833638714e-08
the O 0 1.83452311119936e-08
COL4A3 O 0 4.851680569117889e-05
or O 0 1.5151950805147862e-08
the O 0 3.3558593681703996e-09
COL4A4 O 0 1.5238223340929835e-06
gene O 0 7.516416644648416e-08
, O 0 6.402513186287706e-09
which O 0 1.16827947316267e-09
encode O 0 1.2398806426006104e-08
the O 0 6.369237137704431e-09
alpha3 O 0 5.170500571693992e-06
and O 0 5.2531529348698314e-08
alpha4 O 0 3.7498621168197133e-06
type O 0 5.678073193848832e-07
IV O 0 3.585387457860634e-05
collagen O 0 1.7306540030403994e-05
chains O 0 0.0001360755122732371
, O 0 6.71926869699746e-08
respectively O 0 1.897639378967142e-07
. O 0 1.255425132740129e-07

To O 0 1.8062610251945443e-07
date O 0 8.451933553033086e-08
, O 0 1.7748541525364203e-09
mutation O 0 7.95222021565678e-09
screening O 0 3.790268099379546e-09
in O 0 5.8758670151704e-10
the O 0 6.895563564590645e-10
two O 0 8.904433634882025e-09
genes O 0 2.421143960873451e-07
has O 0 9.961857358575799e-06
been O 0 1.2445290167306666e-06
hampered O 0 8.87029727891786e-06
by O 0 1.5073194914450028e-09
the O 0 4.6271608766801364e-09
lack O 0 2.1289028317994507e-09
of O 0 3.7436437283489e-10
genomic O 0 1.5672371489472425e-07
structure O 0 9.270211620560076e-08
information O 0 3.490914224357766e-08
. O 0 1.7807271035508165e-07

We O 0 7.706141332164407e-06
report O 0 1.1464511118219889e-07
here O 0 5.457569507427706e-09
the O 0 1.0809063644146022e-09
complete O 0 6.659871765180014e-09
characterization O 0 6.971811217226787e-08
of O 0 6.736997626433094e-10
the O 0 3.808987791842355e-09
48 O 0 2.5348283472226285e-08
exons O 0 1.1450536163692959e-07
of O 0 9.143208412609738e-10
the O 0 2.2434587521047433e-09
COL4A4 O 0 1.3761076615992351e-06
gene O 0 2.857811587375636e-08
, O 0 7.533503265655384e-10
a O 0 7.635431176211682e-10
comprehensive O 0 3.301777962150254e-09
gene O 0 5.876075093169675e-08
screen O 0 0.0008351793512701988
, O 0 8.368201065422909e-08
and O 0 9.98139881858151e-09
the O 0 3.5776309692536756e-10
subsequent O 0 1.1531543497866892e-09
detection O 0 3.1103173370183868e-09
of O 0 2.776611440769017e-10
10 O 0 2.2684498723890556e-09
novel O 0 6.252758311120488e-08
mutations O 0 2.0835014424847031e-07
in O 0 5.072074316103681e-09
eight O 0 1.254002881978522e-06
patients O 0 2.4802932330203475e-06
diagnosed O 0 0.0004611654148902744
with O 0 1.2737777979054954e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.1030820132873487e-05

Furthermore O 0 9.66424704529345e-06
, O 0 6.272922092875888e-08
we O 0 2.892468042858809e-09
identified O 0 2.7469457819506715e-09
a O 0 1.1355166806836792e-09
glycine O 0 6.394814278110061e-08
to O 0 1.6441915606790758e-09
alanine O 0 7.741903829128205e-08
substitution O 0 1.0180710496854317e-08
in O 0 1.1724626824971551e-09
the O 0 3.756707389612757e-09
collagenous O 0 1.155702193500474e-06
domain O 0 2.5971631956167585e-08
that O 0 3.996797559580045e-09
is O 0 5.546210601892199e-09
apparently O 0 1.430706930705128e-07
silent O 0 3.864458619773359e-08
in O 0 5.526187285553874e-10
the O 0 1.6579407846606387e-09
heterozygous O 0 6.61653416500485e-08
carriers O 0 9.910676723734468e-09
, O 0 1.4607963727542028e-09
in O 0 4.858907054483552e-09
11 O 0 1.5531718133843242e-07
. O 0 1.391010613360777e-07

5 O 0 3.904373443219811e-06
% O 0 6.254988704768039e-08
of O 0 6.578274591717559e-10
all O 0 8.108719806720899e-10
control O 0 2.69732851165827e-07
individuals O 0 3.798206638094825e-09
, O 0 2.575629043377603e-09
and O 0 1.7638397409314166e-08
in O 0 2.7734370355858573e-09
one O 0 1.9309021936919635e-08
control O 0 3.189305743944715e-07
individual O 0 4.586766522152175e-09
homozygous O 0 8.336116508189662e-08
for O 0 6.006599106989086e-10
this O 0 1.332810417586927e-09
glycine O 0 3.7693271792704763e-07
substitution O 0 2.8978877253393875e-07
. O 0 1.922663130926594e-07

There O 0 6.739265700161923e-06
has O 0 5.476596811604395e-07
been O 0 1.1732127269681314e-08
no O 0 3.6554319571280303e-09
previous O 0 8.277064367234743e-09
finding O 0 1.741355504236708e-09
of O 0 7.826132797372765e-11
a O 0 9.707606940523306e-10
glycine O 0 1.970293084241348e-08
substitution O 0 5.9702918164816765e-09
that O 0 7.556172576528297e-09
is O 0 2.657043474130205e-09
not O 0 2.865865322831951e-10
associated O 0 5.69984559550818e-10
with O 0 3.689585026389608e-10
any O 0 2.830426337752101e-09
obvious O 0 1.689949016281389e-07
phenotype O 0 3.127910076727858e-06
in O 0 1.9093022274319082e-08
homozygous O 0 1.7216891137650236e-05
individuals O 0 1.4917333146513556e-07
. O 0 2.0647044607358112e-07

Founder O 0 0.00034703651908785105
BRCA1 O 0 0.000809880206361413
and O 0 1.7735643496052944e-06
BRCA2 O 0 8.765892562223598e-05
mutations O 0 4.365077074908186e-06
in O 0 2.994595149630186e-08
French O 0 2.6060461095767096e-05
Canadian O 0 0.00011492724297568202
breast B-Disease 1 0.9999916553497314
and I-Disease 1 0.9999778270721436
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.368957211729139e-06
. O 0 5.274865770843462e-07

We O 0 4.776942205353407e-06
have O 0 1.8525259548596296e-08
identified O 0 2.611713334488286e-08
four O 0 4.374494988468314e-09
mutations O 0 6.562915899621657e-08
in O 0 7.72559682893359e-10
each O 0 1.709284491724361e-09
of O 0 2.18316609235103e-09
the O 0 2.984087359436671e-07
breast B-Disease 1 0.7963129878044128
cancer I-Disease 0 5.046797377872281e-05
- O 0 3.9631257095607e-05
susceptibility O 0 5.427568339655409e-06
genes O 0 4.1687968632686534e-07
, O 0 2.3256854220221612e-08
BRCA1 O 0 4.927243026031647e-06
and O 0 1.5762006455588562e-07
BRCA2 O 0 3.832144557236461e-06
, O 0 4.440350753753819e-09
in O 0 4.162509004146386e-09
French O 0 6.206381385709392e-06
Canadian O 0 9.387676982441917e-06
breast B-Disease 1 0.9086900949478149
cancer I-Disease 0 0.0009603862999938428
and O 0 9.629073610994965e-05
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.332874704639835e-07
from O 0 3.533694936663778e-08
Quebec O 0 4.849340712098638e-06
. O 0 5.435921366370167e-07

To O 0 5.663136448674777e-07
identify O 0 6.963776968405e-07
founder O 0 2.171420646845945e-06
effects O 0 9.176129083243723e-07
, O 0 1.0959787744013738e-08
we O 0 5.3685424994398545e-09
examined O 0 1.8951123337274112e-08
independently O 0 3.809912385577263e-08
ascertained O 0 1.6245837741735158e-07
French O 0 7.492483291571261e-07
Canadian O 0 6.083404855417029e-07
cancer B-Disease 0 8.363555252799415e-07
families O 0 3.556792416148369e-09
for O 0 1.1195824128895637e-10
the O 0 2.2778441632897994e-10
distribution O 0 3.716355001515126e-09
of O 0 3.2211960876438184e-10
these O 0 1.3720242719728049e-09
eight O 0 4.867610314818194e-08
mutations O 0 1.5819396139704622e-06
. O 0 1.514895302534569e-07

Mutations O 0 0.0006307758740149438
were O 0 5.036889092480124e-07
found O 0 8.594547296070232e-09
in O 0 2.610815341697048e-09
41 O 0 5.734692365422234e-08
of O 0 1.6180463635606657e-09
97 O 0 1.5687085408444545e-07
families O 0 8.488736824574517e-08
. O 0 1.5744699055630917e-07

Six O 0 1.1778380439864122e-06
of O 0 8.509807081225063e-09
eight O 0 2.4642739404612257e-08
mutations O 0 3.1439142844646994e-07
were O 0 1.7056311918395295e-08
observed O 0 4.996443081495272e-08
at O 0 1.1550656431325024e-08
least O 0 2.0351142993035864e-08
twice O 0 3.910765826731222e-07
. O 0 2.467023136887292e-07

The O 0 1.7544034562888555e-06
BRCA1 O 0 8.850194717524573e-05
C4446T O 0 2.1832645870745182e-05
mutation O 0 3.946435754187405e-06
was O 0 1.1373547437187881e-07
the O 0 4.2672690381273526e-10
most O 0 6.397833929305818e-10
common O 0 5.217601017903917e-09
mutation O 0 5.243623135697817e-08
found O 0 1.4211019028209648e-08
, O 0 3.846704288434921e-09
followed O 0 8.368483683796057e-09
by O 0 1.6361018095878421e-09
the O 0 4.049809732009635e-08
BRCA2 O 0 8.700460602995008e-05
8765delAG O 0 2.5342264052596875e-05
mutation O 0 7.023475518508349e-06
. O 0 4.958165504831413e-07

Together O 0 2.3396416963805677e-06
, O 0 9.213413143527305e-09
these O 0 8.988451649649676e-10
mutations O 0 4.482953031015313e-08
were O 0 3.929478076258874e-09
found O 0 2.1352957180198473e-09
in O 0 3.1796096866543166e-09
28 O 0 4.2476468564700554e-08
of O 0 5.269162883791978e-10
41 O 0 1.772193627402885e-07
families O 0 2.942111221315713e-09
identified O 0 1.896880696961034e-08
to O 0 2.863812520459419e-09
have O 0 1.0169104669444096e-08
a O 0 3.543170734587875e-08
mutation O 0 1.6150106603163294e-06
. O 0 1.4859260488719883e-07

The O 0 5.270163683235296e-07
odds O 0 1.2149415624662652e-06
of O 0 1.2611648392280017e-09
detection O 0 1.8929736000927733e-08
of O 0 4.72710481869143e-10
any O 0 1.1007295075415868e-09
of O 0 4.946145715223338e-10
the O 0 2.8532134432879275e-09
four O 0 1.294645670668615e-07
BRCA1 O 0 3.2595657103229314e-05
mutations O 0 8.055026228248607e-06
was O 0 9.437190783501137e-06
18 O 0 3.097759133652289e-07
. O 0 1.9765080594424944e-07

7x O 0 0.0008460826356895268
greater O 0 1.4034362720849458e-06
if O 0 2.9349163099823272e-08
one O 0 2.60405674801234e-09
or O 0 6.349304970676428e-10
more O 0 2.39478520347447e-10
cases O 0 4.356060845367438e-09
of O 0 5.309422022037324e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 0.00012006593169644475
also O 0 6.416672704290249e-07
present O 0 7.804585422377386e-09
in O 0 3.9248715388851e-09
the O 0 4.319197444146994e-08
family O 0 5.832704346175888e-07
. O 0 3.747370271867112e-07

The O 0 4.3412211425675196e-07
odds O 0 2.0353372747194953e-06
of O 0 1.3750369731724277e-09
detection O 0 1.7037258714935888e-08
of O 0 3.670325154914167e-10
any O 0 6.328654267306888e-10
of O 0 4.155795985116839e-10
the O 0 6.418028331012238e-09
four O 0 5.829634801557404e-07
BRCA2 O 0 0.0001505699910921976
mutations O 0 4.804079253517557e-06
was O 0 3.927992565877503e-06
5 O 0 2.1662361859853263e-07
. O 0 2.4209452931245323e-07

3x O 0 0.00019976720795966685
greater O 0 1.1571822824407718e-06
if O 0 4.5558426364777915e-08
there O 0 3.769842660261702e-09
were O 0 4.600847258728891e-09
at O 0 8.019877539844344e-10
least O 0 8.412650021050183e-10
five O 0 5.255252344404937e-10
cases O 0 1.1593337401194503e-09
of O 0 8.14521339265184e-09
breast B-Disease 0 0.4352986216545105
cancer I-Disease 0 2.0362329451018013e-05
in O 0 2.0469409278689454e-08
the O 0 2.8415492181466107e-08
family O 0 1.0180456229136325e-06
. O 0 3.449198686666932e-07

Interestingly O 0 6.182627839734778e-05
, O 0 6.253426221292102e-08
the O 0 1.8840109472506583e-09
presence O 0 3.3359353057704766e-09
of O 0 6.998250867695788e-10
a O 0 8.006129803561635e-08
breast B-Disease 0 0.00032894063042476773
cancer I-Disease 0 5.040425890001643e-07
case O 0 5.840895767050824e-09
< O 0 2.7509791777902137e-08
36 O 0 1.2457024745060608e-08
years O 0 9.88352621966726e-10
of O 0 2.749376559751937e-10
age O 0 1.9911279736106735e-08
was O 0 2.7404055913393677e-08
strongly O 0 1.6433387983738612e-09
predictive O 0 2.6204403980045754e-08
of O 0 1.2158637430204067e-09
the O 0 2.09556971775271e-09
presence O 0 4.566497402436198e-09
of O 0 1.1630029578268974e-10
any O 0 3.1039684711409166e-10
of O 0 2.239460422659434e-10
the O 0 3.022095684812598e-09
eight O 0 8.814876650831138e-08
mutations O 0 8.372094271180686e-07
screened O 0 2.4180758373404387e-06
. O 0 3.5333721370989224e-07

Carriers O 0 3.866685801767744e-06
of O 0 3.5856868585426582e-09
the O 0 1.6747666586880428e-09
same O 0 6.470944668990342e-09
mutation O 0 3.697683581549427e-08
, O 0 8.111040172842365e-10
from O 0 1.4480791565851803e-10
different O 0 6.465044610770576e-10
families O 0 3.299977180404312e-09
, O 0 2.951991984190272e-10
shared O 0 1.2150268569044442e-09
similar O 0 2.170279067570391e-09
haplotypes O 0 6.606193778679881e-07
, O 0 5.475200293147964e-09
indicating O 0 1.734359145189046e-08
that O 0 1.8873907992045247e-10
the O 0 1.8690990422065568e-10
mutant O 0 1.1958439927184372e-07
alleles O 0 4.4858012415716075e-08
were O 0 1.2232304413828388e-07
likely O 0 3.5805765463692296e-08
to O 0 5.262456692634032e-09
be O 0 2.783931085659219e-09
identical O 0 2.7635323363028874e-08
by O 0 1.057415044414256e-09
descent O 0 1.4169127382501756e-07
for O 0 4.0532061040821077e-10
a O 0 1.1890974427331003e-08
mutation O 0 1.1284961232149726e-07
in O 0 3.3747624694768774e-09
the O 0 9.127374411832534e-09
founder O 0 1.2164337022113614e-06
population O 0 2.0986385962373788e-08
. O 0 7.986226790990258e-08

The O 0 1.070970725436382e-07
identification O 0 4.5198802922641335e-08
of O 0 3.0504958559163242e-09
common O 0 4.164329325817562e-08
BRCA1 O 0 3.5016473702853546e-05
and O 0 8.586708304392232e-07
BRCA2 O 0 7.511715375585482e-05
mutations O 0 1.192101649394317e-06
will O 0 4.529604247238694e-09
facilitate O 0 7.039393956631557e-09
carrier O 0 2.760687500824588e-08
detection O 0 1.823874917761259e-08
in O 0 3.728965580762633e-09
French O 0 6.308488991635386e-06
Canadian O 0 1.0005664080381393e-05
breast B-Disease 1 0.6351227164268494
cancer I-Disease 0 0.0040254974737763405
and O 0 0.00015190594422165304
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.370504939288367e-06
. O 0 5.621702712232945e-07

Are O 0 2.5233198357454967e-06
Dp71 O 0 0.00014583169831894338
and O 0 8.710533165867673e-07
Dp140 O 0 8.284150680992752e-05
brain O 0 6.344064604490995e-05
dystrophin O 0 1.7832939192885533e-05
isoforms O 0 1.7895282553581637e-06
related O 0 2.695070975278213e-07
to O 0 1.2288087702927442e-07
cognitive B-Disease 0 0.00020872082677669823
impairment I-Disease 0 0.0004093759926036
in O 0 4.93989500682801e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 0.9999946355819702
dystrophy I-Disease 1 0.9999933242797852
? O 0 0.00015898495621513575

Molecular O 0 5.176648301130626e-06
study O 0 1.3374922502862319e-07
and O 0 1.7846314648295447e-08
neuropsychological O 0 2.7757653242588276e-07
analysis O 0 1.8606955975997153e-08
were O 0 2.7971641003432524e-08
performed O 0 2.9595492279099744e-08
concurrently O 0 4.2858633975129123e-08
on O 0 4.290869242140616e-07
49 O 0 1.8851316099244286e-06
patients O 0 1.6238897160292254e-07
with O 0 9.619417369322036e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 0.9999959468841553
dystrophy I-Disease 1 0.9999963045120239
( O 0 5.561531907005701e-06
DMD B-Disease 1 1.0
) O 0 9.918017696008974e-08
in O 0 5.44683720349326e-09
order O 0 1.8469762608219753e-08
to O 0 1.869021604150589e-09
find O 0 6.4646656916522716e-09
a O 0 7.958984027389704e-10
molecular O 0 1.1880002759312447e-08
explanation O 0 4.539533193792522e-09
for O 0 3.021022043636634e-10
the O 0 6.706321276084282e-09
cognitive B-Disease 0 2.2235756205191137e-06
impairment I-Disease 0 2.8741735036419414e-07
observed O 0 5.569205896449603e-08
in O 0 2.0497891384252398e-08
most O 0 6.272503014770336e-07
DMD B-Disease 1 1.0
patients O 0 2.9581851777038537e-05
. O 0 2.9604791507154005e-07

Complete O 0 1.6152740727193304e-06
analysis O 0 8.997962908097179e-08
of O 0 1.8071004692643555e-09
the O 0 3.731476905244335e-09
dystrophin O 0 1.2404126437104424e-06
gene O 0 8.67746791755053e-07
was O 0 0.00013130070874467492
performed O 0 4.877462060903781e-07
to O 0 2.7318818318633475e-09
define O 0 4.249558926971986e-08
the O 0 2.744086513573052e-09
localization O 0 6.022171561426148e-08
of O 0 8.192027611819697e-10
deletions O 0 9.174431738756539e-07
and O 0 9.915671483895494e-08
duplications O 0 7.270820105986786e-07
in O 0 5.197041463844698e-09
relation O 0 1.507903846231784e-08
to O 0 4.1881285106626365e-09
the O 0 1.0796418870029356e-08
different O 0 8.787009164734627e-07
DMD B-Disease 1 1.0
promoters O 0 5.59462423552759e-05
. O 0 5.413127723841171e-07

Qualitative O 0 4.779667051479919e-06
analysis O 0 1.532375222268456e-07
of O 0 5.3378399478276606e-09
the O 0 4.582552115550698e-09
Dp71 O 0 4.4530511331686284e-06
transcript O 0 1.9979635908384807e-05
and O 0 6.985241185475388e-08
testing O 0 3.171051865535901e-09
for O 0 8.573467630279552e-11
the O 0 1.8152937486526355e-10
specific O 0 3.578429219608381e-10
first O 0 1.3178154123494323e-09
exon O 0 4.581042745144259e-08
of O 0 4.835756239884859e-09
Dp140 O 0 1.269271024284535e-06
were O 0 2.4705124701540626e-07
also O 0 2.3324852804762486e-07
carried O 0 3.92252388792258e-07
out O 0 2.0066572403720784e-07
. O 0 1.1701671098762745e-07

Neuropsychological O 0 0.00011417506902944297
analysis O 0 2.204622887802543e-06
assessed O 0 7.821441840860643e-07
verbal O 0 4.853662176174112e-06
and O 0 1.3611392546408752e-07
visuospatial O 0 1.8644403098733164e-05
intelligence O 0 1.5325550748457317e-06
, O 0 3.964947481449599e-08
verbal O 0 1.0796345577546163e-06
memory O 0 3.140460830763914e-05
, O 0 1.1976061387031223e-07
and O 0 1.3761402328782424e-07
reading O 0 7.537419151049107e-07
skills O 0 1.0041665063909022e-06
. O 0 2.884143555093033e-07

Comparison O 0 1.4262686818256043e-06
of O 0 1.0939842809420952e-08
molecular O 0 1.0984256704205109e-07
and O 0 2.2744861993828636e-08
psychometric O 0 1.026923200697638e-06
findings O 0 7.342494967588209e-08
demonstrated O 0 5.3512273723299586e-08
that O 0 1.2217102884903852e-09
deletions O 0 1.9117405258839426e-07
and O 0 1.3295180956163222e-08
duplications O 0 4.104940387605893e-07
that O 0 1.1073506556158463e-08
were O 0 8.833352715953424e-09
localized O 0 1.344618425491717e-07
in O 0 1.3022768641235416e-08
the O 0 1.8349185282318103e-08
distal O 0 4.158411229582271e-06
part O 0 1.2015730632697341e-08
of O 0 5.409500070108209e-10
the O 0 1.4665977321470791e-09
gene O 0 6.688721043701662e-08
seemed O 0 2.4007061938391416e-07
to O 0 1.4024513772525893e-09
be O 0 2.6153010868057436e-09
preferentially O 0 5.2396639915741616e-08
associated O 0 2.6000629205213954e-08
with O 0 3.9493162518056124e-08
cognitive B-Disease 0 6.660496001131833e-05
impairment I-Disease 0 7.09387404640438e-06
. O 0 3.933867560590443e-07

Two O 0 8.069366685958812e-07
altered O 0 5.257932116364827e-06
Dp71 O 0 1.8928794816019945e-05
transcripts O 0 8.457155900032376e-07
and O 0 1.208415323361578e-08
two O 0 1.7788158723774927e-09
deleted O 0 5.237235995991796e-07
Dp140 O 0 2.496875026736234e-07
DNA O 0 6.047228851002728e-08
sequences O 0 1.3891387595776905e-07
were O 0 1.633520696486812e-08
found O 0 2.9958964198328886e-09
in O 0 1.6547057057891834e-09
four O 0 4.6237932593840014e-08
patients O 0 6.514799366641455e-08
with O 0 9.679899903858313e-08
severe O 0 0.011384682729840279
cerebral B-Disease 0 0.21134191751480103
dysfunction I-Disease 0 0.003497468773275614
. O 0 1.1635120245045982e-06

These O 0 2.158801351015427e-07
findings O 0 8.533542228406077e-08
suggest O 0 3.40768089301946e-08
that O 0 3.557217853611405e-10
some O 0 1.8420315273104393e-10
sequences O 0 3.307023277443477e-08
located O 0 4.159963395977684e-08
in O 0 4.112155060909117e-09
the O 0 8.000234252847349e-09
distal O 0 1.4913506447555847e-06
part O 0 8.57050075353527e-09
of O 0 4.5213843780089746e-10
the O 0 1.9712806942351335e-09
gene O 0 1.3532800835491798e-07
and O 0 3.4392920156278706e-07
, O 0 1.4350689525599591e-09
in O 0 5.465921604219659e-10
particular O 0 1.7768525539807456e-09
, O 0 1.6269899871801385e-09
some O 0 2.595651471537508e-09
DMD B-Disease 1 0.9999972581863403
isoforms O 0 1.684825292613823e-07
expressed O 0 8.382893490477272e-09
in O 0 4.195532365969257e-09
the O 0 1.3081961469652015e-07
brain O 0 0.0006706411950290203
may O 0 4.796909820470319e-07
be O 0 4.3859052500927476e-10
related O 0 7.571446802856485e-10
to O 0 4.036143419483551e-09
the O 0 3.4377368507421124e-08
cognitive B-Disease 0 1.0024223229265772e-05
impairment I-Disease 0 7.66290952469717e-07
associated O 0 6.500265214981482e-08
with O 0 6.806893679822679e-07
DMD B-Disease 1 1.0
. O 0 7.175237897172337e-07
. O 0 3.005080770890345e-07

I1307K O 0 0.0005024724523536861
APC O 0 8.30907083582133e-05
and O 0 4.227335637096985e-07
hMLH1 O 0 9.536856850900222e-06
mutations O 0 1.9762978809012566e-06
in O 0 4.468105885280238e-09
a O 0 1.7468918755980667e-08
non O 0 1.995690546152673e-08
- O 0 6.6775369305105414e-06
Jewish O 0 5.928467317062314e-07
family O 0 1.458334111248405e-07
with O 0 8.262004769221676e-08
hereditary B-Disease 1 0.9485242366790771
non I-Disease 0 0.00018442478904034942
- I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.85829592536902e-06

We O 0 5.439247615868226e-06
describe O 0 6.841711979177489e-07
a O 0 1.0032057673470263e-07
French O 0 1.7793850929592736e-05
Canadian O 0 8.126894499582704e-06
hereditary B-Disease 1 0.9693827629089355
non I-Disease 0 0.0009027085616253316
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.7422838936909102e-05
HNPCC B-Disease 0 0.02012987807393074
) O 0 6.230959570530104e-07
kindred O 0 2.6744122806121595e-05
which O 0 2.363518234460571e-07
carries O 0 1.369822513197505e-07
a O 0 1.8888730579647017e-08
novel O 0 2.6760264404401823e-07
truncating O 0 6.279462013480952e-06
mutation O 0 1.4981075082687312e-06
in O 0 4.8160607946101663e-08
hMLH1 O 0 1.9737437469302677e-05
. O 0 7.360097811215383e-07

Interestingly O 0 3.140334956697188e-05
, O 0 9.63872324177828e-08
the O 0 1.55896007214551e-08
I1307K O 0 2.254231958431774e-06
APC O 0 1.728723418636946e-06
polymorphism O 0 1.504675196883909e-06
, O 0 4.9745980668092216e-09
associated O 0 1.4764773847986135e-09
with O 0 3.068579002007965e-10
an O 0 1.7479508951367961e-09
increased O 0 2.3514540714586474e-07
risk O 0 7.687209517825977e-07
of O 0 8.7058015196817e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.3106990763844806e-06
is O 0 2.585711023073145e-08
also O 0 4.3363172608223977e-08
present O 0 3.6616984999682245e-09
in O 0 7.402761958985593e-09
this O 0 8.332870393701342e-09
family O 0 4.5695583139604423e-07
. O 0 3.042258640562068e-07

The O 0 6.456436949520139e-07
I1307K O 0 9.558163583278656e-06
polymorphism O 0 1.4492001355392858e-05
has O 0 7.178194323387288e-07
previously O 0 1.312841675371601e-07
only O 0 6.728384072118843e-09
been O 0 9.436438297427685e-09
identified O 0 2.7920258105496032e-08
in O 0 1.87735693657487e-09
individuals O 0 4.94900509462326e-10
of O 0 1.0478462542096167e-09
self O 0 6.079848390072584e-06
- O 0 0.004306726157665253
reported O 0 5.9975259318889584e-06
Ashkenazi O 0 3.7153122320887633e-06
Jewish O 0 1.9552143726286886e-07
origins O 0 8.812352803033718e-07
. O 0 4.407272911066684e-07

In O 0 1.5674045528157876e-07
addition O 0 7.537847679373044e-09
, O 0 1.6596777285826647e-09
in O 0 7.525303158395502e-10
this O 0 1.1107558206546742e-09
family O 0 3.2053868892489845e-08
, O 0 3.212472954317036e-09
there O 0 1.971246943455185e-09
appears O 0 1.771911399828241e-07
to O 0 3.776621682050063e-09
be O 0 8.870699730323395e-09
no O 0 1.313977815442513e-09
relationship O 0 2.637190910093068e-09
between O 0 1.7208382496747276e-09
the O 0 1.994266307647763e-09
I1307K O 0 3.1877246442491014e-07
polymorphism O 0 5.281066819406988e-07
and O 0 7.585789774111618e-09
the O 0 1.0399695549168086e-09
presence O 0 2.4597657244385118e-08
or O 0 1.0862059696137294e-08
absence O 0 1.3320029523811172e-08
of O 0 3.5649083685029836e-09
cancer B-Disease 0 9.17926229249133e-07
. O 0 2.2804460542147353e-08
. O 0 1.6755093668052723e-07

Identification O 0 1.5752433455418213e-06
of O 0 1.9035677922829564e-08
a O 0 2.4723338043486365e-08
novel O 0 1.9417089447415492e-07
mutation O 0 1.8327574480281328e-07
of O 0 7.628297993278466e-10
the O 0 4.481052862104207e-09
CPO O 0 1.0546647899900563e-05
gene O 0 6.903848515094069e-08
in O 0 4.8361621374226615e-09
a O 0 8.970407350261667e-08
Japanese O 0 2.0061168015672592e-06
hereditary B-Disease 0 0.0005277922609820962
coproporphyria I-Disease 0 7.429151446558535e-05
family O 0 1.6506407973793102e-06
. O 0 3.810966688888584e-07

Hereditary B-Disease 1 0.999964714050293
coproporphyria I-Disease 0 0.1460578590631485
( O 0 8.053290912357625e-06
HCP B-Disease 0 0.0012671720469370484
) O 0 1.697104039521946e-07
is O 0 1.6305229166846402e-08
an O 0 1.9986009291983464e-08
autosomal B-Disease 1 0.999957799911499
dominant I-Disease 1 0.9993584752082825
disease I-Disease 0 0.3778761923313141
characterized O 0 1.0420826583867893e-06
by O 0 4.6794634833702276e-09
a O 0 5.414924544311361e-07
deficiency B-Disease 0 0.00016223054262809455
of I-Disease 0 1.7368774196668824e-09
coproporphyrinogen I-Disease 0 2.3865082766860723e-05
oxidase I-Disease 0 2.288800942551461e-06
( O 0 4.7048647644487573e-08
CPO O 0 6.150450644781813e-05
) O 0 7.474439733812233e-09
caused O 0 6.817714837126232e-09
by O 0 1.5998628810631743e-10
a O 0 5.133585556649223e-09
mutation O 0 1.6757172716097557e-07
in O 0 2.7918858336306585e-09
the O 0 2.2400394428245818e-08
CPO O 0 6.611717981286347e-05
gene O 0 2.418626991129713e-06
. O 0 6.868673381177359e-07

Only O 0 7.523501039941038e-07
11 O 0 1.664523381350591e-07
mutations O 0 1.7073701030767552e-07
of O 0 4.919885054910367e-10
the O 0 1.0591428845074802e-09
gene O 0 1.2692187567608926e-07
have O 0 1.6571202365867066e-07
been O 0 2.3384409075788426e-07
reported O 0 2.0609508055713377e-07
in O 0 3.75160347232395e-08
HCP B-Disease 0 0.0020486891735345125
patients O 0 2.1335113160603214e-06
. O 0 2.9815785751452495e-07

We O 0 5.781296749773901e-06
report O 0 1.4864477293485834e-07
another O 0 1.2903051960222456e-08
mutation O 0 9.384138621726379e-08
in O 0 2.9341424845341635e-09
a O 0 4.819203880401801e-08
Japanese O 0 6.243581651688146e-07
family O 0 4.746987087855814e-07
. O 0 2.079027439094716e-07

Polymerase O 0 8.548847836209461e-05
chain O 0 4.801821705768816e-05
reaction O 0 6.84413350882096e-07
- O 0 8.188596893887734e-07
single O 0 9.990716876018269e-08
strand O 0 1.3326150565262651e-06
conformational O 0 1.7189407230944198e-07
polymorphism O 0 4.0162487380257517e-07
and O 0 3.295410611059424e-09
direct O 0 5.08931385923006e-09
sequence O 0 2.1574368247456732e-07
analyses O 0 3.398383512376313e-07
demonstrated O 0 2.5602556519288555e-08
a O 0 1.0373153891407583e-08
C O 0 1.318261553251432e-07
to O 0 3.208394661058378e-09
T O 0 3.185761272561649e-07
substitution O 0 2.757491790461586e-09
in O 0 6.386812190228852e-10
exon O 0 2.9834779979864834e-08
1 O 0 7.101183641111675e-09
of O 0 3.8002340163600934e-10
the O 0 2.1066342004161243e-09
CPO O 0 6.47183640012372e-07
gene O 0 1.799191196028005e-08
at O 0 4.169120160213424e-09
nucleotide O 0 1.586708897605149e-08
position O 0 6.490898840638692e-08
85 O 0 1.6069197528167933e-08
, O 0 3.5726068770003394e-09
which O 0 2.5666802017099144e-08
lies O 0 7.33260065999275e-08
in O 0 7.916350353021073e-10
the O 0 1.7764357762573013e-09
putative O 0 1.8417107128243515e-07
presequence O 0 1.946655743267911e-07
for O 0 8.270069074001185e-10
targeting O 0 4.244981965939587e-08
to O 0 1.899114288050896e-08
mitochondria O 0 8.667724387123599e-07
. O 0 1.5931142627323425e-07

This O 0 2.0191676242120593e-07
mutation O 0 5.106556955070118e-07
changes O 0 1.8492711362227965e-08
the O 0 1.4255533420381994e-09
codon O 0 1.0709236875072747e-07
for O 0 4.688601173974405e-10
glutamine O 0 4.818688736918375e-08
to O 0 1.599061438817273e-09
a O 0 9.698246650202691e-09
termination O 0 1.6090720578176843e-07
codon O 0 5.49621745449258e-07
at O 0 1.5211689685656893e-08
amino O 0 5.67107107940501e-08
acid O 0 1.1522417509013394e-07
position O 0 2.236253493492768e-07
29 O 0 7.513577884310507e-07
. O 0 2.401289975750842e-07

MaeI O 0 8.236581197706982e-05
restriction O 0 5.401205953603494e-07
analysis O 0 8.964370579178649e-08
showed O 0 1.4478631271686027e-07
two O 0 5.232587696468727e-10
other O 0 3.9212699753932156e-10
carriers O 0 3.4481897337457212e-09
in O 0 1.2510164015822056e-09
the O 0 1.2497124224353229e-08
family O 0 4.7418470217053255e-07
. O 0 1.6266439217815787e-07

The O 0 8.116926437651273e-07
C O 0 1.1129597623948939e-05
- O 0 0.00141819566488266
T O 0 0.002262891735881567
mutation O 0 3.119495772807568e-07
is O 0 1.9813681806368777e-09
located O 0 3.54005469382912e-09
within O 0 1.367572277644058e-09
a O 0 3.4582274821559622e-09
recently O 0 8.231364034827493e-08
proposed O 0 1.2430157347864679e-08
putative O 0 1.4317593866053357e-07
alternative O 0 2.561447409732409e-08
translation O 0 3.7609819258932475e-08
initiation O 0 3.088770128556462e-08
codon O 0 6.275381565501448e-07
( O 0 1.3821082056608702e-08
TIC O 0 7.087114113346615e-07
- O 0 3.998420368134248e-07
1 O 0 1.4689809368917395e-08
) O 0 1.4777227219653355e-09
, O 0 6.481119529944124e-10
supporting O 0 4.196700764680372e-09
that O 0 1.0148295537248941e-08
TIC O 0 1.4398233361134771e-06
- O 0 1.399918005517975e-06
1 O 0 2.0785014598345697e-08
is O 0 2.1447492670745305e-09
the O 0 1.5302096256775144e-09
real O 0 1.291027018623936e-07
TIC O 0 1.4695689287691494e-06
rather O 0 1.0167495290147599e-08
than O 0 5.763759691745918e-09
TIC O 0 6.167606443341356e-07
- O 0 5.869549681847275e-07
2 O 0 5.057075114223153e-08
. O 0 1.3856345404406056e-08
. O 0 7.491112796742527e-08

Human B-Disease 0 4.217038167553255e-06
complement I-Disease 0 1.4545724297931883e-05
factor I-Disease 0 0.00018188018293585628
H I-Disease 1 1.0
deficiency I-Disease 1 0.9994155168533325
associated O 0 1.0514180758036673e-05
with O 0 5.299273834680207e-05
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 9.9271283033886e-06

This O 0 9.182014792941118e-08
study O 0 7.647896538287569e-09
reports O 0 1.5469815650703822e-08
on O 0 2.128676790391637e-08
six O 0 2.2520172393569737e-08
cases O 0 9.59348955831274e-09
of O 0 4.646656037721186e-08
deficiency B-Disease 0 0.0021113893017172813
in I-Disease 0 1.3954923883119363e-09
the I-Disease 0 1.0449123788447423e-09
human I-Disease 0 2.3785624581051934e-09
complement I-Disease 0 1.0098863079122111e-08
regulatory I-Disease 0 5.060259411493462e-08
protein I-Disease 0 1.3344930493985885e-07
Factor I-Disease 0 3.0679737506034144e-07
H I-Disease 1 0.9999998807907104
( O 0 6.042986200327505e-08
FH O 0 1.2307021279411856e-05
) O 0 4.7265298341869766e-09
in O 0 8.833044851108696e-10
the O 0 7.013470915140374e-10
context O 0 9.899379094235883e-09
of O 0 3.9289385078689065e-09
an O 0 5.487329985953693e-07
acute B-Disease 1 0.9990434050559998
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 3.8966400097706355e-06

Five O 0 5.723142066926812e-07
of O 0 2.5509294676595573e-09
the O 0 1.2956387074325448e-09
cases O 0 2.7225550702780765e-09
were O 0 8.544907004193192e-09
observed O 0 1.722970743855967e-08
in O 0 2.0358508212581228e-09
children O 0 5.9058393730992975e-08
presenting O 0 4.4904928131472843e-07
with O 0 2.7320995286572725e-05
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 6.286096322583035e-05
HUS B-Disease 1 0.9999357461929321
) O 0 3.04957757180091e-06
. O 0 1.497177663623006e-06

Two O 0 2.578233591066237e-07
of O 0 4.32442170961167e-09
the O 0 4.892665383948724e-09
children O 0 1.1747044226240178e-07
exhibited O 0 9.68538188317325e-07
a O 0 1.5452262687176699e-06
homozygous O 1 0.9986973404884338
deficiency O 0 0.3324691653251648
characterized O 0 5.927212214373867e-07
by O 0 3.6113292356532156e-09
the O 0 8.00114996479806e-09
absence O 0 1.0783864468066895e-08
of O 0 2.524702669148837e-10
the O 0 5.717277762329331e-10
150 O 0 2.081273375864612e-09
- O 0 6.823311338166604e-08
kD O 0 2.0320699434250855e-07
form O 0 1.7414020225814397e-09
of O 0 6.22253304438658e-10
Factor O 0 6.506355276769682e-08
H O 1 1.0
and O 0 5.16002458539333e-08
the O 0 1.680295569350676e-09
presence O 0 1.0840245145971039e-08
, O 0 1.196301502304209e-09
upon O 0 3.2454694487427105e-10
immunoblotting O 0 2.6668141117625055e-07
, O 0 1.2346362820991885e-09
of O 0 8.050371480550211e-11
the O 0 1.0151736118402255e-09
42 O 0 2.1163131691537274e-08
- O 0 1.9724782873709046e-07
kD O 0 8.390734365093522e-07
Factor O 0 1.1879281913707018e-07
H O 1 0.9999700784683228
- O 0 7.51507570839749e-07
like O 0 2.235092999569588e-08
protein O 0 4.328335023728869e-08
1 O 0 8.175891963446702e-09
( O 0 5.640754086044808e-09
FHL O 0 8.613142199465074e-07
- O 0 1.603743612577091e-06
1 O 0 2.3949978000814554e-08
) O 0 1.4398779946134255e-09
and O 0 1.9307870857687703e-09
other O 0 2.8399982365812093e-09
FH O 0 1.0063196896226145e-05
- O 0 1.7641311842453433e-06
related O 0 3.9117423966672504e-08
protein O 0 1.869014027988669e-07
( O 0 1.6195818020037223e-08
FHR O 0 3.480780151221552e-06
) O 0 3.643961576926813e-08
bands O 0 5.481053904077271e-07
. O 0 2.154850022861865e-07

Southern O 0 2.659477831912227e-05
blot O 0 0.00015679447096772492
and O 0 1.5264855335317407e-07
PCR O 0 6.368219374053297e-07
analysis O 0 2.6643767192524592e-09
of O 0 1.849251723973211e-10
DNA O 0 8.311599408727943e-09
of O 0 3.419370897539409e-10
one O 0 9.675669154773914e-09
patient O 0 2.43898853113933e-07
with O 0 1.931274624666912e-07
homozygous O 1 0.7654113173484802
deficiency O 0 0.0015384912258014083
ruled O 0 1.5555242782738787e-07
out O 0 1.335849049155513e-07
the O 0 6.424737408750048e-10
presence O 0 1.7024224252537579e-09
of O 0 1.2979309294003372e-10
a O 0 3.9625469572257543e-10
large O 0 6.335115765310206e-10
deletion O 0 8.245585547683731e-08
of O 0 6.162920174190845e-10
the O 0 2.6447115608618788e-09
FH O 0 4.978301603841828e-06
gene O 0 6.270062868907189e-08
as O 0 1.6090851318040222e-08
the O 0 8.837263365535364e-09
underlying O 0 2.3749018964736024e-06
defect O 0 1.587028918947908e-06
for O 0 4.57798332575976e-09
the O 0 6.264528451538354e-07
deficiency O 0 0.0007039516931399703
. O 0 2.192609400708534e-07

The O 0 1.3313150759586279e-07
other O 0 3.850844532138353e-09
four O 0 3.9131133888758995e-09
children O 0 1.7031052124139023e-08
presented O 0 1.9203646672849572e-08
with O 0 2.0386697485719196e-07
heterozygous O 0 0.27248987555503845
deficiency O 0 0.0013339733704924583
and O 0 1.9982921983796587e-08
exhibited O 0 1.0797760552350155e-07
a O 0 8.708521015421411e-09
normal O 0 6.923469442199348e-08
immunoblotting O 0 2.3234658783621853e-06
pattern O 0 1.4486408872471657e-06
of O 0 5.209782605319901e-10
proteins O 0 3.4044698171697974e-09
of O 0 8.312404653487704e-10
the O 0 4.4307082447403445e-08
FH O 0 0.00038173311622813344
family O 0 1.4860835335639422e-06
. O 0 3.4216617450510967e-07

Factor B-Disease 0 0.3365192413330078
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999183416366577
is O 0 1.144028658472962e-07
the O 0 1.6812261804943773e-08
only O 0 1.3687208593182731e-06
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 4.720212700703996e-07
with O 0 2.588677432413533e-07
HUS B-Disease 1 0.9998977184295654
. O 0 1.92934317055915e-06

These O 0 3.2727129450904613e-07
observations O 0 2.703978623230796e-07
suggest O 0 9.42818303428794e-08
a O 0 3.2319553699977632e-09
role O 0 9.201330364305704e-09
for O 0 7.010612534941174e-09
FH O 0 5.069027974968776e-05
and O 0 1.491167296308049e-07
/ O 0 5.48227444596705e-06
or O 0 7.80534890054696e-08
FH O 0 8.428544788330328e-06
receptors O 0 9.680767476538676e-08
in O 0 2.5112467660903803e-09
the O 0 1.1490492113352957e-08
pathogenesis O 0 3.20305139211996e-06
of O 0 4.0503504550315483e-08
idiopathic O 0 0.018963275477290154
HUS B-Disease 1 0.9999862909317017
. O 0 8.650168297208438e-07
. O 0 8.312846375702065e-07

Further O 0 4.262921606823511e-07
evidence O 0 9.059955452528357e-09
for O 0 4.5528675274297825e-10
a O 0 2.6601469915732423e-09
major O 0 7.3489085927747055e-09
ancient O 0 2.610966873817233e-07
mutation O 0 0.00034983339719474316
underlying O 0 0.0016627388540655375
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.9972772236087621e-07
linkage O 0 4.346249988884665e-05
disequilibrium O 0 5.423912080004811e-05
studies O 0 4.794778263317312e-08
in O 0 6.058876511616518e-09
the O 0 1.0659285898384496e-08
Japanese O 0 3.161062807066628e-07
population O 0 2.5643853263090932e-08
. O 0 5.5266564658040807e-08

The O 0 0.00023907724244054407
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.03761645033955574
DM B-Disease 1 1.0
) O 0 2.13913040170155e-06
mutation O 0 3.6874612305837218e-06
is O 0 1.5187540114425246e-08
an O 0 4.950045706664241e-09
unstable O 0 2.312811375304591e-05
( O 0 5.5180823466116635e-08
CTG O 0 1.99634723685449e-06
) O 0 7.922502653912034e-09
n O 0 1.3340780924409046e-07
repeat O 0 5.883970288778073e-07
, O 0 4.2144119305476124e-09
present O 0 1.323571474642904e-09
at O 0 9.717499027672716e-10
a O 0 1.4543493076502045e-09
copy O 0 1.2753071132465266e-07
number O 0 3.2064184640745452e-09
of O 0 3.018965633039272e-10
5 O 0 6.2803420242119046e-09
- O 0 5.999540348966548e-07
37 O 0 1.90299104474434e-07
repeats O 0 2.0417711255049653e-07
on O 0 2.892248751606985e-08
normal O 0 1.4955245930536876e-08
chromosomes O 0 1.7023137388605392e-07
but O 0 2.9151816516304052e-09
amplified O 0 4.100705908172131e-08
to O 0 2.1065620359195236e-09
50 O 0 4.8451367362645215e-09
- O 0 5.3160082558179056e-08
3000 O 0 5.420485038598599e-08
copies O 0 8.96120795346178e-08
on O 0 6.069975825084839e-06
DM B-Disease 1 1.0
chromosomes O 0 0.00016539153875783086
. O 0 9.396708833264711e-07

Previous O 0 4.015278591396054e-06
findings O 0 3.257597995798278e-07
in O 0 1.6528014512573463e-08
Caucasian O 0 6.113722520240117e-06
populations O 0 9.020266844572689e-08
of O 0 2.0004724543554175e-09
a O 0 1.1213207926630275e-06
DM B-Disease 1 1.0
founder O 0 1.9796141714323312e-05
chromosome O 0 2.7681129722623155e-05
raise O 0 6.294639831594395e-08
a O 0 4.381810025932964e-09
question O 0 5.488605125947288e-09
about O 0 8.69220473376231e-10
the O 0 1.9753709779024575e-10
molecular O 0 5.62916824264903e-09
events O 0 1.2565314122525706e-08
involved O 0 4.636304673510949e-09
in O 0 2.1434405361731024e-09
the O 0 7.627996900794187e-09
expansion O 0 2.1168747821320721e-07
mutation O 0 1.9696710751304636e-06
. O 0 2.770024138953886e-07

To O 0 1.4504777823276527e-07
investigate O 0 7.390279677110811e-08
whether O 0 1.0786785686889289e-08
a O 0 7.519367350994344e-09
founder O 0 3.944062711980223e-07
chromosome O 0 2.7232376851316076e-06
for O 0 4.025702438070766e-09
the O 0 1.3296515533056663e-07
DM B-Disease 1 1.0
mutation O 0 2.4537080207664985e-06
exists O 0 5.7087263805044586e-09
in O 0 3.220041178142452e-10
the O 0 1.1312989434131282e-09
Japanese O 0 3.082978494717281e-08
population O 0 9.088612640262284e-10
, O 0 9.134667466881297e-10
we O 0 1.436279206679103e-09
genotyped O 0 5.988690787717132e-08
families O 0 4.804395214996759e-10
using O 0 1.2072880473112946e-09
polymorphic O 0 2.0039109926983656e-07
markers O 0 2.9775515031360555e-06
near O 0 9.040830377671227e-07
the O 0 1.0005949846458861e-08
( O 0 1.7450002331997894e-08
CTG O 0 2.168023002013797e-06
) O 0 1.2761899981228453e-08
n O 0 7.8100373457346e-07
repeat O 0 2.134203214154695e-06
region O 0 5.140662437952415e-07
and O 0 9.084791230407063e-08
constructed O 0 7.378198006335879e-06
haplotypes O 0 5.484306893777102e-05
. O 0 9.18803834792925e-07

Six O 0 2.010366870308644e-06
different O 0 8.931449002602676e-08
haplotypes O 0 6.595953891519457e-06
were O 0 9.677758328052732e-08
found O 0 6.04657159897215e-08
and O 0 6.492564352811314e-07
DM B-Disease 1 1.0
alleles O 0 7.325691058213124e-06
were O 0 1.684910216681601e-06
always O 0 3.686831462346163e-07
haplotype O 0 5.632185093418229e-06
A O 0 1.065196784111322e-06
. O 0 5.198779717829893e-07

To O 0 6.169865400806884e-07
find O 0 1.091954189291755e-07
an O 0 1.2061396326146223e-09
origin O 0 3.6334315556274532e-09
of O 0 9.252609789456301e-10
the O 0 5.270965441894759e-09
( O 0 9.00609720133616e-09
CTG O 0 5.49758567558456e-07
) O 0 3.072387011471278e-09
n O 0 1.47196999478183e-07
repeat O 0 1.511306493284792e-07
mutation O 0 8.485822888815164e-08
and O 0 2.790554898268738e-09
to O 0 7.395447587654758e-10
investigate O 0 3.237464740735163e-09
the O 0 7.220178899203233e-10
mechanism O 0 2.802449605709967e-09
of O 0 1.2376961955329335e-10
the O 0 3.6575223405499457e-10
expansion O 0 6.800286556085666e-09
mutation O 0 1.2833248241861384e-08
in O 0 5.46156508907103e-10
the O 0 7.475874919116166e-10
Japanese O 0 1.2572890284445748e-08
population O 0 3.446163077125419e-10
we O 0 5.46294065539854e-10
have O 0 2.365495022083053e-10
studied O 0 1.703120755536247e-09
90 O 0 4.276242027145827e-09
Japanese O 0 1.1758465490174785e-07
DM B-Disease 1 0.9999997615814209
families O 0 2.2308679348270744e-08
comprising O 0 2.788107522633254e-09
190 O 0 1.2385806158476953e-08
affected O 0 7.248552424954369e-09
and O 0 4.043910539763829e-09
130 O 0 3.3159164303242505e-08
unaffected O 0 3.5509177109815937e-07
members O 0 4.171937817432081e-08
. O 0 7.661989798180002e-08

The O 0 3.493199756121612e-07
results O 0 9.743174445020486e-08
suggest O 0 3.1800421851357896e-08
that O 0 7.529208367884621e-10
a O 0 2.5993871499707666e-09
few O 0 4.1019951879661676e-09
common O 0 1.1982721481729186e-09
ancestral O 0 8.628748560113308e-08
mutations O 0 3.740443332844734e-07
in O 0 2.4014692456830744e-09
both O 0 1.915996250545504e-08
Caucasian O 0 1.5885638276813552e-05
and O 0 1.1226717333556735e-07
Japanese O 0 1.747631728221677e-08
populations O 0 4.06209288428272e-09
have O 0 1.2395938719933497e-09
originated O 0 1.8785639710472424e-09
by O 0 4.131301897802864e-11
expansion O 0 1.0228722313598837e-09
of O 0 1.3115208918890175e-10
an O 0 4.312813162155038e-10
ancestral O 0 5.4557716566705494e-08
n O 0 6.394301976797578e-07
= O 0 3.0390427241400175e-07
5 O 0 1.6305820693673923e-08
repeat O 0 9.537482270616238e-08
to O 0 8.29022539505786e-09
n O 0 5.214873226577765e-07
= O 0 5.295303822094866e-07
19 O 0 1.452709454952128e-07
- O 0 9.95007439996698e-07
37 O 0 1.870387080771252e-07
copies O 0 2.117212005714464e-07
. O 0 3.5899182648790884e-07

These O 0 1.2660778736517386e-07
data O 0 4.207145565260362e-08
support O 0 6.479170533424394e-09
multistep O 0 2.845167159648554e-07
models O 0 1.4628163569341268e-07
of O 0 2.409787702717381e-09
triplet O 0 1.4487952284980565e-05
repeat O 0 4.4960549416828144e-07
expansion O 0 4.388185814718781e-08
that O 0 7.634546328461056e-09
have O 0 7.824603187600587e-09
been O 0 1.6954684323167157e-09
proposed O 0 9.373433140780207e-10
for O 0 1.4781963431076406e-09
both O 0 2.9787312882945116e-07
DM B-Disease 1 1.0
and O 0 2.933217547251843e-05
Friedreichs B-Disease 0 0.0007547270506620407
ataxia I-Disease 0 0.3206879794597626
. O 0 1.2270487559362664e-07
. O 0 4.48867723434887e-07

The O 0 1.0641271330769086e-07
molecular O 0 3.7470593383659434e-07
basis O 0 5.534134288609494e-07
of O 0 1.306603280681884e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.1159483881992855e-08
the O 0 1.1252266673977829e-08
western O 0 1.0451066856376201e-07
Cape O 0 9.593792356099584e-07
, O 0 7.4055863663602395e-09
South O 0 2.6014172149757542e-08
Africa O 0 6.806582319995869e-08
. O 0 1.5153894139530166e-07

Deficiency B-Disease 1 0.9999897480010986
of I-Disease 0 1.143267311931595e-07
the I-Disease 0 1.5356633298324596e-08
sixth I-Disease 0 6.723088858962001e-07
component I-Disease 0 6.147909914488991e-08
of I-Disease 0 7.783754196744042e-10
human I-Disease 0 6.870492175181653e-09
complement I-Disease 0 1.5351426441156946e-07
( O 0 2.3110620972488505e-08
C6 O 0 1.019257069856394e-05
) O 0 1.5067769254528685e-08
has O 0 2.131029503971149e-07
been O 0 1.3063909420907294e-07
reported O 0 6.254749962408823e-08
in O 0 6.075954739337419e-10
a O 0 2.0203161366083577e-09
number O 0 1.781039649095817e-09
of O 0 4.4461281878405146e-10
families O 0 4.894457727999679e-09
from O 0 2.9272598234264535e-10
the O 0 9.360515695888694e-10
western O 0 3.3037760971410535e-08
Cape O 0 2.937148906312359e-07
, O 0 5.900105737310923e-09
South O 0 2.7447578432315822e-08
Africa O 0 9.3210964280388e-08
. O 0 1.2428775164607941e-07

Meningococcal B-Disease 1 0.9998964071273804
disease I-Disease 1 0.9551302194595337
is O 0 3.528381853357132e-07
endemic O 0 1.3175049673463946e-07
in O 0 7.3424075708317105e-09
the O 0 1.2605162247325552e-08
Cape O 0 1.4836904256299022e-06
and O 0 5.665557267775512e-08
almost O 0 3.6177063567066625e-09
all O 0 8.616964919383463e-10
pedigrees O 0 7.070075298543088e-07
of O 0 3.1511028453223844e-08
total O 0 0.00018729189469013363
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 5.4613103372957994e-08
C6Q0 O 0 7.500142601202242e-06
) O 0 1.3482774896544925e-08
have O 0 1.4928170699590737e-08
been O 0 2.8959636466652228e-08
ascertained O 0 1.2847458208398166e-07
because O 0 2.6346269610399986e-09
of O 0 9.764696606850976e-09
recurrent O 0 0.2780678868293762
disease O 0 0.0007824419881217182
. O 0 4.5652632252313197e-07

We O 0 6.345168003463186e-06
have O 0 2.6563252930600356e-08
sequenced O 0 1.4562104411197652e-07
the O 0 2.8925561945669642e-09
expressed O 0 3.5468472603383816e-09
exons O 0 3.863103188450623e-07
of O 0 1.5995097468746167e-09
the O 0 4.7269090863721885e-09
C6 O 0 2.19690332414757e-06
gene O 0 3.866368203375714e-08
from O 0 1.684695272174963e-09
selected O 0 4.3816013040043345e-09
cases O 0 5.788294288322504e-09
and O 0 6.340670211102406e-08
have O 0 2.269597842996518e-08
found O 0 5.343146813885369e-09
three O 0 7.020434011906218e-09
molecular O 0 1.0873211522266502e-06
defects O 0 0.049858108162879944
leading O 0 5.446019457622242e-08
to O 0 2.2249613707003846e-08
total O 0 1.6439986438854248e-07
deficiency O 0 2.7231670173932798e-05
879delG O 0 1.3389476407610346e-06
, O 0 2.191870684953301e-08
which O 0 2.3110709790330475e-08
is O 0 7.259783330049174e-10
the O 0 7.432355286773884e-10
common O 0 1.0872859057542428e-08
defect O 0 2.8224471293469833e-07
in O 0 2.9098432552387976e-09
the O 0 1.7850773303962342e-08
Cape O 0 3.649693667284737e-07
and O 0 6.176774647315142e-09
hitherto O 0 6.877377956016062e-08
unreported O 0 2.1277754669313254e-08
, O 0 2.4397239783979785e-09
and O 0 3.2420188755821755e-09
1195delC O 0 1.5484080506666942e-07
and O 0 6.010716369075908e-09
1936delG O 0 1.4121009428436082e-07
, O 0 2.577053903607407e-09
which O 0 1.351717493491833e-08
have O 0 7.117537670353613e-09
been O 0 2.3923178105178522e-08
previously O 0 8.870923551285159e-08
reported O 0 7.950980318582879e-08
in O 0 1.8821288971793138e-09
African O 0 1.9619678326421308e-08
- O 0 1.0189150998485275e-05
Americans O 0 3.142777984521672e-07
. O 0 1.1542864086777627e-07

We O 0 1.4599537280446384e-05
also O 0 2.5915824153344147e-07
show O 0 2.9980617455294123e-07
that O 0 4.6318032742576065e-10
the O 0 8.310866439487086e-10
879delG O 0 2.378941417191527e-06
and O 0 2.54994375836759e-07
1195delC O 0 0.00013346606283448637
defects O 0 0.05492503568530083
are O 0 1.4925516378383463e-09
associated O 0 5.322478457969737e-09
with O 0 1.3308627089259062e-08
characteristic O 0 6.688610301353037e-05
C6 O 0 0.14073346555233002
/ O 0 8.334942685905844e-05
C7 O 0 8.717643504496664e-05
region O 0 2.7281583925287123e-07
DNA O 0 4.721901518678351e-07
marker O 0 3.4323886666243197e-06
haplotypes O 0 4.142499619774753e-06
, O 0 5.685103943164904e-09
although O 0 1.568252305794715e-09
small O 0 2.423089284775415e-09
variations O 0 5.148552304490295e-07
were O 0 1.4079148513701512e-07
observed O 0 6.748256282662624e-07
. O 0 1.3977604851334036e-07

The O 0 1.34150764097285e-06
1936delG O 0 3.409084820304997e-05
defect O 0 7.437734893755987e-05
was O 0 8.944555247580865e-07
observed O 0 5.4423953343984977e-08
only O 0 3.4409233240495496e-09
once O 0 2.4026983069802554e-08
in O 0 1.6989775142306485e-09
the O 0 6.870479296594567e-09
Cape O 0 4.01936745220155e-07
, O 0 2.690225819890202e-09
but O 0 8.024069741985329e-10
its O 0 1.3316339142477318e-09
associated O 0 1.1610648442683669e-08
haplotype O 0 2.195948127337033e-06
could O 0 6.464076136580843e-07
be O 0 1.5669794350969823e-08
deduced O 0 9.075271236724802e-07
. O 0 1.6271204117401794e-07

The O 0 1.6015519577194937e-07
data O 0 3.0683011686960526e-08
from O 0 1.0813188122682504e-09
the O 0 5.919399970188977e-10
haplotypes O 0 1.4355249504660605e-06
indicate O 0 1.6924846590882225e-07
that O 0 1.0105372094670884e-09
these O 0 2.9286056912880554e-10
three O 0 2.2736088567398838e-09
molecular O 0 1.4957890925870743e-06
defects O 0 0.10129375755786896
account O 0 1.4752394861261564e-08
for O 0 9.702922909582412e-10
the O 0 6.462769874815422e-08
defects O 0 0.0936121866106987
in O 0 1.2649664649089232e-09
all O 0 2.621672601232916e-10
the O 0 9.529528277596455e-10
38 O 0 1.4517975266414851e-08
unrelated O 0 1.7388305906251844e-08
C6Q0 O 0 4.397911652631592e-06
individuals O 0 5.482850173876841e-09
we O 0 7.618254471708497e-09
have O 0 1.0477264611452597e-09
studied O 0 1.6802442770469384e-09
from O 0 6.590582524168553e-10
the O 0 4.092734151583954e-09
Cape O 0 5.590362661678228e-07
. O 0 1.4827720917764964e-07

We O 0 1.978930777113419e-05
have O 0 5.035332506508894e-08
also O 0 1.7932709539536518e-08
observed O 0 2.3620845723826278e-08
the O 0 3.727088415672597e-09
879delG O 0 3.185365130775608e-06
defect O 0 1.1636308272500173e-06
in O 0 1.3596922698866365e-08
two O 0 4.618716218374175e-07
Dutch O 1 0.9985890984535217
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 0.00019437377341091633
, O 0 1.6152720050399694e-08
but O 0 1.7284765840841487e-09
the O 0 9.212424156856969e-10
879delG O 0 6.569803758793569e-07
defect O 0 2.531099312363949e-07
in O 0 1.2393055470738545e-09
the O 0 5.032459338139006e-09
Cape O 0 2.435462533867394e-07
probably O 0 2.671727088454645e-07
did O 0 3.683801352849514e-08
not O 0 8.843125676172292e-10
come O 0 9.761860209067663e-10
from O 0 1.3146991828527632e-10
The O 0 8.457182731902435e-10
Netherlands O 0 9.0016193610154e-08
. O 0 1.4166094963741216e-08
. O 0 7.169451521349401e-08

Complement B-Disease 1 0.9999343156814575
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.2096326145183411e-06
seven O 0 5.74399727781838e-08
further O 0 2.437980839431475e-08
molecular O 0 6.99057818565052e-06
defects O 1 0.9995710253715515
and O 0 8.23106631742121e-08
their O 0 3.033676421182463e-08
associated O 0 3.44726174716925e-07
marker O 0 0.00012259962386451662
haplotypes O 0 0.0003830173227470368
. O 0 1.5708612863818416e-06

Seven O 0 1.3647439800479333e-06
further O 0 4.5315768915088483e-08
molecular O 0 1.7605903224193753e-07
bases O 0 2.4599310108897043e-06
of O 0 6.8901790655218065e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 5.66103111054872e-08
described O 0 1.0840110462595476e-06
. O 0 2.984272384765063e-07

All O 0 1.1016126677532156e-07
these O 0 2.496204354329734e-09
new O 0 3.910263224327082e-09
molecular O 0 3.7297928656698787e-07
defects O 0 0.00014266509970184416
involve O 0 3.6567426864309027e-09
single O 0 3.805300607950812e-08
- O 0 7.371288006652321e-07
nucleotide O 0 7.496286258401597e-08
events O 0 8.567966780503866e-09
, O 0 2.7215427689242233e-09
deletions O 0 3.470315448339534e-07
and O 0 1.4143084570150677e-07
substitutions O 0 1.4419542537780217e-07
, O 0 1.9360382186306424e-09
some O 0 1.4803058778767308e-10
of O 0 3.8147876524341484e-10
which O 0 9.996221628227886e-09
alter O 0 3.7835820876352955e-07
splice O 0 9.844681699178182e-06
sites O 0 5.249247010397085e-07
, O 0 1.8567675397207495e-08
and O 0 1.5721404622581758e-08
others O 0 2.9540730750454713e-08
codons O 0 1.0659325653250562e-06
. O 0 9.294644343071923e-08

They O 0 7.39548909223231e-07
are O 0 2.937446286210843e-09
distributed O 0 3.420722816116495e-09
along O 0 1.5676070219683425e-08
the O 0 1.0695862862064587e-08
C7 O 0 8.221310963563155e-06
gene O 0 2.604242581583094e-07
, O 0 2.1820765638835837e-08
but O 0 3.753727551014663e-09
predominantly O 0 2.523842024260148e-09
towards O 0 2.6005573250387215e-09
the O 0 1.949095107534049e-09
3 O 0 5.6338866016858447e-08
end O 0 5.684276516149112e-07
. O 0 1.7242601302314142e-07

All O 0 5.18737920174317e-07
were O 0 3.0540252993205286e-08
found O 0 3.0173554765866584e-09
in O 0 2.486282735247869e-09
compound O 0 4.4165716417410295e-07
heterozygous O 0 2.305151383552584e-06
individuals O 0 2.690930323012708e-08
. O 0 1.0392565741312865e-07

The O 0 6.24799395154696e-06
C6 O 0 0.00916706770658493
/ O 0 0.0010900747729465365
C7 O 0 0.00028279173420742154
marker O 0 5.075678927823901e-05
haplotypes O 0 0.0001257457333849743
associated O 0 6.224877324711997e-07
with O 0 6.922466155856455e-08
most O 0 5.136316190146317e-07
C7 B-Disease 1 0.9984487295150757
defects I-Disease 1 0.9986806511878967
are O 0 3.6241722511931584e-08
tabulated O 0 5.3591302275890484e-06
. O 0 7.049755623711462e-08
. O 0 2.4574006829425343e-07

A O 0 3.2385371468990343e-06
genome O 0 2.7230817067902535e-06
- O 0 1.0891487818298629e-06
wide O 0 5.697829408291e-08
search O 0 2.3755621469945254e-08
for O 0 1.5519665552687911e-09
chromosomal O 0 0.00011005860869772732
loci O 0 3.8005896385584492e-06
linked O 0 1.1166828699060716e-05
to O 0 5.0732090528526896e-08
mental O 0 3.9820257370593026e-05
health O 0 6.980167199799325e-08
wellness O 0 5.162604566066875e-07
in O 0 8.791700700783167e-09
relatives O 0 2.540190990885094e-08
at O 0 5.045203366194073e-09
high O 0 4.82249546962521e-08
risk O 0 1.2207924271478987e-07
for O 0 3.118855573802648e-08
bipolar B-Disease 1 0.9999966621398926
affective I-Disease 1 0.9999384880065918
disorder I-Disease 1 0.7742834687232971
among O 0 4.193660085860529e-09
the O 0 1.7672502350407626e-09
Old O 0 2.5073052256630035e-06
Order O 0 7.859787842789956e-08
Amish O 0 1.6399086234741844e-05
. O 0 3.4595791476021986e-07

Bipolar B-Disease 1 0.9999997615814209
affective I-Disease 1 0.9999977350234985
disorder I-Disease 1 0.9999990463256836
( O 0 0.0001015963134705089
BPAD B-Disease 1 1.0
; O 0 0.00025714124785736203
manic B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999998807907104
depressive I-Disease 1 1.0
illness I-Disease 1 0.9624444246292114
) O 0 6.136463781558632e-08
is O 0 8.470133927573897e-09
characterized O 0 5.2223732893708075e-08
by O 0 8.072209567444588e-10
episodes O 0 1.4264891206039465e-06
of O 0 1.6036160843668767e-08
mania B-Disease 0 0.013577965088188648
and O 0 1.857692524254162e-07
/ O 0 1.931272890942637e-05
or O 0 3.9774306515028e-07
hypomania B-Disease 0 0.0016144303372129798
interspersed O 0 1.5901718143140897e-05
with O 0 1.5538127229319798e-08
periods O 0 2.488827703928109e-07
of O 0 1.160723783755202e-08
depression B-Disease 0 1.6877496818779036e-05
. O 0 1.518210126505437e-07

Compelling O 0 5.451804554468254e-06
evidence O 0 1.051976497024043e-07
supports O 0 5.88495794318078e-08
a O 0 8.485511848732585e-09
significant O 0 4.7012744808228035e-09
genetic O 0 9.64571142958448e-08
component O 0 7.566169557549074e-08
in O 0 2.956061173620128e-09
the O 0 5.716070283767749e-09
susceptibility O 0 2.626596142363269e-06
to O 0 9.837231829123994e-08
develop O 0 2.4828873392834794e-06
BPAD B-Disease 1 1.0
. O 0 2.147707618860295e-06

To O 0 4.5742064003206906e-07
date O 0 2.3488900069423835e-07
, O 0 6.3001865946432645e-09
however O 0 1.3481894489686397e-09
, O 0 4.597704716946538e-10
linkage O 0 1.6299190974677913e-07
studies O 0 2.88871881970465e-09
have O 0 1.595467225001812e-08
attempted O 0 1.660423265548161e-07
only O 0 1.5441213863098824e-09
to O 0 6.127978124936817e-10
identify O 0 3.354389122023349e-08
chromosomal O 0 1.1676488611556124e-05
loci O 0 7.364612315541308e-07
that O 0 2.2801023291663114e-08
cause O 0 2.071954519067276e-08
or O 0 4.484344451327615e-09
increase O 0 5.080372122989729e-09
the O 0 3.5721914315445247e-09
risk O 0 4.826010524539015e-08
of O 0 4.846070211783626e-09
developing O 0 1.0220848025710438e-06
BPAD B-Disease 1 1.0
. O 0 1.3158917226974154e-06

To O 0 1.8593728157156875e-07
determine O 0 2.0909631359700143e-08
whether O 0 4.411967680084672e-09
there O 0 2.9988465044539225e-09
could O 0 9.67961888420632e-09
be O 0 7.833051429706472e-10
protective O 0 3.757977395935086e-08
alleles O 0 1.2480759536970254e-08
that O 0 3.156677585991474e-09
prevent O 0 2.1228057534017353e-08
or O 0 1.1060081739344696e-08
reduce O 0 2.6465396985031475e-08
the O 0 2.8813780250658283e-09
risk O 0 4.3690251416705905e-09
of O 0 3.164941364541818e-10
developing O 0 2.6498934602159352e-08
BPAD B-Disease 1 1.0
, O 0 2.4796902309276447e-09
similar O 0 6.278063624520769e-10
to O 0 2.5145925341973907e-09
what O 0 2.319712422149678e-09
is O 0 7.039335780945066e-10
observed O 0 5.530576441259427e-09
in O 0 1.5980277101590445e-09
other O 0 1.2290678341742023e-07
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.586442621714923e-08
we O 0 5.4025530715762216e-09
used O 0 4.275673504139377e-08
mental O 0 5.013806912756991e-06
health O 0 9.395349565011202e-08
wellness O 0 2.318136239409796e-06
( O 0 8.474610346809186e-09
absence O 0 6.54200427163687e-09
of O 0 9.66839497351657e-10
any O 0 4.970654643443595e-08
psychiatric B-Disease 0 0.016281981021165848
disorder I-Disease 0 0.0026297385338693857
) O 0 1.5290163579706473e-09
as O 0 1.3815197874578189e-09
the O 0 2.8659052908608373e-09
phenotype O 0 3.884703801304568e-06
in O 0 9.361055930412476e-09
our O 0 2.8538353902263225e-08
genome O 0 1.147050383565329e-07
- O 0 2.0582101569743827e-06
wide O 0 2.1908849134888442e-07
linkage O 0 1.2916738114654436e-06
scan O 0 3.792479219555389e-06
of O 0 6.412249620169064e-10
several O 0 1.1160117274755521e-09
large O 0 4.563058819684329e-09
multigeneration O 0 7.058904998302751e-07
Old O 0 2.4938694309639686e-07
Order O 0 9.14255071648995e-09
Amish O 0 1.6696010334271705e-06
pedigrees O 0 4.087348770553945e-06
exhibiting O 0 1.0981197107184926e-07
an O 0 1.8368400134249896e-09
extremely O 0 2.737203352864981e-08
high O 0 8.21795111960455e-08
incidence O 0 2.08910096262116e-05
of O 0 1.2321649478508334e-07
BPAD B-Disease 1 1.0
. O 0 1.5871438563408446e-06

We O 0 1.6972420780803077e-05
have O 0 2.3679080030092337e-08
found O 0 5.598437713416615e-09
strong O 0 3.0472333545361607e-09
evidence O 0 4.435802281044232e-10
for O 0 1.623043505150079e-10
a O 0 7.916898248083726e-09
locus O 0 1.589773660271021e-06
on O 0 2.2328999875753652e-06
chromosome O 0 0.00013575721823144704
4p O 0 0.00010432687122374773
at O 0 4.946528164850861e-08
D4S2949 O 0 5.662677153850382e-07
( O 0 9.361841968313911e-09
maximum O 0 2.562268264227896e-08
GENEHUNTER O 0 1.7393650750818779e-06
- O 0 9.98379846350872e-07
PLUS O 0 2.263217879772128e-07
nonparametric O 0 1.3702161822948256e-06
linkage O 0 3.3657377116469434e-06
score O 0 3.3736063187461696e-07
= O 0 1.9322197886140202e-07
4 O 0 2.2965876311786815e-08
. O 0 2.443729441026221e-09
05 O 0 1.0519283222265585e-07
, O 0 6.054370782493379e-09
P O 0 6.932851874807966e-07
= O 0 6.930775953151169e-08
5 O 0 4.632300321105731e-09
. O 0 4.1096048786215533e-10
22 O 0 3.5658060948406956e-09
x O 0 5.359143528949062e-07
10 O 0 1.822817807806132e-08
( O 0 1.3585923497316799e-09
- O 0 1.255378521136663e-07
4 O 0 2.262047793522015e-08
) O 0 1.920590797510613e-09
; O 0 2.0689090440839664e-09
SIBPAL O 0 2.118231918757374e-07
Pempirical O 0 6.812596353711342e-08
value O 0 2.048103686647096e-09
< O 0 9.825396496410121e-09
3 O 0 3.0418676466581474e-09
x O 0 5.07128447679861e-07
10 O 0 2.1325373467107056e-08
( O 0 2.2954567135968773e-09
- O 0 5.880783646716736e-07
5 O 0 4.1375852077862874e-08
) O 0 2.24737783938167e-09
) O 0 1.0038480047214193e-09
and O 0 5.019996862642984e-09
suggestive O 0 1.2909596307508764e-06
evidence O 0 9.815988022410238e-10
for O 0 2.2794739706899492e-10
a O 0 4.990268642757201e-09
locus O 0 1.4477708418780821e-06
on O 0 8.034098755160812e-06
chromosome O 0 0.0422048456966877
4q O 0 0.030842270702123642
at O 0 8.203809187534716e-08
D4S397 O 0 8.106978270916443e-07
( O 0 9.393698263693295e-09
maximum O 0 1.5146229159768154e-08
GENEHUNTER O 0 1.7548485402585356e-06
- O 0 9.181048881146125e-07
PLUS O 0 2.292820084903724e-07
nonparametric O 0 1.504624947301636e-06
linkage O 0 2.352986712139682e-06
score O 0 3.6812804182773107e-07
= O 0 1.8352410791067086e-07
3 O 0 1.6069748198788147e-08
. O 0 2.280097000095793e-09
29 O 0 3.644100843303022e-08
, O 0 1.963767815027495e-09
P O 0 7.689035328439786e-07
= O 0 5.490115384532146e-08
2 O 0 5.28609733763119e-09
. O 0 1.0062518596143377e-09
57 O 0 9.909202347557766e-09
x O 0 9.884389555736561e-07
10 O 0 3.453977726053381e-08
( O 0 2.97216828926139e-09
- O 0 4.384977501104004e-07
3 O 0 2.9598089312798948e-08
) O 0 2.8082551839503367e-09
; O 0 2.936505039130566e-09
SIBPAL O 0 7.69452242366242e-07
Pempirical O 0 1.792021890878459e-07
value O 0 1.3838722390246971e-09
< O 0 7.3761516894421675e-09
1 O 0 2.413969468761934e-09
x O 0 2.861445125290629e-07
10 O 0 1.5616981485777615e-08
( O 0 2.200700288668145e-09
- O 0 1.582016466272762e-06
3 O 0 1.1609390071498638e-07
) O 0 4.224552263565329e-09
) O 0 8.451587762969837e-10
that O 0 9.032620207349851e-10
are O 0 1.1303802338602509e-09
linked O 0 5.407163712334295e-07
to O 0 5.7151684274003856e-08
mental O 0 3.3443928259657696e-05
health O 0 5.31868579400907e-07
wellness O 0 8.01103851699736e-06
. O 0 3.6755201904270507e-07

These O 0 2.6432459776515316e-07
findings O 0 1.572276175920706e-07
are O 0 5.494679822248827e-09
consistent O 0 3.12257562029572e-08
with O 0 8.788428318418084e-10
the O 0 1.626077938965409e-09
hypothesis O 0 2.8439510302291637e-08
that O 0 5.638933764373633e-10
certain O 0 6.334837654442538e-10
alleles O 0 3.6577002759941024e-08
could O 0 9.528208977371833e-08
prevent O 0 2.039738689063597e-08
or O 0 3.932222103486538e-09
modify O 0 5.526024082769254e-08
the O 0 2.7366593435829145e-09
clinical O 0 6.733175439421757e-08
manifestations O 0 1.9565368347684853e-07
of O 0 1.8075425600727613e-08
BPAD B-Disease 1 1.0
and O 0 1.7472659408213076e-07
perhaps O 0 1.2588367681587442e-08
other O 0 4.917364293532955e-09
related O 0 9.067234714166261e-07
affective B-Disease 1 0.9974219799041748
disorders I-Disease 1 0.9354403614997864
. O 0 5.085935299575794e-07

Segregation O 0 0.004730624612420797
distortion O 0 0.06548133492469788
in O 0 5.042746488470584e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 6.79634977132082e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.986283004283905
DM B-Disease 1 1.0
) O 0 7.258374807861401e-06
is O 0 3.975852536086677e-08
an O 0 1.6933652702277868e-08
autosomal B-Disease 1 0.9430215954780579
dominant I-Disease 1 0.9173173904418945
disease I-Disease 0 0.3601948618888855
which O 0 1.6471765320602572e-06
, O 0 4.70155248066817e-09
in O 0 1.6251074930195841e-09
the O 0 1.1294194912636613e-08
typical O 0 5.674911562891793e-07
pedigree O 0 8.74559464136837e-06
, O 0 4.872791503629514e-09
shows O 0 3.833288531041035e-08
a O 0 5.517437617896803e-09
three O 0 8.604536638756599e-09
generation O 0 9.873247108771466e-08
anticipation O 0 1.8366085896559525e-07
cascade O 0 2.884926743718097e-06
. O 0 2.5483393528702436e-07

This O 0 2.465550892338797e-07
results O 0 4.718083914667659e-07
in O 0 3.0231933578761527e-07
infertility B-Disease 1 0.999957799911499
and O 1 0.9454772472381592
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.5389086911454797e-05
CDM B-Disease 0 6.185028178151697e-05
) O 0 3.4273078597379936e-08
with O 0 2.61763677400495e-09
the O 0 1.0624616741949922e-08
disappearance O 0 1.2176604968772153e-06
of O 0 1.2114526271034265e-07
DM B-Disease 1 1.0
in O 0 5.774148803538992e-07
that O 0 3.150965142140194e-07
pedigree O 0 3.94643320760224e-05
. O 0 3.941013346775435e-07

The O 0 2.3384876612908556e-07
concept O 0 8.881217183898116e-08
of O 0 5.980754558265744e-09
segregation O 0 1.0806296586451936e-06
distortion O 0 2.633161420817487e-05
, O 0 2.5425890282093633e-09
where O 0 3.0643925175155573e-09
there O 0 5.805151914728413e-10
is O 0 3.940245907330109e-10
preferential O 0 5.698304939016907e-09
transmission O 0 1.6002206848497735e-07
of O 0 1.8799393985968749e-10
the O 0 5.592127871878461e-10
larger O 0 7.569529891782167e-09
allele O 0 1.2670683702253882e-07
at O 0 1.5269595365907662e-08
the O 0 3.523169311847596e-08
DM B-Disease 1 1.0
locus O 0 7.705376447120216e-06
, O 0 1.0385215176711426e-07
has O 0 1.0427014984770722e-07
been O 0 2.22986820119786e-08
put O 0 1.409595569157318e-07
forward O 0 1.0870914479710336e-07
to O 0 1.601983612431468e-08
explain O 0 9.957728508425134e-08
partially O 0 3.611045542584179e-07
the O 0 3.987895791368601e-09
maintenance O 0 1.4136382731066988e-07
of O 0 1.1218150852698727e-08
DM B-Disease 1 1.0
in O 0 3.786967539554098e-08
the O 0 1.6540754543825642e-08
population O 0 1.9404607698447762e-08
. O 0 5.918581891251051e-08

In O 0 3.1059323646331904e-07
a O 0 1.9741851531307475e-07
survey O 0 5.796781579192611e-07
of O 0 1.7124310858207537e-08
DM B-Disease 1 1.0
in O 0 9.571889592052685e-08
Northern O 0 6.343669838315691e-07
Ireland O 0 1.7404887842076278e-07
, O 0 1.3641106910711187e-08
59 O 0 1.171456744941679e-07
pedigrees O 0 1.8466720348442323e-06
were O 0 1.0604173183992316e-07
ascertained O 0 2.2499903025163803e-06
. O 0 1.3443876412111422e-07

Sibships O 0 0.00045198507723398507
where O 0 3.9752995917297085e-07
the O 0 4.4465631177104115e-09
status O 0 3.3044302849560836e-09
of O 0 1.0820677687206626e-09
all O 0 8.853487942772631e-10
the O 0 1.0340752698567712e-09
members O 0 3.983729790490997e-09
had O 0 7.128299444048025e-07
been O 0 3.565780559711129e-08
identified O 0 7.665132528700269e-08
were O 0 1.122566395395097e-08
examined O 0 5.034091365985205e-09
to O 0 5.96073079783821e-10
determine O 0 1.6238123068390564e-09
the O 0 3.3304170532488797e-09
transmission O 0 2.6615802539708966e-07
of O 0 6.516545636436888e-10
the O 0 1.6781504186269558e-08
DM B-Disease 1 0.9999998807907104
expansion O 0 5.7229460281860156e-08
from O 0 6.880905178974217e-09
affected O 0 9.859958183255912e-09
parents O 0 4.4566923484978815e-09
to O 0 1.1505881802875706e-09
their O 0 4.023432254030013e-08
offspring O 0 1.968319111256278e-06
. O 0 1.3842681312326022e-07

Where O 0 1.3945585806141025e-06
the O 0 5.115105494724048e-08
transmitting O 0 7.776720849506091e-06
parent O 0 3.6681003621197306e-06
was O 0 2.198009951825952e-06
male O 0 5.621895979857072e-07
, O 0 2.2884458772409744e-08
58 O 0 5.201695785217453e-07
. O 0 1.4055912345156685e-07

3 O 0 3.867456598527497e-06
% O 0 7.04686513586239e-08
of O 0 3.9892250613959845e-10
the O 0 2.597632331458044e-09
offspring O 0 1.095909851756005e-06
were O 0 1.8756689712517982e-07
affected O 0 8.613961988146457e-09
, O 0 4.7848542905626346e-09
and O 0 1.261627513571284e-08
in O 0 8.752695790370524e-10
the O 0 1.1674373689984918e-09
case O 0 5.841519712390664e-09
of O 0 4.2569370251044347e-10
a O 0 4.64240379471903e-08
female O 0 1.6322738929375191e-06
transmitting O 0 4.03819694838603e-06
parent O 0 1.5991955137906189e-07
, O 0 9.07914010639388e-09
68 O 0 2.84572621467305e-07
. O 0 1.002046801090728e-07

7 O 0 2.536828105803579e-05
% O 0 1.204037857860385e-06
were O 0 1.3121457698161976e-07
affected O 0 2.75918807801645e-07
. O 0 2.807489067890856e-07

Studies O 0 1.1552790510904742e-06
on O 0 1.36424915808675e-07
meiotic O 0 8.986504326458089e-06
drive O 0 2.3357604277407518e-06
in O 0 1.1261879961921295e-07
DM B-Disease 1 1.0
have O 0 2.47973525802081e-06
shown O 0 5.373400924213456e-08
increased O 0 8.848664911909054e-09
transmission O 0 1.4027497741153638e-07
of O 0 1.322793402591671e-10
the O 0 3.635017009617769e-10
larger O 0 3.2950586703606177e-09
allele O 0 8.373901039249176e-08
at O 0 2.1570329522546672e-08
the O 0 5.899421751109912e-08
DM B-Disease 1 1.0
locus O 0 7.091825409588637e-06
in O 0 1.1019615442364739e-07
non O 0 6.172090252221096e-07
- O 1 0.5569940805435181
DM O 1 1.0
heterozygotes O 0 1.9846933355438523e-05
for O 0 3.213068922036655e-08
CTGn O 0 3.27131238009315e-05
. O 0 4.268999589385203e-07

This O 0 1.0298717967316406e-07
study O 0 1.72952621113609e-08
provides O 0 6.961855980591736e-09
further O 0 5.6685700577929765e-09
evidence O 0 2.867529103056654e-09
that O 0 4.198221770224109e-09
the O 0 1.3737112780631833e-08
DM B-Disease 1 1.0
expansion O 0 7.215125492621155e-07
tends O 0 5.254626671558071e-07
to O 0 7.169339788504203e-09
be O 0 1.639376101536527e-08
transmitted O 0 1.5461313296327717e-06
preferentially O 0 1.501139422543929e-06
. O 0 2.1130908578470553e-07

Diagnosis O 1 0.9764052629470825
of O 0 3.290610766271129e-05
hemochromatosis B-Disease 1 1.0
. O 0 2.6178280677413568e-05

If O 0 1.3390163076110184e-05
untreated O 0 0.00011024493869626895
, O 0 2.396460558884428e-07
hemochromatosis B-Disease 1 1.0
can O 0 1.2108734154026024e-05
cause O 0 1.8822897800419014e-06
serious O 0 2.5067793103517033e-06
illness O 0 8.406415145145729e-05
and O 0 8.358916403494732e-08
early B-Disease 0 3.112254205461795e-07
death I-Disease 0 1.97205986296467e-06
, O 0 1.3614153360208547e-08
but O 0 6.929887774731469e-09
the O 0 1.4727542740899935e-08
disease O 0 3.98416887037456e-06
is O 0 7.241476751573828e-09
still O 0 4.4667451959412574e-08
substantially O 0 5.049330980000377e-07
under O 0 1.636905437862879e-07
- O 1 0.5584664940834045
diagnosed O 0 0.003349474398419261
. O 0 3.683134366383456e-07

The O 0 2.3243157443175733e-07
cornerstone O 0 2.941387151622621e-07
of O 0 1.218800949054355e-09
screening O 0 2.2280188360923603e-08
and O 0 3.1136651035268414e-09
case O 0 2.2617532291491216e-09
detection O 0 2.2287881762395045e-08
is O 0 2.1476760370120473e-09
the O 0 7.624675890660626e-10
measurement O 0 1.2860219555932417e-07
of O 0 2.2210764338836952e-09
serum O 0 5.217275997893012e-07
transferrin O 0 4.345471040778648e-07
saturation O 0 3.6199105579726165e-07
and O 0 2.0370247710843614e-08
the O 0 7.83570008877632e-09
serum O 0 1.2454385114324396e-06
ferritin O 0 1.1025351341231726e-05
level O 0 2.0633579822515458e-07
. O 0 1.222378074317021e-07

Once O 0 1.1807839655375574e-05
the O 0 5.153228244125785e-08
diagnosis O 0 4.229685146128759e-06
is O 0 9.149040636202699e-09
suspected O 0 1.7697649923320569e-07
, O 0 4.193540181773869e-09
physicians O 0 1.7444877542516224e-08
must O 0 9.687745716746576e-09
use O 0 1.1440019598296658e-08
serum O 0 2.853432761185104e-06
ferritin O 0 5.43298119737301e-05
levels O 0 2.1320376220046455e-07
and O 0 3.384943170203769e-08
hepatic O 0 1.0456651580170728e-05
iron O 0 5.551162757910788e-05
stores O 0 4.9012141971616074e-06
on O 0 3.187675758908881e-07
liver O 0 9.733810202305904e-07
biopsy O 0 3.4717427297437098e-06
specimens O 0 5.983014084165461e-09
to O 0 7.827316017561259e-10
assess O 0 3.5816285048895224e-08
patients O 0 8.741305457249382e-09
for O 0 1.457194642728865e-10
the O 0 1.0029389541088563e-09
presence O 0 2.5361435618265205e-08
of O 0 1.3248753205630237e-08
iron B-Disease 0 0.24900497496128082
overload I-Disease 0 0.00046314075007103384
. O 0 3.0790474170316884e-07

Liver O 1 0.5715689063072205
biopsy O 1 0.5825271606445312
is O 0 2.2273417243923177e-07
also O 0 2.242728491808066e-08
used O 0 4.554519872357332e-09
to O 0 1.771404467554305e-09
establish O 0 9.468926087663476e-09
the O 0 2.507465790557717e-09
presence O 0 1.4643510404255267e-08
or O 0 7.942261959215102e-09
absence O 0 9.662869615567615e-09
of O 0 2.052898517845847e-09
cirrhosis B-Disease 0 3.5812063288176432e-06
, O 0 7.0310743893742256e-09
which O 0 7.616558406198237e-08
can O 0 1.054803320243991e-07
affect O 0 3.7755080484203063e-07
prognosis O 0 0.00014436885248869658
and O 0 2.0790969301742734e-07
management O 0 2.2639584074113372e-07
. O 0 1.2721707776108815e-07

A O 0 1.6209219211305026e-06
DNA O 0 1.4616410908274702e-06
- O 0 1.8306836864212528e-06
based O 0 2.4865496328629888e-08
test O 0 6.701091681549087e-09
for O 0 2.5980573248318706e-10
the O 0 1.7255119555414922e-09
HFE O 0 4.5452293306880165e-06
gene O 0 1.2111685521176696e-07
is O 0 7.837239301977661e-09
commercially O 0 6.2638330078357285e-09
available O 0 2.1218047319138122e-09
, O 0 2.549431332710128e-09
but O 0 1.0169914910207467e-09
its O 0 3.147759830568475e-10
place O 0 1.2257114434532923e-08
in O 0 1.4985075402762504e-09
the O 0 1.2101474489156772e-08
diagnosis O 0 9.77432409854373e-06
of O 0 7.258446999003354e-08
hemochromatosis B-Disease 1 1.0
is O 0 1.259435634892725e-06
still O 0 1.241516400796172e-07
being O 0 3.604689879921352e-08
evaluated O 0 1.5523382046467304e-07
. O 0 1.7232869709005172e-07

Currently O 0 1.8830259023161489e-06
, O 0 8.297913467458784e-09
the O 0 7.43780093070967e-10
most O 0 2.656717901228234e-10
useful O 0 2.691384337616398e-10
role O 0 2.5593460684092406e-09
for O 0 8.157179931522762e-10
this O 0 7.050717787393523e-10
test O 0 1.957373152450259e-09
is O 0 1.9917603677477302e-10
in O 0 6.743126196306903e-11
the O 0 3.3936672916290433e-10
detection O 0 1.6619624787495013e-08
of O 0 1.6397390112388166e-08
hemochromatosis B-Disease 1 1.0
in O 0 1.4424934136059164e-07
the O 0 4.791356644773259e-09
family O 0 1.2488141187816382e-08
members O 0 3.8212394359860014e-10
of O 0 3.535990389380572e-10
patients O 0 4.243271511938929e-09
with O 0 4.721625868064905e-10
a O 0 2.8732465295888687e-08
proven O 0 1.5116049212338112e-07
case O 0 4.997355418367988e-09
of O 0 7.29580507119465e-10
the O 0 1.051537097396249e-07
disease O 0 1.2296156455704477e-05
. O 0 1.5234489580961963e-07

It O 0 7.130733479243645e-07
is O 0 4.567380074149696e-08
crucial O 0 2.1038813713403215e-07
to O 0 1.024059656629106e-06
diagnose O 1 0.9999929666519165
hemochromatosis B-Disease 1 1.0
before O 0 0.00019985999097116292
hepatic B-Disease 1 0.9868035912513733
cirrhosis I-Disease 0 0.08033061772584915
develops O 0 5.3815874707652256e-05
because O 0 1.5779843920427084e-07
phlebotomy O 0 9.444532042834908e-05
therapy O 0 2.714657057367731e-05
can O 0 4.927544523525285e-07
avert O 0 0.00019829609664157033
serious O 0 9.249447612091899e-05
chronic O 1 0.9961899518966675
disease O 0 0.0006328928284347057
and O 0 1.1815670575288095e-07
can O 0 6.691974618888707e-08
even O 0 3.7010703834994274e-08
lead O 0 1.6038417527397542e-07
to O 0 1.9899813352708406e-08
normal O 0 1.861310181539011e-07
life O 0 1.3695938605451374e-07
expectancy O 0 1.2295361102587776e-06
. O 0 5.8704485716987165e-09
. O 0 3.965015338280864e-08

Prevalence O 0 0.0009053063695318997
of O 0 6.837485955202283e-08
the O 0 2.225547035550335e-08
I1307K O 0 2.7450359993963502e-06
APC B-Disease 0 9.298790928369272e-07
gene O 0 1.8720555772233638e-07
variant O 0 5.089380010758759e-07
in O 0 1.113263348173632e-08
Israeli O 0 1.4116109241513186e-06
Jews O 0 2.899064277528396e-08
of O 0 2.77121492420207e-10
differing O 0 6.207162339677552e-09
ethnic O 0 6.613078085138113e-08
origin O 0 2.151412203943437e-08
and O 0 1.7651514383487665e-07
risk O 0 7.244325388455763e-07
for O 0 2.4994985778903356e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.6274930153012974e-06

BACKGROUND O 0 0.00013062199286650866
& O 0 3.925766213797033e-05
AIMS O 0 2.5398237539775437e-06
Israeli O 0 1.2488281981859473e-06
Jews O 0 6.68699868811018e-08
of O 0 1.0416369988774932e-09
European O 0 2.2564933033208945e-08
birth O 0 6.626473805226851e-07
, O 0 1.7989647105309814e-08
i O 0 1.0286154150662696e-07
. O 0 5.904819966318087e-10
e O 0 7.735420304300078e-09
. O 0 6.56974863399995e-10
, O 0 1.071460253854184e-09
Ashkenazim O 0 1.2944173022333416e-07
, O 0 1.5701259181710725e-09
have O 0 7.809917157430846e-09
the O 0 8.263265272034914e-08
highest O 0 0.10450886189937592
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.00025553529849275947
of O 0 1.7746983882460654e-09
any O 0 3.0590783239858865e-09
Israeli O 0 1.1816240430562175e-06
ethnic O 0 2.035100578723359e-06
group O 0 3.4216070616821526e-06
. O 0 3.276563234066998e-07

The O 0 1.0955503739751293e-06
I1307K O 0 1.767676258168649e-05
APC B-Disease 0 5.667811365128728e-06
gene O 0 2.3486172722186893e-06
variant O 0 3.13092750729993e-05
was O 0 8.5250749179977e-06
found O 0 3.0405818307599475e-08
in O 0 1.2896162360220842e-08
6 O 0 6.707373358949553e-07
. O 0 3.4777235669025686e-07

1 O 0 1.6700007563485997e-06
% O 0 2.4400558018555785e-08
of O 0 3.4235866919196667e-10
American O 0 6.8439551803578524e-09
Jews O 0 3.1836588476608085e-08
, O 0 1.3760601547119222e-09
28 O 0 2.343519334147004e-08
% O 0 6.225548965232974e-10
of O 0 4.423281463328266e-10
their O 0 1.3120487892592791e-05
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 7.482614705622836e-07
, O 0 1.7793835738189046e-08
but O 0 8.610972379585746e-09
not O 0 2.4363062678389724e-09
in O 0 1.4934201653105106e-09
non O 0 3.2144356509888894e-08
- O 0 1.0780886441352777e-05
Jews O 0 1.0320795809093397e-06
. O 0 1.4959445593376586e-07

We O 0 1.9230278667237144e-06
assessed O 0 4.5282374117050495e-07
the O 0 8.175610410887657e-09
I1307K O 0 1.0303310773451813e-06
prevalence O 0 1.4144624174150522e-06
in O 0 2.5605522147031934e-09
Israeli O 0 7.798411729709187e-07
Jews O 0 1.9082499136402475e-08
of O 0 1.5190362856465356e-10
differing O 0 4.434113076712265e-09
ethnic O 0 3.918440683037261e-08
origin O 0 2.346659222496328e-08
and O 0 6.400269114692492e-08
risk O 0 3.417686400553066e-07
for O 0 1.29494230804994e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.7224430141359335e-06

METHODS O 0 1.454639459552709e-06
DNA O 0 6.159295367069717e-07
samples O 0 3.60246303898748e-08
from O 0 1.3231170603589248e-09
500 O 0 1.8673966817317478e-09
unrelated O 0 3.3057097059696616e-09
Jews O 0 1.4616944987722036e-08
of O 0 3.2002764327465627e-10
European O 0 5.876497954915294e-09
or O 0 7.942882795930473e-09
non O 0 4.23681001393561e-09
- O 0 6.058612598280888e-07
European O 0 1.1717703252145384e-08
origin O 0 2.697372769588924e-09
, O 0 1.1714366143777966e-09
with O 0 2.779462215940498e-10
or O 0 2.7367270671874167e-09
without O 0 3.0013969087860914e-10
a O 0 1.2676377725284738e-09
personal O 0 2.9572920112741485e-08
and O 0 9.139660051005194e-08
/ O 0 4.296226961741922e-06
or O 0 5.405895819876605e-08
family O 0 3.0485139745906054e-08
history O 0 4.81122919282484e-09
of O 0 1.1072613936846665e-09
neoplasia B-Disease 0 2.053351863651187e-06
, O 0 4.7720125628814e-09
were O 0 9.695713565349706e-09
examined O 0 1.3041610458230934e-08
for O 0 5.192748453453078e-10
the O 0 2.0979251669217547e-09
I1307K O 0 1.9644959081688285e-07
variant O 0 1.9106688853298692e-07
by O 0 1.0583229848037945e-09
the O 0 1.6044261474945642e-09
allele O 0 1.0749696599532399e-07
- O 0 2.2838679569758824e-07
specific O 0 3.4233810453088154e-08
oligonucleotide O 0 9.88422198133776e-06
( O 0 1.8423783387788717e-07
ASO O 0 8.321631867147516e-06
) O 0 1.232465329792376e-08
method O 0 1.6044198503095686e-07
. O 0 2.486054597738985e-07

RESULTS O 0 8.05581748863915e-06
In O 0 2.263908172039919e-08
persons O 0 6.287605547328212e-09
at O 0 5.731649377338499e-09
average O 0 1.8261415846154705e-07
risk O 0 2.7798026280834165e-07
for O 0 2.4711985133762937e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 8.280888863509972e-08
I1307K O 0 2.016938196902629e-06
was O 0 3.5398412023823767e-07
found O 0 9.0133847052698e-09
in O 0 6.625687998251806e-09
5 O 0 7.757424214105413e-08
. O 0 1.3594879533229687e-07

0 O 0 5.985292773402762e-06
% O 0 1.3755982308794046e-07
of O 0 2.3729886944323653e-09
120 O 0 1.1966763580062434e-08
European O 0 1.090415757687424e-08
and O 0 4.828413580071356e-08
1 O 0 1.5136561160034034e-07
. O 0 3.037454803234141e-07

6 O 0 2.3200262148748152e-05
% O 0 1.7137288921276195e-07
of O 0 2.4023074640666664e-09
188 O 0 4.426805588764182e-08
non O 0 2.833506762556226e-08
- O 0 1.3899460782340611e-06
European O 0 2.996606696115123e-08
Jews O 0 7.600986151601319e-08
( O 0 1.1715959757907513e-08
P O 0 9.268749749935523e-07
= O 0 1.7269771035444137e-07
0 O 0 2.0697031644090202e-08
. O 0 3.380554280951742e-09
08 O 0 8.042233901051077e-08
) O 0 1.9349981172922526e-08
. O 0 8.092828096550875e-08

It O 0 1.432967110304162e-06
occurred O 0 7.665189514227677e-07
in O 0 3.0554527796766706e-08
15 O 0 4.0206825246968947e-07
. O 0 1.7290783205226035e-07

4 O 0 5.7408651628065854e-06
% O 0 1.1972429092566017e-07
of O 0 5.08256237097271e-09
52 O 0 3.1387045851261064e-07
Ashkenazi O 0 9.959881026588846e-06
Israelis O 0 4.3682625801011454e-06
with O 0 4.216826354763725e-08
familial O 0 0.0005494907381944358
cancer B-Disease 0 8.610280929133296e-05
( O 0 6.302027344418093e-08
P O 0 3.770509920286713e-06
= O 0 2.0433333247638075e-07
0 O 0 1.3765439454971329e-08
. O 0 2.9434923387583467e-09
02 O 0 5.014496551325465e-08
) O 0 4.022763011590769e-09
and O 0 5.558741733580064e-08
was O 0 1.561882072564913e-06
not O 0 2.782879704454899e-09
detected O 0 1.1633724206205898e-08
in O 0 1.0369430869516805e-09
51 O 0 6.34543724231662e-08
non O 0 4.386610630291443e-09
- O 0 2.8392744866323483e-07
European O 0 8.486482627745318e-09
Jews O 0 1.1217338169444702e-08
at O 0 5.100859290507742e-09
increased O 0 1.0293631902413836e-07
cancer B-Disease 0 1.3199037312006112e-06
risk O 0 3.426805221806717e-07
. O 0 1.0054163368522495e-07

Colorectal B-Disease 1 0.9991970658302307
neoplasia I-Disease 0 0.09428708255290985
occurred O 0 0.00011223558976780623
personally O 0 1.9315743884362746e-06
or O 0 2.8119925943315138e-08
in O 0 3.171892970499357e-09
the O 0 5.113785839228058e-09
families O 0 3.1319269400142957e-09
of O 0 4.084668436821204e-10
13 O 0 1.583652142755909e-08
of O 0 3.867330622409071e-10
20 O 0 9.950946733283672e-09
Ashkenazi O 0 1.651314676109905e-07
I1307K O 0 6.128662022319986e-08
carriers O 0 4.982698253996887e-09
, O 0 3.988974150992419e-10
8 O 0 4.1263210626141245e-09
of O 0 3.2190830556722005e-10
whom O 0 3.467936551260209e-07
also O 0 1.5554930996586336e-06
had O 0 4.5553269956144504e-06
a O 0 2.700612355965859e-08
personal O 0 1.368228822684614e-06
or O 0 9.736467632137646e-08
family O 0 5.184035956062871e-08
history O 0 1.6641067190903414e-08
of O 0 1.2552379580199613e-08
noncolonic O 0 0.00011707151134032756
neoplasia B-Disease 0 0.0002981690049637109
. O 0 8.866016401043453e-07

CONCLUSIONS O 0 4.808057838090463e-06
The O 0 5.7857249657899956e-08
I1307K O 0 4.189364062767709e-06
APC O 0 1.8154846657125745e-06
variant O 0 3.7324543882277794e-06
may O 0 7.187689732290892e-08
represent O 0 8.431782494433548e-10
a O 0 3.116213953546776e-09
susceptibility O 0 7.451900501109776e-07
gene O 0 9.839500307862181e-07
for O 0 1.798296125343768e-07
colorectal B-Disease 1 1.0
, I-Disease 0 3.948285325350298e-07
or I-Disease 0 1.0196296251763215e-08
other I-Disease 0 1.0597086541608292e-09
, I-Disease 0 1.7556768483473206e-08
cancers I-Disease 0 7.428247954521794e-06
in O 0 5.302971839427073e-09
Ashkenazi O 0 1.3156158274796326e-05
Jews O 0 4.543988438854285e-07
, O 0 1.7099440086099094e-08
and O 0 4.9268205515318186e-08
partially O 0 1.1052637773900642e-06
explains O 0 1.4456774977134046e-07
the O 0 2.3268869053794106e-09
higher O 0 3.0929676597679645e-08
incidence O 0 0.0008805058896541595
of O 0 2.285879963892512e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 7.872150575849446e-08
European O 0 1.2325445197802765e-07
Israelis O 0 1.3657159797730856e-05
. O 0 3.4827749573196343e-07

Systematic O 0 6.0309580476314295e-06
analysis O 0 3.7616317172251e-07
of O 0 2.9511840082818708e-08
coproporphyrinogen O 0 1.8452796211931854e-05
oxidase O 0 1.2727601642836817e-05
gene O 0 0.00031835021218284965
defects O 1 0.9792989492416382
in O 0 1.1101637653609941e-07
hereditary B-Disease 0 0.15636588633060455
coproporphyria I-Disease 0 0.00037682484253309667
and O 0 2.7767927690547367e-07
mutation O 0 2.558606638558558e-06
update O 0 1.2238738236192148e-05
. O 0 9.819289061852032e-07

Hereditary B-Disease 1 0.9997228980064392
coproporphyria I-Disease 0 0.01682553067803383
( O 0 5.117582531966036e-06
HC B-Disease 0 0.00023007637355476618
) O 0 2.881424450151826e-07
is O 0 3.382465152412806e-08
an O 0 8.59599396108024e-08
acute O 1 0.7923317551612854
hepatic B-Disease 1 0.9999833106994629
porphyria I-Disease 1 0.9999996423721313
with O 0 2.16255102714058e-05
autosomal O 1 0.9999194145202637
dominant O 0 0.006869721692055464
inheritance O 0 0.002879415638744831
caused O 0 2.157685230486095e-05
by O 0 1.265469062872171e-08
deficient B-Disease 0 9.27531800698489e-06
activity I-Disease 0 8.242346183351401e-08
of I-Disease 0 5.005549752468141e-09
coproporphyrinogen I-Disease 0 6.31447765044868e-05
III I-Disease 0 7.979253132361919e-05
oxidase I-Disease 0 4.430367880559061e-06
( O 0 1.774906621676564e-07
CPO O 0 2.5308791009592824e-05
) O 0 7.940735002875954e-08
. O 0 1.4265501135923842e-07

Clinical O 0 0.00010486927203601226
manifestations O 0 7.668153557460755e-06
of O 0 1.578914066158177e-08
the O 0 5.579859418958222e-08
disease O 0 1.6135318219312467e-05
are O 0 4.910793993673224e-09
characterized O 0 6.448326530517079e-07
by O 0 5.747512243914343e-09
acute O 0 6.047741408110596e-06
attacks O 0 2.2829868612461723e-05
of O 0 4.5333189291341114e-07
neurological B-Disease 1 0.9987712502479553
dysfunction I-Disease 0 0.048855431377887726
often O 0 7.334592737606727e-07
precipitated O 0 3.6254658652978833e-07
by O 0 7.267708101998949e-10
drugs O 0 9.165423087154068e-09
, O 0 4.712927825778479e-09
fasting O 0 1.3938113170297584e-06
, O 0 5.62620572353012e-09
cyclical O 0 1.982278035939089e-06
hormonal O 0 4.2889569158433005e-06
changes O 0 4.37150298182587e-08
, O 0 1.1086482842870282e-08
or O 0 1.6409771319558786e-07
infectious B-Disease 0 3.388568075024523e-05
diseases I-Disease 0 1.7323034626315348e-05
. O 0 1.674902421200386e-07

Skin O 1 0.9999994039535522
photosensitivity O 1 0.9997807145118713
may O 0 0.001201388775371015
also O 0 3.979483267357864e-07
be O 0 1.748295019865509e-08
present O 0 4.581461965358358e-08
. O 0 2.818579503127694e-07

The O 0 8.118644814203435e-07
seven O 0 1.7470892998971976e-07
exons O 0 3.09872461912164e-06
, O 0 1.0693537610961812e-08
the O 0 2.6157300769824587e-09
exon O 0 1.2769395425493713e-06
/ O 0 3.1380989184981445e-06
intron O 0 9.953307016985491e-05
boundaries O 0 1.8338030713493936e-05
and O 0 7.745079955157053e-08
part O 0 2.6971875843884163e-09
of O 0 5.957446203019856e-10
3 O 0 8.16680501003475e-09
noncoding O 0 1.4160116279526846e-07
sequence O 0 3.646401935952781e-08
of O 0 4.861278046774942e-10
the O 0 4.074896864381117e-09
CPO O 0 7.0368778324336745e-06
gene O 0 6.625639770163616e-08
were O 0 2.2328517701453166e-08
systematically O 0 2.444961921810318e-07
analyzed O 0 1.1982956849010407e-08
by O 0 2.791708808569382e-10
an O 0 2.6746554970813463e-10
exon O 0 8.0065881036262e-08
- O 0 6.188699330778036e-07
by O 0 5.268733449526053e-09
- O 0 1.5419758483403712e-06
exon O 0 1.282253197132377e-05
denaturing O 0 0.0003358774119988084
gradient O 0 5.425484414445236e-05
gel O 0 0.000199121015612036
electrophoresis O 0 5.922553827986121e-05
( O 0 2.1521555026993155e-07
DGGE O 0 4.219576567265904e-06
) O 0 6.705132449269513e-09
strategy O 0 5.1086509245124034e-08
followed O 0 5.0168282861307034e-09
by O 0 1.3630040152090572e-10
direct O 0 6.923120410284866e-10
sequencing O 0 1.623729417588038e-08
in O 0 1.2033821716883608e-09
seven O 0 9.299251146899223e-09
unrelated O 0 9.18476459332851e-08
heterozygous O 0 2.3958443762239767e-06
HC B-Disease 0 1.053024607244879e-05
patients O 0 4.4734551352121343e-07
from O 0 8.824663666473498e-09
France O 0 1.2324993576839915e-06
, O 0 1.1394354793026196e-08
Holland O 0 1.2486746072681854e-06
, O 0 9.962872304924986e-09
and O 0 2.0805877909424453e-08
Czech O 0 2.2236426389099506e-07
Republic O 0 3.3409170896447904e-07
. O 0 6.01985220782808e-07

Seven O 0 5.63807452635956e-06
novel O 0 1.0631791838022764e-06
mutations O 0 2.0777124518644996e-06
and O 0 9.047521842830974e-09
two O 0 2.5613582366190712e-09
new O 0 4.870796033173974e-08
polymorphisms O 0 0.00048219450400210917
were O 0 5.538611844713159e-07
detected O 0 1.6985381989798043e-06
. O 0 1.7529272611227498e-07

Among O 0 5.364562980503251e-07
these O 0 1.139659389082226e-08
mutations O 0 1.4650920832082193e-07
two O 0 3.3646267993958645e-09
are O 0 3.813203530711462e-09
missense O 0 1.208310277434066e-05
( O 0 2.2233408003557997e-08
G197W O 0 7.163285999922664e-07
, O 0 5.231671984518016e-09
W427R O 0 2.0155853519554512e-07
) O 0 3.4514402447172188e-09
, O 0 5.407653769218257e-10
two O 0 1.7243934058441823e-09
are O 0 3.860861408355731e-09
nonsense O 0 1.717801296763355e-06
( O 0 2.4888542338175057e-09
Q306X O 0 1.1147873379968587e-07
, O 0 3.536592796393734e-09
Q385X O 0 1.024190936504965e-07
) O 0 1.3957159872290958e-09
, O 0 2.2540562472084247e-10
two O 0 3.7159136878628374e-10
are O 0 5.029539562606544e-10
small O 0 1.77567693881997e-09
deletions O 0 8.47456362862431e-07
( O 0 8.3320434995926e-09
662de14bp O 0 1.4557787153535173e-07
; O 0 3.969099715561697e-09
1168del3bp O 0 1.1443822245382762e-07
removing O 0 1.0402774641704582e-08
a O 0 3.557097283390931e-09
glycine O 0 1.6473400421546103e-07
at O 0 1.6595803842278656e-08
position O 0 7.700873538851738e-08
390 O 0 5.205983555356397e-08
) O 0 8.443535648439138e-09
, O 0 6.683043451971571e-09
and O 0 1.783256742271533e-08
one O 0 2.938314702660705e-09
is O 0 7.79610154211241e-10
a O 0 1.8754207076199236e-09
splicing O 0 9.037123618327314e-07
mutation O 0 3.7802169572387356e-07
( O 0 1.1820648460059147e-08
IVS1 O 0 1.4463189472735394e-06
- O 0 2.900701701946673e-06
15c O 0 1.3288926083987462e-06
- O 0 8.089901371022279e-07
- O 0 2.7333328489476116e-06
> O 0 2.839948933797132e-07
g O 0 1.3205382174419356e-06
) O 0 6.937955099317605e-09
which O 0 2.8695208431628316e-09
creates O 0 1.8930892409230182e-08
a O 0 2.2010737676936287e-09
new O 0 7.025738657517877e-09
acceptor O 0 1.7772271121430094e-07
splice O 0 3.3634427381912246e-05
site O 0 7.212309810711304e-06
. O 0 7.163832833612105e-07

The O 0 5.599134169642639e-07
pathological O 0 1.6026123148549232e-06
significance O 0 7.166266158264989e-08
of O 0 3.0919871107926156e-09
the O 0 6.3838077046796116e-09
point O 0 6.967383683331718e-07
mutations O 0 4.178265271548298e-07
G197W O 0 3.1317918569584435e-07
, O 0 3.3575622282455697e-09
W427R O 0 1.9679893625834666e-07
, O 0 3.1789608723187257e-09
and O 0 9.428480218787172e-10
the O 0 2.586349467925686e-10
in O 0 1.005175831458871e-09
- O 0 2.4205098725360585e-06
frame O 0 1.8851907952921465e-05
deletion O 0 4.722486721675523e-07
390delGly O 0 7.230720484585618e-07
were O 0 1.4463941155895554e-08
assessed O 0 5.460099483656222e-09
by O 0 2.8073060542865846e-10
their O 0 3.0869076184103506e-09
respective O 0 5.353616217007584e-08
expression O 0 2.4174863000325786e-08
in O 0 1.5323037283465624e-09
a O 0 2.7823490178491284e-09
prokaryotic O 0 8.823653807610299e-09
system O 0 4.045253021445205e-09
using O 0 3.944511384190719e-09
site O 0 2.8832880616391776e-07
- O 0 6.172976554807974e-06
directed O 0 1.0411051789560588e-06
mutagenesis O 0 1.8403132344246842e-05
. O 0 4.82991481476347e-07

These O 0 4.703357774360484e-07
mutations O 0 2.9872273898945423e-06
resulted O 0 6.361044313507591e-08
in O 0 3.125738556875035e-09
the O 0 5.246221235211124e-09
absence O 0 6.881931824409548e-08
or O 0 2.0813578416323253e-08
a O 0 2.0013931845141997e-08
dramatic O 0 7.037744467197626e-07
decrease O 0 9.044865691976156e-07
of O 0 9.880364970626943e-09
CPO O 0 9.040806617122144e-05
activity O 0 1.221897150571749e-06
. O 0 2.0915501863782993e-07

The O 0 5.103908051751205e-07
two O 0 6.368899363451419e-08
polymorphisms O 0 9.430781210539863e-05
were O 0 5.425708238249172e-08
localized O 0 4.6750145088481077e-07
in O 0 1.8031522941441835e-08
noncoding O 0 4.699023065768415e-06
part O 0 2.480817506977928e-08
of O 0 6.224836202051165e-10
the O 0 1.4158118011309284e-09
gene O 0 1.6289812165837247e-08
1 O 0 4.708677892040214e-09
) O 0 7.575188254449472e-10
a O 0 6.368362726050236e-09
C O 0 6.18331910118286e-07
/ O 0 1.8673459862839081e-06
G O 0 9.779209904081654e-06
polymorphism O 0 5.330965109351382e-07
in O 0 3.6733032171554214e-09
the O 0 1.0973802311298186e-08
promotor O 0 8.567791155655868e-06
region O 0 1.2538554017282877e-07
, O 0 3.3964600021363367e-09
142 O 0 2.6772152494913826e-08
bp O 0 4.750959021748713e-07
upstream O 0 3.031964368460649e-08
from O 0 7.820317171614022e-10
the O 0 3.6945285719625076e-10
transcriptional O 0 4.351164051286105e-08
initiation O 0 8.573410426038208e-09
site O 0 5.978316153232299e-08
( O 0 3.9886107749964594e-09
- O 0 2.23790053155426e-07
142C O 0 1.3451766562866396e-06
/ O 0 1.4200878695191932e-06
G O 0 7.538722911704099e-06
) O 0 5.841386041538499e-09
, O 0 1.6146305403808014e-09
and O 0 2.4589201785829573e-09
2 O 0 4.012409959841534e-09
) O 0 5.321399987323616e-10
a O 0 2.250230002331932e-09
6 O 0 2.7316593431692127e-08
bp O 0 3.390116205537197e-07
deletion O 0 3.1861625870988064e-07
polymorphism O 0 2.261036939898986e-07
in O 0 2.5528958946807734e-09
the O 0 3.5548117782724376e-09
3 O 0 2.2046968695121905e-08
noncoding O 0 4.180006669685099e-07
part O 0 1.0506987280223257e-08
of O 0 5.519887325000639e-10
the O 0 3.4957234884558375e-09
CPO O 0 1.9950491605413845e-06
gene O 0 2.7891410070424172e-08
, O 0 4.130581210404216e-09
574 O 0 4.136685305411447e-08
bp O 0 2.3640771473765199e-07
downstream O 0 2.8797094486776587e-08
of O 0 2.907994123280133e-10
the O 0 3.281611427041753e-09
last O 0 2.4218437033596274e-07
base O 0 2.2095507645758516e-08
of O 0 3.5492003780390746e-10
the O 0 2.6036641731508325e-09
normal O 0 5.406576519817463e-08
termination O 0 1.1524505794113793e-07
codon O 0 9.559589670971036e-07
( O 0 3.271414072969492e-08
+ O 0 7.190006385826564e-07
574 O 0 1.8328254327570903e-06
delATTCTT O 0 4.591628112393664e-06
) O 0 2.006033383850081e-07
. O 0 1.586400912856334e-07

Five O 0 4.960737442161189e-06
intragenic O 0 1.4015440683579072e-05
dimorphisms O 0 1.438712661183672e-05
are O 0 2.0341051509831232e-08
now O 0 2.2040955727220535e-08
well O 0 6.067735203174607e-09
characterized O 0 1.4717340945935575e-07
and O 0 3.417281391193683e-08
the O 0 1.6476322528546916e-09
high O 0 8.64881410933549e-09
degree O 0 8.855869371160452e-10
of O 0 7.001041413268183e-10
allelic O 0 4.795254540113092e-07
heterogeneity O 0 1.4503494867312838e-06
in O 0 7.520589662135535e-08
HC B-Disease 0 0.0002406112034805119
is O 0 6.161986334518588e-07
demonstrated O 0 3.5645566498487824e-08
with O 0 6.89378831797427e-10
seven O 0 1.7564296683758585e-09
new O 0 7.841542415398806e-10
different O 0 1.6297231342221608e-09
mutations O 0 2.296364343123969e-08
making O 0 9.898430963772853e-10
a O 0 2.5023250138644926e-09
total O 0 9.818927892979445e-10
of O 0 6.965398258174105e-10
nineteen O 0 1.7609828546483186e-06
CPO O 0 0.0001236053794855252
gene B-Disease 0 9.227499504049774e-06
defects I-Disease 0 0.14418074488639832
reported O 0 9.985417364077875e-07
so O 0 1.2318003506095465e-08
far O 0 1.819257455792922e-08
. O 0 6.441132960333107e-09
. O 0 4.599743874678097e-08

Coincidence O 0 2.263320675410796e-05
of O 0 2.078168392927182e-08
two O 0 1.2458830411787858e-08
novel O 0 2.389130884239421e-07
arylsulfatase O 0 3.196520992787555e-06
A O 0 4.385441343401908e-08
alleles O 0 7.142957656469662e-07
and O 0 6.630506987903573e-08
mutation O 0 1.4875156466587214e-06
459 O 0 5.344801365936291e-07
+ O 0 5.750880518462509e-07
1G O 0 2.2497975805890746e-05
> O 0 2.450880174365011e-07
A O 0 2.3683053740342075e-08
within O 0 3.882750121420031e-09
a O 0 1.718238351600121e-08
family O 0 2.943297943147627e-07
with O 0 1.01221417025954e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999998807907104
: O 0 1.2828524909025418e-08
molecular O 0 2.9162563919271633e-08
basis O 0 1.1896736928918017e-08
of O 0 3.632107947737495e-09
phenotypic O 0 1.0260625458613504e-05
heterogeneity O 0 0.00022026689839549363
. O 0 2.662626002347679e-06

In O 0 1.7347635150599672e-07
a O 0 6.598449431294284e-08
family O 0 4.757483296202736e-08
with O 0 6.900461979597594e-09
three O 0 1.4642539269971167e-07
siblings O 0 7.728197488177102e-06
, O 0 5.040874384576455e-09
one O 0 3.1774454178901124e-09
developed O 0 5.974326455771006e-08
classical O 0 1.798848643375095e-07
late O 0 1.62376763910288e-05
infantile O 1 0.9999921321868896
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.5543602785328403e-05
MLD B-Disease 1 0.9999998807907104
) O 0 4.136890652262082e-08
, O 0 6.799197205253904e-09
fatal O 0 3.740461238521675e-07
at O 0 4.931624530968293e-08
age O 0 3.9154745223868304e-08
5 O 0 1.4923587698945084e-08
years O 0 7.576160143685229e-09
, O 0 9.574291359726317e-10
with O 0 5.505128353178179e-09
deficient O 0 1.319078182859812e-05
arylsulfatase O 0 4.1724420043465216e-06
A O 0 2.6166603106503317e-07
( O 0 3.6719463025747245e-08
ARSA O 0 1.4387648661795538e-05
) O 0 8.02499222629649e-09
activity O 0 1.3206316928915385e-08
and O 0 4.794702856969479e-09
increased O 0 4.069081427360288e-08
galactosylsulfatide O 0 0.00017020069935824722
( O 0 1.2483590126066701e-06
GS O 1 1.0
) O 0 1.9994097044673254e-07
excretion O 0 1.340845187769446e-06
. O 0 2.464093427079206e-07

The O 0 1.2644683522466948e-07
two O 0 1.2792924053428578e-08
other O 0 3.0578881649034884e-09
siblings O 0 4.282376721675973e-06
, O 0 2.401621479464211e-08
apparently O 0 3.3120608122771955e-07
healthy O 0 1.8826684211603606e-08
at O 0 1.2923585535062898e-09
12 O 0 1.998531118374558e-09
( O 0 7.886239439258702e-10
1 O 0 1.2684843175847504e-09
/ O 0 8.845563570503145e-08
2 O 0 2.545827015865143e-08
) O 0 2.6715163414792187e-09
and O 0 1.2562535012250464e-08
15 O 0 1.754746214999159e-08
years O 0 4.109113049821644e-09
, O 0 1.6273313807602108e-09
respectively O 0 6.60233689941947e-09
, O 0 2.143154320677354e-09
and O 0 4.634723893559567e-08
their O 0 1.6819157622194325e-08
father O 0 5.782282528343785e-07
, O 0 1.2024213624783897e-08
apparently O 0 8.011305681066005e-07
healthy O 0 1.0211807399684858e-08
as O 0 1.0790442983577009e-09
well O 0 1.9412149665498646e-09
, O 0 8.88307261082133e-10
presented O 0 3.3574742985820194e-08
ARSA O 0 0.0003385056625120342
and O 0 7.186062703112839e-06
GS O 1 1.0
values O 0 8.91184583906579e-08
within O 0 8.195716327819014e-10
the O 0 9.098204412083533e-10
range O 0 6.149058862092716e-08
of O 0 5.6952980997948544e-08
MLD B-Disease 1 1.0
patients O 0 9.521089850750286e-06
. O 0 3.498013825264934e-07

Mutation O 0 2.491946543159429e-05
screening O 0 1.298228994528472e-06
and O 0 2.297998591416217e-08
sequence O 0 4.768912376107437e-08
analysis O 0 1.4348534804753399e-08
disclosed O 0 8.95293936764574e-08
the O 0 1.6806225300314281e-09
involvement O 0 9.978771586816038e-09
of O 0 3.6413733139895044e-10
three O 0 6.333149560333595e-09
different O 0 2.153431921669835e-08
ARSA O 0 0.004185251891613007
mutations O 0 1.1489328244351782e-06
being O 0 3.1870233119235536e-09
the O 0 2.7711516414896664e-10
molecular O 0 6.92402135626935e-09
basis O 0 3.119984492983008e-09
of O 0 4.124487862355863e-09
intrafamilial O 0 6.98147778166458e-06
phenotypic O 0 9.941093594534323e-06
heterogeneity O 0 8.155742398230359e-05
. O 0 1.99119426724792e-06

The O 0 1.0455637493578251e-06
late O 0 4.075492597621633e-06
infantile O 0 0.05359489843249321
patient O 0 6.583281356142834e-05
inherited O 0 9.245955152437091e-05
from O 0 2.199594177909603e-07
his O 0 1.7186256400236744e-06
mother O 0 5.921951469645137e-06
the O 0 4.183282609204753e-09
frequent O 0 4.7770146949233094e-08
0 O 0 2.6074079784166315e-08
- O 0 7.828926982256235e-07
type O 0 3.2185499776460347e-07
mutation O 0 3.082402884047042e-07
459 O 0 1.156185760464723e-07
+ O 0 1.0543970319076834e-07
1G O 0 1.4924618199074757e-06
> O 0 5.091239074772602e-08
A O 0 2.4189162672882958e-08
, O 0 8.528704853461022e-09
and O 0 4.262108532770981e-08
from O 0 1.3475113469496591e-08
his O 0 5.3224715657052e-07
father O 0 4.543927616396104e-07
a O 0 1.499992485776147e-08
novel O 0 2.2492319828870677e-07
, O 0 3.6453642326961244e-09
single O 0 3.3968245105597816e-08
basepair O 0 7.368483920799918e-07
microdeletion O 0 2.884845002881775e-07
of O 0 1.4447802954009603e-09
guanine O 0 6.748488345920123e-08
at O 0 4.2068948324924804e-09
nucleotide O 0 9.363541408902165e-08
7 O 0 1.2273373428683954e-08
in O 0 2.0092330021981297e-09
exon O 0 5.488062697622809e-07
1 O 0 1.2130909965435421e-07
( O 0 4.785742291346651e-08
7delG O 0 2.3036348011373775e-06
) O 0 5.425428994954018e-08
. O 0 1.456827192214405e-07

The O 0 3.8767956311858143e-07
two O 0 3.7747733472315304e-07
clinically O 0 0.0002320498606422916
unaffected O 0 1.7758489775587805e-05
siblings O 0 1.286103724851273e-05
carried O 0 3.327523643292807e-07
the O 0 5.44941469726723e-09
maternal O 0 1.4881385368425981e-06
mutation O 0 5.433050205283507e-07
459 O 0 2.5983061391343654e-07
+ O 0 2.250484953947307e-07
1G O 0 7.066030320856953e-06
> O 0 2.590324470475025e-07
A O 0 1.910136830929332e-07
and O 0 2.8097032256368948e-08
, O 0 1.5004952835795393e-09
on O 0 2.579740510100237e-08
their O 0 9.94612658899996e-09
paternal O 0 5.161983835932915e-07
allele O 0 1.2284397143957904e-07
, O 0 1.989805875624029e-09
a O 0 4.334181902265755e-09
novel O 0 1.1889199669212758e-07
cytosine O 0 2.979069222419639e-07
to O 0 3.900311629223552e-09
thymidine O 0 4.021100608042616e-07
transition O 0 9.643945020343381e-08
at O 0 6.768194893425061e-09
nucleotide O 0 1.7767746385288774e-07
2435 O 0 1.6433619975941838e-06
in O 0 5.03463848389174e-09
exon O 0 5.694341780326795e-07
8 O 0 1.6499735977504315e-07
, O 0 3.5044955826180058e-09
resulting O 0 2.713084423788814e-09
in O 0 2.3984145225419695e-10
substitution O 0 4.963593980278347e-09
of O 0 1.386821102400404e-09
alanine O 0 2.905025667132577e-06
464 O 0 8.400814976994297e-07
by O 0 1.8990563788179315e-08
valine O 0 0.00017961837875191122
( O 0 1.3252234509764094e-07
A464V O 0 3.7674547002097825e-06
) O 0 1.4589851105029084e-07
. O 0 2.755543277999095e-07

The O 0 2.199351911258418e-06
fathers O 0 1.126802817452699e-05
genotype O 0 2.264499562443234e-05
thus O 0 2.9488668928934203e-07
was O 0 4.527542216692382e-07
7delG O 0 8.595487088314258e-06
/ O 0 1.6451340343337506e-05
A464V O 0 3.1639981898479164e-05
. O 0 7.195644684543367e-07

Mutation O 0 0.00030031241476535797
A464V O 0 0.00011611171794356778
was O 0 4.386592991068028e-06
not O 0 3.4103191381973375e-09
found O 0 2.1476516121055056e-09
in O 0 2.184407321692561e-09
18 O 0 7.537707347182732e-08
unrelated O 0 1.295100332754373e-06
MLD B-Disease 1 1.0
patients O 0 2.6623467874742346e-06
and O 0 6.922783057916604e-08
50 O 0 4.887128213226788e-08
controls O 0 3.885400474246126e-06
. O 0 6.097588993725367e-07

A464V O 0 0.00033276539761573076
, O 0 4.557055035547819e-07
although O 0 1.269343385956745e-07
clearly O 0 2.025130498850558e-07
modifying O 0 8.379586802220729e-07
ARSA O 0 0.026058033108711243
and O 0 3.3484233426861465e-05
GS O 1 1.0
levels O 0 1.2140369562985143e-06
, O 0 1.469942212395381e-08
apparently O 0 2.3362832735074335e-07
bears O 0 1.0518700577222262e-07
little O 0 1.0105376091473772e-08
significance O 0 4.572389578072489e-09
for O 0 1.1366673158264007e-09
clinical O 0 1.1410670452960403e-07
manifestation O 0 6.955619369364285e-07
of O 0 5.855175899682763e-08
MLD B-Disease 1 1.0
, O 0 6.038803945784821e-08
mimicking O 0 2.1163832570891827e-06
the O 0 3.585551766605022e-08
frequent O 0 8.366846486751456e-06
ARSA O 0 0.006792138796299696
pseudodeficiency O 0 0.00023689529916737229
allele O 0 6.046458292985335e-05
. O 0 1.717313239169016e-06

Our O 0 1.2035032341373153e-05
results O 0 3.2923972526077705e-07
demonstrate O 0 3.008885940403161e-08
that O 0 5.497413080313152e-10
in O 0 4.5541354021239044e-10
certain O 0 3.078669541523027e-09
genetic O 0 1.1874541314682574e-06
conditions O 0 7.850070687709376e-06
MLD B-Disease 1 0.9999997615814209
- O 0 7.442623609676957e-05
like O 0 6.336595674838463e-07
ARSA O 0 0.022996356710791588
and O 0 7.287769676622702e-06
GS O 1 1.0
values O 0 2.743002767147118e-07
need O 0 6.040886457725492e-09
not O 0 7.020456993522828e-10
be O 0 5.555185755845571e-10
paralleled O 0 1.407769758543509e-07
by O 0 3.2526847881797494e-09
clinical O 0 3.800455772307032e-07
disease O 0 1.4689579757032334e-06
, O 0 6.218914272437814e-10
a O 0 1.7511010419468676e-09
finding O 0 1.1398441301935236e-08
with O 0 9.340527462597947e-09
serious O 0 1.5590322277603264e-07
diagnostic O 0 1.8995110622199718e-06
and O 0 2.2933710397410323e-07
prognostic O 0 6.448622298194095e-05
implications O 0 1.834434215197689e-06
. O 0 4.2497535446273105e-07

Moreover O 0 3.522842234815471e-05
, O 0 2.539242416332854e-07
further O 0 1.9182110122528684e-07
ARSA O 0 0.0009315756033174694
alleles O 0 3.4433624023222364e-06
functionally O 0 1.7832179537435877e-06
similar O 0 1.8425323489168477e-08
to O 0 9.005050038979334e-09
A464V O 0 3.7176373552938458e-06
might O 0 5.001907084078994e-07
exist O 0 1.9986162058671653e-08
which O 0 4.45480772270912e-08
, O 0 1.2404287597078678e-09
together O 0 3.2464617660821204e-09
with O 0 7.723195971642838e-10
0 O 0 1.2048710473777646e-08
- O 0 1.6302203675877536e-06
type O 0 6.409730985978968e-07
mutations O 0 5.619194212158618e-07
, O 0 6.197732993484806e-09
may O 0 7.9786751427946e-08
cause O 0 4.032444067547658e-08
pathological O 0 1.7033349877237924e-06
ARSA O 1 0.7905988693237305
and O 0 0.00015420462295878679
GS O 1 1.0
levels O 0 4.428241311416059e-07
, O 0 1.7194209389614912e-09
but O 0 1.5941765685312248e-09
not O 0 9.507651332896216e-10
clinical O 0 1.6365143906682533e-08
outbreak O 0 8.964592268512206e-08
of O 0 9.682310508907221e-10
the O 0 5.595579821715546e-08
disease O 0 4.715241630037781e-06
. O 0 1.690944628762736e-08
. O 0 1.7613292868645658e-07

Human O 0 0.0017604536842554808
MLH1 O 1 0.9997738003730774
deficiency O 1 0.9998292922973633
predisposes O 0 0.0026774576399475336
to O 0 3.989240212831646e-06
hematological B-Disease 1 0.8207715153694153
malignancy I-Disease 1 0.9909737706184387
and O 0 4.036467544210609e-06
neurofibromatosis B-Disease 0 0.0032297277357429266
type I-Disease 0 4.008005362265976e-06
1 I-Disease 0 1.0775453347378061e-06
. O 0 8.272497211692098e-07

Heterozygous O 0 0.0005139594431966543
germ O 0 0.0007330123917199671
- O 0 0.010084562934935093
line O 0 0.0001425647351425141
mutations O 0 4.070863894867216e-07
in O 0 1.992669362849142e-09
the O 0 4.127761243921668e-09
DNA O 0 8.603716992183763e-07
mismatch O 0 6.34505704510957e-05
repair O 0 1.4899368579790462e-05
genes O 0 1.834644081100123e-06
lead O 0 2.4010732886381447e-06
to O 0 1.5594500837323721e-06
hereditary B-Disease 1 0.9999996423721313
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.1757218089769594e-05

The O 0 1.6764058727858355e-06
disease O 0 2.149449755961541e-05
susceptibility O 0 3.3345870633638697e-06
of O 0 1.119115911052404e-08
individuals O 0 4.723207425172404e-08
who O 0 4.5089291234035045e-06
constitutionally O 0 1.204368982143933e-05
lack O 0 2.2296173796121366e-08
both O 0 3.4535938553403867e-09
wild O 0 2.2721670234204794e-07
- O 0 7.836746226530522e-05
type O 0 3.875694005728292e-07
alleles O 0 1.6864747465206165e-07
is O 0 2.0481163431895766e-08
unknown O 0 1.6398523428051703e-07
. O 0 3.22068984814905e-07

We O 0 1.5418479961226694e-05
have O 0 2.375335661497502e-08
identified O 0 1.344007660719626e-08
three O 0 3.196837461416635e-09
offspring O 0 1.1824407408767001e-07
in O 0 6.9636483246426906e-09
a O 0 3.785180297199986e-06
hereditary B-Disease 1 0.9999997615814209
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 9.089276318263728e-06
who O 0 1.4065743698665756e-06
developed O 0 6.554134301950398e-07
hematological B-Disease 0 5.083991709398106e-05
malignancy I-Disease 0 3.306483995402232e-05
at O 0 1.7561927023734825e-08
a O 0 8.817832686247584e-09
very O 0 6.1013438745760595e-09
early O 0 2.4529628106506607e-08
age O 0 2.0919046050948964e-08
, O 0 4.330064640178932e-10
and O 0 6.116759543317585e-09
at O 0 3.2544968942005426e-09
least O 0 8.519417393770823e-10
two O 0 3.492949263161904e-10
of O 0 2.4182125746285976e-10
them O 0 9.811743417742491e-09
displayed O 0 2.2450390133599285e-06
signs O 0 6.077032139728544e-07
of O 0 3.604406328960863e-09
neurofibromatosis B-Disease 0 0.00010324005415895954
type I-Disease 0 1.903080004694857e-07
1 I-Disease 0 7.460797490921323e-08
( O 0 7.738036345017463e-08
NF1 B-Disease 0 2.4170487449737266e-05
) O 0 8.988030941736724e-08
. O 0 2.0799021172024368e-07

DNA O 0 6.161966211948311e-06
sequence O 0 6.584016887245525e-07
analysis O 0 3.348073818187913e-08
and O 0 6.518625639273523e-09
allele O 0 1.2524499481969542e-07
- O 0 1.5490121541006374e-07
specific O 0 4.752783056005683e-09
amplification O 0 2.1022165697104356e-07
in O 0 3.142494264807283e-09
two O 0 3.3626779583073585e-08
siblings O 0 1.0908484910032712e-05
revealed O 0 1.4040199403098086e-06
a O 0 1.7567596444223454e-07
homozygous O 0 0.0001224306906806305
MLH1 O 0 0.0006251982413232327
mutation O 0 1.5924883882689755e-06
( O 0 3.000123882657135e-08
C676T O 0 6.957570235499588e-07
- O 0 9.845461136137601e-06
- O 0 4.813081613974646e-05
> O 0 1.0457054031576263e-06
Arg226Stop O 0 7.771353011776228e-06
) O 0 1.0223992319424724e-07
. O 0 1.4269555492774089e-07

Thus O 0 2.440312982798787e-06
, O 0 3.458394459698866e-08
a O 0 3.541150661590109e-08
homozygous O 0 4.506719051278196e-06
germ O 0 0.0001588034356245771
- O 0 0.01645590551197529
line O 0 0.011263078078627586
MLH1 O 0 0.00046583538642153144
mutation O 0 2.9058458039799007e-06
and O 0 7.50738990973332e-08
consequent O 0 1.9827144569717348e-05
mismatch O 1 0.9944203495979309
repair O 1 0.9979349374771118
deficiency O 1 0.8974063396453857
results O 0 8.834771847432421e-08
in O 0 1.1085234952190604e-08
a O 0 8.324849432028714e-07
mutator O 1 0.9212334156036377
phenotype O 0 0.0012723724357783794
characterized O 0 2.1207069949014112e-06
by O 0 2.0395635402792323e-08
leukemia B-Disease 0 0.005965224001556635
and O 0 2.7700214104697807e-06
/ O 1 0.827714204788208
or O 0 0.18279384076595306
lymphoma B-Disease 1 1.0
associated O 0 1.3602909803012153e-06
with O 0 1.2625667977772537e-07
neurofibromatosis B-Disease 0 0.005649869330227375
type I-Disease 0 1.3428516467683949e-06
1 I-Disease 0 1.7206430413807539e-07
. O 0 6.794299167722784e-08
. O 0 3.804295829468174e-07

Missense O 0 0.046195659786462784
mutations O 0 0.000527586555108428
in O 0 1.1633618157702585e-07
the O 0 5.3583537606982645e-09
most O 0 1.246134306853719e-09
ancient O 0 2.7446152017773784e-09
residues O 0 6.893689885600907e-08
of O 0 1.2159496742825127e-09
the O 0 1.6148653969594307e-08
PAX6 O 0 1.7210586520377547e-05
paired O 0 1.3900878457207e-06
domain O 0 1.9024467690087477e-07
underlie O 0 1.266128947463585e-06
a O 0 4.5486014954576603e-08
spectrum O 0 1.2037038459311589e-06
of O 0 4.920800833474459e-08
human O 0 9.436430264031515e-05
congenital B-Disease 1 1.0
eye I-Disease 1 0.9999958276748657
malformations I-Disease 1 0.9998916387557983
. O 0 5.884783604415134e-06

Mutations O 0 0.00017086431034840643
of O 0 2.9012712232656668e-08
the O 0 1.1588390691485984e-08
human O 0 6.637276328547159e-08
PAX6 O 0 0.0002674427814781666
gene O 0 0.000771015475038439
underlie O 1 0.9801732897758484
aniridia B-Disease 1 1.0
( O 0 0.0016904916847124696
congenital B-Disease 1 0.9999996423721313
absence I-Disease 0 7.123127829800069e-07
of I-Disease 0 2.5128281677666564e-09
the I-Disease 0 1.93485778510194e-08
iris I-Disease 0 0.010704134590923786
) O 0 5.9389709150536873e-08
, O 0 4.877664050439989e-09
a O 0 1.8338408125373462e-08
rare O 0 3.879251266880601e-07
dominant O 0 0.007861532270908356
malformation B-Disease 1 0.5590047836303711
of I-Disease 0 2.129334575329267e-08
the I-Disease 0 3.375122048510093e-07
eye I-Disease 1 0.8372066617012024
. O 0 2.912371201091446e-06

The O 0 5.784808649877959e-07
spectrum O 0 1.8816633655660553e-06
of O 0 2.589600178737328e-08
PAX6 O 0 9.668721031630412e-05
mutations O 0 1.0542242307565175e-05
in O 0 1.2236563406986534e-07
aniridia B-Disease 1 1.0
patients O 0 4.3725722207454965e-06
is O 0 4.264187669633657e-09
highly O 0 1.5169553391203294e-09
biased O 0 1.2068723265201697e-07
, O 0 2.943671750799126e-09
with O 0 1.7133219287757129e-09
92 O 0 2.094076378966747e-08
% O 0 7.100218746280973e-10
of O 0 9.547370533047328e-11
all O 0 1.8278301094909466e-09
reported O 0 4.548350034383475e-07
mutations O 0 2.6982496592609095e-07
leading O 0 5.2557886931481335e-08
to O 0 6.624538251287504e-09
premature O 0 7.402256585464784e-08
truncation O 0 6.493895625681034e-07
of O 0 2.654682917935247e-09
the O 0 5.589411600226413e-09
protein O 0 2.1429966068353679e-07
( O 0 9.916443666213581e-09
nonsense O 0 1.8662230161226034e-07
, O 0 3.071846388369437e-10
splicing O 0 2.3819868744112682e-08
, O 0 2.6588786727899105e-09
insertions O 0 1.24338967566473e-07
and O 0 6.918371653341637e-09
deletions O 0 2.0695262037406792e-07
) O 0 5.1527049294008975e-09
and O 0 2.300845025615672e-08
just O 0 5.4706102758927955e-08
2 O 0 8.561383602057049e-09
% O 0 1.2262252324646283e-09
leading O 0 2.1603134836567506e-09
to O 0 1.973887026052168e-10
substitution O 0 1.5285381849139412e-09
of O 0 7.450111083606714e-10
one O 0 2.080790117986453e-08
amino O 0 2.862399561820439e-08
acid O 0 1.2416413674998239e-08
by O 0 3.86486759262894e-10
another O 0 6.819262488022559e-09
( O 0 1.5108403417229965e-08
missense O 0 2.116318682965357e-06
) O 0 4.599709058084045e-08
. O 0 2.481622800587502e-07

The O 0 2.253717497069374e-07
extraordinary O 0 7.121084166783476e-08
conservation O 0 9.165493253249224e-09
of O 0 3.8074818298206026e-10
the O 0 2.610202942676665e-09
PAX6 O 0 1.7599737702767015e-06
protein O 0 9.333318473636609e-08
at O 0 1.1401246169384649e-08
the O 0 2.5952453519551e-09
amino O 0 7.11010486043051e-08
acid O 0 6.671927366141972e-08
level O 0 8.307827314979477e-09
amongst O 0 8.097935655371202e-09
vertebrates O 0 1.3368158136017882e-08
predicts O 0 1.9929561290155107e-07
that O 0 1.8459646033974764e-09
pathological O 0 4.1387738747289404e-07
missense O 0 4.422004712978378e-05
mutations O 0 3.917711637768662e-06
should O 0 2.2726821313767687e-08
in O 0 1.5577348300155336e-09
fact O 0 1.2523180714651971e-08
be O 0 5.4381485981025435e-09
common O 0 4.84463757999265e-09
even O 0 1.907303825987583e-08
though O 0 1.2427833873118743e-08
they O 0 2.2119108766816e-09
are O 0 9.779340670590386e-10
hardly O 0 7.092117471074744e-08
ever O 0 4.3466101828926185e-08
seen O 0 1.5922120155664743e-07
in O 0 2.7819259784678252e-08
aniridia B-Disease 1 1.0
patients O 0 5.567932021222077e-06
. O 0 2.453272429647768e-07

This O 0 3.337843850204081e-07
indicates O 0 3.2120155424308905e-07
that O 0 1.9269239537322846e-09
there O 0 1.0969946062644453e-09
is O 0 5.90840210090704e-10
a O 0 2.115763120258407e-09
heavy O 0 3.465054533080547e-06
ascertainment O 0 0.00010479350748937577
bias O 0 0.00022009917302057147
in O 0 4.267060038642967e-09
the O 0 1.0928470350890507e-09
selection O 0 2.8017281827885654e-09
of O 0 1.2830745355074669e-09
patients O 0 1.444384256643616e-08
for O 0 9.66214663833398e-10
PAX6 O 0 5.4635884225717746e-06
mutation O 0 1.3340908822101483e-07
analysis O 0 5.984577278184133e-09
and O 0 3.5499672090821832e-09
that O 0 1.1636624996924638e-09
the O 0 4.75658268328516e-09
missing O 0 1.4494037259282777e-06
PAX6 O 0 0.0002375759358983487
missense O 0 0.0003957637818530202
mutations O 0 2.6665937184588984e-05
frequently O 0 3.1442518775293138e-06
may O 0 7.755270416964777e-07
underlie O 0 1.616715599084273e-05
phenotypes O 0 1.779789090505801e-05
distinct O 0 3.4482678756830865e-07
from O 0 1.043588895299763e-07
textbook O 0 0.00019764996250160038
aniridia B-Disease 1 1.0
. O 0 1.0184012353420258e-05

Here O 0 6.561152986250818e-06
we O 0 4.106983908513939e-08
present O 0 4.161310407369001e-09
four O 0 7.838330873255472e-09
novel O 0 7.234776830955525e-07
PAX6 O 0 0.00012370040349196643
missense O 0 0.0003252456954214722
mutations O 0 1.0139558980881702e-05
, O 0 8.539725371292661e-09
two O 0 3.1108333686802325e-09
in O 0 7.216506947571588e-09
association O 0 3.3376028607534636e-09
with O 0 6.580511691112179e-09
atypical O 0 1.3994125765748322e-05
phenotypes O 0 6.572542042704299e-05
ectopia B-Disease 0 5.7026561989914626e-05
pupillae I-Disease 0 9.33342453208752e-05
( O 0 7.265040125048472e-08
displaced B-Disease 0 1.0195244612987153e-06
pupils I-Disease 0 7.171249194470874e-07
) O 0 1.8378086963366513e-07
and O 0 2.4824308638926595e-05
congenital B-Disease 1 0.9999992847442627
nystagmus I-Disease 0 0.0007252205978147686
( O 0 3.800796122277461e-08
searching B-Disease 0 2.221133001967246e-07
gaze I-Disease 0 0.0003410349600017071
) O 0 2.3672397375662513e-08
, O 0 4.126242014734771e-09
and O 0 2.017667455334049e-08
two O 0 1.5083641002888726e-08
in O 0 3.1211406792408525e-08
association O 0 3.2108189440549495e-09
with O 0 1.6982000250465035e-09
more O 0 1.2712969343908753e-08
recognizable O 0 0.00023400125792250037
aniridia B-Disease 1 0.9999998807907104
phenotypes O 0 0.00040344020817428827
. O 0 7.10258177605283e-07

Strikingly O 0 0.0006497857975773513
, O 0 4.0650908772477123e-07
all O 0 3.584784247223638e-09
four O 0 1.0953832507709649e-08
mutations O 0 1.5519458429480437e-07
are O 0 7.670390433922591e-10
located O 0 1.0813462125724982e-08
within O 0 1.7466578183800152e-09
the O 0 2.5686819338233136e-09
PAX6 O 0 4.818458819499938e-06
paired O 0 1.6399818605350447e-06
domain O 0 3.4060570897054276e-07
and O 0 5.992346530092618e-08
affect O 0 1.3952882405021683e-08
amino O 0 2.9675305768250837e-08
acids O 0 1.1381430908841139e-08
which O 0 4.469316472466289e-09
are O 0 1.8091722564506085e-10
highly O 0 5.782244127949809e-10
conserved O 0 6.937769914117098e-09
in O 0 3.2352485135334064e-09
all O 0 1.263505078341609e-09
known O 0 2.6020076759891708e-08
paired O 0 2.726964396515541e-07
domain O 0 2.2450488756931009e-07
proteins O 0 4.3125956494804996e-07
. O 0 1.7961023957013822e-07

Our O 0 1.868719482445158e-05
results O 0 2.4434095280412294e-07
support O 0 1.1529481369620953e-08
the O 0 1.900367196938646e-09
hypothesis O 0 1.9847806953521285e-08
that O 0 8.494154268845477e-10
the O 0 1.9561853525917883e-10
under O 0 7.036329296994381e-10
- O 0 5.242763023716179e-08
representation O 0 9.864698391481852e-09
of O 0 2.9359785713722886e-09
missense O 0 2.9802316930727102e-05
mutations O 0 1.9066656022914685e-06
is O 0 9.34810273633957e-09
caused O 0 2.2149093226175864e-08
by O 0 1.7831538468016106e-09
ascertainment O 0 1.0239609764539637e-05
bias O 0 0.0005553869996219873
and O 0 1.1026342860986915e-07
suggest O 0 2.80516250228402e-08
that O 0 6.645567984797651e-10
a O 0 2.033708534909806e-09
substantial O 0 1.4048777252639866e-08
burden O 0 8.767725745428834e-08
of O 0 1.69942482308727e-09
PAX6 B-Disease 0 3.130801997031085e-05
- I-Disease 0 0.0001974350307136774
related I-Disease 0 7.686066396672686e-07
disease I-Disease 0 1.3596447388408706e-05
remains O 0 5.4973348539988365e-08
to O 0 3.366026124496102e-09
be O 0 7.3097239372543754e-09
uncovered O 0 9.171982355837827e-07
. O 0 2.6670626596114744e-08
. O 0 1.213781786191248e-07

The O 0 2.2298115709418198e-07
chromosomal O 0 1.3569631846621633e-05
order O 0 4.3074990685454395e-08
of O 0 1.7589205647539075e-09
genes O 0 1.7769067994777288e-07
controlling O 0 3.9328847378783394e-07
the O 0 5.067297248473324e-09
major O 0 1.4335377329643961e-08
histocompatibility O 0 2.488443158199516e-07
complex O 0 1.5173439393834087e-08
, O 0 3.205776533121707e-09
properdin O 0 2.812822117448377e-07
factor O 0 2.9977385906931886e-08
B O 0 6.071732059353963e-07
, O 0 5.0096303993996116e-08
and O 0 4.7802732296986505e-06
deficiency B-Disease 0 5.3975039918441325e-05
of I-Disease 0 4.823244581508845e-10
the I-Disease 0 3.3550013878169693e-09
second I-Disease 0 6.93949360197621e-08
component I-Disease 0 7.609573771105715e-08
of I-Disease 0 4.821794075127173e-09
complement I-Disease 0 4.992418212168559e-07
. O 0 4.043681940402166e-07

The O 0 3.676214248571341e-07
relationship O 0 1.2981853103610774e-07
of O 0 1.257451476277538e-09
the O 0 1.2075137556522009e-09
genes O 0 4.529675479147954e-08
coding O 0 5.313220867719792e-07
for O 0 5.722091245274896e-09
HLA O 0 4.978262950317003e-06
to O 0 5.168621086681924e-09
those O 0 8.813355045766968e-10
coding O 0 8.864733302971217e-08
for O 0 1.3982953683822075e-09
properdin O 0 2.941322634342214e-07
Factor O 0 1.7772636695667643e-08
B O 0 7.968713333639244e-08
allotypes O 0 8.976335834631755e-07
and O 0 6.599116630923163e-08
for O 0 2.5301719830395086e-08
deficiency B-Disease 0 1.5967822037055157e-05
of I-Disease 0 2.578153801557903e-10
the I-Disease 0 1.8424259895510886e-09
second I-Disease 0 2.0263682287691154e-08
component I-Disease 0 2.229613116355722e-08
of I-Disease 0 7.271604429703871e-10
complement I-Disease 0 7.974490756623709e-08
( O 0 2.862121206703705e-08
C2 O 0 1.0701885912567377e-05
) O 0 1.579224218062336e-08
was O 0 8.350948377255918e-08
studied O 0 2.2239845520743984e-09
in O 0 1.3635923501453817e-09
families O 0 2.3866060239186027e-09
of O 0 8.383273519818601e-10
patients O 0 7.568608850760938e-08
with O 0 1.9446925136890059e-07
connective O 1 0.9999953508377075
tissue O 1 0.999897837638855
disorders O 1 0.9589079022407532
. O 0 8.363571168956696e-07

Patients O 0 0.00175298226531595
were O 0 3.2904324598348467e-07
selected O 0 1.8825895509166912e-08
because O 0 4.614258308777153e-09
they O 0 2.733299586665794e-09
were O 0 4.3463344034933016e-09
heterozygous O 0 1.3830712930484879e-07
or O 0 3.370718104633852e-08
homozygous O 0 7.992549217306077e-05
for O 0 1.1671644642774481e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.3727142231800826e-06

12 O 0 4.468442512006732e-06
families O 0 1.0376819403745685e-07
with O 0 5.800927294075109e-09
15 O 0 4.4652285424717775e-08
matings O 0 5.6865169426600914e-06
informative O 0 2.2210972019820474e-05
for O 0 5.691366459359415e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 2.3599955056852195e-07
found O 0 1.1576862135598276e-07
. O 0 1.427716540547408e-07

Of O 0 6.213756478246069e-07
57 O 0 1.2119141956645763e-06
informative O 0 7.615118988724134e-07
meioses O 0 3.428083800827153e-06
, O 0 7.299623128176336e-09
two O 0 2.7030122584648097e-09
crossovers O 0 7.097299885572284e-07
were O 0 5.0075193769316684e-08
noted O 0 2.2856193382381207e-08
between O 0 1.9344489032846468e-07
the O 0 4.494290624279529e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.6360515903434134e-07
and O 0 1.1309952974158932e-08
the O 0 2.553110167724526e-09
HLA O 0 3.432591938690166e-06
- O 0 2.4791370378807187e-06
B O 0 7.135196256058407e-08
gene O 0 3.070115894843184e-08
, O 0 8.502696879908456e-10
with O 0 1.9939916384714707e-10
a O 0 1.5647625417614108e-09
recombinant O 0 2.7084686493594745e-08
fraction O 0 3.1341755857283715e-08
of O 0 6.076258607379259e-09
0 O 0 1.1614705641704859e-07
. O 0 1.2847739583321527e-07

035 O 0 0.04094273969531059
. O 0 0.00013489805860444903

A O 0 8.30295539344661e-06
lod O 0 0.0002840265806298703
score O 0 3.538953706083703e-06
of O 0 5.841497507930171e-09
13 O 0 1.0482829537750149e-07
was O 0 2.1516584070013778e-08
calculated O 0 1.9081699775824745e-08
for O 0 2.2931285759142384e-09
linkage O 0 0.002984248334541917
between O 1 0.7779128551483154
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 5.754447585104572e-08
HLA O 0 2.590015810710611e-06
- O 0 1.3059216144029051e-06
B O 0 5.837780392425884e-08
at O 0 1.180464614947141e-09
a O 0 6.440417088526829e-10
maximum O 0 2.1539732220077212e-09
likelihood O 0 1.5638911277093825e-09
value O 0 3.603050358069737e-10
of O 0 9.530049666084395e-11
the O 0 1.5843544531879417e-10
recombinant O 0 2.9269653367691717e-09
fraction O 0 4.623411431481372e-09
of O 0 1.4202611309244162e-09
0 O 0 4.9046274597230877e-08
. O 0 5.555572712978574e-08

04 O 0 0.004816053900867701
. O 0 3.4441836760379374e-05

18 O 0 4.264966264599934e-05
families O 0 1.8335161655613774e-07
with O 0 1.0461294053243364e-08
21 O 0 5.661830115855082e-08
informative O 0 6.22765696789429e-08
matings O 0 1.916195742523996e-06
for O 0 6.432514521037547e-09
both O 0 1.0042469078541671e-08
properdin O 0 1.8407361039862735e-06
Factor O 0 5.452921314486048e-08
B O 0 1.9284036056888e-07
allotype O 0 1.3191361176723149e-06
and O 0 4.047693735742541e-08
HLA O 0 8.851671736920252e-06
- O 0 1.5866848116274923e-05
B O 0 5.333217814040836e-07
were O 0 1.943068106413648e-08
found O 0 5.6311684204501944e-08
. O 0 8.135838669431905e-08

Of O 0 4.50715248234701e-07
72 O 0 9.993572120947647e-07
informative O 0 3.5537161124921113e-07
meioses O 0 5.062498075858457e-06
, O 0 1.2515228853260396e-08
three O 0 8.477326396416629e-09
recombinants O 0 4.807846835319651e-06
were O 0 1.4868020059566334e-07
found O 0 1.372888824846541e-08
, O 0 7.997880691057446e-10
giving O 0 3.201882370351683e-10
a O 0 3.8648970135390925e-10
recombinant O 0 3.9418788233547275e-09
fraction O 0 4.999109570746896e-09
of O 0 1.9392092376335768e-09
0 O 0 7.727932427314954e-08
. O 0 1.0797431571063498e-07

042 O 0 0.0042671095579862595
. O 0 2.887126538553275e-05

A O 0 4.5405672608467285e-06
lod O 0 0.0001505300751887262
score O 0 5.496978019436938e-07
of O 0 1.192399179394954e-09
16 O 0 1.117211390067041e-08
between O 0 8.641196203029722e-09
HLA O 0 9.484214388066903e-06
- O 0 1.3771232261206023e-05
B O 0 2.9771692311442166e-07
and O 0 2.8949074248885154e-09
Factor O 0 5.775336209268289e-09
B O 0 3.8946936342654226e-08
allotypes O 0 2.668712113518268e-07
was O 0 8.342797030991278e-08
calculated O 0 8.639136517274437e-09
at O 0 8.034637399845224e-10
a O 0 1.8104124865914173e-09
maximum O 0 3.432951922732741e-09
likelihood O 0 1.9091737080145776e-09
value O 0 4.969095135365365e-10
of O 0 6.469259850039322e-11
the O 0 2.2918025810447773e-10
recombinant O 0 5.701261684976089e-09
fraction O 0 1.0866349597904446e-08
of O 0 2.121541609056976e-09
0 O 0 8.221541492048345e-08
. O 0 8.348909830147022e-08

04 O 0 0.004395442549139261
. O 0 3.76963616872672e-05

A O 0 1.858400878518296e-06
crossover O 0 2.226733158749994e-06
was O 0 5.237533514446113e-06
shown O 0 5.579997619520327e-08
to O 0 1.8877159835284374e-09
have O 0 7.371089072449877e-09
occurred O 0 1.6482081477420252e-08
between O 0 9.191661320961941e-10
genes O 0 8.279543273204126e-09
for O 0 1.3121971287333167e-09
Factor O 0 1.7205831426281293e-08
B O 0 1.2865199039424624e-07
and O 0 1.866735210853676e-08
HLA O 0 5.148422587808454e-06
- O 0 1.2158711797383148e-05
D O 0 6.872166068205843e-06
, O 0 1.9888004576529283e-09
in O 0 9.299850334265614e-10
which O 0 1.1991187598425768e-08
HLA O 0 2.3252343908097828e-06
- O 0 3.5477532946970314e-06
D O 0 1.7792361859392258e-06
segregared O 0 2.8089084480598103e-07
with O 0 7.974913174280118e-09
HLA O 0 1.8621303752297536e-05
- O 0 9.224877430824563e-06
A O 0 8.172883667612041e-07
and O 0 2.2487257922421122e-07
B O 0 1.236847651853168e-06
. O 0 1.8230304021926713e-07

These O 0 8.457771372150091e-08
studies O 0 1.4525896929740156e-08
suggest O 0 1.0426791874351693e-08
that O 0 1.962928014576093e-10
the O 0 2.56336535331414e-10
genes O 0 9.1675209645814e-09
for O 0 1.088949819205709e-09
Factor O 0 1.2560791162741225e-07
B O 0 0.00020902293908875436
and O 0 0.07985695451498032
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.3458231196139536e-09
located O 0 2.3155746209369e-09
outside O 0 3.400511427997799e-09
those O 0 3.471224696571795e-10
for O 0 2.7075050534897116e-10
HLA O 0 4.345240995462518e-06
, O 0 3.855003871677809e-09
that O 0 3.252099978201528e-10
the O 0 4.23122759052319e-10
order O 0 1.0990135468347262e-09
of O 0 3.5374272955301933e-10
genese O 0 1.3577817981058615e-06
is O 0 1.5991657775771273e-08
HLA O 0 7.456933985849901e-07
- O 0 6.95420055762952e-07
A O 0 1.088770247292814e-07
, O 0 6.622314696613785e-09
- O 0 1.0757629524960066e-06
B O 0 1.2375184610391443e-07
, O 0 2.480314620356694e-09
- O 0 1.0080085388608495e-07
D O 0 1.896465278150572e-07
, O 0 8.004106821779544e-10
Factor O 0 4.400789954672746e-09
B O 0 1.1405905553374396e-07
allotype O 0 9.791025513550267e-05
, O 0 6.891805969644338e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 9.864806749249055e-10
that O 0 1.5039816614326185e-10
the O 0 4.525146091172161e-10
genes O 0 8.881133339855296e-08
coding O 0 0.00018196309974882752
for O 0 0.0002584148314781487
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.1481401546452616e-08
Factor O 0 2.1870890876130034e-08
B O 0 3.494158562489247e-08
allotypes O 0 1.3113276509102434e-07
are O 0 3.5425318234416636e-10
approximately O 0 1.0147032103446918e-09
3 O 0 5.9366573879060525e-09
- O 0 5.372703526518308e-07
- O 0 3.6907472349412274e-06
5 O 0 1.4412718130074609e-08
centimorgans O 0 9.052082816651819e-08
from O 0 7.442711447147587e-10
the O 0 9.132071765449723e-10
HLA O 0 4.989253170606389e-07
- O 0 1.6443593153780967e-07
A O 0 3.102314494185521e-08
and O 0 1.5666357100485584e-08
HLA O 0 2.5166627892758697e-06
- O 0 3.7638776575477095e-06
B O 0 1.6463631880014873e-07
loci O 0 4.8318501200128594e-08
, O 0 1.0527181348862769e-09
and O 0 1.668670202015221e-09
that O 0 4.640150486068251e-10
the O 0 1.3570202739288106e-09
apparent O 0 1.2764911616613972e-07
lack O 0 2.0758774699203286e-09
of O 0 3.200337495012917e-10
recombinants O 0 1.5370764572253393e-07
between O 0 2.624105155391021e-09
the O 0 1.0409378914388867e-09
Factor O 0 2.33784476222354e-08
B O 0 6.419231226573174e-07
gene O 0 2.670879621291533e-05
and O 1 0.6036245822906494
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
gene O 0 2.637806915117835e-07
suggests O 0 6.095925897398047e-08
that O 0 6.360771909186269e-10
these O 0 2.1327750676647383e-10
two O 0 2.521782560549468e-09
genes O 0 3.538859232321556e-07
lie O 0 2.0105296698602615e-06
in O 0 1.4062443431939187e-09
close O 0 4.3588393339177856e-08
proximity O 0 4.413914211909287e-08
to O 0 4.86611604344489e-08
one O 0 3.5129431807945366e-08
another O 0 8.967688103211913e-08
. O 0 3.001743777986121e-07

Distribution O 0 1.777380816747609e-06
of O 0 7.055204065409271e-08
emerin O 0 1.0899781955231447e-05
and O 0 1.2713678643194726e-07
lamins O 0 1.8980997992912307e-05
in O 0 3.574482931867351e-08
the O 0 5.6658272740151006e-08
heart O 0 3.980302608397324e-06
and O 0 1.124939075225484e-08
implications O 0 1.6241072486877783e-08
for O 0 8.496313874672978e-09
Emery B-Disease 1 0.5468130111694336
- I-Disease 1 0.9999760389328003
Dreifuss I-Disease 1 0.9999971389770508
muscular I-Disease 1 0.9988188147544861
dystrophy I-Disease 1 0.9621436595916748
. O 0 4.000955414085183e-06

Emerin O 0 0.0009405225864611566
is O 0 3.4936695669784967e-07
a O 0 3.189858688301683e-08
nuclear O 0 8.79603305747878e-08
membrane O 0 1.0719414689219775e-07
protein O 0 2.0325254013187077e-07
which O 0 4.7186958340716956e-08
is O 0 8.066733947487137e-09
missing O 0 4.7478287967805954e-08
or O 0 1.2744069799452973e-08
defective O 0 1.8706238051890978e-06
in O 0 1.59243526809405e-07
Emery B-Disease 1 0.9823523163795471
- I-Disease 1 0.9999990463256836
Dreifuss I-Disease 1 0.9999998807907104
muscular I-Disease 1 0.9999942779541016
dystrophy I-Disease 1 0.9999856948852539
( O 0 9.136571861745324e-06
EDMD B-Disease 1 0.9999996423721313
) O 0 1.0890335033764131e-06
. O 0 6.88330942466564e-07

It O 0 7.089587143127574e-06
is O 0 4.944283205077227e-08
one O 0 3.60410412625356e-09
member O 0 2.1330976984756944e-09
of O 0 3.9810466034850833e-10
a O 0 2.0834550085169212e-08
family O 0 1.8740811924544687e-07
of O 0 6.991170309333938e-09
lamina O 0 1.4665400158264674e-05
- O 0 2.6200159481959417e-05
associated O 0 4.672999409649492e-08
proteins O 0 1.197071330949484e-08
which O 0 6.569576438408831e-09
includes O 0 1.0210619905137719e-08
LAP1 O 0 9.833244803303387e-06
, O 0 2.4294259048929234e-08
LAP2 O 0 7.83153336669784e-06
and O 0 1.4698194661377784e-07
lamin O 0 9.056449925992638e-05
B O 0 3.461672349658329e-06
receptor O 0 2.539179604355013e-06
( O 0 2.294622447607253e-07
LBR O 0 6.195784226292744e-05
) O 0 2.6737970415524615e-07
. O 0 4.5847357910133724e-07

A O 0 1.4496138192043873e-06
panel O 0 5.922127002122579e-07
of O 0 7.311104166518589e-09
16 O 0 4.9665512591445804e-08
monoclonal O 0 7.826232604202232e-07
antibodies O 0 3.1792842491995543e-07
( O 0 9.569366632433685e-09
mAbs O 0 4.4326017700768716e-07
) O 0 1.52273660347646e-08
has O 0 6.811868047407188e-08
been O 0 2.5938318160001472e-08
mapped O 0 2.7816558940685354e-06
to O 0 5.624253063274409e-09
six O 0 1.3322156711126354e-09
specific O 0 2.4534377307539046e-10
sites O 0 5.381962875361523e-09
throughout O 0 2.550773814391505e-09
the O 0 9.027453229393245e-10
emerin O 0 4.079067039697293e-08
molecule O 0 2.6530935226531938e-09
using O 0 1.8076727892335498e-09
phage O 0 3.6425859661903814e-08
- O 0 7.914530897323857e-08
displayed O 0 2.7621782194842126e-08
peptide O 0 3.6271510239771487e-09
libraries O 0 8.687513486371756e-10
and O 0 1.8227577225360392e-09
has O 0 4.70018957088314e-09
been O 0 1.118933945498668e-09
used O 0 8.509381532739724e-10
to O 0 9.127909539330403e-10
localize O 0 8.838781582198862e-07
emerin O 0 2.8593656224984443e-06
in O 0 6.514710104710275e-09
human O 0 3.384865721045571e-08
and O 0 2.791382485156646e-07
rabbit O 0 0.15889225900173187
heart O 0 0.0001059203059412539
. O 0 6.374721124302596e-07

Several O 0 1.1808782574007637e-06
mAbs O 0 2.3075239369063638e-05
against O 0 1.0798193272876233e-07
different O 0 3.108059587475509e-08
emerin O 0 6.683671927021351e-06
epitopes O 0 2.9858701964258216e-05
did O 0 2.7060575575887924e-06
not O 0 1.1709793135139535e-08
recognize O 0 1.3129363374275727e-08
intercalated O 0 1.1208787498162565e-07
discs O 0 7.991574238985777e-05
in O 0 1.6024809212922264e-07
the O 0 2.121563653645353e-07
heart O 0 9.612680514692329e-06
, O 0 2.496814843766515e-08
though O 0 7.57517693017462e-09
they O 0 1.887190181903975e-09
recognized O 0 5.364366728599634e-09
cardiomyocyte O 0 3.8299126003948913e-07
nuclei O 0 1.2698774298769422e-07
strongly O 0 3.46729081002195e-08
, O 0 3.021790373480826e-09
both O 0 1.652141756736114e-09
at O 0 1.6836391836250186e-08
the O 0 8.483003632875352e-09
rim O 0 6.1720056692138314e-06
and O 0 9.649465226857501e-08
in O 0 5.241030276437186e-09
intranuclear O 0 4.532727871264797e-06
spots O 0 1.727942617435474e-05
or O 0 2.287517020249652e-07
channels O 0 3.774035576498136e-06
. O 0 3.771347962810978e-07

A O 0 1.3261163985589519e-05
polyclonal O 0 0.0002600044244900346
rabbit O 0 8.593531674705446e-05
antiserum O 0 3.308830855530687e-05
against O 0 4.332754315328202e-07
emerin O 0 2.8826889320043847e-05
did O 0 7.408202691294719e-07
recognize O 0 1.4015109073284293e-08
both O 0 2.090045247982175e-09
nuclear O 0 1.9431494635568924e-08
membrane O 0 3.878118803868347e-08
and O 0 8.280221841516777e-09
intercalated O 0 3.1874563433120784e-08
discs O 0 1.0651699085428845e-05
but O 0 2.6091143467965594e-08
, O 0 6.334716640132854e-10
after O 0 5.53462609076405e-10
affinity O 0 1.0772099878764152e-09
purification O 0 4.675618114902136e-09
against O 0 7.888180109105747e-10
a O 0 2.405714516484636e-09
pure O 0 1.0859988464062553e-08
- O 0 6.5566241573833395e-06
emerin O 0 7.70730275689857e-06
band O 0 7.289746690730681e-07
on O 0 1.3496771700260979e-08
a O 0 3.6965182026449384e-09
western O 0 2.3906439494680853e-08
blot O 0 0.00031860286253504455
, O 0 6.415999109776749e-08
it O 0 3.537053316904348e-08
stained O 0 0.0002506946329958737
only O 0 5.423264060055999e-09
the O 0 1.726802589807619e-09
nuclear O 0 5.823300597285197e-08
membrane O 0 2.743460640886042e-07
. O 0 1.8422306879983807e-07

These O 0 1.7039656086126342e-07
results O 0 8.036545295908581e-08
would O 0 9.944988832444324e-09
not O 0 1.4269843084946388e-09
be O 0 6.832812649015807e-10
expected O 0 2.1289598972629165e-09
if O 0 7.653233602411547e-10
immunostaining O 0 1.2920456526899216e-07
at O 0 2.2151576128948136e-09
intercalated O 0 9.265665568136683e-09
discs O 0 1.2074210644641425e-05
were O 0 3.333526876758697e-07
due O 0 3.4221390166067067e-09
to O 0 5.81082348904971e-10
a O 0 1.311879382903669e-09
product O 0 3.8745238128967685e-09
of O 0 6.658733980868803e-11
the O 0 8.637978665682056e-10
emerin O 0 2.1024212060183345e-07
gene O 0 3.409618543059878e-08
and O 0 2.2088518392138212e-07
, O 0 5.4038622465668595e-09
therefore O 0 1.6278250969392616e-09
, O 0 8.82112549671632e-10
cast O 0 4.882888759993875e-08
some O 0 1.3068395254833831e-09
doubt O 0 1.998386345292147e-09
upon O 0 1.4463788500229668e-10
the O 0 5.026835059318557e-10
hypothesis O 0 6.524573592514571e-08
that O 0 4.986189594546886e-08
cardiac B-Disease 0 5.850433444720693e-05
defects I-Disease 0 0.22776363790035248
in O 0 1.3183922931148118e-07
EDMD B-Disease 1 1.0
are O 0 2.4692428723938065e-07
caused O 0 7.406210755789289e-08
by O 0 4.918243590168458e-10
absence O 0 1.0430252217474845e-08
of O 0 2.8957802822304757e-09
emerin O 0 1.286655697185779e-05
from O 0 1.2780729363726095e-08
intercalated O 0 6.858540473331232e-07
discs O 0 0.00017499245586805046
. O 0 9.203736226481851e-07

Although O 0 5.3396115617943e-06
emerin O 0 0.00010309110803063959
was O 0 1.2978674703845172e-06
abundant O 0 1.1624163853696245e-08
in O 0 1.0209055822940627e-09
the O 0 1.4621427402161657e-09
membranes O 0 3.112449675768403e-08
of O 0 7.245106736775142e-10
cardiomyocyte O 0 1.228878431902558e-06
nuclei O 0 4.291671302780742e-07
, O 0 4.4837225487981414e-08
it O 0 6.827308141055255e-08
was O 0 1.8264775007992284e-06
absent O 0 1.2759441503362723e-08
from O 0 3.3127584009307043e-10
many O 0 3.1003061229384343e-10
non O 0 1.1345452577415926e-08
- O 0 5.056148438598029e-06
myocyte O 0 3.046455094590783e-05
cells O 0 2.406464147952647e-07
in O 0 4.770765560380141e-09
the O 0 2.9949724478228745e-08
heart O 0 4.357810666988371e-06
. O 0 2.958238098926813e-07

This O 0 5.468982777756537e-08
distribution O 0 3.6198272823639854e-08
of O 0 1.7743464475472592e-09
emerin O 0 1.131214048655238e-05
was O 0 5.573742782871705e-07
similar O 0 1.6333018271197375e-09
to O 0 7.944761293288138e-09
that O 0 2.0419523849568577e-09
of O 0 3.083386879154659e-10
lamin O 0 3.2382129120378522e-06
A O 0 2.318192571237887e-07
, O 0 2.484775274425033e-09
a O 0 1.793820869622209e-09
candidate O 0 2.089224970802661e-08
gene O 0 4.050960811241566e-08
for O 0 1.1367431440589826e-09
an O 0 7.409217239739974e-09
autosomal O 0 1.2230477295815945e-05
form O 0 8.887538172075438e-08
of O 0 5.19144236932334e-07
EDMD B-Disease 1 1.0
. O 0 6.2674962464370765e-06

In O 0 1.0809285413415637e-06
contrast O 0 1.2942434750584653e-06
, O 0 1.0072762535173752e-07
lamin O 0 0.0008197743445634842
B1 O 0 0.11745750904083252
was O 0 2.7334554033586755e-06
absent O 0 1.3362402739858226e-07
from O 0 4.204047332478922e-09
cardiomyocyte O 0 6.641809591201309e-07
nuclei O 0 1.2681975647410582e-07
, O 0 7.253213141211745e-09
showing O 0 2.4340718596249644e-07
that O 0 8.033124387907264e-09
lamin O 0 0.00011669679952319711
B1 O 0 0.0010298608103767037
is O 0 4.411221254940756e-08
not O 0 1.279589434410866e-09
essential O 0 8.738850199030423e-10
for O 0 3.7921676909746793e-10
localization O 0 4.900307715161034e-08
of O 0 1.4066117159927671e-09
emerin O 0 1.646764985707705e-06
to O 0 9.582078241976433e-09
the O 0 1.1053059800758547e-08
nuclear O 0 4.1008675566445163e-07
lamina O 0 1.2697088095592335e-05
. O 0 2.651016473009804e-07

Lamin O 0 0.17152024805545807
B1 O 1 0.9592352509498596
is O 0 4.184368663118221e-06
also O 0 5.187339411349967e-07
almost O 0 7.783049227327865e-08
completely O 0 1.135876573243877e-06
absent O 0 9.456816201236506e-07
from O 0 3.962837880067127e-08
skeletal O 0 0.002462409669533372
muscle O 0 4.5483924623113126e-05
nuclei O 0 8.972459909273311e-06
. O 0 4.5362727973952133e-07

In O 0 1.7678263247944415e-05
EDMD B-Disease 1 0.9999998807907104
, O 0 3.414447036220736e-08
the O 0 8.202346579722075e-10
additional O 0 4.098389627671395e-09
absence O 0 2.4660511854790457e-08
of O 0 3.778293233835939e-09
lamin O 0 0.00285761128179729
B1 O 0 0.0982811450958252
from O 0 9.962553804143681e-08
heart O 0 1.8934772015199997e-05
and O 0 4.941652491652349e-07
skeletal O 0 0.0004767868958879262
muscle O 0 5.469031293614535e-06
nuclei O 0 3.5704465517483186e-07
which O 0 5.8398736513254335e-08
already O 0 7.422629977327233e-08
lack O 0 1.3386989294872365e-08
emerin O 0 5.021746346756117e-06
may O 0 1.0234977310119575e-07
offer O 0 6.728073098649645e-10
an O 0 1.2210062128037436e-10
alternative O 0 3.4274889593177704e-09
explanation O 0 2.1218249379728604e-09
of O 0 6.176653077893945e-10
why O 0 8.931155370817123e-09
these O 0 1.2461272014263614e-09
tissues O 0 4.054903257610931e-08
are O 0 1.0571771236200789e-09
particularly O 0 7.0370309579459445e-09
affected O 0 1.6431515703629884e-08
. O 0 8.129227069275657e-09
. O 0 9.165829339963238e-08

Genetic O 0 1.6594480257481337e-05
mapping O 0 3.0415674245887203e-06
of O 0 2.6815744291752708e-08
the O 0 3.2631628954504777e-08
copper B-Disease 0 2.4170947654056363e-05
toxicosis I-Disease 0 9.679209324531257e-05
locus O 0 2.2354631710186368e-06
in O 0 3.5943436671459494e-08
Bedlington O 0 7.330228254431859e-05
terriers O 0 3.8600355765083805e-05
to O 0 3.784591484645716e-08
dog O 0 6.120774924056605e-05
chromosome O 0 4.246776006766595e-05
10 O 0 6.224961168754817e-08
, O 0 1.1840589619893649e-09
in O 0 7.470957741340101e-10
a O 0 9.900398723061699e-09
region O 0 2.785228900847869e-07
syntenic O 0 4.395299129100749e-06
to O 0 8.029585885083179e-09
human O 0 2.5657111990540216e-08
chromosome O 0 4.639885082724504e-05
region O 0 5.608502533505089e-07
2p13 O 0 7.470830951206153e-06
- O 0 4.0489103412255645e-05
p16 O 0 2.9691651434404776e-05
. O 0 6.141206085885642e-07

Abnormal O 1 0.9872338771820068
hepatic B-Disease 1 0.9947368502616882
copper I-Disease 0 0.0005019657546654344
accumulation I-Disease 0 2.7342766770743765e-06
is O 0 9.056759786574275e-09
recognized O 0 1.0206608891394353e-08
as O 0 2.6542338105173258e-08
an O 0 2.483673597453162e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 8.915737339521002e-07
man O 0 0.0007914384477771819
, O 0 2.583857394711231e-08
mouse O 0 0.00016209571913350374
, O 0 7.635772902858662e-08
rat O 0 0.00022981107758823782
and O 0 3.06438579400492e-07
dog O 0 8.164628525264561e-05
. O 0 3.949174072204187e-07

The O 0 3.1817353374208324e-07
major O 0 1.342354352118491e-07
cause O 0 1.7831419540925708e-07
of O 0 1.3246984842396614e-08
hepatic B-Disease 0 0.0010168793378397822
copper I-Disease 0 0.0003195376193616539
accumulation I-Disease 0 2.2286494640866295e-06
in O 0 5.612125875131824e-08
man O 0 7.928225386422127e-06
is O 0 4.328811975540248e-09
a O 0 1.1343894712467772e-08
dysfunctional O 0 4.644875843951013e-06
ATP7B O 0 1.326021538261557e-05
gene O 0 1.1309552974125836e-06
, O 0 6.01118941290224e-08
causing O 0 1.1301973472654936e-06
Wilson B-Disease 0 6.318429223028943e-05
disease I-Disease 0 0.0001077766646631062
( O 0 1.4434897366299992e-07
WD B-Disease 0 0.0005525515880435705
) O 0 8.179878250302863e-07
. O 0 7.29882515315694e-07

Mutations O 0 0.0001973580801859498
in O 0 3.881396892779776e-08
the O 0 6.20725648659004e-09
ATP7B O 0 2.73785667559423e-06
genes O 0 2.1617887568936567e-07
have O 0 2.017491169681307e-07
also O 0 2.4241498408628104e-07
been O 0 1.679915868635362e-07
demonstrated O 0 3.254001867958323e-08
in O 0 6.911565986200685e-09
mouse O 0 0.0005400036461651325
and O 0 1.4446413842961192e-06
rat O 0 0.0004190826148260385
. O 0 5.401896032708464e-07

The O 0 3.758852358259901e-07
ATP7B O 0 9.573014722263906e-06
gene O 0 1.4418981209018966e-06
has O 0 1.0892889577007736e-06
been O 0 2.6792942975362166e-08
excluded O 0 1.658213477639947e-08
in O 0 7.450124961394522e-10
the O 0 8.979336163505991e-10
much O 0 7.3373396247689016e-09
rarer O 0 4.562504045679816e-07
human O 0 1.299935803444896e-07
copper B-Disease 0 8.671808609506115e-05
overload I-Disease 0 0.0018537298310548067
disease O 0 4.212383828416932e-06
non B-Disease 0 4.939607833875925e-08
- I-Disease 0 4.809314759768313e-06
Indian I-Disease 0 1.5124109609132574e-07
childhood I-Disease 0 6.915583526279079e-06
cirrhosis I-Disease 0 4.223182622808963e-05
, O 0 2.7262149870921348e-08
indicating O 0 5.793056629954663e-07
genetic O 0 3.5891830520995427e-06
heterogeneity O 0 0.00013231423508841544
. O 0 1.4808291552981245e-06

By O 0 1.4600679776322067e-07
investigating O 0 2.3064170306952292e-07
the O 0 2.7530944635145715e-08
common O 0 1.020365857584693e-06
autosomal O 0 0.391528844833374
recessive O 1 0.9947592616081238
copper B-Disease 0 0.07686671614646912
toxicosis I-Disease 0 0.06600792706012726
( O 0 2.2583968473099958e-07
CT B-Disease 0 1.6764484826126136e-05
) O 0 1.6177294170915957e-08
in O 0 7.260244405671301e-09
Bedlington O 0 6.353176286211237e-05
terriers O 0 0.00021124730119481683
, O 0 9.611606799353467e-08
we O 0 2.7171200400744056e-08
have O 0 1.7367283167146752e-09
identified O 0 3.319166941295748e-09
a O 0 6.933110197060444e-10
new O 0 3.004691828678574e-09
locus O 0 5.988645170873497e-07
involved O 0 6.203483593480996e-08
in O 0 1.060797217178333e-06
progressive O 1 0.9629974365234375
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.549960984448262e-06

We O 0 1.3529680700230529e-06
examined O 0 2.173592861254292e-07
whether O 0 1.281157935295596e-08
the O 0 7.406716129310098e-09
WD B-Disease 0 0.0001008734543574974
gene O 0 4.77134199172724e-06
ATP7B O 0 0.0003240503720007837
was O 0 1.8309177676201216e-06
also O 0 1.4604739639878517e-08
causative O 0 7.431044224404104e-08
for O 0 1.46768341924286e-09
CT B-Disease 0 2.215878339484334e-06
by O 0 2.248243591296273e-09
investigating O 0 7.528838885662026e-09
the O 0 3.0744093937329353e-09
chromosomal O 0 4.5294687879504636e-05
co O 0 8.245431672548875e-06
- O 0 1.2348673408268951e-05
localization O 0 6.118442570368643e-07
of O 0 5.634678945654059e-09
ATP7B O 0 1.973186772374902e-05
and O 0 3.3162010026899225e-08
C04107 O 0 2.044491225206002e-07
, O 0 8.419296371187102e-10
using O 0 3.802454795476251e-09
fluorescence O 0 3.421462224650895e-08
in O 0 2.8552602504561264e-09
situ O 0 3.0805102824160713e-07
hybridization O 0 3.151650389554561e-07
( O 0 2.8319938394361088e-08
FISH O 0 1.3924758945904614e-07
) O 0 4.9157350190398574e-08
. O 0 1.1334727645362364e-07

C04107 O 0 0.0003709597513079643
is O 0 3.6275443449085287e-07
an O 0 1.264909244014234e-08
anonymous O 0 5.608833930637047e-07
microsatellite O 0 4.658461330109276e-05
marker O 0 0.0001033401204040274
closely O 0 2.9094396722939564e-06
linked O 0 2.9015259315201547e-06
to O 0 9.108925524969891e-08
CT B-Disease 0 0.000563429610338062
. O 0 8.714504815543478e-07

However O 0 2.293656280016876e-06
, O 0 1.0235621061838174e-07
BAC O 0 6.168315849208739e-06
clones O 0 1.8390304603599361e-06
containing O 0 7.568493742837745e-08
ATP7B O 0 1.2740256352117285e-05
and O 0 2.7841076999379766e-08
C04107 O 0 5.810696848129737e-07
mapped O 0 2.0216409666318214e-06
to O 0 8.52844550536247e-09
the O 0 6.185298051519794e-09
canine O 0 2.3525950382463634e-05
chromosome O 0 6.639607454417273e-05
regions O 0 1.9399080031234917e-07
CFA22q11 O 0 4.8988586058840156e-06
and O 0 9.738177197959885e-08
CFA10q26 O 0 6.715207746310625e-06
, O 0 1.1432145896606016e-08
respectively O 0 1.8752427166646157e-08
, O 0 1.3489352967965829e-09
demonstrating O 0 1.1696266177807502e-08
that O 0 3.978103180202197e-09
WD B-Disease 0 6.435120303649455e-05
cannot O 0 7.929867962275239e-08
be O 0 2.1921207071784465e-09
homologous O 0 6.136288277502899e-08
to O 0 4.398173913955361e-08
CT B-Disease 0 0.00023311006953008473
. O 0 1.302087753174419e-06

The O 0 7.175415817073372e-07
copper O 0 1.052757852448849e-06
transport O 0 3.040941365384242e-08
genes O 0 1.6171469496839563e-07
CTR1 O 0 8.354631972906645e-06
and O 0 1.1862651660976553e-07
CTR2 O 0 0.00010627663868945092
were O 0 7.371316428361752e-07
also O 0 9.010706492063036e-08
excluded O 0 1.463052967665135e-08
as O 0 2.861759496042282e-09
candidate O 0 7.144985492146816e-09
genes O 0 6.644747418960151e-09
for O 0 5.040305395276334e-10
CT B-Disease 0 1.5185392840066925e-05
since O 0 3.5988682611787226e-07
they O 0 5.892817789288074e-09
both O 0 8.754331703997309e-10
mapped O 0 3.867507984978147e-06
to O 0 1.9054311906074872e-08
canine O 0 0.0001336652785539627
chromosome O 0 0.000352199946064502
region O 0 4.300375167076709e-06
CFA11q22 O 0 5.7487282902002335e-05
. O 0 7.846768994568265e-07

2 O 0 5.1385337428655475e-05
- O 0 0.00022083005751483142
22 O 0 5.241031431069132e-06
. O 0 4.919393177260645e-07

5 O 0 0.00012590098776854575
. O 0 8.24648577690823e-06

A O 0 2.2537249151355354e-06
transcribed O 0 3.1134820801526075e-06
sequence O 0 4.583603470109665e-07
identified O 0 1.087952270495407e-07
from O 0 1.2790331016532264e-09
the O 0 8.768653581014973e-10
C04107 O 0 2.6426411636748526e-07
- O 0 3.4740637033792154e-07
containing O 0 5.1016012747595596e-08
BAC O 0 4.659143087337725e-06
was O 0 2.615308005715633e-07
found O 0 1.6943982883432795e-09
to O 0 2.9003721646603253e-10
be O 0 2.1460738741652108e-10
homologous O 0 2.1759825052924953e-09
to O 0 9.016698498953701e-10
a O 0 4.058398506145977e-09
gene O 0 1.1925003207124973e-07
expressed O 0 5.283033122083225e-09
from O 0 8.743402113431387e-10
human O 0 4.777267470501556e-09
chromosome O 0 3.6613412248698296e-06
2p13 O 0 8.761821845837403e-07
- O 0 2.423142859697691e-06
p16 O 0 4.3575968788900354e-07
, O 0 3.732466336003881e-09
a O 0 9.034864412171828e-09
region O 0 1.3589239244993223e-07
devoid O 0 1.034474621519621e-07
of O 0 3.1849070603051644e-10
any O 0 1.3176922886160014e-09
positional O 0 3.511320073812385e-06
candidate O 0 2.3499974304286297e-06
genes O 0 4.5170158955443185e-06
. O 0 7.352261377491232e-07

Molecular O 0 2.2726360384695e-06
analysis O 0 1.768631108234331e-07
of O 0 5.53382628609711e-09
the O 0 4.46540537879514e-09
APC B-Disease 0 2.699464403121965e-07
gene O 0 4.1800543471026685e-08
in O 0 6.790513484844496e-09
205 O 0 4.65202987243174e-08
families O 0 2.0745803297472776e-08
: O 0 2.615939465044903e-09
extended O 0 1.6679555869814067e-07
genotype O 0 1.3701671377930325e-05
- O 0 4.170008105575107e-05
phenotype O 0 7.784882654959802e-06
correlations O 0 1.1945597861995338e-06
in O 0 8.467678114243427e-09
FAP B-Disease 0 7.203293534985278e-07
and O 0 1.7321209355714018e-08
evidence O 0 2.351299599467893e-09
for O 0 3.3151920098006826e-10
the O 0 5.92366877771866e-10
role O 0 8.745907997820268e-09
of O 0 2.8350837233404036e-09
APC B-Disease 0 3.402443553568446e-07
amino O 0 2.3831773887650343e-08
acid O 0 3.5708922041521873e-08
changes O 0 4.56297364337388e-08
in O 0 3.633763526522671e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.035635076463222504
. O 0 1.4737230458194972e-06

BACKGROUND O 0 8.51159929879941e-05
/ O 0 0.00014023171388544142
AIMS O 0 9.866015489023994e-07
The O 0 5.940327341136253e-09
development O 0 1.9186696675888015e-08
of O 0 2.5038025341928005e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.0293000463643693e-07
a O 0 6.365557414511613e-09
variable O 0 2.9984704497110215e-08
range O 0 3.545990168163371e-08
of O 0 2.2177280012414258e-09
extracolonic O 0 3.3554657420609146e-05
manifestations O 0 7.506511337851407e-06
in O 0 2.667694388946984e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 8.506031917931978e-06
FAP B-Disease 0 1.6097970728878863e-05
) O 0 8.418405172960775e-08
is O 0 6.336980273857762e-09
the O 0 2.3588282438424812e-09
result O 0 6.179130984662606e-09
of O 0 6.864372403825314e-10
the O 0 1.1045872660986333e-08
dominant O 0 1.1166700460307766e-05
inheritance O 0 3.2949636079138145e-05
of O 0 5.139082986715948e-06
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999994039535522
coli I-Disease 1 1.0
( O 0 1.0252224456053227e-06
APC B-Disease 0 3.829243723885156e-06
) O 0 1.1671912858446376e-07
gene O 0 4.67714653495932e-06
mutations O 0 1.738144965202082e-05
. O 0 6.25281757038465e-07

In O 0 2.184384015890828e-07
this O 0 3.0433477959945776e-09
study O 0 1.9947647977858196e-09
, O 0 3.002198767365627e-10
direct O 0 1.4466112752131721e-09
mutation O 0 1.5478375914312892e-08
analysis O 0 1.4371425161030515e-09
of O 0 2.5673874137766006e-10
the O 0 2.390970976762219e-09
APC B-Disease 0 1.4422141703107627e-07
gene O 0 7.619406261483164e-08
was O 0 3.0577493816963397e-06
performed O 0 3.609643783875072e-08
to O 0 2.7762740995029844e-09
determine O 0 4.688918409101461e-08
genotype O 0 3.8140824472066015e-06
- O 0 1.102543501474429e-05
phenotype O 0 1.5044126939756097e-06
correlations O 0 1.0107770975764652e-07
for O 0 2.0081527551951694e-09
nine O 0 9.710374371252328e-08
extracolonic O 0 6.029336418578168e-06
manifestations O 0 4.930684553983156e-07
and O 0 1.0915101711361785e-08
to O 0 6.584526257569223e-10
investigate O 0 4.642577877689291e-09
the O 0 5.06324937532554e-09
incidence O 0 3.144500851703924e-06
of O 0 3.0516773552591303e-09
APC B-Disease 0 1.4120485047897091e-06
mutations O 0 3.658035723219655e-07
in O 0 1.702712282281027e-08
non O 0 2.127708057741984e-06
- O 1 0.9998218417167664
FAP O 1 0.9997256398200989
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.61859372080653e-06

METHODS O 0 3.1353019949165173e-06
The O 0 1.1094419249957355e-07
APC B-Disease 0 1.7341692455374869e-06
gene O 0 7.774946197969257e-07
was O 0 3.966612212025211e-07
analysed O 0 1.421727375827686e-07
in O 0 5.966910521237878e-09
190 O 0 5.899793364960715e-08
unrelated O 0 1.0213311441020778e-07
FAP B-Disease 0 2.15966542782553e-06
and O 0 9.57676533630547e-08
15 O 0 1.5386824259167042e-07
non O 0 1.5194543721008813e-06
- O 1 0.9999363422393799
FAP O 1 0.9999721050262451
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 2.778967200356419e-06
using O 0 2.0084281970866869e-07
denaturing O 0 0.00022754484962206334
gradient O 0 3.993895370513201e-05
gel O 0 7.37089867470786e-05
electrophoresis O 0 7.800572348060086e-06
, O 0 1.5688096155486164e-08
the O 0 1.0072158662666197e-09
protein O 0 3.775284085349995e-08
truncation O 0 6.270882408898615e-07
test O 0 2.8385102268657647e-08
, O 0 1.5248980966831027e-09
and O 0 7.666221546465124e-10
direct O 0 1.13488507480497e-08
sequencing O 0 6.529541565214458e-07
. O 0 2.9955211289234285e-07

RESULTS O 0 1.186734425573377e-05
Chain O 0 8.666668691148516e-06
terminating O 0 8.202321168937488e-07
signals O 0 1.226941549248295e-06
were O 0 1.634717428089516e-08
only O 0 1.3576131330239605e-09
identified O 0 2.697878365154338e-08
in O 0 5.640356182112782e-09
patients O 0 2.3981336028100486e-08
belonging O 0 6.530310514563098e-09
to O 0 3.424489580794443e-09
the O 0 7.434060478317406e-09
FAP B-Disease 0 1.8382678490524995e-06
group O 0 6.277470276927488e-08
( O 0 8.093180348112128e-09
105 O 0 1.1086360274248364e-07
patients O 0 1.337397890210923e-07
) O 0 3.586563934732112e-08
. O 0 1.0888615520343592e-07

Amino O 0 1.779127342160791e-05
acid O 0 2.1326486603356898e-06
changes O 0 3.083648891788471e-08
were O 0 2.727888359643771e-09
identified O 0 4.346699444823798e-09
in O 0 9.906854225860684e-10
four O 0 3.03012583913187e-08
patients O 0 1.4561876149343789e-08
, O 0 1.0135871031380361e-09
three O 0 5.098602873232494e-09
of O 0 3.5762612871081956e-09
whom O 0 3.3215549137821654e-06
belonged O 0 2.908508349719341e-07
to O 0 5.530681690402162e-09
the O 0 5.752776033318696e-09
non O 0 6.823376708098294e-08
- O 0 2.2030164473108016e-05
FAP O 0 5.813662028231192e-06
group O 0 9.107707228395157e-07
of O 0 1.5838900253584143e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 5.205352863413282e-05
. O 0 6.436407602450345e-07

Genotype O 1 0.8352277278900146
- O 0 0.4767817258834839
phenotype O 0 0.000662108650431037
correlations O 0 7.78210687712999e-06
identified O 0 5.851921400790161e-07
significant O 0 1.0072739975441891e-08
differences O 0 1.0431176633574069e-06
in O 0 1.3607714066665721e-08
the O 0 5.13030640192369e-09
nature O 0 9.818726276478174e-09
of O 0 5.685339421468427e-10
certain O 0 5.766035648946399e-09
extracolonic O 0 1.6191719623748213e-05
manifestations O 0 2.919680355262244e-07
in O 0 1.2337048715949095e-08
FAP B-Disease 0 4.762386197398882e-06
patients O 0 5.116891443890381e-08
belonging O 0 1.3711694890616855e-08
to O 0 4.9954493874793116e-09
three O 0 3.1570404956937637e-08
mutation O 0 3.7724341837019892e-06
subgroups O 0 8.05995205155341e-06
. O 0 5.847107331646839e-07

CONCLUSIONS O 0 2.5379727958352305e-05
Extended O 0 7.578765689686406e-06
genotype O 0 0.00013329666398931295
- O 0 0.00019614504708442837
phenotype O 0 1.9721937860595062e-05
correlations O 0 1.3004012089368189e-06
made O 0 2.55912286917237e-08
in O 0 8.641768411976614e-10
this O 0 3.514373791979608e-10
study O 0 9.500199515954932e-10
may O 0 1.0894598290178692e-07
have O 0 1.3548090427306647e-09
the O 0 1.9639390114178923e-10
potential O 0 1.3261565179334411e-09
to O 0 4.037527256972595e-10
determine O 0 4.734539982287345e-10
the O 0 5.014988424534295e-10
most O 0 1.630157536736121e-10
appropriate O 0 4.042435830520219e-10
surveillance O 0 3.0091268143905836e-08
and O 0 3.607645959746719e-09
prophylactic O 0 6.361032234281083e-08
treatment O 0 9.480690899010824e-09
regimens O 0 4.8256332263463264e-08
for O 0 5.762371135809019e-10
those O 0 3.4424791905962593e-09
patients O 0 7.515266631230588e-09
with O 0 2.6735451630344187e-09
mutations O 0 5.328418524186418e-07
associated O 0 1.815347694389402e-08
with O 0 1.4078660015570676e-08
life O 0 1.9903286556655075e-06
threatening O 0 8.549246558686718e-05
conditions O 0 6.116568329161964e-06
. O 0 1.8876544061185996e-07

This O 0 1.1462663707106913e-07
study O 0 1.399651594624629e-08
also O 0 9.390867639069711e-09
provided O 0 1.740339428124571e-09
evidence O 0 1.171532759691729e-09
for O 0 1.976313279694608e-10
the O 0 3.134162041007471e-09
pathological O 0 2.0873635264706536e-07
nature O 0 1.4785184632160053e-08
of O 0 6.640069050156683e-10
amino O 0 3.963715045074423e-08
acid O 0 2.7499245547346618e-08
changes O 0 2.6919093620847434e-09
in O 0 1.889740364191539e-09
APC O 0 1.897272028372754e-07
associated O 0 7.158380999072733e-09
with O 0 2.4177708723982505e-09
both O 0 8.355055314268611e-09
FAP B-Disease 0 2.116694304277189e-06
and O 0 2.822611406827491e-07
non O 0 3.1204940569296014e-06
- O 1 0.9999866485595703
FAP O 1 0.999969482421875
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 9.166978088614997e-06
. O 0 4.043079826487883e-08
. O 0 1.3716919511352899e-07

Inherited B-Disease 1 0.999991774559021
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999949932098389
and O 0 0.0009350423351861537
cancer B-Disease 0 0.0006075425771996379
risk O 0 4.378346147859702e-07
of O 0 4.197133307570766e-09
the O 0 3.407323490023373e-08
APC O 0 8.140561476466246e-06
I1307K O 0 1.4015654414833989e-05
polymorphism O 0 1.522532693343237e-05
. O 0 5.444009048005682e-07

Germ O 0 0.006686019711196423
- O 0 0.049458570778369904
line O 0 0.00014530590851791203
and O 0 2.278107125164297e-08
somatic O 0 6.302496444732242e-07
truncating O 0 2.7568785299081355e-06
mutations O 0 1.4347926935442956e-06
of O 0 2.228366380307989e-09
the O 0 3.882320687154106e-09
APC B-Disease 0 2.0920347765240876e-07
gene O 0 6.64662564986429e-08
are O 0 4.397643138531748e-09
thought O 0 1.2287544315370269e-08
to O 0 1.748745503959981e-08
initiate O 0 1.5756995708215982e-05
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.01897362433373928
formation O 0 5.680679350916762e-06
in O 0 1.1869664376717992e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 3.626366742537357e-05
sporadic O 1 0.9722573161125183
colorectal O 1 1.0
carcinogenesis O 1 0.9940627217292786
, O 0 2.0812326511077117e-06
respectively O 0 2.472292408128851e-06
. O 0 7.921430551505182e-07

Recently O 0 7.885306695243344e-05
, O 0 7.457624917606154e-08
an O 0 1.3396695308642848e-08
isoleucine O 0 0.0002117076510330662
- O 0 2.2186819478520192e-05
- O 0 4.503127638599835e-05
> O 0 1.0671653853933094e-06
lysine O 0 1.7037931456798106e-06
polymorphism O 0 9.842267445492325e-07
at O 0 2.1500339286717463e-08
codon O 0 7.36054005301412e-07
1307 O 0 1.2094479870938812e-06
( O 0 1.4335787668073863e-08
I1307K O 0 1.4036663742444944e-07
) O 0 1.5580496892653173e-09
of O 0 1.5431136923815814e-10
the O 0 1.8514619837262103e-09
APC B-Disease 0 1.0248826498582275e-07
gene O 0 6.366676785773961e-08
has O 0 1.0138876405108022e-07
been O 0 4.648994078593205e-09
identified O 0 3.475439713795936e-09
in O 0 4.449640378378916e-10
6 O 0 8.776606108540363e-09
% O 0 1.136552407743352e-09
- O 0 2.1557914919867471e-07
7 O 0 1.4505165779610252e-07
% O 0 1.3482254201946375e-09
of O 0 2.3994761733092673e-10
the O 0 3.7436316269179315e-09
Ashkenazi O 0 3.6915989767294377e-06
Jewish O 0 1.0698926899976868e-07
population O 0 3.780227331162678e-08
. O 0 5.088277887921322e-08

To O 0 2.3146183991684666e-07
assess O 0 3.236877148538042e-07
the O 0 6.480838976585801e-09
risk O 0 1.4342925069854573e-08
of O 0 2.5439361728274434e-10
this O 0 1.1975342939507527e-09
common O 0 2.5514612644883528e-08
APC B-Disease 0 6.682280968561827e-07
allelic O 0 1.5066984815348405e-06
variant O 0 9.161447451333515e-06
in O 0 1.089301463252923e-06
colorectal O 1 1.0
carcinogenesis O 0 0.018620887771248817
, O 0 4.584416615216469e-07
we O 0 5.0786596261787054e-08
have O 0 1.8826962211448972e-09
analyzed O 0 7.836940874028642e-09
a O 0 1.4454639707395245e-09
large O 0 2.944862353970734e-09
cohort O 0 7.830698223187937e-08
of O 0 7.496779863558345e-10
unselected O 0 5.248273282631999e-06
Ashkenazi O 0 7.946331606945023e-06
Jewish O 0 1.2845865171584592e-07
subjects O 0 8.481745084054637e-08
with O 0 4.9260780343729493e-08
adenomatous B-Disease 0 0.00020099151879549026
polyps I-Disease 0 0.0035305223427712917
and O 0 6.041482834007184e-07
. O 0 1.996863971953644e-07
or O 0 0.005441620480269194
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 3.110538671080576e-08
for O 0 1.2235128465931666e-09
the O 0 1.0153464735651596e-08
APC O 0 3.2548948638577713e-06
I1307K O 0 5.490667263075011e-06
polymorphism O 0 4.399517820274923e-06
. O 0 3.0211870694074605e-07

The O 0 2.0821616999455728e-06
APC O 0 1.3359564036363736e-05
I1307K O 0 4.9567556743568275e-06
allele O 0 3.2649613785906695e-06
was O 0 1.1947838629566832e-07
identified O 0 1.5072826542450457e-08
in O 0 8.409168916756471e-10
48 O 0 1.8023992964799618e-08
( O 0 1.3099740181488073e-09
10 O 0 1.479197431208945e-09
. O 0 4.0342248985858475e-10
1 O 0 4.41108438664628e-09
% O 0 1.3713702395889982e-09
) O 0 7.122884504440208e-10
of O 0 1.3987514480007235e-09
476 O 0 1.283549750041857e-06
patients O 0 6.502888254544814e-07
. O 0 1.7064097335151018e-07

Compared O 0 5.923691333009629e-06
with O 0 7.4433113006477925e-09
the O 0 9.884394414072517e-10
frequency O 0 3.4708111940062736e-08
in O 0 1.0390712734675844e-09
two O 0 1.9149943852880824e-09
separate O 0 8.653946004244517e-09
population O 0 2.497175799476281e-09
control O 0 4.339130299513272e-08
groups O 0 2.4262063469393524e-09
, O 0 7.681487668165232e-10
the O 0 1.90519777731879e-09
APC O 0 4.6711014078937296e-07
I1307K O 0 8.966881637206825e-07
allele O 0 3.329952278363635e-07
is O 0 3.923531721738982e-09
associated O 0 1.8290228220863014e-09
with O 0 2.422764766585317e-10
an O 0 4.982866341762815e-10
estimated O 0 1.6453373774538704e-08
relative O 0 3.994932384898675e-08
risk O 0 1.9420529184799307e-08
of O 0 1.1979751635138314e-09
1 O 0 1.345624127679912e-07
. O 0 2.392934561612492e-07

5 O 0 2.070851951430086e-05
- O 0 3.659868161776103e-05
1 O 0 1.1945472806473845e-06
. O 0 5.635401407744212e-07

7 O 0 9.923493053065613e-05
for O 0 1.606316800462082e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 0 0.462702214717865
( O 0 5.503277407115093e-07
both O 0 1.3266763687624916e-07
P O 0 0.0006239996291697025
= O 0 1.0962946362269577e-05
. O 0 7.665468615414284e-08
01 O 0 2.921695795521373e-06
) O 0 8.516826000004585e-08
. O 0 2.731602819494583e-07

Furthermore O 0 3.932010258722585e-06
, O 0 5.0322697120464e-08
compared O 0 3.550815463881918e-08
with O 0 3.8652383516080135e-09
noncarriers O 0 5.436234459921252e-06
, O 0 1.6963911164680212e-08
APC O 0 2.0921686427755048e-07
I1307K O 0 3.1782141718394996e-07
carriers O 0 3.5049051660962505e-08
had O 0 6.195170954015339e-08
increased O 0 2.8331268442371993e-09
numbers O 0 6.3346234924210876e-09
of O 0 3.496030354099844e-09
adenomas B-Disease 0 0.0002856641367543489
and O 0 1.96656310436083e-05
colorectal B-Disease 1 1.0
cancers I-Disease 0 0.24232372641563416
per O 0 2.8751495051437814e-07
patient O 0 1.2132209121773485e-06
( O 0 2.8234074633815e-08
P O 0 1.941060872923117e-05
= O 0 1.9928813799197087e-06
. O 0 7.626425713169738e-09
03 O 0 7.939886614849456e-08
) O 0 3.497010458985983e-09
, O 0 1.6502867961065704e-09
as O 0 4.178760892870059e-09
well O 0 4.021711408341844e-09
as O 0 2.4839270640342193e-09
a O 0 1.6674936986760258e-08
younger O 0 2.0905271469473519e-07
age O 0 2.005719323960875e-08
at O 0 1.2932519943831267e-08
diagnosis O 0 5.618944214802468e-06
. O 0 1.8839513415969122e-07

We O 0 4.9646419029159006e-06
conclude O 0 2.9918354016444937e-07
that O 0 2.9947651025707955e-09
the O 0 5.2677187056815455e-09
APC O 0 6.643932124461571e-07
I1307K O 0 1.3065445045867818e-06
variant O 0 1.6782901184342336e-06
leads O 0 5.628236294796807e-07
to O 0 4.144670029404551e-08
increased O 0 1.5458998632311705e-06
adenoma B-Disease 1 1.0
formation O 0 3.001468940055929e-07
and O 0 1.1087688100985815e-08
directly O 0 5.528656643605245e-09
contributes O 0 1.0741576517148133e-08
to O 0 7.535040924544489e-10
3 O 0 5.030194483168771e-09
% O 0 7.676595470407221e-10
- O 0 1.031029412956741e-07
4 O 0 5.4789950354461325e-08
% O 0 1.635558799506498e-09
of O 0 4.749499682432656e-10
all O 0 2.097118212418536e-08
Ashkenazi O 0 0.0019478719914332032
Jewish O 0 0.14141146838665009
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.32253716806008e-06

The O 0 2.185467593562862e-07
estimated O 0 6.351006476279508e-08
relative O 0 2.4710844925834863e-08
risk O 0 1.1608676686591934e-08
for O 0 4.2045986137217994e-10
carriers O 0 1.2261230253329813e-08
may O 0 4.717379820107226e-09
justify O 0 1.216214018384676e-09
specific O 0 2.6588062307375537e-10
clinical O 0 2.578715907475271e-09
screening O 0 3.3961877754506986e-09
for O 0 2.31698285557691e-10
the O 0 3.8234485022492493e-10
360 O 0 2.3238541757564235e-08
, O 0 9.149349611270452e-10
000 O 0 1.4225113309507265e-09
Americans O 0 7.564994186637364e-10
expected O 0 1.1908763974943781e-09
to O 0 7.747850139239176e-10
harbor O 0 8.508268933837826e-08
this O 0 1.733705679018982e-10
allele O 0 1.4854862229185528e-08
, O 0 6.036967037381658e-10
and O 0 6.464144775009117e-10
genetic O 0 1.768849600125577e-08
testing O 0 5.117444690228012e-09
in O 0 8.603809331653167e-10
the O 0 1.3296491685466094e-09
setting O 0 5.821190995902725e-08
of O 0 3.943849247178832e-09
long O 0 5.522098831534095e-07
- O 0 2.619911356305238e-06
term O 0 9.865266292763408e-08
- O 0 2.2031125013199926e-07
outcome O 0 1.1375136388380724e-08
studies O 0 2.2398032317738625e-09
may O 0 4.161746947062284e-09
impact O 0 9.919981280859247e-09
significantly O 0 3.6839287531620357e-06
on O 1 0.940373957157135
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 9.152060442829679e-07
in O 0 4.613536663811146e-09
this O 0 3.5348526328249363e-09
population O 0 2.0996356653313342e-08
. O 0 7.60345102435167e-08

Localization O 0 3.2781765185063705e-05
of O 0 6.353769066436143e-08
human O 0 5.29055803610845e-08
BRCA1 O 0 1.2477908967412077e-05
and O 0 1.3413670103545883e-06
its O 0 5.248115186873292e-08
loss O 0 6.993919896558509e-07
in O 0 3.501110157344556e-08
high O 0 4.884826012130361e-06
- O 0 0.03072240948677063
grade O 0 4.23631354351528e-06
, O 0 3.6002578696070486e-08
non B-Disease 0 4.432838807133521e-07
- I-Disease 0 0.3012942373752594
inherited I-Disease 1 0.8403327465057373
breast I-Disease 1 0.9998908042907715
carcinomas I-Disease 1 1.0
. O 0 1.3889434740121942e-05

Although O 0 8.632022172605502e-07
the O 0 1.3058186532077798e-08
link O 0 2.162504273428567e-07
between O 0 7.105278143626492e-08
the O 0 6.246154526934333e-08
BRCA1 O 0 0.010129790753126144
tumour B-Disease 1 1.0
- O 0 0.00011045601422665641
suppressor O 0 0.0004210642073303461
gene O 0 2.9258029826451093e-05
and O 0 2.4529017537133768e-05
hereditary B-Disease 1 0.9999983310699463
breast I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 6.557722258548893e-07
established O 0 1.0469118016942502e-08
, O 0 2.6972699629368435e-09
the O 0 4.849332047029975e-10
role O 0 2.256278186507643e-08
, O 0 1.2534436599764831e-08
if O 0 5.410666359395577e-10
any O 0 2.1270592232003338e-10
, O 0 3.3302249846656196e-10
of O 0 2.687762512554315e-10
BRCA1 O 0 8.917684795051173e-07
in O 0 2.1340754940979423e-08
non B-Disease 0 5.402375222729461e-07
- I-Disease 0 0.3096602261066437
familial I-Disease 0 0.4264352321624756
cancers I-Disease 1 0.7465823888778687
is O 0 1.0132729499900961e-07
unclear O 0 2.6552748977337615e-07
. O 0 1.6420055715116177e-07

BRCA1 O 0 0.010971440002322197
mutations O 0 0.0003663645766209811
are O 0 3.614397314777307e-08
rare O 0 1.1816771561257156e-08
in O 0 1.3640066853781718e-08
sporadic B-Disease 0 0.04634103924036026
cancers I-Disease 1 0.9924206137657166
, O 0 9.777745901828894e-08
but O 0 1.763281431976793e-08
loss O 0 2.0088050334265972e-08
of O 0 1.5668649711031435e-09
BRCA1 O 0 5.7080492297245655e-06
resulting O 0 8.16793033209251e-08
from O 0 7.792523071259438e-09
reduced O 0 9.76307958922007e-08
expression O 0 1.0645311476764618e-07
or O 0 1.6701930505291784e-08
incorrect O 0 2.54327488846684e-07
subcellular O 0 4.86329508930794e-06
localization O 0 2.049108843493741e-06
is O 0 8.04862931857997e-09
postulated O 0 9.735948225397806e-08
to O 0 8.489866587524375e-09
be O 0 1.782776370973238e-09
important O 0 5.418814841284814e-10
in O 0 2.9995959049955445e-09
non B-Disease 0 2.0781156706561887e-07
- I-Disease 0 0.08388463407754898
familial I-Disease 1 0.9783431887626648
breast I-Disease 1 0.9999994039535522
and I-Disease 1 0.9999673366546631
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 2.916935272878618e-06

Epigenetic O 0 0.0004781397874467075
loss O 0 0.0003062019241042435
, O 0 3.0996383770798275e-07
however O 0 1.7184939693493106e-08
, O 0 4.589532309751121e-09
has O 0 6.311349665111265e-08
not O 0 1.4070464793292103e-09
received O 0 5.672871616901887e-10
general O 0 6.589853107641375e-10
acceptance O 0 1.3782805119433306e-08
due O 0 2.5997242136810428e-09
to O 0 1.1288805445985872e-09
controversy O 0 1.7108639838170348e-08
regarding O 0 4.753489601938554e-09
the O 0 1.9143515661568244e-09
subcellular O 0 6.27291001364938e-07
localization O 0 1.376694171995041e-07
of O 0 6.793813289718287e-10
BRCA1 O 0 4.290943138585135e-07
proteins O 0 1.7328742885069914e-08
, O 0 2.37839459238387e-09
reports O 0 7.797667400666342e-09
of O 0 5.143619419278878e-10
which O 0 4.991784763319629e-08
have O 0 1.3626986650194794e-08
ranged O 0 1.0640520997640124e-07
from O 0 4.840977063658158e-10
exclusively O 0 2.4448900681761643e-09
nuclear O 0 1.1439976077554093e-08
, O 0 7.657774969693776e-10
to O 0 4.004426235049152e-10
conditionally O 0 5.372427480665465e-08
nuclear O 0 1.1209082551033589e-08
, O 0 4.2332456984262024e-10
to O 0 4.630654748538632e-10
the O 0 3.907668855163138e-09
ER O 0 1.3225485417933669e-05
/ O 0 1.1633989061010652e-06
golgi O 0 1.2566750910991686e-06
, O 0 6.910287453365527e-09
to O 0 2.0486192742197318e-09
cytoplasmic O 0 1.9754752145217935e-07
invaginations O 0 9.15920281840954e-07
into O 0 1.299150920175407e-08
the O 0 1.5627767524506453e-08
nucleus O 0 6.767835998289229e-07
. O 0 1.3287224476243864e-07

In O 0 3.0238791737247084e-07
an O 0 7.49236672703546e-09
attempt O 0 4.963137598679168e-07
to O 0 6.614465064558317e-08
resolve O 0 8.652569363221119e-07
this O 0 2.31348673551679e-09
issue O 0 1.881476663356807e-08
, O 0 2.6025983146382714e-08
we O 0 1.3733549408811996e-08
have O 0 1.0958533636085122e-08
comprehensively O 0 2.116463974743965e-06
characterized O 0 3.1243843068295973e-07
19 O 0 8.547453234086788e-08
anti O 0 4.73238713993851e-07
- O 0 3.0498096748488024e-05
BRCA1 O 0 7.692410872550681e-05
antibodies O 0 4.405093477544142e-06
. O 0 3.1747396178616327e-07

These O 0 1.958661357548408e-07
reagents O 0 6.757645678590052e-07
detect O 0 3.8830859239169513e-07
a O 0 3.461568809370874e-08
220 O 0 1.2766055590418546e-07
- O 0 7.519340670114616e-07
kD O 0 2.4910414140322246e-06
protein O 0 1.6384485945764027e-07
localized O 0 2.95211975753773e-07
in O 0 4.126627928258131e-09
discrete O 0 1.3858254988008412e-07
nuclear O 0 1.5873830250257015e-07
foci O 0 2.3220038656290853e-06
in O 0 5.989316598231653e-09
all O 0 2.904176676921111e-09
epithelial O 0 2.847596931587759e-07
cell O 0 7.415875188598875e-06
lines O 0 7.468665717169642e-05
, O 0 3.2643443503843628e-09
including O 0 8.946479113092209e-10
those O 0 2.5354363053509132e-09
derived O 0 1.6861104512599923e-08
from O 0 2.2630274543189444e-08
breast B-Disease 0 0.0006064313347451389
malignancies I-Disease 0 0.000391885987482965
. O 0 1.0025149776993203e-06

Immunohistochemical O 0 0.0016177670331671834
staining O 0 0.00014250955427996814
of O 0 1.5855871993153414e-07
human O 0 2.6074110337503953e-07
breast O 0 0.0003777801466640085
specimens O 0 4.615488649051258e-07
also O 0 5.506522029463667e-07
revealed O 0 2.6091449853993254e-06
BRCA1 O 0 1.6987707567750476e-05
nuclear O 0 6.750676675437717e-07
foci O 0 1.5710555089754052e-05
in O 0 1.1207804817559008e-07
benign O 0 0.011164599098265171
breast O 0 0.004673927556723356
, O 0 2.4163574607882765e-07
invasive B-Disease 0 4.806137440027669e-05
lobular I-Disease 1 0.9989945292472839
cancers I-Disease 1 0.9999144077301025
and O 0 4.246612206770806e-06
low B-Disease 0 0.00016023566422518343
- I-Disease 1 0.9342820048332214
grade I-Disease 0 0.0004505676624830812
ductal I-Disease 1 0.9861424565315247
carcinomas I-Disease 1 1.0
. O 0 2.075474549201317e-05

Conversely O 0 7.445029768859968e-05
, O 0 3.8355963738467835e-07
BRCA1 O 0 1.1277424164291006e-05
expression O 0 6.958213703001093e-07
was O 0 1.1380104751879117e-06
reduced O 0 6.930181228881338e-08
or O 0 1.2628384560287031e-08
undetectable O 0 2.0646572806981567e-07
in O 0 2.3263453385879984e-09
the O 0 2.470739168813907e-09
majority O 0 2.443202529178734e-09
of O 0 5.630647614829343e-10
high O 0 2.3385078407045512e-07
- O 0 0.0001970154989976436
grade O 0 9.237194831257511e-07
, O 0 1.94608347214853e-08
ductal B-Disease 0 0.00014186596672516316
carcinomas I-Disease 1 1.0
, O 0 2.0238968545527314e-07
suggesting O 0 2.1161964980365155e-07
that O 0 2.630168305373104e-09
absence O 0 5.105998734933337e-09
of O 0 9.2567575826763e-10
BRCA1 O 0 4.852491201745579e-06
may O 0 4.3419538542366354e-07
contribute O 0 1.601570320808321e-09
to O 0 8.513099114537681e-10
the O 0 1.827150430955271e-09
pathogenesis O 0 7.594189810333773e-08
of O 0 3.9621991798632905e-10
a O 0 3.1834874736347274e-09
significant O 0 2.418444333684988e-09
percentage O 0 1.0236168179744709e-07
of O 0 5.8140638969916836e-09
sporadic B-Disease 0 0.48455730080604553
breast I-Disease 1 0.9997562766075134
cancers I-Disease 1 0.9217804670333862
. O 0 1.6133714098032215e-07
. O 0 3.290005565759202e-07

